Clustering O 0 0.00039764976827427745
of O 0 6.451083027059212e-05
missense O 0 0.00015759187226649374
mutations O 0 6.028468305885326e-06
in O 0 4.4375860852596816e-06
the O 0 3.130231561954133e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999895095825195
telangiectasia I-Disease 1 0.9999984502792358
gene O 0 2.961634709208738e-05
in O 0 4.6566292439820245e-06
a O 0 1.0378940714872442e-05
sporadic B-Disease 0 0.0007764705223962665
T I-Disease 1 0.9999957084655762
- I-Disease 1 0.9806112051010132
cell I-Disease 1 0.9853235483169556
leukaemia I-Disease 1 0.9999661445617676
. O 0 0.00013674813089892268

Ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999549388885498
telangiectasia I-Disease 1 0.9999991655349731
( O 0 0.028757575899362564
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
) O 0 3.398740773263853e-06
is O 0 2.71943832785837e-07
a O 0 6.887669883326453e-07
recessive B-Disease 0 1.2611022611963563e-05
multi I-Disease 1 0.8945319056510925
- I-Disease 1 0.9999600648880005
system I-Disease 1 0.9999181032180786
disorder I-Disease 1 0.9999998807907104
caused O 0 0.00641845865175128
by O 0 1.1390679901523981e-06
mutations O 0 4.132424180625094e-07
in O 0 2.0867325645212986e-07
the O 0 5.970322831672092e-07
ATM O 0 6.326623406494036e-05
gene O 0 2.108218723151367e-06
at O 0 6.325646609184332e-06
11q22 O 0 0.00030780406086705625
- O 0 4.4182237616041675e-05
q23 O 0 0.006134052760899067
( O 0 6.4080709307745565e-06
ref O 0 0.00037210711161606014
. O 0 3.8003506688255584e-06
3 O 0 1.2654042620852124e-05
) O 0 5.202596184972208e-06
. O 0 1.441361746401526e-05

The O 0 8.954219083534554e-05
risk O 0 4.031872595078312e-05
of O 0 0.0004135639755986631
cancer B-Disease 1 0.9999963045120239
, O 0 5.283099199004937e-06
especially O 0 9.471616067457944e-06
lymphoid B-Disease 1 0.9999927282333374
neoplasias I-Disease 1 0.9999693632125854
, O 0 7.785930392856244e-06
is O 0 9.318907245869923e-07
substantially O 0 4.643830834538676e-06
elevated O 0 0.0001826551160775125
in O 0 6.116883014328778e-06
A B-Disease 1 0.9999947547912598
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 2.935321936092805e-05
and O 0 6.918717190274037e-07
has O 0 7.404952953038446e-07
long O 0 8.436421694568708e-07
been O 0 1.1602112408581888e-06
associated O 0 4.5205283640825655e-06
with O 0 1.0688820111681707e-05
chromosomal O 1 0.999991774559021
instability O 1 0.9995799660682678
. O 0 0.000566756003536284

By O 0 9.643942030379549e-05
analysing O 0 0.003482131753116846
tumour B-Disease 1 0.9999998807907104
DNA O 0 0.00034842200693674386
from O 0 7.764152542222291e-06
patients O 0 2.6099164642801043e-06
with O 0 4.5875393084315874e-07
sporadic B-Disease 0 8.549410267733037e-05
T I-Disease 1 0.9998133778572083
- I-Disease 0 0.0011019775411114097
cell I-Disease 0 0.004318344406783581
prolymphocytic I-Disease 1 0.9991544485092163
leukaemia I-Disease 1 0.9999990463256836
( O 0 9.921497257892042e-05
T B-Disease 1 0.9999765157699585
- I-Disease 0 0.01038757897913456
PLL I-Disease 1 0.9999507665634155
) O 0 1.9034063143408275e-06
, O 0 4.630615535461402e-07
a O 0 5.094061066301947e-07
rare O 0 4.300998625694774e-06
clonal B-Disease 1 0.7799199819564819
malignancy I-Disease 1 0.9992221593856812
with O 0 8.564798577026522e-07
similarities O 0 1.1613159358603298e-06
to O 0 3.5865372183252475e-07
a O 0 1.5085963696037652e-06
mature B-Disease 0 1.9650407921290025e-05
T I-Disease 1 0.9966262578964233
- I-Disease 0 0.0013529595453292131
cell I-Disease 0 0.0021910760551691055
leukaemia I-Disease 1 0.7455178499221802
seen O 0 2.7794362722488586e-06
in O 0 1.1824874945887132e-06
A B-Disease 1 0.7914388179779053
- I-Disease 1 0.9736570119857788
T I-Disease 1 0.9999984502792358
, O 0 1.1423446721892105e-06
we O 0 7.017330716507786e-08
demonstrate O 0 2.4685812149982667e-07
a O 0 1.290988791424752e-07
high O 0 3.7912391803729406e-07
frequency O 0 1.4729079111930332e-07
of O 0 4.875220724898099e-07
ATM O 0 0.00010845327051356435
mutations O 0 4.769503902934957e-06
in O 0 1.3926015526521951e-05
T B-Disease 1 0.9945359230041504
- I-Disease 0 0.008986753411591053
PLL I-Disease 1 0.9976179003715515
. O 0 7.796599675202742e-05

In O 0 2.7426616725279018e-05
marked O 0 1.955156221811194e-05
contrast O 0 2.0405964278324973e-06
to O 0 2.96322156145834e-07
the O 0 1.6972509229162824e-06
ATM O 0 0.0002759084163699299
mutation O 0 2.5165427359752357e-06
pattern O 0 3.4397323815937852e-06
in O 0 1.411500534231891e-06
A B-Disease 1 0.9865251779556274
- I-Disease 1 0.9988214373588562
T I-Disease 1 0.9999992847442627
, O 0 7.946505320433062e-07
the O 0 2.9954753699712455e-07
most O 0 1.1382531539538832e-07
frequent O 0 2.7619421416602563e-07
nucleotide O 0 8.182187798411178e-07
changes O 0 2.59740176034029e-07
in O 0 8.741456554162141e-07
this O 0 1.2400175819493597e-06
leukaemia B-Disease 1 0.7669980525970459
were O 0 8.089962648227811e-06
missense O 0 0.00021669070702046156
mutations O 0 3.8742484321119264e-05
. O 0 4.61038616776932e-05

These O 0 1.1702329175022896e-05
clustered O 0 2.3269618395715952e-05
in O 0 1.2766240615746938e-06
the O 0 1.1564751503101434e-06
region O 0 7.512689421673713e-07
corresponding O 0 3.71266281717908e-07
to O 0 2.8492948445091315e-07
the O 0 1.0455607935000444e-06
kinase O 0 5.2539621719915885e-06
domain O 0 1.0446239002703805e-06
, O 0 2.586552625416516e-07
which O 0 8.136102280786872e-08
is O 0 4.7885361453836595e-08
highly O 0 1.4488631450149114e-07
conserved O 0 6.825445666436281e-07
in O 0 2.9046165650470357e-07
ATM O 0 6.573933933395892e-05
- O 0 6.669752565358067e-06
related O 0 1.2663970210269326e-06
proteins O 0 5.868917014595354e-07
in O 0 1.3910943152950495e-06
mouse O 0 1.634652835491579e-05
, O 0 1.4922810578354984e-06
yeast O 0 1.270468328584684e-05
and O 0 9.394322660227772e-06
Drosophila O 0 0.00013047920947428793
. O 0 3.804907464655116e-05

The O 0 7.984679541550577e-05
resulting O 0 3.057203866774216e-05
amino O 0 6.177287559694378e-06
- O 0 1.5964456906658597e-05
acid O 0 4.2874271457549185e-06
substitutions O 0 2.559563199611148e-06
are O 0 9.144925883219912e-08
predicted O 0 1.0208086678176187e-06
to O 0 2.9323098260647384e-07
interfere O 0 1.902734766190406e-06
with O 0 1.5826201433810638e-06
ATP O 1 0.9999775886535645
binding O 0 1.0363600267737638e-05
or O 0 7.084511253196979e-06
substrate O 0 7.14262350811623e-05
recognition O 0 5.6923374359030277e-05
. O 0 6.128419045126066e-05

Two O 0 1.62079741130583e-05
of O 0 2.595143814687617e-05
seventeen O 0 0.00015030145004857332
mutated O 0 0.0002522143768146634
T B-Disease 1 0.8690720796585083
- I-Disease 0 0.00019192861509509385
PLL I-Disease 0 0.32927265763282776
samples O 0 9.63668389886152e-06
had O 0 1.2411273928591982e-06
a O 0 6.68549375859584e-07
previously O 0 4.1147018237097654e-06
reported O 0 1.142651672125794e-05
A B-Disease 1 0.9670125842094421
- I-Disease 1 0.9995864033699036
T I-Disease 1 0.999998927116394
allele O 0 9.625410893931985e-05
. O 0 3.69495501217898e-05

In O 0 4.371426985017024e-05
contrast O 0 1.2370963304420002e-05
, O 0 1.167307573268772e-06
no O 0 5.305570311975316e-07
mutations O 0 2.8782494609913556e-07
were O 0 3.5524084296412184e-07
detected O 0 2.2466260816145223e-06
in O 0 2.0100263498079585e-07
the O 0 4.608288577401254e-07
p53 O 0 6.105856300564483e-06
gene O 0 1.5879933243923006e-06
, O 0 2.266209264689678e-07
suggesting O 0 5.441200983113959e-07
that O 0 6.778029160159349e-08
this O 0 7.793037184455898e-07
tumour B-Disease 1 1.0
suppressor O 0 0.0011170884827151895
is O 0 5.394626327870355e-07
not O 0 1.4500670886263833e-07
frequently O 0 3.7838634625586565e-07
altered O 0 2.1491007373697357e-06
in O 0 2.4499902337993262e-06
this O 0 9.957012480299454e-06
leukaemia B-Disease 1 0.9998726844787598
. O 0 0.0001514757750555873

Occasional O 0 0.0005734957521781325
missense O 0 0.0004018923209514469
mutations O 0 1.8550119420979172e-05
in O 0 3.943268438888481e-06
ATM O 0 0.00014444485714193434
were O 0 3.3134112982224906e-06
also O 0 6.746750500497001e-07
found O 0 7.824874046491459e-07
in O 0 1.3826442000208772e-06
tumour B-Disease 1 0.9999997615814209
DNA O 0 3.58906872861553e-05
from O 0 1.3055492900093668e-06
patients O 0 9.27379858239874e-07
with O 0 6.067193680792116e-07
B B-Disease 0 0.009407184086740017
- I-Disease 0 3.7686295399907976e-05
cell I-Disease 0 3.929796002921648e-05
non I-Disease 0 3.604833909776062e-05
- I-Disease 0 0.33979564905166626
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9999133348464966
( O 0 1.2040634828736074e-05
B B-Disease 0 0.0014617848210036755
- I-Disease 0 1.5139929928409401e-05
NHL I-Disease 0 0.00011269933020230383
) O 0 6.96685219736537e-07
and O 0 7.178385885708849e-07
a O 0 3.96907125832513e-06
B B-Disease 0 0.004101746249943972
- I-Disease 0 8.237279689637944e-05
NHL I-Disease 0 0.007119756657630205
cell O 0 0.00043650579755194485
line O 0 7.42635311326012e-05
. O 0 2.356086224608589e-05

The O 0 2.6712312319432385e-05
evidence O 0 1.0735906471381895e-05
of O 0 3.593368091969751e-06
a O 0 5.669724032486556e-07
significant O 0 4.5242532564770954e-07
proportion O 0 6.35408412108518e-07
of O 0 1.5523706906606094e-06
loss O 0 0.00039761484367772937
- O 0 2.053162461379543e-05
of O 0 1.48467042890843e-05
- O 0 1.9751636500586756e-05
function O 0 4.6178175239219854e-07
mutations O 0 1.462278049757515e-07
and O 0 1.0971294983619373e-07
a O 0 2.283759101828764e-07
complete O 0 9.232395541403093e-07
absence O 0 2.1850560187886003e-06
of O 0 1.5211245454338496e-06
the O 0 7.015109417807253e-07
normal O 0 3.4681613669818034e-07
copy O 0 1.1721076589310542e-06
of O 0 4.623832694505836e-07
ATM O 0 2.651005343068391e-05
in O 0 4.512868088113464e-07
the O 0 3.652897362371732e-07
majority O 0 1.874281423397406e-07
of O 0 3.454954139670008e-06
mutated O 0 0.000161185918841511
tumours B-Disease 1 0.9999966621398926
establishes O 0 1.2532171240309253e-05
somatic O 0 1.9911103663616814e-05
inactivation O 0 5.247277658781968e-05
of O 0 1.0369899428042118e-06
this O 0 1.3367869655667164e-07
gene O 0 3.227968363717082e-07
in O 0 2.3525508652255667e-07
the O 0 8.032611731323414e-07
pathogenesis O 0 0.00018560302851255983
of O 0 1.0694581760617439e-05
sporadic B-Disease 0 0.0010266300523653626
T I-Disease 1 0.9999213218688965
- I-Disease 0 0.0003099129826296121
PLL I-Disease 1 0.9892582297325134
and O 0 1.615634459994908e-06
suggests O 0 1.2943298770551337e-06
that O 0 1.6502930577644292e-07
ATM O 0 3.532740447553806e-05
acts O 0 2.696194087548065e-06
as O 0 5.43413534614956e-06
a O 0 0.00013316138938535005
tumour B-Disease 1 1.0
suppressor O 0 0.2643694579601288
. O 0 0.00013558643695432693

As O 0 3.0082032026257366e-05
constitutional O 0 1.5404328223667108e-05
DNA O 0 4.427942621987313e-05
was O 0 8.50461219670251e-06
not O 0 1.1368233288067131e-07
available O 0 2.3872476617725624e-07
, O 0 3.247021425067942e-07
a O 0 1.309095182477904e-06
putative O 0 0.0001977070642169565
hereditary O 1 0.9999822378158569
predisposition O 1 0.9828721284866333
to O 0 0.00011947115126531571
T B-Disease 1 0.9999997615814209
- I-Disease 1 0.823494553565979
PLL I-Disease 1 0.9975306391716003
will O 0 5.564984348893631e-07
require O 0 3.715797447512159e-07
further O 0 1.227502252731938e-06
investigation O 0 8.278082532342523e-06
. O 0 5.636806235997938e-06
. O 0 2.373405732214451e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.0004888053517788649
kinase O 0 0.00017928043962456286
is O 0 2.4057192149484763e-06
involved O 0 1.1069885204051388e-06
in O 0 3.265146517605899e-07
the O 0 4.461496132535103e-07
modulation O 0 1.525520588074869e-06
of O 0 2.510597823857097e-06
the O 0 3.327458671265049e-06
Ca2 O 0 4.352463292889297e-05
+ O 0 3.549448592821136e-05
homeostasis O 0 0.000280718260910362
in O 0 2.9958411687402986e-05
skeletal O 1 0.9999821186065674
muscle O 1 0.9325822591781616
cells O 0 0.0003276958013884723
. O 0 5.769818017142825e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999958276748657
DM B-Disease 1 1.0
) O 0 0.0017072911141440272
, O 0 5.863205842615571e-06
the O 0 2.993658654304454e-06
most O 0 3.4107156352547463e-06
prevalent O 1 0.9990171194076538
muscular B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.0022293166257441044
adults O 0 8.424157385888975e-06
, O 0 2.529518951632781e-06
is O 0 9.196340329253871e-07
caused O 0 5.3497137741942424e-06
by O 0 1.1917175015696557e-06
( O 0 5.221494575380348e-06
CTG O 1 0.9978991746902466
) O 0 1.753607307364291e-06
n O 0 2.0470893105084542e-06
- O 0 2.056393213933916e-06
repeat O 0 1.214797862303385e-06
expansion O 0 9.346231308882125e-07
in O 0 2.3408395577462215e-07
a O 0 3.6054677821084624e-07
gene O 0 2.701122809867229e-07
encoding O 0 3.304841982298967e-07
a O 0 7.719548875684268e-07
protein O 0 1.0551872264841222e-06
kinase O 0 1.6135210898937657e-05
( O 0 5.4540359997190535e-06
DM B-Disease 1 0.9999991655349731
protein O 0 3.65024038728734e-06
kinase O 0 7.394681688310811e-06
; O 0 1.3269083183331531e-06
DMPK O 1 0.8231786489486694
) O 0 6.092200806051551e-07
and O 0 2.1867998611924122e-07
involves O 0 4.5103772094989836e-07
changes O 0 3.0480029522550467e-07
in O 0 1.9513859115249943e-06
cytoarchitecture O 0 0.0006416483665816486
and O 0 9.044590115081519e-06
ion O 0 0.0007533474708907306
homeostasis O 0 0.02478303574025631
. O 0 9.115009743254632e-05

To O 0 5.650104867527261e-06
obtain O 0 4.437725237949053e-06
clues O 0 6.065577963454416e-06
to O 0 4.918393869957072e-07
the O 0 6.536232035614375e-07
normal O 0 5.868088805982552e-07
biological O 0 1.422348759660963e-06
role O 0 9.554357802699087e-07
of O 0 3.1787312764208764e-06
DMPK O 1 0.9931961297988892
in O 0 2.5103943244175753e-06
cellular O 0 1.984206937777344e-05
ion O 0 4.045167224830948e-05
homeostasis O 0 0.0001124567206716165
, O 0 7.480545605176303e-07
we O 0 8.469119450182916e-08
have O 0 2.27272547448365e-08
compared O 0 1.5532059194356407e-07
the O 0 3.23250617384474e-07
resting O 0 5.8079196605831385e-05
[ O 0 4.239522240823135e-06
Ca2 O 0 3.967016255046474e-06
+ O 0 7.072367679938907e-06
] O 0 4.0291602090292145e-06
i O 0 8.342676096617652e-07
, O 0 8.290292186075021e-08
the O 0 1.0183840970512392e-07
amplitude O 0 3.132275594452949e-07
and O 0 2.320307146419509e-07
shape O 0 1.1907325188076356e-06
of O 0 1.404989689035574e-06
depolarization O 0 3.240356454625726e-05
- O 0 4.48286191385705e-05
induced O 0 8.396305202040821e-05
Ca2 O 0 1.066057120624464e-05
+ O 0 4.448411800694885e-06
transients O 0 8.063757377385627e-06
, O 0 2.787939763493341e-07
and O 0 9.044195792284881e-08
the O 0 1.1923047793516162e-07
content O 0 2.434882162560825e-07
of O 0 1.7043213347278652e-06
ATP O 1 0.997913658618927
- O 0 2.372625021962449e-05
driven O 0 8.151748261298053e-06
ion O 0 1.5746059943921864e-05
pumps O 0 2.2849120796308853e-05
in O 0 9.975709645004827e-07
cultured O 0 2.7493078960105777e-05
skeletal O 0 0.0851714238524437
muscle O 0 2.3253933250089176e-05
cells O 0 1.0394425089543802e-06
of O 0 8.809369660411903e-07
wild O 0 2.8644915346376365e-06
- O 0 1.0582049981167074e-05
type O 0 6.5773288042692e-06
and O 0 2.4772532469796715e-06
DMPK O 1 0.999944806098938
[ O 0 0.00012577127199620008
- O 0 0.0003552412672434002
/ O 0 0.0008001076057553291
- O 0 0.000236405452596955
] O 0 0.00018328720761928707
knockout O 0 0.47646042704582214
mice O 0 0.00021017967083025724
. O 0 3.536599615472369e-05

In O 0 3.0564606277039275e-05
vitro O 0 0.00011735898442566395
- O 0 7.934758468763903e-05
differentiated O 0 0.00014759479381609708
DMPK O 1 0.9986740350723267
[ O 0 0.00012371904449537396
- O 0 0.0004150681779719889
/ O 0 0.0001421619817847386
- O 0 3.8075791962910444e-05
] O 0 1.7467025827500038e-05
myotubes O 0 4.22200646426063e-05
exhibit O 0 3.992262008978287e-06
a O 0 1.3884040299672051e-06
higher O 0 2.5088913844228955e-06
resting O 0 9.078784933080897e-05
[ O 0 9.237096492142882e-06
Ca2 O 0 5.495816822076449e-06
+ O 0 7.87675344326999e-06
] O 0 2.9182097023294773e-06
i O 0 3.322130055494199e-07
than O 0 2.481285932276478e-08
do O 0 3.6020711746687084e-08
wild O 0 6.049883722880622e-07
- O 0 4.600477495841915e-06
type O 0 8.781196811469272e-06
myotubes O 0 0.00017516738444101065
because O 0 3.152305509956932e-07
of O 0 3.9771310866854037e-07
an O 0 1.500946211763221e-07
altered O 0 7.186098969214072e-07
open O 0 5.28861676230008e-07
probability O 0 1.1836512925356146e-07
of O 0 2.777102565687528e-07
voltage O 0 4.762386197398882e-06
- O 0 6.165234481159132e-06
dependent O 0 1.2805785445380025e-06
l O 0 2.851495764844003e-06
- O 0 5.3172625484876335e-06
type O 0 5.636397418129491e-06
Ca2 O 0 6.703377948724665e-06
+ O 0 8.601817171438597e-06
and O 0 3.856135208479827e-06
Na O 0 0.0010267074685543776
+ O 0 3.379621557542123e-05
channels O 0 6.970681170059834e-06
. O 0 1.5032716873975005e-05

The O 0 0.00010628748714225367
mutant O 0 0.0002950369962491095
myotubes O 0 0.0013152306200936437
exhibit O 0 2.1805803044117056e-05
smaller O 0 3.1590664093528176e-06
and O 0 1.3679717767445254e-06
slower O 0 6.986559583310736e-06
Ca2 O 0 4.11416021961486e-06
+ O 0 1.833753799473925e-06
responses O 0 2.236170359992684e-07
upon O 0 4.2349137174824136e-07
triggering O 0 3.74492287846806e-06
by O 0 1.0833796295628417e-06
acetylcholine O 0 1.5029979294922668e-05
or O 0 1.495706328569213e-06
high O 0 1.581362812430598e-05
external O 0 2.20605252252426e-05
K O 0 0.0002619984152261168
+ O 0 0.00015332507609855384
. O 0 2.8728394681820646e-05

In O 0 2.454788045724854e-05
addition O 0 8.131546564982273e-06
, O 0 1.3946263379693846e-06
we O 0 1.133044804646488e-07
observed O 0 1.950301538045096e-07
that O 0 3.229504130786154e-08
these O 0 5.622379006808842e-08
Ca2 O 0 4.3431732592580374e-06
+ O 0 9.525276254862547e-06
transients O 0 1.3735243555856869e-05
partially O 0 4.277046173228882e-06
result O 0 2.324105281559241e-07
from O 0 2.106688157255121e-07
an O 0 4.540159181942727e-08
influx O 0 2.3735903198485175e-07
of O 0 6.241212417990027e-07
extracellular O 0 1.4608467608923092e-06
Ca2 O 0 1.465423565605306e-06
+ O 0 8.766067480792117e-07
through O 0 2.035984465464935e-07
the O 0 5.633724526887818e-07
l O 0 6.351482625177596e-06
- O 0 1.6313701053149998e-05
type O 0 1.3060825040156487e-05
Ca2 O 0 3.735717837116681e-05
+ O 0 4.542484748526476e-05
channel O 0 2.3960883481777273e-05
. O 0 2.1226707758614793e-05

Neither O 0 7.729640492470935e-05
the O 0 4.912285476166289e-06
content O 0 1.3418735989034758e-06
nor O 0 9.446405897506338e-07
the O 0 2.0477655482409318e-07
activity O 0 4.132782578381011e-07
of O 0 2.364021611356293e-06
Na O 0 0.00760387210175395
+ O 0 2.834457700373605e-05
/ O 0 2.382217462582048e-05
K O 0 2.139428943337407e-05
+ O 0 8.783306839177385e-06
ATPase O 0 3.590205596992746e-05
and O 0 2.6976651952281827e-06
sarcoplasmic O 0 7.915275637060404e-05
reticulum O 0 2.912523996201344e-05
Ca2 O 0 2.13118164538173e-05
+ O 0 1.6137119018821977e-05
- O 0 1.0942514563794248e-05
ATPase O 0 1.8143795387004502e-05
are O 0 1.3654076269631332e-07
affected O 0 1.3248269397081458e-06
by O 0 3.859217940771487e-06
DMPK O 1 0.9997720122337341
absence O 0 0.000774714513681829
. O 0 9.992354898713529e-05

In O 0 3.230279980925843e-05
conclusion O 0 1.1507330782478675e-05
, O 0 2.5430520054214867e-06
our O 0 8.234063102463551e-07
data O 0 9.749901437317021e-07
suggest O 0 1.1909791055586538e-06
that O 0 3.618129369442613e-07
DMPK O 1 0.9472655057907104
is O 0 6.742473033227725e-07
involved O 0 3.787683340306103e-07
in O 0 3.489923301458475e-07
modulating O 0 7.4066165325348265e-06
the O 0 3.688354581754538e-07
initial O 0 7.188326094365038e-07
events O 0 2.7782095912698423e-07
of O 0 9.436735126655549e-07
excitation O 0 2.0428091374924406e-05
- O 0 4.2781277443282306e-05
contraction O 0 1.7741849660524167e-05
coupling O 0 1.2159720427007414e-05
in O 0 1.0770558219519444e-05
skeletal O 1 0.9999730587005615
muscle O 0 0.10460371524095535
. O 0 1.712962875899393e-05
. O 0 2.3337863240158185e-05

Constitutional O 0 0.001365829142741859
RB1 O 1 0.9999463558197021
- O 0 0.0017136377282440662
gene O 0 4.092910967301577e-05
mutations O 0 6.933711574674817e-06
in O 0 3.1148958896665135e-06
patients O 0 7.961153642099816e-06
with O 0 4.207754045637557e-06
isolated O 0 0.0005754467565566301
unilateral B-Disease 0 0.00035182363353669643
retinoblastoma I-Disease 1 0.978203535079956
. O 0 0.0004029547271784395

In O 0 5.797549965791404e-05
most O 0 1.2307747965678573e-05
patients O 0 1.2093467375962064e-05
with O 0 1.2765327710440033e-06
isolated O 0 4.971870657755062e-05
unilateral B-Disease 0 3.7943271308904514e-05
retinoblastoma I-Disease 1 0.999153733253479
, O 0 4.1618641262175515e-05
tumor B-Disease 1 0.9967417120933533
development O 0 5.3723633754998446e-06
is O 0 3.587898902424058e-07
initiated O 0 1.089748252525169e-06
by O 0 3.4322735587011266e-07
somatic O 0 2.1630294213537127e-05
inactivation O 0 3.5773959098150954e-05
of O 0 1.0288316616424709e-06
both O 0 2.7876791364178644e-07
alleles O 0 7.82530662490899e-07
of O 0 5.634381977870362e-06
the O 0 4.5611192035721615e-05
RB1 O 1 0.9999582767486572
gene O 0 0.00013793844846077263
. O 0 5.253320705378428e-05

However O 0 5.3515410399995744e-05
, O 0 4.801258455700008e-06
some O 0 6.701260417685262e-07
of O 0 2.6509455892664846e-06
these O 0 1.1499687389004976e-06
patients O 0 1.754440563672688e-05
can O 0 1.0666850585039356e-06
transmit O 0 0.00017782073700800538
retinoblastoma B-Disease 1 0.8627742528915405
predisposition O 0 0.0007237665704451501
to O 0 3.470888714218745e-06
their O 0 1.2872375009465031e-05
offspring O 0 0.00011712086416082457
. O 0 5.440815948531963e-05

To O 0 5.423232778412057e-06
determine O 0 1.784344135558058e-06
the O 0 8.571383887101547e-07
frequency O 0 6.774758389838098e-07
and O 0 2.5616873244871385e-07
nature O 0 4.3423017359600635e-07
of O 0 1.4083904034123407e-06
constitutional O 0 1.5644160157535225e-05
RB1 O 1 0.999976396560669
- O 0 0.00021648954134434462
gene O 0 6.1192231441964395e-06
mutations O 0 1.214925305248471e-06
in O 0 7.695124395468156e-07
patients O 0 1.3904392517360975e-06
with O 0 3.219977600110724e-07
isolated O 0 1.575665191921871e-05
unilateral B-Disease 0 1.2905661606055219e-05
retinoblastoma I-Disease 0 0.026650935411453247
, O 0 1.8331295450479956e-06
we O 0 2.1045836717803468e-07
analyzed O 0 9.444000284020149e-07
DNA O 0 6.186755854287185e-06
from O 0 3.278608801338123e-06
peripheral O 0 0.0913112536072731
blood O 0 7.95464584371075e-05
and O 0 7.521731731685577e-06
from O 0 0.0011843994725495577
tumor B-Disease 1 0.9999995231628418
tissue O 1 0.9930700659751892
. O 0 0.00013197376392781734

The O 0 3.067386933253147e-05
analysis O 0 7.843858838896267e-06
of O 0 4.7192817874019966e-05
tumors B-Disease 1 0.999904990196228
from O 0 9.570166184857953e-06
54 O 0 2.3133872673497535e-05
( O 0 1.3246248045106768e-06
71 O 0 1.2379980034893379e-05
% O 0 5.459643830363348e-07
) O 0 2.4956062816272606e-07
of O 0 1.1115437246189686e-06
76 O 0 3.591075073927641e-05
informative O 0 1.2137754310970195e-05
patients O 0 4.989299668523017e-06
showed O 0 3.703609763761051e-06
loss O 0 9.600239536666777e-06
of O 0 3.895569989254e-06
constitutional O 0 2.3744447389617562e-05
heterozygosity O 1 0.9999293088912964
( O 0 0.000610549293924123
LOH O 1 0.9999995231628418
) O 0 3.271227978984825e-05
at O 0 0.0001889521663542837
intragenic O 0 0.019658099859952927
loci O 0 0.00033199030440300703
. O 0 9.243611566489562e-05

Three O 0 2.6748919481178746e-05
of O 0 4.7806122893234715e-05
13 O 0 0.00011534465738805011
uninformative O 1 0.914864718914032
patients O 0 9.360333206132054e-05
had O 0 1.3006929293624125e-05
constitutional O 0 4.4311567762633786e-05
deletions O 0 0.00045753264566883445
. O 0 9.608170512365177e-05

For O 0 2.264685281261336e-05
39 O 0 1.6428291928605177e-05
randomly O 0 4.250387974025216e-06
selected O 0 3.258689685026184e-05
tumors B-Disease 1 0.9999421834945679
, O 0 7.983187060744967e-06
SSCP O 1 0.9998501539230347
, O 0 5.2051173042855226e-06
hetero O 0 0.0004863138310611248
- O 0 1.2873566447524354e-05
duplex O 0 1.7229647710337304e-05
analysis O 0 3.678753728308948e-07
, O 0 2.2346608830048353e-07
sequencing O 0 1.6263071529465378e-06
, O 0 3.765877636396908e-07
and O 0 2.744570508639299e-07
Southern O 0 1.7764385802365723e-06
blot O 0 1.4912405276845675e-05
analysis O 0 4.5019842787041853e-07
were O 0 2.4195281866923324e-07
used O 0 7.536413022535271e-07
to O 0 1.653702156545478e-06
identify O 0 1.2908911230624653e-05
mutations O 0 4.70534578198567e-05
. O 0 5.1638271543197334e-05

Mutations O 0 4.8446021537529305e-05
were O 0 7.450355496985139e-06
detected O 0 9.321234756498598e-06
in O 0 9.386569672642509e-07
21 O 0 5.036667516833404e-06
( O 0 6.245153940653836e-07
91 O 0 8.316752428072505e-06
% O 0 5.661332806994324e-07
) O 0 3.4020868611150945e-07
of O 0 1.0046386705653276e-05
23 O 0 0.053085535764694214
tumors B-Disease 1 0.9999998807907104
with O 0 0.00042032290366478264
LOH O 1 0.9999998807907104
. O 0 0.0005263478960841894

In O 0 3.051616658922285e-05
6 O 0 3.97031290049199e-05
( O 0 2.3293248432310065e-06
38 O 0 4.408342192618875e-06
% O 0 4.104752520106558e-07
) O 0 2.0745929418808373e-07
of O 0 1.972298832697561e-06
16 O 0 0.0023732269182801247
tumors B-Disease 1 1.0
without O 0 5.169271389604546e-05
LOH O 1 0.9999994039535522
, O 0 9.87580619948858e-07
one O 0 3.263577639245341e-07
mutation O 0 5.119640036355122e-07
was O 0 2.6169050215685274e-06
detected O 0 1.8589859109852114e-06
, O 0 1.0711035258736956e-07
and O 0 1.386035677342079e-07
in O 0 2.9201649454080325e-07
9 O 0 1.6770359252404887e-06
( O 0 2.1560423135724704e-07
56 O 0 1.3822923392581288e-06
% O 0 2.1093136126637546e-07
) O 0 1.0519323012658788e-07
of O 0 9.758720125319087e-07
the O 0 8.296126907225698e-05
tumors B-Disease 1 1.0
without O 0 0.00014071741316001862
LOH O 1 0.9999998807907104
, O 0 2.9849466045561712e-06
both O 0 4.585667454648501e-07
mutations O 0 1.3855839142706827e-06
were O 0 2.529683115426451e-06
found O 0 1.8835409719031304e-05
. O 0 2.8259315513423644e-05

Thus O 0 4.1605744627304375e-05
, O 0 4.600648480845848e-06
a O 0 1.1634776910796063e-06
total O 0 7.212339596662787e-07
of O 0 1.471661221330578e-06
45 O 0 1.3612941529572709e-06
mutations O 0 5.519034402823308e-07
were O 0 5.616204816760728e-07
identified O 0 1.8465452740201727e-06
in O 0 4.5020842662779614e-06
tumors B-Disease 1 0.9999761581420898
of O 0 6.222043884918094e-05
36 O 0 0.0007956226472742856
patients O 0 0.0002053512289421633
. O 0 5.321637945598923e-05

Thirty O 0 0.00020180706633254886
- O 0 2.5863508199108765e-05
nine O 0 5.483780114445835e-06
of O 0 2.2007827737979824e-06
the O 0 1.8873010958486702e-06
mutations O 0 1.367948243569117e-06
- O 0 5.289103228278691e-06
including O 0 6.802324605814647e-07
34 O 0 2.905239171013818e-06
small O 0 5.701601253349509e-07
mutations O 0 8.092625307654089e-07
, O 0 6.767396598661435e-07
2 O 0 9.011098427436082e-07
large O 0 7.709940632594225e-07
structural O 0 3.2356820156564936e-05
alterations O 0 9.938056609826162e-05
, O 0 1.3876997400075197e-06
and O 0 7.894823284004815e-07
hypermethylation O 0 0.0055091725662350655
in O 0 3.9465221561840735e-06
3 O 0 7.099698996171355e-05
tumors O 1 0.9999969005584717
- O 0 1.0083052984555252e-05
were O 0 6.054310119907313e-07
not O 0 6.861250056999779e-08
detected O 0 8.389837944378087e-07
in O 0 1.6046953987824963e-07
the O 0 5.359036663321604e-07
corresponding O 0 7.71320719650248e-06
peripheral O 1 0.9861280918121338
blood O 0 0.004072784446179867
DNA O 0 0.0005346316611394286
. O 0 6.734422640874982e-05

In O 0 4.726996485260315e-05
6 O 0 3.6854286008747295e-05
( O 0 3.0136295663396595e-06
17 O 0 3.5847187973558903e-06
% O 0 5.104263323119085e-07
) O 0 1.0422759544326254e-07
of O 0 2.274460655371513e-07
the O 0 7.236191095216782e-07
36 O 0 9.076561582332943e-06
patients O 0 2.2199926661414793e-06
, O 0 2.0436139891444327e-07
a O 0 4.018915262804512e-07
mutation O 0 4.842861471843207e-07
was O 0 2.7528089958650526e-06
detected O 0 7.922730560494529e-07
in O 0 4.997681557483702e-08
constitutional O 0 1.5516616258537397e-07
DNA O 0 2.0025520370836603e-06
, O 0 1.3535731113734073e-07
and O 0 9.058404515371876e-08
1 O 0 4.3297802676534047e-07
of O 0 3.637316865479079e-07
these O 0 9.326787164809502e-08
mutations O 0 4.738718644148321e-07
is O 0 1.8431902049087512e-07
known O 0 5.090778358862735e-07
to O 0 2.0908481701553683e-07
be O 0 2.433686461245088e-07
associated O 0 1.449428509658901e-06
with O 0 1.2529700370578212e-06
reduced O 0 8.737175812711939e-05
expressivity O 0 0.008108795620501041
. O 0 0.00012886032345704734

The O 0 2.9175695090088993e-05
presence O 0 8.287829587061424e-06
of O 0 2.6730524496088037e-06
a O 0 8.110550311357656e-07
constitutional O 0 2.908928991018911e-06
mutation O 0 1.6920275811571628e-06
was O 0 5.135447281645611e-06
not O 0 7.66181429412427e-08
associated O 0 1.1398793731132173e-07
with O 0 5.569216199319271e-08
an O 0 1.5009747755811986e-07
early O 0 5.824116669828072e-06
age O 0 2.2849470042274334e-05
at O 0 0.0001128235089709051
treatment O 0 0.00023127369058784097
. O 0 4.051088762935251e-05

In O 0 7.502974040107802e-05
1 O 0 9.349628089694306e-05
patient O 0 6.058625513105653e-05
, O 0 2.9696170713577885e-06
somatic O 0 0.00012188414257252589
mosaicism O 0 0.31910789012908936
was O 0 2.753873741312418e-05
demonstrated O 0 2.00137196770811e-06
by O 0 1.6519291534677905e-07
molecular O 0 1.321291506428679e-06
analysis O 0 2.795082423290296e-07
of O 0 7.068578042890294e-07
DNA O 0 1.8426664610160515e-05
and O 0 2.747005282799364e-06
RNA O 0 5.517323370440863e-05
from O 0 2.969748675241135e-05
peripheral O 1 0.9891771674156189
blood O 0 0.004679547622799873
. O 0 7.70165934227407e-05

In O 0 0.00013126515841577202
2 O 0 0.00011892884504050016
patients O 0 6.778171609767014e-06
without O 0 9.017305160341493e-07
a O 0 8.782058102951851e-07
detectable O 0 3.117006053798832e-05
mutation O 0 1.8926001530417125e-06
in O 0 1.5743798940093257e-06
peripheral O 1 0.5518826842308044
blood O 0 0.00029635181999765337
, O 0 4.267361418897053e-06
mosaicism O 1 0.5121120810508728
was O 0 1.309887011302635e-05
suggested O 0 9.482165523877484e-07
because O 0 2.207642921803199e-07
1 O 0 9.801597116165794e-07
of O 0 8.238721420639195e-07
the O 0 4.8283854994224384e-06
patients O 0 0.00034634998883120716
showed O 0 0.04386906325817108
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 2.1164094050618587e-06
the O 0 2.3659522412344813e-06
other O 0 1.1625071465459769e-06
later O 0 2.3120725018088706e-05
developed O 0 7.972020102897659e-05
bilateral B-Disease 0 0.00016398598381783813
retinoblastoma I-Disease 1 0.9753408432006836
. O 0 0.0002368239511270076

In O 0 2.862624933186453e-05
conclusion O 0 7.747391464363318e-06
, O 0 1.9005802869287436e-06
our O 0 5.023093194722605e-07
results O 0 3.4704873996815877e-07
emphasize O 0 7.923009661681135e-07
that O 0 6.140725616887721e-08
the O 0 6.28819577741524e-07
manifestation O 0 4.89822486997582e-05
and O 0 1.5010249398983433e-06
transmissibility O 0 0.0006579605396836996
of O 0 1.5693529348936863e-05
retinoblastoma B-Disease 0 8.905807771952823e-05
depend O 0 2.304904285210796e-07
on O 0 3.591568713545712e-07
the O 0 1.7291706910782523e-07
nature O 0 3.171029732129682e-07
of O 0 4.1771016867642174e-07
the O 0 3.864403765874158e-07
first O 0 9.047324738276075e-07
mutation O 0 3.2209234746005677e-07
, O 0 8.349738322976918e-08
its O 0 3.931759096076348e-08
time O 0 5.202796771186513e-08
in O 0 1.7741517410740926e-07
development O 0 9.276876653530053e-07
, O 0 1.98953415520009e-07
and O 0 5.451517282040186e-08
the O 0 1.4879951493185217e-07
number O 0 4.926801722149321e-08
and O 0 8.285328334523001e-08
types O 0 4.4787864794670895e-07
of O 0 1.9921553757740185e-06
cells O 0 2.032951215369394e-06
that O 0 1.5622246962720965e-07
are O 0 1.614539542060811e-07
affected O 0 3.89769911635085e-06
. O 0 6.027663403074257e-06
. O 0 2.2673219064017758e-05

Hereditary B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.999998927116394
of I-Disease 0 0.15651652216911316
the I-Disease 0 0.0027590636163949966
fifth I-Disease 1 0.9048792719841003
component I-Disease 0 0.0004147982399445027
of I-Disease 0 4.9845843022922054e-05
complement I-Disease 0 3.503801781334914e-05
in O 0 1.668518416408915e-05
man O 0 0.00033064090530388057
. O 0 4.315937985666096e-05

I O 0 0.19367413222789764
. O 0 0.0006359262624755502

Clinical O 0 0.03130798041820526
, O 0 6.112368282629177e-05
immunochemical O 1 0.6909546852111816
, O 0 1.0696784556785133e-05
and O 0 2.9207430998212658e-06
family O 0 1.234159844898386e-05
studies O 0 2.0342878997325897e-05
. O 0 3.1146588298724964e-05

The O 0 5.71856799069792e-05
first O 0 1.6764821339165792e-05
recognized O 0 1.039902326738229e-05
human O 0 7.925262252683751e-06
kindred O 0 0.2547275125980377
with O 0 0.0001328885118709877
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9746302962303162
the I-Disease 0 0.15395057201385498
fifth I-Disease 1 0.9645065069198608
component I-Disease 0 0.00033560904557816684
of I-Disease 0 4.393799463286996e-05
complement I-Disease 0 0.0001702091540209949
( O 0 7.41887852200307e-05
C5 O 1 0.9999947547912598
) O 0 3.823708084382815e-06
is O 0 2.15515115087328e-06
described O 0 1.7541929992148653e-05
. O 0 2.2725364033249207e-05

The O 0 9.540100290905684e-05
proband O 0 0.004822356626391411
, O 0 4.693791652243817e-06
a O 0 1.8585534462545183e-06
20 O 0 3.2507193736819318e-06
- O 0 1.1061084478569683e-05
year O 0 3.061542656723759e-06
- O 0 5.072755811852403e-05
old O 0 0.001786496490240097
black O 0 9.569729445502162e-05
female O 0 1.5505020201089792e-05
with O 0 0.00019286200404167175
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.874483048915863
age O 0 0.020611673593521118
11 O 0 5.088153193355538e-05
, O 0 4.122880000068108e-06
lacked O 0 0.00022670766338706017
serum O 0 0.44295695424079895
hemolytic O 1 0.9999978542327881
complement O 0 5.4625834309263155e-05
activity O 0 2.0448380382731557e-05
, O 0 1.8170920839111204e-06
even O 0 1.4290558283391874e-06
during O 0 2.4977278371807188e-05
remission O 0 0.0009594912407919765
. O 0 4.3237156205577776e-05

C5 O 1 0.9989804625511169
was O 0 0.0009958721930161119
undetectable O 0 0.0023386755492538214
in O 0 7.789665687596425e-06
her O 0 1.0171365829592105e-05
serum O 0 2.5565441319486126e-05
by O 0 9.53386006585788e-07
both O 0 2.85473379335599e-06
immunodiffusion O 1 0.6266083717346191
and O 0 0.00011724645446520299
hemolytic O 1 0.9999985694885254
assays O 0 0.004190875682979822
. O 0 0.00020123698050156236

Other O 0 1.926207187352702e-05
complement O 0 2.181474701501429e-05
components O 0 2.3293283447856084e-05
were O 0 2.0111415324208792e-06
normal O 0 1.3316367812876706e-06
during O 0 2.484597416696488e-06
remission O 0 4.2655152356019244e-05
of O 0 2.7740112273022532e-05
lupus O 1 0.9999979734420776
, O 0 4.221536983095575e-06
but O 0 2.4930257040978177e-06
C1 O 1 0.9911603331565857
, O 0 1.4102833119977731e-05
C4 O 1 0.9999957084655762
, O 0 2.1750953237642534e-05
C2 O 1 0.985527753829956
, O 0 4.759993316838518e-06
and O 0 6.374140411935514e-06
C3 O 1 0.9999912977218628
levels O 0 9.098519512917846e-05
fell O 0 0.4481191635131836
during O 0 0.00024433108046650887
exacerbations O 1 0.82596355676651
. O 0 0.00015459890710189939

A O 0 0.00041789101669564843
younger O 0 0.0001142242836067453
half O 0 3.595783346099779e-05
- O 0 0.00015672466543037444
sister O 0 7.880300836404786e-05
, O 0 2.049005161097739e-06
who O 0 1.2117801588829025e-06
had O 0 4.650890332413837e-06
no O 0 6.999878223723499e-06
underlying O 1 0.9993131160736084
disease O 1 0.9999767541885376
, O 0 8.771354259806685e-06
was O 0 8.234106644522399e-05
also O 0 7.007085400800861e-07
found O 0 8.980265988611791e-07
to O 0 7.798144565640541e-07
lack O 0 5.0387370720272884e-05
immunochemically O 1 0.9999431371688843
detectable O 1 0.9997673630714417
C5 O 1 0.9997352957725525
. O 0 0.00012173849972896278

By O 0 0.00025387475034222007
hemolytic O 1 0.9999673366546631
assay O 0 0.00032696398557163775
, O 0 1.3510029020835645e-05
she O 0 5.958172550890595e-06
exhibited O 0 1.0253338587062899e-05
1 O 0 3.779935468628537e-06
- O 0 3.4261424843862187e-06
2 O 0 1.608016532372858e-06
% O 0 1.8877317131682503e-07
of O 0 3.442297611400136e-07
the O 0 7.720535677435691e-07
normal O 0 7.732141966698691e-06
serum O 0 0.004574520513415337
C5 O 1 0.9468144774436951
level O 0 2.563425141488551e-06
and O 0 3.3337303761982184e-07
normal O 0 2.7719426043404383e-07
concentrations O 0 9.768161817191867e-07
of O 0 8.257875379058532e-07
other O 0 6.005012664900278e-07
complement O 0 1.3199955901654903e-05
components O 0 0.00015248992713168263
. O 0 7.575514609925449e-05

C5 O 1 0.9911989569664001
levels O 0 2.4525415938114747e-05
of O 0 4.735692073154496e-06
other O 0 6.757832693438104e-07
family O 0 1.0671591326172347e-06
members O 0 1.4409302195872442e-07
were O 0 3.3731043913576286e-07
either O 0 4.1858785948534205e-07
normal O 0 4.3270063088129973e-07
or O 0 1.8810322899298626e-07
approximately O 0 3.920426081549522e-07
half O 0 7.493183602491627e-07
- O 0 2.6195341433776775e-06
normal O 0 5.969081939838361e-07
, O 0 1.7775458616142714e-07
consistent O 0 5.056410259385302e-07
with O 0 3.0135066708680824e-07
autosomal O 0 2.162975761166308e-05
codominant O 0 0.1152271181344986
inheritance O 0 1.4887480574543588e-05
of O 0 1.4927003576303832e-05
the O 0 2.5610461307223886e-05
gene O 0 0.00016420861356891692
determining O 0 0.019088011234998703
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0007297508418560028

Normal O 0 0.005595268681645393
hemolytic O 1 0.9999880790710449
titers O 0 0.020957117900252342
were O 0 1.7213344108313322e-05
restored O 0 4.9158385081682354e-05
to O 0 1.069579070644977e-06
both O 0 1.911648951136158e-06
homozygous O 0 0.00022315110254567116
C5 B-Disease 1 1.0
- I-Disease 1 0.9998887777328491
deficient I-Disease 1 0.9999995231628418
( O 0 0.00034557917388156056
C5D B-Disease 1 1.0
) O 0 1.0689605005609337e-05
sera O 0 0.00010642531560733914
by O 0 3.5695239830602077e-07
addition O 0 8.036021768020873e-07
of O 0 4.657663794205291e-06
highly O 0 5.456668441183865e-05
purified O 0 0.12476850301027298
human O 0 0.0002762561198323965
C5 O 1 0.9999608993530273
. O 0 0.0001363034243695438

In O 0 3.8471585867227986e-05
specific O 0 1.534254442958627e-05
C5 O 1 0.9994478821754456
titrations O 0 0.0009586301166564226
, O 0 4.51916594101931e-06
however O 0 1.1707066960298107e-06
, O 0 2.8639132665375655e-07
it O 0 1.2896906298465183e-07
was O 0 1.0424265610708972e-06
noted O 0 1.503176463302225e-07
that O 0 2.461948156451399e-08
when O 0 1.1293165869119548e-07
limited O 0 7.663027901116948e-08
amounts O 0 2.259797327042179e-07
of O 0 1.8208355641036178e-06
C5 O 0 0.08680147677659988
were O 0 9.850861033555702e-07
assayed O 0 5.22507116329507e-06
in O 0 3.323572173030698e-07
the O 0 1.9716263466307282e-07
presence O 0 2.4357134975616646e-07
of O 0 3.317846619665943e-07
low O 0 2.6777113362186356e-06
dilutions O 0 3.156060483888723e-05
of O 0 3.90983632314601e-06
either O 0 1.4958096471673343e-05
C5D B-Disease 1 1.0
serum O 0 0.0004353789845481515
, O 0 1.5221156672851066e-06
curving O 0 8.399369107792154e-06
rather O 0 2.565161310030817e-07
than O 0 1.1429904844817429e-07
linear O 0 9.400608291798562e-07
dose O 0 6.2124508986016735e-06
- O 0 4.393761173560051e-06
response O 0 4.956482371198945e-07
plots O 0 1.8242980104332673e-06
were O 0 8.026317459552956e-07
consistently O 0 1.4027726820131647e-06
obtained O 0 6.993919896558509e-07
, O 0 3.5494790040502266e-07
suggesting O 0 1.1750242947528022e-06
some O 0 5.373840963329712e-07
inhibitory O 0 2.569356183812488e-05
effect O 0 2.1725805709138513e-05
. O 0 3.3484684536233544e-05

Further O 0 2.293929355801083e-05
studies O 0 6.8539907260856126e-06
suggested O 0 1.8278087736689486e-06
that O 0 3.1466589689443936e-07
low O 0 4.445740160008427e-06
dilutions O 0 0.000169973645824939
of O 0 5.427388896350749e-05
C5D B-Disease 1 1.0
serum O 0 0.0005834519979543984
contain O 0 3.885073965648189e-06
a O 0 2.4169046355382307e-06
factor O 0 3.6406172512215562e-06
( O 0 5.676405407939455e-07
or O 0 3.905964831574238e-07
factors O 0 3.145551659144985e-07
) O 0 4.0894519770517945e-07
interfering O 0 7.421843406518747e-07
at O 0 8.285784929285001e-07
some O 0 1.2004556992906146e-07
step O 0 3.3448509384470526e-07
in O 0 3.112728848009283e-07
the O 0 2.0262193629605463e-06
hemolytic O 1 0.9999395608901978
assay O 0 0.00021619703329633921
of O 0 0.0010008672252297401
C5 O 1 0.9999872446060181
, O 0 1.8033090327662649e-06
rather O 0 3.988762102835608e-07
than O 0 2.852788441032317e-07
a O 0 2.7705102638719836e-06
true O 0 5.5865628382889554e-05
C5 O 1 0.9998713731765747
inhibitor O 0 0.0009251273586414754
or O 0 3.8308597140712664e-05
inactivator O 0 0.008472362533211708
. O 0 0.00011926214938284829

Of O 0 0.00020050515013281256
clinical O 0 0.00020398208289407194
interest O 0 2.3213174245029222e-06
are O 0 3.3385026654286776e-07
( O 0 5.917125918131205e-07
a O 0 6.322374019873678e-07
) O 0 2.8640386062761536e-07
the O 0 4.762481466968893e-07
documentation O 0 3.365945667610504e-05
of O 0 0.003598709823563695
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.9689220190048218
vasculitis B-Disease 1 1.0
, O 0 0.02133382111787796
and O 1 0.650402307510376
arthritis B-Disease 1 1.0
in O 0 1.2757448530464899e-05
an O 0 1.0477588148205541e-06
individual O 0 3.5448786093184026e-06
lacking O 0 0.09106075018644333
C5 O 1 0.999998927116394
( O 0 3.700855586430407e-06
and O 0 2.59101881283641e-07
its O 0 4.887449449597625e-07
biologic O 0 2.8583501261891797e-05
functions O 0 4.634114532109379e-07
) O 0 2.41623553165482e-07
, O 0 3.010485158938536e-07
and O 0 2.4188199176933267e-07
( O 0 9.525699056212034e-07
b O 0 6.548151304741623e-06
) O 0 1.5510816808728123e-07
a O 0 4.615924069639732e-07
remarkable O 0 2.5763335997908143e-06
propensity O 0 2.2113979866844602e-05
to O 0 6.812115771026583e-06
bacterial B-Disease 1 0.9999998807907104
infections I-Disease 1 0.9999563694000244
in O 0 1.4490138937617303e-06
the O 0 4.286777311790502e-06
proband O 0 0.0816163495182991
, O 0 6.013621032252559e-07
even O 0 1.857389690940181e-07
during O 0 2.965070393656788e-07
periods O 0 4.715430179658142e-07
of O 0 6.934424732207844e-07
low O 0 5.102884188090684e-06
- O 0 5.728876203647815e-06
dose O 0 4.2228493839502335e-06
or O 0 5.234764444139728e-07
alternate O 0 2.94821325041994e-06
- O 0 4.229328624205664e-05
day O 0 6.953941192477942e-05
corticosteroid O 1 0.9606527090072632
therapy O 0 0.13339975476264954
. O 0 5.4198375437408686e-05

Other O 0 6.986906100792112e-06
observations O 0 1.4289113096310757e-05
indicate O 0 3.8046912322897697e-06
that O 0 3.9104372717702063e-07
the O 0 2.139587422789191e-06
C5D B-Disease 1 0.9999996423721313
state O 0 1.3158064575691242e-06
is O 0 4.157790840508824e-07
compatible O 0 2.887508571802755e-06
with O 0 3.7194030255705e-07
normal O 0 1.8081757389154518e-06
coagulation O 0 5.3366904467111453e-05
function O 0 3.383482010121952e-07
and O 0 2.0820951363020868e-07
the O 0 2.2850488790027157e-07
capacity O 0 1.4197953532857355e-06
to O 0 8.828781687952869e-07
mount O 0 0.0007408909150399268
a O 0 3.513974297675304e-05
neutrophilic O 1 0.9998189806938171
leukocytosis O 1 0.9611861705780029
during O 0 0.003965734504163265
pyogenic B-Disease 1 0.999904990196228
infection I-Disease 0 0.06651238352060318
. O 0 1.5450079445145093e-05
. O 0 4.1887924453476444e-05

Susceptibility O 1 0.7332075238227844
to O 0 0.0025505106896162033
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.000541367509867996
twins O 0 0.00037845547194592655
: O 0 1.2182249520265032e-06
the O 0 8.538065117136284e-07
role O 0 1.1171579217261751e-06
of O 0 2.7539197162695928e-06
genes O 0 1.8411258224659832e-06
, O 0 4.746534614241682e-06
HLA O 1 0.9995787739753723
, O 0 1.8696287042985205e-06
and O 0 1.4420548950511147e-06
the O 0 7.157671461754944e-06
environment O 0 2.8425951313693076e-05
. O 0 3.559258402674459e-05

OBJECTIVE O 0 0.00016611414321232587
To O 0 2.526551270420896e-06
determine O 0 9.862469596555457e-07
the O 0 1.0046244369732449e-06
relative O 0 1.8367396705798456e-06
effects O 0 3.5079328881693073e-06
of O 0 1.7989325442613335e-06
genetic O 0 4.927041118207853e-06
and O 0 7.2779448601068e-07
environmental O 0 5.55497535970062e-06
factors O 0 1.1414211940063979e-06
in O 0 2.2700862700730795e-06
susceptibility O 0 0.0006458705174736679
to O 0 0.00015797672676853836
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.5329164266586304
AS B-Disease 1 0.9999790191650391
) O 0 3.938030931749381e-05
. O 0 3.3148029615404084e-05

METHODS O 0 0.0002220516762463376
Twins O 0 0.00020162721921224147
with O 0 3.862023731926456e-06
AS B-Disease 0 0.0011206783819943666
were O 0 8.564732638660644e-07
identified O 0 5.541629093386291e-07
from O 0 3.9389880157614243e-07
the O 0 1.9477213299978757e-06
Royal O 1 0.7968349456787109
National O 1 0.5748258829116821
Hospital O 1 0.9999998807907104
for O 1 0.8689236640930176
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.10186503082513809
. O 0 0.00027511068037711084

Clinical O 0 0.003791259601712227
and O 0 2.7235568268224597e-05
radiographic O 0 0.002270050812512636
examinations O 0 7.219565304694697e-05
were O 0 4.534414074441884e-06
performed O 0 8.970423550636042e-06
to O 0 5.027214342590014e-07
establish O 0 8.805364814179484e-06
diagnoses O 1 0.5136311650276184
, O 0 2.3025297195999883e-05
and O 0 0.001555051770992577
disease O 1 0.9999834299087524
severity O 0 0.011817519553005695
was O 0 8.717452874407172e-05
assessed O 0 2.6278814857505495e-06
using O 0 2.5844002493613516e-07
a O 0 3.190991435531032e-07
combination O 0 8.388237802137155e-07
of O 0 1.4398121948033804e-06
validated O 0 2.703893551370129e-05
scoring O 0 2.128161577275023e-05
systems O 0 0.0003433845704421401
. O 0 3.2911444577621296e-05

HLA O 0 0.24188759922981262
typing O 0 0.00011790593271143734
for O 0 1.6849660823936574e-05
HLA O 1 0.9754010438919067
- O 0 0.00022054306464269757
B27 O 0 0.023987552151083946
, O 0 1.0893267244682647e-05
HLA O 1 0.9280577301979065
- O 0 9.855245298240334e-05
B60 O 0 0.001220546429976821
, O 0 1.8556894474386354e-06
and O 0 2.042306050498155e-06
HLA O 1 0.9991519451141357
- O 0 0.005539242643862963
DR1 O 1 0.9995195865631104
was O 0 3.547408778104e-05
performed O 0 2.7665787456498947e-06
by O 0 2.4816273480610107e-07
polymerase O 0 5.37032974534668e-06
chain O 0 1.554262439640297e-06
reaction O 0 1.7408092389814556e-07
with O 0 4.268877518143199e-08
sequence O 0 1.9661661099235062e-07
- O 0 8.884654789653723e-07
specific O 0 1.682919190670873e-07
primers O 0 4.819258720090147e-06
, O 0 4.6022017841096385e-07
and O 0 5.490874173119664e-07
zygosity O 0 0.0002727551618590951
was O 0 8.81830601429101e-06
assessed O 0 6.830167876614723e-06
using O 0 3.2024406664277194e-06
microsatellite O 0 0.0002924967266153544
markers O 0 0.0004146746650803834
. O 0 8.323338261106983e-05

Genetic O 0 0.00021447057952173054
and O 0 6.484590812760871e-06
environmental O 0 7.984580406628083e-06
variance O 0 1.9997542040073313e-06
components O 0 3.7737440834462177e-06
were O 0 4.1847252418847347e-07
assessed O 0 1.1315001984257833e-06
with O 0 1.4865241837469512e-07
the O 0 7.215359687506862e-07
program O 0 2.0303316432546126e-06
Mx O 0 0.00011151986109325662
, O 0 1.0230819924572643e-07
using O 0 4.4072180571674835e-08
data O 0 7.781060418210473e-08
from O 0 6.799730556394934e-08
this O 0 3.369355283666664e-08
and O 0 8.072739632325465e-08
previous O 0 3.168037494560849e-07
studies O 0 3.505741688059061e-07
of O 0 1.6154403965629172e-06
twins O 0 2.7187817977392115e-05
with O 0 3.3755384265532484e-06
AS B-Disease 1 0.9988470077514648
. O 0 0.00013946933904662728

RESULTS O 0 0.00016741549188736826
Six O 0 1.251206049346365e-05
of O 0 1.2146322660555597e-05
8 O 0 2.8552280127769336e-05
monozygotic O 0 0.0007522383239120245
( O 0 3.2201485737459734e-05
MZ O 1 0.9999953508377075
) O 0 5.510075425263494e-06
twin O 0 1.980520573852118e-05
pairs O 0 1.6863859855220653e-06
were O 0 5.194257482799003e-06
disease O 0 0.0013468797551468015
concordant O 0 4.202379932394251e-05
, O 0 1.3141398085281253e-06
compared O 0 8.568736689085199e-07
with O 0 1.1287480106147996e-07
4 O 0 1.024139692162862e-06
of O 0 1.6644518154862453e-06
15 O 0 2.992494046338834e-06
B27 O 0 0.00012540924944914877
- O 0 8.585278919781558e-06
positive O 0 1.276917600989691e-06
dizygotic O 0 9.555803990224376e-05
( O 0 3.007313807756873e-06
DZ O 1 0.9839351773262024
) O 0 1.2029086065012962e-06
twin O 0 3.857389401673572e-06
pairs O 0 5.370838493945485e-07
( O 0 4.289625223918847e-07
27 O 0 2.6213158434984507e-06
% O 0 2.654135755619791e-07
) O 0 8.32955251439671e-08
and O 0 1.0851233867015253e-07
4 O 0 6.665941896244476e-07
of O 0 1.7574781168150366e-06
32 O 0 1.8886330508394167e-05
DZ O 1 0.9971779584884644
twin O 0 3.238014687667601e-05
pairs O 0 1.926199502122472e-06
overall O 0 3.5052510156674543e-06
( O 0 7.971295303832449e-07
12 O 0 1.3531590639104252e-06
. O 0 6.050368028809316e-07
5 O 0 2.5283300146838883e-06
% O 0 1.5934575685605523e-06
) O 0 2.3502082058257656e-06
. O 0 1.2146114386268891e-05

Nonsignificant O 0 0.17778339982032776
increases O 0 5.122730362927541e-05
in O 0 5.5916866585903335e-06
similarity O 0 3.0066082672419725e-06
with O 0 3.1581009807268856e-07
regard O 0 1.6407875591539778e-06
to O 0 5.488774377226946e-07
age O 0 6.64259641780518e-05
at O 1 0.9616434574127197
disease O 1 0.9999758005142212
onset O 1 0.8016468286514282
and O 0 7.389236316157621e-07
all O 0 3.8374770383597934e-07
of O 0 8.959462320490275e-06
the O 0 0.001999732805415988
disease O 1 0.9998959302902222
severity O 0 4.408169479575008e-05
scores O 0 2.7429948659118963e-06
assessed O 0 2.850995542758028e-06
were O 0 7.870856393310532e-07
noted O 0 1.3755618510913337e-06
in O 0 5.47433319297852e-06
disease O 0 0.08862082660198212
- O 0 0.00018911290680989623
concordant O 0 0.02683466486632824
MZ O 1 0.9999929666519165
twins O 0 0.0001764679473126307
compared O 0 1.7483172996435314e-05
with O 0 6.791022315155715e-06
concordant O 0 0.014144659042358398
DZ O 1 0.9999783039093018
twins O 0 0.004803194664418697
. O 0 0.00024917765404097736

HLA O 1 0.9999154806137085
- O 0 0.0024200824555009604
B27 O 0 0.10722710937261581
and O 0 1.292755132453749e-05
B60 O 0 0.0006915635312907398
were O 0 3.1724923701403895e-06
associated O 0 1.298414758821309e-06
with O 0 3.568383988294954e-07
the O 0 4.54358960269019e-05
disease O 1 0.9896558523178101
in O 0 4.860800800088327e-06
probands O 1 0.9970310926437378
, O 0 9.633408808440436e-07
and O 0 3.059156199469726e-07
the O 0 4.670473572332412e-07
rate O 0 7.839662998776475e-07
of O 0 7.033516794763273e-06
disease O 0 0.07645167410373688
concordance O 0 2.993074303958565e-05
was O 0 1.5405634258058853e-05
significantly O 0 6.75267244787392e-07
increased O 0 2.596047181668837e-07
among O 0 5.032572403251834e-07
DZ O 1 0.5704988837242126
twin O 0 6.333125384117011e-06
pairs O 0 2.2232947571865225e-07
in O 0 2.1563589314155251e-07
which O 0 1.0032440656004837e-07
the O 0 5.916990630794317e-07
co O 0 1.5524254195042886e-05
- O 0 2.0134628357482143e-05
twin O 0 2.76710470643593e-05
was O 0 5.2971595323469955e-06
positive O 0 3.430012611715938e-07
for O 0 2.810663488617138e-07
both O 0 9.132530749411671e-07
B27 O 0 0.014103583991527557
and O 0 7.9499208368361e-05
DR1 O 1 0.9996219873428345
. O 0 9.198782936437055e-05

Additive O 0 0.0002846422139555216
genetic O 0 5.78489743929822e-05
effects O 0 1.7435921108699404e-05
were O 0 1.0055397297037416e-06
estimated O 0 1.0176128171224263e-06
to O 0 1.8049213679205423e-07
contribute O 0 5.480311529026949e-07
97 O 0 5.002077159588225e-06
% O 0 2.3749420563490276e-07
of O 0 4.256291958881775e-07
the O 0 6.782684067729861e-07
population O 0 4.1549645857230644e-07
variance O 0 6.771878815925447e-06
. O 0 2.02130431716796e-05

CONCLUSION O 0 0.0005633858381770551
Susceptibility O 0 0.0005827466957271099
to O 0 5.38392896487494e-06
AS B-Disease 0 0.0046608648262917995
is O 0 9.61079877015436e-07
largely O 0 1.4083838095757528e-06
genetically O 0 1.1293687975921785e-06
determined O 0 8.320261599692458e-07
, O 0 3.5348350024833053e-07
and O 0 1.4175560636431328e-07
the O 0 5.57966188807768e-07
environmental O 0 3.4641723232198274e-06
trigger O 0 2.9214897949714214e-06
for O 0 9.015748787533084e-07
the O 0 4.248850018484518e-05
disease O 1 0.9966869950294495
is O 0 4.651382823794847e-06
probably O 0 3.713921250891872e-05
ubiquitous O 0 0.00021394749637693167
. O 0 2.800837864924688e-05

HLA O 1 0.9997598528862
- O 0 0.0009567469242028892
B27 O 0 0.0004250123747624457
accounts O 0 2.0986080926377326e-06
for O 0 7.217513484647498e-07
a O 0 5.734877390750626e-07
minority O 0 4.586843544984731e-07
of O 0 1.4111923292148276e-06
the O 0 4.054295914102113e-06
overall O 0 4.823787821806036e-05
genetic O 0 0.0001926217955769971
susceptibility O 0 0.0004362664185464382
to O 0 2.1086483684484847e-05
AS B-Disease 1 0.9983896017074585
. O 0 9.916255658026785e-05

Cell O 0 0.0006173556321300566
cycle O 0 9.524937195237726e-05
- O 0 4.3677187932189554e-05
dependent O 0 7.693716725043487e-06
colocalization O 0 0.00029934136546216905
of O 0 3.782989733736031e-05
BARD1 O 1 0.9999479055404663
and O 0 1.0789482985273935e-05
BRCA1 O 0 2.0645777112804353e-05
proteins O 0 4.0817022295414063e-07
in O 0 6.76046852277068e-07
discrete O 0 7.353296041401336e-06
nuclear O 0 9.385833982378244e-05
domains O 0 6.137268064776435e-05
. O 0 4.363938205642626e-05

Germ O 1 0.9998366832733154
- O 0 0.0006981684709899127
line O 0 3.363314317539334e-05
mutations O 0 2.230895006505307e-06
of O 0 2.5368196929775877e-06
the O 0 1.3404358469415456e-05
BRCA1 O 0 0.061541907489299774
gene O 0 9.26774100662442e-06
predispose O 0 7.161147095757769e-06
women O 0 4.7485627874266356e-07
to O 0 7.103502639438375e-07
early O 0 6.423557351808995e-05
- O 0 0.41891202330589294
onset O 1 0.9999990463256836
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9985669255256653
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.2578852824372007e-06
compromising O 0 6.424451566999778e-05
the O 0 4.232033006701386e-06
genes O 0 2.6821533083420945e-06
presumptive O 0 0.00014805827231612056
function O 0 2.6829259240912506e-06
as O 0 5.193465312913759e-06
a O 0 5.0445549277355894e-05
tumor B-Disease 1 0.9996176958084106
suppressor O 0 0.004597683437168598
. O 0 0.00011957612150581554

Although O 0 1.720154432405252e-05
the O 0 3.672629873108235e-06
biochemical O 0 2.1297675630194135e-05
properties O 0 1.0701570317905862e-05
of O 0 2.2616399292019196e-05
BRCA1 O 0 9.436105756321922e-05
polypeptides O 0 3.7272363897500327e-06
are O 0 1.0754556711844998e-07
not O 0 6.126394680450176e-08
understood O 0 6.095391427152208e-07
, O 0 1.1865684257372777e-07
their O 0 1.411161179021292e-07
expression O 0 7.531527330684185e-07
pattern O 0 1.442079678781738e-06
and O 0 2.8837280297011603e-07
subcellular O 0 1.0597965228953399e-05
localization O 0 7.26021607988514e-06
suggest O 0 6.384497623912466e-07
a O 0 4.3712114461413876e-07
role O 0 1.1436308113843552e-06
in O 0 1.6627066088403808e-06
cell O 0 3.500925959087908e-05
- O 0 3.8885435060365126e-05
cycle O 0 3.5993827623315156e-05
regulation O 0 6.619074702030048e-05
. O 0 3.8334652344929054e-05

When O 0 0.0002544657909311354
resting O 0 0.015378779731690884
cells O 0 1.0098525308421813e-05
are O 0 3.761606421903707e-07
induced O 0 1.819905810407363e-05
to O 0 6.417920985768433e-07
proliferate O 0 1.751576564856805e-05
, O 0 4.1174399711962906e-07
the O 0 4.034506559946749e-07
steady O 0 4.149814685661113e-06
- O 0 1.912120978886378e-06
state O 0 2.3219806166707713e-07
levels O 0 4.026215663088806e-07
of O 0 6.107144940870057e-07
BRCA1 O 0 4.897643975709798e-06
increase O 0 1.6003718883439433e-07
in O 0 2.5121158842011937e-07
late O 0 1.029790746542858e-05
G1 O 0 0.0030997369904071093
and O 0 2.3648912872431538e-07
reach O 0 2.1578360076546232e-07
a O 0 1.1337755267959437e-07
maximum O 0 3.7218265447336307e-07
during O 0 9.84640973911155e-06
S O 0 0.0003179880150128156
phase O 0 0.00012072028766851872
. O 0 3.511415343382396e-05

Moreover O 0 0.00015557417646050453
, O 0 8.43441466713557e-06
in O 0 4.50461766376975e-06
S O 0 0.0003699715598486364
phase O 0 9.563735511619598e-05
cells O 0 1.6178029909497127e-05
, O 0 2.743952336459188e-06
BRCA1 O 0 9.026192856254056e-06
polypeptides O 0 1.936909256983199e-06
are O 0 1.5577836620650487e-07
hyperphosphorylated O 0 5.9248588513582945e-05
and O 0 7.612032959514181e-07
accumulate O 0 6.195659807417542e-06
into O 0 2.3196710117190378e-06
discrete O 0 8.696359145687893e-06
subnuclear O 0 0.0003528652305249125
foci O 0 0.00025310253840871155
termed O 0 0.0002161461306968704
" O 0 5.434618651634082e-05
BRCA1 O 0 0.000373147486243397
nuclear O 0 0.0003452064411249012
dots O 0 0.0005027317092753947
. O 0 6.710452726110816e-05

" O 0 0.000868441304191947
BRCA1 O 0 0.0029215142130851746
associates O 0 0.00025741278659552336
in O 0 5.699454504792811e-06
vivo O 0 2.308340663148556e-05
with O 0 9.21684147670021e-07
a O 0 5.634736680804053e-06
structurally O 0 0.00012475968105718493
related O 0 2.084056723106187e-05
protein O 0 4.439608164830133e-05
termed O 0 0.0028226745780557394
BARD1 O 1 0.9999595880508423
. O 0 0.00019172593601979315

Here O 0 3.2777075830381364e-05
we O 0 1.3532545608541113e-06
show O 0 7.396300247819454e-07
that O 0 5.7886282434083114e-08
the O 0 2.6703924049797934e-07
steady O 0 3.166075657645706e-06
- O 0 1.655690539337229e-06
state O 0 2.717006850616599e-07
levels O 0 7.185200843196071e-07
of O 0 2.1798857687826967e-06
BARD1 O 1 0.9999692440032959
, O 0 5.948759280727245e-07
unlike O 0 2.7275575575913535e-07
those O 0 1.3295476719576982e-07
of O 0 3.480365194263868e-06
BRCA1 O 0 0.0001502359809819609
, O 0 5.283025643620931e-07
remain O 0 5.862908665221767e-07
relatively O 0 5.543251404560579e-07
constant O 0 1.6335103509845794e-06
during O 0 6.716534244333161e-06
cell O 0 7.443602953571826e-05
cycle O 0 6.432775990106165e-05
progression O 0 0.00032224657479673624
. O 0 2.7991021852358244e-05

However O 0 0.0002314078010385856
, O 0 4.694436938734725e-05
immunostaining O 0 0.0044831400737166405
revealed O 0 9.985010547097772e-05
that O 0 3.969290901295608e-06
BARD1 O 1 0.9995232820510864
resides O 0 0.00010585933341644704
within O 0 3.5770897284237435e-06
BRCA1 O 0 4.2095958633581176e-05
nuclear O 0 2.2966918550082482e-05
dots O 0 8.52106859383639e-06
during O 0 3.4072957078024046e-06
S O 0 3.0708870326634496e-05
phase O 0 3.5273562843940454e-06
of O 0 8.437081646661682e-07
the O 0 8.450642212665116e-07
cell O 0 7.75880107539706e-06
cycle O 0 1.2095218835384003e-06
, O 0 1.2582312081121927e-07
but O 0 3.753385513505236e-08
not O 0 2.4619295047045853e-08
during O 0 8.747545052756323e-07
the O 0 4.128297860006569e-06
G1 O 1 0.7961770296096802
phase O 0 0.00035696211853064597
. O 0 3.7258552765706554e-05

Nevertheless O 0 0.0009060712181963027
, O 0 3.3659071050351486e-05
BARD1 O 0 0.09453140199184418
polypeptides O 0 1.5186854398052674e-05
are O 0 2.5339178932881623e-07
found O 0 3.5691257949110877e-07
exclusively O 0 2.8799217943742406e-07
in O 0 1.1521846232653843e-07
the O 0 2.3775413637849852e-07
nuclear O 0 1.9426179278525524e-06
fractions O 0 9.509107030680752e-07
of O 0 6.245463737286627e-07
both O 0 3.379363988642581e-07
G1 O 0 0.018876230344176292
- O 0 1.2408017028064933e-05
and O 0 3.3968844945775345e-06
S O 0 0.0005822406383231282
- O 0 6.259477231651545e-05
phase O 0 0.0001446081732865423
cells O 0 4.735303082270548e-05
. O 0 1.9376409909455106e-05

Therefore O 0 9.854522068053484e-05
, O 0 1.2721948223770596e-05
progression O 0 2.575803591753356e-05
to O 0 1.4583439451598679e-06
S O 0 0.00017761993512976915
phase O 0 1.27747371152509e-05
is O 0 2.524619162613817e-07
accompanied O 0 7.771595278427412e-07
by O 0 1.6028155869207694e-07
the O 0 3.224331805995462e-07
aggregation O 0 1.984593154702452e-06
of O 0 2.702477786442614e-06
nuclear O 0 8.799157512839884e-05
BARD1 O 0 0.20813892781734467
polypeptides O 0 1.7103759091696702e-05
into O 0 1.7270134776481427e-05
BRCA1 O 0 0.0002621408202685416
nuclear O 0 0.00024128681980073452
dots O 0 0.0002246839867439121
. O 0 4.5842920371796936e-05

This O 0 1.9546901967260055e-05
cell O 0 6.611100252484903e-05
cycle O 0 2.479257818777114e-05
- O 0 1.3739265341428109e-05
dependent O 0 3.906131496478338e-06
colocalization O 0 0.00022697757231071591
of O 0 2.1337318685255013e-05
BARD1 O 1 0.9999908208847046
and O 0 9.271585440728813e-06
BRCA1 O 0 9.469909855397418e-05
indicates O 0 2.240506546513643e-06
a O 0 7.821203666935617e-07
role O 0 1.376347881887341e-06
for O 0 1.6697284763722564e-06
BARD1 O 1 0.9999135732650757
in O 0 2.247479642392136e-05
BRCA1 O 0 0.027758881449699402
- O 0 0.0006590767297893763
mediated O 0 0.003208381123840809
tumor B-Disease 1 0.9999607801437378
suppression O 1 0.7852208018302917
. O 0 0.00016524623788427562

Ethnic O 0 4.8623336624586955e-05
differences O 0 1.546316889289301e-05
in O 0 8.907501978683285e-06
the O 0 1.2641739886021242e-05
HFE O 1 0.9980953335762024
codon O 0 0.00030108331702649593
282 O 0 0.0005992607912048697
( O 0 0.00013340920850168914
Cys O 1 0.9999915361404419
/ O 1 0.843630850315094
Tyr O 1 0.9975942969322205
) O 0 4.822610571864061e-05
polymorphism O 0 0.00022438469750341028
. O 0 5.7680023019202054e-05

Recent O 0 2.4977516659419052e-05
studies O 0 6.8887929955963045e-06
have O 0 3.7550509546235844e-07
shown O 0 1.8008722690865397e-06
that O 0 4.939098744216608e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9997507929801941
HH B-Disease 1 1.0
) O 0 2.8058184398105368e-05
is O 0 1.4748802641406655e-06
likely O 0 5.162746674614027e-07
to O 0 2.7412428948991874e-07
be O 0 3.4681812621784047e-07
caused O 0 3.0421620067500044e-06
by O 0 1.3748878018304822e-06
homozygosity O 0 0.0005497953970916569
for O 0 8.380690132980817e-07
a O 0 2.341215122214635e-06
Cys282Tyr O 0 0.020658941939473152
mutation O 0 1.2093822761016781e-06
in O 0 3.6735511343977123e-07
the O 0 1.6452532918265206e-06
HFE O 1 0.9944181442260742
gene O 0 1.4865405319142155e-05
located O 0 3.4861539461417124e-05
4 O 0 5.382597373682074e-05
. O 0 2.7020476409234107e-05

5 O 0 0.0004217855166643858
Mb O 0 0.0035794670693576336
telomeric O 0 0.002004555892199278
to O 0 6.0482463595690206e-05
HLA O 1 0.9999415874481201
- O 0 0.0060362485237419605
A O 0 0.0009850166970863938
. O 0 0.00015276980411726981

Population O 0 5.253411472949665e-06
studies O 0 2.1747819118900225e-06
of O 0 1.3169690191716654e-06
this O 0 1.656851509324042e-07
polymorphism O 0 8.686774322086421e-07
are O 0 2.993470360479478e-08
facilitated O 0 7.034134910099965e-07
by O 0 2.501682843103481e-07
the O 0 1.1055684581151581e-06
fact O 0 7.484241564270633e-07
that O 0 1.7670227236976643e-07
the O 0 2.4458765892632073e-06
Cys282Tyr O 1 0.9474480152130127
mutation O 0 9.163544746115804e-06
creates O 0 7.547837867605267e-06
a O 0 8.008702025108505e-06
Rsal O 0 0.0030404357239603996
restriction O 0 3.090014433837496e-05
site O 0 0.00014916541113052517
. O 0 2.8736916647176258e-05

We O 0 1.040169081534259e-05
have O 0 5.859834573129774e-07
studied O 0 4.96489292345359e-06
the O 0 1.0572763358140946e-06
codon O 0 3.366282908245921e-05
282 O 0 8.288970275316387e-05
( O 0 2.4421322450507432e-05
Cys O 1 0.9999990463256836
/ O 0 0.4802887737751007
Tyr O 1 0.934349775314331
) O 0 2.8365946036501555e-06
polymorphism O 0 2.339965021747048e-06
in O 0 2.6033634981104115e-07
different O 0 6.400561858299625e-08
ethnic O 0 3.858405079881777e-07
groups O 0 1.9256540326750837e-06
. O 0 2.087949906126596e-05

In O 0 3.267343345214613e-05
agreement O 0 4.48529317509383e-06
with O 0 6.896693776070606e-07
previous O 0 1.981535206141416e-06
observations O 0 4.262541551725008e-06
the O 0 2.7261269224254647e-06
Tyr O 1 0.7622151374816895
allele O 0 1.2041906529702828e-06
appeared O 0 3.3143550126624177e-07
to O 0 4.993603752723175e-08
be O 0 7.072760155324431e-08
rare O 0 4.826935082746786e-07
or O 0 4.254940506598359e-07
absent O 0 2.4898395167838316e-06
in O 0 9.391987418894132e-07
Asiatic O 0 0.0012829693732783198
( O 0 1.707369960968208e-06
Indian O 0 2.3572206373501103e-06
, O 0 1.0847628573174006e-06
Chinese O 0 2.3957529720064485e-06
) O 0 1.2516205742940656e-06
populations O 0 1.9033336684515234e-06
. O 0 1.118175896408502e-05

The O 0 5.0274964451091364e-05
highest O 0 3.843275408144109e-05
allele O 0 2.2858735064801294e-06
frequency O 0 1.02107355814951e-06
( O 0 3.8820567738184764e-07
7 O 0 5.893460865991074e-07
. O 0 1.895201506840749e-07
5 O 0 4.0426951386507426e-07
% O 0 2.5930580704880413e-07
) O 0 1.8315117245037982e-07
was O 0 5.680425147147616e-06
found O 0 1.4786912743147695e-06
in O 0 1.4496234825855936e-06
Swedes O 0 0.00016741517174523324
. O 0 5.685963333235122e-05

Saamis O 0 0.16793735325336456
( O 0 2.2324455130728893e-05
2 O 0 1.3831328033120371e-05
% O 0 8.874780519363412e-07
) O 0 2.9356058917073824e-07
and O 0 4.567149005652027e-07
Mordvinians O 0 0.04972543194890022
( O 0 1.6406014538006275e-06
1 O 0 2.031966687354725e-06
. O 0 2.5184294827340636e-07
8 O 0 1.7373093896821956e-06
% O 0 2.99904286293895e-07
) O 0 1.4414042937005433e-07
had O 0 6.701861252622621e-07
significantly O 0 6.029688961461943e-07
lower O 0 1.1933699397559394e-06
frequencies O 0 8.49707760153251e-07
of O 0 2.1484777334990213e-06
the O 0 6.073369149817154e-06
Tyr O 1 0.5677468180656433
allele O 0 5.5017502745613456e-05
. O 0 2.787206176435575e-05

Comparisons O 0 5.631869862554595e-05
with O 0 2.5277033728343667e-06
allele O 0 1.768962874848512e-06
frequencies O 0 1.162173475677264e-06
based O 0 7.192859357019188e-07
on O 0 9.538406402498367e-07
prevalence O 0 6.596042112505529e-06
estimates O 0 9.540754035697319e-07
of O 0 3.887913408107124e-06
HH B-Disease 1 0.9999936819076538
showed O 0 1.0743926395662129e-05
some O 0 3.0785483318140905e-07
disagreements O 0 2.1408814063761383e-06
with O 0 2.7544029990167473e-07
the O 0 2.38003303820733e-06
RFLP O 0 0.00023082074767444283
data O 0 2.6470499960851157e-06
, O 0 6.583100571333489e-07
particularly O 0 1.0001257351177628e-06
in O 0 3.20523940899875e-06
Finns O 0 0.00036635372089222074
. O 0 5.3535524784820154e-05

The O 0 6.343617133097723e-05
newly O 0 0.0002855219936463982
described O 0 0.00017436982307117432
HFE O 1 0.9998965263366699
marker O 0 0.0002786078548524529
provides O 0 1.5783471098984592e-06
a O 0 4.188234754565201e-07
new O 0 2.607130227261223e-07
approach O 0 2.152348486106348e-07
to O 0 4.38328413565614e-08
the O 0 2.0521250121419143e-07
screening O 0 1.7520960682304576e-06
of O 0 2.2067345071263844e-06
HH B-Disease 1 0.9999127388000488
as O 0 1.2097260650989483e-06
well O 0 1.8119408196071163e-07
as O 0 1.612159366004562e-07
studies O 0 2.4588516112089565e-07
of O 0 4.018060906219034e-07
the O 0 7.937462100926496e-07
relationship O 0 6.614098424506665e-07
between O 0 7.366256227214762e-07
the O 0 1.7880536688608117e-05
HFE O 1 0.9999991655349731
Tyr O 1 0.9993828535079956
allele O 0 8.591241567046382e-06
and O 0 1.377038415739662e-06
different O 0 4.43531780547346e-06
disorders O 1 0.9996154308319092
including O 0 0.11940117925405502
cancer B-Disease 1 0.9999998807907104

Autosomal B-Disease 1 0.9989344477653503
dominant I-Disease 1 0.9999898672103882
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999973773956299
associated O 0 5.616921407636255e-05
with O 0 2.011099240917247e-06
a O 0 6.0069824030506425e-06
missense O 0 2.42517635342665e-05
mutation O 0 1.9838853404507972e-06
encoding O 0 3.6998781069996767e-06
Gly23 O 0 0.022924771532416344
- O 0 0.0003732447512447834
- O 0 0.0005138651467859745
> O 0 0.00017050282622221857
Val O 0 0.003099521156400442
in O 0 1.606441401236225e-05
neurophysin O 1 0.9995518326759338
II O 1 0.9999992847442627
. O 0 0.00024848204338923097

Autosomal B-Disease 1 0.9994354844093323
dominant I-Disease 1 0.9999887943267822
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9710529446601868
ADNDI B-Disease 1 1.0
) O 0 4.766763959196396e-05
is O 0 7.456780167558463e-06
an O 0 0.0001567031431477517
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999595880508423
by O 0 0.0005153010715730488
progressive O 1 0.9999983310699463
degeneration O 1 1.0
of O 0 0.18859060108661652
the O 0 0.0026195987593382597
magnocellular O 1 0.9999696016311646
neurons O 0 4.4199136027600616e-05
of O 0 1.4923998605809174e-05
the O 0 2.8600597943295725e-05
hypothalamus O 0 0.00045579031575471163
leading O 0 4.7550100134685636e-05
to O 0 1.5851411490075407e-06
decreased O 0 8.643994078738615e-06
ability O 0 3.0233633196985465e-07
to O 0 2.2164756785514328e-07
produce O 0 1.054431777447462e-06
the O 0 4.147476374782855e-06
hormone O 0 6.433697126340121e-05
arginine O 0 0.00015504282782785594
vasopressin O 0 0.00035942776594311
( O 0 4.018636900582351e-05
AVP O 1 0.999387264251709
) O 0 4.275533865438774e-05
. O 0 3.644050229922868e-05

Affected O 0 5.8778798120329157e-05
individuals O 0 1.4490844932879554e-06
are O 0 1.9666835271436867e-07
not O 0 3.635631458109856e-07
symptomatic O 0 0.003709848038852215
at O 0 0.00028669441235251725
birth O 0 0.0001964518305612728
, O 0 1.5191385500656907e-06
but O 0 3.6354339272293146e-07
usually O 0 1.1075787824665895e-06
develop O 0 0.00021452661894727498
diabetes B-Disease 1 0.9999895095825195
insipidus I-Disease 1 0.9938821792602539
at O 0 0.00038911873707547784
1 O 0 2.4150351237040013e-05
- O 0 5.5253160098800436e-05
6 O 0 2.731974564085249e-05
yr O 0 0.0006864304305054247
of O 0 1.494660409662174e-05
age O 0 0.00014586061297450215
. O 0 3.0945819162297994e-05

The O 0 5.507325113285333e-05
genetic O 0 3.517635559546761e-05
locus O 0 3.731800461537205e-05
of O 0 1.6086843970697373e-05
the O 0 4.8759622586658224e-05
disease O 1 0.9119826555252075
is O 0 1.0652252058207523e-06
the O 0 7.892694156907964e-06
AVP O 1 0.9999995231628418
- O 0 0.012719755060970783
neurophysin O 1 0.9993385672569275
II O 1 0.9999998807907104
( O 0 3.056078639929183e-05
NPII O 1 0.9999780654907227
) O 0 1.3832232070853934e-06
gene O 0 1.1309552974125836e-06
, O 0 3.420620942051755e-07
and O 0 3.365338443472865e-07
mutations O 0 1.0386546591689694e-06
that O 0 4.4811363864027953e-07
cause O 0 2.1173615095904097e-05
ADNDI B-Disease 1 0.9996166229248047
have O 0 1.6116905499075074e-07
been O 0 1.4132501746644266e-07
found O 0 9.814142742925469e-08
in O 0 4.241267248517033e-08
both O 0 2.2784286457522285e-08
the O 0 1.674846430432808e-07
signal O 0 8.055450280153309e-07
peptide O 0 8.528560329068569e-07
of O 0 6.643273309236974e-07
the O 0 2.847783662218717e-06
prepro O 0 0.13928274810314178
- O 0 0.0018309620209038258
AVP O 1 0.9999955892562866
- O 0 0.0008187324274331331
NPII O 1 0.9997331500053406
precursor O 0 0.0002312300493940711
and O 0 7.2358502620772924e-06
within O 0 2.046242298092693e-05
NPII O 1 0.9997127652168274
itself O 0 0.00023902389511931688
. O 0 6.123307684902102e-05

An O 0 5.222257459536195e-05
affected O 0 2.8661188480327837e-05
girl O 0 4.32484557677526e-05
who O 0 1.78862728716922e-06
presented O 0 2.5408266992599238e-06
at O 0 6.112766186561203e-06
9 O 0 3.733558060048381e-06
months O 0 8.526966439603711e-07
of O 0 1.2660939319175668e-06
age O 0 5.5898685786814895e-06
and O 0 7.054665047689923e-07
her O 0 1.8817764839695883e-06
similarly O 0 2.3143102225731127e-06
affected O 0 2.763712245723582e-06
younger O 0 1.0924476555373985e-05
brother O 0 3.6748508136952296e-05
and O 0 6.488490953415749e-07
father O 0 8.442751095572021e-06
were O 0 3.270092179263884e-07
all O 0 7.003104229852397e-08
found O 0 1.1248215514569893e-07
to O 0 5.023504812129431e-08
have O 0 3.4592783748621514e-08
a O 0 2.9325866535145906e-07
novel O 0 1.4944943131922628e-06
missense O 0 8.447720574622508e-06
mutation O 0 1.5389758800665732e-06
( O 0 6.13312920449971e-07
G1758 O 0 0.0001500810612924397
- O 0 5.539275662158616e-05
- O 0 7.174092024797574e-05
> O 0 1.955779043782968e-05
T O 0 0.00011544125300133601
) O 0 1.6171854611002345e-07
encoding O 0 1.8798971268552123e-07
the O 0 2.0554352886392735e-07
amino O 0 3.814020885783975e-07
acid O 0 1.6769989770182292e-06
substitution O 0 5.821839749842184e-06
Gly23 O 0 0.015200864523649216
- O 0 0.0004067341797053814
- O 0 0.0004959054640494287
> O 0 0.00021092608221806586
Val O 0 0.008880777284502983
within O 0 4.159550735494122e-05
NPII O 1 0.9990493655204773
. O 0 0.00010002393537433818

The O 0 9.391562343807891e-05
mutation O 0 3.585189188015647e-05
was O 0 2.259861139464192e-05
confirmed O 0 2.1280125110934023e-06
by O 0 1.0336536888644332e-06
restriction O 0 4.947669367538765e-06
endonuclease O 0 9.088520891964436e-05
analysis O 0 1.4459064914262854e-05
. O 0 1.8986827853950672e-05

A O 0 0.0014908511657267809
T1 O 1 0.9787089228630066
- O 0 7.270165224326774e-05
weighted O 0 1.2009532838419545e-05
magnetic O 0 3.096169893979095e-05
resonance O 0 1.914013955683913e-05
imaging O 0 5.9654292272171006e-05
of O 0 5.645569672196871e-06
the O 0 1.722877823340241e-05
fathers O 0 0.17419831454753876
pituitary O 1 0.9999916553497314
gland O 1 0.9996836185455322
demonstrates O 0 0.00010602883412502706
an O 0 2.0151839635218494e-05
attenuated O 0 0.2950800955295563
posterior O 0 0.0068190572783350945
pituitary O 1 0.9983088970184326
bright O 0 0.02493763156235218
spot O 0 0.0016819927841424942
. O 0 0.0001899659400805831

This O 0 2.0198824131512083e-05
mutation O 0 7.529748927481705e-06
may O 0 6.883742571517359e-07
be O 0 1.0696641794538664e-07
valuable O 0 1.0665426088962704e-06
for O 0 1.821603490270718e-07
developing O 0 1.0881863090617117e-06
models O 0 2.1285584352881415e-06
of O 0 1.4104608453635592e-05
dominantly B-Disease 1 0.9999939203262329
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 1.3427782505459618e-05
as O 0 6.941398851267877e-07
the O 0 2.617254324377427e-07
early O 0 1.303591034229612e-06
age O 0 1.1387410268071108e-06
of O 0 1.6792251926744939e-06
onset O 1 0.892052173614502
of O 0 0.044090211391448975
symptoms O 1 0.9982039928436279
suggests O 0 3.952839506382588e-06
that O 0 9.460770655778106e-08
this O 0 1.5891916405053053e-07
mutation O 0 7.556736250080576e-07
may O 0 2.712600064569415e-07
be O 0 9.621053465025398e-08
particularly O 0 3.7380075923465483e-07
deleterious O 0 3.5494251733325655e-06
to O 0 6.739040259162721e-07
the O 0 6.1640230342163704e-06
magnocellular O 1 0.7661534547805786
neuron O 0 0.0006293992046266794
. O 0 1.9881465050275438e-05
. O 0 2.0913914340781048e-05

Frequent O 0 0.00037515274016186595
inactivation O 0 0.0029865324031561613
of O 0 0.000988208339549601
PTEN O 1 0.9999958276748657
/ O 1 0.6681077480316162
MMAC1 O 1 0.9999222755432129
in O 0 0.00014133100921753794
primary O 1 0.9999648332595825
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00043742425623349845

Sporadic B-Disease 1 0.9999864101409912
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 2.3222928575705737e-05
the O 0 6.176869192131562e-06
most O 0 1.2343118669377873e-06
common O 0 3.864588052238105e-06
male B-Disease 0 0.00015595857985317707
cancer I-Disease 1 0.789724588394165
in O 0 5.536811045203649e-07
the O 0 8.506937092533917e-07
Western O 0 5.3004041546955705e-06
world O 0 8.5981764641474e-06
, O 0 2.6788609375216765e-07
yet O 0 7.273344948544036e-08
many O 0 1.8313066618702578e-08
of O 0 1.904530790852732e-07
the O 0 3.310794625122071e-07
major O 0 4.500285285757855e-06
genetic O 0 1.9674707800731994e-06
events O 0 5.257202815300843e-07
involved O 0 4.3956413264822913e-07
in O 0 2.7470267127682746e-07
the O 0 9.930024589266395e-07
progression O 0 4.440340489964001e-05
of O 0 4.5439114728651475e-06
this O 0 1.0014227882493287e-06
often O 0 5.579365733865416e-06
fatal O 1 0.9999812841415405
cancer B-Disease 1 0.9982556700706482
remain O 0 2.582109118520748e-06
to O 0 1.2431186178218923e-06
be O 0 2.8218678380653728e-06
elucidated O 0 0.0009003968443721533
. O 0 5.5919204896781594e-05

Numerous O 0 0.00031367174233309925
cytogenetic O 0 0.013749702833592892
and O 0 3.235607800888829e-05
allelotype O 0 0.021169057115912437
studies O 0 3.885251771862386e-06
have O 0 1.5657327878670912e-07
reported O 0 1.0994616559401038e-06
frequent O 0 1.9709939351741923e-06
loss O 0 2.647427754709497e-05
of O 0 3.342961281305179e-05
heterozygosity O 1 0.9976639747619629
on O 0 6.881935405544937e-05
chromosomal O 0 0.07085634022951126
arm O 1 0.5735515356063843
10q O 1 0.637475311756134
in O 0 7.913751323940232e-05
sporadic B-Disease 1 0.9998581409454346
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003142341738566756

Deletion O 0 0.00021188736718613654
mapping O 0 5.8297438954468817e-05
studies O 0 9.322710866399575e-06
have O 0 7.508392059207836e-07
unambiguously O 0 1.354320647806162e-05
identified O 0 2.291666532983072e-06
a O 0 9.850136848399416e-07
region O 0 1.19374215046264e-06
of O 0 6.289950306381797e-06
chromosome O 0 9.932620741892606e-06
10q23 O 0 0.00013146833225619048
to O 0 3.124375496099674e-07
be O 0 1.8116729449957347e-07
the O 0 4.449216532975697e-07
minimal O 0 3.721425855474081e-06
area O 0 4.667731445806567e-06
of O 0 9.676208719611168e-06
loss O 0 0.002821681322529912
. O 0 5.896248694625683e-05

A O 0 0.0002016097423620522
new O 0 3.927683792426251e-05
tumor B-Disease 1 0.6939738988876343
suppressor O 0 0.0008158237906172872
gene O 0 2.68142503045965e-05
, O 0 1.4208778338797856e-05
PTEN O 1 0.9999626874923706
/ O 0 0.023721951991319656
MMAC1 O 1 0.9999675750732422
, O 0 6.0407032833609264e-06
was O 0 1.7723230484989472e-05
isolated O 0 3.836957148450892e-06
recently O 0 1.4830566215096042e-06
at O 0 9.869667110251612e-07
this O 0 4.0624819064305484e-08
region O 0 2.4816890231704747e-07
of O 0 1.0518215276533738e-06
chromosome O 0 7.19016225048108e-06
10q23 O 0 0.00023754648282192647
and O 0 7.7186291491671e-07
found O 0 3.157113042107085e-07
to O 0 7.337511220839588e-08
be O 0 1.1137927202753417e-07
inactivated O 0 1.2204262930026744e-05
by O 0 2.2957475209750555e-07
mutation O 0 6.470274911407614e-07
in O 0 6.016620659465843e-07
three O 0 4.635099685401656e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.10319909453392029
lines O 0 5.672613042406738e-05
. O 0 2.6399249691166915e-05

We O 0 4.374225318315439e-05
screened O 0 0.0002624887565616518
80 O 0 0.0006936791469343007
prostate B-Disease 1 0.9999997615814209
tumors I-Disease 1 0.9999603033065796
by O 0 2.1592800294456538e-06
microsatellite O 0 2.7953250537393615e-05
analysis O 0 1.2872087609139271e-06
and O 0 1.5488823237319593e-06
found O 0 2.8834690510848304e-06
chromosome O 0 2.1397015643742634e-06
10q23 O 0 2.2662798073724844e-05
to O 0 2.647842904934805e-07
be O 0 2.526444973227626e-07
deleted O 0 2.395341880401247e-06
in O 0 7.631942366970179e-07
23 O 0 7.938257112982683e-06
cases O 0 4.615555099007906e-06
. O 0 2.2981508664088324e-05

We O 0 1.305657860939391e-05
then O 0 3.6082235510548344e-06
proceeded O 0 2.4428813958365936e-06
with O 0 8.95304168579969e-08
sequence O 0 7.258419998379395e-08
analysis O 0 1.2021811812701344e-07
of O 0 4.5143576699047117e-07
the O 0 2.8319022931100335e-06
entire O 0 0.0007153384503908455
PTEN O 1 0.9999995231628418
/ O 1 0.5380063056945801
MMAC1 O 1 0.9999369382858276
coding O 0 1.4905323951097671e-05
region O 0 8.497320891365234e-07
and O 0 2.781008845431643e-07
tested O 0 8.544638490093348e-07
for O 0 1.2959266371126432e-07
homozygous O 0 1.48430876834027e-06
deletion O 0 9.585470479578362e-07
with O 0 2.4773851237114286e-07
new O 0 1.7953573205886642e-06
intragenic O 0 0.034471459686756134
markers O 0 1.4204781109583564e-05
in O 0 5.034117975810659e-07
these O 0 1.4329231134979636e-07
23 O 0 2.1117139112902805e-06
cases O 0 2.461725898683653e-07
with O 0 8.323055453729467e-07
10q23 O 1 0.7506940364837646
loss O 0 0.0735146775841713
of O 0 0.001196966040879488
heterozygosity O 1 0.9999415874481201
. O 0 0.0003054129774682224

The O 0 2.2259167963056825e-05
identification O 0 6.894096713949693e-06
of O 0 3.4998165574506857e-06
the O 0 2.1792413917864906e-06
second O 0 9.830638191488106e-06
mutational O 0 8.093521319096908e-05
event O 0 7.0587625486950856e-06
in O 0 7.797609100634872e-07
10 O 0 9.170635166810825e-07
( O 0 3.6815259818467894e-07
43 O 0 3.0038052045711083e-06
% O 0 1.5055351241244352e-06
) O 0 7.553259820269886e-06
tumors B-Disease 1 0.9999972581863403
establishes O 0 0.02769562602043152
PTEN O 1 0.9999996423721313
/ O 1 0.6247037649154663
MMAC1 O 1 0.998789370059967
as O 0 2.3565282845083857e-06
a O 0 1.5412407492476632e-06
main O 0 3.2598218240309507e-06
inactivation O 0 3.0923991289455444e-05
target O 0 1.274891587854654e-06
of O 0 1.1611066383920843e-06
10q O 0 0.003521408187225461
loss O 0 0.0001723528403090313
in O 0 2.284703077748418e-05
sporadic B-Disease 1 0.9999608993530273
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.457102502579801e-05
. O 0 6.705705891363323e-05

Risk O 0 0.00018965773051604629
reversals O 0 8.366860129171982e-05
in O 0 7.074769200698938e-06
predictive O 0 2.9511405955418013e-05
testing O 0 0.0001491945586167276
for O 0 0.00014711903349962085
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0005064975703135133

The O 0 2.58389536611503e-05
first O 0 5.867367690370884e-06
predictive O 0 9.762586159922648e-06
testing O 0 1.9205102944397368e-05
for O 0 1.975005397980567e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.6802586691919714e-05
HD B-Disease 1 0.8660330176353455
) O 0 3.9870315049483906e-07
was O 0 9.849394473349093e-07
based O 0 7.110362076900856e-08
on O 0 9.352849872357183e-08
analysis O 0 1.4729711494965159e-07
of O 0 1.1028778317268007e-06
linked O 0 6.661584393441444e-06
polymorphic O 0 1.568618245073594e-05
DNA O 0 1.1079802789026871e-05
markers O 0 2.9084383186273044e-06
to O 0 1.733182557472901e-07
estimate O 0 7.467558589269174e-07
the O 0 2.1110906800458906e-07
likelihood O 0 6.378205057444575e-07
of O 0 1.1067510286011384e-06
inheriting O 0 2.637157194840256e-05
the O 0 2.3945560769789154e-06
mutation O 0 3.653319254226517e-06
for O 0 4.950514721713262e-06
HD B-Disease 0 0.008381475694477558
. O 0 4.788017031387426e-05

Limits O 0 2.683673483261373e-05
to O 0 2.0170266452623764e-06
accuracy O 0 4.583289410220459e-06
included O 0 1.5867822185100522e-06
recombination O 0 2.178098611693713e-06
between O 0 3.6025323879584903e-07
the O 0 8.406128131355217e-07
DNA O 0 1.7270744137931615e-05
markers O 0 1.4251280845201109e-05
and O 0 5.392024036154908e-07
the O 0 1.0361288786953082e-06
mutation O 0 2.108449962179293e-06
, O 0 6.669420145044569e-07
pedigree O 0 4.624711436918005e-06
structure O 0 3.6160224681225372e-06
, O 0 4.559359183531342e-07
and O 0 1.4143800797228323e-07
whether O 0 1.364013684224119e-07
DNA O 0 8.181852422239899e-07
samples O 0 2.23420059342061e-07
were O 0 9.874528217324041e-08
available O 0 1.1053801785010364e-07
from O 0 1.0831533927557757e-06
family O 0 4.430422450241167e-06
members O 0 2.154637513740454e-06
. O 0 1.8368224118603393e-05

With O 0 1.2370797776384279e-05
direct O 0 5.039492407377111e-06
tests O 0 4.012438239442417e-06
for O 0 2.9603688744828105e-07
the O 0 2.6535863071330823e-06
HD B-Disease 1 0.9155462980270386
mutation O 0 1.6031839322749875e-06
, O 0 1.9090404634880542e-07
we O 0 3.759633315780775e-08
have O 0 8.240236049061878e-09
assessed O 0 2.276767645525979e-07
the O 0 1.1240816633062423e-07
accuracy O 0 4.790646812580235e-07
of O 0 3.7422060472636076e-07
results O 0 2.626079833589756e-07
obtained O 0 2.814939534800942e-07
by O 0 1.446830566464996e-07
linkage O 0 2.8550905426527606e-06
approaches O 0 1.1661270491458708e-06
when O 0 3.6951459492229333e-07
requested O 0 3.174400546868128e-07
to O 0 1.1262610399853656e-07
do O 0 8.484042979262085e-08
so O 0 4.499958095038892e-08
by O 0 9.227239416986777e-08
the O 0 6.248048975976417e-07
test O 0 5.2802129175688606e-06
individuals O 0 1.272132180929475e-06
. O 0 1.8216333046439104e-05

For O 0 1.469503877160605e-05
six O 0 2.5642393666203134e-06
such O 0 5.066546577836561e-07
individuals O 0 4.073764614531683e-07
, O 0 8.815463274913782e-07
there O 0 1.0612645837682066e-06
was O 0 1.813663220673334e-05
significant O 0 2.317950475116959e-06
disparity O 0 1.1985402124992106e-05
between O 0 1.5751892306070658e-06
the O 0 7.849666872061789e-06
tests O 0 4.606167567544617e-05
. O 0 2.170613151974976e-05

Three O 0 2.6036268536699936e-05
went O 0 3.6417706724023446e-05
from O 0 4.074144271726254e-06
a O 0 2.883864908653777e-06
decreased O 0 2.653088995430153e-05
risk O 0 1.1173891607541009e-06
to O 0 7.359530229678057e-08
an O 0 1.4152138305689732e-07
increased O 0 5.679762580257375e-07
risk O 0 7.41389897029876e-07
, O 0 1.8269568613504816e-07
while O 0 1.7539774432862032e-07
in O 0 9.806770862041958e-08
another O 0 2.9055530603727675e-07
three O 0 2.31764005320656e-07
the O 0 2.2343656382872723e-06
risk O 0 1.845645601861179e-05
was O 0 0.0001939625944942236
decreased O 0 0.0001879588235169649
. O 0 2.8736038075294346e-05

Knowledge O 0 0.00012608635006472468
of O 0 1.6684960428392515e-05
the O 0 7.0633486757287756e-06
potential O 0 2.3444190446753055e-06
reasons O 0 6.713555080750666e-07
for O 0 7.508034371994654e-08
these O 0 2.4358289607562256e-08
changes O 0 5.668637470535032e-08
in O 0 1.4639732626164914e-07
results O 0 2.1269849526106555e-07
and O 0 1.930066844124667e-07
impact O 0 1.0943389270323678e-06
of O 0 7.686960543651367e-07
these O 0 1.7089178072637878e-07
risk O 0 1.0140544191017398e-06
reversals O 0 4.245539003022714e-06
on O 0 1.5042031691336888e-06
both O 0 4.524580958786828e-07
patients O 0 8.156112585311348e-07
and O 0 1.6829000060170074e-07
the O 0 1.1089209692727309e-06
counseling O 0 1.8239192286273465e-05
team O 0 4.323312623455422e-06
can O 0 1.0884234313834895e-07
assist O 0 4.6470105985463306e-07
in O 0 1.4406099069219636e-07
the O 0 2.8738088531099493e-07
development O 0 6.048175578143855e-07
of O 0 1.1853541082018637e-06
strategies O 0 8.066650707405643e-07
for O 0 3.134887549549603e-07
the O 0 1.5608397916366812e-06
prevention O 0 0.00012504075129982084
and O 0 5.684878487954848e-07
, O 0 3.334735083626583e-07
where O 0 1.888914908931838e-07
necessary O 0 3.1417354762197647e-07
, O 0 2.658941582467378e-07
management O 0 1.524784693174297e-06
of O 0 2.294023715876392e-06
a O 0 1.6834711686897208e-06
risk O 0 1.7687706304059247e-06
reversal O 0 1.7814094235291122e-06
in O 0 2.011320532346872e-07
any O 0 2.657717175225116e-07
predictive O 0 5.263049388304353e-06
testing O 0 1.2503018297138624e-05
program O 0 5.597710242000176e-06
. O 0 2.663677605596604e-06
. O 0 1.0496406503079925e-05

A O 0 0.0005085972370579839
novel O 0 9.406512981513515e-05
common O 0 1.7912692783284e-05
missense O 0 8.708154928172007e-05
mutation O 0 8.738832548260689e-06
G301C O 0 6.746782310074195e-05
in O 0 1.3681204791282653e-06
the O 0 1.689157784312556e-06
N O 0 2.9322132832021452e-05
- O 0 3.1579274946125224e-05
acetylgalactosamine O 0 0.0007210259209387004
- O 0 6.764982390450314e-05
6 O 0 6.573169230250642e-05
- O 0 9.985068027162924e-05
sulfate O 0 0.00028345308965072036
sulfatase O 0 0.06644141674041748
gene O 0 3.288258449174464e-05
in O 0 2.894305180234369e-05
mucopolysaccharidosis B-Disease 1 0.9996182918548584
IVA I-Disease 1 0.9999996423721313
. O 0 0.0005079182446934283

Mucopolysaccharidosis B-Disease 1 0.9999538660049438
IVA I-Disease 1 0.9999998807907104
( O 0 0.002743363380432129
MPS B-Disease 1 0.9999990463256836
IVA I-Disease 1 1.0
) O 0 5.5791788327042013e-05
is O 0 2.5012056994455634e-06
an O 0 3.5252510315331165e-06
autosomal B-Disease 1 0.9660255908966064
recessive I-Disease 1 0.9999897480010986
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9995651841163635
by O 0 3.31146948155947e-05
a O 0 0.00013517205661628395
genetic B-Disease 1 0.9990424513816833
defect I-Disease 1 0.9993460774421692
in O 0 5.974542546027806e-06
N O 0 0.00017478900554124266
- O 0 5.632815009448677e-05
acetylgalactosamine O 0 0.002359541831538081
- O 0 7.403401104966179e-05
6 O 0 8.815222827252e-05
- O 0 0.00019944786617998034
sulfate O 0 0.005380154121667147
sulfatase O 1 0.9991104006767273
( O 0 0.0002466955338604748
GALNS O 1 0.9999908208847046
) O 0 0.00010634862701408565
. O 0 6.589661643374711e-05

In O 0 2.5583975002518855e-05
previous O 0 1.1171418918820564e-05
studies O 0 6.438350283133332e-06
, O 0 8.952193297773192e-07
we O 0 1.705950865016348e-07
have O 0 4.2189341797893576e-08
found O 0 1.3433827916742302e-07
two O 0 5.46081082575256e-08
common O 0 3.627353919455345e-07
mutations O 0 7.055485866658273e-07
in O 0 7.785192792653106e-07
Caucasians O 0 1.7978563846554607e-05
and O 0 1.9816334315692075e-06
Japanese O 0 7.938966882647946e-05
, O 0 5.382671588449739e-06
respectively O 0 1.532943861093372e-05
. O 0 1.7290503819822334e-05

To O 0 2.939781370514538e-05
characterize O 0 0.00011437435750849545
the O 0 9.74149315879913e-06
mutational O 0 0.00020829377172049135
spectrum O 0 7.993120561877731e-06
in O 0 3.160791663958662e-07
various O 0 1.1900259266894864e-07
ethnic O 0 7.658848488745207e-08
groups O 0 5.265551905608845e-08
, O 0 1.1589422399538307e-07
mutations O 0 1.3409048449375405e-07
in O 0 1.8351360608903633e-07
the O 0 1.3113442491885507e-06
GALNS O 1 0.999165415763855
gene O 0 3.384832098163315e-06
in O 0 1.3036707287028548e-06
Colombian O 0 5.147832780494355e-05
MPS B-Disease 1 0.9999973773956299
IVA I-Disease 1 1.0
patients O 0 0.00016267278988379985
were O 0 1.8902478586824145e-06
investigated O 0 1.698576488706749e-05
, O 0 6.066690048101009e-07
and O 0 3.1577576464769663e-07
genetic O 0 9.34405647967651e-07
backgrounds O 0 3.8220312603698403e-07
were O 0 2.8366031301629846e-07
extensively O 0 2.313871164005832e-06
analyzed O 0 5.293531444294786e-07
to O 0 6.890680026572227e-08
identify O 0 3.4612523336363665e-07
racial O 0 9.594707535143243e-07
origin O 0 3.32369580746672e-07
, O 0 2.2122985399164463e-07
based O 0 4.442005092641921e-07
on O 0 1.0784541473185527e-06
mitochondrial O 0 4.165758582530543e-06
DNA O 0 2.2662517949356697e-05
( O 0 2.9846532925148495e-06
mtDNA O 0 1.4493411072180606e-05
) O 0 5.242985935183242e-06
lineages O 0 3.4491895348764956e-05
. O 0 2.2933038053452037e-05

Three O 0 3.8111753383418545e-05
novel O 0 6.262718670768663e-05
missense O 0 0.00018767551227938384
mutations O 0 1.282546691072639e-05
never O 0 4.345833531260723e-06
identified O 0 1.137073127210897e-06
previously O 0 1.119974172070215e-06
in O 0 1.047639415219237e-07
other O 0 6.23269471589083e-08
populations O 0 8.591273825686585e-08
and O 0 9.860976746267625e-08
found O 0 2.987777918406209e-07
in O 0 1.660863659935785e-07
16 O 0 9.550020649840008e-07
out O 0 3.657760316855274e-07
of O 0 1.6045024722188828e-06
19 O 0 1.3203619346313644e-05
Colombian O 0 6.827256584074348e-05
MPS B-Disease 1 0.9992415904998779
IVA I-Disease 1 1.0
unrelated O 0 0.00010549473518040031
alleles O 0 3.9545889194414485e-06
account O 0 1.6247105349975755e-06
for O 0 5.871979738003574e-06
84 O 0 0.0003061917086597532
. O 0 8.279908797703683e-05

2 O 0 8.501476258970797e-05
% O 0 4.323741450207308e-06
of O 0 1.7101874618674628e-06
the O 0 1.7080848238038016e-06
alleles O 0 1.0699820904847002e-06
in O 0 8.085806371127546e-07
this O 0 1.1001801567545044e-06
study O 0 1.3104793652018998e-05
. O 0 2.2244928914005868e-05

The O 0 0.0001396266306983307
G301C O 0 0.008719912730157375
and O 0 5.204548506299034e-05
S162F O 0 0.001648828387260437
mutations O 0 6.800224582548253e-06
account O 0 3.5734583434532396e-06
for O 0 6.295939783740323e-06
68 O 0 0.0004299299616832286
. O 0 7.807796646375209e-05

4 O 0 0.00022429443197324872
% O 0 2.2121108486317098e-05
and O 0 1.1375362191756722e-05
10 O 0 5.5743716075085104e-05
. O 0 6.918072904227301e-05

5 O 0 4.667897883336991e-05
% O 0 2.4874852897482924e-06
of O 0 2.5142039703496266e-06
mutations O 0 1.3319859135663137e-06
, O 0 1.072971940629941e-06
respectively O 0 2.285520395162166e-06
, O 0 5.512106895366742e-07
whereas O 0 5.797644462290918e-07
the O 0 7.449292525052442e-07
remaining O 0 1.4945064322091639e-05
F69V O 1 0.9984310269355774
is O 0 1.4408755077965907e-06
limited O 0 4.338245389590156e-07
to O 0 2.454842729093798e-07
a O 0 2.2523281586472876e-06
single O 0 7.945240213302895e-06
allele O 0 1.2860054994234815e-05
. O 0 1.4442058272834402e-05

The O 0 8.96044512046501e-05
skewed O 0 7.091856241459027e-05
prevalence O 0 5.590154978563078e-05
of O 0 1.2576683730003424e-05
G301C O 0 0.00273201335221529
in O 0 1.9337530829943717e-06
only O 0 8.641989097668556e-07
Colombian O 0 1.1242525033594575e-05
patients O 0 2.992742338392418e-06
and O 0 7.955301271067583e-07
haplotype O 0 4.145645561948186e-06
analysis O 0 3.867113491651253e-07
by O 0 2.1606797417916823e-07
restriction O 0 6.477670808635594e-07
fragment O 0 2.7570679321797797e-06
length O 0 2.3274699856301595e-07
polymorphisms O 0 3.591908068756311e-07
in O 0 2.0920627719078766e-07
the O 0 9.081496159524249e-07
GALNS O 1 0.9972358345985413
gene O 0 1.7688482785160886e-06
suggest O 0 2.6747889592115826e-07
that O 0 1.3269014687011804e-07
G301C O 0 1.9761715520871803e-05
originated O 0 2.4697781100258e-06
from O 0 1.5161684814302134e-06
a O 0 1.739443064252555e-06
common O 0 5.972429335088236e-06
ancestor O 0 0.00020618425332941115
. O 0 5.862116449861787e-05

Investigation O 0 7.660334085812792e-05
of O 0 2.191186649724841e-05
the O 0 6.727451363985892e-06
genetic O 0 8.723047358216718e-06
background O 0 1.8253630287290434e-06
by O 0 6.026762662258989e-07
means O 0 4.629144996215473e-07
of O 0 1.1720371730916668e-06
mtDNA O 0 2.719502845138777e-06
lineages O 0 1.0070762073155493e-06
indicate O 0 3.9926973727233417e-07
that O 0 4.139084452958741e-08
all O 0 1.307668497929626e-07
our O 0 7.47117042010359e-07
patients O 0 6.35081278232974e-07
are O 0 3.4986200603270845e-08
probably O 0 4.567279745515407e-07
of O 0 2.0820266399823595e-06
native O 0 1.819126555346884e-05
American O 0 0.00010908711556112394
descent O 0 0.0004722904122900218

Low O 0 7.015197479631752e-05
frequency O 0 1.393482307321392e-05
of O 0 1.513774896011455e-05
BRCA1 O 0 0.00011124605225631967
germline O 0 5.964177762507461e-05
mutations O 0 2.014911842707079e-06
in O 0 1.092504817279405e-06
45 O 0 2.007590046559926e-05
German O 1 0.9999943971633911
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.511753549100831e-05
. O 0 0.00012539452291093767

In O 0 1.6394644262618385e-05
this O 0 1.5816862060091808e-06
study O 0 1.5673762163714855e-06
we O 0 2.034637276437934e-07
investigated O 0 3.7659171994164353e-06
45 O 0 6.383410891430685e-06
German O 1 0.9999581575393677
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.51323432521167e-07
for O 0 1.0208544836132205e-06
germline O 0 8.764839731156826e-05
mutations O 0 1.474397777201375e-06
in O 0 6.55631026802439e-07
the O 0 7.884013029979542e-06
BRCA1 O 0 0.004058859311044216
gene O 0 4.2620464228093624e-05
. O 0 2.0814406525460072e-05

We O 0 1.4782535799895413e-05
identified O 0 7.28180248188437e-06
four O 0 2.4880259843484964e-06
germline O 0 7.385912613244727e-05
mutations O 0 2.119530108757317e-06
in O 0 1.504016836406663e-06
three O 0 6.18759986537043e-06
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9995056390762329
families O 0 2.070932083597654e-07
and O 0 3.6622736843128223e-07
in O 0 9.462184493713721e-07
one O 0 2.5590854420443065e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.6706351491156965e-05
. O 0 2.5488449750810105e-07
among O 0 6.319806544752282e-08
these O 0 2.76681824118441e-08
were O 0 3.4338449950155336e-07
one O 0 5.433915362118569e-07
frameshift O 0 1.81001396413194e-05
mutation O 0 8.750865276851982e-07
, O 0 3.7911416939095943e-07
one O 0 4.1916632653737906e-07
nonsense O 0 1.2949401934747584e-05
mutation O 0 1.6498302102263551e-06
, O 0 2.919738903983671e-07
one O 0 3.0776502057960897e-07
novel O 0 1.8282898963661864e-06
splice O 0 5.0248167099198326e-05
site O 0 2.3172709916252643e-05
mutation O 0 1.7460944263802958e-06
, O 0 4.656273233649699e-07
and O 0 1.116785142585286e-06
one O 0 4.727894520328846e-06
missense O 0 0.0002580423606559634
mutation O 0 4.742528835777193e-05
. O 0 4.33536697528325e-05

The O 0 6.50939327897504e-05
missense O 0 0.00023827713448554277
mutation O 0 1.7195017790072598e-05
was O 0 1.969580989680253e-05
also O 0 1.2814239198633004e-06
found O 0 1.5504873545069131e-06
in O 0 2.8440217647585087e-06
2 O 0 3.69979243259877e-05
. O 0 2.84376601484837e-05

8 O 0 0.00010054530139314011
% O 0 4.0096379052556586e-06
of O 0 1.4904009049132583e-06
the O 0 6.160728958093387e-07
general O 0 1.4395458265425987e-06
population O 0 1.2562371409785555e-07
, O 0 2.2190201320881897e-07
suggesting O 0 4.7462310703849653e-07
that O 0 4.5295031725345325e-08
it O 0 2.512669539100898e-07
is O 0 4.0375743992626667e-07
not O 0 9.092693176171451e-07
disease O 0 0.15852698683738708
associated O 0 1.9617582438513637e-05
. O 0 3.901004674844444e-05

The O 0 4.216421802993864e-05
average O 0 1.4082967936701607e-05
age O 0 2.8737273169099353e-05
of O 0 0.0005594901158474386
disease O 1 0.99997878074646
onset O 1 0.9923690557479858
in O 0 3.88878834201023e-06
those O 0 1.0165942967432784e-06
families O 0 1.7152869986603037e-06
harbouring O 1 0.8833819031715393
causative O 0 0.007271350361406803
mutations O 0 1.5274308680091053e-05
was O 0 5.3356419812189415e-05
between O 0 9.495255653746426e-06
32 O 0 7.481724605895579e-05
. O 0 2.902459164033644e-05

3 O 0 0.0004954938776791096
and O 0 7.182361150626093e-05
37 O 0 0.0005703622009605169
. O 0 0.00011937729141209275

4 O 0 0.00010085220128530636
years O 0 1.0341355846321676e-05
, O 0 1.5991802229109453e-06
whereas O 0 1.026475615617528e-06
the O 0 1.1799415915447753e-06
family O 0 8.934428478823975e-06
harbouring O 0 0.041540492326021194
the O 0 6.974709776841337e-06
missense O 0 4.028202238259837e-05
mutation O 0 1.4155527878756402e-06
had O 0 3.990112702467741e-07
an O 0 1.3700773138225486e-07
average O 0 7.3988826443383e-07
age O 0 1.734301463329757e-06
of O 0 3.6668204757006606e-06
onset O 0 0.017931461334228516
of O 0 0.00042054374353028834
51 O 0 0.001159665989689529
. O 0 0.00013639795361086726

2 O 0 0.0007373712141998112
years O 0 0.00027653228607960045
. O 0 0.0001503142120782286

These O 0 5.554043127631303e-06
findings O 0 4.883507699560141e-06
show O 0 3.5460518574836897e-06
that O 0 8.392447057303798e-07
BRCA1 O 0 4.9974110879702494e-05
is O 0 9.028087220031011e-07
implicated O 0 9.468780262977816e-06
in O 0 6.541769721479795e-07
a O 0 4.022818984594778e-07
small O 0 4.89477770315716e-07
fraction O 0 3.970324542024173e-06
of O 0 0.00017810921417549253
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.1819524199127045e-07
suggesting O 0 1.0996147921105148e-06
the O 0 3.232462688629312e-07
involvement O 0 1.739171011649887e-06
of O 0 3.4963368307217024e-06
another O 0 2.150175532733556e-05
susceptibility O 0 0.0019321542931720614
gene O 0 5.596075425273739e-05
( O 0 3.1547664548270404e-05
s O 0 0.0004916571779176593
) O 0 0.00014859484508633614

Paternal O 0 0.022041471675038338
transmission O 1 0.774891197681427
of O 1 0.999984860420227
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999772310256958

We O 0 2.2137000996735878e-05
report O 0 8.19186789158266e-06
a O 0 4.472300133784302e-06
rare O 0 4.419910055730725e-06
case O 0 4.702927981270477e-06
of O 0 0.00011656177957775071
paternally O 1 0.9999991655349731
transmitted O 1 0.9999992847442627
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
DM B-Disease 1 1.0
) O 0 0.08905211091041565
. O 0 0.0002690283872652799

The O 0 9.379212860949337e-05
proband O 0 0.00239722547121346
is O 0 2.3017112198431278e-06
a O 0 2.225336402261746e-06
23 O 0 7.882764293754008e-06
year O 0 4.0195154724642634e-06
old O 0 0.013882910832762718
, O 0 0.0001173295677290298
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999959468841553
male O 0 0.026858385652303696
who O 0 0.19814333319664001
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9613355398178101

He O 0 0.00019118888303637505
presented O 0 0.00012199391494505107
with O 0 9.962546027963981e-05
respiratory O 1 0.9999990463256836
and O 0 0.00021287555864546448
feeding O 0 0.12126941233873367
difficulties O 0 0.020439032465219498
at O 0 0.17017962038516998
birth O 0 0.004169209394603968
. O 0 5.661464456352405e-05

His O 0 0.000642252853140235
two O 0 7.127450953703374e-05
sibs O 1 0.999907374382019
suffer O 0 0.022138679400086403
from O 0 0.0007166058057919145
childhood O 1 0.9999979734420776
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.010893220081925392

Their O 0 2.3075150238582864e-05
late O 0 6.352976197376847e-05
father O 0 6.149764521978796e-05
had O 0 4.134503342356766e-06
the O 0 7.658394451937056e-07
adult O 0 8.214376521209488e-07
type O 0 9.289243280363735e-06
of O 0 0.00017989313346333802
DM B-Disease 1 1.0
, O 0 1.022489414026495e-05
with O 0 9.62638296186924e-07
onset O 0 0.0015371894696727395
around O 0 5.129020792082883e-06
30 O 0 5.652238542097621e-06
years O 0 5.804842203360749e-06
. O 0 1.377157423121389e-05

Only O 0 1.1099273251602426e-05
six O 0 2.0497539026109735e-06
other O 0 2.9085165920150757e-07
cases O 0 4.3643470348797564e-07
of O 0 7.070667834341293e-06
paternal O 0 0.001867487677372992
transmission O 1 0.587604820728302
of O 1 0.9999730587005615
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.787392102414742e-05
been O 0 1.1900267054443248e-05
reported O 0 1.5882184015936218e-05
recently O 0 7.868076500017196e-05
. O 0 2.0448534996830858e-05

We O 0 1.1097420610894915e-05
review O 0 4.713784619525541e-06
the O 0 1.3192819778851117e-06
sex O 0 1.3330419506019098e-06
related O 0 2.444307256155298e-06
effects O 0 1.6911348211579025e-05
on O 0 1.2455273463274352e-05
transmission O 0 0.0007671114290133119
of O 1 0.9484429359436035
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.2258574664592743

Decreased O 0 0.0005136989057064056
fertility O 0 0.0002500686969142407
of O 0 9.935349225997925e-06
males O 0 9.037709673975769e-07
with O 0 4.2967209878952417e-07
adult O 0 2.1483921955223195e-05
onset O 1 0.9999949932098389
DM B-Disease 1 1.0
and O 0 5.882163895876147e-05
contraction O 0 8.120548591250554e-05
of O 0 2.0108461740164785e-06
the O 0 1.2015499351036851e-06
repeat O 0 3.047635345865274e-06
upon O 0 1.7826874909587787e-06
male O 0 3.5299740375194233e-06
transmission O 0 2.337591922696447e-06
contribute O 0 2.1754883050562057e-07
to O 0 1.2182269415461633e-07
the O 0 3.8305006455630064e-07
almost O 0 6.423285299206327e-07
absent O 0 2.1284142803779105e-06
occurrence O 0 1.1085784308306756e-06
of O 0 1.961603402378387e-06
paternal O 0 6.35992328170687e-05
transmission O 0 0.0007000059704296291
of O 1 0.8786808848381042
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.373965322971344

Also O 0 1.1583921150304377e-05
the O 0 5.603703357337508e-06
fathers O 0 6.545691121573327e-06
of O 0 3.6703504520119168e-06
the O 0 5.827417226100806e-06
reported O 0 3.482817919575609e-05
congenitally O 0 0.008918562904000282
affected O 0 3.355907665536506e-06
children O 0 1.320845512964297e-06
showed O 0 2.66110805569042e-06
, O 0 3.660625225165859e-07
on O 0 5.376142553359387e-07
average O 0 1.1440017715358408e-06
, O 0 1.3044765410086256e-06
shorter O 0 2.1376219592639245e-05
CTG O 1 0.9978613257408142
repeat O 0 3.299981835880317e-05
lengths O 0 1.721462467685342e-05
and O 0 1.017378963297233e-06
hence O 0 2.0673044218710857e-06
less O 0 1.8821748426489648e-06
severe O 1 0.5995669960975647
clinical O 1 0.9978141784667969
symptoms O 0 0.0038906256668269634
than O 0 6.445529265874939e-07
the O 0 2.615647417769651e-06
mothers O 0 2.1311968794179847e-06
of O 0 1.2673353921854869e-05
children O 0 8.502369018970057e-05
with O 0 0.14882220327854156
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9871277809143066

We O 0 2.0875597328995354e-05
conclude O 0 2.355313154112082e-05
that O 0 1.6721841120670433e-06
paternal O 0 5.992065416648984e-05
transmission O 0 0.00042496787500567734
of O 1 0.9979368448257446
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.006881257984787226
rare O 0 6.355618097586557e-05
and O 0 1.8211480892205145e-06
preferentially O 0 7.505473604396684e-06
occurs O 0 7.251486522363848e-07
with O 0 2.3267377002866851e-07
onset O 0 0.00021928141359239817
of O 0 0.0005169443902559578
DM B-Disease 1 1.0
past O 0 2.019624298554845e-05
30 O 0 3.65991013495659e-06
years O 0 6.173968358780257e-07
in O 0 4.6596537117693515e-07
the O 0 1.895996433631808e-06
father O 0 7.515046308981255e-05
. O 0 9.607365427655168e-06
. O 0 1.994896592805162e-05

The O 0 0.0002912300988100469
RB1 O 1 0.9990361928939819
gene O 0 2.491243321856018e-05
mutation O 0 3.003364327014424e-06
in O 0 9.75319380813744e-07
a O 0 5.666325250786031e-06
child O 0 0.00012812761997338384
with O 0 7.70499391364865e-05
ectopic B-Disease 1 0.9999977350234985
intracranial I-Disease 1 0.9999996423721313
retinoblastoma I-Disease 1 0.9999536275863647
. O 0 0.0007564029074274004

The O 0 0.0003836826072074473
RB1 O 1 0.9977548718452454
gene O 0 3.1329105695476755e-05
mutation O 0 7.686824574193452e-06
was O 0 1.1794964848377276e-05
investigated O 0 1.2656360013352241e-05
in O 0 1.2460266134439735e-06
a O 0 3.644685193648911e-06
child O 0 3.374990410520695e-05
with O 0 6.446957740990911e-06
ectopic B-Disease 1 0.9998461008071899
intracranial I-Disease 1 0.9999442100524902
retinoblastoma I-Disease 0 0.0009839845588430762
using O 0 2.578243311290862e-06
DNA O 0 4.1802886698860675e-06
obtained O 0 5.674738190464268e-07
from O 0 3.6723810126204626e-07
both O 0 3.283329306214e-07
the O 0 4.564437858789461e-06
pineal B-Disease 1 0.9999567270278931
and I-Disease 0 0.00014744329382665455
retinal I-Disease 1 0.9999997615814209
tumours I-Disease 1 0.9999998807907104
of O 0 0.000216169428313151
the O 0 0.00033691860153339803
patient O 0 0.0902814269065857
. O 0 7.864910730859265e-05

A O 0 0.00044235147652216256
nonsense O 0 0.00041390256956219673
mutation O 0 1.1184969480382279e-05
in O 0 3.4411498290864984e-06
exon O 0 7.107489363988861e-05
17 O 0 1.6655294530210085e-05
( O 0 2.031821168202441e-06
codon O 0 1.2353551028354559e-05
556 O 0 2.9984363209223375e-05
) O 0 4.1884584334184183e-07
of O 0 1.6187328810701729e-06
the O 0 5.980699825158808e-06
RB1 O 1 0.9999713897705078
gene O 0 8.313667422044091e-06
was O 0 6.447370196838165e-06
found O 0 5.466874881676631e-07
to O 0 1.0216702150955825e-07
be O 0 1.2224583656461618e-07
present O 0 6.08137497692951e-07
homozygously O 0 0.00014204530452843755
in O 0 1.455522010473942e-06
both O 0 8.039900194489746e-07
the O 0 1.0246954843751155e-05
retinal B-Disease 1 0.9994803071022034
and I-Disease 0 1.935807267727796e-05
the I-Disease 0 0.0021668896079063416
pineal I-Disease 1 0.9999998807907104
tumours I-Disease 1 0.9999998807907104
. O 0 0.0004621878906618804

The O 0 3.197165278834291e-05
same O 0 4.682444341597147e-06
mutation O 0 3.836049927485874e-06
was O 0 1.1501078006403986e-05
present O 0 1.998259676838643e-06
heterozygously O 0 0.00010653080971678719
in O 0 5.078688900539419e-07
the O 0 3.449547421041643e-07
DNA O 0 1.6749356746004196e-06
from O 0 2.43727953375128e-07
the O 0 2.562398435657087e-07
constitutional O 0 4.35447702784586e-07
cells O 0 5.774820692749927e-07
of O 0 6.623491231039225e-07
the O 0 1.4700719930260675e-06
patient O 0 1.9706219973159023e-05
, O 0 7.311176659641205e-07
proving O 0 1.692851583356969e-05
it O 0 1.432260603451141e-07
to O 0 8.846879495649773e-08
be O 0 1.252478654123479e-07
of O 0 2.6909515327133704e-06
germline O 0 0.00014990240742918104
origin O 0 1.0770804692583624e-05
. O 0 2.3965043510543182e-05

The O 0 3.956649379688315e-05
initial O 0 2.1798714442411438e-05
mutation O 0 5.555886218644446e-06
was O 0 8.197229362849612e-06
shown O 0 2.8498274673438573e-07
to O 0 1.8936893297905044e-07
have O 0 1.128790003690483e-07
occurred O 0 1.28757835682336e-06
in O 0 9.502562079433119e-07
the O 0 3.3719768453011056e-06
paternally O 0 0.0005045998841524124
derived O 0 0.00014500346151180565
RB1 O 1 0.9949289560317993
allele O 0 0.00010657338862074539
. O 0 4.899981286143884e-05

The O 0 5.713521022698842e-05
mutation O 0 9.968462109100074e-06
is O 0 6.979727231737343e-07
in O 0 3.0205879397726676e-07
an O 0 1.458790279684763e-07
area O 0 8.38580604067829e-07
of O 0 1.0552777212069486e-06
the O 0 9.636422646508436e-07
gene O 0 6.080337016101112e-07
that O 0 4.7517794143914216e-08
encodes O 0 1.9349526780843007e-07
the O 0 3.4223634770569333e-07
protein O 0 4.646194895485678e-07
- O 0 1.727729795675259e-06
binding O 0 4.812379188479099e-07
region O 0 3.4300094853279006e-07
known O 0 5.563333616009913e-07
as O 0 2.823763907144894e-07
the O 0 1.142113774221798e-06
pocket O 0 0.01607145369052887
region O 0 1.0794832405736088e-06
and O 0 3.026674733064283e-07
has O 0 3.042258640562068e-07
been O 0 3.1791572041584004e-07
detected O 0 1.1972445008723298e-06
in O 0 1.366804127655996e-07
other O 0 8.264116502232355e-08
cases O 0 5.473761461871618e-07
of O 0 3.05913963529747e-05
retinoblastoma B-Disease 1 0.8939216136932373
. O 0 3.581420605769381e-05
. O 0 6.233945896383375e-05

Low O 0 8.605002949479967e-05
levels O 0 5.553857590712141e-06
of O 0 9.27144537854474e-06
beta O 0 1.4810869288339745e-05
hexosaminidase O 0 0.0017501083202660084
A O 0 1.298174902331084e-05
in O 0 6.800502205805969e-07
healthy O 0 1.6867044223545236e-06
individuals O 0 1.1736776173165708e-07
with O 0 1.5483033166674431e-06
apparent O 1 0.9945881366729736
deficiency O 1 0.9999995231628418
of O 0 0.1805611550807953
this O 0 4.6551442210329697e-05
enzyme O 0 0.00030334509210661054
. O 0 6.213381129782647e-05

Appreciable O 0 0.002241108100861311
beta O 0 0.00032494563492946327
hexosaminidase O 0 0.028641629964113235
A O 0 0.00041695209802128375
( O 0 8.857465218170546e-06
hex O 0 0.00017495172505732626
A O 0 2.8859431040473282e-05
) O 0 7.099710046531982e-07
activity O 0 4.590462765463599e-07
has O 0 1.9776091164658283e-07
been O 0 4.3417014694568934e-07
detected O 0 4.137706127949059e-06
in O 0 9.404033676219115e-07
cultured O 0 0.021733593195676804
skin O 1 0.9998217225074768
fibroblasts O 0 0.1692865639925003
and O 0 0.00029339155298657715
melanoma B-Disease 1 1.0
tissue O 1 0.9931286573410034
from O 0 1.4396240658243187e-05
healthy O 0 4.027216618851526e-06
individuals O 0 1.2231056700784393e-07
previously O 0 3.4491172300477047e-06
reported O 0 2.3173581666924292e-06
as O 0 2.3939189759403234e-06
having O 0 0.0007439307519234717
deficiency B-Disease 1 0.9994723200798035
of I-Disease 0 0.001133434008806944
hex I-Disease 0 0.20437200367450714
A I-Disease 0 3.680595546029508e-05
activity O 0 1.2964670759174624e-06
indistinguishable O 0 1.8783930499921553e-06
from O 0 2.8686309860859183e-07
that O 0 7.413234470732277e-08
of O 0 1.284262339140696e-06
patients O 0 7.684589036216494e-06
with O 0 3.6983565223636106e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.11315416544675827
TSD B-Disease 1 0.9999997615814209
) O 0 0.00013512618897948414
. O 0 8.731212437851354e-05

Identification O 0 0.0002058628888335079
and O 0 1.7343516446999274e-05
quantitation O 0 0.0013879071921110153
of O 0 9.898722055368125e-05
hex O 0 0.0023683602921664715
A O 0 0.00015174047439359128
, O 0 5.142848294781288e-06
amounting O 0 2.9757471565972082e-05
to O 0 5.2694826990773436e-06
3 O 0 5.666325523634441e-05
. O 0 3.333954373374581e-05

5 O 0 0.00024401565315201879
% O 0 3.3598364097997546e-05
- O 0 0.00026431269361637533
6 O 0 0.00014025245036464185
. O 0 3.894518158631399e-05

9 O 0 0.00010231966734863818
% O 0 2.8658685096161207e-06
of O 0 2.0522907107078936e-06
total O 0 1.1147718623760738e-06
beta O 0 8.438428267254494e-06
hexosaminidase O 0 0.000143960423883982
activity O 0 1.4972533790569287e-06
, O 0 1.6341697062216554e-07
has O 0 1.3556608280396176e-07
been O 0 1.7229056936685083e-07
obtained O 0 4.99879263315961e-07
by O 0 9.792039463718538e-07
cellulose O 0 0.05972704291343689
acetate O 0 0.0007351954118348658
gel O 0 0.00017437548376619816
electrophoresis O 0 5.887427323614247e-05
, O 0 6.641963409492746e-06
DEAE O 0 0.446919709444046
- O 0 3.166083843098022e-05
cellulose O 0 0.00027916915132664144
ion O 0 2.893482451327145e-05
- O 0 1.5978470401023515e-05
exchange O 0 4.561974492389709e-06
chromatography O 0 0.00021233188454061747
, O 0 7.232331881823484e-06
radial O 0 0.00042092177318409085
immunodiffusion O 0 0.005176190286874771
, O 0 1.1656483366095927e-05
and O 0 1.4373797057487536e-05
radioimmunoassay O 0 0.3303253650665283
. O 0 9.27891960600391e-05

Previous O 0 0.00021293503232300282
family O 0 1.6799454897409305e-05
studies O 0 2.1124551494722255e-06
suggested O 0 8.076588642325078e-07
that O 0 6.441577937721377e-08
these O 0 3.3306601920912726e-08
individuals O 0 3.164938533473105e-08
may O 0 1.538267184741926e-07
be O 0 8.5834116703154e-08
compound O 0 5.197844984650146e-06
heterozygotes O 0 2.2809258553024847e-06
for O 0 1.2330583842867782e-07
the O 0 4.852482220485399e-07
common O 0 2.278132342325989e-06
mutant O 0 5.964729280094616e-05
TSD B-Disease 1 0.997349739074707
gene O 0 3.3322919534839457e-06
and O 0 5.337374773262127e-07
a O 0 1.4875695342198014e-06
rare O 0 4.341765361459693e-06
( O 0 3.5733219192479737e-06
allelic O 0 0.00011875546624651179
) O 0 8.2321066656732e-06
mutant O 0 0.0001633402134757489
gene O 0 5.923197386437096e-05
. O 0 3.51964590663556e-05

Thus O 0 4.1562201658962294e-05
, O 0 2.3762543150951387e-06
the O 0 1.0197558140134788e-06
postulated O 0 9.092744221561588e-06
rate O 0 1.2957749504494132e-06
mutant O 0 6.9176876422716305e-06
gene O 0 1.2342142099441844e-06
appears O 0 3.333100835334335e-07
to O 0 3.4325477571428564e-08
code O 0 6.810426356196331e-08
for O 0 5.97507820998544e-08
the O 0 2.397747778104531e-07
expression O 0 2.9155012271075975e-07
of O 0 5.458737177832518e-07
low O 0 2.0992965801269747e-06
amounts O 0 1.0072741361000226e-06
of O 0 2.7198088901059236e-06
hex O 0 0.00025276976521126926
A O 0 0.00012431673530954868
. O 0 3.7562796933343634e-05

Heterozygotes O 0 0.0007609871099703014
for O 0 1.5851526768528856e-05
the O 0 1.215573229274014e-05
rare O 0 2.926489651144948e-05
mutant O 0 4.2849427700275555e-05
may O 0 1.2300532716835733e-06
be O 0 3.3284598544014443e-07
indistinguishable O 0 4.9520776883582585e-06
from O 0 1.1391375664970838e-06
heterozygotes O 0 6.860686426080065e-06
for O 0 8.280350698441907e-07
the O 0 5.655630502587883e-06
common O 0 4.962620005244389e-05
TSD B-Disease 1 0.9999822378158569
mutant O 0 0.0011731425765901804
. O 0 8.524303848389536e-05

However O 0 3.258540527895093e-05
, O 0 2.5070758056244813e-06
direct O 0 1.618391820557008e-06
visualization O 0 3.0478646294795908e-05
and O 0 2.610458977869712e-06
quantitation O 0 0.0008329246193170547
of O 0 2.6655869078240357e-05
hex O 0 0.0003653854364529252
A O 0 1.0697733159759082e-05
by O 0 3.5490862160258985e-07
the O 0 4.417949241997121e-07
methods O 0 1.6947698213698459e-06
described O 0 5.001104455004679e-06
may O 0 5.656163466483122e-07
prevent O 0 1.3417661648418289e-06
false O 0 3.114325636488502e-06
- O 0 8.385187356907409e-06
positive O 0 7.994270845301799e-07
prenatal O 0 2.898547609220259e-05
diagnosis O 0 3.0449537007370964e-05
of O 0 1.0510741049074568e-05
TSD B-Disease 1 0.999994158744812
in O 0 5.807311481476063e-06
fetuses O 0 2.6416675609652884e-05
having O 0 2.445704012643546e-06
the O 0 1.3640791394209373e-06
incomplete O 0 2.600425432319753e-05
hex B-Disease 0 0.22797775268554688
A I-Disease 1 0.7300176620483398
deficiency I-Disease 1 0.9981638789176941
of O 0 3.996237865067087e-05
the O 0 1.2146438166382723e-05
type O 0 3.626128091127612e-05
described O 0 4.2721949284896255e-06
in O 0 6.754798391739314e-07
the O 0 1.8911712231783895e-06
four O 0 1.0061488865176216e-05
healthy O 0 7.771480159135535e-05
individuals O 0 1.6152760508703068e-05

The O 0 0.0003538267919793725
tumor B-Disease 1 0.9902894496917725
suppressor O 0 0.002398398006334901
gene O 0 0.0001369889359921217
Smad4 O 1 0.9994753003120422
/ O 0 0.009525293484330177
Dpc4 O 0 0.03174392506480217
is O 0 4.08453274758358e-07
required O 0 1.236151376815542e-07
for O 0 1.846659927196015e-07
gastrulation O 0 0.0007176446379162371
and O 0 3.6783467294299044e-07
later O 0 1.9128926851408323e-06
for O 0 4.485878548621258e-07
anterior O 0 1.8975424609379843e-05
development O 0 2.0913337266392773e-06
of O 0 8.551970495318528e-06
the O 0 2.3442009478458203e-05
mouse O 0 0.0003904590557795018
embryo O 0 0.00016271173080895096
. O 0 4.9029076762963086e-05

Mutations O 0 9.981897892430425e-05
in O 0 1.4667806681245565e-05
the O 0 5.642949327011593e-05
SMAD4 O 1 0.9999995231628418
/ O 1 0.9977836012840271
DPC4 O 1 0.9999990463256836
tumor B-Disease 1 0.9993973970413208
suppressor O 0 0.00023466258426196873
gene O 0 4.2314927668485325e-06
, O 0 5.885299856345227e-07
a O 0 5.37984533366398e-07
key O 0 3.018600182258524e-06
signal O 0 2.678528744581854e-06
transducer O 0 6.840643436589744e-06
in O 0 4.3569070840021595e-07
most O 0 8.081766509349109e-07
TGFbeta O 0 0.23525023460388184
- O 0 4.374358832137659e-05
related O 0 6.431268502637977e-06
pathways O 0 7.8417724580504e-06
, O 0 3.9923165218169743e-07
are O 0 2.259788089986614e-08
involved O 0 1.158382119115231e-07
in O 0 2.0318452698120382e-07
50 O 0 1.9338490346854087e-06
% O 0 1.8523140852266806e-06
of O 0 0.0002245096693513915
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999994039535522
. O 0 0.00020904884149786085

Homozygous O 0 0.0017572202486917377
Smad4 O 0 0.40447673201560974
mutant O 0 0.0019669844768941402
mice O 0 0.0002116452669724822
die O 0 5.3444622608367354e-05
before O 0 1.2223527846799698e-05
day O 0 1.6590935047133826e-05
7 O 0 5.6371565733570606e-05
. O 0 3.0386096113943495e-05

5 O 0 0.0005440879613161087
of O 0 0.00027530407533049583
embryogenesis O 0 0.007677646819502115
. O 0 0.00034644544939510524

Mutant O 0 0.00015076824638526887
embryos O 0 3.134685903205536e-05
have O 0 5.281912649479636e-07
reduced O 0 1.4237491541280178e-06
size O 0 1.945239546330413e-06
, O 0 8.639509019303659e-07
fail O 0 1.057531449077942e-06
to O 0 5.475886837302824e-07
gastrulate O 0 0.0007878792239353061
or O 0 1.4703117585668224e-06
express O 0 1.0883056802413194e-06
a O 0 1.267826633011282e-06
mesodermal O 0 0.0031525720842182636
marker O 0 0.00029359583277255297
, O 0 1.6668345779180527e-06
and O 0 2.2487095066026086e-06
show O 0 7.0051473812782206e-06
abnormal O 0 7.257115794345737e-05
visceral O 0 0.0006178209441713989
endoderm O 1 0.8575968742370605
development O 0 0.00023283751215785742
. O 0 0.00011114829976577312

Growth B-Disease 1 0.998760461807251
retardation I-Disease 1 0.999951958656311
of O 0 0.0002944828011095524
the O 0 0.00027933873934671283
Smad4 O 1 0.9999974966049194
- O 0 0.03764224424958229
deficient O 0 0.00024967206991277635
embryos O 0 4.487689693633001e-06
results O 0 1.1043587164749624e-06
from O 0 2.4746959752519615e-06
reduced O 0 1.1786114555434324e-05
cell O 0 4.934169555781409e-05
proliferation O 0 9.704459444037639e-06
rather O 0 3.1588177762387204e-07
than O 0 4.555947157314222e-07
increased O 0 5.046123987995088e-06
apoptosis O 0 0.00025897991145029664
. O 0 2.2969392375671305e-05

Aggregation O 0 0.00019935544696636498
of O 0 5.398312350735068e-05
mutant O 0 0.0005283802165649831
Smad4 O 1 0.9929018616676331
ES O 0 0.10123136639595032
cells O 0 6.910895990586141e-06
with O 0 6.002058512422082e-07
wild O 0 2.2352809537551366e-05
- O 0 0.00010866163938771933
type O 0 0.0001302868768107146
tetraploid O 0 0.0005268216482363641
morulae O 0 0.14387033879756927
rescues O 0 0.001028047758154571
the O 0 0.0002000357781071216
gastrulation B-Disease 1 0.999920129776001
defect I-Disease 1 0.9773001670837402
. O 0 0.0001749597431626171

These O 0 9.654667337599676e-06
results O 0 6.315905466180993e-06
indicate O 0 3.818591721937992e-06
that O 0 6.490477630904934e-07
Smad4 O 0 0.0065701971761882305
is O 0 4.103966091406619e-07
initially O 0 4.246528817475337e-07
required O 0 5.028949701113561e-08
for O 0 4.8759364545958306e-08
the O 0 2.1013828188642947e-07
differentiation O 0 3.222249006284983e-06
of O 0 1.0835470902748057e-06
the O 0 2.5684244064905215e-06
visceral O 0 0.00015671075379941612
endoderm O 0 0.03149097412824631
and O 0 1.174208819065825e-06
that O 0 2.493460442565265e-07
the O 0 2.130012489942601e-06
gastrulation B-Disease 1 0.9795514345169067
defect I-Disease 0 0.0003783010761253536
in O 0 1.7365954363413039e-06
the O 0 3.6994865695305634e-06
epiblast O 1 0.9959883093833923
is O 0 9.99912117549684e-07
secondary O 0 9.600367775419727e-06
and O 0 2.453960632919916e-06
non O 0 5.929872713750228e-05
- O 0 0.0009240525541827083
cell O 0 0.0002614897966850549
autonomous O 0 3.558037133188918e-05
. O 0 7.373547850875184e-05

Rescued O 0 0.0013146044220775366
embryos O 0 0.0004450289416126907
show O 0 0.00014236966671887785
severe O 1 0.8675742149353027
anterior O 1 0.5212920308113098
truncations O 1 0.9925931096076965
, O 0 2.298413892276585e-05
indicating O 0 8.793615961621981e-06
a O 0 1.2654854799620807e-06
second O 0 2.496839897503378e-06
important O 0 1.3717601632379228e-06
role O 0 1.9424585389060667e-06
for O 0 2.6191919459961355e-06
Smad4 O 1 0.9998852014541626
in O 0 5.608320498140529e-05
anterior O 0 0.1545954942703247
patterning O 0 0.08660603314638138
during O 0 0.0005882593686692417
embryogenesis O 0 0.05051267892122269
. O 0 0.0001160817191703245

Prevalence O 0 0.0010848753154277802
of O 0 9.099794260691851e-05
p16 O 0 0.0018400871194899082
and O 0 2.4686647520866245e-05
CDK4 O 1 0.9999756813049316
germline O 0 0.0005573538946919143
mutations O 0 3.765547262446489e-06
in O 0 3.64068341696111e-06
48 O 0 0.0008712148992344737
melanoma B-Disease 1 1.0
- O 1 0.5616834163665771
prone O 0 0.004263828508555889
families O 0 3.312299440949573e-06
in O 0 1.4518243006023113e-05
France O 0 0.0005620158044621348
. O 0 8.383191743632779e-05

The O 0 0.0003337932575959712
French O 0 0.11137533187866211
Familial B-Disease 1 0.9999977350234985
Melanoma I-Disease 1 1.0
Study O 0 0.008222135715186596
Group O 0 0.0004385859938338399
. O 0 0.00010585750715108588

Germline O 0 0.0032065424602478743
mutations O 0 3.85484891012311e-05
in O 0 7.985493539308663e-06
the O 0 8.146604159264825e-06
p16 O 0 0.0005655623972415924
and O 0 6.54983750791871e-06
CDK4 O 1 0.9996178150177002
genes O 0 7.062595273055194e-07
have O 0 6.464730262223384e-08
been O 0 1.8929020484392822e-07
reported O 0 2.1809204042710917e-07
in O 0 1.4929187841516978e-07
a O 0 4.1829096630863205e-07
subset O 0 2.8569670575961936e-06
of O 0 3.87312175007537e-05
melanoma B-Disease 1 0.9999997615814209
pedigrees O 0 6.716733332723379e-05
, O 0 9.175683430839854e-07
but O 0 1.3112388330682734e-07
their O 0 2.5205991960319807e-07
prevalence O 0 6.375733391905669e-06
is O 0 1.5574421752262424e-07
not O 0 1.3997696157730388e-07
well O 0 1.3235767255537212e-06
known O 0 2.7094612960354425e-05
. O 0 4.540756708593108e-05

We O 0 9.893331480270717e-06
searched O 0 2.478239002812188e-05
for O 0 8.68206200266286e-07
such O 0 1.2500186130637303e-06
germline O 0 6.107422814238816e-05
mutations O 0 1.9804335806838935e-06
in O 0 1.4149979961075587e-06
48 O 0 2.2045065634301864e-05
French O 1 0.8165158033370972
melanoma B-Disease 1 1.0
- O 1 0.6490219235420227
prone O 0 0.0025651617906987667
families O 0 9.741119129103026e-07
selected O 0 1.752236357788206e-06
according O 0 4.076333652847097e-07
to O 0 2.1848256892553763e-07
two O 0 2.1950404516246635e-07
major O 0 5.389399575506104e-06
criteria O 0 1.3704644743484096e-06
families O 0 1.1624988616176779e-07
with O 0 1.8914367672095977e-07
at O 0 5.447522198664956e-06
least O 0 1.6654760770506982e-07
three O 0 1.0509736370067913e-07
affected O 0 4.593462676893978e-07
members O 0 2.1052882459571265e-07
( O 0 3.976558389240381e-07
n O 0 7.108714044079534e-07
= O 0 7.620349720127706e-07
20 O 0 6.089511543905246e-07
) O 0 1.333874593001383e-07
or O 0 9.965803116074312e-08
families O 0 2.4687619060159705e-08
with O 0 4.8963464394091716e-08
two O 0 7.625498454899571e-08
affected O 0 4.405167715049174e-07
members O 0 1.702104270862037e-07
, O 0 1.565985030538286e-07
one O 0 8.053670086383136e-08
of O 0 3.2847793818291393e-07
them O 0 1.614191660337383e-07
affected O 0 2.00047779230772e-07
before O 0 2.818254074554716e-07
the O 0 1.4501570433367306e-07
age O 0 4.613288240307156e-07
of O 0 4.380400753234426e-07
50 O 0 8.912727480492322e-07
( O 0 2.2472359262337704e-07
n O 0 5.464951300382381e-07
= O 0 9.696656206870102e-07
28 O 0 1.6759551044742693e-06
) O 0 2.3896117795629834e-07
, O 0 1.6388017343160755e-07
and O 0 9.664550759680424e-08
one O 0 2.4534924136787595e-07
additional O 0 9.913627536661807e-07
minor O 0 0.00025894830469042063
criterion O 0 0.007036532741039991
. O 0 5.5341650295304134e-05

Sixteen O 0 0.0005143446614965796
different O 0 1.1947515304200351e-05
p16 O 0 0.00047505844850093126
germline O 0 0.00018462128355167806
mutations O 0 4.423498921823921e-06
were O 0 1.5043867733766092e-06
found O 0 7.516910613958316e-07
in O 0 2.945418202671135e-07
21 O 0 1.219143086927943e-06
families O 0 1.6255026480394008e-07
, O 0 3.134734924969962e-07
while O 0 4.5370123302745924e-07
one O 0 6.054177106307179e-07
germline O 0 6.428440246963874e-05
mutation O 0 1.8229519582746434e-06
, O 0 1.0907411933658295e-06
Arg24His O 0 0.006560571491718292
, O 0 2.392319174759905e-06
was O 0 8.379071914532688e-06
detected O 0 4.8444735512021e-06
in O 0 7.515089919252205e-07
the O 0 8.931191587180365e-06
CDK4 O 1 0.9999649524688721
gene O 0 0.00012080182932550088
. O 0 4.06980725529138e-05

The O 0 3.0148083169478923e-05
frequency O 0 1.1786755749199074e-05
of O 0 1.5346817235695198e-05
p16 O 0 0.00014313275460153818
gene O 0 2.878979103115853e-06
mutation O 0 5.427343126029882e-07
in O 0 2.9118388056303957e-07
our O 0 2.3730629550300364e-07
sample O 0 4.331225795795035e-07
( O 0 3.2728030419093557e-07
44 O 0 1.2756103160427301e-06
% O 0 3.4387770142529916e-07
) O 0 1.1238844166427953e-07
is O 0 9.090770447528485e-08
among O 0 1.0633642943957966e-07
the O 0 3.890328628131101e-07
highest O 0 3.4195616080978652e-06
rates O 0 4.955471126777411e-07
yet O 0 2.896102841987158e-07
reported O 0 3.4439725027368695e-07
and O 0 1.798121331830771e-07
the O 0 1.452305127713771e-06
CDK4 O 1 0.9997425675392151
mutation O 0 1.8505186289985431e-06
is O 0 1.6761646293161903e-07
the O 0 3.6292641425461625e-07
second O 0 2.229133997388999e-06
mutation O 0 7.181248520282679e-07
detected O 0 1.825154072321311e-06
in O 0 1.9418311580921e-07
this O 0 3.3444300129303883e-07
gene O 0 5.4237916629062966e-06
worldwide O 0 6.460246368078515e-06
. O 0 1.489500755269546e-05

In O 0 2.5470095351920463e-05
summary O 0 1.8736249330686405e-05
, O 0 4.2903070607280824e-06
our O 0 1.2126633919251617e-06
results O 0 7.330068569899595e-07
show O 0 7.078278372318891e-07
frequent O 0 6.814116204623133e-07
involvement O 0 1.5155527535171132e-06
of O 0 1.4339746030600509e-06
the O 0 3.422670715735876e-06
p16 O 0 0.0001934701722348109
gene O 0 4.2188121369690634e-06
in O 0 1.9667920696520014e-06
familial B-Disease 1 0.9828391671180725
melanoma I-Disease 1 0.9999990463256836
and O 0 2.0091247279196978e-06
confirm O 0 2.064000909740571e-06
the O 0 7.936183124002127e-07
role O 0 7.964152359818399e-07
of O 0 1.5632232361895149e-06
the O 0 8.86392081156373e-06
CDK4 O 1 0.9999674558639526
gene O 0 4.60344017483294e-06
as O 0 2.2080228063714458e-06
a O 0 1.814216739148833e-05
melanoma B-Disease 1 0.9999970197677612
- O 0 0.0007109816069714725
predisposing O 0 0.0008797449409030378
gene O 0 3.116390871582553e-05
. O 0 5.6952167142299e-06
. O 0 2.0413541278685443e-05

Progression O 0 0.0011508825700730085
of O 0 0.0001282956072827801
somatic O 0 0.042461104691028595
CTG O 1 0.9996916055679321
repeat O 0 6.180447235237807e-05
length O 0 3.935649147024378e-06
heterogeneity O 0 1.1283899766567629e-05
in O 0 1.1070222853959422e-06
the O 0 3.911376097676111e-06
blood O 0 0.0006097336881794035
cells O 0 7.2540293331258e-05
of O 0 0.13269031047821045
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999703168869019
. O 0 0.0018540190067142248

The O 0 6.111511902417988e-05
genetic O 0 2.8046199076925404e-05
basis O 0 1.0799653864523862e-05
of O 0 0.021346725523471832
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999990463256836
DM B-Disease 1 1.0
) O 0 3.1166462576948106e-05
is O 0 7.24887229353044e-07
the O 0 5.758926135968068e-07
expansion O 0 2.893920964197605e-06
of O 0 2.2632900709140813e-06
an O 0 1.3822896107740235e-06
unstable O 0 0.0006183043005876243
CTG O 1 0.9958754181861877
repeat O 0 7.4551730904204305e-06
in O 0 9.95419441096601e-07
the O 0 8.228756200878706e-07
34 O 0 3.753926876015612e-06
UTR O 0 0.00018466584151610732
of O 0 7.1658810156804975e-06
the O 0 1.9102175428997725e-05
DM B-Disease 1 0.9999998807907104
protein O 0 1.2273077118152287e-05
kinase O 0 2.914299511758145e-05
gene O 0 6.904150723130442e-06
on O 0 4.8361275730712805e-06
chromosome O 0 1.594771856616717e-05
19 O 0 2.666311411303468e-05
. O 0 3.0272429285105318e-05

One O 0 1.4670995369669981e-05
of O 0 7.4929075708496384e-06
the O 0 4.3320660552126355e-06
principal O 0 1.5111296306713484e-05
features O 0 1.9404551494517364e-06
of O 0 7.679643204028253e-06
the O 0 0.00016030932602006942
DM B-Disease 1 1.0
mutation O 0 5.792686806671554e-06
is O 0 2.1059490507013834e-07
an O 0 1.760931240823993e-07
extraordinarily O 0 2.8340148219285766e-06
high O 0 3.3043611438188236e-06
level O 0 2.275763336001546e-06
of O 0 3.206462224625284e-06
somatic O 0 0.0017878328217193484
mosaicism O 1 0.9186634421348572
, O 0 1.1782761930589913e-06
due O 0 8.240488682531577e-07
to O 0 1.3285881550473277e-07
an O 0 1.7976429944610572e-07
extremely O 0 6.325166737042309e-07
high O 0 2.2083386284066364e-06
degree O 0 1.85785529538407e-06
of O 0 1.8482186305845971e-06
somatic O 0 0.00010672797361621633
instability O 0 5.063955995865399e-06
both O 0 3.2987995268740633e-07
within O 0 4.705699723217549e-07
and O 0 5.438441235128266e-07
between O 0 7.768728096380073e-07
different O 0 2.111089770551189e-06
tissues O 0 0.0009443648741580546
. O 0 5.844060069648549e-05

This O 0 3.49671536241658e-05
instability O 0 8.14209706732072e-05
appears O 0 4.7014927986310795e-06
to O 0 2.7845067052112427e-07
be O 0 1.5195659841538145e-07
biased O 0 1.1789123846028815e-06
towards O 0 6.207022238413629e-07
further O 0 2.2241792407839966e-07
expansion O 0 1.2580370594150736e-06
and O 0 1.2799836213162052e-07
continuous O 0 4.5012242821940163e-07
throughout O 0 1.725865814705685e-07
the O 0 2.0783892296094564e-07
life O 0 4.5791384195581486e-07
of O 0 3.4910283375211293e-07
an O 0 7.24323427903073e-08
individual O 0 1.1014130762987406e-07
, O 0 1.625529080229171e-07
features O 0 3.172027902564878e-07
that O 0 4.475229786748969e-08
could O 0 8.19928871464981e-08
be O 0 5.463998675736548e-08
associated O 0 1.5363349348263e-07
with O 0 1.2348424149877246e-07
the O 0 2.592556256786338e-06
progressive O 0 0.0001254707167390734
nature O 0 1.1298501704004593e-05
of O 0 8.145203173626214e-05
the O 0 0.029604535549879074
disease O 1 0.9999114274978638
. O 0 0.00012900576984975487

Although O 0 1.464267734263558e-05
increasing O 0 3.5201176160626346e-06
measured O 0 2.2872995941725094e-06
allele O 0 1.341187839898339e-06
size O 0 1.1889873121617711e-06
between O 0 1.4677481203762e-06
patients O 0 4.520761194726219e-06
clearly O 0 9.805028184928233e-07
correlates O 0 3.0686283025715966e-06
with O 0 2.4392770114900486e-07
an O 0 3.8510785316248075e-07
increased O 0 1.6607731367912493e-06
severity O 0 3.449485666351393e-05
of O 0 8.927378803491592e-05
symptoms O 0 0.0007415937725454569
and O 0 5.737744004363776e-07
an O 0 2.5066594844247447e-07
earlier O 0 1.3431206298264442e-06
age O 0 1.3458619605444255e-06
of O 0 2.7623104870144743e-06
onset O 0 0.1227799728512764
, O 0 4.817576950699731e-07
this O 0 4.132364139763922e-08
correlation O 0 2.1658188131823408e-07
is O 0 6.225210569255069e-08
not O 0 3.090809386208093e-08
precise O 0 2.836140993167646e-07
and O 0 2.4755004801590985e-07
measured O 0 1.6952515125012724e-06
allele O 0 9.021588880386844e-07
length O 0 1.9756996039177466e-07
cannot O 0 6.710072852911253e-08
be O 0 3.247727065058825e-08
used O 0 1.1829076385083681e-07
as O 0 1.2479728184189298e-07
an O 0 1.4409535253889771e-07
accurate O 0 7.290066719178867e-07
predictor O 0 1.044071905198507e-05
of O 0 3.5684590784512693e-06
age O 0 2.153352033928968e-05
of O 0 7.187979645095766e-05
onset O 1 0.9967689514160156
. O 0 0.00017374711751472205

In O 0 1.78719601535704e-05
order O 0 3.5234695587860188e-06
to O 0 5.063189973952831e-07
further O 0 9.24640460198134e-07
characterize O 0 4.385522515804041e-06
the O 0 1.5338856655944255e-06
dynamics O 0 7.517138874391094e-05
of O 0 0.00034864875487983227
DM B-Disease 1 1.0
CTG O 1 0.9999973773956299
repeat O 0 0.0001311005325987935
somatic O 0 6.90884844516404e-05
instability O 0 9.302203579863999e-06
, O 0 1.0216043619948323e-06
we O 0 8.372958859581558e-08
have O 0 3.2901994018175174e-08
studied O 0 1.0393017646492808e-06
repeat O 0 8.105045026240987e-07
length O 0 1.0856058452191064e-07
changes O 0 5.351145304643978e-08
over O 0 1.584424751399638e-07
time O 0 1.7780237726583437e-07
in O 0 1.4368739584824652e-06
111 O 1 0.9992808699607849
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.014576905407011509
with O 0 1.9413641894061584e-06
varying O 0 8.537604117009323e-06
clinical O 0 0.004835257772356272
severity O 0 0.00019774948304984719
and O 0 1.3935128663433716e-05
CTG O 1 0.935669481754303
repeat O 0 4.720820470538456e-06
size O 0 4.6021838784326974e-07
over O 0 1.8209452434803097e-07
time O 0 7.109372290869942e-08
intervals O 0 1.6353746445929573e-07
of O 0 3.2107965353134205e-07
1 O 0 1.8453869188306271e-06
- O 0 1.718952444207389e-05
7 O 0 1.1144169548060745e-05
years O 0 1.3143268006388098e-05
. O 0 1.1066295883210842e-05

We O 0 8.791930667939596e-06
have O 0 6.413357027668098e-07
found O 0 4.917376372759463e-07
a O 0 3.3178778835463163e-07
direct O 0 4.429753630574851e-07
progression O 0 6.7439204940455966e-06
of O 0 1.1969317483817576e-06
the O 0 1.2676887308771256e-06
size O 0 1.485471443629649e-06
heterogeneity O 0 4.075710421602707e-06
over O 0 5.016883619646251e-07
time O 0 2.2468866234248708e-07
related O 0 3.3264512921959977e-07
to O 0 1.5294916977381945e-07
initial O 0 5.8063037613464985e-06
CTG O 0 0.18776428699493408
repeat O 0 3.0825340218143538e-06
size O 0 1.1867001603604876e-06
and O 0 2.1592441612483526e-07
the O 0 3.555132934707217e-07
time O 0 1.8891671516030328e-07
interval O 0 1.019538103719242e-06
and O 0 1.4763239164494735e-07
always O 0 3.3820398925854533e-07
biased O 0 1.420567400600703e-06
towards O 0 1.2281192312002531e-06
further O 0 1.7094472468670574e-06
expansion O 0 4.059263665112667e-05
. O 0 3.753014243557118e-05

Attempts O 0 5.684764983016066e-05
to O 0 2.9674511097255163e-06
mathematically O 0 1.1837911188194994e-05
model O 0 2.9679436011065263e-06
the O 0 2.1089908841531724e-06
dynamics O 0 1.3592661161965225e-05
have O 0 3.738759914995171e-07
proved O 0 4.381805865705246e-06
only O 0 2.056572583342131e-07
partially O 0 3.0355054150277283e-06
successful O 0 1.5884916138020344e-06
suggesting O 0 4.5610116217176255e-07
that O 0 1.740466437638588e-08
individual O 0 2.5553866578320594e-08
specific O 0 1.0882013157242909e-07
genetic O 0 3.0913543014321476e-06
and O 0 4.149078449700028e-06
/ O 0 0.0019132758025079966
or O 0 1.0258356724079931e-06
environmental O 0 1.3930513205195894e-06
factors O 0 2.4965513034658215e-07
also O 0 1.545266030689163e-07
play O 0 3.1659260457672644e-07
a O 0 4.071748946898879e-07
role O 0 9.584491635905579e-07
in O 0 2.2519479898619466e-06
somatic O 0 0.000586534442845732
mosaicism O 1 0.5812163949012756
. O 0 1.425807840860216e-05
. O 0 3.3928616176126525e-05

Aspartylglucosaminuria B-Disease 1 0.9997257590293884
among O 0 0.0001435227895854041
Palestinian O 0 0.0005355686298571527
Arabs O 0 0.00032657929114066064
. O 0 0.00016013637650758028

Aspartylglucosaminuria B-Disease 1 0.9999992847442627
( O 1 0.6800246834754944
AGU B-Disease 1 1.0
) O 0 4.619271567207761e-05
is O 0 3.0315795811475255e-06
a O 0 4.3486320464580785e-06
rare O 0 0.0045979819260537624
disorder B-Disease 1 0.9999876022338867
of I-Disease 1 0.9999139308929443
glycoprotein I-Disease 1 0.9999996423721313
metabolism I-Disease 1 0.9999383687973022
caused O 0 0.00545448949560523
by O 0 3.859652679238934e-06
the O 0 0.00013846001820638776
deficiency B-Disease 1 0.9999643564224243
of I-Disease 0 0.0007200621766969562
the I-Disease 0 0.0006307497387751937
lysosomal I-Disease 1 0.9999974966049194
enzyme I-Disease 0 0.0025401348248124123
aspartylglucosaminidase I-Disease 1 0.9994639754295349
( O 0 0.00014275082503445446
AGA O 1 0.9999916553497314
) O 0 0.000119045827887021
. O 0 0.00012432420044206083

AGU B-Disease 1 1.0
is O 0 0.0003580890770535916
inherited O 1 0.9645835757255554
as O 0 1.82096628122963e-05
an O 0 2.320579187653493e-05
autosomal O 1 0.9082636833190918
recessive O 1 0.8142147064208984
trait O 0 0.02490834891796112
and O 0 1.8004489902523346e-05
occurs O 0 2.013743824136327e-06
with O 0 1.9982088872438908e-07
a O 0 1.0682671245376696e-06
high O 0 4.87949046146241e-06
frequency O 0 1.0229507552139694e-06
in O 0 1.9048557931000687e-07
Finland O 0 3.601653588702902e-06
because O 0 2.1730166110955906e-07
of O 0 1.520392174825247e-06
a O 0 5.399926067184424e-06
founder O 0 0.12630437314510345
effect O 0 5.040284668211825e-05
. O 0 3.250706504331902e-05

While O 0 0.0001140769018093124
very O 0 5.2662026064353995e-06
few O 0 4.378898665891029e-06
patients O 0 7.591504527226789e-06
with O 0 6.2346366576093715e-06
AGU B-Disease 1 1.0
have O 0 7.024173100944608e-07
been O 0 5.561461193792638e-07
reported O 0 5.798152642455534e-07
from O 0 4.060755145474104e-07
non O 0 3.483406771920272e-06
- O 0 6.819337613706011e-06
Finnish O 0 0.0001415018632542342
origin O 0 1.2545626759674633e-06
, O 0 1.165942421721411e-06
we O 0 1.4536645949192462e-06
diagnosed O 1 0.9655452370643616
the O 0 8.877913387550507e-06
disorder O 1 0.999254047870636
in O 0 7.639941031811759e-06
8 O 0 7.066014950396493e-05
patients O 0 2.334704731765669e-06
originating O 0 9.487249599260394e-07
from O 0 8.670817237543815e-07
3 O 0 1.3916038597017177e-06
unrelated O 0 2.076993496302748e-06
families O 0 9.37569382131187e-08
, O 0 1.21192996971331e-07
all O 0 5.568855243609505e-08
Palestinian O 0 7.872681067055964e-07
Arabs O 0 9.640126563681406e-07
from O 0 1.004986643238226e-06
the O 0 1.4515007933368906e-06
region O 0 3.830946297966875e-06
of O 0 1.6298554328386672e-05
Jerusalem O 0 0.005358871538192034
. O 0 0.0001005519152386114

The O 0 0.00011595195246627554
clinical O 0 0.23479317128658295
diagnosis O 1 0.9796762466430664
of O 1 0.9909396171569824
AGU B-Disease 1 1.0
is O 0 2.4782531909295358e-05
often O 0 1.4982246057115844e-06
difficult O 0 7.749201245133008e-07
, O 0 2.7904960120395117e-07
in O 0 1.355402190483801e-07
particular O 0 1.1059474758212673e-07
early O 0 3.9514947047791793e-07
in O 0 1.563279710126153e-07
the O 0 3.0238072667998495e-07
course O 0 2.848886197170941e-06
of O 0 2.52290601565619e-06
the O 0 0.0004220477712806314
disease O 1 0.9999700784683228
, O 0 9.243027534466819e-07
and O 0 2.6226211957691703e-07
most O 0 1.7800903151510283e-07
of O 0 1.1313771892673685e-06
the O 0 6.5385161178710405e-06
patients O 0 1.5478100976906717e-05
are O 0 3.5177814083908743e-07
diagnosed O 0 0.18078084290027618
after O 0 3.0087078357610153e-06
the O 0 1.0868069466596353e-06
age O 0 4.435216396814212e-06
of O 0 4.34525736636715e-06
5 O 0 1.531237649032846e-05
years O 0 3.083093906752765e-05
. O 0 3.176297104801051e-05

However O 0 4.227518002153374e-05
, O 0 3.9513765841547865e-06
since O 0 2.0542313450278016e-06
these O 0 3.723331758465065e-07
patients O 0 1.656740892030939e-06
excrete O 0 1.2033747225359548e-05
early O 0 1.7776978893380146e-06
large O 0 3.058123638766119e-07
amounts O 0 3.5258659636383527e-07
of O 0 1.7888901311380323e-06
aspartylglucosamine O 0 0.0007761347224004567
in O 0 1.7493946415925166e-06
urine O 0 1.046674788085511e-05
, O 0 3.678381688132504e-07
biochemical O 0 7.297729553101817e-06
screening O 0 3.8128312098706374e-06
is O 0 2.41944746903755e-07
easy O 0 4.5278184757080453e-07
by O 0 8.924907888285816e-07
urine O 0 5.9934543969575316e-05
chromatography O 0 0.0017625782638788223
. O 0 2.2810108930571005e-05
. O 0 4.771007297676988e-05

Detection O 0 0.0002936759265139699
of O 0 3.20203835144639e-05
heterozygous O 0 5.6088256314978935e-06
carriers O 0 1.4840554740658263e-06
of O 0 4.489324510359438e-06
the O 0 2.5976694814744405e-05
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999872446060181
telangiectasia I-Disease 1 0.9999994039535522
( O 0 9.675214096205309e-05
ATM O 0 0.4628423750400543
) O 0 5.070063707535155e-06
gene O 0 3.4629536003194517e-06
by O 0 2.589608129710541e-06
G2 O 1 0.9827751517295837
phase O 0 0.0002677994780242443
chromosomal O 0 0.000539771281182766
radiosensitivity O 0 0.027012797072529793
of O 0 0.000556027633138001
peripheral O 1 0.9999879598617554
blood O 1 0.9925447106361389
lymphocytes O 0 0.026178669184446335
. O 0 9.060587763087824e-05

In O 0 0.0010219987016171217
ataxia B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999383687973022
telangiectasia I-Disease 1 0.9999996423721313
( O 0 0.01914895512163639
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.2246046935615595e-05
patients O 0 2.3023039830150083e-06
, O 0 1.8147146363389766e-07
mutations O 0 1.355955561166411e-07
in O 0 1.856987665860288e-07
a O 0 3.5752168514591176e-07
single O 0 1.091000285668997e-06
gene O 0 1.3379110441746889e-06
, O 0 6.671131700386468e-07
ATM O 0 0.0005728178657591343
, O 0 8.470119610137772e-07
result O 0 5.656438020196219e-07
in O 0 9.130422995440313e-07
an O 0 3.353095235070214e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.2440595785155892e-05
embraces O 0 0.00011524042929522693
a O 0 3.1260076411854243e-06
variety O 0 1.8077653294312768e-06
of O 0 5.330432941264007e-06
clinical O 0 0.0005775794852524996
features O 0 8.022369911486749e-06
and O 0 2.8945034955540905e-06
manifests O 0 4.864216680289246e-05
extreme O 0 5.0303257012274116e-05
radiosensitivity O 0 0.0359543077647686
and O 0 1.6272690572805004e-06
a O 0 2.0797879187739454e-06
strong O 0 2.296841103088809e-06
pre O 0 0.0005259486497379839
- O 0 0.00010973573080264032
disposition O 0 0.00025128619745373726
to O 0 2.5593002646928653e-05
malignancy B-Disease 1 0.99988853931427
. O 0 7.928722334327176e-05

Heterozygotes O 0 0.00045528594637289643
for O 0 7.417544111376628e-06
the O 0 6.7248274717712775e-06
ATM O 0 0.0006596633465960622
gene O 0 2.05064725378179e-06
have O 0 9.302128489707684e-08
no O 0 2.7588882289819594e-07
clinical O 0 1.6771174387031351e-06
expression O 0 6.949148314561171e-07
of O 0 1.1082232958870009e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
but O 0 1.64608661634702e-06
may O 0 1.3189536502977717e-06
be O 0 2.1091418602736667e-06
cancer B-Disease 1 0.9526785612106323
prone O 0 2.1214969819993712e-05
with O 0 3.845169942451321e-07
a O 0 1.5608277408318827e-06
moderate O 0 1.751701802277239e-06
increase O 0 3.671162573937181e-07
in O 0 1.2757295735355e-06
in O 0 4.773326054419158e-06
vitro O 0 0.0003201001381967217
radiosensitivity O 0 0.016830122098326683
. O 0 4.532610182650387e-05

We O 0 3.467235364951193e-05
performed O 0 5.268687891657464e-05
a O 0 9.063595825864468e-06
blind O 0 6.40423531876877e-05
chromosomal O 0 1.2796489500033204e-05
analysis O 0 1.6418222230640822e-06
on O 0 3.228049990866566e-06
G2 O 1 0.9233048558235168
- O 0 1.9168252038070932e-05
phase O 0 1.5987372535164468e-05
lymphocytes O 0 6.74896500640898e-06
from O 0 6.769888614144293e-07
7 O 0 2.687791720745736e-06
unrelated O 0 9.362455784867052e-06
A B-Disease 1 0.9997617602348328
- I-Disease 1 0.9999833106994629
T I-Disease 1 1.0
patients O 0 1.1213336620130576e-05
, O 0 6.26406858827977e-07
13 O 0 1.6011350680855685e-06
obligate O 0 7.230007668113103e-06
A B-Disease 1 0.9918950200080872
- I-Disease 1 0.9992780089378357
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.0002288079704158008
( O 0 8.489601555083937e-07
parents O 0 1.1728529614174477e-07
of O 0 4.920829042021069e-07
the O 0 1.6866578107510577e-06
patients O 0 3.7463235003087902e-06
) O 0 1.9294962783078518e-07
, O 0 1.8540696089530684e-07
and O 0 2.079870426996422e-07
14 O 0 6.09042899668566e-07
normal O 0 1.688059683147003e-07
controls O 0 2.9766215448034927e-07
following O 0 3.0475493417725374e-07
X O 0 9.535274330119137e-06
- O 0 2.421535100438632e-06
irradiation O 0 3.9248657230928075e-06
with O 0 2.719933718253742e-07
1 O 0 2.2727701889380114e-06
Gy O 0 0.00016221971600316465
in O 0 5.234664399722533e-07
order O 0 1.708409342882078e-07
to O 0 1.1562453039459797e-07
evaluate O 0 7.11922325535852e-07
this O 0 9.521850330429515e-08
cytogenetic O 0 9.515888450550847e-06
method O 0 3.79754283130751e-07
as O 0 2.337442026600911e-07
a O 0 3.334474172334012e-07
tool O 0 1.6383107777073747e-06
for O 0 2.0674707457146724e-07
detection O 0 1.5872312360443175e-05
of O 0 6.445341114158509e-06
ATM O 0 0.02370796911418438
carriers O 0 5.6985896662808955e-05
. O 0 3.233756797271781e-05

Both O 0 0.00024969966034404933
A B-Disease 1 0.9995854496955872
- I-Disease 1 0.9998544454574585
T I-Disease 1 0.9999995231628418
homozygotes O 0 0.0026140729896724224
and O 0 1.0759818906080909e-05
heterozygotes O 0 0.00012598108150996268
showed O 0 5.784627319371793e-06
significantly O 0 1.0074143119709333e-06
increased O 0 4.089436345111608e-07
levels O 0 5.449634841170337e-07
of O 0 1.2666422435358982e-06
radiation O 1 0.8335728049278259
- O 0 0.0009617295581847429
induced O 1 0.7292109727859497
chromatid O 1 0.7046121954917908
damage O 0 5.7531866332283244e-05
relative O 0 1.0726486152634607e-06
to O 0 1.709996837462313e-07
that O 0 1.2941704596869386e-07
of O 0 3.422758936721948e-06
normal O 0 9.622347533877473e-06
controls O 0 4.1948605939978734e-05
. O 0 3.517749792081304e-05

These O 0 6.987545930314809e-06
results O 0 2.7503240289661335e-06
show O 0 1.362066768706427e-06
that O 0 1.604473425231845e-07
the O 0 1.2370670674499706e-06
G2 O 1 0.9999244213104248
- O 0 0.00018099545559380203
phase O 0 0.00018439751875121146
chromosomal O 0 0.0001003018842311576
radiosensitivity O 0 0.00020069029415026307
assay O 0 5.419964963948587e-06
can O 0 8.016276353828289e-08
be O 0 2.115505992605904e-08
used O 0 6.480470915448677e-08
for O 0 6.412953013068545e-08
the O 0 4.3211340994275815e-07
detection O 0 2.125121682183817e-05
of O 0 2.296520870004315e-05
A B-Disease 1 0.9999871253967285
- I-Disease 1 0.9999909400939941
T I-Disease 1 0.9999997615814209
heterozygotes O 0 0.0019548535346984863
. O 0 5.475726356962696e-05

In O 0 3.370692866155878e-05
combination O 0 1.2334303391980939e-05
with O 0 1.1083860727012507e-06
molecular O 0 2.733686960709747e-05
genetic O 0 9.195909115078393e-06
analyses O 0 4.924837867292808e-06
, O 0 6.292910939009744e-07
this O 0 8.616397906280326e-08
test O 0 9.241873044629756e-07
may O 0 1.0440367503861125e-07
be O 0 2.449428393447306e-08
of O 0 2.201848019467434e-07
value O 0 2.7412167469265114e-07
in O 0 2.2565971846688626e-07
studies O 0 5.275212515698513e-07
of O 0 1.2748963627018384e-06
familial B-Disease 0 7.480098429368809e-05
and I-Disease 0 2.6398151931061875e-06
sporadic I-Disease 0 0.00013341072190087289
cancers I-Disease 0 0.0056107840500772
aimed O 0 2.375227950324188e-06
at O 0 2.970806463054032e-06
determination O 0 2.626232742386492e-07
of O 0 1.9866162404014176e-07
the O 0 3.8577391592298227e-07
potential O 0 6.349553132167784e-07
involvement O 0 1.0423957519378746e-06
of O 0 2.1278704025462503e-06
ATM O 0 0.15028755366802216
mutations O 0 3.3104138310591225e-06
in O 0 4.134823029744439e-06
tumor B-Disease 1 0.9997389912605286
risk O 0 6.705558462272165e-06
or O 0 1.7802154843593598e-06
development O 0 5.815075837745098e-06
. O 0 8.321489076479338e-06
. O 0 2.8181568268337287e-05

Ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9995033740997314
telangiectasia I-Disease 1 0.9999831914901733
: O 0 1.9804108887910843e-05
identification O 0 1.3585105989477597e-05
and O 0 2.401446408839547e-06
detection O 0 2.8474567443481646e-05
of O 0 1.1429634469095618e-05
founder O 1 0.8787950277328491
- O 0 3.6654779250966385e-05
effect O 0 1.5988416635082103e-06
mutations O 0 3.0533618655681494e-07
in O 0 1.4082411325944122e-07
the O 0 7.314559411497612e-07
ATM O 0 0.00034132186556234956
gene O 0 1.546129965390719e-06
in O 0 5.466353627525677e-07
ethnic O 0 1.131294084188994e-06
populations O 0 4.558960426948033e-06
. O 0 2.1285044567775913e-05

To O 0 1.4809824278927408e-05
facilitate O 0 5.967863216937985e-06
the O 0 2.829677669069497e-06
evaluation O 0 1.1433634426794015e-05
of O 0 1.2191198948130477e-05
ATM O 0 0.10840920358896255
heterozygotes O 0 7.609682506881654e-05
for O 0 2.2618226012127707e-06
susceptibility O 0 2.2198077203938738e-05
to O 0 5.696405764865631e-07
other O 0 3.838860266114352e-06
diseases O 1 0.9996329545974731
, O 0 1.0870826372411102e-06
such O 0 7.612722470184963e-07
as O 0 0.0019387269858270884
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999949932098389
, O 0 8.616987088316819e-07
we O 0 9.465896511073879e-08
have O 0 2.1669960048598114e-08
attempted O 0 4.7342516040771443e-07
to O 0 6.077837610973802e-08
define O 0 1.7071747038244212e-07
the O 0 2.1677695372090966e-07
most O 0 8.836205012130449e-08
common O 0 2.124505442679947e-07
mutations O 0 1.7721700373840577e-07
and O 0 6.759592707794582e-08
their O 0 5.1969255565609274e-08
frequencies O 0 5.168288907952956e-07
in O 0 1.7581066913407994e-06
ataxia B-Disease 1 0.9997699856758118
- I-Disease 1 0.6548632383346558
telangiectasia I-Disease 1 0.9999985694885254
( O 0 9.551386756356806e-05
A B-Disease 1 0.9999841451644897
- I-Disease 1 0.9997267127037048
T I-Disease 1 0.9999996423721313
) O 0 2.519669578759931e-06
homozygotes O 0 2.565580689406488e-05
from O 0 1.3322452332431567e-06
10 O 0 8.701541105438082e-07
ethnic O 0 5.531796887225937e-07
populations O 0 2.9989021186338505e-06
. O 0 1.6770736692706123e-05

Both O 0 2.6290486857760698e-05
genomic O 0 4.427697422215715e-05
mutations O 0 3.380170937816729e-06
and O 0 7.516459277212562e-07
their O 0 6.316293479358137e-07
effects O 0 6.152946298243478e-06
on O 0 3.008377916557947e-06
cDNA O 0 3.1728119211038575e-05
were O 0 3.6092146729060914e-06
characterized O 0 4.258601984474808e-05
. O 0 2.6955929570249282e-05

Protein O 0 0.000127349907415919
- O 0 0.00012500819866545498
truncation O 0 0.00015582361083943397
testing O 0 2.0756804588017985e-05
of O 0 3.0902103844709927e-06
the O 0 1.565702859807061e-06
entire O 0 1.117535157391103e-05
ATM O 0 0.00011583536252146587
cDNA O 0 3.1379640859086066e-05
detected O 0 1.0059733540401794e-05
92 O 0 8.327554496645462e-06
( O 0 5.621911327580165e-07
66 O 0 1.2144631909905002e-05
% O 0 5.071308351034531e-07
) O 0 4.641217117296037e-07
truncating O 0 1.9960309145972133e-05
mutations O 0 2.1275782273733057e-06
in O 0 1.2372888704703655e-06
140 O 0 1.1632552741502877e-05
mutant O 0 6.893699173815548e-05
alleles O 0 1.395289564243285e-05
screened O 0 0.0001354800770059228
. O 0 7.624796853633597e-05

The O 0 0.00020238342403899878
haplotyping O 0 0.3565142750740051
of O 0 0.00016130952280946076
patients O 0 3.546779407770373e-05
with O 0 9.511284133623121e-07
identical O 0 1.1028979315597098e-05
mutations O 0 3.478735834505642e-06
indicates O 0 1.4223404605218093e-06
that O 0 5.7425623367635126e-08
almost O 0 1.5568643618735223e-07
all O 0 2.4373020934831402e-08
of O 0 1.0994085641868878e-07
these O 0 4.642270923227443e-08
represent O 0 2.4401239784310746e-07
common O 0 4.935229185321077e-07
ancestry O 0 6.229687983250187e-07
and O 0 2.4585281721556385e-07
that O 0 1.022467515099379e-07
very O 0 4.094540599908214e-07
few O 0 1.3748904166277498e-06
spontaneously O 0 6.59698125673458e-05
recurring O 0 0.0005502349231392145
ATM O 0 0.19136856496334076
mutations O 0 2.8722832212224603e-05
exist O 0 1.862323915702291e-05
. O 0 3.7661327951354906e-05

Assays O 0 0.00018269868451170623
requiring O 0 1.6788548236945644e-05
minimal O 0 6.371295967255719e-06
amounts O 0 1.4928191376384348e-06
of O 0 1.4870305449221632e-06
genomic O 0 3.2602972623863025e-06
DNA O 0 3.088000994466711e-06
were O 0 2.2673529542771576e-07
designed O 0 1.0516549764361116e-06
to O 0 2.0526496768979996e-07
allow O 0 1.8298688075901737e-07
rapid O 0 2.217138217019965e-06
screening O 0 2.2115950741863344e-06
for O 0 3.4301925211366324e-07
common O 0 8.384774332625966e-07
ethnic O 0 1.7156828562292503e-06
mutations O 0 1.5637835531379096e-05
. O 0 1.98004454432521e-05

These O 0 7.90460308053298e-06
rapid O 0 3.268063301220536e-05
assays O 0 2.077405406453181e-05
detected O 0 9.10993003344629e-06
mutations O 0 8.383527756450349e-07
in O 0 3.888503670168575e-07
76 O 0 6.090468104957836e-06
% O 0 3.6091623201173206e-07
of O 0 8.828790214465698e-07
Costa O 0 1.1907657608389854e-05
Rican O 0 2.6470237571629696e-05
patients O 0 3.3634466944931773e-06
( O 0 3.3274540101047023e-07
3 O 0 1.4412656810236513e-06
) O 0 1.3622002370539121e-07
, O 0 5.4091966461555785e-08
50 O 0 1.3525846043194178e-07
% O 0 3.984119345545878e-08
of O 0 1.7708657651382964e-07
Norwegian O 0 2.6615634851623327e-05
patients O 0 3.71496162188123e-06
( O 0 4.376913977921504e-07
1 O 0 2.2068525140639395e-06
) O 0 2.1041682884970214e-07
, O 0 1.0187668664229932e-07
25 O 0 2.6032964228761557e-07
% O 0 9.538209866377656e-08
of O 0 6.993166721258604e-07
Polish O 1 0.9964907765388489
patients O 0 0.00010490767454029992
( O 0 2.1110495254106354e-06
4 O 0 7.758556421322282e-06
) O 0 3.832850552498712e-07
, O 0 2.2805292587690928e-07
and O 0 1.934375148948675e-07
14 O 0 7.364816383415018e-07
% O 0 2.160613945534351e-07
of O 0 1.2116530569983297e-06
Italian O 0 0.003025715472176671
patients O 0 6.337993545457721e-05
( O 0 9.526007715976448e-07
1 O 0 4.311454176786356e-06
) O 0 4.405209779179131e-07
, O 0 8.790565431127106e-08
as O 0 9.660865174510036e-08
well O 0 7.182522665516444e-08
as O 0 2.0079454543520114e-07
in O 0 3.2521720072509197e-07
patients O 0 4.848448611483036e-07
of O 0 1.7855220448836917e-06
Amish O 1 0.518274188041687
/ O 0 0.0010157335782423615
Mennonite O 0 0.001627081772312522
and O 0 4.142479610891314e-06
Irish O 0 0.00018288675346411765
English O 0 5.650385719491169e-05
backgrounds O 0 3.709815428010188e-05
. O 0 5.7275628932984546e-05

Additional O 0 2.058286736428272e-05
mutations O 0 2.695960120036034e-06
were O 0 4.348306390511425e-07
observed O 0 4.935981792186794e-07
in O 0 2.2901647867001884e-07
Japanese O 0 5.206676178204361e-06
, O 0 6.649623855992104e-07
Utah O 0 1.7398051568306983e-05
Mormon O 0 1.4904428098816425e-05
, O 0 6.058272106201912e-07
and O 0 5.784858672086557e-07
African O 0 4.193957011011662e-06
American O 0 7.458495383616537e-05
patients O 0 0.00012053510727128014
. O 0 4.554225961328484e-05

These O 0 6.939168542885454e-06
assays O 0 1.2769864952133503e-05
should O 0 5.692348850061535e-07
facilitate O 0 1.013608766697871e-06
screening O 0 3.2486334475834155e-06
for O 0 1.3800280385112274e-06
A B-Disease 1 0.7880406975746155
- I-Disease 1 0.9813306927680969
T I-Disease 1 0.9999939203262329
heterozygotes O 0 1.6826859791763127e-05
in O 0 4.326973339630058e-07
the O 0 4.41948316165508e-07
populations O 0 7.565332111880707e-07
studied O 0 1.1830168659798801e-05
. O 0 4.47845013695769e-06
. O 0 1.9945618987549096e-05

The O 0 0.00022063769574742764
von B-Disease 1 0.8936570882797241
Hippel I-Disease 1 0.9999324083328247
- I-Disease 1 0.9827060699462891
Lindau I-Disease 1 0.9999969005584717
tumor I-Disease 1 0.9999639987945557
suppressor O 0 0.0009081123280338943
gene O 0 3.809407417065813e-06
is O 0 3.003972040005465e-07
required O 0 2.1427204899282515e-07
for O 0 3.7697154198212957e-07
cell O 0 1.1177377018611878e-05
cycle O 0 6.143547125248006e-06
exit O 0 6.0966972341702785e-06
upon O 0 3.583051011446514e-06
serum O 0 5.4486819863086566e-05
withdrawal O 0 2.2436401195591316e-05
. O 0 2.7908370611839928e-05

The O 0 8.35070968605578e-05
inactivation O 0 0.0003651408478617668
of O 0 3.0797560611972585e-05
the O 0 1.5348807210102677e-05
von B-Disease 1 0.616243302822113
Hippel I-Disease 1 0.9999004602432251
- I-Disease 1 0.6331703066825867
Lindau I-Disease 1 0.9999849796295166
( I-Disease 0 0.0003368124598637223
VHL I-Disease 1 0.9999998807907104
) I-Disease 0 0.0003453720419202
tumor I-Disease 1 0.9999992847442627
suppressor O 1 0.9935852885246277
gene O 0 8.875464845914394e-05
predisposes O 0 0.0003854160604532808
affected O 0 1.2037130545650143e-06
individuals O 0 7.474955765474078e-08
to O 0 4.000926594471821e-07
the O 0 1.273974612558959e-05
human O 1 0.9883058071136475
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.0834739441634156e-05
is O 0 2.2669169084110763e-06
associated O 0 2.931978769993293e-06
with O 0 2.477281668689102e-06
sporadic B-Disease 1 0.993441104888916
renal I-Disease 1 1.0
cell I-Disease 1 0.9999997615814209
carcinomas I-Disease 1 1.0
( O 0 0.09617895632982254
RCC B-Disease 1 1.0
) O 0 0.0004029086558148265
and O 0 0.00031756749376654625
brain B-Disease 1 0.999853253364563
hemangioblastomas I-Disease 1 0.9984344840049744
. O 0 0.0001953259197762236

VHL O 1 0.9491239190101624
- O 0 0.00038403665530495346
negative O 0 2.554073216742836e-05
786 O 0 0.0004367226210888475
- O 0 0.00014896427455823869
0 O 0 6.199915515026078e-05
RCC B-Disease 1 0.9999967813491821
cells O 0 9.042382771440316e-06
are O 0 1.942512710684241e-07
tumorigenic O 0 9.141994814854115e-05
in O 0 3.0932562822272303e-06
nude O 0 0.00016652078193146735
mice O 0 8.100593731796835e-06
which O 0 4.4143610011815326e-07
is O 0 2.402075836016593e-07
suppressed O 0 8.934258403314743e-06
by O 0 8.481088116241153e-07
the O 0 4.129723492951598e-06
reintroduction O 0 0.0002660937316250056
of O 0 0.00016008569218683988
VHL B-Disease 1 0.9999895095825195
. O 0 0.00031732296338304877

Remarkably O 0 0.0010272660292685032
, O 0 1.521342528576497e-05
this O 0 1.3463304640026763e-06
occurs O 0 7.621592317264003e-07
without O 0 4.4855104874841345e-07
affecting O 0 7.343586503338884e-07
the O 0 7.68987888477568e-07
growth O 0 1.4808603054916603e-06
rate O 0 4.2248166209901683e-07
and O 0 3.042484877369134e-07
cell O 0 2.0737536488013575e-06
cycle O 0 5.780540277555701e-07
profile O 0 3.0860911692798254e-07
of O 0 2.875253812817391e-07
these O 0 1.2111939895476098e-07
cells O 0 1.7656931277088006e-06
in O 0 8.510442057740875e-07
culture O 0 1.5189013538474683e-05
. O 0 1.7287453374592587e-05

The O 0 0.0001020622075884603
786 O 0 0.0013660977128893137
- O 0 0.00017923036648426205
0 O 0 2.2730067939846776e-05
cell O 0 2.9540211471612565e-05
line O 0 4.579113010549918e-06
, O 0 4.7120988710958045e-07
like O 0 4.633124319752824e-07
many O 0 1.7521310837764759e-06
cancer B-Disease 1 0.999354898929596
cells O 0 4.8984384193317965e-06
, O 0 5.958644919701328e-07
fails O 0 7.509480042244832e-07
to O 0 1.4807118020598864e-07
exit O 0 3.4659005905268714e-06
the O 0 1.5936658428472583e-06
cell O 0 2.7055339160142466e-05
cycle O 0 5.202467491471907e-06
upon O 0 6.337832473946037e-06
serum O 0 0.0001323127216892317
withdrawal O 0 6.952051626285538e-05
. O 0 4.0451399399898946e-05

Here O 0 5.80339583393652e-05
, O 0 3.4624811178218806e-06
it O 0 3.4802781101461733e-07
is O 0 7.541087398976742e-08
shown O 0 3.752139932089449e-08
that O 0 1.2901033130674477e-08
reintroduction O 0 1.3493369124262244e-06
of O 0 5.075154945188842e-07
the O 0 8.078313840087503e-07
wild O 0 1.4175862816045992e-05
- O 0 8.896183135220781e-05
type O 0 0.0001470360002713278
VHL B-Disease 1 0.999858021736145
gene O 0 5.706013325834647e-06
restores O 0 7.93084836914204e-06
the O 0 3.707132805175206e-07
ability O 0 4.892920060228789e-07
of O 0 4.710369466920383e-06
VHL O 1 0.9999916553497314
- O 0 0.0030579809099435806
negative O 0 8.237861038651317e-05
RCC B-Disease 1 1.0
cancer I-Disease 1 0.9999123811721802
cells O 0 1.0622487707223627e-06
to O 0 1.1594475068932297e-07
exit O 0 1.5876676116022281e-06
the O 0 6.50585889161448e-07
cell O 0 5.219742433837382e-06
cycle O 0 1.7191780443681637e-06
and O 0 9.222442258760566e-07
enter O 0 1.458539736631792e-05
G0 O 1 0.9994003772735596
/ O 0 0.0001588732557138428
quiescence O 0 0.00019540342327672988
in O 0 1.3162007235223427e-05
low O 0 8.401126251555979e-05
serum O 0 0.0006339167011901736
. O 0 6.367302557919174e-05

Both O 0 0.00012683241220656782
VHL O 1 0.9978252649307251
- O 0 0.00021358186495490372
positive O 0 5.4053875828685705e-06
and O 0 4.955965778208338e-06
VHL O 1 0.9998764991760254
- O 0 0.000477898953249678
negative O 0 3.8155758375069126e-05
RCC B-Disease 1 0.999998927116394
cells O 0 6.776052487111883e-06
exit O 0 3.215808419554378e-06
the O 0 9.877973070615553e-07
cell O 0 1.0447869499330409e-05
cycle O 0 3.7426880226121284e-06
by O 0 1.5254042864398798e-06
contact O 0 1.9482695279293694e-05
inhibition O 0 4.5632506953552365e-05
. O 0 3.154273144900799e-05

The O 0 0.0001370947720715776
cyclin O 0 0.0005173817044124007
- O 0 9.41396938287653e-05
dependent O 0 1.669646917434875e-05
kinase O 0 5.539777339436114e-05
inhibitor O 0 7.812764670234174e-05
, O 0 4.168583927821601e-06
p27 O 0 0.00041149742901325226
, O 0 1.1193965292477515e-06
accumulates O 0 9.118230991589371e-06
upon O 0 1.0585072232061066e-06
serum O 0 7.205765541584697e-06
withdrawal O 0 1.0147307420993457e-06
, O 0 1.6527341983874066e-07
only O 0 3.141315474408657e-08
in O 0 3.984590790651055e-08
the O 0 1.0340485090409857e-07
presence O 0 5.848618798154348e-07
of O 0 5.995381343382178e-06
VHL B-Disease 1 0.9999947547912598
, O 0 8.074401307567314e-07
as O 0 1.9305178966533276e-07
a O 0 1.1203251659708258e-07
result O 0 1.4450944263444399e-07
of O 0 3.279023701452388e-07
the O 0 7.662924303986074e-07
stabilization O 0 1.834380418586079e-05
of O 0 9.245450200978667e-06
the O 0 1.3871539522369858e-05
protein O 0 1.9694176444318146e-05
. O 0 2.3771297492203303e-05

We O 0 1.003154739009915e-05
propose O 0 5.525609140022425e-06
that O 0 3.681923033127532e-07
the O 0 6.43287307866558e-07
loss O 0 1.0325982657377608e-05
of O 0 3.541871137713315e-06
wild O 0 6.69021756039001e-05
- O 0 0.000255810737144202
type O 0 0.0005207743379287422
VHL B-Disease 1 0.9996600151062012
gene O 0 3.3367630294378614e-06
results O 0 7.528970513703825e-07
in O 0 2.660189579728467e-07
a O 0 2.813922321820428e-07
specific O 0 3.7517401096920366e-07
cellular O 0 0.0001996864884858951
defect O 0 0.0006732296897098422
in O 0 1.7243897900698357e-06
serum O 0 8.306092058774084e-05
- O 0 1.2915375918964855e-05
dependent O 0 1.0724236290116096e-06
growth O 0 8.874594072949549e-07
control O 0 1.809567834243353e-06
, O 0 2.996138448452257e-07
which O 0 2.138998524969793e-07
may O 0 2.0877407678199233e-06
initiate O 0 4.633477874449454e-05
tumor B-Disease 1 0.9974283576011658
formation O 0 0.0013162908144295216
. O 0 6.078080696170218e-05

This O 0 1.5918543795123696e-05
is O 0 3.6340650240163086e-06
corrected O 0 9.021261575981043e-06
by O 0 2.9162603709664836e-07
the O 0 3.106080441739323e-07
reintroduction O 0 5.6658332141523715e-06
of O 0 2.1104899587953696e-06
wild O 0 1.801763028197456e-05
- O 0 0.00034604931715875864
type O 0 0.044963289052248
VHL B-Disease 1 0.9999996423721313
, O 0 2.7625643269857392e-05
implicating O 1 0.9988940358161926
VHL B-Disease 1 0.9999643564224243
as O 0 4.381739472592017e-06
the O 0 4.776801233674632e-06
first O 0 1.59986739163287e-05
tumor B-Disease 1 0.9470072388648987
suppressor O 0 2.1715282855439e-05
involved O 0 5.934554110353929e-07
in O 0 1.545833470117941e-07
the O 0 2.1852716258763394e-07
regulation O 0 7.940838600006828e-07
of O 0 2.8186298095533857e-06
cell O 0 2.2981290385359898e-05
cycle O 0 2.4503801796527114e-06
exit O 0 5.404851435741875e-06
, O 0 3.30754431843161e-07
which O 0 1.137608478529728e-07
is O 0 1.038967241129285e-07
consistent O 0 2.754077286226675e-07
with O 0 1.1406340405528681e-07
its O 0 9.20103332191502e-07
gatekeeper O 0 6.038523497409187e-05
function O 0 4.923458050143381e-07
in O 0 9.157412250715424e-07
the O 0 1.978179716388695e-05
kidney O 1 0.9999970197677612
. O 0 1.867646824393887e-05
. O 0 2.8542590371216647e-05

Piebaldism B-Disease 1 0.9999983310699463
with O 0 0.005421592388302088
deafness B-Disease 1 1.0
: O 0 2.4970137019408867e-05
molecular O 0 4.383449777378701e-05
evidence O 0 7.903940058895387e-06
for O 0 1.0562081342868623e-06
an O 0 3.937184374080971e-06
expanded O 1 0.5070111155509949
syndrome O 1 0.9999959468841553
. O 0 0.00023353895812761039

In O 0 3.0886501917848364e-05
a O 0 6.465694241342135e-06
South O 0 1.1577637451409828e-05
African O 0 6.130163455964066e-06
girl O 0 2.330541428818833e-05
of O 0 2.056242556136567e-05
Xhosa O 1 0.9995100498199463
stock O 0 0.00013846160436514765
with O 0 1.4992313481343444e-05
severe O 1 0.9998799562454224
piebaldism B-Disease 1 0.9999986886978149
and O 0 0.06143234297633171
profound O 1 0.9999998807907104
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 9.378872346132994e-05
identified O 0 9.663232958700974e-06
a O 0 1.8444931129124598e-06
novel O 0 2.871372998924926e-06
missense O 0 6.133554961706977e-06
substitution O 0 4.1905304897227325e-06
at O 0 5.881136985408375e-06
a O 0 9.174405590783863e-07
highly O 0 9.211902920469583e-07
conserved O 0 2.1054481749160914e-06
residue O 0 1.1253358934482094e-05
in O 0 4.4224722728358756e-07
the O 0 3.3088281270465814e-07
intracellular O 0 1.86229522114445e-06
kinase O 0 2.8907929845445324e-06
domain O 0 5.509153311322734e-07
of O 0 8.286922934530594e-07
the O 0 3.819192897935864e-06
KIT O 1 0.9931923747062683
proto O 0 0.017252996563911438
- O 0 0.00048756261821836233
oncogene O 0 0.005167032591998577
, O 0 2.473722088325303e-05
R796G O 0 0.002491698833182454
. O 0 7.197026570793241e-05

Though O 0 0.00026571625494398177
auditory B-Disease 0 0.0033853191416710615
anomalies I-Disease 0 0.0002628002257551998
have O 0 8.951877816798515e-07
been O 0 5.110473466629628e-07
observed O 0 7.229417633425328e-07
in O 0 6.625039077334804e-07
mice O 0 3.309678504592739e-06
with O 0 4.6461684632959077e-07
dominant O 0 2.5438346710870974e-05
white O 0 4.8571062507107854e-05
spotting O 0 0.19972002506256104
( O 0 1.9015531506738625e-05
W O 0 0.493202805519104
) O 0 9.459937473366153e-07
due O 0 2.5071476557059214e-06
to O 0 2.254343826280092e-06
KIT O 1 0.999998927116394
mutations O 0 0.0003051673120353371
, O 0 8.338774205185473e-05
deafness B-Disease 1 1.0
is O 0 2.237423359474633e-06
not O 0 4.603492129717779e-07
typical O 0 3.4151294130424503e-06
in O 0 2.0505535758275073e-06
human O 0 1.5258672647178173e-05
piebaldism B-Disease 0 0.24196000397205353
. O 0 9.207120456267148e-05

Thus O 0 3.580495103960857e-05
, O 0 3.232399649277795e-06
the O 0 1.3322096492629498e-06
occurrence O 0 2.495937587809749e-05
of O 0 0.1430424302816391
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 0.023724863305687904
this O 0 7.773844117764384e-06
patient O 0 8.759725460549816e-05
extends O 0 4.171972705080407e-06
considerably O 0 1.85423368748161e-06
the O 0 5.996017193865555e-07
phenotypic O 0 3.1724257496534847e-06
range O 0 1.4326132031783345e-06
of O 0 3.5246323477622354e-06
piebaldism B-Disease 0 0.0005565923056565225
due O 0 2.9057184747216525e-06
to O 0 1.2912255442643072e-06
KIT O 1 0.9999608993530273
gene O 0 4.930571321892785e-06
mutation O 0 4.99593795666442e-07
in O 0 3.170945319652674e-07
humans O 0 7.958366836646746e-07
and O 0 4.901812644675374e-07
tightens O 0 1.4099417057877872e-05
the O 0 1.5552824379483354e-06
clinical O 0 1.6233821952482685e-05
similarity O 0 1.4599860378439189e-06
between O 0 1.1312509968774975e-06
piebaldism B-Disease 0 0.012174545787274837
and O 0 4.630244347936241e-07
the O 0 5.594858407675929e-07
various O 0 5.492156560649164e-07
forms O 0 1.2314099876675755e-05
of O 1 0.9683336019515991
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00033322031958959997
. O 0 0.00021500659931916744

Cycloheximide O 0 0.016381574794650078
facilitates O 0 3.962566188420169e-05
the O 0 3.643562649813248e-06
identification O 0 5.185675036045723e-06
of O 0 6.613887308049016e-06
aberrant O 0 2.5922450731741264e-05
transcripts O 0 1.3843760825693607e-05
resulting O 0 3.894830570061458e-06
from O 0 1.7525088651382248e-06
a O 0 1.0135778438780108e-06
novel O 0 2.647279870870989e-06
splice O 0 7.102095696609467e-05
- O 0 2.5296099920524284e-05
site O 0 1.5882760635577142e-05
mutation O 0 1.685708980403433e-06
in O 0 1.3723818028665846e-06
COL17A1 O 1 0.9946904182434082
in O 0 3.162710981996497e-06
a O 0 8.377737685805187e-06
patient O 0 8.254390559159219e-05
with O 0 6.455632956203772e-06
generalized O 1 0.9987291693687439
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999922513961792
. O 0 0.0013610848691314459

Patients O 0 0.001648942125029862
with O 0 5.363107266020961e-05
generalized O 1 0.9991920590400696
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999890327453613
often O 0 2.0145613234490156e-05
show O 0 1.1093568900832906e-05
decreased O 0 7.965277291077655e-06
expression O 0 2.3735071863484336e-06
of O 0 6.49074627290247e-06
type O 0 0.008804618380963802
XVII O 1 1.0
collagen O 1 0.9999899864196777
, O 0 2.862051951524336e-05
a O 0 8.63195145939244e-06
transmembrane O 0 8.950974734034389e-05
hemidesmosomal O 0 0.0004653310461435467
protein O 0 6.074730663385708e-06
encoded O 0 3.3684095797070768e-06
by O 0 1.1284953870926984e-05
COL17A1 O 1 0.9963461756706238
. O 0 0.00021080383157823235

This O 0 1.3057114301773254e-05
report O 0 3.2993891636579065e-06
documents O 0 6.311040124273859e-06
a O 0 2.4951807517936686e-06
novel O 0 1.1193228601769079e-05
splice O 0 0.00023104313004296273
- O 0 3.7337944377213717e-05
site O 0 1.609654282219708e-05
mutation O 0 1.6774133655417245e-06
in O 0 7.831921493561822e-07
COL17A1 O 1 0.9993582367897034
in O 0 2.196951527366764e-06
a O 0 6.434114766307175e-06
patient O 0 5.9429432440083474e-05
with O 0 2.769286993498099e-06
generalized O 1 0.9963627457618713
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999954700469971
, O 0 1.783156221790705e-05
and O 0 1.2485031675169012e-06
applies O 0 5.43562578059209e-07
a O 0 1.8765814502330613e-07
new O 0 3.073614038839878e-07
methodology O 0 1.5657685707992641e-06
to O 0 1.496358237318418e-07
define O 0 9.048144420376047e-07
and O 0 8.627183092357882e-07
characterize O 0 1.0513418601476587e-05
the O 0 2.3288985175895505e-06
resulting O 0 9.891689842334017e-06
mRNA O 0 3.38118479703553e-05
splice O 0 0.000461713905679062
variants O 0 9.329206659458578e-05
. O 0 6.135202420409769e-05

Mutational O 0 0.0015801836270838976
analysis O 0 4.3805666791740805e-05
of O 0 7.04622725606896e-05
COL17A1 O 1 0.9955794215202332
identified O 0 1.4958868632675149e-05
a O 0 4.607612481777323e-06
maternally O 0 0.00010586750431684777
inherited O 0 0.004067533183842897
G O 0 0.00171381002292037
- O 0 3.130879485979676e-05
to O 0 2.8535525871120626e-06
- O 0 0.000132673405460082
T O 0 0.009238287806510925
transversion O 0 0.00011198735592188314
at O 0 3.1401646083395462e-06
the O 0 6.443126494559692e-07
- O 0 2.775386519715539e-06
1 O 0 1.6234125723713078e-06
position O 0 1.78170841991232e-06
of O 0 3.1558267892251024e-06
exon O 0 0.00017874293553177267
32 O 0 7.374553388217464e-05
. O 0 3.4963086363859475e-05

This O 0 8.63234708958771e-06
acceptor O 0 4.8665966460248455e-05
splice O 0 0.00032852377626113594
- O 0 6.16564866504632e-05
site O 0 2.2482579879579134e-05
mutation O 0 1.146885665548325e-06
led O 0 1.1409423450459144e-06
to O 0 1.8447676097821386e-07
the O 0 9.05615593183029e-07
formation O 0 1.4874282896926161e-05
of O 0 6.828851837781258e-06
aberrant O 0 3.337902671773918e-05
transcripts O 0 8.724136932869442e-06
present O 0 2.755359219008824e-06
at O 0 1.1984042430412956e-05
extremely O 0 6.623758508794708e-06
low O 0 2.0418196072569117e-05
levels O 0 1.773066833266057e-05
. O 0 1.85667031473713e-05

Based O 0 7.313276000786573e-05
on O 0 8.039593922148924e-06
our O 0 1.7252781390197924e-06
recent O 0 8.746494017941586e-07
finding O 0 1.8239500150230015e-06
that O 0 6.354557058330101e-07
cycloheximide O 0 0.00024475660757161677
stabilized O 0 0.00017732565174810588
mutant O 0 7.608063606312498e-05
COL17A1 O 0 0.08447719365358353
transcripts O 0 3.709840530063957e-05
in O 0 1.8407098423267598e-06
keratinocytes O 0 1.9896051526302472e-05
homozygous O 0 2.2393551262211986e-06
for O 0 3.21681625337078e-07
a O 0 2.1857563297089655e-06
frameshift O 0 4.720528158941306e-05
mutation O 0 1.4292152172856731e-06
, O 0 2.404055976512609e-07
the O 0 2.95548886697361e-07
effects O 0 1.8224965288027306e-06
of O 0 1.2068258001818322e-06
the O 0 1.2139594218751881e-06
splice O 0 0.0001158328159363009
- O 0 9.082225005840883e-06
site O 0 4.3601717152341735e-06
mutation O 0 4.0563196535003954e-07
on O 0 1.8249002664560976e-07
splicing O 0 2.7321236757416045e-06
of O 0 2.2334177174343495e-06
COL17A1 O 0 0.2851843237876892
transcripts O 0 7.083031505317194e-06
were O 0 6.268138008636015e-07
determined O 0 5.672790734934097e-07
using O 0 4.960185151503538e-07
reverse O 0 2.20112269744277e-06
transcriptase O 0 4.6400673454627395e-06
polymerase O 0 6.020712135068607e-06
chain O 0 1.8626896007845062e-06
reaction O 0 2.585844924851699e-07
of O 0 3.213906154542201e-07
total O 0 2.86271699678764e-07
RNA O 0 1.889869508886477e-06
from O 0 8.557638011552626e-07
keratinocytes O 0 5.558451903198147e-06
incubated O 0 3.757615786526003e-06
for O 0 1.8868259985538316e-06
2 O 0 2.4363494958379306e-05
. O 0 1.9658917153719813e-05

5 O 0 0.0001355846325168386
h O 0 6.27933768555522e-05
in O 0 2.000379936362151e-06
the O 0 8.042093782023585e-07
presence O 0 1.1727963737939717e-06
or O 0 3.4904257972812047e-07
absence O 0 2.9859315873181913e-06
of O 0 4.945669388689566e-06
10 O 0 1.4761938473384362e-05
microg O 0 0.07619283348321915
cycloheximide O 0 0.00228724698536098
per O 0 2.1545987692661583e-05
ml O 0 0.0005372991436161101
. O 0 6.947372457943857e-05

Using O 0 1.733943099679891e-05
this O 0 1.0979988473991398e-06
approach O 0 2.174956080125412e-06
, O 0 7.297704769371194e-07
an O 0 4.282178451830987e-07
abnormally O 0 2.3198866983875632e-05
spliced O 0 2.5127028493443504e-05
transcript O 0 1.9435650756349787e-05
was O 0 8.791947038844228e-06
identified O 0 3.8215210906855646e-07
that O 0 7.312488037314324e-08
contains O 0 2.2826030487976823e-07
an O 0 1.1322066484353854e-07
extra O 0 4.7166980721158325e-07
264 O 0 3.4611441606102744e-06
bases O 0 1.3452126950141974e-06
upstream O 0 2.229440269729821e-06
from O 0 1.0187080761170364e-06
exon O 0 1.3199931345297955e-05
32 O 0 2.849484189937357e-06
, O 0 3.3112840469584626e-07
resulting O 0 6.895911610627081e-07
in O 0 5.246604359854246e-07
a O 0 1.4169088444759836e-06
premature O 0 2.7802057957160287e-05
termination O 0 3.0357856303453445e-05
codon O 0 3.408454358577728e-05
27 O 0 1.6291389329126105e-05
bp O 0 1.7724649296724238e-05
downstream O 0 9.57519660005346e-06
from O 0 1.8166415429732297e-06
the O 0 3.726418754013139e-06
cryptic O 0 0.00016097500338219106
splice O 0 0.0006884768372401595
site O 0 0.00026328000240027905
. O 0 8.486928709316999e-05

Three O 0 1.5196431377262343e-05
other O 0 2.0156921891612e-06
splice O 0 0.00010082546214107424
variants O 0 1.0359973202866968e-05
, O 0 1.037214474308712e-06
including O 0 6.312542382147512e-07
one O 0 4.132782578381011e-07
derived O 0 1.0521405329200206e-06
from O 0 7.321950192817894e-07
the O 0 6.440103561544674e-07
skipping O 0 1.339883601758629e-05
of O 0 2.031980102401576e-06
exon O 0 2.881300861190539e-05
32 O 0 4.548867309495108e-06
, O 0 4.1315058751933975e-07
were O 0 4.1194982713932404e-07
also O 0 1.3046084177403827e-06
identified O 0 1.1736271517293062e-05
. O 0 2.1188281607464887e-05

These O 0 8.339960004377645e-06
results O 0 5.750898708356544e-06
indicate O 0 2.1911889689363306e-06
the O 0 1.010748860608146e-06
usefulness O 0 1.2195815543236677e-05
of O 0 8.828521458781324e-06
cycloheximide O 0 0.4357728660106659
treatment O 0 1.4844835277472157e-05
in O 0 7.088877964633866e-07
evaluating O 0 2.362883378737024e-06
the O 0 1.5006957028163015e-06
abnormal O 0 3.3378896659996826e-06
processing O 0 2.9937184535810957e-06
of O 0 1.5351427009591134e-06
mRNA O 0 2.3774966848577606e-06
due O 0 1.1907541193068027e-06
to O 0 4.894077392236795e-07
splice O 0 0.0001060449139913544
- O 0 1.9229586541769095e-05
site O 0 1.7463678886997513e-05
mutations O 0 1.0621434967106325e-06
, O 0 5.313195288181305e-07
because O 0 6.175893645377073e-07
( O 0 1.055937104865734e-06
i O 0 1.6127772823892883e-06
) O 0 3.3363701845701144e-07
aberrant O 0 3.2597843073745025e-06
splicing O 0 3.786758270507562e-06
often O 0 3.922213807072694e-07
generates O 0 1.8859858528230689e-06
a O 0 1.6298721448038123e-06
premature O 0 8.710552720003761e-06
termination O 0 5.65800428375951e-06
codon O 0 8.473613888781983e-06
, O 0 8.763100254327583e-07
( O 0 7.266647230608214e-07
ii O 0 0.1210721805691719
) O 0 7.449278314197727e-07
transcripts O 0 6.522149305965286e-06
with O 0 8.21738524336979e-07
premature O 0 9.258731006411836e-05
termination O 0 6.41496226307936e-05
codons O 0 4.69529595648055e-06
can O 0 1.1268873123526646e-07
occur O 0 1.2156051809597557e-07
at O 0 1.7563419305588468e-06
low O 0 2.112056336045498e-06
or O 0 9.298311738348275e-07
undetectable O 0 5.9896668972214684e-05
levels O 0 4.579815424676781e-07
due O 0 4.27916546641427e-07
to O 0 2.07048969969037e-07
nonsense O 0 4.990546585759148e-06
- O 0 2.5647309485066216e-06
mediated O 0 2.3936338493513176e-06
mRNA O 0 1.3839647863278515e-06
decay O 0 7.715751962678041e-06
, O 0 2.890501491492614e-07
and O 0 4.777306230607792e-07
( O 0 7.338951490964973e-07
iii O 0 0.09830145537853241
) O 0 5.221451715442527e-07
the O 0 3.4696699913183693e-07
levels O 0 3.372281298652524e-07
of O 0 3.001325978857494e-07
these O 0 1.3008002497372217e-07
transcripts O 0 2.89529589281301e-06
can O 0 1.8253459188599663e-07
be O 0 3.688276990487793e-07
increased O 0 1.4986848100306815e-06
by O 0 9.815948942559771e-06
cycloheximide O 0 0.01008380576968193
. O 0 0.00010124746768269688

A O 0 0.00023373992007691413
deletion O 0 6.149911496322602e-05
mutation O 0 9.474904800299555e-06
in O 0 3.576561084628338e-06
COL17A1 O 1 0.9979957342147827
in O 0 2.1837477106601e-06
five O 0 1.6370129287679447e-06
Austrian O 0 0.0007152528851293027
families O 0 2.1279577140376205e-06
with O 0 9.833366675593425e-06
generalized O 1 0.9993420243263245
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999523162841797
represents O 0 6.844623567303643e-05
propagation O 0 8.01024361862801e-05
of O 0 1.712670382403303e-05
an O 0 9.161105481325649e-06
ancestral O 0 0.0017538712127134204
allele O 0 7.898204785306007e-05
. O 0 3.799776459345594e-05

Patients O 0 0.00428495928645134
with O 0 9.46021536947228e-05
generalized O 1 0.9995255470275879
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999998927116394
, O 0 5.972407598164864e-05
a O 0 6.961512553971261e-06
usually O 0 1.911721938085975e-06
nonlethal O 0 8.318998152390122e-05
form O 0 1.0006361662817653e-05
of O 0 0.00047811673721298575
junctional B-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999949932098389
, O 0 1.3101169315632433e-05
have O 0 9.779682841326576e-07
generalized O 0 3.6375502531882375e-05
blistering B-Disease 1 0.7088995575904846
, O 0 0.004525159019976854
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 1 0.9817973375320435
patchy B-Disease 1 0.9999998807907104
alopecia I-Disease 1 1.0
, O 0 0.4906676113605499
and O 1 0.9704802632331848
dental B-Disease 1 1.0
abnormalities I-Disease 1 0.9999998807907104
. O 0 0.003105789888650179

Skin B-Disease 1 0.9999991655349731
fragility I-Disease 1 0.9842590689659119
in O 0 1.449208411941072e-05
most O 0 1.5161859892032226e-06
cases O 0 8.833447395772964e-07
is O 0 2.0314905668783467e-07
due O 0 5.197649102228752e-07
to O 0 9.211711926582211e-08
mutations O 0 1.688715087766468e-07
in O 0 1.018389994555946e-07
the O 0 3.208305088264751e-07
gene O 0 1.1585470929276198e-06
encoding O 0 3.4145205063396133e-06
type O 0 0.00040773925138637424
XVII O 1 1.0
collagen O 1 0.9999991655349731
( O 0 0.000735461013391614
COL17A1 O 1 0.9999951124191284
) O 0 5.89299997955095e-05
. O 0 4.261770664015785e-05

Recently O 0 0.0002688550448510796
, O 0 4.259298748365836e-06
we O 0 9.818577382247895e-07
reported O 0 1.8948649085359648e-06
five O 0 1.4581353298126487e-06
Austrian O 0 9.206945105688646e-05
families O 0 2.152579554604017e-06
with O 0 1.2563283235067502e-05
generalized O 1 0.9997645020484924
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999731779098511
who O 0 4.430966146173887e-05
share O 0 5.206477908359375e-06
the O 0 6.426203981391154e-06
same O 0 2.9532297048717737e-05
COL17A1 O 1 0.9999872446060181
mutation O 0 0.0001278263225685805
. O 0 5.453277481137775e-05

Affected O 0 7.754992839181796e-05
individuals O 0 1.4550431615134585e-06
in O 0 7.940733439681935e-07
three O 0 2.165058958780719e-07
families O 0 9.776198339750408e-08
are O 0 3.6929964863929854e-08
homozygous O 0 6.526739753098809e-07
for O 0 4.191263371922105e-07
4003delTC O 0 0.00019849852833431214
, O 0 8.691547463968163e-07
whereas O 0 4.242214117766707e-07
those O 0 9.22657008572969e-08
in O 0 1.8423678227463824e-07
two O 0 1.5741380821054918e-07
others O 0 6.067986078051035e-07
are O 0 3.78371908027475e-07
compound O 0 9.617960313335061e-05
heterozygotes O 0 0.0006291269091889262
. O 0 7.345806079683825e-05

To O 0 1.1765024282794911e-05
determine O 0 4.754009296448203e-06
if O 0 5.142682653058728e-07
the O 0 4.853417294725659e-07
occurrence O 0 1.8485818600311177e-06
of O 0 1.998122343138675e-06
4003delTC O 0 7.879098848206922e-05
in O 0 4.3872068999917246e-07
these O 0 5.093842148085059e-08
unrelated O 0 1.2474403092710418e-06
families O 0 1.1548259948312989e-07
signifies O 0 3.2970049232972087e-06
propagation O 0 4.247624474373879e-06
of O 0 1.2049960105287028e-06
an O 0 4.000827402705909e-07
ancestral O 0 2.0424018657649867e-05
allele O 0 1.2128508615205646e-06
or O 0 4.11871241112749e-07
a O 0 9.124242410507577e-07
mutational O 0 6.72123787808232e-05
hot O 0 4.211178020341322e-05
spot O 0 3.2739335438236594e-05
, O 0 6.718518648085592e-07
haplotypes O 0 2.2359047306963475e-06
were O 0 2.6801436092682707e-07
determined O 0 5.102759814690216e-07
for O 0 3.515993967084796e-07
polymorphisms O 0 3.0877181416144595e-06
both O 0 4.607985601978726e-07
within O 0 2.5242343326681294e-06
and O 0 1.2072368917870335e-05
flanking O 1 0.8011069297790527
COL17A1 O 1 0.9999957084655762
. O 0 0.000270510878181085

Five O 0 0.0001038948175846599
intragenic O 0 0.000941030855756253
polymorphisms O 0 2.550482895458117e-05
were O 0 1.5639315051885205e-06
chosen O 0 2.710288072194089e-06
based O 0 1.8395691085970611e-06
on O 0 4.534128947852878e-06
their O 0 1.0155634299735539e-05
informativeness O 0 0.25660187005996704
. O 0 9.73944625002332e-05

One O 0 2.044257053057663e-05
of O 0 4.346678906586021e-06
these O 0 3.850064729249425e-07
, O 0 4.232079504618014e-07
not O 0 9.317167837252782e-08
previously O 0 1.6849182884470792e-06
reported O 0 7.838601163712156e-07
, O 0 2.8192701506668527e-07
was O 0 9.641638825996779e-06
2988 O 0 0.0003288051811978221
A O 0 9.905907063512132e-06
or O 0 1.2605495385287213e-06
C O 0 2.8229742383700795e-05
that O 0 8.01860053911696e-08
introduces O 0 1.515700205345638e-06
a O 0 2.813331718698464e-07
new O 0 2.0982967896543414e-07
restriction O 0 6.195638775352563e-07
site O 0 7.104097221599659e-06
for O 0 1.982771436814801e-06
Eco0109 O 0 0.10355598479509354
I O 0 0.0009657107293605804
. O 0 4.816961518372409e-05

All O 0 2.906974077632185e-05
the O 0 8.00964880909305e-06
4003delTC O 0 0.00015520922897849232
alleles O 0 2.050514467555331e-06
showed O 0 2.402566678938456e-06
the O 0 6.19988725247822e-07
same O 0 3.6668654956883984e-07
haplotype O 0 2.6414470539748436e-06
for O 0 3.2860199894457764e-07
these O 0 2.9095596687511716e-07
five O 0 2.4470641619700473e-06
polymorphic O 0 0.0001052442385116592
markers O 0 0.0003458620049059391
. O 0 6.375845259753987e-05

Fourteen O 0 0.0003527702356223017
microsatellite O 0 0.0003703029069583863
polymorphisms O 0 1.6040148693718947e-05
were O 0 1.0545624036240042e-06
selected O 0 1.4146661442282493e-06
based O 0 7.402609298878815e-07
on O 0 3.079450152654317e-07
their O 0 2.0139751200076716e-07
high O 0 1.085835447156569e-05
heterozygosity O 0 0.0006498737493529916
and O 0 6.006146691106551e-07
their O 0 2.866623844965943e-07
location O 0 3.18598176818341e-06
within O 0 3.0038797831366537e-06
10q23 O 0 0.001025997451506555
- O 0 0.00030339599470607936
q25 O 0 0.019290609285235405
near O 0 0.0017002577660605311
COL17A1 O 1 0.9993259906768799
. O 0 0.00013866217341274023

Three O 0 2.7276088076177984e-05
families O 0 3.7864440400880994e-06
shared O 0 1.6431285985163413e-05
microsatellite O 0 0.00022860254102852196
polymorphisms O 0 3.878166899085045e-05
covering O 0 9.9080047220923e-05
at O 0 3.0351546229212545e-05
most O 0 1.3318679066287586e-06
19 O 0 9.3228263722267e-06
cM O 0 1.531850648461841e-05
, O 0 5.821528930027853e-07
whereas O 0 9.050517633113486e-07
the O 0 3.656529088402749e-07
others O 0 2.203717741622313e-07
shared O 0 3.50825359873852e-07
smaller O 0 3.26890727819773e-07
regions O 0 2.8518010708467045e-07
consistent O 0 8.488378853144241e-07
with O 0 4.279667678019905e-07
cross O 0 7.1216663855011575e-06
- O 0 9.431486432731617e-06
over O 0 7.173021003836766e-07
events O 0 3.458520154708822e-07
during O 0 1.084589143829362e-06
passage O 0 3.6644743772740185e-07
of O 0 5.788031671727367e-07
this O 0 1.294153122444186e-07
mutation O 0 2.815361028751795e-07
through O 0 4.985624286746315e-07
several O 0 1.9027656890102662e-06
generations O 0 5.2811028581345454e-05
. O 0 5.255801079329103e-05

These O 0 8.988835361378733e-06
results O 0 6.453724836319452e-06
indicate O 0 2.5730284960445715e-06
that O 0 6.481811283265415e-07
4003delTC O 0 6.49992871331051e-05
occurs O 0 1.342680093330273e-06
on O 0 9.283974691243202e-07
a O 0 1.6497390333825024e-06
single O 0 3.4180879993073177e-06
ancestral O 0 5.0507642299635336e-05
allele O 0 1.4967243259889074e-05
. O 0 3.875755737681175e-06
. O 0 1.3976894479128532e-05

The O 0 0.00023065094137564301
haptoglobin O 0 0.003935444634407759
- O 0 0.0004921731888316572
gene O 0 3.9167163777165115e-05
deletion O 0 4.0414422983303666e-05
responsible O 0 3.112084596068598e-05
for O 0 3.43166284437757e-05
anhaptoglobinemia B-Disease 1 0.9882661700248718
. O 0 0.0002451122854836285

We O 0 1.1017773431376554e-05
have O 0 4.299778879612859e-07
found O 0 4.651000722333265e-07
an O 0 2.0912111153847945e-07
allelic O 0 1.3719401977141388e-05
deletion O 0 4.85762166135828e-06
of O 0 2.8072126951883547e-06
the O 0 3.8481157389469445e-06
haptoglobin O 0 0.0016258020186796784
( O 0 3.0606640848418465e-06
Hp O 0 7.793246913934126e-05
) O 0 5.491449996952724e-07
gene O 0 5.472278985507728e-07
from O 0 2.0889646634714154e-07
an O 0 1.950880061940552e-07
individual O 0 5.182167228667822e-07
with O 0 4.145265847910196e-06
anhaptoglobinemia B-Disease 1 0.9992504715919495
. O 0 7.369274680968374e-05

The O 0 0.00016292938380502164
Hp O 0 0.0006725909188389778
gene O 0 1.958746724994853e-05
cluster O 0 4.402318154461682e-05
consists O 0 3.989849119534483e-06
of O 0 2.5013775939441985e-06
coding O 0 4.964940217178082e-06
regions O 0 4.2906810904241866e-07
of O 0 1.4431597037400934e-06
the O 0 1.0216540431429166e-06
alpha O 0 1.072033410309814e-05
chain O 0 2.106608917529229e-06
and O 0 2.6337070835324994e-07
beta O 0 1.2097664239263395e-06
chain O 0 9.169113468487922e-07
of O 0 3.54246168399186e-07
the O 0 8.787813499111508e-07
haptoglobin O 0 7.634605572093278e-05
gene O 0 3.162955181323923e-06
( O 0 8.558511694900517e-07
Hp O 0 2.006330578296911e-05
) O 0 2.919463213402196e-07
and O 0 2.0502277209288877e-07
of O 0 6.108938919169304e-07
the O 0 6.110273602644156e-07
alpha O 0 9.493679499428254e-06
chain O 0 2.9089210329402704e-06
and O 0 1.89829464147806e-07
beta O 0 6.622543651246815e-07
chain O 0 7.132488235583878e-07
of O 0 3.290576842118753e-07
the O 0 4.295880842164479e-07
haptoglobin O 0 3.144368383800611e-05
- O 0 4.930533577862661e-06
related O 0 4.11752034779056e-06
gene O 0 3.1368601867143298e-06
( O 0 1.1231359167140909e-06
Hpr O 0 0.00012838898692280054
) O 0 6.400086363100854e-07
, O 0 2.7105338062938245e-07
in O 0 1.722542606330535e-07
tandem O 0 8.385707587876823e-06
from O 0 2.6799571060109884e-06
the O 0 3.7890085877734236e-06
5 O 0 2.3204907847684808e-05
side O 0 3.4136490285163745e-05
. O 0 2.0051387764397077e-05

Southern O 0 0.0003344296710565686
blot O 0 0.0005432702018879354
and O 0 4.823742074222537e-06
PCR O 0 4.754334077006206e-05
analyses O 0 2.870568096113857e-06
have O 0 1.7918645767167618e-07
indicated O 0 3.502015601952735e-07
that O 0 4.089474359147971e-08
the O 0 1.1431691859797866e-07
individual O 0 6.681032260758002e-08
with O 0 2.970702723814611e-07
anhaptoglobinemia B-Disease 0 0.03936002403497696
was O 0 1.8413069483358413e-05
homozygous O 0 6.930947620276129e-07
for O 0 1.1391089316248326e-07
the O 0 3.199633624717535e-07
gene O 0 6.773582867936057e-07
deletion O 0 1.0851736078620888e-06
and O 0 1.3376032370615576e-07
that O 0 6.787809780917087e-08
the O 0 4.834523110730515e-07
gene O 0 1.0911292065429734e-06
deletion O 0 1.1449163821453112e-06
was O 0 2.9559073482232634e-06
included O 0 4.224965834964678e-07
at O 0 9.943529448719346e-07
least O 0 7.990036010596668e-08
from O 0 2.455523997468845e-07
the O 0 5.635481556964805e-07
promoter O 0 0.000516542058903724
region O 0 1.3144795047992375e-06
of O 0 3.5364471386856167e-06
Hp O 0 0.0002399937220616266
to O 0 1.8672855048862402e-06
Hpr O 0 0.00019867101218551397
alpha O 0 1.2209140550112352e-05
but O 0 2.0999465277782292e-07
not O 0 9.16668554395983e-08
to O 0 4.4612110627895163e-07
Hpr O 0 0.00012162500934209675
beta O 0 5.400974259828217e-05
( O 0 1.3108005077810958e-05
Hpdel O 0 0.06539911776781082
) O 0 1.7546646631672047e-05
. O 0 3.0033759685466066e-05

In O 0 2.856628088920843e-05
addition O 0 1.2327012882451527e-05
, O 0 1.7803224636736559e-06
we O 0 1.595702343593075e-07
found O 0 2.493377166956634e-07
seven O 0 2.2394847576379107e-07
individuals O 0 2.9774408716320977e-08
with O 0 2.3531926274245052e-07
hypohaptoglobinemia B-Disease 0 0.40454965829849243
in O 0 7.487482776014076e-07
three O 0 2.402098573384137e-07
families O 0 1.0692318141991564e-07
, O 0 2.0626045227345458e-07
and O 0 1.9498459380429267e-07
the O 0 4.443288617039798e-07
genotypes O 0 2.547849135225988e-06
of O 0 9.728827308208565e-07
six O 0 4.009069698440726e-07
of O 0 9.872152304524207e-07
the O 0 9.889038210530998e-07
seven O 0 6.929434448466054e-07
individuals O 0 4.808305220649345e-08
were O 0 4.685878991494974e-07
found O 0 8.731825005270366e-07
to O 0 7.044035896797141e-07
be O 0 4.440939392225118e-06
Hp2 O 1 0.9998589754104614
/ O 1 0.6985762119293213
Hpdel O 1 0.9773566126823425
. O 0 0.00013317062985152006

The O 0 0.00011342392099322751
phenotypes O 0 7.231831114040688e-05
and O 0 3.847576408588793e-06
genotypes O 0 1.6531028450117446e-05
in O 0 7.893227120803203e-07
one O 0 3.7294796584319556e-07
of O 0 3.718477330494352e-07
these O 0 5.7502454353652865e-08
three O 0 1.4403585169020516e-07
families O 0 1.1857945736437614e-07
showed O 0 7.353215778493905e-07
the O 0 2.8050723699379887e-07
father O 0 2.3643553959118435e-06
to O 0 1.6355026843939413e-07
be O 0 3.2095627489070466e-07
hypohaptoglobinemic B-Disease 0 0.0025374731048941612
( O 0 2.9469454148056684e-06
Hp2 O 0 0.4285191297531128
) O 0 1.0768468428068445e-06
and O 0 1.2573293588502565e-06
Hp2 O 1 0.9993264675140381
/ O 0 0.0034453568514436483
Hpdel O 0 0.32152920961380005
, O 0 1.7031660490829381e-06
the O 0 1.3965963034934248e-06
mother O 0 1.2106078202123172e-06
to O 0 1.346209472785631e-07
be O 0 1.3099739248900732e-07
Hp2 O 0 0.0001585191785125062
- O 0 8.811892257654108e-06
1 O 0 2.9262216685310705e-06
and O 0 1.229511440214992e-06
Hp1 O 1 0.9971857666969299
/ O 0 0.00045287192915566266
Hp2 O 0 0.008880998939275742
, O 0 5.601756356554688e-07
one O 0 9.134849676684098e-08
of O 0 1.512895693167593e-07
the O 0 2.483966738964227e-07
two O 0 5.469160058169109e-08
children O 0 1.8192615414136526e-07
to O 0 9.321932026296054e-08
be O 0 3.619185520165047e-07
hypohaptoglobinemic B-Disease 0 0.04375800862908363
( O 0 3.812816657955409e-06
Hp2 O 0 0.35191741585731506
) O 0 8.602855814388022e-07
and O 0 1.370214818052773e-06
Hp2 O 1 0.9998489618301392
/ O 0 0.013006451539695263
Hpdel O 1 0.9148955941200256
, O 0 8.120278494061495e-07
and O 0 1.5935199826344615e-07
the O 0 1.9651874083592702e-07
other O 0 1.2398609783303982e-07
child O 0 8.743649573261791e-07
to O 0 1.9721473165645875e-07
be O 0 4.0861615957510367e-07
Hp1 O 0 0.05501847714185715
and O 0 4.757614988193382e-06
Hp1 O 1 0.9999773502349854
/ O 0 0.021350862458348274
Hpdel O 0 0.4786495864391327
, O 0 1.7028947922881343e-06
showing O 0 1.4445448641708936e-06
an O 0 2.8779587069038826e-07
anomalous O 0 1.8112694306182675e-05
inheritance O 0 1.5948722648317926e-05
of O 0 3.3161850296892226e-05
Hp O 0 0.004200063645839691
phenotypes O 0 2.460948053339962e-05
in O 0 1.5400814845634159e-06
the O 0 6.9300358518376015e-06
child O 0 3.280318560427986e-05
with O 0 6.906692306074547e-06
Hp1 O 1 0.9994537234306335
. O 0 0.00024222498177550733

The O 0 0.0005762274377048016
Hp2 O 1 0.9999866485595703
/ O 1 0.8581154346466064
Hpdel O 0 0.3718247413635254
individuals O 0 9.862045544650755e-07
had O 0 2.0907832549710292e-06
an O 0 3.597718887249357e-07
extremely O 0 1.0442155371492845e-06
low O 0 2.7110377232020255e-06
level O 0 1.2526820682978723e-06
of O 0 1.7925343627211987e-06
Hp O 0 6.242356903385371e-05
( O 0 1.6649535155011108e-06
mean O 0 1.6905339634831762e-06
+ O 0 6.258149369386956e-06
/ O 0 6.866459898446919e-06
- O 0 6.08872596785659e-06
SD O 0 5.36738516530022e-05
= O 0 1.3913119119024486e-06
0 O 0 6.060855639589136e-07
. O 0 1.8091779452333867e-07
049 O 0 1.902780968521256e-05
+ O 0 2.754928345893859e-06
/ O 0 2.766576244539465e-06
- O 0 1.6406060012741364e-06
0 O 0 7.706713063271309e-07
. O 0 1.8698270309869258e-07
043 O 0 1.5941088349791244e-05
mg O 0 2.9249495128169656e-05
/ O 0 9.411962309968658e-06
ml O 0 8.473726666125003e-06
; O 0 2.561623944075109e-07
n O 0 7.605175937897002e-07
= O 0 7.360877134487964e-07
6 O 0 9.049680897987855e-07
) O 0 1.3875870763513376e-07
, O 0 6.011899955638e-08
compared O 0 7.065330720479324e-08
with O 0 1.708594155047649e-08
the O 0 2.039717941215713e-07
level O 0 7.353460773629195e-07
( O 0 1.9377799276298902e-07
1 O 0 4.4731905290973373e-07
. O 0 1.1865333249261312e-07
64 O 0 1.8541824147177977e-06
+ O 0 2.619854058139026e-06
/ O 0 3.972301328758476e-06
- O 0 2.750840849330416e-06
1 O 0 1.1827345360870822e-06
. O 0 3.320768087178294e-07
07 O 0 3.610545172705315e-05
mg O 0 6.226554251043126e-05
/ O 0 1.3667323401023168e-05
ml O 0 6.704190127493348e-06
) O 0 1.2594232146057038e-07
obtained O 0 2.651658803642931e-07
from O 0 4.459347735519259e-07
52 O 0 2.2071428702474805e-06
healthy O 0 8.460786489195016e-07
volunteers O 0 2.158316647182801e-06
having O 0 3.154196292598499e-06
phenotype O 0 9.951119864126667e-06
Hp2 O 0 0.002783629111945629
, O 0 1.1133025736853597e-06
whereas O 0 7.005688757999451e-07
the O 0 6.221672492756625e-07
serum O 0 1.4833247405476868e-05
Hp O 0 2.2520560378325172e-05
level O 0 1.1524730325618293e-06
of O 0 4.371011073089903e-07
an O 0 1.2290139750348317e-07
individual O 0 3.2051184462034144e-07
with O 0 1.8796205267790356e-06
Hp1 O 1 0.999972939491272
/ O 0 0.16666638851165771
Hpdel O 1 0.8328621983528137
was O 0 0.00024330499581992626
0 O 0 5.031966793467291e-05
. O 0 2.9278904548846185e-05

50 O 0 0.0002020369574893266
mg O 0 0.0021248094271868467
/ O 0 0.00035441727959550917
ml O 0 0.00012217459152452648
, O 0 1.7807266203817562e-06
which O 0 3.214423998088023e-07
was O 0 2.64254299509048e-06
approximately O 0 4.462419269657403e-07
half O 0 2.207116551744548e-07
the O 0 2.21689646195955e-07
level O 0 7.676411541979178e-07
of O 0 1.221864522449323e-06
Hp O 0 3.4035394492093474e-05
in O 0 1.5852197066124063e-06
control O 0 3.156579168717144e-06
sera O 0 5.0230017222929746e-05
from O 0 9.272224019696296e-07
the O 0 7.053884587548964e-07
Hp1 O 0 0.0006581010529771447
phenotype O 0 3.6738349535880843e-06
( O 0 7.00438647527335e-07
1 O 0 1.0052003744931426e-06
. O 0 2.7109629741062236e-07
26 O 0 1.7989325442613335e-06
+ O 0 2.3206046080304077e-06
/ O 0 3.392336111573968e-06
- O 0 1.6564802081120433e-06
0 O 0 5.322496576809499e-07
. O 0 1.0166044717152545e-07
33 O 0 1.242726284544915e-06
mg O 0 1.8655002349987626e-05
/ O 0 8.046964467212092e-06
ml O 0 8.208634426409844e-06
; O 0 2.197836863615521e-07
n O 0 6.813394861637789e-07
= O 0 5.064841275270737e-07
9 O 0 8.0135214375332e-07
) O 0 1.4230906231205154e-07
, O 0 7.409912683442599e-08
showing O 0 6.768448770344548e-07
a O 0 9.457158967052237e-07
gene O 0 4.328650902607478e-06
- O 0 4.0837403503246605e-05
dosage O 0 8.555974636692554e-05
effect O 0 1.7842670786194503e-05
. O 0 1.9426441212999634e-05

The O 0 2.849363772838842e-05
other O 0 4.61560830444796e-06
allele O 0 1.623939533601515e-05
( O 0 4.850025106861722e-06
Hp2 O 0 0.002035819459706545
) O 0 1.0137780463992385e-06
of O 0 1.4301697319751838e-06
individuals O 0 2.3994999764909153e-07
with O 0 1.9009102061318117e-06
Hp2 O 1 0.9999997615814209
/ O 1 0.9988798499107361
Hpdel O 1 0.9998201727867126
was O 0 5.1213475671829656e-05
found O 0 6.349589511955855e-07
to O 0 4.4581057068171503e-08
have O 0 3.0028832753714596e-08
, O 0 6.546262909523648e-08
in O 0 5.818371207055861e-08
all O 0 9.106771869937802e-08
exons O 0 2.3275597413885407e-06
, O 0 3.101415870787605e-07
no O 0 2.636415956658311e-07
mutation O 0 4.7057534402483725e-07
, O 0 1.6215899734106642e-07
by O 0 5.929140343141626e-07
DNA O 0 4.786351200891659e-05
sequencing O 0 0.00010146666318178177
. O 0 4.409451503306627e-05

On O 0 1.5058888493513223e-05
the O 0 1.4630775240220828e-06
basis O 0 2.6863617108574545e-07
of O 0 4.2867137040047965e-07
the O 0 2.9981964644321124e-07
present O 0 4.845130092689942e-07
study O 0 3.0927645866540843e-07
, O 0 1.0711341502656069e-07
the O 0 1.595763023942709e-07
mechanism O 0 8.598418048677559e-07
of O 0 5.937502919550752e-06
anhaptoglobinemia B-Disease 0 0.03786209225654602
and O 0 4.1253008475905517e-07
the O 0 3.707797304741689e-07
mechanism O 0 9.389336810272653e-07
of O 0 1.4508862022921676e-06
anomalous O 0 3.785115040955134e-05
inheritance O 0 1.979230910365004e-05
of O 0 3.3119118597824126e-05
Hp O 0 0.0010351547971367836
phenotypes O 0 4.117508069612086e-05
were O 0 5.897200026083738e-06
well O 0 1.0465979357832111e-05
explained O 0 4.8117046389961615e-05
. O 0 3.753744749701582e-05

However O 0 5.3647956519853324e-05
, O 0 4.916048965242226e-06
the O 0 2.847175210263231e-06
mechanism O 0 1.3341840713110287e-05
of O 0 7.395336433546618e-05
hypohaptoglobinemia B-Disease 1 0.9983872175216675
remains O 0 0.004226015880703926
unknown O 0 0.0005911203916184604

ATM O 0 0.007898760959506035
mutations O 0 9.664130629971623e-05
and O 0 1.2769864952133503e-05
phenotypes O 0 9.411617065779865e-05
in O 0 4.658639227272943e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999922513961792
telangiectasia I-Disease 1 0.9999933242797852
families O 0 4.551097845251206e-06
in O 0 3.829141860478558e-06
the O 0 4.770358827954624e-06
British O 0 4.9135516746900976e-05
Isles O 0 4.585761053021997e-05
: O 0 5.144704005033418e-07
expression O 0 2.814998367739463e-07
of O 0 7.434842927978025e-07
mutant O 0 1.1941921911784448e-05
ATM O 0 7.785685011185706e-05
and O 0 5.278704975353321e-07
the O 0 1.195575350720901e-06
risk O 0 6.3647134993516374e-06
of O 0 0.00019917268946301192
leukemia B-Disease 1 1.0
, O 1 0.9802523851394653
lymphoma B-Disease 1 1.0
, O 0 0.0010033432627096772
and O 1 0.5222632884979248
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 0.00013564800610765815

We O 0 9.679577487986535e-06
report O 0 2.6703976345743285e-06
the O 0 9.107064329327841e-07
spectrum O 0 4.546764102997258e-06
of O 0 3.1168867735686945e-06
59 O 0 2.1622150597977452e-05
ATM O 0 0.00013226678129285574
mutations O 0 1.3182506108933012e-06
observed O 0 1.4531350416291389e-06
in O 0 2.4522153125872137e-06
ataxia B-Disease 1 0.9999895095825195
- I-Disease 1 0.9993411898612976
telangiectasia I-Disease 1 0.9999997615814209
( O 0 0.0005620733718387783
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
) O 0 7.923252269392833e-06
patients O 0 3.02863486467686e-06
in O 0 1.0514003179196152e-06
the O 0 4.721450750366785e-06
British O 0 0.0007102519157342613
Isles O 0 0.006897224113345146
. O 0 8.67212365847081e-05

Of O 0 0.00014913255290593952
51 O 0 0.00012602543574757874
ATM O 0 0.000664542312733829
mutations O 0 5.663461706717499e-06
identified O 0 1.8296399275641306e-06
in O 0 3.816036269199685e-07
families O 0 8.584181188098228e-08
native O 0 4.1306233811155835e-07
to O 0 1.3556503120071284e-07
the O 0 8.492986012242909e-07
British O 0 2.6871872250922024e-05
Isles O 0 4.82488758279942e-05
, O 0 5.564835987570405e-07
11 O 0 7.813829938640993e-07
were O 0 7.100359766809561e-07
founder O 0 5.689841782441363e-05
mutations O 0 1.0486904784556828e-06
, O 0 2.926158515492716e-07
and O 0 3.3795282661230885e-07
2 O 0 7.930622132334975e-07
of O 0 5.75876185848756e-07
these O 0 2.0459228267100116e-07
11 O 0 2.065130956907524e-06
conferred O 0 7.967313649714924e-06
a O 0 4.416905994730769e-06
milder O 0 4.044739034725353e-05
clinical O 0 0.00034380535362288356
phenotype O 0 6.509336344606709e-06
with O 0 2.334236484102803e-07
respect O 0 8.395080612899619e-07
to O 0 2.8098215807403903e-06
both O 0 2.7164129278389737e-05
cerebellar B-Disease 1 0.9999998807907104
degeneration I-Disease 1 1.0
and O 0 0.0011366636026650667
cellular O 1 0.760546088218689
features O 0 0.00016923976363614202
. O 0 0.00010396538709755987

We O 0 1.9644186977529898e-05
report O 0 3.876864866469987e-06
, O 0 6.143503128441807e-07
in O 0 2.6999947522199363e-07
two O 0 3.905450682850642e-07
A B-Disease 1 0.9528370499610901
- I-Disease 1 0.9841751456260681
T I-Disease 1 0.9999825954437256
families O 0 1.4778282775296248e-07
, O 0 1.6231248878284532e-07
an O 0 2.485099344085029e-07
ATM O 0 0.00017404840036761016
mutation O 0 2.769360889942618e-06
( O 0 1.1662649512800272e-06
7271T O 0 0.00014863029355183244
- O 0 5.239312304183841e-05
- O 0 3.677736094687134e-05
> O 0 2.3901864551589824e-05
G O 0 0.00012442500155884773
) O 0 4.894749849881919e-07
that O 0 1.6134590907768143e-07
may O 0 2.2467752103239036e-07
be O 0 6.236024319150602e-08
associated O 0 1.4149951255149062e-07
with O 0 5.632457700244231e-08
an O 0 2.1627083413022774e-07
increased O 0 7.381080422419473e-07
risk O 0 2.709176897042198e-06
of O 0 0.0001270265638595447
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9853856563568115
in O 0 2.7375281774766336e-07
both O 0 1.651551002623819e-07
homozygotes O 0 1.3828216651745606e-05
and O 0 3.3833626389423443e-07
heterozygotes O 0 1.3526556358556263e-05
( O 0 3.6497354471975996e-07
relative O 0 7.816505558366771e-07
risk O 0 9.278080597141525e-07
12 O 0 7.67606763929507e-07
. O 0 2.250171746709384e-07
7 O 0 1.180562890112924e-06
; O 0 1.9454233779470087e-07
P O 0 1.965082083188463e-05
= O 0 2.0758707250934094e-06
. O 0 4.45091842493639e-07
0025 O 0 0.00024729888536967337
) O 0 7.034067266431521e-07
, O 0 1.4053058805529872e-07
although O 0 9.145815482725084e-08
there O 0 1.1201456828757728e-07
is O 0 1.1337246519360633e-07
a O 0 4.4316678327049885e-07
less O 0 1.36506548642501e-06
severe O 0 0.22727704048156738
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999924898147583
T I-Disease 1 0.9999996423721313
phenotype O 0 2.5777885639399756e-06
in O 0 1.38305821906215e-07
terms O 0 1.584767801432463e-07
of O 0 4.5601899500979926e-07
the O 0 1.265013679585536e-06
degree O 0 4.028890180052258e-05
of O 0 0.005655568093061447
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.004581556189805269

This O 0 1.050068203767296e-05
mutation O 0 1.0056261089630425e-05
( O 0 5.156216047907947e-06
7271T O 0 0.0002946535823866725
- O 0 5.813382813357748e-05
- O 0 5.563606828218326e-05
> O 0 2.151338594558183e-05
G O 0 5.212391624809243e-05
) O 0 2.804213750096096e-07
also O 0 8.200257894941387e-08
allows O 0 4.506872386400573e-08
expression O 0 1.2211336297696107e-07
of O 0 2.6733482627605554e-07
full O 0 1.0409056585558574e-06
- O 0 3.9264718907361384e-06
length O 0 7.190054134298407e-07
ATM O 0 1.419945965608349e-05
protein O 0 8.627973215880047e-07
at O 0 1.9303811313875485e-06
a O 0 4.2544414213807613e-07
level O 0 6.078064416215057e-07
comparable O 0 1.2051120847900165e-06
with O 0 1.4759550026610668e-07
that O 0 1.532034872298027e-07
in O 0 1.4410994708669023e-06
unaffected O 0 3.356604793225415e-05
individuals O 0 2.5415877189516323e-06
. O 0 2.4836712327669375e-05

In O 0 1.4989568626333494e-05
addition O 0 3.146639983242494e-06
, O 0 8.01454632437526e-07
we O 0 8.868453704735657e-08
have O 0 3.678592008782289e-08
studied O 0 1.735009618641925e-06
18 O 0 2.73842601927754e-06
A B-Disease 1 0.999247670173645
- I-Disease 1 0.9999963045120239
T I-Disease 1 1.0
patients O 0 1.0400242899777368e-05
, O 0 1.9632224734777992e-07
in O 0 1.2816704497708997e-07
15 O 0 4.168852569819137e-07
families O 0 6.053875978295764e-08
, O 0 3.162661244004994e-07
who O 0 1.3813038322041393e-06
developed O 0 0.3263045847415924
leukemia B-Disease 1 1.0
, O 1 0.9937553405761719
lymphoma B-Disease 1 1.0
, O 0 0.0014285979559645057
preleukemic O 1 0.9999994039535522
T O 1 0.999998927116394
- O 0 0.0025922933127731085
cell O 0 0.00021452231158036739
proliferation O 0 0.00025271749473176897
, O 0 5.9951985349471215e-06
or O 0 0.006366534624248743
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.1944073271006346e-05
mostly O 0 7.69585221860325e-06
in O 0 1.2550445717351977e-05
childhood O 1 0.654025673866272
. O 0 9.657719056122005e-05

A O 0 0.0001784723426681012
wide O 0 2.2428957890952006e-05
variety O 0 5.553857590712141e-06
of O 0 8.177224117389414e-06
ATM O 0 0.021633535623550415
mutation O 0 2.8992913030378986e-06
types O 0 9.53458709318511e-07
, O 0 4.498250518736313e-07
including O 0 7.731573532510083e-07
missense O 0 1.578161391080357e-05
mutations O 0 1.1719903341145255e-06
and O 0 6.718294116581092e-07
in O 0 3.0749970392207615e-06
- O 0 2.6616700779413804e-05
frame O 0 2.7453517759568058e-05
deletions O 0 6.914568075444549e-06
, O 0 5.347998239813023e-07
were O 0 5.414124188973801e-07
seen O 0 1.5141037010835134e-06
in O 0 1.0119207445313805e-06
these O 0 1.1768275953727425e-06
patients O 0 2.4382157789659686e-05
. O 0 3.36723642249126e-05

We O 0 1.0445549378346186e-05
also O 0 1.8088243223246536e-06
show O 0 6.924572062416701e-07
that O 0 4.9071072538708904e-08
25 O 0 3.690292942337692e-07
% O 0 1.3628343253913044e-07
of O 0 3.4130025028389355e-07
all O 0 5.82723941988661e-07
A B-Disease 1 0.9999854564666748
- I-Disease 1 0.9999957084655762
T I-Disease 1 1.0
patients O 0 4.843466285819886e-06
carried O 0 9.447297202314076e-07
in O 0 6.443925144594687e-07
- O 0 1.5958459698595107e-05
frame O 0 1.68260248756269e-05
deletions O 0 1.4362753063323908e-05
or O 0 2.3368877464235993e-06
missense O 0 2.4386738004977815e-05
mutations O 0 1.3080218650429742e-06
, O 0 3.583193688427855e-07
many O 0 1.1268186028701166e-07
of O 0 6.868306741125707e-07
which O 0 1.8379067512341862e-07
were O 0 4.022918744794879e-07
also O 0 2.3741790755593684e-07
associated O 0 3.044473260160885e-07
with O 0 2.4955966182460543e-07
expression O 0 1.4943518635845976e-06
of O 0 4.3338804971426725e-06
mutant O 0 9.370344196213409e-05
ATM O 0 0.002533852821215987
protein O 0 5.016873910790309e-05
. O 0 5.1565093599492684e-05

The O 0 0.0003619935305323452
DMPK O 1 0.9999555349349976
gene O 0 0.00015383555728476495
of O 0 0.00031543447403237224
severely O 1 0.9999914169311523
affected O 1 0.9998947381973267
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999978542327881
is O 0 0.0006662550731562078
hypermethylated O 1 0.9999674558639526
proximal O 0 0.031763579696416855
to O 0 5.334511115506757e-06
the O 0 1.2492291716625914e-05
largely O 0 2.606781890790444e-05
expanded O 0 0.0001314813707722351
CTG O 1 0.960601270198822
repeat O 0 0.0004739288706332445
. O 0 7.91197016951628e-05

Using O 0 4.897748294752091e-05
methylation O 0 5.865818093298003e-05
- O 0 2.7258067348157056e-05
sensitive O 0 1.448429156880593e-05
restriction O 0 2.179894181608688e-06
enzymes O 0 1.407375407325162e-06
, O 0 4.76693003292894e-07
we O 0 8.774266291311505e-08
characterized O 0 2.6861158630708815e-07
the O 0 2.7560744797483494e-07
methylation O 0 9.763430171005893e-07
pattern O 0 8.144655225805764e-07
on O 0 2.6693840027292026e-07
the O 0 3.604336313856038e-07
5 O 0 6.120712896517944e-07
side O 0 3.2606627087261586e-07
of O 0 3.672997479498008e-07
the O 0 8.719209745322587e-07
CTG O 1 0.9868265390396118
repeat O 0 4.195053406874649e-06
in O 0 5.000828764423204e-07
the O 0 1.00730869689869e-06
DMPK O 1 0.9879342317581177
gene O 0 1.2299078662181273e-06
of O 0 1.0458719543748884e-06
normal O 0 4.3392381599005603e-07
individuals O 0 5.648853829143263e-08
and O 0 2.820824818172696e-07
of O 0 9.893340575217735e-06
patients O 0 6.275076157180592e-05
affected O 0 1.3231464436103124e-05
with O 0 0.0005145716713741422
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 0.00022088228433858603
showing O 0 2.5611656383262016e-05
expansions O 0 2.61254081124207e-05
of O 0 1.185136534331832e-05
the O 0 8.88840077095665e-06
repetitive O 0 0.0004624349530786276
sequence O 0 2.030562791333068e-05
. O 0 2.601469896035269e-05

The O 0 0.00012975411664228886
gene O 0 3.244933395762928e-05
segment O 0 1.60810614033835e-05
analyzed O 0 2.4652763386256993e-06
corresponds O 0 1.214962480844406e-06
to O 0 3.294218799965165e-07
the O 0 9.956054327631136e-07
genomic O 0 1.692348268989008e-05
SacI O 0 0.0011641251621767879
- O 0 6.383290747180581e-05
HindIII O 0 0.00031525775557383895
fragment O 0 3.197933983756229e-05
carrying O 0 1.2703337233688217e-05
exons O 0 2.8732696591760032e-05
11 O 0 1.3225699149188586e-05
- O 0 8.352430450031534e-05
15 O 0 4.528013232629746e-05
. O 0 4.6994449803605676e-05

There O 0 5.139891436556354e-05
is O 0 8.333497135026846e-06
constitutive O 0 3.0377086659427732e-05
methylation O 0 1.4736492630618159e-05
in O 0 2.092033810185967e-06
intron O 0 4.3241772800683975e-05
12 O 0 1.577561420162965e-06
at O 0 1.1512865967233665e-06
restriction O 0 2.9556974823208293e-07
sites O 0 5.567388825511443e-07
of O 0 8.100037689473538e-07
SacII O 0 0.0005557389813475311
and O 0 2.5695808290038258e-06
HhaI O 0 0.005565233062952757
, O 0 1.4217438319974463e-06
localized O 0 5.111485734232701e-06
1 O 0 1.8344902628086857e-06
, O 0 3.5863934044755297e-07
159 O 0 2.70583313977113e-06
- O 0 5.593238256551558e-06
1 O 0 3.0275259632617235e-06
, O 0 3.4133051940443693e-07
232 O 0 4.250991878507193e-06
bp O 0 7.5355173976277e-06
upstream O 0 3.642360752564855e-06
of O 0 1.046195166054531e-06
the O 0 1.858821065070515e-06
CTG O 1 0.9951531887054443
repeat O 0 1.1367195838829502e-05
, O 0 6.613619234485668e-07
whereas O 0 2.343309830621365e-07
most O 0 7.130964974066956e-08
, O 0 7.2305766707359e-08
if O 0 1.5286758525689947e-08
not O 0 1.3069274551469334e-08
all O 0 1.8214832309126905e-08
, O 0 3.7198603308752354e-08
of O 0 8.496188286244433e-08
the O 0 9.483461838044605e-08
other O 0 5.913447864713817e-08
sites O 0 5.575768113885715e-07
of O 0 2.9038681077508954e-06
SacII O 1 0.6315115690231323
, O 0 3.016594291693764e-06
HhaI O 0 0.33665817975997925
, O 0 1.1641624269032036e-06
and O 0 1.0521334843360819e-06
HpaII O 0 0.03013531118631363
in O 0 5.187250167182356e-07
this O 0 1.376804448227631e-07
region O 0 2.3178367314358184e-07
are O 0 7.638249144292786e-08
unmethylated O 0 9.726388088893145e-05
, O 0 5.207622280067881e-07
in O 0 2.0703910763586464e-07
normal O 0 2.2189841786257603e-07
individuals O 0 2.3504490798131883e-08
and O 0 1.0489490165355164e-07
most O 0 2.0773310893673624e-07
of O 0 2.807732016663067e-06
the O 0 4.690248897532001e-05
patients O 0 0.0006416545365937054
. O 0 4.5560118451248854e-05

In O 0 2.1653058865922503e-05
a O 0 3.0231808523240034e-06
number O 0 9.118536468122329e-07
of O 0 7.165703664213652e-06
young O 0 5.1986557082273066e-05
and O 0 2.3818018235033378e-05
severely O 1 0.9935508966445923
affected O 0 1.7082908016163856e-05
patients O 0 1.227408392878715e-05
, O 0 5.352299581318221e-07
however O 0 4.21996844579553e-07
, O 0 1.255693433677152e-07
complete O 0 4.871674263995374e-07
methylation O 0 1.1138409945488092e-06
of O 0 4.074872208548186e-07
these O 0 3.581389051987571e-08
restriction O 0 1.4913536006133654e-07
sites O 0 4.4938255427950935e-07
was O 0 1.4642417909271899e-06
found O 0 2.842916160261666e-07
in O 0 2.972981576476741e-07
the O 0 1.8455365307090688e-06
mutated O 0 3.9522819861304015e-05
allele O 0 2.1643209038302302e-05
. O 0 1.790907117538154e-05

In O 0 2.855407728930004e-05
most O 0 2.4358071186725283e-06
of O 0 3.3554852052475326e-06
these O 0 1.0492726687516551e-06
patients O 0 9.380088158650324e-06
, O 0 8.173866490324144e-07
the O 0 2.208903197242762e-06
onset O 0 0.3570680618286133
of O 0 0.003182911779731512
the O 1 0.9997302889823914
disease O 1 1.0
was O 1 0.9999992847442627
congenital O 1 1.0
. O 0 0.0058449930511415005

Preliminary O 0 0.00019720116688404232
in O 0 2.6869773137150332e-05
vivo O 0 0.0001432220306014642
footprinting O 0 0.00045869749737903476
data O 0 3.7464590150193544e-06
gave O 0 1.9701312794495607e-06
evidence O 0 4.967285462953441e-07
for O 0 1.3968171685974085e-07
protein O 0 7.998144724297163e-07
- O 0 9.944943485606927e-06
DNA O 0 8.270782927866094e-06
contact O 0 6.396022058652306e-07
in O 0 1.4134158732304059e-07
normal O 0 2.609532998576469e-07
genes O 0 1.6399070545958239e-07
at O 0 1.673747533459391e-06
an O 0 7.146473421926203e-07
Sp1 O 0 8.793672168394551e-05
consensus O 0 7.993722306309792e-07
binding O 0 2.3534529702828877e-07
site O 0 1.9578169485612307e-06
upstream O 0 1.3168760233384091e-06
of O 0 9.531823934594286e-07
the O 0 1.6494526562382816e-06
CTG O 1 0.9265547394752502
repeat O 0 6.6693460212263744e-06
and O 0 4.3597873400358367e-07
for O 0 1.2364839108158776e-07
a O 0 2.555029254835972e-07
significant O 0 2.0333668260263948e-07
reduction O 0 9.394557878295018e-07
of O 0 6.764047952856345e-07
this O 0 1.045942283894874e-07
interaction O 0 2.322002785604127e-07
in O 0 5.3227859098115e-07
cells O 0 1.0217241879217909e-06
with O 0 4.0729375427872583e-07
a O 0 8.078212886175606e-06
hypermethylated O 1 0.9964637160301208
DMPK O 1 0.9999923706054688
gene O 0 3.97817711927928e-05
. O 0 5.2635109568655025e-06
. O 0 1.5116830581973772e-05

The O 0 0.0012602114584296942
hemochromatosis B-Disease 1 0.9999997615814209
gene O 0 5.9820060414494947e-05
product O 0 1.516478369012475e-05
complexes O 0 1.9345117834745906e-05
with O 0 2.6127104320039507e-06
the O 0 6.593444595637266e-06
transferrin O 0 0.00023304163187276572
receptor O 0 5.021473043598235e-06
and O 0 1.9715203052328434e-06
lowers O 0 1.942692142620217e-05
its O 0 6.018927365403215e-07
affinity O 0 7.525424621235288e-07
for O 0 3.9216786262841197e-07
ligand O 0 5.747927934862673e-05
binding O 0 3.41187187586911e-05
. O 0 3.8378508179448545e-05

We O 0 1.888789665827062e-05
recently O 0 1.726733535178937e-05
reported O 0 2.879841531466809e-06
the O 0 6.039103936927859e-07
positional O 0 1.4868637663312256e-05
cloning O 0 1.0383990229456685e-05
of O 0 2.3947982299432624e-06
a O 0 1.5847451777517563e-06
candidate O 0 2.2771246221964248e-06
gene O 0 7.3791479735518806e-06
for O 0 2.660289464984089e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999831914901733
HFE O 1 0.9999997615814209
. O 0 0.0009905711049214005

The O 0 4.287795309210196e-05
gene O 0 7.1857957664178684e-06
product O 0 3.5793659662886057e-06
, O 0 5.708260459869052e-07
a O 0 2.989750385040679e-07
member O 0 5.20998696629249e-07
of O 0 8.667261681694072e-07
the O 0 2.4040382413659245e-06
major O 0 4.8273584980051965e-05
histocompatibility O 1 0.9997765421867371
complex O 0 0.0001259793934877962
class O 0 8.906818402465433e-05
I O 0 0.0001783838524715975
- O 0 6.254158051888226e-06
like O 0 5.435470029624412e-07
family O 0 1.1306824490020517e-06
, O 0 4.876183083979413e-07
was O 0 3.732102186404518e-06
found O 0 2.640507545947912e-07
to O 0 7.618345421178674e-08
have O 0 5.8058446938957786e-08
a O 0 3.9656438843849173e-07
mutation O 0 1.2722741757897893e-06
, O 0 8.914699947126792e-07
Cys O 0 0.0064456528052687645
- O 0 2.5372783056809567e-05
282 O 0 8.985953172668815e-05
- O 0 6.569571269210428e-05
- O 0 4.4152966438559815e-05
> O 0 4.1787061491049826e-05
Tyr O 1 0.5596468448638916
( O 0 5.321127900970168e-06
C282Y O 0 0.0002351192379137501
) O 0 5.467281880555674e-07
, O 0 1.9584484789447743e-07
in O 0 2.607383748909342e-07
85 O 0 2.6686636829253985e-06
% O 0 6.54454083814926e-07
of O 0 4.0911786527431104e-06
patient O 0 0.00014564534649252892
chromosomes O 0 3.357757304911502e-05
. O 0 5.1166378398193046e-05

This O 0 1.9258288375567645e-05
mutation O 0 1.4063371963857207e-05
eliminates O 0 3.5975463106296957e-05
the O 0 2.6774814614327624e-06
ability O 0 1.5429865243277163e-06
of O 0 7.225479293992976e-06
HFE O 1 0.9280852675437927
to O 0 2.0293327906983905e-06
associate O 0 1.4719991668243892e-05
with O 0 1.7234938241017517e-06
beta2 O 1 0.950648844242096
- O 0 0.0009899814613163471
microglobulin O 1 0.8895576000213623
( O 0 1.1865318811032921e-05
beta2m O 0 0.023787712678313255
) O 0 1.6731490859456244e-06
and O 0 1.611610287000076e-06
prevents O 0 1.8653401639312506e-05
cell O 0 0.0002076069504255429
- O 0 8.18589614937082e-05
surface O 0 4.084215470356867e-05
expression O 0 1.6675465303706005e-05
. O 0 1.612896448932588e-05

A O 0 0.0003447177296038717
second O 0 6.41327424091287e-05
mutation O 0 4.727064606413478e-06
that O 0 2.312330309450772e-07
has O 0 2.0636355202441337e-07
no O 0 2.010465323110111e-07
effect O 0 4.478094979276648e-07
on O 0 1.44595765050326e-06
beta2m O 0 0.003751132870092988
association O 0 1.9977178453700617e-05
, O 0 4.166604867350543e-06
H63D O 1 0.9999260902404785
, O 0 2.8161605314380722e-06
was O 0 6.131285772426054e-06
found O 0 3.514233810619771e-07
in O 0 6.717154121815838e-08
eight O 0 1.2135097904319991e-07
out O 0 1.4402348824660294e-07
of O 0 8.121401720018184e-07
nine O 0 3.1020479127619183e-06
patients O 0 1.4622656863139127e-06
heterozygous O 0 8.752776352594083e-07
for O 0 7.024748924777668e-07
the O 0 1.0787632163555827e-05
C282Y O 1 0.7348162531852722
mutant O 0 0.0005088014295324683
. O 0 6.243071402423084e-05

In O 0 1.588021586940158e-05
this O 0 7.965155077727104e-07
report O 0 1.2703911806966062e-06
, O 0 2.8923105332978594e-07
we O 0 5.197242813892444e-08
demonstrate O 0 5.545731482925476e-07
in O 0 3.6876264175589313e-07
cultured O 0 1.1956098205700982e-05
293 O 0 4.38467031926848e-05
cells O 0 8.231666470237542e-06
overexpressing O 0 9.741146641317755e-05
wild O 0 9.422972652828321e-06
- O 0 9.621403478377033e-06
type O 0 5.9868111748073716e-06
or O 0 2.054552624031203e-06
mutant O 0 3.375076994416304e-05
HFE O 0 0.014863641001284122
proteins O 0 3.45071867968727e-07
that O 0 5.884172793457765e-08
both O 0 8.278425411845092e-08
the O 0 5.109664584779239e-07
wild O 0 8.5867368397885e-06
- O 0 3.895799818565138e-05
type O 0 3.118739550700411e-05
and O 0 8.693870768183842e-06
H63D O 1 0.9999980926513672
HFE O 1 0.9967864751815796
proteins O 0 2.68939174929983e-06
form O 0 2.4229393602581695e-06
stable O 0 6.912972366990289e-06
complexes O 0 1.2362494999251794e-05
with O 0 1.4027324368726113e-06
the O 0 1.2150864677096251e-05
transferrin O 0 0.0007541759987361729
receptor O 0 3.902109892806038e-05
( O 0 1.814222014218103e-05
TfR O 0 0.021695448085665703
) O 0 1.690588214842137e-05
. O 0 2.9184406230342574e-05

The O 0 0.00030795144266448915
C282Y O 0 0.05797634273767471
mutation O 0 2.128366395481862e-05
nearly O 0 5.5879177125461865e-06
completely O 0 1.0511322216189e-05
prevents O 0 1.455764959246153e-06
the O 0 8.031317975110142e-07
association O 0 1.956933829205809e-06
of O 0 2.0495524495345308e-06
the O 0 5.45758939551888e-06
mutant O 0 0.00010006876982515678
HFE O 1 0.8196597695350647
protein O 0 4.075959168403642e-06
with O 0 1.3631064348373911e-06
the O 0 2.034392673522234e-05
TfR O 1 0.851205587387085
. O 0 0.0001230778725584969

Studies O 0 6.274406041484326e-05
on O 0 1.7229680452146567e-05
cell O 0 2.911463161581196e-05
- O 0 2.4951807063189335e-05
associated O 0 2.770238097582478e-06
transferrin O 0 3.6883120628772303e-05
at O 0 7.680742783122696e-06
37 O 0 5.286894520395435e-06
degrees O 0 3.830135028692894e-06
C O 0 1.27103057820932e-05
suggest O 0 3.833054904589517e-07
that O 0 5.647087064630796e-08
the O 0 3.420585130697873e-07
overexpressed O 0 5.179081199457869e-05
wild O 0 6.692052920698188e-06
- O 0 1.8560169337433763e-05
type O 0 3.1998712074710056e-05
HFE O 0 0.4656919538974762
protein O 0 1.4413097915166873e-06
decreases O 0 7.4848918529824e-07
the O 0 2.6054797785945993e-07
affinity O 0 7.672181254747557e-07
of O 0 7.93976369095617e-07
the O 0 4.289210664865095e-06
TfR O 0 0.01320645771920681
for O 0 7.40677205612883e-06
transferrin O 0 0.002918243408203125
. O 0 7.192121120169759e-05

The O 0 0.0002420541422907263
overexpressed O 1 0.5261585712432861
H63D O 1 0.9996654987335205
protein O 0 8.20920649857726e-06
does O 0 6.372411007760093e-07
not O 0 7.956032277434133e-08
have O 0 1.641046942779667e-08
this O 0 1.9559671216029528e-08
effect O 0 1.694117202077905e-07
, O 0 1.0730154542670789e-07
providing O 0 1.2435450003067672e-07
the O 0 1.1944101174776733e-07
first O 0 2.3029025442156126e-07
direct O 0 5.175095196818802e-08
evidence O 0 2.5283756599492335e-07
for O 0 9.833854619500926e-08
a O 0 4.429136879480211e-07
functional O 0 1.2648207530219224e-06
consequence O 0 2.309931005584076e-06
of O 0 2.2269837245403323e-06
the O 0 1.6457430319860578e-05
H63D O 1 0.9999959468841553
mutation O 0 9.740941459313035e-05
. O 0 3.5370616387808695e-05

Addition O 0 5.831094676977955e-05
of O 0 3.670241858344525e-05
soluble O 0 0.0003536790609359741
wild O 0 0.00032742193434387445
- O 0 0.006770106498152018
type O 1 0.5956674218177795
HFE O 1 1.0
/ O 1 0.9857662916183472
beta2m O 1 0.8526262640953064
heterodimers O 0 0.0008471757173538208
to O 0 4.963529136148281e-06
cultured O 0 7.965067925397307e-05
cells O 0 7.778500730637461e-06
also O 0 8.341697252944869e-07
decreased O 0 1.8946788031826145e-06
the O 0 3.6061211972082674e-07
apparent O 0 1.4435051980399294e-06
affinity O 0 7.890254209996783e-07
of O 0 1.1224784657315467e-06
the O 0 1.5032538840387133e-06
TfR O 0 0.00010107729758601636
for O 0 2.137526280421298e-07
its O 0 2.848066742444644e-07
ligand O 0 3.400634113859269e-06
under O 0 3.571312163330731e-06
steady O 0 7.909874511824455e-06
- O 0 2.361351562285563e-06
state O 0 1.5116106055756973e-07
conditions O 0 3.3685591915855184e-07
, O 0 1.1208958738961883e-07
both O 0 4.945867715377972e-08
in O 0 3.7741219216513855e-07
293 O 0 2.1181047486606985e-05
cells O 0 4.061362233187538e-06
and O 0 1.4986134146965924e-06
in O 0 1.5599689504597336e-05
HeLa O 1 0.9988677501678467
cells O 0 0.00013231764023657888
. O 0 4.889241245109588e-05

Furthermore O 0 0.00012262861127965152
, O 0 7.660208211746067e-06
at O 0 8.856113709043711e-06
4 O 0 3.062272526221932e-06
degrees O 0 4.131894002057379e-06
C O 0 4.78854235552717e-05
, O 0 2.8106126137572573e-07
the O 0 3.7320771184568e-07
added O 0 9.975851753551979e-07
soluble O 0 6.797358309995616e-06
complex O 0 6.739085620210972e-06
of O 0 3.886748891090974e-05
HFE O 1 0.9999998807907104
/ O 0 0.1183377206325531
beta2m O 0 0.0009167258976958692
inhibited O 0 9.943378245225176e-06
binding O 0 1.241617496816616e-06
of O 0 3.4351724025327712e-06
transferrin O 0 5.216777208261192e-05
to O 0 3.219097834517015e-06
HeLa O 1 0.9788591861724854
cell O 0 6.850826321169734e-05
TfR O 0 0.00016673494246788323
in O 0 1.5499136907237698e-06
a O 0 2.309043566128821e-06
concentration O 0 0.00040775947854854167
- O 0 5.280367622617632e-05
dependent O 0 8.125236490741372e-06
manner O 0 1.3948983905720524e-05
. O 0 2.7471851353766397e-05

Scatchard O 0 0.0003760421241167933
plots O 0 5.692343256669119e-05
of O 0 7.762339009786956e-06
these O 0 3.737177394214086e-07
data O 0 9.08598394744331e-07
indicate O 0 4.621571463303553e-07
that O 0 1.0816167872462756e-07
the O 0 1.1102077905889018e-06
added O 0 4.150162567384541e-06
heterodimer O 0 6.270063749980181e-05
substantially O 0 4.524358246271731e-06
reduced O 0 9.76632691163104e-07
the O 0 4.775711772708746e-07
affinity O 0 1.608168417988054e-06
of O 0 4.594580332195619e-06
TfR O 0 0.0032520571257919073
for O 0 1.8788763554766774e-05
transferrin O 0 0.0022006311919540167
. O 0 8.927540329750627e-05

These O 0 6.9072457336005755e-06
results O 0 3.8529701669176575e-06
establish O 0 3.2308034860761836e-06
a O 0 3.1488491458731005e-06
molecular O 0 4.75878878205549e-05
link O 0 1.286326914851088e-05
between O 0 3.003644906129921e-06
HFE O 1 0.9976242184638977
and O 0 1.981831701414194e-06
a O 0 1.0346143426431809e-06
key O 0 1.394328478454554e-06
protein O 0 3.5544482557270385e-07
involved O 0 4.6211923176997516e-07
in O 0 1.138898596764193e-06
iron O 0 0.47388437390327454
transport O 0 1.963478462130297e-05
, O 0 1.2878300594820757e-06
the O 0 1.7352479062537896e-06
TfR O 1 0.8511144518852234
, O 0 1.1830808261947823e-06
and O 0 3.764305063214124e-07
raise O 0 7.882470072217984e-07
the O 0 3.7435088984238973e-07
possibility O 0 1.2264268889339291e-06
that O 0 9.906447218099856e-08
alterations O 0 4.823350991500774e-06
in O 0 4.2738432171063323e-07
this O 0 9.715894577766448e-08
regulatory O 0 5.272174803394591e-07
mechanism O 0 8.041219530241506e-07
may O 0 3.2846384101503645e-07
play O 0 2.2113304964932468e-07
a O 0 2.9984107641212177e-07
role O 0 4.483393638565758e-07
in O 0 4.5330116904551687e-07
the O 0 2.16242278838763e-06
pathogenesis O 1 0.999637246131897
of O 1 0.9983110427856445
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.002214775886386633
. O 0 0.0003210928989574313

Genomic O 0 0.0002624579647090286
organization O 0 2.7327278075972572e-05
of O 0 1.8993401681655087e-05
the O 0 3.4849079384002835e-05
UBE3A O 1 0.9999978542327881
/ O 0 0.13293752074241638
E6 O 1 0.96947181224823
- O 0 0.0004594118508975953
AP O 0 0.00023787148529663682
gene O 0 1.1868238289025612e-05
and O 0 2.936229293482029e-06
related O 0 3.520579048199579e-05
pseudogenes O 0 0.0005090097547508776
. O 0 9.820160630624741e-05

The O 0 0.0002782728406600654
UBE3A O 0 0.16577407717704773
gene O 0 2.8362313969410025e-05
encodes O 0 1.117686497309478e-05
the O 0 8.75595196703216e-06
E6 O 0 0.035550061613321304
- O 0 0.00021566481154877692
AP O 0 0.00010246561578242108
ubiquitin O 0 4.718151831184514e-05
- O 0 1.742727545206435e-05
protein O 0 1.2423257658156217e-06
ligase O 0 1.0639039828674868e-05
and O 0 9.010239523377095e-07
has O 0 3.5323176916790544e-07
recently O 0 9.81750986284169e-07
been O 0 1.5446029522081517e-07
shown O 0 1.1520868525849437e-07
to O 0 1.0752690826620892e-07
be O 0 3.7364679883467034e-07
mutated O 0 4.845115472562611e-05
in O 0 0.041232023388147354
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.47220656275749207
who O 0 3.596901296987198e-05
lack O 0 0.00027581662288866937
15q11 O 1 0.9998478889465332
- O 0 0.018161064013838768
q13 O 1 0.6622069478034973
deletions O 0 0.00012072328536305577
or O 0 2.5296172680100426e-05
chromosome O 0 2.3072334442986175e-05
15 O 0 3.742042827070691e-05
paternal O 0 0.0011568911140784621
uniparental B-Disease 1 0.999932050704956
disomy I-Disease 1 0.9979280233383179
. O 0 0.0005453642224892974

Previous O 0 0.0003807761240750551
UBE3A O 0 0.015236668288707733
cDNA O 0 8.102239371510223e-05
analysis O 0 4.588704541674815e-06
has O 0 1.133469936576148e-06
shown O 0 4.2457313043087197e-07
a O 0 4.548757601696707e-07
coding O 0 2.2528524823428597e-06
region O 0 1.205891521749436e-06
of O 0 2.82840960608155e-06
approximately O 0 1.538439028081484e-05
2 O 0 3.87715372198727e-05
. O 0 2.0525711079244502e-05

6 O 0 0.0002988879568874836
kb O 0 0.0004509212449193001
and O 0 9.648371815274004e-06
a O 0 1.0975782060995698e-05
3 O 0 2.86812264675973e-05
- O 0 7.93852741480805e-05
untranslated O 0 0.04901076853275299
region O 0 1.046125908032991e-05
( O 0 3.426913735893322e-06
UTR O 0 0.012815427966415882
) O 0 1.3636160929308971e-06
of O 0 3.861544882965973e-06
< O 0 1.6998434148263186e-05
50 O 0 4.444582828000421e-06
bp O 0 1.9744875316973776e-05
, O 0 3.8777127997491334e-07
whereas O 0 5.456842586681887e-07
Northern O 0 4.791386913893803e-07
analysis O 0 1.4407034143459896e-07
has O 0 1.4144771398605371e-07
indicated O 0 1.59103564101315e-07
mRNA O 0 1.2245996572346485e-07
sizes O 0 1.8155559189381165e-07
of O 0 1.2810158978027175e-06
5 O 0 5.945174962107558e-06
- O 0 4.234700099914335e-05
8 O 0 5.0344289775239304e-05
kb O 0 0.0007402945775538683
. O 0 5.144456372363493e-05

We O 0 6.866525382065447e-06
have O 0 2.3895753997749125e-07
analyzed O 0 1.0270230177411577e-06
additional O 0 1.0488975021871738e-06
cDNA O 0 2.0839273929595947e-05
clones O 0 1.4421771084016655e-05
and O 0 3.3347606631650706e-07
provide O 0 1.2092203860447626e-07
evidence O 0 5.21086121807457e-07
for O 0 2.0660930033500335e-07
an O 0 7.177633278843132e-07
additional O 0 3.588909294194309e-06
0 O 0 2.2451040422311053e-05
. O 0 1.4382243534782901e-05

5 O 0 7.379901217063889e-05
kb O 0 0.00018300588999409229
of O 0 2.696572664717678e-05
5 O 0 2.8908460080856457e-05
- O 0 5.945052544120699e-05
UTR O 0 0.0014229280641302466
and O 0 5.683394192601554e-06
> O 0 1.472724943596404e-05
2 O 0 4.399522367748432e-06
kb O 0 5.266879452392459e-05
of O 0 1.1367521437932737e-05
3 O 0 8.39153362903744e-05
- O 0 0.0009368270984850824
UTR O 1 0.9870981574058533
. O 0 9.585566294845194e-05

We O 0 6.868797754577827e-06
have O 0 2.918441452948173e-07
established O 0 9.925224730977789e-07
the O 0 4.4287398281994683e-07
genomic O 0 2.948044539152761e-06
organization O 0 9.187162390844605e-07
of O 0 4.914656528853811e-06
UBE3A O 0 0.3986057937145233
and O 0 7.636456871296105e-07
the O 0 3.938860402286082e-07
sequence O 0 5.95360063471162e-07
of O 0 2.9477550924639218e-06
intron O 0 0.0024390900507569313
- O 0 0.0007610189495608211
exon O 0 0.00048446308937855065
borders O 0 3.431538425502367e-05
. O 0 3.2102387194754556e-05

We O 0 1.6561562006245367e-05
have O 0 8.361146797142283e-07
also O 0 8.028706020013487e-07
mapped O 0 2.816361984514515e-06
two O 0 1.4660732006177568e-07
highly O 0 1.8259340777149191e-06
homologous O 0 1.6313463220285485e-06
processed O 0 8.887239346222486e-06
pseudogenes O 0 2.4421417037956417e-05
, O 0 4.116817308386089e-06
UBE3AP1 O 1 0.9060643315315247
and O 0 7.576286861876724e-06
UBE3AP2 O 1 0.9841710925102234
, O 0 9.992924105972634e-07
to O 0 1.5031190514491755e-07
chromosomes O 0 2.7586463602347067e-07
2 O 0 4.697391204899759e-07
and O 0 1.968513316796816e-07
21 O 0 8.57679765431385e-07
, O 0 1.497116244308927e-07
respectively O 0 5.180650646252616e-07
, O 0 1.391453707810797e-07
and O 0 7.994228212737653e-08
determined O 0 2.2073314198678418e-07
their O 0 1.6749150688610825e-07
genomic O 0 9.011665497382637e-06
organization O 0 1.3512761142919771e-05
. O 0 2.125618266290985e-05

These O 0 8.707429515197873e-06
results O 0 3.310508418508107e-06
will O 0 3.767487157801952e-07
form O 0 3.315847152407514e-07
the O 0 2.289252023501831e-07
basis O 0 1.1223998086506981e-07
for O 0 1.1593789395192289e-07
studies O 0 3.5419415667092835e-07
of O 0 8.300796707771951e-07
mutation O 0 1.240237565980351e-06
and O 0 7.701239610469202e-07
imprinting O 0 0.00019637297373265028
of O 0 0.00016415570280514657
UBE3A O 1 0.9998290538787842
. O 0 9.365734877064824e-05

Mutation O 0 0.0001870552368927747
spectrum O 0 7.195221405709162e-05
and O 0 1.2882506780442782e-05
genotype O 0 8.696462464286014e-05
- O 0 9.756279905559495e-05
phenotype O 0 3.265652048867196e-05
analyses O 0 1.3627692169393413e-05
in O 0 2.6729820092441514e-05
Cowden B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999003410339355
and O 0 9.420247806701809e-05
Bannayan B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
Zonana I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
, O 0 3.1206316634779796e-05
two O 0 3.98566153307911e-05
hamartoma B-Disease 1 0.9999997615814209
syndromes I-Disease 1 0.9999921321868896
with O 0 0.005191505420953035
germline O 1 0.9999992847442627
PTEN O 1 0.9999988079071045
mutation O 0 0.0008198817376978695
. O 0 0.00015471158258151263

The O 0 0.0022453931160271168
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.2341497391462326
gene O 0 0.0003927740326616913
PTEN O 1 0.9375473260879517
, O 0 5.4988836382108275e-06
which O 0 9.445225828130788e-07
maps O 0 9.234877325070556e-06
to O 0 6.717744781781221e-06
10q23 O 0 0.025216683745384216
. O 0 7.344825280597433e-05

3 O 0 8.785130921751261e-05
and O 0 3.3441476716689067e-06
encodes O 0 2.8933277462783735e-06
a O 0 1.4967537254051422e-06
403 O 0 5.1524798436730634e-06
amino O 0 9.523736821392959e-07
acid O 0 1.809980290090607e-06
dual O 0 1.8663632772586425e-06
specificity O 0 4.4247731239011046e-06
phosphatase O 0 0.0001288341445615515
( O 0 1.8673389376999694e-06
protein O 0 1.8786348618959892e-06
tyrosine O 0 1.3216684237704612e-05
phosphatase O 0 6.512895197374746e-05
; O 0 6.172243161017832e-07
PTPase O 0 0.0004161347169429064
) O 0 5.070704105492041e-07
, O 0 2.285142528535289e-07
was O 0 2.092033810185967e-06
shown O 0 2.1945925254840404e-07
recently O 0 4.258541252966097e-07
to O 0 8.049861577319462e-08
play O 0 4.4776123786505195e-07
a O 0 7.284027105924906e-07
broad O 0 3.57244289261871e-06
role O 0 4.5753936319670174e-06
in O 0 6.428410415537655e-06
human O 0 7.410074613289908e-05
malignancy B-Disease 1 0.9998290538787842
. O 0 0.00010673163342289627

Somatic O 1 0.8734505772590637
PTEN O 1 0.998999297618866
deletions O 0 0.00018571932741906494
and O 0 9.657263035478536e-06
mutations O 0 3.202471134500229e-06
were O 0 6.5456515585538e-07
observed O 0 7.917329298834375e-07
in O 0 1.0321642776034423e-06
sporadic B-Disease 0 6.776146619813517e-05
breast I-Disease 1 0.9999111890792847
, I-Disease 0 5.237789446255192e-05
brain I-Disease 1 0.9997515082359314
, I-Disease 0 0.00012536118447314948
prostate I-Disease 1 1.0
and I-Disease 1 0.6619290113449097
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.1708143949508667
lines O 0 1.6202217238969752e-06
and O 0 2.0183340154744656e-07
in O 0 2.517586494832358e-07
several O 0 7.347229029619484e-07
primary O 0 0.0007441987982019782
tumours B-Disease 1 0.9999992847442627
such O 0 4.30172485721414e-06
as O 0 0.00022590605658479035
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999889135360718
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999995231628418
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.020480796694755554

In O 0 3.710279270308092e-05
addition O 0 1.9667018932523206e-05
, O 0 1.6803702237666585e-05
PTEN O 1 0.9977534413337708
was O 0 2.2695845473208465e-05
identified O 0 1.0754449704108993e-06
as O 0 3.3577117619643104e-07
the O 0 6.753729167030542e-07
susceptibility O 0 1.615146902622655e-05
gene O 0 1.219480395775463e-06
for O 0 4.6832516886752273e-07
two O 0 7.003663995419629e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.0005209835944697261
CD B-Disease 1 0.9996170997619629
; O 0 1.2504068763519172e-05
MIM O 1 0.9998745918273926
158350 O 0 0.013482031412422657
) O 0 1.9945223357353825e-06
and O 0 2.038149887084728e-06
Bannayan B-Disease 1 0.5087226033210754
- I-Disease 0 0.0006541869952343404
Zonana I-Disease 1 0.9996100068092346
( I-Disease 0 1.9793762476183474e-05
BZS I-Disease 1 0.5118675231933594
) I-Disease 0 3.1618544653611025e-06
or I-Disease 0 3.629981392805348e-06
Ruvalcaba I-Disease 0 0.028673408553004265
- I-Disease 0 0.0005851114983670413
Riley I-Disease 1 0.9466861486434937
- I-Disease 1 0.8734732866287231
Smith I-Disease 1 0.9998619556427002
syndrome I-Disease 1 0.9999994039535522
( O 0 0.004054172430187464
MIM O 1 0.9999998807907104
153480 O 1 0.999764621257782
) O 0 0.00015457547851838171
. O 0 8.024915587157011e-05

Constitutive O 0 0.0006367844180203974
DNA O 0 0.00012655335012823343
from O 0 1.4493577509711031e-05
37 O 0 2.579230203991756e-05
CD B-Disease 0 0.00017346076492685825
families O 0 5.650226739817299e-07
and O 0 1.0202354587818263e-06
seven O 0 2.8190411285322625e-06
BZS B-Disease 0 0.11846566945314407
families O 0 1.7519055290904362e-06
was O 0 2.3361359126283787e-05
screened O 0 2.971587127831299e-05
for O 0 7.233111318782903e-06
germline O 1 0.8554498553276062
PTEN O 1 0.9997770190238953
mutations O 0 0.00021323839609976858
. O 0 0.00010551948798820376

PTEN O 1 0.9565306305885315
mutations O 0 4.38609640696086e-05
were O 0 4.486902071221266e-06
identified O 0 2.085496362269623e-06
in O 0 5.696400080523745e-07
30 O 0 8.672305398249591e-07
of O 0 1.424489482815261e-06
37 O 0 7.793307304382324e-06
( O 0 7.113562787708361e-07
81 O 0 1.589818566571921e-05
% O 0 1.1858357993332902e-06
) O 0 6.179799925121188e-07
CD B-Disease 0 4.153680129093118e-05
families O 0 1.3833484047154343e-07
, O 0 2.0359223640298296e-07
including O 0 2.3472418320125144e-07
missense O 0 1.296477421419695e-05
and O 0 2.3391039576381445e-06
nonsense O 0 9.409096674062312e-05
point O 0 1.22941164590884e-05
mutations O 0 1.8810048914019717e-06
, O 0 5.312739403962041e-07
deletions O 0 4.673865078075323e-06
, O 0 9.954136430678773e-07
insertions O 0 1.7873682736535557e-05
, O 0 1.881360049083014e-06
a O 0 3.874924004776403e-06
deletion O 0 6.104534259065986e-05
/ O 0 6.0220827435841784e-05
insertion O 0 4.863455978920683e-05
and O 0 7.386625384242507e-06
splice O 0 0.0024011379573494196
site O 0 0.0005066189914941788
mutations O 0 9.934826812241226e-05
. O 0 5.035067806602456e-05

These O 0 7.119017482182244e-06
mutations O 0 4.045520654472057e-06
were O 0 8.36399408399302e-07
scattered O 0 3.062740006498643e-06
over O 0 6.289071166065696e-07
the O 0 9.13797521207016e-07
entire O 0 3.2252651180897374e-06
length O 0 7.546503297817253e-07
of O 0 4.027811883133836e-06
PTEN O 1 0.9582000970840454
, O 0 3.0625540148321306e-07
with O 0 3.7325040835867185e-08
the O 0 1.3437286838779983e-07
exception O 0 1.8165810899972712e-07
of O 0 1.9246959936936037e-07
the O 0 4.4406240817806975e-07
first O 0 3.2770744837762322e-06
, O 0 9.23213974601822e-07
fourth O 0 2.2027579689165577e-05
and O 0 3.505003633108572e-06
last O 0 2.3201013391371816e-05
exons O 0 0.00014208162610884756
. O 0 4.8013596824603155e-05

A O 0 0.0004463883233256638
hot O 0 0.00029781219200231135
spot O 0 5.4381234804168344e-05
for O 0 5.5407590480172075e-06
PTEN O 0 0.2311786264181137
mutation O 0 2.859646656361292e-06
in O 0 1.4564313914888771e-06
CD B-Disease 0 0.00021047284826636314
was O 0 5.8305799939262215e-06
identified O 0 3.3617072858760366e-07
in O 0 2.3332682985710562e-07
exon O 0 5.515032626135508e-06
5 O 0 7.559094115094922e-07
that O 0 6.479012171212162e-08
contains O 0 3.4852769204007927e-07
the O 0 1.1988784081040649e-06
PTPase O 0 0.08982870727777481
core O 0 8.505205914843827e-05
motif O 0 1.5287861970136873e-05
, O 0 4.771633257405483e-07
with O 0 1.4522134961225674e-07
13 O 0 7.782935540490143e-07
of O 0 5.001190857001347e-07
30 O 0 1.3475674904839252e-06
( O 0 3.2957680673462164e-07
43 O 0 2.9724558316956973e-06
% O 0 9.270297027796914e-07
) O 0 6.815824917794089e-07
CD B-Disease 0 0.00010574350744718686
mutations O 0 1.0966750778607093e-06
identified O 0 9.330645980298868e-07
in O 0 7.726207513769623e-07
this O 0 1.2845612218370661e-06
exon O 0 0.00040975178126245737
. O 0 6.285987910814583e-05

Seven O 0 6.131979898782447e-05
of O 0 2.3651249648537487e-05
30 O 0 1.9835561033687554e-05
( O 0 1.8117971194442362e-06
23 O 0 4.6157711039995775e-06
% O 0 7.238875809889578e-07
) O 0 1.2246567848706036e-07
were O 0 1.2300458251957025e-07
within O 0 1.368651254551878e-07
the O 0 5.168978987057926e-07
core O 0 0.00010646174632711336
motif O 0 1.3432304513116833e-05
, O 0 3.365617828876566e-07
the O 0 1.9130081341245386e-07
majority O 0 5.542945302750013e-08
( O 0 4.5200266640677e-08
five O 0 5.4474845967433794e-08
of O 0 2.715985942813859e-07
seven O 0 6.26270036718779e-07
) O 0 1.6420494830526877e-07
of O 0 4.850724053540034e-07
which O 0 1.5325008462241385e-07
were O 0 7.244767061820312e-07
missense O 0 1.7486909200670198e-05
mutations O 0 9.928471627063118e-07
, O 0 5.093740469419572e-07
possibly O 0 1.3935388096797396e-06
pointing O 0 9.610376991986413e-07
to O 0 9.456405081209596e-08
the O 0 3.085605726482754e-07
functional O 0 7.959232561915996e-07
significance O 0 2.1334299162845127e-06
of O 0 2.0650129499699688e-06
this O 0 1.14924409899686e-06
region O 0 1.080341371562099e-05
. O 0 2.343485721212346e-05

Germline O 1 0.9809804558753967
PTEN O 1 0.9856058955192566
mutations O 0 1.7332866264041513e-05
were O 0 2.3775803583703237e-06
identified O 0 1.030109046951111e-06
in O 0 2.601045707706362e-07
four O 0 1.7540961039230751e-07
of O 0 9.443045883017476e-07
seven O 0 2.6104517019120976e-06
( O 0 2.4125083655235358e-06
57 O 0 2.977461917907931e-05
% O 0 4.553867711365456e-06
) O 0 5.75260992263793e-06
BZS B-Disease 0 0.09369930624961853
families O 0 6.769702395104105e-06
studied O 0 0.0002828046854119748
. O 0 0.00010303705494152382

Interestingly O 0 0.00042307155672460794
, O 0 1.1206429917365313e-05
none O 0 2.455505864418228e-06
of O 0 1.144718794421351e-06
these O 0 3.371242485172843e-07
mutations O 0 1.3240262433100725e-06
was O 0 4.574102604237851e-06
observed O 0 1.4611031247113715e-06
in O 0 5.252281312095874e-07
the O 0 6.036942522769095e-06
PTPase O 1 0.99480801820755
core O 0 0.03262423351407051
motif O 0 0.001025235396809876
. O 0 5.136760591994971e-05

It O 0 1.717225313768722e-05
is O 0 1.564893864269834e-06
also O 0 3.3190869430654857e-07
worthy O 0 4.095960321137682e-06
of O 0 1.4836932678008452e-06
note O 0 1.1564200121938484e-06
that O 0 1.1626895712879559e-07
a O 0 6.08835023285792e-07
single O 0 1.0889129953284282e-06
nonsense O 0 1.2508386134868488e-05
point O 0 2.6580821668176213e-06
mutation O 0 6.031368116055091e-07
, O 0 3.012860076978541e-07
R233X O 0 3.890075095114298e-05
, O 0 4.7216536813721177e-07
was O 0 1.1368302921255236e-06
observed O 0 1.6465091334794124e-07
in O 0 9.416105939408226e-08
the O 0 1.92867204873437e-07
germline O 0 8.663247172080446e-06
DNA O 0 2.3754046196700074e-06
from O 0 4.270665385774919e-07
two O 0 1.2795051418379444e-07
unrelated O 0 3.3196045023942133e-06
CD B-Disease 0 0.0002936792734544724
families O 0 5.755961751674477e-07
and O 0 1.6176295503100846e-06
one O 0 7.795656529197004e-06
BZS B-Disease 1 0.9973976612091064
family O 0 0.00010776658746181056
. O 0 9.541718463879079e-05

Genotype O 0 0.0009068655199371278
- O 0 0.0001959349465323612
phenotype O 0 2.8496846425696276e-05
studies O 0 2.0946570202795556e-06
were O 0 4.2404988676025823e-07
not O 0 7.514696420685141e-08
performed O 0 1.151843434854527e-06
on O 0 4.432593527781137e-07
this O 0 1.5111407947188127e-07
small O 0 1.3865964092474314e-06
group O 0 3.889299932779977e-06
of O 0 2.0597437469405122e-05
BZS B-Disease 1 0.9901060461997986
families O 0 1.9563480236683972e-05
. O 0 6.204889359651133e-05

However O 0 7.103240204742178e-05
, O 0 1.6146263078553602e-05
genotype O 0 4.815927968593314e-05
- O 0 3.0943901947466657e-05
phenotype O 0 1.0861399459827226e-05
analysis O 0 2.2922588414076017e-06
inthe O 0 8.288582466775551e-05
group O 0 3.691169695230201e-06
of O 0 8.381637599086389e-06
CD B-Disease 0 0.0873214602470398
families O 0 3.209798649095319e-07
revealed O 0 1.5865551858951221e-06
two O 0 5.76419125764005e-08
possible O 0 1.5122725471883314e-07
associations O 0 3.743098204722628e-07
worthy O 0 6.6022284954669885e-06
of O 0 2.5575773179298267e-06
follow O 0 1.8863654531742213e-06
- O 0 8.734500624996144e-06
up O 0 2.327666152268648e-06
in O 0 7.592291240143823e-07
independent O 0 1.329936139882193e-06
analyses O 0 2.9517825169023126e-05
. O 0 2.3093443815014325e-05

The O 0 2.1985923012834974e-05
first O 0 1.2864373275078833e-05
was O 0 1.0236836715193931e-05
an O 0 6.640251513090334e-07
association O 0 2.4908085833885707e-06
noted O 0 5.997709422445041e-07
in O 0 3.068822138629912e-07
the O 0 6.326137622636452e-07
group O 0 9.993086678150576e-07
of O 0 4.819920832233038e-06
CD B-Disease 0 0.2714398205280304
families O 0 1.5590024986522621e-06
with O 0 2.8613449103431776e-05
breast B-Disease 1 1.0
disease I-Disease 1 0.9999821186065674
. O 0 0.00014059267414268106

A O 0 0.00010628130257828161
correlation O 0 1.3030023183091544e-05
was O 0 1.9510900528985076e-05
observed O 0 8.413386467509554e-07
between O 0 1.7852281075647625e-07
the O 0 4.08339559498927e-07
presence O 0 3.6977864965592744e-06
/ O 0 1.3955689610156696e-05
absence O 0 2.126367235177895e-06
of O 0 4.153979716647882e-06
a O 0 1.1326659659971483e-05
PTEN O 1 0.9989903569221497
mutation O 0 1.1179754437762313e-06
and O 0 2.1221728729869938e-07
the O 0 7.283464924512373e-07
type O 0 9.535883691569325e-06
of O 0 3.640729482867755e-05
breast O 1 0.9997227787971497
involvement O 0 0.00015099816664587706
( O 0 9.862791557679884e-06
unaffected O 0 0.00035845578531734645
versus O 0 0.06922046095132828
benign O 1 0.9988453388214111
versus O 1 0.9944092631340027
malignant O 1 0.9999994039535522
) O 0 5.697654705727473e-05
. O 0 6.356406811391935e-05

Specifically O 0 4.3747386371251196e-05
and O 0 3.643507398010115e-06
more O 0 3.437550901708164e-07
directly O 0 7.846260245969461e-07
, O 0 4.7087522148103744e-07
an O 0 4.7260593305509246e-07
association O 0 1.0284707059327047e-05
was O 0 4.3143078073626384e-05
also O 0 3.85767293664685e-07
observed O 0 2.240433047973056e-07
between O 0 8.79742572124087e-08
the O 0 2.2970266400079709e-07
presence O 0 8.748996265239839e-07
of O 0 2.111329422405106e-06
a O 0 1.8699833162827417e-05
PTEN O 1 0.9999964237213135
mutation O 0 0.000156905734911561
and O 0 0.0032295528799295425
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999954700469971
. O 0 0.0002745515084825456

Secondly O 0 0.0008638455765321851
, O 0 1.2230873835505918e-05
there O 0 1.995045295188902e-06
appeared O 0 1.610797539797204e-06
to O 0 1.5450804369265825e-07
be O 0 1.0898506275225373e-07
an O 0 3.4601930565258954e-07
interdependent O 0 2.341194158361759e-05
association O 0 1.3811003555019852e-05
between O 0 2.255270828754874e-06
mutations O 0 2.8334986836853204e-06
upstream O 0 5.492060154210776e-06
and O 0 4.704084517470619e-07
within O 0 3.1184990234578436e-07
the O 0 2.0689237771875923e-06
PTPase O 0 0.10565314441919327
core O 0 9.600093471817672e-05
motif O 0 1.8697908672038466e-05
, O 0 5.727449661208084e-07
the O 0 5.234450100033428e-07
core O 0 8.198620889743324e-06
motif O 0 4.382716724649072e-06
containing O 0 9.08895685824973e-07
the O 0 1.7345384151212784e-07
majority O 0 1.3018861011460103e-07
of O 0 8.039540375648357e-07
missense O 0 1.589675957802683e-05
mutations O 0 1.035801005855319e-06
, O 0 2.875862321616296e-07
and O 0 1.382831271712348e-07
the O 0 5.426815050668665e-07
involvement O 0 1.4352224297908833e-06
of O 0 1.034424826684699e-06
all O 0 6.418251814466203e-07
major O 0 7.282113074325025e-05
organ O 1 0.9999648332595825
systems O 1 0.9854463338851929
( O 0 1.4994787306932267e-05
central O 0 2.8640313757932745e-05
nervous O 0 0.002433350309729576
system O 0 0.0001298518036492169
, O 0 0.0008749293629080057
thyroid O 1 1.0
, O 0 0.035919442772865295
breast O 1 0.9999998807907104
, O 1 0.5037031769752502
skin O 1 0.9999997615814209
and O 1 0.7891940474510193
gastrointestinal O 1 1.0
tract O 1 0.9999998807907104
) O 0 0.0003807517932727933
. O 0 0.00012795193470083177

However O 0 3.285418642917648e-05
, O 0 1.6731045207052375e-06
these O 0 9.21050045121774e-08
observations O 0 1.4737032643097336e-06
would O 0 1.7742533486853063e-07
need O 0 1.1173119673912879e-07
to O 0 6.09030124110177e-08
be O 0 6.500872729020557e-08
confirmed O 0 1.9896289416010404e-07
by O 0 1.17653307540877e-07
studying O 0 7.429002835124265e-07
a O 0 1.7711072075599077e-07
larger O 0 2.015817841538592e-07
number O 0 1.6320016982263041e-07
of O 0 2.301281028849189e-06
CD B-Disease 0 0.0016779324505478144
families O 0 4.136100415053079e-06
. O 0 1.611023981240578e-05

Molecular O 1 0.9778003692626953
defects O 1 0.9996943473815918
leading O 0 0.00017637880227994174
to O 0 5.1007632464461494e-06
human O 0 1.176954810944153e-05
complement B-Disease 0 0.000604428758379072
component I-Disease 1 0.9999994039535522
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.213034571876051e-06
an O 0 1.0793339697556803e-06
African O 0 9.269852853321936e-06
- O 0 8.483626879751682e-05
American O 0 5.246362343314104e-05
family O 0 5.1991963118780404e-05
. O 0 4.199688191874884e-05

Complement B-Disease 0 0.010351760312914848
component I-Disease 1 0.9999877214431763
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.01642841100692749
C6D B-Disease 1 0.9999997615814209
) O 0 2.5316854589618742e-05
was O 0 0.011535236611962318
diagnosed O 0 0.027337651699781418
in O 0 5.868995458513382e-07
a O 0 6.418839006983035e-07
16 O 0 2.395312094449764e-06
- O 0 6.487015070888447e-06
year O 0 1.7837486439020722e-06
- O 0 8.92367370397551e-06
old O 0 5.3783751354785636e-05
African O 0 5.364924163586693e-06
- O 0 4.32192646258045e-05
American O 0 3.875667243846692e-05
male O 0 8.89045768417418e-05
with O 0 0.00020766675879713148
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.0012361304834485054

The O 0 0.0003039460862055421
patients O 0 0.0001242063008248806
father O 0 0.00010372258839197457
and O 0 1.3568562735599698e-06
two O 0 5.545837211684557e-07
brothers O 0 4.716509647550993e-05
also O 0 2.005154783546459e-06
had O 0 1.998716288653668e-05
C6D B-Disease 1 0.9999960660934448
, O 0 1.431722694178461e-06
but O 0 2.3108512436920137e-07
gave O 0 8.29519422040903e-07
no O 0 1.7719435163598973e-07
history O 0 2.197982666984899e-06
of O 0 0.00011612999514909461
meningitis B-Disease 1 0.9999992847442627
or O 0 3.775856748688966e-05
other O 0 3.544683204381727e-05
neisserial B-Disease 1 0.9999977350234985
infection I-Disease 1 0.9982374906539917
. O 0 9.617648902349174e-05

By O 0 1.661389433138538e-05
using O 0 8.291181075037457e-06
exon O 0 5.6041502830339596e-05
- O 0 1.126299048337387e-05
specific O 0 7.151245426939568e-07
polymerase O 0 1.0645077963999938e-05
chain O 0 4.155996975896414e-06
reaction O 0 1.0057680128738866e-06
( O 0 9.532042213322711e-07
PCR O 0 3.701931200339459e-05
) O 0 1.80122253823356e-06
/ O 0 1.0785904123622458e-05
single O 0 1.9074113879469223e-06
- O 0 5.7512825151206926e-06
strand O 0 3.934977485187119e-06
conformation O 0 1.2520431482698768e-06
polymorphism O 0 7.759458071632253e-07
as O 0 1.5536977571173338e-07
a O 0 2.92356162390206e-07
screening O 0 7.99291456132778e-07
step O 0 3.664911503165058e-07
and O 0 5.932947289011281e-08
nucleotide O 0 2.7372328759156517e-07
sequencing O 0 6.383103823281999e-07
of O 0 3.525969987094868e-07
target O 0 1.370514155496494e-06
exons O 0 2.2920664832781767e-06
, O 0 1.8343277474741626e-07
we O 0 8.037005017058618e-08
determined O 0 1.7842663169176376e-07
that O 0 3.3581404323967945e-08
the O 0 3.6049658547199215e-07
proband O 0 0.0002477744419593364
was O 0 6.927901722519891e-06
a O 0 5.650760499520402e-07
compound O 0 9.431396392756142e-06
heterozygote O 0 1.3527408555091824e-05
for O 0 1.3078796428089845e-06
two O 0 4.313074441597564e-06
C6 O 1 0.9999932050704956
gene O 0 0.00010932516306638718
mutations O 0 2.9283095500431955e-05
. O 0 2.3876920749899e-05

The O 0 5.154337122803554e-05
first O 0 1.1905125575140119e-05
, O 0 2.4200091957027325e-06
1195delC O 0 4.1297971620224416e-05
located O 0 7.561894108221168e-06
in O 0 9.6818166639423e-07
exon O 0 2.693639908102341e-05
7 O 0 5.787032932857983e-06
, O 0 4.3153028173037455e-07
is O 0 1.4272019654981705e-07
a O 0 3.347981873957906e-07
novel O 0 9.970174232876161e-07
mutation O 0 4.1463076172476576e-07
, O 0 1.320036773222455e-07
while O 0 1.6307213002164644e-07
the O 0 2.2428874046909186e-07
second O 0 2.7420742299000267e-06
, O 0 5.023758831157465e-07
1936delG O 0 1.6996165868476965e-05
in O 0 4.3416724793132744e-07
exon O 0 2.0016139387735166e-05
12 O 0 2.1361213384807343e-06
, O 0 3.8284957781797857e-07
has O 0 1.2715837272025965e-07
been O 0 1.9285637620214402e-07
described O 0 3.7479418324437574e-07
before O 0 4.802755597665964e-07
to O 0 6.928079869794601e-07
cause O 0 2.0208572095725685e-05
C6D B-Disease 1 0.9989340901374817
in O 0 1.3829014733346412e-06
an O 0 4.784660632140003e-07
unrelated O 0 6.526249762828229e-06
African O 0 5.629827228403883e-06
- O 0 3.467318310867995e-05
American O 0 9.91889555734815e-06
individual O 0 3.4824502108676825e-06
. O 0 2.3058390070218593e-05

Both O 0 4.124034967389889e-05
mutations O 0 1.6594069165876135e-05
result O 0 5.816767497890396e-06
in O 0 4.414193881530082e-06
premature O 0 0.00011852502211695537
termination O 0 0.0002536395622882992
codons O 0 0.00016126877744682133
and O 0 4.332185199018568e-05
C6 O 1 0.9996254444122314
null O 0 0.0002941427519544959
alleles O 0 6.31219008937478e-05
. O 0 5.831639646203257e-05

Allele O 0 0.00013142082025296986
- O 0 5.068356404080987e-05
specific O 0 2.781931698336848e-06
PCR O 0 6.846242467872798e-05
indicated O 0 5.035361027694307e-06
that O 0 2.2924133702417748e-07
the O 0 1.2061273082508706e-06
probands O 0 0.0003724703856278211
two O 0 1.1352701676514698e-06
brothers O 0 3.8619942642981187e-05
also O 0 2.733160727075301e-06
inherited O 0 0.0015040941070765257
the O 0 3.947700861317571e-06
1195delC O 0 0.0006301316898316145
mutation O 0 1.1487499023132841e-06
from O 0 3.9437844634448993e-07
their O 0 1.232816089213884e-07
heterozygous O 0 8.761520575717441e-07
mother O 0 1.3367288147492218e-06
and O 0 2.7087381226920115e-07
the O 0 7.679757914047514e-07
1936delG O 0 5.043683995609172e-05
mutation O 0 6.477424108197738e-07
from O 0 3.3963229384426086e-07
their O 0 5.112852932143142e-07
homozygous O 0 1.2683813110925257e-05
father O 0 4.65166122012306e-05
. O 0 1.1025508683815133e-05
. O 0 2.6885301849688403e-05

PAX6 O 1 0.9974266886711121
mutations O 0 0.0015010193455964327
reviewed O 0 0.0013462065253406763
. O 0 0.0005091227940283716

Mutations O 0 0.0002287351235281676
in O 0 4.4065891415812075e-05
PAX6 O 1 0.6067847013473511
are O 0 9.87374392025231e-07
responsible O 0 4.068646376254037e-06
for O 0 1.7825310578700737e-06
human O 0 1.8203585568699054e-05
aniridia B-Disease 1 0.9999996423721313
and O 0 2.6160364541283343e-06
have O 0 2.6828084287444653e-07
also O 0 2.579618012532592e-07
been O 0 2.834980818988697e-07
found O 0 2.9933252676528355e-07
in O 0 5.875020860912628e-07
patients O 0 2.831777919709566e-06
with O 0 1.6378937743866118e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 0.004547186195850372
with O 1 0.9997484087944031
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.31066372990608215
with O 0 0.0004220888076815754
autosomal B-Disease 1 0.9997466206550598
dominant I-Disease 1 0.999997615814209
keratitis I-Disease 1 0.9999998807907104
, O 0 0.00011706615623552352
and O 0 1.7882515749079175e-05
with O 0 5.4271615226753056e-05
isolated B-Disease 1 0.9998338222503662
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0024493515957146883

No O 0 7.052928413031623e-05
locus O 0 4.1385410440852866e-05
other O 0 1.3427594467430026e-06
than O 0 1.5923108094284544e-06
chromosome O 0 5.859572411281988e-06
11p13 O 0 0.00015039263234939426
has O 0 8.688315915605926e-07
been O 0 1.1394156445021508e-06
implicated O 0 2.2500658815260977e-05
in O 0 5.925476671109209e-06
aniridia B-Disease 1 0.9999982118606567
, O 0 5.063608568889322e-06
and O 0 3.1225752081809333e-06
PAX6 O 1 0.9999774694442749
is O 0 1.5150931176322047e-06
clearly O 0 1.0803462373587536e-06
the O 0 5.283257564769883e-07
major O 0 3.2269974781229394e-06
, O 0 4.0116168520398787e-07
if O 0 6.383359618666873e-08
not O 0 3.200176124096288e-08
only O 0 1.0457707588784615e-07
, O 0 5.911473976993875e-07
gene O 0 4.213528427499114e-06
responsible O 0 2.076068449241575e-05
. O 0 4.043793887831271e-05

Twenty O 0 0.0002530185738578439
- O 0 5.060656985733658e-05
eight O 0 7.146471943997312e-06
percent O 0 4.583875579555752e-06
of O 0 4.432882178662112e-06
identified O 0 9.15481723495759e-06
PAX6 O 1 0.7716490626335144
mutations O 0 4.124720362597145e-06
are O 0 4.3709113128898025e-07
C O 0 0.002157951006665826
- O 0 0.00023862201487645507
T O 0 0.00038933302857913077
changes O 0 9.188283911498729e-07
at O 0 1.1487748452054802e-05
CpG O 0 0.00014709055540151894
dinucleotides O 0 0.00011181994341313839
, O 0 7.853446959416033e-07
20 O 0 4.804903710464714e-07
% O 0 1.2631134893581475e-07
are O 0 1.1712608660729984e-08
splicing O 0 1.3423306199911167e-06
errors O 0 5.539496669371147e-06
, O 0 3.7820021248080593e-07
and O 0 1.2433422114099812e-07
more O 0 3.8743554142683934e-08
than O 0 9.717673776776792e-08
30 O 0 4.869403369411884e-07
% O 0 1.699818596989644e-07
are O 0 2.8728628365115583e-08
deletion O 0 2.133108409907436e-06
or O 0 1.4462417539107264e-06
insertion O 0 4.129159060539678e-05
events O 0 2.895624675147701e-05
. O 0 8.073195203905925e-05

There O 0 4.7436733439099044e-05
is O 0 6.356839548971038e-06
a O 0 4.578436346491799e-06
noticeably O 0 7.464963709935546e-05
elevated O 0 0.00030074879759922624
level O 0 2.2777435333409812e-06
of O 0 9.526715984975453e-07
mutation O 0 4.0571089243712777e-07
in O 0 2.3223969947139267e-07
the O 0 4.876871457781817e-07
paired O 0 2.26106567424722e-06
domain O 0 8.851856136971037e-07
compared O 0 6.344977236949489e-07
with O 0 1.4450448304614838e-07
the O 0 6.570455752807902e-07
rest O 0 2.9570944661827525e-06
of O 0 2.5012775495270034e-06
the O 0 9.48828619584674e-06
gene O 0 4.150976019445807e-05
. O 0 2.04613297682954e-05

Increased O 0 5.9282727306708694e-05
mutation O 0 1.8179714970756322e-05
in O 0 2.2790211460232968e-06
the O 0 4.9016625780495815e-06
homeodomain O 0 0.00015282048843801022
is O 0 1.061048010342347e-06
accounted O 0 2.6320024062442826e-06
for O 0 2.2866751692163234e-07
by O 0 6.874669793432986e-07
the O 0 6.751366072421661e-06
hypermutable O 1 0.5486530065536499
CpG O 0 0.0020128032192587852
dinucleotide O 0 0.0003609349951148033
in O 0 7.147235464799451e-06
codon O 0 0.00010285387543262914
240 O 0 6.797976675443351e-05
. O 0 3.877042399835773e-05

Very O 0 2.179611510655377e-05
nearly O 0 9.607190804672427e-06
all O 0 1.068671622306283e-06
mutations O 0 1.1274393045823672e-06
appear O 0 3.971313162765e-07
to O 0 3.715712466600962e-07
cause O 0 5.645580131385941e-06
loss O 0 3.8440852222265676e-05
of O 0 1.7029321952577448e-06
function O 0 3.3150379863400303e-07
of O 0 5.763992589891132e-07
the O 0 8.301913112518378e-07
mutant O 0 7.554152944067027e-06
allele O 0 4.814132239516766e-07
, O 0 1.2126479020935221e-07
and O 0 3.123678027350252e-08
more O 0 1.805881666427922e-08
than O 0 6.55573444419133e-08
80 O 0 8.768776069700834e-07
% O 0 2.440582420604187e-07
of O 0 1.2165601219749078e-06
exonic O 0 0.0002635045093484223
substitutions O 0 1.905990211525932e-05
result O 0 6.037829734850675e-06
in O 0 6.757156825187849e-06
nonsense O 0 0.00033019614056684077
codons O 0 0.00019539057393558323
. O 0 4.814339627046138e-05

In O 0 3.820837082457729e-05
a O 0 8.136098585964646e-06
gene O 0 1.9089852685283404e-06
with O 0 2.190696903880962e-07
such O 0 4.837585265704547e-07
extraordinarily O 0 1.6011066691135056e-05
high O 0 8.03806779003935e-06
sequence O 0 4.890442824034835e-07
conservation O 0 1.6388078165618936e-06
throughout O 0 2.8286206088523613e-07
evolution O 0 7.536571047239704e-07
, O 0 1.6991704399060836e-07
there O 0 1.067939621179903e-07
are O 0 5.700384164697425e-08
presumed O 0 7.385773642454296e-06
undiscovered O 0 0.00035840345663018525
missense O 0 2.202048199251294e-05
mutations O 0 1.6135618352564052e-06
, O 0 2.1369025660078478e-07
these O 0 4.955754207003338e-08
are O 0 2.8477941782512062e-08
hypothesized O 0 5.395239099925675e-07
to O 0 1.0014927198653822e-07
exist O 0 3.964940447076515e-07
in O 0 3.530441858856648e-07
as O 0 1.5987501456038444e-06
- O 0 1.1711506886058487e-05
yet O 0 2.050815510301618e-06
unidentified O 0 1.4716734767716844e-05
phenotypes O 0 2.6353769499110058e-05
. O 0 3.887401362590026e-06
. O 0 1.9045057342736982e-05

Genetic O 0 0.0003410023055039346
heterogeneity O 0 0.00015062540478538722
and O 0 7.787481990817469e-06
penetrance O 0 8.408187568420544e-05
analysis O 0 2.735447651502909e-06
of O 0 5.7862653193296865e-06
the O 0 2.372778908465989e-05
BRCA1 O 0 0.0018255396280437708
and O 0 1.0293008017470129e-05
BRCA2 O 0 0.0003858984273392707
genes O 0 5.719715773011558e-06
in O 0 3.896438647643663e-05
breast B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9993782043457031
families O 0 8.40500979393255e-06
. O 0 5.0327875214861706e-05

The O 1 0.9286386966705322
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9977130889892578
Consortium O 0 0.010076811537146568
. O 0 0.0002556103281676769

The O 0 7.605640712426975e-05
contribution O 0 0.00011065042053814977
of O 0 0.00011977958638453856
BRCA1 O 0 0.014189762994647026
and O 0 1.7747552192304283e-05
BRCA2 O 0 0.16118395328521729
to O 0 7.646087760804221e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.24710504710674286
assessed O 0 8.506892299919855e-06
by O 0 6.192914838720753e-07
linkage O 0 5.083145424578106e-06
and O 0 3.558531886937999e-07
mutation O 0 4.780788458447205e-07
analysis O 0 1.7332850177353976e-07
in O 0 3.005688427037967e-07
237 O 0 2.757414904408506e-06
families O 0 1.8834197135220165e-07
, O 0 1.8087224873397645e-07
each O 0 2.9478758989398557e-08
with O 0 6.60568986177168e-08
at O 0 1.5271917845893768e-06
least O 0 9.196736527883331e-08
four O 0 8.727448630452272e-08
cases O 0 1.5580572210183163e-07
of O 0 4.139468364883214e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9998630285263062
, O 0 5.247345029602002e-07
collected O 0 1.0048946705865092e-06
by O 0 8.141145144691109e-07
the O 0 0.0013288859045132995
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.8150210976600647
Consortium O 0 0.0013755252584815025
. O 0 0.00010307547927368432

Families O 0 1.4040538189874496e-05
were O 0 3.499779722915264e-06
included O 0 3.4623888041096507e-06
without O 0 8.219752771765343e-07
regard O 0 8.937590791902039e-07
to O 0 1.6196055696582334e-07
the O 0 3.454564421190298e-07
occurrence O 0 7.91493039287161e-06
of O 0 0.0002802708186209202
ovarian B-Disease 1 1.0
or I-Disease 0 3.13801210722886e-05
other I-Disease 0 2.7448177206679247e-05
cancers I-Disease 1 0.9995644688606262
. O 0 4.991062087356113e-05

Overall O 0 0.004176591522991657
, O 0 0.0003188197733834386
disease O 1 0.9997220635414124
was O 0 0.003162100212648511
linked O 0 3.1713756470708176e-05
to O 0 1.6284924413412227e-06
BRCA1 O 0 3.268848740844987e-05
in O 0 3.7778525552312203e-07
an O 0 1.3049788094576797e-07
estimated O 0 3.6461486274674826e-07
52 O 0 1.472165195082198e-06
% O 0 9.091707653396952e-08
of O 0 1.278018544326187e-07
families O 0 5.104715938841764e-08
, O 0 1.4793992875183903e-07
to O 0 2.6336820724282006e-07
BRCA2 O 0 7.5148486757825594e-06
in O 0 3.130603261070064e-07
32 O 0 1.141409256888437e-06
% O 0 1.5441493417256424e-07
of O 0 2.2978767333370342e-07
families O 0 5.813911840846231e-08
, O 0 1.083679705971008e-07
and O 0 5.652076495721303e-08
to O 0 9.121652766452826e-08
neither O 0 7.481544912479876e-07
gene O 0 2.2236721974877582e-07
in O 0 1.5784659979090065e-07
16 O 0 8.797011901151564e-07
% O 0 1.8051245831429696e-07
( O 0 6.633112548115605e-08
95 O 0 1.1180585488546058e-06
% O 0 3.349869359681179e-07
confidence O 0 1.914540689540445e-06
interval O 0 1.188792612083489e-05
[ O 0 2.712827335926704e-05
CI O 1 0.9660457372665405
] O 0 1.4693357115902472e-05
6 O 0 4.044008164783008e-06
% O 0 4.275400442566024e-07
- O 0 1.475176986787119e-06
28 O 0 2.752885166046326e-06
% O 0 4.948727223563765e-07
) O 0 2.2874820615470526e-07
, O 0 3.2982237030410033e-07
suggesting O 0 2.5049248506547883e-06
other O 0 2.945824235212058e-06
predisposition O 0 0.0032677955459803343
genes O 0 4.128174623474479e-05
. O 0 8.345504465978593e-05

The O 0 5.248078014119528e-05
majority O 0 7.713927516306285e-06
( O 0 2.344001131859841e-06
81 O 0 1.820605029934086e-05
% O 0 6.160581733638537e-07
) O 0 1.3830660350322432e-07
of O 0 8.354260785381484e-07
the O 0 7.020076736807823e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.5837718453658454e-07
were O 0 4.024192890028644e-07
due O 0 1.1323529633955332e-06
to O 0 3.982740963692777e-07
BRCA1 O 0 2.2901282136444934e-05
, O 0 2.994076169215987e-07
with O 0 6.302303745542304e-08
most O 0 1.3934629805589793e-07
others O 0 2.571154311681312e-07
( O 0 3.330216031827149e-07
14 O 0 2.1247678887448274e-06
% O 0 5.222801746640471e-07
) O 0 3.9092626025194477e-07
due O 0 5.788550879515242e-06
to O 0 2.6051888198708184e-05
BRCA2 O 0 0.09141233563423157
. O 0 0.00010179898526985198

Conversely O 0 0.00021491335064638406
, O 0 4.708680990006542e-06
the O 0 1.0268339565300266e-06
majority O 0 3.027454340553959e-07
of O 0 6.593781449737435e-07
families O 0 1.326516922972587e-07
with O 0 4.970342502019776e-07
male B-Disease 0 7.148107670218451e-06
and I-Disease 0 3.2592963634670014e-06
female I-Disease 1 0.5257924199104309
breast I-Disease 1 1.0
cancer I-Disease 1 0.9997407793998718
were O 0 1.6477043800477986e-06
due O 0 5.459380190586671e-06
to O 0 2.291541932208929e-06
BRCA2 O 0 0.00023641808365937322
( O 0 3.344322749398998e-06
76 O 0 8.330897253472358e-05
% O 0 6.09307107879431e-06
) O 0 4.665190317609813e-06
. O 0 2.4489565475960262e-05

The O 0 6.0068952734582126e-05
largest O 0 5.045541547588073e-05
proportion O 0 5.274928298604209e-06
( O 0 1.9625706499937223e-06
67 O 0 1.2798418538295664e-05
% O 0 4.184458077816089e-07
) O 0 1.0063391897574547e-07
of O 0 4.509615791903343e-07
families O 0 1.0593014820869939e-07
due O 0 9.344573186353955e-07
to O 0 2.1336018107831478e-07
other O 0 2.3383850589198119e-07
genes O 0 4.650504195069516e-07
was O 0 4.409321718412684e-06
found O 0 4.293918891562498e-07
in O 0 8.626592773453012e-08
families O 0 2.5436866835093497e-08
with O 0 3.369779122408545e-08
four O 0 1.747822580000502e-07
or O 0 3.704772097989917e-07
five O 0 1.9996633682239917e-07
cases O 0 6.14150508226885e-07
of O 0 1.4090437616687268e-05
female O 1 0.9605034589767456
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999929666519165
only O 0 1.831628651416395e-05
. O 0 4.292820085538551e-05

These O 0 8.36847448226763e-06
estimates O 0 8.349987183464691e-06
were O 0 1.9940923721151194e-06
not O 0 3.4735401754915074e-07
substantially O 0 1.405066086590523e-06
affected O 0 3.994410917584901e-07
either O 0 1.0289372198712954e-07
by O 0 1.496506740750192e-07
changing O 0 8.04150374733581e-07
the O 0 6.307270723482361e-07
assumed O 0 3.084533773289877e-06
penetrance O 0 1.1833925782411825e-05
model O 0 7.464020086445089e-07
for O 0 7.050346653159068e-07
BRCA1 O 0 1.5075053852342535e-05
or O 0 3.9180412159112166e-07
by O 0 4.5109231905371416e-07
including O 0 1.1390267218303052e-06
or O 0 3.1177607979770983e-06
excluding O 0 5.7993573136627674e-05
BRCA1 O 0 0.00027406582375988364
mutation O 0 5.060567218606593e-06
data O 0 1.0664292858564295e-05
. O 0 1.748514114296995e-05

Among O 0 2.8559852580656298e-05
those O 0 2.4007663341762964e-06
families O 0 1.2685111414612038e-06
with O 0 1.0577035027381498e-05
disease O 1 0.9995063543319702
due O 0 8.50300129968673e-05
to O 0 3.366081273270538e-06
BRCA1 O 0 2.7549558581085876e-05
that O 0 5.79239411990784e-08
were O 0 1.4520777824600373e-07
tested O 0 6.254934987737215e-07
by O 0 5.4376535274514026e-08
one O 0 8.224239422816026e-08
of O 0 3.073696461797226e-07
the O 0 2.79977513173435e-07
standard O 0 5.131424813953345e-07
screening O 0 3.9423403563887405e-07
methods O 0 2.2789508591358754e-07
, O 0 1.2548758832053863e-07
mutations O 0 1.0758804336319372e-07
were O 0 9.727279604021533e-08
detected O 0 4.154025532443484e-07
in O 0 7.230397613966488e-08
the O 0 9.909356890602794e-08
coding O 0 5.468366452987539e-07
sequence O 0 1.1964417012677586e-07
or O 0 1.3174509660984768e-07
splice O 0 3.6249650747777196e-06
sites O 0 3.6581860740625416e-07
in O 0 1.4039059692549927e-07
an O 0 8.184554189938353e-08
estimated O 0 3.2541638006478024e-07
63 O 0 2.648153667905717e-06
% O 0 2.3245796398896346e-07
( O 0 2.92298182102968e-07
95 O 0 4.245316176820779e-06
% O 0 1.5227764151859446e-06
CI O 0 0.16799789667129517
51 O 0 1.9972969312220812e-05
% O 0 2.6665343284548726e-06
- O 0 1.3749488971370738e-05
77 O 0 3.277454379713163e-05
% O 0 5.331205557013163e-06
) O 0 6.229603059182409e-06
. O 0 1.504822193965083e-05

The O 0 4.098886711290106e-05
estimated O 0 8.426190106547438e-06
sensitivity O 0 7.28854865883477e-06
was O 0 5.311170752975158e-06
identical O 0 5.131762463861378e-07
for O 0 1.1738634242419721e-07
direct O 0 2.0756141339006717e-07
sequencing O 0 1.484338554291753e-06
and O 0 7.134638053685194e-07
other O 0 7.875669325585477e-07
techniques O 0 3.6508572520688176e-05
. O 0 3.3223572245333344e-05

The O 0 5.972350845695473e-05
penetrance O 0 0.0010162857361137867
of O 0 0.00021364029089454561
BRCA2 O 0 0.0026458268985152245
was O 0 3.410879799048416e-05
estimated O 0 1.2844704997405643e-06
by O 0 2.6752405801744317e-07
maximizing O 0 1.1375329449947458e-05
the O 0 3.832765742117772e-06
LOD O 0 0.34036484360694885
score O 0 6.14968485024292e-06
in O 0 2.475940164003987e-06
BRCA2 O 0 8.276222797576338e-05
- O 0 9.363232493342366e-06
mutation O 0 9.383401788909396e-07
families O 0 1.2165307339273568e-07
, O 0 1.4684631821637595e-07
over O 0 4.86288740830787e-07
all O 0 4.864469360654766e-07
possible O 0 4.079502105014399e-06
penetrance O 0 0.0002588616916909814
functions O 0 1.5342777260229923e-05
. O 0 3.948624726035632e-05

The O 0 2.2922260541236028e-05
estimated O 0 8.56333917909069e-06
cumulative O 0 2.560069151513744e-05
risk O 0 6.737235253240215e-06
of O 0 4.995357448933646e-05
breast B-Disease 1 0.9999966621398926
cancer I-Disease 1 0.8450707197189331
reached O 0 6.792667136323871e-06
28 O 0 4.095925305591663e-06
% O 0 4.095305996543175e-07
( O 0 2.4565173362134374e-07
95 O 0 2.682613740034867e-06
% O 0 1.3597850738733541e-06
CI O 0 0.09762076288461685
9 O 0 1.056597557180794e-05
% O 0 4.857010367231851e-07
- O 0 2.0764803139172727e-06
44 O 0 2.108693252012017e-06
% O 0 1.9972428333403514e-07
) O 0 4.873332670740638e-08
by O 0 9.03369681282129e-08
age O 0 8.27100564038119e-07
50 O 0 4.406381890476041e-07
years O 0 1.8353006225879653e-07
and O 0 9.907505216233403e-08
84 O 0 5.8375571825308725e-06
% O 0 3.5650637641992944e-07
( O 0 3.066110423333157e-07
95 O 0 3.59097703039879e-06
% O 0 8.048937729654426e-07
CI O 0 0.04577205330133438
43 O 0 9.332059562439099e-06
% O 0 6.954770697120694e-07
- O 0 2.5012868718476966e-06
95 O 0 2.7151620543008903e-06
% O 0 3.3323414072583546e-07
) O 0 1.184337818926906e-07
by O 0 3.596329634092399e-07
age O 0 8.692445589986164e-06
70 O 0 2.3529966711066663e-05
years O 0 1.6229672837653197e-05
. O 0 2.3155811504693702e-05

The O 0 0.00046880930312909186
corresponding O 1 0.9848088622093201
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0003369796322658658
were O 0 1.7473255866207182e-05
0 O 0 5.153402889845893e-05
. O 0 2.1412533897091635e-05

4 O 0 0.00010239168477710336
% O 0 6.774546363885747e-06
( O 0 1.3413695114650181e-06
95 O 0 4.251004156685667e-06
% O 0 9.623335017749923e-07
CI O 0 0.0005935126100666821
0 O 0 2.348832140341983e-06
% O 0 4.0506370169168804e-07
- O 0 2.0095194486202672e-06
1 O 0 1.1382992397557246e-06
% O 0 2.0360369035188342e-07
) O 0 3.285615335357761e-08
by O 0 4.907079187432828e-08
age O 0 6.155548817332601e-07
50 O 0 3.534672998739552e-07
years O 0 3.224408828828018e-07
and O 0 1.9062224509980297e-07
27 O 0 9.682463542048936e-07
% O 0 1.4528480107856012e-07
( O 0 1.3376350693761196e-07
95 O 0 1.3975447927805362e-06
% O 0 4.664958055400348e-07
CI O 0 0.0012458005221560597
0 O 0 1.763572640811617e-06
% O 0 2.4720230840102886e-07
- O 0 9.88093120213307e-07
47 O 0 1.5667022807974718e-06
% O 0 2.384232686836185e-07
) O 0 8.917252358742189e-08
by O 0 1.1810386979504983e-07
age O 0 3.6718174669658765e-06
70 O 0 1.178731781692477e-05
years O 0 1.686792165855877e-05
. O 0 2.0832259906455874e-05

The O 0 0.00010510854190215468
lifetime O 0 0.0004838490567635745
risk O 0 7.456340244971216e-05
of O 0 0.2159680724143982
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
appears O 0 3.233512870792765e-06
similar O 0 1.6537023839191534e-07
to O 0 1.4096910661010043e-07
the O 0 1.2190722600280424e-06
risk O 0 3.8143077745189657e-06
in O 0 1.751594822962943e-06
BRCA1 O 0 4.0775885281618685e-05
carriers O 0 7.589322876810911e-07
, O 0 3.053082195947354e-07
but O 0 9.620136154353531e-08
there O 0 8.514990668118116e-08
was O 0 9.601233159628464e-07
some O 0 1.022998077360171e-07
suggestion O 0 1.0547465763011132e-06
of O 0 1.312499080086127e-06
a O 0 1.211592916661175e-06
lower O 0 1.3930279237683862e-05
risk O 0 2.8931567612744402e-06
in O 0 2.3674667772866087e-06
BRCA2 O 0 5.7565288443583995e-05
carriers O 0 2.808848876156844e-06
< O 0 7.149935299821664e-06
50 O 0 1.5184286894509569e-06
years O 0 1.1399090453778626e-06
of O 0 5.195357061893446e-06
age O 0 7.333766552619636e-05
. O 0 3.977190863224678e-05

Eye B-Disease 1 0.9999362230300903
movement I-Disease 0 0.06790663301944733
abnormalities I-Disease 1 0.9327219128608704
correlate O 0 8.56783808558248e-05
with O 0 7.975439984875266e-06
genotype O 0 0.00015663562226109207
in O 0 1.9068847905145958e-05
autosomal O 1 0.8755189776420593
dominant O 1 0.9999833106994629
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999996423721313
. O 0 0.0011136443354189396

We O 0 4.579389496939257e-05
compared O 0 4.857004023506306e-05
horizontal O 0 0.00011343647202011198
eye O 0 0.0006481844466179609
movements O 0 1.4250165804696735e-05
( O 0 3.921165443898644e-06
visually O 0 1.1073127097915858e-05
guided O 0 0.00010940628999378532
saccades O 0 0.004647187422960997
, O 0 6.995720468694344e-06
antisaccades O 0 0.0006439098506234586
, O 0 1.4613762004955788e-06
and O 0 2.858739378552855e-07
smooth O 0 1.1912254649359966e-06
pursuit O 0 6.155094069981715e-06
) O 0 2.0091485453122004e-07
in O 0 1.3356758188365347e-07
control O 0 5.86745670716482e-07
subjects O 0 2.619856559249456e-06
( O 0 4.5513655777540407e-07
n O 0 1.3525283293347456e-06
= O 0 8.51701884130307e-07
14 O 0 1.284152062908106e-06
) O 0 3.240388934955263e-07
and O 0 3.2653616699462873e-07
patients O 0 5.104531624056108e-07
with O 0 7.613057562139147e-08
three O 0 1.9866504885612812e-07
forms O 0 1.209941842716944e-06
of O 0 3.7554200389422476e-05
autosomal O 0 0.06983474642038345
dominant O 1 0.6918736696243286
cerebellar B-Disease 1 0.999980092048645
ataxias I-Disease 1 0.9999966621398926
type I-Disease 1 0.9985482096672058
I I-Disease 1 0.9971651434898376
spinocerebellar B-Disease 1 0.9999114274978638
ataxias I-Disease 0 0.004050656221807003
1 I-Disease 0 1.126473034673836e-05
and I-Disease 0 9.854957170318812e-07
2 I-Disease 0 4.156896466156468e-06
( O 0 1.7286970432905946e-06
SCA1 B-Disease 0 0.07575623691082001
, O 0 8.158726245710568e-07
n O 0 8.09319658401364e-07
= O 0 7.126545256141981e-07
11 O 0 6.136019692348782e-07
; O 0 2.3269461735253572e-07
SCA2 B-Disease 0 0.0005124070448800921
, O 0 7.428577646351187e-07
n O 0 9.926342272592592e-07
= O 0 6.989358780629118e-07
10 O 0 5.498991413332988e-07
) O 0 2.8051206868440204e-07
and O 0 1.4701463442179374e-06
SCA3 B-Disease 1 1.0
/ O 0 0.001008996507152915
Machado B-Disease 0 0.0005855572526343167
- I-Disease 0 0.00012716581113636494
Joseph I-Disease 1 0.8463870286941528
disease I-Disease 1 0.9977606534957886
( O 0 3.071930041187443e-05
MJD B-Disease 1 1.0
) O 0 8.989650268631522e-06
( O 0 2.1152432054805104e-06
n O 0 5.7225965974794235e-06
= O 0 7.752572855679318e-06
16 O 0 1.4861706404190045e-05
) O 0 4.898251063423231e-06
. O 0 9.962085641745944e-06

In O 0 0.00031568389385938644
SCA1 B-Disease 1 0.9973016977310181
, O 0 2.5991115762735717e-05
saccade O 0 0.0002161508600693196
amplitude O 0 2.5721557904034853e-05
was O 0 2.0547135136439465e-05
significantly O 0 2.234544581369846e-06
increased O 0 1.2166378837719094e-06
, O 0 7.872959031374194e-07
resulting O 0 3.107249995082384e-06
in O 0 5.116206466482254e-06
hypermetria B-Disease 0 0.020425740629434586
. O 0 6.129933899501339e-05

The O 0 0.00010920366912614554
smooth O 0 6.426987965824082e-05
pursuit O 0 0.0001778025907697156
gain O 0 7.003186328802258e-05
was O 0 0.00031559905619360507
decreased O 0 0.00037462805630639195
. O 0 2.6376248570159078e-05

In O 0 0.0003512640541885048
SCA2 B-Disease 1 0.9990863800048828
, O 0 2.5112223738688044e-05
saccade O 0 0.0003120426263194531
velocity O 0 6.913817924214527e-05
was O 0 7.438827014993876e-05
markedly O 0 7.949390419526026e-05
decreased O 0 7.136059866752476e-05
. O 0 3.0724982934771106e-05

The O 0 3.139628461212851e-05
percentage O 0 1.3116871741658542e-05
of O 0 8.575509127695113e-06
errors O 0 8.724287908989936e-05
in O 0 1.3295721146278083e-05
antisaccades O 1 0.9989728927612305
was O 0 0.0002625250199344009
greatly O 0 3.837209533230634e-06
increased O 0 7.002743132034084e-07
and O 0 5.372298801376019e-07
was O 0 3.4690817756199976e-06
significantly O 0 3.050058694498148e-07
correlated O 0 7.766512908347067e-07
with O 0 4.3922557324549416e-07
age O 0 3.362935967743397e-05
at O 1 0.7727108001708984
disease O 1 0.9999074935913086
onset O 1 0.9930272698402405
. O 0 0.0001064659227267839

In O 0 2.8004345949739218e-05
addition O 0 7.458629170287168e-06
, O 0 1.9468075151962694e-06
a O 0 9.938154335031868e-07
correlation O 0 4.839209850615589e-07
between O 0 3.522165457070514e-07
smooth O 0 2.160701569664525e-06
pursuit O 0 1.2965047062607482e-05
gain O 0 1.908306330733467e-06
and O 0 1.5247614726376923e-07
the O 0 2.386293829204078e-07
number O 0 3.26573825759624e-07
of O 0 2.4977139219117817e-06
trinucleotide O 0 0.017927516251802444
repeats O 0 5.750932905357331e-05
was O 0 0.00010508167906664312
found O 0 3.806620588875376e-05
. O 0 3.693820326589048e-05

In O 0 0.0007235975936055183
SCA3 B-Disease 1 0.9999997615814209
, O 0 7.063832890708e-05
gaze B-Disease 0 0.0013706085737794638
- I-Disease 0 0.00020588841289281845
evoked I-Disease 0 0.0006772238411940634
nystagmus I-Disease 0 0.025511763989925385
was O 0 3.4648095606826246e-05
often O 0 4.2467800653867016e-07
present O 0 4.45247223979095e-07
as O 0 1.3428530110104475e-06
was O 0 3.007113264175132e-05
saccade O 0 0.0003233871248085052
hypometria O 0 0.0004783971235156059
and O 0 1.8816094780049752e-06
smooth O 0 9.785180736798793e-06
pursuit O 0 4.009847543784417e-05
gain O 0 2.260307337564882e-05
was O 0 0.0001967168354894966
markedly O 0 8.901647379389033e-05
decreased O 0 0.00012907478958368301
. O 0 4.2413401388330385e-05

Three O 0 2.161445991077926e-05
major O 0 2.9606631869683042e-05
criteria O 0 1.4949441720091272e-05
, O 0 3.7559782413154608e-06
saccade O 0 6.105669308453798e-05
amplitude O 0 8.034542588575277e-06
, O 0 6.91981881573156e-07
saccade O 0 1.2049134056724142e-05
velocity O 0 2.180073124691262e-06
, O 0 2.0887715379558358e-07
and O 0 6.520891560057862e-08
presence O 0 3.1200283956422936e-07
of O 0 1.4056356576475082e-06
gaze B-Disease 0 7.134209590731189e-05
- I-Disease 0 2.5713905415614136e-05
evoked I-Disease 0 0.00011060103861382231
nystagmus I-Disease 0 0.00010401168401585892
, O 0 5.507341143129452e-07
permitted O 0 3.2472536304339883e-07
the O 0 1.822388924210827e-07
correct O 0 8.298770808323752e-07
assignment O 0 1.3279006907396251e-06
of O 0 6.168306754261721e-07
90 O 0 9.555760698276572e-07
% O 0 1.1427866297708533e-07
of O 0 2.493332260655734e-07
the O 0 1.1022049193343264e-06
SCA1 B-Disease 1 0.9985455274581909
, O 0 5.162072511666338e-07
90 O 0 3.229720277886372e-07
% O 0 6.562527943287932e-08
of O 0 1.6465781982333283e-07
the O 0 1.1355689366610022e-06
SCA2 B-Disease 1 0.9999570846557617
, O 0 8.622996006124595e-07
and O 0 3.590835717659502e-07
93 O 0 3.978708718932467e-06
% O 0 2.5227106448255654e-07
of O 0 3.262102836742997e-07
the O 0 1.5378975604107836e-06
patients O 0 4.963799256074708e-06
with O 0 1.883535901470168e-06
SCA3 B-Disease 1 1.0
to O 0 9.138315135714947e-07
their O 0 9.18905527669267e-07
genetically O 0 9.807939932215959e-06
confirmed O 0 6.096976449043723e-06
patient O 0 4.934579010296147e-06
group O 0 6.774861844860425e-07
and O 0 4.971029738953803e-07
, O 0 6.409871389223554e-07
therefore O 0 8.340560384567652e-07
, O 0 8.065289307523926e-07
may O 0 6.056816346244887e-07
help O 0 4.950567813466478e-07
orient O 0 0.0003258621145505458
diagnoses O 0 0.00014382459630724043
of O 0 7.319374708458781e-05
SCA1 B-Disease 1 0.9999996423721313
, O 0 3.392483267816715e-05
SCA2 B-Disease 1 0.9999512434005737
, O 0 3.6600565636035753e-06
and O 0 3.2842419841472292e-06
SCA3 B-Disease 1 0.9999995231628418
at O 0 3.1562412914354354e-05
early O 0 5.343748398445314e-06
clinical O 0 1.3696211681235582e-05
stages O 0 1.8145525245927274e-05
of O 0 1.6909123587538488e-05
the O 0 0.001352019258774817
diseases O 1 0.9999994039535522
. O 0 5.928668542765081e-05
. O 0 6.935954297659919e-05

Genetic O 0 8.8155509729404e-05
basis O 0 7.150316832849057e-06
and O 0 5.006897481507622e-06
molecular O 0 0.00013623286213260144
mechanism O 0 0.00021122596808709204
for O 0 0.008859539404511452
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.1623307317495346

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999971389770508
causes O 0 0.000269589654635638
more O 0 2.2735591755917994e-06
than O 0 1.0961219913951936e-06
300 O 0 3.798571469815215e-06
, O 0 9.706325272418326e-07
000 O 0 6.3096804296947084e-06
sudden O 0 5.98198312218301e-06
deaths O 0 6.886408527861931e-07
each O 0 1.0772561154226423e-07
year O 0 6.282626827669446e-07
in O 0 8.729418823349988e-07
the O 0 7.691456630709581e-06
USA O 0 0.15010946989059448
alone O 0 6.606298120459542e-05
. O 0 4.3911019020015374e-05

In O 0 2.8794467652915046e-05
approximately O 0 1.104092280002078e-05
5 O 0 5.896097263757838e-06
- O 0 7.679042937525082e-06
12 O 0 2.4233506792370463e-06
% O 0 1.523319639318288e-07
of O 0 1.7918439709774248e-07
these O 0 8.812338592179003e-08
cases O 0 1.8279605740190163e-07
, O 0 8.793885797331313e-08
there O 0 8.992026323539903e-08
are O 0 3.9274194563176934e-08
no O 0 9.600482826499501e-07
demonstrable O 0 0.24752089381217957
cardiac O 1 0.9999593496322632
or O 0 4.640035695047118e-05
non O 0 0.45137959718704224
- O 1 0.999862551689148
cardiac O 1 0.9999996423721313
causes O 0 5.108883215143578e-06
to O 0 1.485540650492112e-07
account O 0 1.6235102862083295e-07
for O 0 1.691174418283481e-07
the O 0 1.5402504232042702e-06
episode O 0 9.389629667566624e-06
, O 0 2.9802231438225135e-07
which O 0 1.3952848121334682e-07
is O 0 1.9891167823971045e-07
therefore O 0 5.978823764962726e-07
classified O 0 1.9603165128501132e-05
as O 0 0.00014987413305789232
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9837227463722229
IVF B-Disease 1 1.0
) O 0 0.0001094121253117919
. O 0 5.96170975768473e-05

A O 0 0.0001588101004017517
distinct O 0 1.0244386430713348e-05
group O 0 6.298984317254508e-06
of O 0 6.224726530490443e-05
IVF B-Disease 1 1.0
patients O 0 0.0002171448722947389
has O 0 6.380754484780482e-07
been O 0 2.7849048933603626e-07
found O 0 1.8740489338142652e-07
to O 0 7.145219882431775e-08
present O 0 4.929950705445663e-07
with O 0 6.258556481952837e-07
a O 0 9.923711331794038e-06
characteristic O 0 0.0016680435510352254
electrocardiographic O 1 0.9672903418540955
pattern O 0 0.0004976444761268795
. O 0 0.00010044343798654154

Because O 0 3.887171624228358e-05
of O 0 9.249983122572303e-06
the O 0 2.0222155399096664e-06
small O 0 1.106910417547624e-06
size O 0 1.052731704476173e-06
of O 0 1.2169222145530512e-06
most O 0 2.6083836246471037e-07
pedigrees O 0 4.849511697102571e-06
and O 0 4.577483423418016e-07
the O 0 8.959743809100473e-07
high O 0 2.352761111978907e-05
incidence O 0 2.690805195015855e-05
of O 0 4.272736532584531e-06
sudden B-Disease 0 0.00010956947517115623
death I-Disease 0 3.73850780306384e-05
, O 0 4.193198321900127e-07
however O 0 7.275995272948421e-08
, O 0 6.853154133068529e-08
molecular O 0 1.0412074971100083e-06
genetic O 0 5.924341621721396e-07
studies O 0 3.0077416113272193e-07
of O 0 1.5221447711155633e-06
IVF B-Disease 1 0.9998910427093506
have O 0 2.82485189018189e-07
not O 0 1.09644126666808e-07
yet O 0 4.7605149688934034e-07
been O 0 1.1408183127059601e-06
done O 0 7.610206012031995e-06
. O 0 1.6454006981803104e-05

Because O 0 0.006048858631402254
IVF B-Disease 1 1.0
causes O 1 0.9997120499610901
cardiac O 1 1.0
rhythm O 1 0.9999994039535522
disturbance O 1 0.9998695850372314
, O 0 2.796220542222727e-06
we O 0 2.576294093614706e-07
investigated O 0 1.9330707345943665e-06
whether O 0 5.951420689598308e-07
malfunction O 0 0.0004265226889401674
of O 0 2.9556679237430217e-06
ion O 0 2.525545824028086e-05
channels O 0 1.9964670627814485e-06
could O 0 7.961555752444838e-07
cause O 0 2.0739830688398797e-06
the O 0 3.455398882579175e-06
disorder O 0 0.014015719294548035
by O 0 1.1648121471807826e-06
studying O 0 7.524687589466339e-06
mutations O 0 6.384954645000107e-07
in O 0 4.4181513203511713e-07
the O 0 4.157285275141476e-06
cardiac O 1 0.5846570134162903
sodium O 0 6.807636236771941e-05
channel O 0 4.916550824418664e-05
gene O 0 7.410697435261682e-05
SCN5A O 0 0.4377027451992035
. O 0 8.71712836669758e-05

We O 0 1.3084762031212449e-05
have O 0 9.479634286435612e-07
now O 0 1.1854750709971995e-06
identified O 0 1.0434728210384492e-06
a O 0 8.386334116039507e-07
missense O 0 1.5681096556363627e-05
mutation O 0 1.7478504332757439e-06
, O 0 7.950341114337789e-07
a O 0 1.7881361600302625e-06
splice O 0 0.00023815786698833108
- O 0 5.0468839617678896e-05
donor O 0 5.851351943420013e-06
mutation O 0 3.5463899621390738e-06
, O 0 4.925425400870154e-07
and O 0 5.392661819314526e-07
a O 0 1.7849704363470664e-06
frameshift O 0 2.299907100677956e-05
mutation O 0 9.766308721737005e-07
in O 0 2.5833233507910336e-07
the O 0 7.001567610132042e-07
coding O 0 3.94260632674559e-06
region O 0 1.0388062037236523e-06
of O 0 5.384961241361452e-06
SCN5A O 1 0.9991890788078308
in O 0 3.174508037773194e-06
three O 0 3.065039663852076e-06
IVF B-Disease 1 0.9999451637268066
families O 0 7.421004283969523e-06
. O 0 4.179662573733367e-05

We O 0 1.5938718206598423e-05
show O 0 5.021324795961846e-06
that O 0 2.1793817950310768e-07
sodium O 0 9.718440878714318e-07
channels O 0 4.2170961478404934e-07
with O 0 1.7517324124582956e-07
the O 0 9.73541659732291e-07
missense O 0 2.8475329600041732e-05
mutation O 0 3.661526079667965e-06
recover O 0 1.4159378224576358e-05
from O 0 3.21156699101266e-06
inactivation O 0 7.725491741439328e-05
more O 0 1.7685331954453432e-07
rapidly O 0 7.74175589413062e-07
than O 0 1.384408108151547e-07
normal O 0 1.7879642655316275e-07
and O 0 9.237911058335158e-08
that O 0 5.171138184323354e-08
the O 0 8.546407457288296e-07
frameshift O 0 5.383290408644825e-05
mutation O 0 1.054601739269856e-06
causes O 0 9.762853778738645e-07
the O 0 4.369206862975261e-07
sodium O 0 8.053253282014339e-07
channel O 0 4.4417254230211256e-07
to O 0 1.0467285704862661e-07
be O 0 2.33498909096852e-07
non O 0 7.438207831000909e-06
- O 0 4.712347072199918e-05
functional O 0 8.142454316839576e-05
. O 0 4.035276288050227e-05

Our O 0 4.6543900680262595e-05
results O 0 7.359989467659034e-06
indicate O 0 2.472874712111661e-06
that O 0 3.651009876648459e-07
mutations O 0 1.2828766102757072e-06
in O 0 1.1867227840411942e-06
cardiac O 0 0.15513315796852112
ion O 0 0.00012733909534290433
- O 0 8.354676538147032e-05
channel O 0 2.8192212084832136e-06
genes O 0 1.668253162279143e-07
contribute O 0 1.9662354588945163e-07
to O 0 1.1179920278436839e-07
the O 0 9.234129834112537e-07
risk O 0 1.5958406720528728e-06
of O 0 3.7298818824638147e-06
developing O 0 6.893752288306132e-05
IVF B-Disease 1 0.9999958276748657
. O 0 2.2536372853210196e-05
. O 0 3.66312924597878e-05

Molecular O 0 0.00032569869654253125
heterogeneity O 0 0.00026967551093548536
in O 0 2.7784381018136628e-05
mucopolysaccharidosis B-Disease 1 0.9987146854400635
IVA I-Disease 1 0.9999990463256836
in O 0 8.73335920914542e-06
Australia O 0 9.307163963967469e-06
and O 0 1.0792896318889689e-06
Northern O 0 4.54012160844286e-06
Ireland O 0 5.279553533910075e-06
: O 0 6.534786507472745e-07
nine O 0 2.318666702194605e-06
novel O 0 2.504213171050651e-06
mutations O 0 1.1530535175552359e-06
including O 0 2.43215799855534e-06
T312S O 0 0.34574389457702637
, O 0 2.343319465580862e-06
a O 0 1.3305983657119214e-06
common O 0 1.1900888239324559e-06
allele O 0 1.3205659570303396e-06
that O 0 3.256016896102665e-07
confers O 0 2.7445164960226975e-05
a O 0 3.343955904711038e-05
mild O 0 0.00547992205247283
phenotype O 0 0.0005096204695291817
. O 0 6.4212414145004e-05

Mucopolysaccharidosis B-Disease 1 0.9999788999557495
IVA I-Disease 1 0.9999998807907104
( O 0 0.014447485096752644
MPS B-Disease 1 0.9999990463256836
IVA I-Disease 1 1.0
) O 0 9.548171510687098e-05
is O 0 3.4818624499166617e-06
an O 0 5.765967216575518e-06
autosomal B-Disease 1 0.9988414645195007
recessive I-Disease 1 0.9999940395355225
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9985836744308472
by O 0 1.6343816241715103e-05
a O 0 8.157975389622152e-05
genetic B-Disease 1 0.9979788661003113
defect I-Disease 1 0.9991481304168701
in O 0 7.583269507449586e-06
N O 0 0.00012385974696371704
- O 0 4.35067449870985e-05
acetylgalactosamine O 0 0.0016954917227849364
- O 0 5.5524229537695646e-05
6 O 0 2.9080722015351057e-05
- O 0 6.520464376080781e-05
sulfate O 0 0.0026580211706459522
sulfatase O 1 0.9993126392364502
( O 0 0.00015252918819896877
GALNS O 1 0.9999947547912598
) O 0 4.909045674139634e-05
. O 0 3.913039472536184e-05

Previous O 0 6.2249404436443e-05
studies O 0 1.5491406884393655e-05
of O 0 1.4128934708423913e-05
patients O 0 5.8907357924908865e-06
from O 0 1.7133643268607557e-06
a O 0 3.1420577215612866e-06
British O 0 0.00011656645074253902
- O 0 4.025241287308745e-05
Irish O 0 1.1185993571416475e-05
population O 0 1.1904970165232953e-07
showed O 0 6.20593937128433e-07
that O 0 5.8302802585785685e-08
the O 0 8.377469384868164e-07
I113F O 0 0.25046560168266296
mutation O 0 1.7231305946552311e-06
is O 0 1.9005136664418387e-07
the O 0 1.1166876845436491e-07
most O 0 1.789181993672173e-07
common O 0 3.682151259454258e-07
single O 0 9.625675829738611e-07
mutation O 0 1.357116389044677e-06
among O 0 3.392779262867407e-06
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 1.0
patients O 0 0.42270028591156006
and O 0 1.6473666619276628e-05
produces O 0 0.00013223930727690458
a O 0 7.377845759037882e-05
severe O 1 0.9956841468811035
clinical O 1 0.9935018420219421
phenotype O 0 0.0019245435250923038
. O 0 0.00012114257697248831

We O 0 1.0283392839482985e-05
studied O 0 2.0314151697675698e-05
mutations O 0 1.9754199911403703e-06
in O 0 9.390411719323311e-07
the O 0 1.3664513289768365e-06
GALNS O 1 0.9844663143157959
gene O 0 1.90961350199359e-06
from O 0 8.13499013929686e-07
23 O 0 2.2536517008120427e-06
additional O 0 1.86395482160151e-06
MPS B-Disease 1 0.9997851252555847
IVA I-Disease 1 1.0
patients O 0 0.0017925320426002145
( O 0 1.2274517757759895e-06
15 O 0 1.1825156889244681e-06
from O 0 5.90685317547468e-07
Australia O 0 1.2364738495307392e-06
, O 0 1.864289345121506e-07
8 O 0 4.606100389992207e-07
from O 0 3.7128717167433933e-07
Northern O 0 1.5269615687429905e-06
Ireland O 0 4.12824692830327e-06
) O 0 2.67922104058016e-07
, O 0 1.136924225875191e-07
with O 0 5.9481081393641944e-08
various O 0 6.030787176314334e-07
clinical O 0 0.20854757726192474
phenotypes O 0 0.008580365218222141
( O 0 3.079153975704685e-05
severe O 1 0.5579081773757935
, O 0 2.337375917704776e-06
16 O 0 2.052948502750951e-06
cases O 0 1.2764485290972516e-07
; O 0 7.860927553338115e-08
intermediate O 0 6.547976227011532e-06
, O 0 3.9735937207296956e-07
4 O 0 1.4400691270566313e-06
cases O 0 2.9164050374674844e-07
; O 0 4.309220287268545e-07
mild O 0 1.3041932106716558e-05
, O 0 1.175584657175932e-06
3 O 0 7.171589459176175e-06
cases O 0 2.2537399217981147e-06
) O 0 5.8381860981171485e-06
. O 0 3.0266595786088146e-05

We O 0 1.4017165085533634e-05
found O 0 3.2248374282062287e-06
two O 0 2.5110236379077833e-07
common O 0 8.33245110243297e-07
mutations O 0 4.467750613912358e-07
that O 0 8.47828403038875e-08
together O 0 2.1420892437618022e-07
accounted O 0 1.349187641608296e-06
for O 0 2.129493452684983e-07
32 O 0 1.4939299717298127e-06
% O 0 2.3328189513449615e-07
of O 0 4.180122346042481e-07
the O 0 7.250296789607091e-07
44 O 0 4.260391506250016e-06
unrelated O 0 4.260928108124062e-06
alleles O 0 8.614390480943257e-07
in O 0 7.761566962471989e-07
these O 0 1.413035988662159e-06
patients O 0 6.189312261994928e-05
. O 0 2.9020855436101556e-05

One O 0 4.1275605326518416e-05
is O 0 6.316098279057769e-06
the O 0 4.676303888118127e-06
T312S O 0 0.02510571852326393
mutation O 0 3.672230604934157e-06
, O 0 5.877677153875993e-07
a O 0 9.763634807313792e-07
novel O 0 1.981797822736553e-06
mutation O 0 1.1317570169921964e-06
found O 0 5.701851364392496e-07
exclusively O 0 2.6876377887674607e-06
in O 0 4.274611455912236e-06
milder O 0 0.0002925563894677907
patients O 0 0.00016148725990206003
. O 0 5.171480734134093e-05

The O 0 3.6178073060000315e-05
other O 0 3.104744109805324e-06
is O 0 9.186181273435068e-07
the O 0 1.0008861863752827e-06
previously O 0 6.170422238938045e-06
described O 0 5.917830094404053e-06
I113F O 0 0.006633692421019077
that O 0 1.521545414107095e-06
produces O 0 2.466850128257647e-05
a O 0 3.50211194017902e-05
severe O 1 0.9073585867881775
phenotype O 0 0.0011638058349490166
. O 0 8.509027247782797e-05

The O 0 0.00016927931574173272
I113F O 0 0.0023513755295425653
and O 0 1.2502207937359344e-05
T312S O 0 0.00031851991661824286
mutations O 0 2.0196446257614298e-06
accounted O 0 3.2292753076035297e-06
for O 0 4.3320684994796466e-07
8 O 0 2.6460304525244283e-06
( O 0 4.5869794007558085e-07
18 O 0 8.98986343145225e-07
% O 0 2.2244060460252513e-07
) O 0 7.095527365663656e-08
and O 0 1.939436344855494e-07
6 O 0 2.583631157904165e-06
( O 0 3.0169979936545133e-07
14 O 0 1.0939090770989424e-06
% O 0 1.2653114822569478e-07
) O 0 4.958486954365071e-08
of O 0 4.3887175138479506e-07
44 O 0 4.088397417945089e-06
unrelated O 0 6.442858193622669e-06
alleles O 0 2.528701315895887e-06
, O 0 3.7798347420903156e-06
respectively O 0 2.6937657821690664e-05
. O 0 2.3948025045683607e-05

The O 0 4.568093208945356e-05
relatively O 0 1.3949568710813764e-05
high O 0 4.243901275913231e-05
residual O 0 0.0016654004575684667
GALNS O 1 0.9294263124465942
activity O 0 2.547489430071437e-06
seen O 0 1.4072746807869407e-06
when O 0 2.0825896740461758e-07
the O 0 3.2329560895050236e-07
T312S O 0 2.57840129052056e-05
mutant O 0 5.137529115017969e-06
cDNA O 0 8.719321158423554e-06
is O 0 4.365520851479232e-07
overexpressed O 0 1.7028904039761983e-05
in O 0 4.927219947603589e-07
mutant O 0 6.504893008241197e-06
cells O 0 8.824412702779227e-07
provides O 0 1.269252720703662e-07
an O 0 7.772042209808205e-08
explanation O 0 3.1012885415293567e-07
for O 0 2.7230453270021826e-07
the O 0 7.240254490170628e-06
mild O 0 0.014326117001473904
phenotype O 0 1.8438144252286293e-05
in O 0 1.977351757886936e-06
patients O 0 2.6893967515206896e-06
with O 0 6.495884008472785e-07
this O 0 1.8261639525007922e-06
mutation O 0 2.7242836949881166e-05
. O 0 1.8349244783166796e-05

The O 0 2.2331843865686096e-05
distribution O 0 3.0071187211433426e-06
and O 0 4.5238820689519343e-07
relative O 0 6.761165423085913e-07
frequencies O 0 3.0743265710952983e-07
of O 0 5.722202445213043e-07
the O 0 7.646702897545765e-07
I113F O 0 0.0005594503600150347
and O 0 1.4171506563798175e-06
T312S O 0 0.00014382117660716176
mutations O 0 5.130260660735075e-07
in O 0 3.399920274205215e-07
Australia O 0 8.607229915469361e-07
corresponded O 0 5.443059194476518e-07
to O 0 7.876896290781588e-08
those O 0 5.638046474132352e-08
observed O 0 1.7781883343559457e-07
in O 0 1.2826927786591114e-07
Northern O 0 1.090928435587557e-06
Ireland O 0 1.7138055454779533e-06
and O 0 1.1048152259718336e-07
are O 0 1.7718379652365002e-08
unique O 0 4.1484899071519976e-08
to O 0 3.704552042904652e-08
these O 0 2.235391427518607e-08
two O 0 3.371515333583375e-08
populations O 0 1.3665044207300525e-07
, O 0 2.5182563945236325e-07
suggesting O 0 3.4471301546545874e-07
that O 0 2.4251573194078446e-08
both O 0 6.735667312796068e-08
mutations O 0 9.357346897331809e-08
were O 0 1.7075556968393357e-07
probably O 0 5.399495535129972e-07
introduced O 0 2.8966417175979586e-07
to O 0 1.6513888567715185e-07
Australia O 0 6.20715240984282e-07
by O 0 1.5122220986540924e-07
Irish O 0 2.6763020741782384e-06
migrants O 0 4.0207785900747695e-07
during O 0 1.0075373211293481e-06
the O 0 1.8944655266750487e-06
19th O 0 0.00014454171468969434
century O 0 0.00028998000198043883
. O 0 6.037746061338112e-05

Haplotype O 0 0.00021370408649090677
analysis O 0 3.992886377091054e-06
using O 0 8.557037290302105e-06
6 O 0 2.557982770667877e-05
RFLPs O 0 0.0005673094419762492
provides O 0 1.024411290018179e-06
additional O 0 3.7031011856925033e-07
data O 0 6.864390798000386e-07
that O 0 1.2123311421419203e-07
the O 0 7.011477123342047e-07
I113F O 0 0.00031138554913923144
mutation O 0 1.1835976465590647e-06
originated O 0 1.6868378907020087e-06
from O 0 9.941727512341458e-07
a O 0 1.967660409718519e-06
common O 0 4.392977643874474e-06
ancestor O 0 0.000291895295958966
. O 0 5.5505381169496104e-05

The O 0 4.7518729843432084e-05
other O 0 3.821305654128082e-06
9 O 0 1.420468652213458e-05
novel O 0 5.195580342842732e-06
mutations O 0 1.1070973187088384e-06
identified O 0 5.905073408030148e-07
in O 0 2.60269843010974e-07
these O 0 1.123271431424655e-07
23 O 0 4.033127879665699e-06
patients O 0 8.346440267814614e-07
were O 0 1.4810098036832642e-07
each O 0 5.0170889664968854e-08
limited O 0 1.585008106985697e-07
to O 0 1.7856706335805939e-07
a O 0 1.8006179516305565e-06
single O 0 6.815481810917845e-06
family O 0 1.7837550331023522e-05
. O 0 3.120545079582371e-05

These O 0 6.372949428623542e-06
data O 0 6.170551841933047e-06
provide O 0 1.7200078445966938e-06
further O 0 8.36312437968445e-07
evidence O 0 1.9831456938845804e-06
for O 0 2.618497489947913e-07
extensive O 0 7.254907814058242e-06
allelic O 0 5.8195731980958953e-05
heterogeneity O 0 4.322556924307719e-05
in O 0 7.574459232273512e-06
MPS B-Disease 1 0.9872474670410156
IVA I-Disease 1 1.0
in O 0 7.519307473558001e-06
British O 0 0.002486997051164508
- O 0 0.01067491713911295
Irish O 0 0.008905666880309582
patients O 0 5.185902409721166e-06
and O 0 1.5228360439323296e-07
provide O 0 9.94269697685013e-08
evidence O 0 3.7361436966421024e-07
for O 0 1.2371290836199478e-07
their O 0 1.762065124921719e-07
transmission O 0 1.1876228427354363e-06
to O 0 1.8472464091701113e-07
Australia O 0 1.5498737866437295e-06
by O 0 5.727002303501649e-07
British O 0 2.9028020435362123e-05
- O 0 6.218584894668311e-05
Irish O 0 3.0372537366929464e-05
migrants O 0 3.386659727766528e-06
. O 0 4.8194333430728875e-06
. O 0 1.4647397620137781e-05

Identification O 0 0.00010624462447594851
of O 0 5.1221046305727214e-05
constitutional O 0 0.00013806740753352642
WT1 O 1 0.9999756813049316
mutations O 0 3.666949487524107e-05
, O 0 5.317992872733157e-06
in O 0 4.702725618699333e-06
patients O 0 8.012826583581045e-06
with O 0 2.581106855359394e-06
isolated O 1 0.7672370076179504
diffuse B-Disease 1 0.9999990463256836
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.3314715943124611e-05
and O 0 1.1857385970870382e-06
analysis O 0 1.3147201798346941e-06
of O 0 1.2659933418035507e-05
genotype O 0 0.00021231934078969061
/ O 0 9.799328836379573e-05
phenotype O 0 3.4238364605698735e-06
correlations O 0 1.1191200428584125e-06
by O 0 2.512250034669705e-07
use O 0 7.03726129813731e-07
of O 0 2.2962826733419206e-06
a O 0 4.736414666695055e-06
computerized O 0 0.0007592131150886416
mutation O 0 2.0542236597975716e-05
database O 0 2.5359742721775547e-05
. O 0 3.383530201972462e-05

Constitutional O 0 0.000114451177068986
mutations O 0 8.957309546531178e-06
of O 0 9.310422683483921e-06
the O 0 1.4586148608941585e-05
WT1 O 1 0.9972354769706726
gene O 0 1.1450494639575481e-05
, O 0 1.3267044778331183e-06
encoding O 0 2.025042931563803e-06
a O 0 8.332686775247566e-06
zinc O 1 0.9935773015022278
- O 0 0.031031295657157898
finger O 0 0.0007999757071956992
transcription O 0 2.3509262973675504e-05
factor O 0 5.9487929320312105e-06
involved O 0 2.741276603046572e-06
in O 0 6.6626644183998e-06
renal O 1 0.9999996423721313
and O 0 4.8387704737251624e-05
gonadal O 1 0.999983549118042
development O 0 2.3859758584876545e-05
, O 0 7.498559853047482e-07
are O 0 4.2629622498679964e-08
found O 0 1.9780542004355084e-07
in O 0 2.0991234350731247e-07
most O 0 4.5479075083676435e-07
patients O 0 2.958617869808222e-06
with O 0 2.382576440140838e-06
Denys B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9905591011047363
DDS B-Disease 1 1.0
) O 0 5.3314615797717124e-05
, O 0 3.7320169212762266e-06
or O 0 3.215146716684103e-05
diffuse B-Disease 1 0.9999415874481201
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 1 0.9658232927322388
DMS B-Disease 1 1.0
) O 0 1.561138742545154e-05
associated O 0 6.5143481151608285e-06
with O 0 2.385225116086076e-06
pseudohermaphroditism B-Disease 1 0.9999998807907104
and O 0 0.00017701009346637875
/ O 1 0.7075523138046265
or O 0 0.0009644919191487134
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9999995231628418
( O 0 0.000195288477698341
WT B-Disease 1 0.9999995231628418
) O 0 5.7473196648061275e-05
. O 0 4.630376861314289e-05

Most O 0 6.115814903751016e-05
mutations O 0 5.8178367908112705e-05
in O 0 6.58753197058104e-05
DDS B-Disease 1 1.0
patients O 0 0.00024300313089042902
lie O 0 2.8016527721774764e-05
in O 0 2.323457010788843e-06
exon O 0 3.864234531647526e-05
8 O 0 5.118314675200963e-06
or O 0 1.0772556606752914e-06
exon O 0 1.9302564396639355e-05
9 O 0 5.686587428499479e-06
, O 0 9.688633326732088e-07
encoding O 0 3.4244371818203945e-06
zinc O 0 0.00688976189121604
finger O 0 0.00012640994100365788
2 O 0 1.1534842087712605e-05
or O 0 1.0319859029550571e-05
zinc O 1 0.5134416818618774
finger O 0 0.0003235740587115288
3 O 0 5.450448043120559e-06
, O 0 5.332358341547661e-07
respectively O 0 6.987013421166921e-07
, O 0 1.2226250589719712e-07
with O 0 7.325345308117903e-08
a O 0 1.481399863223487e-06
hot O 0 0.0001180154868052341
spot O 0 8.292795973829925e-05
( O 0 4.255721705703763e-06
R394W O 0 0.00018332252511754632
) O 0 1.6937148075157893e-06
in O 0 1.828628228395246e-06
exon O 0 0.000276899547316134
9 O 0 0.00010161162208532915
. O 0 4.985744089935906e-05

We O 0 1.2504402548074722e-05
analyzed O 0 7.602342975587817e-06
a O 0 8.410441978412564e-07
series O 0 1.1343739743097103e-06
of O 0 2.006622025874094e-06
24 O 0 1.2823510587622877e-05
patients O 0 2.9929592528787907e-06
, O 0 5.06118112753029e-07
10 O 0 1.1958945833612233e-06
with O 0 6.714438427479763e-07
isolated B-Disease 0 0.0021499719005078077
DMS I-Disease 1 1.0
( O 0 0.0001486523833591491
IDMS B-Disease 1 0.9999985694885254
) O 0 2.623974751259084e-06
, O 0 7.853641363908537e-07
10 O 0 9.763765547177172e-07
with O 0 1.3590008620667504e-06
DDS B-Disease 1 1.0
, O 0 3.4145853078371147e-06
and O 0 8.476058610540349e-07
4 O 0 6.700668109260732e-06
with O 0 4.8151796363526955e-06
urogenital B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999960660934448
and O 0 0.003532183589413762
/ O 1 0.9966046810150146
or O 0 0.0011629508808255196
WT B-Disease 1 0.9999980926513672
. O 0 0.00018512156384531409

We O 0 3.327033846289851e-05
report O 0 1.4592493243981153e-05
WT1 O 0 0.00926091056317091
heterozygous O 0 9.065505764738191e-06
mutations O 0 1.0920183513007942e-06
in O 0 7.547727136625326e-07
16 O 0 6.43790826870827e-06
patients O 0 2.1911534986429615e-06
, O 0 5.423203788268438e-07
4 O 0 3.0200112632883247e-06
of O 0 3.4063014027196914e-06
whom O 0 5.764053639722988e-06
presented O 0 2.212503386544995e-05
with O 0 3.7686873838538304e-05
IDMS B-Disease 1 0.9999997615814209
. O 0 0.0006308663869276643

One O 0 6.625211972277611e-05
male O 0 2.495656553946901e-05
and O 0 2.738744569796836e-06
two O 0 3.0640021577710286e-06
female O 0 0.0008029044256545603
IDMS B-Disease 1 1.0
patients O 0 0.04247445985674858
with O 0 0.00013756855332758278
WT1 O 1 1.0
mutations O 0 0.006543850991874933
underwent O 1 0.9999039173126221
normal O 0 0.00028966277022846043
puberty O 0 0.013208916410803795
. O 0 4.873074794886634e-05

Two O 0 3.810921043623239e-05
mutations O 0 1.926795084727928e-05
associated O 0 9.913126632454805e-06
with O 0 3.591888116716291e-06
IDMS B-Disease 1 0.9999152421951294
are O 0 2.0127501443312212e-07
different O 0 8.039059196107701e-08
from O 0 7.054019306451664e-07
those O 0 5.542194685403956e-07
described O 0 1.848023384809494e-05
in O 0 9.138325549429283e-05
DDS B-Disease 1 1.0
patients O 0 0.09924576431512833
. O 0 0.00013778594438917935

No O 0 0.0003728722222149372
WT1 O 1 0.7535162568092346
mutations O 0 1.637281820876524e-05
were O 0 3.2783900678623468e-06
detected O 0 6.602020675927633e-06
in O 0 3.824452221579122e-07
the O 0 5.800696953883744e-07
six O 0 1.3261897038319148e-06
other O 0 5.927760412305361e-06
IDMS B-Disease 1 1.0
patients O 0 0.00034974500886164606
, O 0 1.9498679648677353e-06
suggesting O 0 3.3803030419221614e-06
genetic O 0 5.512803454621462e-06
heterogeneity O 0 2.7104691980639473e-05
of O 0 6.142608617665246e-05
this O 0 5.6142653193091974e-05
disease O 1 0.9998598098754883
. O 0 0.00011192693636985496

We O 0 2.2100175556261092e-05
analyzed O 0 4.135798735660501e-05
genotype O 0 9.558967576595023e-05
/ O 0 7.211336196633056e-05
phenotype O 0 6.434083843487315e-06
correlations O 0 5.700596375390887e-06
, O 0 6.189921464283543e-07
on O 0 2.726894479110342e-07
the O 0 1.79093007091069e-07
basis O 0 2.1098509250805364e-07
of O 0 4.2793288912434946e-07
the O 0 4.901700663140218e-07
constitution O 0 2.747846679085342e-07
of O 0 1.7683337318885606e-06
a O 0 4.3819645725307055e-06
WT1 O 1 0.8160886764526367
mutation O 0 1.486412315898633e-06
database O 0 8.169766942955903e-07
of O 0 1.4706117781315697e-06
84 O 0 5.715389852412045e-05
germ O 1 0.9998196959495544
- O 0 0.0002487261954229325
line O 0 2.0040204617544077e-05
mutations O 0 1.4057710586712346e-06
, O 0 2.0867864236606692e-07
to O 0 6.847169231605221e-08
compare O 0 4.492677305734105e-07
the O 0 2.664106659722165e-07
distribution O 0 2.0410720935615245e-07
and O 0 2.2539151700584625e-07
type O 0 1.5438062064276892e-06
of O 0 1.9874948975484585e-06
mutations O 0 9.557492148815072e-07
, O 0 1.8822130698481487e-07
according O 0 1.3327124293027737e-07
to O 0 2.3955536221365037e-07
the O 0 1.7673846741672605e-06
different O 0 2.2110150439402787e-06
symptoms O 0 0.0036317172925919294
. O 0 4.615929719875567e-05

This O 0 1.7022457541315816e-05
demonstrated O 0 2.8604363251361065e-05
( O 0 2.9358177471294766e-06
1 O 0 4.211255145492032e-06
) O 0 3.2142645522981184e-07
the O 0 6.630506277360837e-07
association O 0 1.7057667491826578e-06
between O 0 4.6416420218520216e-07
mutations O 0 7.455802801814571e-07
in O 0 5.363627906262991e-07
exons O 0 3.3014948712661862e-06
8 O 0 1.9868352865159977e-06
and O 0 4.335718415404699e-07
9 O 0 4.181556505500339e-06
and O 0 9.204368325299583e-07
DMS B-Disease 1 0.9998973608016968
; O 0 1.216868781739322e-06
( O 0 1.0660158977771061e-06
2 O 0 3.6406452181836357e-06
) O 0 3.558878063358861e-07
among O 0 4.799188673132448e-07
patients O 0 1.5984087440301664e-06
with O 0 1.1299711104584276e-06
DMS B-Disease 1 0.9999994039535522
, O 0 2.1368182387959678e-06
a O 0 7.00943814990751e-07
higher O 0 3.395684871065896e-07
frequency O 0 3.881989982801315e-07
of O 0 4.044723311835696e-07
exon O 0 1.1922338671865873e-05
8 O 0 1.687869371380657e-06
mutations O 0 2.805527117288875e-07
among O 0 2.2950098355067894e-07
46 O 0 3.7663301100110402e-06
, O 0 3.6085539250052534e-06
XY O 0 0.16498912870883942
patients O 0 2.142123094017734e-06
with O 0 3.267217891789187e-07
female O 0 2.088246446874109e-06
phenotype O 0 2.4062492229859345e-06
than O 0 1.884677374164312e-07
among O 0 7.019459076218482e-07
46 O 0 1.211014296131907e-05
, O 0 4.2733681766549125e-06
XY O 0 0.20382264256477356
patients O 0 1.3246386743048788e-06
with O 0 1.8508455923438305e-07
sexual O 0 8.635752237751149e-07
ambiguity O 0 5.22333220942528e-06
or O 0 2.67839072876086e-06
male O 0 2.4191390366468113e-06
phenotype O 0 1.1679501312755747e-06
; O 0 1.4862307295970822e-07
and O 0 4.4642922603088664e-07
( O 0 6.264886565077177e-07
3 O 0 1.1563637372091762e-06
) O 0 1.2541555349798728e-07
statistically O 0 1.2011977901238424e-07
significant O 0 6.479481839960499e-08
evidence O 0 1.8082413077991077e-07
that O 0 2.183150726864369e-08
mutations O 0 1.5347592352554784e-07
in O 0 2.4268169340757595e-07
exons O 0 2.478983333276119e-06
8 O 0 3.360932851137477e-06
and O 0 6.555184199896757e-07
9 O 0 4.019469997729175e-06
preferentially O 0 3.188163873346639e-06
affect O 0 3.622210442699725e-07
amino O 0 3.062092730488075e-07
acids O 0 1.229790171919376e-07
with O 0 5.864654184506435e-08
different O 0 8.082939473297301e-08
functions O 0 1.0947711643893854e-06
. O 0 3.258541028117179e-06
. O 0 1.2100630556233227e-05

The O 0 0.0003083174815401435
185delAG O 0 0.024463295936584473
BRCA1 O 0 0.0006764017743989825
mutation O 0 8.588161108491477e-06
originated O 0 6.33107811154332e-06
before O 0 1.4998744291006005e-06
the O 0 4.993113407181227e-07
dispersion O 0 4.327635451772949e-06
of O 0 1.147412945101678e-06
Jews O 0 2.451892896715435e-06
in O 0 3.2891711043703253e-07
the O 0 4.445458614554809e-07
diaspora O 0 1.3032952210778603e-06
and O 0 3.8917909250812954e-07
is O 0 2.368769145277838e-07
not O 0 8.462999545599814e-08
limited O 0 7.813241040821595e-07
to O 0 2.541847152315313e-06
Ashkenazim O 0 0.0023072385229170322
. O 0 8.135120151564479e-05

The O 0 0.00011305582302156836
185delAG O 0 0.001316976617090404
mutation O 0 3.627805563155562e-05
in O 0 7.512892807426397e-06
BRCA1 O 0 0.00014717823069076985
is O 0 1.7171805666293949e-06
detected O 0 1.0301148904545698e-05
in O 0 7.972450930537889e-07
Ashkenazi O 0 2.815572588588111e-05
Jews O 0 2.729204425122589e-06
both O 0 5.710111850021349e-07
in O 0 3.3475298550911248e-06
familial B-Disease 1 0.999523401260376
breast I-Disease 1 1.0
and I-Disease 1 0.9999803304672241
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.548299330053851e-06
in O 0 1.8082378119288478e-06
the O 0 1.2301776450840407e-06
general O 0 7.471643584722187e-06
population O 0 2.280989065184258e-06
. O 0 1.5036057448014617e-05

All O 0 3.368437319295481e-05
tested O 0 0.00010365593334427103
Ashkenazi O 0 0.00024524133186787367
mutation O 0 4.2428796405147295e-06
carriers O 0 6.819979603278625e-07
share O 0 4.026219642128126e-07
the O 0 4.378725861897692e-07
same O 0 4.480653785776667e-07
allelic O 0 3.306979124317877e-05
pattern O 0 1.3515467799152248e-05
at O 0 2.378918907197658e-05
the O 0 3.0190896723070182e-05
BRCA1 O 0 0.0013176730135455728
locus O 0 0.0004397345765028149
. O 0 9.768456220626831e-05

Our O 0 3.777077654376626e-05
previous O 0 1.2453930139599834e-05
study O 0 3.210348268112284e-06
showed O 0 3.326973001094302e-06
that O 0 8.866238232485557e-08
this O 0 1.4724444952207705e-07
Ashkenazi O 0 8.619185973657295e-05
mutation O 0 1.0813894277816871e-06
also O 0 2.515894550469966e-07
occurs O 0 1.9208708579299127e-07
in O 0 1.567101151067618e-07
Iraqi O 0 1.1970220157309086e-06
Jews O 0 1.3314386251295218e-06
with O 0 2.2807945754266257e-07
a O 0 1.6831131688377354e-06
similar O 0 4.940342478221282e-06
allelic O 0 0.0006568872486241162
pattern O 0 0.00017911879695020616
. O 0 6.851232319604605e-05

We O 0 1.1674484085233416e-05
extended O 0 4.912923031952232e-06
our O 0 7.866759688113234e-07
analysis O 0 2.261921139279366e-07
to O 0 8.585916333458954e-08
other O 0 1.5410586229336332e-07
non O 0 2.953582679765532e-06
- O 0 1.3358060641621705e-05
Ashkenazi O 0 2.1119893062859774e-05
subsets O 0 5.749132469645701e-06
354 O 0 1.1213550351385493e-05
of O 0 1.9252572656114353e-06
Moroccan O 0 7.687337529205251e-06
origin O 0 1.037509264278924e-06
, O 0 4.4434835899664904e-07
200 O 0 2.2601559521717718e-06
Yemenites O 0 5.4850970627740026e-05
and O 0 8.12976281849842e-07
150 O 0 4.502921456150943e-06
Iranian O 0 1.006995535135502e-05
Jews O 0 3.6527624615700915e-05
. O 0 3.9482591091655195e-05

Heteroduplex O 0 0.004436561372131109
analysis O 0 1.574083580635488e-05
complemented O 0 2.7326545023242943e-05
by O 0 2.0418676740519004e-06
direct O 0 1.350463435301208e-06
DNA O 0 6.491383828688413e-06
sequencing O 0 4.452881512406748e-06
of O 0 3.836470568785444e-06
abnormally O 0 1.9820905436063185e-05
migrating O 0 5.1675233407877386e-06
bands O 0 9.776747901923954e-06
were O 0 2.220422402388067e-06
employed O 0 2.9356018785620108e-05
. O 0 1.6304757082252763e-05

Four O 0 1.5138803973968606e-05
of O 0 1.1289238500467036e-05
Moroccan O 0 2.4298662538058124e-05
origin O 0 3.108165628873394e-06
( O 0 1.156924099632306e-06
1 O 0 1.7803021137297037e-06
. O 0 1.6096245758490113e-07
1 O 0 8.012131615942053e-07
% O 0 1.495257038186537e-07
) O 0 6.079066139363931e-08
and O 0 6.372520289232853e-08
none O 0 2.1175451081489882e-07
of O 0 6.270308290368121e-07
the O 0 1.8232161664855084e-06
Yemenites O 0 0.016694681718945503
or O 0 1.507444380877132e-06
Iranians O 0 2.5714439289004076e-06
was O 0 4.762231583299581e-06
a O 0 8.328581770911114e-07
carrier O 0 2.3562249680253444e-06
of O 0 1.4790381328566582e-06
the O 0 3.956599357479718e-06
185delAG O 0 0.0022292814683169127
mutation O 0 4.598618397722021e-05
. O 0 2.4269762434414588e-05

BRCA1 O 0 0.0018539335578680038
allelic O 0 0.0003282401885371655
patterns O 0 1.816204166971147e-05
were O 0 1.9497413177305134e-06
determined O 0 7.779492534609744e-07
for O 0 1.0532432526133562e-07
four O 0 1.3736881498971343e-07
of O 0 4.111091413960821e-07
these O 0 5.927924817683561e-08
individuals O 0 3.597917341835455e-08
and O 0 1.4714632357026858e-07
for O 0 2.634827467318246e-07
12 O 0 1.4539764379151165e-06
additional O 0 4.744479724649864e-07
non O 0 1.1399089999031276e-05
- O 0 6.016422776156105e-05
Ashkenazi O 0 0.00038096163189038634
185delAG O 0 0.0001702406443655491
mutation O 0 2.883623210436781e-06
carriers O 0 1.8652458493306767e-06
who O 0 3.6510691643343307e-06
had O 0 0.00030953212990425527
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004685861349571496

Six O 0 0.00012168857938377187
non O 0 0.0002183232136303559
- O 0 0.00022349008941091597
Ashkenazi O 0 0.00022635688947048038
individuals O 0 6.618944894398737e-07
shared O 0 4.090059064765228e-06
the O 0 4.309834821469849e-06
common O 0 7.522793566749897e-06
Ashkenazi O 0 0.03844043239951134
haplotype O 0 4.061408981215209e-05
, O 0 8.815833325570566e-07
four O 0 2.7273520686321717e-07
had O 0 6.663196359113499e-07
a O 0 6.653100399489631e-07
closely O 0 2.8863803436252056e-07
related O 0 1.383630888085463e-06
pattern O 0 5.912854248890653e-06
, O 0 6.661779252681299e-07
and O 0 3.0936053008190356e-07
the O 0 8.372365414288652e-07
rest O 0 5.239231995801674e-06
( O 0 6.147241720100283e-07
n O 0 1.8574070281829336e-06
= O 0 1.6330305925293942e-06
6 O 0 3.0465137115243124e-06
) O 0 4.0574491322331596e-07
displayed O 0 3.9260112316696905e-06
a O 0 2.098824325003079e-06
distinct O 0 5.986742507957388e-06
BRCA1 O 0 0.00029896319028921425
allelic O 0 0.0003595472080633044
pattern O 0 0.00018378840468358248
. O 0 6.17127152509056e-05

We O 0 1.993839214264881e-05
conclude O 0 1.542988138680812e-05
that O 0 8.990360811367282e-07
the O 0 4.272724709153408e-06
185delAG O 0 0.31860771775245667
BRCA1 O 0 0.0005282638012431562
mutation O 0 3.2260986699839123e-06
occurs O 0 3.132430776986439e-07
in O 0 9.389724908714925e-08
some O 0 1.0372782099921096e-07
non O 0 4.009706572105642e-06
- O 0 1.1486629773571622e-05
Ashkenazi O 0 2.246976328024175e-05
populations O 0 2.3171097041085886e-07
at O 0 1.1010597518179566e-06
rates O 0 1.8087881414885487e-07
comparable O 0 8.580282155890018e-07
with O 0 1.3898079487262294e-07
that O 0 3.3387860298716987e-07
of O 0 1.2134744793002028e-05
Ashkenazim O 0 0.04626493901014328
. O 0 8.88653303263709e-05

The O 0 2.6415013053338043e-05
majority O 0 2.5669992282928433e-06
of O 0 4.039991836179979e-06
Jewish O 0 5.1286740927025676e-05
185delAG O 0 0.03392608091235161
mutation O 0 5.137921107234433e-06
carriers O 0 1.0315344525224646e-06
have O 0 1.21400873354105e-07
a O 0 4.0774418152977887e-07
common O 0 5.702966063836357e-07
allelic O 0 4.042845466756262e-05
pattern O 0 1.806988802854903e-05
, O 0 1.2207324289192911e-06
supporting O 0 7.900735568000528e-07
the O 0 6.772820597689133e-07
founder O 0 0.00016083879745565355
effect O 0 8.143148875205952e-07
notion O 0 1.7395325357938418e-06
, O 0 2.2413628641970718e-07
but O 0 4.8623213899645634e-08
dating O 0 9.195489383273525e-07
the O 0 1.2100981905405206e-07
mutations O 0 1.7292167342475295e-07
origin O 0 8.283890906568558e-08
to O 0 1.211620315189066e-07
an O 0 3.2281559469993226e-07
earlier O 0 1.4669867596239783e-06
date O 0 2.3657942165300483e-06
than O 0 6.866380886094703e-07
currently O 0 3.569276032067137e-06
estimated O 0 8.169336069840938e-06
. O 0 1.686724863247946e-05

However O 0 4.774867193191312e-05
, O 0 2.389747123743291e-06
the O 0 7.620305950695183e-07
different O 0 1.1783016162780768e-07
allelic O 0 2.498642606951762e-05
pattern O 0 1.3123128155712038e-05
at O 0 1.060037175193429e-05
the O 0 4.904697561869398e-06
BRCA1 O 0 0.00014285213546827435
locus O 0 5.5595278354303446e-06
even O 0 2.1804586936013948e-07
in O 0 1.0264438543572396e-07
some O 0 7.51402282617164e-08
Jewish O 0 2.0307015802245587e-06
mutation O 0 1.0900081406362006e-06
carriers O 0 6.477479814748222e-07
, O 0 3.884756267780176e-07
might O 0 2.03050092295598e-07
suggest O 0 2.1290041729571385e-07
that O 0 5.591099139223843e-08
the O 0 6.00449709509121e-07
mutation O 0 1.178415573122038e-06
arose O 0 2.90604543806694e-06
independently O 0 3.0225812679418596e-06
. O 0 3.837520580418641e-06
. O 0 2.163743192795664e-05

Crystal O 0 0.15455053746700287
structure O 0 0.00011443164112279192
of O 0 0.00011086904851254076
the O 0 0.0013723319862037897
hemochromatosis B-Disease 1 1.0
protein O 0 0.000783383147791028
HFE O 1 0.9999701976776123
and O 0 5.856030384165933e-06
characterization O 0 1.4396542610484175e-05
of O 0 4.667050234274939e-06
its O 0 1.8862664319385658e-06
interaction O 0 2.052488525805529e-06
with O 0 2.4302801193698542e-06
transferrin O 0 0.0011371521977707744
receptor O 0 7.97309257904999e-05
. O 0 3.787516106967814e-05

HFE O 1 0.9742302894592285
is O 0 3.4903918276540935e-05
an O 0 1.1906374311365653e-05
MHC O 1 0.6312137246131897
- O 0 7.665726298000664e-05
related O 0 7.766099770378787e-06
protein O 0 1.892026148198056e-06
that O 0 2.2468115901119745e-07
is O 0 2.245800487798988e-07
mutated O 0 9.05607805634645e-07
in O 0 6.679260877717752e-07
the O 0 1.7828824638854712e-05
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9965900182723999

HFE O 1 0.7342621088027954
binds O 0 0.00013898078759666532
to O 0 9.181765562971123e-06
transferrin O 0 0.0002929002221208066
receptor O 0 2.4928975108196028e-05
( O 0 7.17432612873381e-06
TfR O 0 0.0006006617331877351
) O 0 1.2867731129517779e-06
and O 0 3.5587015645432984e-07
reduces O 0 9.65473645919701e-07
its O 0 1.5234213890380488e-07
affinity O 0 7.126654395506193e-07
for O 0 7.481551733690139e-07
iron O 0 0.3457896113395691
- O 0 2.6318457457819022e-05
loaded O 0 2.7882269932888448e-05
transferrin O 0 0.00013970374129712582
, O 0 8.189712389139459e-06
implicating O 0 0.24866941571235657
HFE O 1 0.9999908208847046
in O 0 0.0004277863772585988
iron O 1 0.9999994039535522
metabolism O 1 0.9905765056610107
. O 0 0.0001881835050880909

The O 0 0.0003869477368425578
2 O 0 0.0006223017117008567
. O 0 0.00019468464597593993

6 O 0 0.0005268105887807906
A O 0 0.00034814278478734195
crystal O 0 0.03877164423465729
structure O 0 5.676341606886126e-05
of O 0 0.0005085051525384188
HFE O 1 0.9999982118606567
reveals O 0 5.80093364987988e-05
the O 0 1.5177512295849738e-06
locations O 0 2.952518343590782e-06
of O 0 6.37042467133142e-05
hemochromatosis B-Disease 1 1.0
mutations O 0 1.2754187991959043e-05
and O 0 4.940116468787892e-06
a O 0 2.31911035371013e-05
patch O 1 0.9999699592590332
of O 0 0.00034264280111528933
histidines O 1 0.9934408068656921
that O 0 2.2285847478542564e-07
could O 0 1.8507360266539763e-07
be O 0 1.2272734295493137e-07
involved O 0 4.6645931206512614e-07
in O 0 2.0377767668833258e-06
pH O 0 0.00022424888447858393
- O 0 8.204433106584474e-05
dependent O 0 1.342264840786811e-05
interactions O 0 1.8428649127599783e-05
. O 0 5.192185199121013e-05

We O 0 1.5272955351974815e-05
also O 0 3.579795929908869e-06
demonstrate O 0 6.345827841869323e-06
that O 0 9.749539913173066e-07
soluble O 0 0.0002489575126674026
TfR O 1 0.8617146611213684
and O 0 2.450685133226216e-05
HFE O 1 0.9980902075767517
bind O 0 4.987244665244361e-06
tightly O 0 7.436086889356375e-06
at O 0 6.063588443794288e-06
the O 0 6.348161036839883e-07
basic O 0 2.080081685562618e-06
pH O 0 4.6071995711827185e-06
of O 0 8.494533858538489e-07
the O 0 1.8932572629637434e-06
cell O 0 2.7787058570538647e-05
surface O 0 5.086913461127551e-06
, O 0 2.7668059487950813e-07
but O 0 9.197912476111014e-08
not O 0 6.02714678166194e-08
at O 0 1.5312957657442894e-06
the O 0 2.5112276489380747e-06
acidic O 0 9.485652844887227e-05
pH O 0 0.00012551403779070824
of O 0 3.570473563740961e-05
intracellular O 0 0.00021356577053666115
vesicles O 0 0.0008229699451476336
. O 0 5.44166105100885e-05

TfR O 1 0.827989399433136
HFE O 1 0.7608022093772888
stoichiometry O 0 0.00034816598054021597
( O 0 2.4294769900734536e-05
2 O 0 1.7370495697832666e-05
1 O 0 9.184278496832121e-06
) O 0 9.414990245204535e-07
differs O 0 1.2977685628356994e-06
from O 0 1.8188743524660822e-06
TfR O 0 0.00028307040338404477
transferrin O 0 4.017655737698078e-05
stoichiometry O 0 1.576545946591068e-05
( O 0 1.3913862630943186e-06
2 O 0 2.9048817395960214e-06
2 O 0 2.941214688689797e-06
) O 0 4.858965212406474e-07
, O 0 1.943472653920253e-07
implying O 0 6.651323474216042e-07
a O 0 1.0852206600020509e-07
different O 0 2.3361554468692702e-08
mode O 0 4.4733525328410906e-07
of O 0 1.6448173312255676e-07
binding O 0 3.3378023545083124e-07
for O 0 5.153424922355043e-07
HFE O 1 0.9983830451965332
and O 0 2.853906153177377e-06
transferrin O 0 4.920645369566046e-05
to O 0 1.5883038031461183e-06
TfR O 0 0.009330207481980324
, O 0 9.392005608788168e-07
consistent O 0 9.019902904583432e-07
with O 0 1.3969517453915614e-07
our O 0 5.446745490189642e-07
demonstration O 0 1.1932576853723731e-05
that O 0 5.88264015277673e-07
HFE O 1 0.9922475814819336
, O 0 3.73262901121052e-06
transferrin O 0 8.74974939506501e-05
, O 0 1.0691803709050873e-06
and O 0 1.532367946310842e-06
TfR O 0 0.002020086394622922
form O 0 3.0044757295399904e-06
a O 0 6.781961474189302e-06
ternary O 0 0.0009639973286539316
complex O 0 0.03840746358036995
. O 0 0.0002142467419616878

Identification O 0 0.0001315950066782534
of O 0 2.4720950023038313e-05
three O 0 3.14105409415788e-06
novel O 0 7.166837804106763e-06
mutations O 0 9.94707647805626e-07
and O 0 3.1477694051318394e-07
a O 0 2.7776377464761026e-07
high O 0 1.4892686976963887e-06
frequency O 0 3.3035942692549725e-07
of O 0 3.821838276962808e-07
the O 0 6.391595661625615e-07
Arg778Leu O 0 0.003986463416367769
mutation O 0 9.929219686455326e-07
in O 0 8.143179570652137e-07
Korean O 0 0.00011986893514404073
patients O 0 1.483201685914537e-05
with O 0 7.881493729655631e-06
Wilson B-Disease 1 0.9999895095825195
disease I-Disease 1 0.9999265670776367
. O 0 0.00013918780314270407

Four O 0 6.389942427631468e-05
mutations O 0 2.1779367671115324e-05
- O 0 0.00016391921963077039
- O 0 0.00015760269889142364
R778L O 0 0.003506571054458618
, O 0 5.480089384946041e-06
A874V O 0 0.00025507231475785375
, O 0 2.9957548122183653e-06
L1083F O 0 0.00014571881911251694
, O 0 1.0409255537524587e-06
and O 0 5.410279300122056e-07
2304delC O 0 4.264413291821256e-05
- O 0 1.128290023189038e-05
- O 0 4.725843155028997e-06
in O 0 6.449667466768005e-07
the O 0 9.010153689814615e-07
copper O 0 0.002551883226260543
- O 0 2.0123072317801416e-05
transporting O 0 2.0770250557688996e-05
enzyme O 0 4.524082214629743e-06
, O 0 9.56650183070451e-07
P O 0 4.2345953261246905e-05
- O 0 1.4572953659808263e-05
type O 0 1.1168383935000747e-05
ATPase O 0 0.00013068343105260283
( O 0 6.006644525768934e-06
ATP7B O 1 0.9989156723022461
) O 0 8.786389003034856e-07
, O 0 1.8480905339401943e-07
were O 0 1.7451159806114447e-07
identified O 0 5.905737907596631e-07
in O 0 7.772329126964905e-07
Korean O 0 0.005503607913851738
Patients O 0 0.00017493704217486084
with O 0 1.523531955172075e-05
Wilson B-Disease 1 0.9999986886978149
disease I-Disease 1 0.9999921321868896
. O 0 0.00021061438019387424

Arg778Leu O 1 0.9546396136283875
, O 0 2.089635017910041e-05
the O 0 3.882858891302021e-06
most O 0 6.212541734385013e-07
frequently O 0 6.162409249554912e-07
reported O 0 8.708639143151231e-07
mutation O 0 3.3111734865087783e-07
of O 0 4.3958931428278447e-07
this O 0 1.513344329850952e-07
enzyme O 0 1.6888790241864626e-06
, O 0 5.60258456516749e-07
was O 0 5.169026280782418e-06
found O 0 3.110313571141887e-07
in O 0 1.0037857123279537e-07
six O 0 9.816127288786447e-08
of O 0 3.1792572485755954e-07
eight O 0 8.934445645536471e-07
unrelated O 0 1.640881600906141e-05
patients O 0 3.93091522710165e-06
studied O 0 9.005204447021242e-06
, O 0 2.8326050482974097e-07
an O 0 1.690311677293721e-07
allele O 0 4.715960812973208e-07
frequency O 0 3.679448354887427e-07
of O 0 1.866979346232256e-06
37 O 0 5.7784684031503275e-05
. O 0 2.530710116843693e-05

5 O 0 0.0001583667180966586
% O 0 1.0974829820042942e-05
, O 0 1.4057187627258827e-06
which O 0 3.787455682413565e-07
is O 0 1.665936792960565e-07
considerably O 0 6.990478595980676e-07
higher O 0 2.377357901650612e-07
than O 0 3.550673355334766e-08
those O 0 3.67690091707118e-08
in O 0 1.6810152203561302e-07
other O 0 2.554614866312477e-07
Asian O 0 5.8284731494495645e-06
populations O 0 5.152676749275997e-06
. O 0 1.793123738025315e-05

The O 0 4.191373955109157e-05
novel O 0 2.5431261747144163e-05
single O 0 5.001896170142572e-06
nucleotide O 0 4.956698830937967e-06
deletion O 0 1.0481971912668087e-05
, O 0 1.5080166804182227e-06
2304delC O 0 5.19236309628468e-05
, O 0 1.9635685930552427e-06
was O 0 7.812377589289099e-06
found O 0 1.1960097481278353e-06
in O 0 1.1737384966181708e-06
one O 0 5.58576493858709e-06
patient O 0 0.0001388177479384467
. O 0 4.8430410970468074e-05

Since O 0 3.225118052796461e-05
a O 0 7.920359166746493e-06
mutation O 0 5.586574843619019e-06
at O 0 6.55796839055256e-06
cDNA O 0 1.3051512723905034e-05
nucleotide O 0 1.3139482689439319e-05
2302 O 0 0.0012091674143448472
( O 0 3.177800408593612e-06
2302insC O 0 4.441462078830227e-05
) O 0 4.88103580664756e-07
had O 0 7.350909072556533e-07
been O 0 2.5584697027625225e-07
previously O 0 7.32179671558697e-07
described O 0 6.803297765145544e-07
, O 0 8.928110162287339e-08
this O 0 3.963631911574339e-08
region O 0 1.5556327070953557e-07
of O 0 7.705853590778133e-07
the O 0 7.840052603569347e-06
ATP7B O 1 0.9999998807907104
gene O 0 1.2992672054679133e-05
may O 0 5.380060770221462e-07
be O 0 3.652186819635972e-07
susceptible O 0 1.3960002434032504e-05
to O 0 1.8321262587051024e-06
gene O 0 4.862106652581133e-05
rearrangements O 0 0.15777195990085602
causing O 1 0.9942559599876404
Wilson B-Disease 1 0.9999823570251465
disease I-Disease 1 0.9969227910041809
. O 0 0.00012407453323248774

Disruption O 0 0.0006304251146502793
of O 0 2.5873425329336897e-05
splicing O 0 2.3968999812495895e-05
regulated O 0 5.277605396258878e-06
by O 0 2.820633199007716e-06
a O 0 8.442460966762155e-06
CUG O 1 0.9998313188552856
- O 0 8.9685243437998e-05
binding O 0 9.137721463048365e-06
protein O 0 2.3478591174352914e-05
in O 0 0.00011869138688780367
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.06065062806010246

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999993085861206
DM B-Disease 1 1.0
) O 0 0.0016629518941044807
is O 0 7.777254722896032e-06
caused O 0 1.061834154825192e-05
by O 0 9.517617627352593e-07
a O 0 3.4306381166970823e-06
CTG O 1 0.9049612283706665
expansion O 0 1.1971101230301429e-05
in O 0 1.426769472345768e-06
the O 0 1.6966974953902536e-06
3 O 0 5.182788754609646e-06
untranslated O 0 0.00022696286032442003
region O 0 2.3796403638698393e-06
of O 0 7.360635208897293e-06
the O 0 0.00014837710477877408
DM B-Disease 1 1.0
gene O 0 0.0009617964387871325
. O 0 9.197046892950311e-05

One O 0 2.3686978238401935e-05
model O 0 1.6369149307138287e-05
of O 0 0.000164094366482459
DM B-Disease 1 1.0
pathogenesis O 1 0.999962329864502
suggests O 0 9.704005606181454e-06
that O 0 2.5694779992591066e-07
RNAs O 0 6.095162916608388e-06
from O 0 3.4710632235146477e-07
the O 0 1.7598348733827152e-07
expanded O 0 5.961475721960596e-07
allele O 0 1.7393156781508878e-07
create O 0 1.125982791450042e-07
a O 0 2.1555591445121536e-07
gain O 0 4.6556246502404974e-07
- O 0 1.8997394590769545e-06
of O 0 2.6687068839237327e-06
- O 0 6.09918106420082e-06
function O 0 3.031429969269084e-07
mutation O 0 1.5419817600559327e-07
by O 0 4.9976058846823435e-08
the O 0 2.5351846488774754e-07
inappropriate O 0 7.265483077389945e-07
binding O 0 1.6253989087999798e-07
of O 0 5.110269398755918e-07
proteins O 0 2.5687674565233465e-07
to O 0 7.48081617985008e-07
the O 0 1.1683327102218755e-05
CUG O 1 0.9998040795326233
repeats O 0 0.00014272850239649415
. O 0 5.4376567277358845e-05

Data O 0 5.8418088883627206e-05
presented O 0 2.7737360142054968e-05
here O 0 4.406370862852782e-06
indicate O 0 1.6323983800248243e-06
that O 0 1.6893206122858828e-07
the O 0 3.942968191950058e-07
conserved O 0 5.916532245464623e-06
heterogeneous O 0 2.6685729608288966e-05
nuclear O 0 0.00017358138575218618
ribonucleoprotein O 0 0.0029180420096963644
, O 0 8.667280781082809e-06
CUG O 0 0.04646681621670723
- O 0 1.5444084056071006e-05
binding O 0 1.7596717043488752e-06
protein O 0 2.910968760261312e-06
( O 0 4.3853929128090385e-06
CUG O 1 0.9989301562309265
- O 0 0.00016785348998382688
BP O 0 0.005515631288290024
) O 0 1.2632884818231105e-06
, O 0 6.395516152224445e-07
may O 0 3.543505897596333e-07
mediate O 0 1.7572735941939754e-06
the O 0 1.660614771026303e-06
trans O 0 2.380284968239721e-05
- O 0 3.139927866868675e-05
dominant O 0 6.299266715359408e-06
effect O 0 1.1213592188141774e-06
of O 0 1.906143893393164e-06
the O 0 6.4679265960876364e-06
RNA O 0 0.00017612770898267627
. O 0 3.100327376159839e-05

CUG O 1 0.9999692440032959
- O 0 0.05543738603591919
BP O 0 0.2651572823524475
was O 0 5.2731618779944256e-05
found O 0 5.89463013511704e-07
to O 0 8.244971638760035e-08
bind O 0 1.8230008436148637e-07
to O 0 9.578135262700016e-08
the O 0 1.2179461919004098e-06
human O 0 1.0749758075689897e-05
cardiac O 1 0.9999969005584717
troponin O 1 0.9999964237213135
T O 1 0.9983819723129272
( O 0 6.9555735535686836e-06
cTNT O 0 0.00016415790014434606
) O 0 9.68859581007564e-07
pre O 0 3.628923514042981e-05
- O 0 1.6963407688308507e-05
messenger O 0 1.6650657926220447e-05
RNA O 0 4.652434199670097e-06
and O 0 6.461499992838071e-07
regulate O 0 2.007621333177667e-06
its O 0 1.7989342495638994e-06
alternative O 0 2.079813930322416e-05
splicing O 0 0.00020086392760276794
. O 0 3.93811751564499e-05

Splicing O 0 0.0005366437835618854
of O 0 0.00015642309153918177
cTNT O 1 0.7527617812156677
was O 0 0.0009445421164855361
disrupted O 0 0.00239833677187562
in O 0 0.00016642537957523018
DM B-Disease 1 1.0
striated O 1 0.9999926090240479
muscle O 0 0.015556968748569489
and O 0 2.8208726234879578e-06
in O 0 2.2586671093449695e-06
normal O 0 3.0529881769325584e-06
cells O 0 1.554161599415238e-06
expressing O 0 2.0603624761861283e-06
transcripts O 0 8.180126314982772e-06
that O 0 9.170232715405291e-07
contain O 0 2.3387572582578287e-05
CUG O 1 0.9996310472488403
repeats O 0 0.000313892203848809
. O 0 7.187952724052593e-05

Altered O 0 0.0001336721470579505
expression O 0 1.594726199982688e-05
of O 0 8.626347153040115e-06
genes O 0 2.2890519630891504e-06
regulated O 0 5.88915736443596e-06
posttranscriptionally O 0 0.0003238953067921102
by O 0 8.32344994705636e-06
CUG O 1 0.9999991655349731
- O 0 0.04967851936817169
BP O 0 0.052552174776792526
therefore O 0 3.2483578706887783e-06
may O 0 6.962973202462308e-07
contribute O 0 1.621843466637074e-06
to O 0 9.79129436018411e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999864101409912
. O 0 3.9154841942945495e-05
. O 0 6.578649481525645e-05

Identification O 0 6.447220948757604e-05
of O 0 3.099135938100517e-05
a O 0 8.289172910735942e-06
novel O 0 1.6828911611810327e-05
nonsense O 0 6.56256452202797e-05
mutation O 0 1.5177946579569834e-06
and O 0 2.7071163799519127e-07
a O 0 4.092011067768908e-07
missense O 0 2.135383965651272e-06
substitution O 0 1.2447308108676225e-06
in O 0 6.897641355863016e-07
the O 0 7.276286169144441e-07
vasopressin O 0 2.328448863408994e-05
- O 0 4.161780816502869e-05
neurophysin O 0 0.21016043424606323
II O 1 0.9999845027923584
gene O 0 1.5032381952551077e-06
in O 0 1.6761870824666403e-07
two O 0 2.2032490676338057e-07
Spanish O 0 9.690716069599148e-06
kindreds O 0 0.0002805130206979811
with O 0 1.2086584320059046e-05
familial B-Disease 1 0.9999936819076538
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999980926513672
. O 0 0.0014698824379593134

Familial B-Disease 1 0.9999921321868896
neurohypophyseal I-Disease 1 0.9999998807907104
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9995081424713135
FNDI B-Disease 1 1.0
) O 0 9.574639989295974e-05
is O 0 3.043697233806597e-06
an O 0 6.356275662255939e-06
autosomal B-Disease 1 0.999983549118042
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999980926513672
by O 1 0.7202296853065491
deficiency O 1 0.9999998807907104
in O 0 7.841231126803905e-05
the O 0 0.00014342402573674917
antidiuretic O 1 0.6071470975875854
hormone O 0 0.0001563919213367626
arginine O 0 0.00010753911192296073
vasopressin O 0 0.00012582656927406788
( O 0 7.938174348964822e-06
AVP O 1 0.6862726807594299
) O 0 7.39242238978477e-07
encoded O 0 3.7658347196156683e-07
by O 0 2.6091348104273493e-07
the O 0 2.9506236387533136e-06
AVP O 1 0.9999785423278809
- O 0 0.0005887321312911808
neurophysin O 1 0.9901371002197266
II O 1 0.9999995231628418
( O 0 4.705229002865963e-05
AVP O 1 0.9999802112579346
- O 0 0.0005946765886619687
NPII O 1 0.9994356036186218
) O 0 7.921643373265397e-06
gene O 0 7.62383388064336e-06
on O 0 8.661842912260909e-06
chromosome O 0 7.883352373028174e-05
20p13 O 0 0.0019726024474948645
. O 0 7.993067265488207e-05

In O 0 2.758473601716105e-05
this O 0 1.425456957804272e-06
study O 0 1.8821496041709906e-06
, O 0 3.0364961389750533e-07
we O 0 3.87866627704625e-08
analyzed O 0 1.3400764942161913e-07
two O 0 3.7808764119517946e-08
families O 0 8.617236346708523e-08
with O 0 2.452271132824535e-07
FNDI B-Disease 1 0.9999575614929199
using O 0 6.519647399727546e-07
direct O 0 2.5140693082903454e-07
automated O 0 4.0138197618944105e-06
fluorescent O 0 9.443655471841339e-06
, O 0 3.690518326493475e-07
solid O 0 2.69344695880136e-06
phase O 0 2.381619879088248e-06
, O 0 3.664149517135229e-07
single O 0 3.5112893215227814e-07
- O 0 1.94933431885147e-06
stranded O 0 2.2439323856815463e-06
DNA O 0 1.301509087170416e-06
sequencing O 0 1.0431525652165874e-06
of O 0 1.4553040728060296e-06
PCR O 0 0.00012571742990985513
- O 0 0.00010275858949171379
amplified O 0 0.0004885514499619603
AVP O 1 0.9997138381004333
- O 0 0.00205670902505517
NPII O 1 0.9991543292999268
DNA O 0 0.0009835332166403532
. O 0 5.996987601974979e-05

In O 0 1.50663154272479e-05
one O 0 2.0435488750081277e-06
of O 0 2.7446590138424654e-06
the O 0 3.115079834969947e-06
families O 0 3.8289482517939177e-07
, O 0 5.166115784049907e-07
affected O 0 3.2883178846532246e-07
individuals O 0 4.9623658071595855e-08
presented O 0 9.023929123941343e-07
a O 0 9.80419599727611e-07
novel O 0 2.913407342930441e-06
nonsense O 0 1.3542663509724662e-05
mutation O 0 6.260001441660279e-07
in O 0 3.421847907247866e-07
exon O 0 3.820985057245707e-06
3 O 0 6.011384243720386e-07
of O 0 7.849665166759223e-07
the O 0 5.411130246102402e-07
gene O 0 4.966182132193353e-07
, O 0 1.1714310943489181e-07
consisting O 0 2.856755259017518e-07
in O 0 2.142438688679249e-07
a O 0 7.44289422982547e-07
G O 0 3.637113331933506e-05
to O 0 1.9630442693596706e-06
T O 0 0.00037170189898461103
transition O 0 1.9862102362822043e-06
at O 0 2.968543640236021e-06
nucleotide O 0 1.766956529536401e-06
2101 O 0 0.00014808027481194586
, O 0 5.342818667486426e-07
which O 0 1.737980852567489e-07
produces O 0 3.31921995666562e-07
a O 0 2.2603103388973977e-07
stop O 0 7.407722364405345e-07
signal O 0 7.635007364115154e-07
in O 0 3.295736803465843e-07
codon O 0 8.650525160192046e-06
82 O 0 2.0557876268867403e-05
( O 0 6.1121136241126806e-06
Glu O 1 0.9770554304122925
) O 0 6.801904419262428e-06
of O 0 5.381679511629045e-05
NPII O 1 0.9999926090240479
. O 0 0.00023061838874127716

The O 0 0.00010584640403976664
premature O 0 0.00016733427764847875
termination O 0 9.018435230245814e-05
eliminates O 0 3.174513403791934e-05
part O 0 2.848984195225057e-06
of O 0 2.503360519767739e-06
the O 0 4.974813236913178e-06
C O 0 0.02694479562342167
- O 0 1.637174136703834e-05
terminal O 0 7.501287200284423e-06
domain O 0 9.838130381467636e-07
of O 0 2.600435664135148e-06
NPII O 1 0.9525169134140015
, O 0 6.611550702473323e-07
including O 0 4.39863129031437e-07
a O 0 5.674316412296321e-07
cysteine O 0 3.701166406244738e-06
residue O 0 2.2613356122747064e-05
in O 0 8.617028015578398e-07
position O 0 1.5163362832026905e-06
85 O 0 3.8435273381765e-06
, O 0 2.6062949132210633e-07
which O 0 7.394411483119256e-08
could O 0 9.022727454066626e-08
be O 0 4.409816511952158e-08
involved O 0 1.4789803515213862e-07
in O 0 1.8189855666150834e-07
the O 0 1.2200678156659706e-06
correct O 0 6.6254074226890225e-06
folding O 0 0.00014142443251330405
of O 0 3.052125975955278e-05
the O 0 4.7318048018496484e-05
prohormone O 1 0.9983835220336914
. O 0 0.00013129170110914856

In O 0 2.289407711941749e-05
the O 0 7.736021871096455e-06
second O 0 1.387540305586299e-05
family O 0 4.479783001443138e-06
, O 0 6.520568263113091e-07
a O 0 6.081978085603623e-07
G279A O 0 3.4374148526694626e-05
substitution O 0 3.4279005376447458e-06
at O 0 8.191929737222381e-06
position O 0 3.1981828669813694e-06
- O 0 3.520970494719222e-06
1 O 0 8.559866842006159e-07
of O 0 4.4442165858527005e-07
the O 0 4.946414833284507e-07
signal O 0 1.9456308564258507e-06
peptide O 0 2.7395440156396944e-06
was O 0 2.448060740789515e-06
observed O 0 3.311776879399986e-07
in O 0 2.13478827504332e-07
all O 0 2.79680222092793e-07
affected O 0 1.8519256173021859e-06
individuals O 0 1.1818730172308278e-06
. O 0 2.2447229639510624e-05

This O 0 3.460757579887286e-05
missense O 0 0.00019337426056154072
mutation O 0 1.166491347248666e-05
, O 0 2.2750689367967425e-06
which O 0 1.2543102911877213e-06
replaces O 0 0.01648637279868126
Ala O 1 0.7446770668029785
with O 0 7.4338681770314e-06
Thr O 1 0.9999964237213135
, O 0 3.907044174411567e-06
is O 0 5.345509634935297e-07
frequent O 0 1.8496417624191963e-06
among O 0 1.573174085933715e-05
FNDI B-Disease 1 1.0
patients O 0 0.00026812931173481047
and O 0 2.054029437204008e-06
is O 0 9.932118700817227e-07
thought O 0 7.863744144742668e-07
to O 0 1.0754413182212375e-07
reduce O 0 4.933144168717263e-07
the O 0 5.979012485113344e-07
efficiency O 0 4.685084149969043e-06
of O 0 3.633974984040833e-06
cleavage O 0 2.0005452824989334e-05
by O 0 2.8126014512963593e-06
signal O 0 5.548945046029985e-05
peptidases O 0 0.00038896576734259725
. O 0 8.784513738646638e-06
. O 0 2.4105163902277127e-05

Genetic O 0 0.00033446948509663343
heterogeneity O 0 0.00040427042404189706
of O 0 0.00043353543151170015
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999991655349731
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.508966670371592e-05
due O 0 2.4381250113947317e-05
to O 0 4.717503998108441e-06
TWIST O 0 0.20506161451339722
and O 0 9.792071796255186e-05
FGFR O 1 0.9999960660934448
mutations O 0 0.00018059328431263566
. O 0 6.60753357806243e-05

Thirty O 0 0.0009372744243592024
- O 0 0.0001413399149896577
two O 0 2.503005134713021e-06
unrelated O 0 2.053311254712753e-05
patients O 0 3.989685410488164e-06
with O 0 4.654022234262811e-07
features O 0 3.4343534025538247e-06
of O 0 0.008638638071715832
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3623625818581786e-05
a O 0 1.3033850336796604e-05
common O 0 3.976215884904377e-05
autosomal B-Disease 0 0.0354626439511776
dominant I-Disease 1 0.990759015083313
condition I-Disease 1 0.9520399570465088
of O 1 0.9991601705551147
craniosynostosis B-Disease 1 1.0
and O 1 0.9983481168746948
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9997391104698181
, O 0 7.585852472402621e-06
were O 0 1.760628606461978e-06
screened O 0 3.816836851910921e-06
for O 0 4.5425107941809983e-07
mutations O 0 8.38219193610712e-07
in O 0 8.423060080531286e-07
TWIST O 0 0.00022930373961571604
, O 0 1.4716931218572427e-05
FGFR2 O 1 0.9999734163284302
, O 0 1.727125527395401e-05
and O 0 2.4432785721728578e-05
FGFR3 O 1 0.9998970031738281
. O 0 0.0001512711023679003

Nine O 0 0.00026307825464755297
novel O 0 6.93712427164428e-05
and O 0 5.690884336218005e-06
three O 0 3.691085112222936e-06
recurrent O 0 0.4070914685726166
TWIST O 0 0.005694944877177477
mutations O 0 2.343321511943941e-06
were O 0 8.372053912353294e-07
found O 0 5.97018072312494e-07
in O 0 6.723140018038976e-07
12 O 0 3.2192756407312118e-06
families O 0 2.0975317056581844e-06
. O 0 2.439634408801794e-05

Seven O 0 4.282078589312732e-05
families O 0 1.9184135453542694e-06
were O 0 1.2803269555661245e-06
found O 0 7.729641424703004e-07
to O 0 1.8118491595942032e-07
have O 0 1.2498082924139453e-07
the O 0 2.664821067810408e-06
FGFR3 O 1 0.9999991655349731
P250R O 1 0.9878270030021667
mutation O 0 2.6997165605280316e-06
, O 0 3.297321313766588e-07
and O 0 1.6434030669643107e-07
one O 0 1.308600445781849e-07
individual O 0 8.012531083068097e-08
was O 0 5.446779596240958e-06
found O 0 2.448319662562426e-07
to O 0 6.637770155748512e-08
have O 0 7.863221185289149e-08
an O 0 1.4050380059416057e-06
FGFR2 O 1 0.9999463558197021
VV269 O 1 0.6236349940299988
- O 0 0.00029958918457850814
270 O 0 0.00023332085402216762
deletion O 0 0.00019957283802796155
. O 0 6.10148417763412e-05

To O 0 1.4036441825737711e-05
date O 0 3.149194162688218e-05
, O 0 2.4556579774070997e-06
our O 0 8.722104212210979e-07
detection O 0 6.525185654027155e-06
rate O 0 5.836633363287547e-07
for O 0 2.7258749923930736e-07
TWIST O 0 4.634808283299208e-05
or O 0 4.993979018763639e-06
FGFR O 1 0.9991313815116882
mutations O 0 2.00138742911804e-06
is O 0 3.5244337937001546e-07
68 O 0 3.0842750220472226e-06
% O 0 3.065411817715358e-07
in O 0 5.115779231346096e-07
our O 0 4.041317424707813e-06
Saethre B-Disease 1 0.999998927116394
- I-Disease 1 0.9999992847442627
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0029517831280827522
, O 0 1.7537610119688907e-06
including O 0 1.0539281447563553e-06
our O 0 2.196429932155297e-06
five O 0 5.770698408014141e-06
patients O 0 9.909487744153012e-06
elsewhere O 0 4.1957932808145415e-06
reported O 0 3.5642347029352095e-06
with O 0 3.2081384233606514e-06
TWIST O 0 0.026286479085683823
mutations O 0 0.0001141763714258559
. O 0 8.344661182491109e-05

More O 0 8.993757546704728e-06
than O 0 1.973021198864444e-06
35 O 0 2.0878921986877685e-06
different O 0 2.027147729677381e-07
TWIST O 0 1.3464368748827837e-05
mutations O 0 3.182985608418676e-07
are O 0 2.6703355970880693e-08
now O 0 1.5931097152588336e-07
known O 0 3.928566343347484e-07
in O 0 3.1049611948219535e-07
the O 0 2.46957301897055e-06
literature O 0 2.650482019816991e-05
. O 0 2.0636722183553502e-05

The O 0 3.484811168164015e-05
most O 0 2.66335246124072e-06
common O 0 1.7903133766594692e-06
phenotypic O 0 7.495351383113302e-06
features O 0 2.7524492907105014e-06
, O 0 5.894315222576552e-07
present O 0 3.113114814823348e-07
in O 0 1.5431217548211862e-07
more O 0 4.1952784357590645e-08
than O 0 8.847115395838046e-08
a O 0 3.946790627651353e-07
third O 0 2.697878699109424e-06
of O 0 2.6794944005814614e-06
our O 0 3.3914786854438717e-06
patients O 0 2.8157871838629944e-06
with O 0 5.143815542396624e-07
TWIST O 0 0.0018105978379026055
mutations O 0 3.094067778874887e-06
, O 0 7.994606789907266e-07
are O 0 2.3717868202766113e-07
coronal B-Disease 1 0.640753448009491
synostosis I-Disease 1 0.5254145264625549
, O 0 9.88694591796957e-06
brachycephaly B-Disease 1 0.5024464726448059
, O 0 1.401632198394509e-05
low B-Disease 0 0.030283406376838684
frontal I-Disease 1 0.9999958276748657
hairline I-Disease 1 0.9999998807907104
, O 0 0.0001000843258225359
facial B-Disease 1 0.9999809265136719
asymmetry I-Disease 1 0.8680934309959412
, O 0 0.0002468416641931981
ptosis B-Disease 1 0.999964714050293
, O 0 4.148383959545754e-05
hypertelorism B-Disease 1 0.9127334356307983
, O 0 1.3484735063684639e-05
broad B-Disease 0 5.8134050050284714e-05
great I-Disease 0 0.004603457171469927
toes I-Disease 0 0.15438468754291534
, O 0 1.882632204797119e-05
and O 0 2.3940032406244427e-05
clinodactyly B-Disease 1 0.8544288277626038
. O 0 9.119843889493495e-05

Significant O 0 9.757182124303654e-05
intra O 0 0.0009653061279095709
- O 0 0.0002173922403017059
and O 0 8.01252099336125e-06
interfamilial O 0 0.0009707715944387019
phenotypic O 0 2.5476216251263395e-05
variability O 0 1.2365749171294738e-05
is O 0 6.061329145268246e-07
present O 0 5.070781412541692e-07
for O 0 6.626852382396464e-07
either O 0 3.691930032800883e-06
TWIST O 0 0.0003040597075596452
mutations O 0 1.7841497538029216e-05
or O 0 1.9757062545977533e-05
FGFR O 1 0.999908447265625
mutations O 0 9.388205216964707e-05
. O 0 4.119958612136543e-05

The O 0 5.0026035751216114e-05
overlap O 0 6.249387752177427e-06
in O 0 3.7590853025903925e-06
clinical O 0 1.480650644225534e-05
features O 0 2.9391314910753863e-06
and O 0 6.496237006103911e-07
the O 0 1.0884064067795407e-06
presence O 0 1.47198545619176e-06
, O 0 2.3263959292307845e-07
in O 0 1.1609765948605855e-07
the O 0 1.3263714038203034e-07
same O 0 1.0603323374880347e-07
genes O 0 7.634579191062585e-08
, O 0 7.912976229818014e-08
of O 0 2.1362384927670064e-07
mutations O 0 1.2685289618730167e-07
for O 0 5.552055881707929e-08
more O 0 5.733390651130321e-08
than O 0 1.562376610309002e-07
one O 0 7.510912496400124e-07
craniosynostotic B-Disease 0 0.012355869635939598
condition I-Disease 0 1.6388832591474056e-05
- O 0 6.7310515987628605e-06
such O 0 6.834355872342712e-07
as O 0 2.6935549612971954e-06
Saethre B-Disease 1 0.9440581202507019
- I-Disease 0 0.0003851916117127985
Chotzen I-Disease 1 0.8618696331977844
, I-Disease 0 4.575899765768554e-06
Crouzon I-Disease 0 0.13701830804347992
, I-Disease 0 5.878546289750375e-06
and I-Disease 0 7.910643944342155e-06
Pfeiffer I-Disease 1 0.9999966621398926
syndromes I-Disease 1 0.9995836615562439
- O 0 0.0002425279380986467
support O 0 4.684038685809355e-06
the O 0 2.3530742510047276e-06
hypothesis O 0 5.139479981153272e-06
that O 0 2.888826031721692e-07
TWIST O 0 1.908838930830825e-05
and O 0 7.720271355537989e-07
FGFRs O 0 0.00016526780382264405
are O 0 6.473293012732029e-08
components O 0 6.953145543775463e-07
of O 0 4.2927683807647554e-07
the O 0 2.931918459125882e-07
same O 0 3.0258581773523474e-07
molecular O 0 4.614908448274946e-06
pathway O 0 1.0777406487250119e-06
involved O 0 1.956572219796726e-07
in O 0 1.4471451947883907e-07
the O 0 2.9274676194290805e-07
modulation O 0 4.376202014100272e-06
of O 0 4.8164882173296064e-05
craniofacial O 1 1.0
and O 0 0.011316581629216671
limb O 1 0.9999969005584717
development O 0 2.2991856894805096e-05
in O 0 9.667113772593439e-06
humans O 0 9.360089279653039e-06
. O 0 4.489718776312657e-06
. O 0 9.990732905862387e-06

Mutation O 0 5.6947919802041724e-05
analysis O 0 1.1135840395581909e-05
of O 0 0.00012755785428453237
UBE3A O 1 0.9999998807907104
in O 1 0.9998239874839783
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9999644756317139
. O 0 0.001492425799369812

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.5435025691986084
AS B-Disease 1 0.9999995231628418
) O 0 2.912262971221935e-05
is O 0 3.206914698239416e-06
caused O 0 8.962239917309489e-06
by O 0 2.747262215052615e-06
chromosome O 0 2.7543464966583997e-05
15q11 O 0 0.01686944253742695
- O 0 8.277304004877806e-05
q13 O 0 0.00030433779465965927
deletions O 0 6.916098300280282e-06
of O 0 2.999391199409729e-06
maternal O 0 9.813038559514098e-06
origin O 0 1.0984649634337984e-06
, O 0 5.765053288087074e-07
by O 0 8.803843911664444e-07
paternal O 0 0.00011391210864530876
uniparental B-Disease 1 0.9999909400939941
disomy I-Disease 1 0.999988317489624
( O 0 0.0002553302620071918
UPD B-Disease 1 0.9999998807907104
) O 0 5.46374531040783e-06
15 O 0 3.884518264385406e-06
, O 0 4.67507675239176e-07
by O 0 1.1297167930024443e-06
imprinting O 1 0.8887165784835815
defects O 1 0.9987982511520386
, O 0 2.2678727873426396e-06
and O 0 6.258974849515653e-07
by O 0 5.362384740692505e-07
mutations O 0 1.8707542039919645e-06
in O 0 1.6597805370111018e-06
the O 0 1.978508043976035e-05
UBE3A O 1 0.9999732971191406
gene O 0 0.00017680414021015167
. O 0 3.573508729459718e-05

UBE3A O 0 0.17401129007339478
encodes O 0 0.00016436872829217464
a O 0 3.46956767316442e-05
ubiquitin O 0 0.0002152024389943108
- O 0 5.3227791795507073e-05
protein O 0 5.782045718660811e-06
ligase O 0 5.682049595634453e-05
and O 0 7.203168024716433e-06
shows O 0 1.5559395251329988e-05
brain O 0 0.00029514136258512735
- O 0 6.030087752151303e-05
specific O 0 1.4407282833417412e-05
imprinting O 0 0.0019055078737437725
. O 0 7.344159530475736e-05

Here O 0 6.247246346902102e-05
we O 0 7.00592181601678e-06
describe O 0 2.7967538699158467e-05
UBE3A O 1 0.5191711783409119
coding O 0 9.462976595386863e-05
- O 0 6.0953141655772924e-05
region O 0 4.05996797780972e-06
mutations O 0 2.2405324671126436e-06
detected O 0 6.959136499062879e-06
by O 0 6.982463673921302e-07
SSCP O 0 0.07213849574327469
analysis O 0 1.020096306092455e-06
in O 0 7.930773335829144e-07
13 O 0 5.145482646184973e-06
AS B-Disease 0 0.0007556068594567478
individuals O 0 4.5702597617491847e-07
or O 0 3.7186371173447696e-06
families O 0 4.616228579834569e-06
. O 0 4.054961755173281e-05

Two O 0 1.225763753609499e-05
identical O 0 3.488847869448364e-05
de O 0 0.00012171806883998215
novo O 0 0.0001562446414027363
5 O 0 1.3603424122266006e-05
- O 0 2.4044733436312526e-05
bp O 0 2.4389435566263273e-05
duplications O 0 1.7747923266142607e-05
in O 0 2.312655396963237e-06
exon O 0 2.5796018235269003e-05
16 O 0 3.6733583783643553e-06
were O 0 2.223804585810285e-06
found O 0 1.3817460057907738e-05
. O 0 1.619969043531455e-05

Among O 0 2.9881541195209138e-05
the O 0 4.538480880000861e-06
other O 0 6.87489261963492e-07
11 O 0 2.5465396902291104e-06
unique O 0 7.638568604306784e-07
mutations O 0 6.310290814326436e-07
, O 0 3.882348948991421e-07
8 O 0 9.082483529709862e-07
were O 0 2.368970086763511e-07
small O 0 3.1914629516904824e-07
deletions O 0 3.0073940706643043e-06
or O 0 6.715303015880636e-07
insertions O 0 1.574512862134725e-05
predicted O 0 4.242135219101328e-06
to O 0 7.066057605698006e-07
cause O 0 1.1539419574546628e-05
frameshifts O 0 0.001538870739750564
, O 0 1.6735177723603556e-06
1 O 0 2.7476523882796755e-06
was O 0 4.0001655179366935e-06
a O 0 3.4873445997618546e-07
mutation O 0 1.7327462842331443e-07
to O 0 9.606621631519374e-08
a O 0 4.326544456034753e-07
stop O 0 9.12794121177285e-07
codon O 0 3.559621745807817e-06
, O 0 3.159944697017636e-07
1 O 0 9.55463065110962e-07
was O 0 2.29799570661271e-06
a O 0 6.335846478577878e-07
missense O 0 5.566163963521831e-06
mutation O 0 8.180525696843688e-07
, O 0 2.6498082661419176e-07
and O 0 3.6040719919583353e-07
1 O 0 3.434890686548897e-06
was O 0 1.4093798199610319e-05
predicted O 0 1.5102604038474965e-06
to O 0 1.926859312106899e-07
cause O 0 1.3352049563764012e-06
insertion O 0 3.9962042137631215e-06
of O 0 1.3623759969050298e-06
an O 0 5.545069825529936e-07
isoleucine O 0 9.752484766067937e-05
in O 0 8.596180123277009e-07
the O 0 1.0201021041211789e-06
hect O 0 5.166334449313581e-05
domain O 0 1.1743700270017143e-06
of O 0 9.496790767116181e-07
the O 0 2.7267979021416977e-06
UBE3A O 0 0.11641638725996017
protein O 0 1.2903650485895923e-06
, O 0 2.3684280847646733e-07
which O 0 6.609546687741386e-08
functions O 0 1.3004206778077787e-07
in O 0 8.585750492784427e-07
E2 O 0 0.0002791459846775979
binding O 0 6.336200840451056e-06
and O 0 5.402048373071011e-06
ubiquitin O 0 0.0001421622437192127
transfer O 0 0.00013749759818892926
. O 0 0.00010322665912099183

Eight O 0 7.121566886780784e-05
of O 0 1.8470313079888e-05
the O 0 4.144119884585962e-06
cases O 0 1.8914273596237763e-06
were O 0 2.579593456175644e-06
familial O 0 0.00013452977873384953
, O 0 2.2957394776312867e-06
and O 0 1.0992446277668932e-06
five O 0 1.6022715954022715e-06
were O 0 6.231569386727642e-06
sporadic O 0 8.947867900133133e-05
. O 0 4.109226574655622e-05

In O 0 5.2390772907529026e-05
two O 0 3.831508820439922e-06
familial O 0 0.0001274456299142912
cases O 0 3.599940100684762e-06
and O 0 2.149904275938752e-06
one O 0 1.2485401157391607e-06
sporadic O 0 1.1559311133169103e-05
case O 0 2.584207777545089e-06
, O 0 2.2616479782300303e-06
mosaicism O 0 0.0014711719704791903
for O 0 3.4457145829946967e-06
UBE3A O 1 0.9991458654403687
mutations O 0 3.7370846257545054e-06
was O 0 6.084163942432497e-06
detected O 0 1.9814103779935976e-06
in O 0 1.5820255327980703e-07
the O 0 2.1844320485797653e-07
mother O 0 1.5154140555750928e-06
of O 0 4.0494396102985775e-07
three O 0 2.898987645494344e-07
AS B-Disease 1 0.9639747738838196
sons O 0 0.001657260349020362
, O 0 9.578425306244753e-07
in O 0 3.249344615596783e-07
the O 0 6.813608592892706e-07
maternal O 0 7.55064547774964e-06
grandfather O 0 6.756935908924788e-05
of O 0 3.011745093317586e-06
two O 0 3.762097833259759e-07
AS B-Disease 0 0.036923814564943314
first O 0 7.057382845232496e-06
cousins O 0 1.4240169548429549e-05
, O 0 4.278047640582372e-07
and O 0 1.9969820641563274e-07
in O 0 3.2762915225248435e-07
the O 0 1.1851349199787364e-06
mother O 0 6.733869668096304e-06
of O 0 3.11164171762357e-06
an O 0 5.256458280200604e-06
AS B-Disease 1 0.99998939037323
daughter O 1 0.904560387134552
. O 0 9.49343666434288e-05

The O 0 1.2210573004267644e-05
frequencies O 0 3.2451005154143786e-06
with O 0 4.5548523530669627e-07
which O 0 1.8421462755213724e-07
we O 0 6.733278468118442e-08
detected O 0 8.897339398572512e-07
mutations O 0 1.246085616912751e-07
were O 0 1.4166100470447418e-07
5 O 0 6.249181296880124e-07
( O 0 1.715822293135716e-07
14 O 0 5.534773208637489e-07
% O 0 1.687914732428908e-07
) O 0 6.330375157403978e-08
of O 0 2.6164806854467315e-07
35 O 0 7.157755135267507e-07
in O 0 2.0932782263116678e-07
sporadic O 0 1.2557165973703377e-06
cases O 0 1.4153110328152252e-07
and O 0 1.621461649392586e-07
8 O 0 1.2971423757335288e-06
( O 0 2.0989533311421837e-07
80 O 0 7.529300773967407e-07
% O 0 1.8789346256653516e-07
) O 0 6.379001860068456e-08
of O 0 3.045080063657224e-07
10 O 0 9.575082913215738e-07
in O 0 1.959617748070741e-06
familial O 0 0.00015764206182211637
cases O 0 4.197077487333445e-06
. O 0 7.670493687328417e-06
. O 0 3.664551695692353e-05

The O 0 0.001015906105749309
hemochromatosis B-Disease 1 0.9999979734420776
845 O 0 0.2594442367553711
G O 0 0.20071351528167725
- O 0 0.0006145898951217532
- O 0 0.00019613924087025225
> O 0 2.1759726223535836e-05
A O 0 8.262560186267365e-06
and O 0 1.1921868008357706e-06
187 O 0 6.295267212408362e-06
C O 0 9.468934877077118e-05
- O 0 1.5584730135742575e-05
- O 0 3.5699053114512935e-05
> O 0 2.240193498437293e-05
G O 0 9.994175343308598e-05
mutations O 0 1.9729984614969e-06
: O 0 5.588661906585912e-07
prevalence O 0 3.4668855732888915e-06
in O 0 7.815014555490052e-07
non O 0 1.882154720078688e-05
- O 0 0.00012065976625308394
Caucasian O 0 0.00010127073619514704
populations O 0 9.342851626570337e-06
. O 0 3.2008658308768645e-05

Hemochromatosis B-Disease 1 0.9999995231628418
, O 0 0.00021266823750920594
the O 0 0.024696024134755135
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999997615814209
, O 0 0.00012725594569928944
leads O 0 0.0001853313879109919
, O 0 4.232800165482331e-06
if O 0 1.6531723758816952e-06
untreated O 1 0.9373559951782227
, O 0 1.9241908830736065e-06
to O 0 4.188425009488128e-06
progressive O 1 0.9998660087585449
iron B-Disease 1 1.0
overload I-Disease 1 0.9999997615814209
and O 0 0.004038625862449408
premature B-Disease 0 0.3782888948917389
death I-Disease 0 0.001131970901042223
. O 0 9.006447362480685e-05

The O 0 0.001169648370705545
hemochromatosis B-Disease 1 1.0
gene O 0 0.00022111575526650995
, O 0 2.108419175783638e-05
HFE O 1 0.9999934434890747
, O 0 5.584955488302512e-06
recently O 0 5.2253003559599165e-06
has O 0 2.336240783051835e-07
been O 0 2.3349222999513586e-07
identified O 0 5.684000257133448e-07
, O 0 1.5525719732067955e-07
and O 0 1.6906375321923406e-07
characterization O 0 3.629621232903446e-06
of O 0 1.631147256375698e-06
this O 0 3.0884703505762445e-07
gene O 0 1.8851137610909063e-06
has O 0 2.530488814045384e-07
shown O 0 1.6253228807272535e-07
that O 0 4.127432973177747e-08
it O 0 9.159781910739184e-08
contains O 0 1.86198136020721e-07
two O 0 6.044334810439977e-08
mutations O 0 2.063062822799111e-07
that O 0 4.8167684951749834e-08
result O 0 2.912399850174552e-07
in O 0 2.5763628741515276e-07
amino O 0 2.7595407914304815e-07
acid O 0 8.281597843051713e-07
substitutions O 0 2.8599383767868858e-06
- O 0 4.0297327359439805e-06
cDNA O 0 6.089771432016278e-06
nucleotides O 0 1.949760189745575e-06
845 O 0 2.1822423150297254e-05
G O 0 3.504617416183464e-05
- O 0 1.5771909602335654e-05
- O 0 1.1918189557036385e-05
> O 0 8.038459782255813e-06
A O 0 8.44825990498066e-06
( O 0 1.0858642554012476e-06
C282Y O 0 5.3718395065516233e-05
) O 0 3.29070871885051e-07
and O 0 3.016201048922085e-07
187 O 0 7.2764919423207175e-06
C O 0 8.85229601408355e-05
- O 0 3.18265228997916e-05
- O 0 4.515598629950546e-05
> O 0 4.5226664951769635e-05
G O 0 0.0004161577671766281
( O 0 1.887828329927288e-05
H63D O 1 0.9997959733009338
) O 0 2.039093305938877e-05
. O 0 1.9242117559770122e-05

Although O 0 0.00614089984446764
hemochromatosis B-Disease 1 1.0
is O 0 1.4617422493756749e-05
common O 0 2.831508027156815e-06
in O 0 3.558172466000542e-06
Caucasians O 0 0.00011764359078370035
, O 0 2.6546872504695784e-06
affecting O 0 3.460114385234192e-06
> O 0 1.0008260687754955e-05
= O 0 5.770555162598612e-06
1 O 0 1.0090142495755572e-05
/ O 0 5.188029717828613e-06
300 O 0 6.762190309927973e-07
individuals O 0 2.6432958932787187e-08
of O 0 3.1375614639728155e-07
northern O 0 5.826044571222155e-07
European O 0 7.115910420907312e-07
origin O 0 9.640889402362518e-07
, O 0 3.782802764362714e-07
it O 0 6.957571230259418e-08
has O 0 5.509963330041501e-08
not O 0 2.1930835814032434e-08
been O 0 6.868909707691273e-08
recognized O 0 1.8834232662356953e-07
in O 0 1.562361688911551e-07
other O 0 4.2268118249921827e-07
populations O 0 2.3203037926577963e-06
. O 0 1.2039291505061556e-05

The O 0 2.4232065698015504e-05
present O 0 3.0281034923973493e-06
study O 0 9.303509500568907e-07
used O 0 6.897055868648749e-07
PCR O 0 1.571496068208944e-05
and O 0 5.056776331002766e-07
restriction O 0 2.4436899366264697e-06
- O 0 7.831944458303042e-06
enzyme O 0 1.4022081131770392e-06
digestion O 0 1.9187045836588368e-06
to O 0 1.145423809134627e-07
analyze O 0 4.713186569915706e-07
the O 0 1.357646794986067e-07
frequency O 0 1.6837844896144816e-07
of O 0 1.7046269817910797e-07
the O 0 5.188848604120722e-07
845 O 0 2.359803329454735e-05
G O 0 3.565094812074676e-05
- O 0 9.967958249035291e-06
- O 0 8.792510016064625e-06
> O 0 3.1997296900954098e-06
A O 0 1.4216461750038434e-06
and O 0 2.0505032694018155e-07
187 O 0 2.5292874852311797e-06
C O 0 2.1278428903315216e-05
- O 0 7.85419706517132e-06
- O 0 7.6188985076441895e-06
> O 0 4.430296030477621e-06
G O 0 9.898295502352994e-06
mutations O 0 4.3202854271839897e-07
in O 0 8.288227490993449e-07
HLA O 0 0.004588723182678223
- O 0 5.161785338714253e-06
typed O 0 2.3949169190018438e-06
samples O 0 6.412934681065963e-07
from O 0 5.506926186171768e-07
non O 0 3.694719680424896e-06
- O 0 7.014259153947933e-06
Caucasian O 0 5.138338110555196e-06
populations O 0 1.7457634271522693e-07
, O 0 2.4488846861459024e-07
comprising O 0 1.3995121435073088e-06
Australian O 0 2.055419099633582e-05
Aboriginal O 0 1.73694352270104e-05
, O 0 5.147913384462299e-07
Chinese O 0 1.4342741678774473e-06
, O 0 1.369740630252636e-06
and O 0 1.4473787359747803e-06
Pacific O 0 4.792709296452813e-05
Islanders O 0 0.00021524124895222485
. O 0 5.136672189109959e-05

Results O 0 4.2134237446589395e-05
showed O 0 1.368490484310314e-05
that O 0 3.110696411567915e-07
the O 0 1.7098711850849213e-06
845 O 0 0.00023429036082234234
G O 0 0.001974390586838126
- O 0 0.00017507320444565266
- O 0 9.97366732917726e-05
> O 0 1.4145301065582316e-05
A O 0 5.053829227108508e-06
mutation O 0 1.1562401596165728e-06
was O 0 1.3409704706646153e-06
present O 0 1.401731992700661e-07
in O 0 8.543378271497204e-08
these O 0 2.3593962339418795e-08
populations O 0 6.888787140724162e-08
( O 0 7.501120791175708e-08
allele O 0 7.791307155002869e-08
frequency O 0 8.90922819962725e-08
0 O 0 9.45146396702512e-08
. O 0 2.5138790604728456e-08
32 O 0 1.6392955615174287e-07
% O 0 6.94606114848284e-08
) O 0 5.271108705073857e-08
, O 0 5.705703287617325e-08
and O 0 7.546914559952711e-08
, O 0 2.1219358359303442e-07
furthermore O 0 8.763292385083332e-07
, O 0 2.478084866197605e-07
it O 0 1.9462102329725894e-07
was O 0 1.4606517879656167e-06
always O 0 1.7318443212843704e-07
seen O 0 2.5932388325600186e-07
in O 0 1.5026677147034206e-07
conjunction O 0 2.286065182488528e-06
with O 0 1.3112892247590935e-06
HLA O 1 0.9999728202819824
haplotypes O 0 1.6116140614030883e-05
common O 0 7.555144065918284e-07
in O 0 1.045665499077586e-06
Caucasians O 0 2.210862840001937e-05
, O 0 7.996733870641037e-07
suggesting O 0 1.1557782499949099e-06
that O 0 3.454156001225783e-07
845 O 0 7.253780495375395e-05
G O 0 0.001772354356944561
- O 0 0.000400626944610849
- O 0 9.781822882359847e-05
> O 0 8.964283551904373e-06
A O 0 5.958320343779633e-06
may O 0 3.0231933578761527e-07
have O 0 2.004395938115522e-08
been O 0 3.931166503434724e-08
introduced O 0 1.376181018031275e-07
into O 0 5.831525839994356e-08
these O 0 2.8367132642870274e-08
populations O 0 1.9682165941503627e-07
by O 0 1.4597368362956331e-06
Caucasian O 0 0.00014543981524184346
admixture O 0 0.0002512536302674562
. O 0 6.792476051487029e-05

187 O 0 0.0004257633991073817
C O 0 0.0012069694930687547
- O 0 0.00014537019887939095
- O 0 0.00012584804790094495
> O 0 3.909771839971654e-05
G O 0 7.724991155555472e-05
was O 0 1.0265755008731503e-05
present O 0 6.421655598387588e-07
at O 0 1.7544135744174127e-06
an O 0 1.8763881826089346e-07
allele O 0 3.7430197608046e-07
frequency O 0 5.907264153393044e-07
of O 0 2.0826084892178187e-06
2 O 0 2.2852347683510743e-05
. O 0 2.6560584956314415e-05

68 O 0 0.00043110124533995986
% O 0 5.581292043643771e-06
in O 0 9.93264848148101e-07
the O 0 5.29290502981894e-07
two O 0 1.5016520649169252e-07
populations O 0 5.054712914898118e-07
analyzed O 0 5.227004749031039e-06
( O 0 2.2859171622258145e-06
Australian O 0 3.1363757443614304e-05
Aboriginal O 0 7.256175013026223e-05
and O 0 4.312576947995694e-06
Chinese O 0 3.41264640155714e-05
) O 0 2.4513605239917524e-05
. O 0 3.915383422281593e-05

In O 0 2.0053914340678602e-05
the O 0 7.344858204305638e-06
Australian O 0 3.399404158699326e-05
Aboriginal O 0 1.2669608622672968e-05
samples O 0 3.3762530620151665e-06
, O 0 8.775946298555937e-07
187 O 0 4.811888175026979e-06
C O 0 5.859612065250985e-05
- O 0 3.0104387406026945e-05
- O 0 2.369845606153831e-05
> O 0 1.6223280908889137e-05
G O 0 4.818128945771605e-05
was O 0 7.952472515171394e-06
found O 0 2.2488673323550756e-07
to O 0 7.87622056463988e-08
be O 0 6.762675042182309e-08
associated O 0 3.8653882938888273e-07
with O 0 9.63162619882496e-07
HLA O 1 0.9999885559082031
haplotypes O 0 1.58940765686566e-05
common O 0 1.1218255622225115e-06
in O 0 1.177302351607068e-06
Caucasians O 0 2.7091642550658435e-05
, O 0 7.978489975357661e-07
suggesting O 0 4.609360928498063e-07
that O 0 4.9441887028933706e-08
it O 0 1.1578673309031728e-07
was O 0 1.7455166698709945e-06
introduced O 0 7.148846066229453e-07
by O 0 5.398187568061985e-07
recent O 0 4.5922715798951685e-06
admixture O 0 0.00011794327292591333
. O 0 6.810948252677917e-05

In O 0 1.7367181499139406e-05
the O 0 4.6200207179936115e-06
Chinese O 0 2.61024001702026e-06
samples O 0 2.4076080080703832e-06
analyzed O 0 1.4745651242265012e-06
, O 0 3.520634095366404e-07
187 O 0 2.3602212877449347e-06
C O 0 2.906552799686324e-05
- O 0 1.9612065443652682e-05
- O 0 1.728971255943179e-05
> O 0 8.65951460582437e-06
G O 0 5.244121348368935e-05
was O 0 6.747767656634096e-06
present O 0 5.861136855855875e-07
in O 0 3.7340919334383216e-07
association O 0 8.685481702741527e-07
with O 0 1.9596272693434003e-07
a O 0 9.831442184804473e-07
wide O 0 2.2435856408264954e-06
variety O 0 1.46593083627522e-06
of O 0 1.802850965759717e-05
HLA O 1 0.9999947547912598
haplotypes O 0 3.934712731279433e-05
, O 0 1.3585344049715786e-06
showing O 0 1.250681521014485e-06
this O 0 6.58257306440646e-08
mutation O 0 1.1187428583525616e-07
to O 0 5.501100375226997e-08
be O 0 6.895110260529691e-08
widespread O 0 1.3652518191520358e-06
and O 0 3.456469244156324e-07
likely O 0 4.787988814314303e-07
to O 0 2.0750836426941532e-07
predate O 0 6.13490055911825e-06
the O 0 3.230231584439025e-07
more O 0 1.0587196896949536e-07
genetically O 0 2.364154624956427e-06
restricted O 0 1.963106114999391e-06
845 O 0 7.166434079408646e-05
G O 0 0.00044079552753828466
- O 0 0.0005020468379370868
- O 0 0.0002636980207171291
> O 0 6.273017061175779e-05
A O 0 6.747915176674724e-05
mutation O 0 2.4082964955596253e-05
. O 0 2.8715219741570763e-05

Genotype O 0 0.004470875486731529
- O 0 0.0012441426515579224
phenotype O 0 0.00027077304548583925
correlations O 0 0.00016906880773603916
in O 0 9.722418326418847e-05
attenuated B-Disease 1 0.9998493194580078
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999932050704956
. O 0 0.0008145483443513513

Germ O 1 0.9999561309814453
- O 0 0.0012952560791745782
line O 0 4.752317181555554e-05
mutations O 0 4.502698175201658e-06
of O 0 6.844884865131462e-06
the O 0 3.9043836295604706e-05
tumor B-Disease 1 0.9999970197677612
suppressor O 0 0.3254114091396332
APC O 0 0.0034222875256091356
are O 0 1.2090051768609555e-06
implicated O 0 3.0089433494140394e-05
in O 0 1.786349093890749e-05
attenuated B-Disease 1 0.995837926864624
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999996423721313
( O 0 0.16256190836429596
AAPC B-Disease 1 1.0
) O 0 2.7443020371720195e-05
, O 0 3.964191364502767e-06
a O 0 5.200592113396851e-06
variant O 0 0.00016010005492717028
of O 0 0.00762554258108139
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9970147609710693
FAP B-Disease 1 0.9999997615814209
) O 0 0.0005008111475035548
. O 0 0.00015248337876982987

AAPC B-Disease 1 0.9999961853027344
is O 0 2.8433158149709925e-05
recognized O 0 7.5991683843312785e-06
by O 0 9.280504968955938e-07
the O 0 1.3272208434500499e-06
occurrence O 0 7.57857787903049e-06
of O 0 9.376260095450561e-06
< O 0 0.00016280764248222113
100 O 0 3.9886843296699226e-05
colonic B-Disease 1 0.9997217059135437
adenomas I-Disease 0 0.4097009599208832
and O 0 1.198766426568909e-06
a O 0 1.1403701591916615e-06
later O 0 5.493181106430711e-06
onset O 0 0.07068540155887604
of O 1 0.9990377426147461
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.1882587386935484e-05
age O 0 1.4582921721739694e-05
> O 0 1.082165545085445e-05
40 O 0 4.685486601374578e-06
years O 0 6.3903180489433e-06
) O 0 6.506071713374695e-06
. O 0 1.4549068509950303e-05

The O 0 4.0867249481379986e-05
aim O 0 1.5657085896236822e-05
of O 0 2.6460429580765776e-06
this O 0 2.269853922598486e-07
study O 0 6.090202759878593e-07
was O 0 1.991680619539693e-06
to O 0 1.558112074917517e-07
assess O 0 3.5006007692572894e-06
genotype O 0 1.6764388419687748e-05
- O 0 3.5986136936116964e-05
phenotype O 0 1.5843999790376984e-05
correlations O 0 1.7343449144391343e-05
in O 0 2.4085653421934694e-05
AAPC B-Disease 1 0.9999889135360718
families O 0 2.9421207727864385e-05
. O 0 7.580385135952383e-05

By O 0 4.67849567939993e-05
protein O 0 2.20471883949358e-05
- O 0 4.7517325583612546e-05
truncation O 0 0.0002381292579229921
test O 0 4.191449625068344e-05
( O 0 3.6043957152287476e-06
PTT O 0 0.0011395392939448357
) O 0 1.27697353491385e-06
assay O 0 4.827621523872949e-06
, O 0 2.698049001992331e-07
the O 0 3.829028685231606e-07
entire O 0 2.4875325834727846e-06
coding O 0 1.857389293036249e-06
region O 0 5.599956125479366e-07
of O 0 7.459259450115496e-07
the O 0 2.3367138055618852e-06
APC B-Disease 0 0.03547167778015137
gene O 0 4.941680799674941e-06
was O 0 9.036847586685326e-06
screened O 0 3.364011263329303e-06
in O 0 2.57389729085844e-07
affected O 0 2.1350204804093664e-07
individuals O 0 3.7595043522742344e-08
from O 0 2.819890823957394e-06
11 O 0 0.00011450072634033859
AAPC B-Disease 1 1.0
kindreds O 0 0.007819239981472492
, O 0 4.2614847188815475e-06
and O 0 6.978855253692018e-07
their O 0 4.3054947695964074e-07
phenotypic O 0 1.131109365815064e-05
differences O 0 2.235979309261893e-06
were O 0 5.511678409675369e-06
examined O 0 0.00016226335719693452
. O 0 6.488285725936294e-05

Five O 0 5.57887542527169e-05
novel O 0 9.519534069113433e-05
germ O 1 0.9995977282524109
- O 0 0.0032476175110787153
line O 0 0.00016522132500540465
APC B-Disease 0 0.0010785736376419663
mutations O 0 2.9531122436310397e-06
were O 0 1.0331874591429369e-06
identified O 0 2.553390004322864e-06
in O 0 2.73047726295772e-06
seven O 0 1.820618854253553e-05
kindreds O 0 0.0021752736065536737
. O 0 0.00015102738689165562

Mutations O 0 2.3605191017850302e-05
were O 0 3.2184684641833883e-06
located O 0 8.048008567129727e-06
in O 0 3.4692132544478227e-07
three O 0 6.808335228924989e-08
different O 0 2.3107844526748522e-08
regions O 0 8.396515482900213e-08
of O 0 6.192318551256903e-07
the O 0 3.3722019452397944e-06
APC B-Disease 0 0.06287230551242828
gene O 0 2.548714064687374e-06
( O 0 4.4161589585201e-07
1 O 0 1.1129448012070497e-06
) O 0 1.2929120885019074e-07
at O 0 8.324674922732811e-07
the O 0 3.1434916536454693e-07
5 O 0 6.278607997955987e-07
end O 0 8.965582196651667e-07
spanning O 0 3.0335315841512056e-06
exons O 0 1.7286705542574055e-06
4 O 0 8.145765946210304e-07
and O 0 1.9785881022471585e-07
5 O 0 6.847724307590397e-07
, O 0 3.558490959676419e-07
( O 0 2.3448723140973016e-07
2 O 0 6.453838636844011e-07
) O 0 7.969184423473052e-08
within O 0 1.685678796548018e-07
exon O 0 3.3647845611994853e-06
9 O 0 1.5437857427968993e-06
, O 0 1.3329615455859312e-07
and O 0 1.203024027063293e-07
( O 0 2.5158297489724646e-07
3 O 0 5.780132141808281e-07
) O 0 1.5898268657110748e-07
at O 0 1.7110962744482094e-06
the O 0 8.985355179902399e-07
3 O 0 2.6731338493846124e-06
distal O 0 1.2952972610946745e-05
end O 0 3.6133610592514742e-06
of O 0 4.073297077411553e-06
the O 0 1.1971181265835185e-05
gene O 0 4.251233258401044e-05
. O 0 3.8548194424947724e-05

Variability O 0 0.00021054429817013443
in O 0 8.378776328754611e-06
the O 0 3.0115238587313797e-06
number O 0 2.2006631752446992e-06
of O 0 0.4421007037162781
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.04418522119522095
most O 0 1.1733524161172681e-06
apparent O 0 3.0829426123091253e-06
in O 0 3.2495552204636624e-07
individuals O 0 4.01893807122633e-08
with O 0 1.3423519362731895e-07
mutations O 0 6.820929456807789e-07
in O 0 1.0010742244048743e-06
region O 0 2.165904788853368e-06
1 O 0 5.757330200140132e-06
, O 0 1.3814014891977422e-06
and O 0 2.377165628786315e-06
upper O 1 0.8867848515510559
- O 1 0.9929585456848145
gastrointestinal O 1 0.9996895790100098
manifestations O 0 0.006749724969267845
were O 0 4.1471084841759875e-06
more O 0 6.930293352525041e-07
severe O 0 9.351829794468358e-05
in O 0 4.0032418837654404e-06
them O 0 1.0123934771399945e-05
. O 0 3.115876825177111e-05

In O 0 3.142215791740455e-05
individuals O 0 7.907663643891283e-07
with O 0 8.245858111877169e-07
mutations O 0 1.5729885944892885e-06
in O 0 7.674727839912521e-07
either O 0 8.909396456147078e-07
region O 0 1.656093218116439e-06
2 O 0 3.3572102893231204e-06
or O 0 7.826359365026292e-07
region O 0 5.524316293303855e-07
3 O 0 1.2878927009296604e-06
, O 0 2.461733004111011e-07
the O 0 1.3969170709060563e-07
average O 0 2.0453023807931459e-07
number O 0 2.2742786143226112e-07
of O 0 2.9880025067541283e-06
adenomas B-Disease 1 0.821238100528717
tended O 0 3.7692980185966007e-06
to O 0 2.4702086420802516e-07
be O 0 1.533955895638428e-07
lower O 0 6.674243309134908e-07
than O 0 6.182056466741415e-08
those O 0 3.9493162518056124e-08
in O 0 9.752471186175171e-08
individuals O 0 2.786843644742021e-08
with O 0 9.482593554821506e-08
mutations O 0 5.846933959219314e-07
in O 0 4.181027577487839e-07
region O 0 1.1228371477045584e-06
1 O 0 2.5013657705130754e-06
, O 0 3.0491600000459584e-07
although O 0 2.8263502827030607e-07
age O 0 2.6644372610462597e-06
at O 0 1.6792871974757873e-05
diagnosis O 0 0.00030640632030554116
was O 0 2.6846180844586343e-05
similar O 0 1.0416989425721113e-05
. O 0 2.6618428819347173e-05

In O 0 9.68390959315002e-05
all O 0 6.194147135829553e-05
AAPC B-Disease 1 0.9999985694885254
kindreds O 0 0.0018563942285254598
, O 0 4.117579010198824e-06
a O 0 2.2115505089459475e-06
predominance O 0 8.886380965122953e-05
of O 0 6.456400296883658e-05
right O 0 0.06464825570583344
- O 1 0.9999954700469971
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9915534853935242
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999973773956299
sparing O 0 0.002805424155667424
was O 0 0.000709311745595187
observed O 0 8.416465425398201e-05
. O 0 5.042515476816334e-05

No O 0 0.0008027541916817427
desmoid B-Disease 1 0.9999358654022217
tumors I-Disease 1 0.999992847442627
were O 0 1.0235987247142475e-05
found O 0 6.337898867059266e-06
in O 0 3.943986484955531e-06
these O 0 3.958845354645746e-06
kindreds O 0 0.001156734535470605
. O 0 8.528864418622106e-05

Our O 0 2.779837632260751e-05
data O 0 2.812320190059836e-06
suggest O 0 1.1217572364330408e-06
that O 0 2.0353554930352402e-07
, O 0 4.560233151096327e-07
in O 0 1.4343344219014398e-06
AAPC B-Disease 1 0.9999996423721313
families O 0 5.056738245912129e-07
, O 0 3.461503297330637e-07
the O 0 2.841425441602041e-07
location O 0 9.59003273237613e-07
of O 0 1.3289230764712556e-06
the O 0 9.825464985624421e-06
APC B-Disease 1 0.9953497648239136
mutation O 0 1.0903203474299517e-05
may O 0 1.5297193840524415e-06
partially O 0 8.679887287144084e-06
predict O 0 1.2250917507117265e-06
specific O 0 8.797238706392818e-07
phenotypic O 0 4.672966679208912e-05
expression O 0 5.702389535144903e-05
. O 0 4.350475501269102e-05

This O 0 2.0615792891476303e-05
should O 0 2.1746823222201783e-06
help O 0 1.0050690661955741e-06
in O 0 4.984183874512382e-07
the O 0 6.075554779272352e-07
design O 0 1.0099084647663403e-05
of O 0 3.0202472771634348e-06
tailored O 0 1.681634967098944e-05
clinical O 0 0.008918562904000282
- O 0 0.0003785655426327139
management O 0 8.275638538179919e-05
protocols O 0 1.579430499987211e-05
in O 0 5.788815542473458e-07
this O 0 2.1896734381243732e-07
subset O 0 3.970127636421239e-06
of O 0 2.83095141639933e-05
FAP B-Disease 1 0.9999963045120239
patients O 0 0.0002503795549273491
. O 0 1.2597186469065491e-05
. O 0 3.265340274083428e-05

Wilms B-Disease 1 0.9999936819076538
' I-Disease 0 0.0577942356467247
tumor I-Disease 1 0.649287223815918
1 O 0 2.61720906564733e-05
and O 0 6.873207439639373e-06
Dax O 1 0.999853253364563
- O 0 4.382388215162791e-05
1 O 0 6.537331955769332e-06
modulate O 0 6.8703966462635435e-06
the O 0 1.3369888165470911e-06
orphan O 0 3.860970537061803e-05
nuclear O 0 3.154513979097828e-05
receptor O 0 6.183322966535343e-06
SF O 1 0.5916247963905334
- O 0 1.6569430954405107e-05
1 O 0 2.0296656657592393e-06
in O 0 3.340126966122625e-07
sex O 0 7.581278964607918e-07
- O 0 2.472186224622419e-06
specific O 0 9.320613685304124e-07
gene O 0 5.484742814587662e-06
expression O 0 1.1737356544472277e-05
. O 0 2.1212461433606222e-05

Products O 0 0.00022903802164364606
of O 0 6.73653485137038e-05
steroidogenic O 0 0.0026859573554247618
factor O 0 2.3996628442546353e-05
1 O 0 2.1838059183210135e-05
( O 0 4.199003342364449e-06
SF O 1 0.9977352619171143
- O 0 5.807083289255388e-05
1 O 0 5.7477182053844444e-06
) O 0 8.872089551914542e-07
and O 0 3.5247937830718e-06
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9998258948326111
1 O 0 4.399917088449001e-05
( O 0 8.97734753380064e-06
WT1 O 1 0.8638139963150024
) O 0 7.065989962029562e-07
genes O 0 1.254972659125997e-07
are O 0 2.348109973127066e-08
essential O 0 3.353657120896969e-07
for O 0 3.986103820352582e-07
mammalian O 0 1.4735608601768035e-05
gonadogenesis O 0 0.0001717910636216402
prior O 0 3.5966627365269233e-06
to O 0 1.7082608110285946e-06
sexual O 0 1.344854445051169e-05
differentiation O 0 0.00012880933354608715
. O 0 4.997420546715148e-05

In O 0 2.8566115361172706e-05
males O 0 7.187632490968099e-06
, O 0 8.197862371162046e-06
SF O 1 0.999697208404541
- O 0 0.0001132924880948849
1 O 0 1.0397724508948158e-05
participates O 0 2.484106971678557e-06
in O 0 3.489936375444813e-07
sexual O 0 3.822122494057112e-07
development O 0 4.904547949990956e-07
by O 0 3.0857910360282403e-07
regulating O 0 2.1367020508478163e-06
expression O 0 6.122177751421987e-07
of O 0 2.0489583221205976e-06
the O 0 5.603404588327976e-06
polypeptide O 0 0.0001539934892207384
hormone O 0 7.183916022768244e-05
Mullerian O 0 0.3177047669887543
inhibiting O 0 0.00021806961740367115
substance O 0 0.000581565429456532
( O 0 4.048389018862508e-05
MIS O 1 0.9999216794967651
) O 0 4.162661934969947e-05
. O 0 2.7409567337599583e-05

Here O 0 5.294521542964503e-05
, O 0 4.6655372898385394e-06
we O 0 4.848689059144817e-07
show O 0 1.1442079994594678e-06
that O 0 5.71741338717402e-07
WT1 O 1 0.569148063659668
- O 0 0.0001956623891601339
KTS O 1 0.8532925248146057
isoforms O 0 7.57273983253981e-06
associate O 0 1.333567070105346e-05
and O 0 2.8051626941305585e-06
synergize O 0 0.000123272038763389
with O 0 9.237554877472576e-06
SF O 1 0.9999949932098389
- O 0 0.00015473828534595668
1 O 0 9.931626664183568e-06
to O 0 1.316422753916413e-06
promote O 0 1.4919859495421406e-05
MIS O 1 0.9965272545814514
expression O 0 7.113502942956984e-05
. O 0 3.4353761293459684e-05

In O 0 9.450036304770038e-05
contrast O 0 8.261178300017491e-05
, O 0 3.443746754783206e-05
WT1 O 1 0.9973576664924622
missense O 0 0.00016440980834886432
mutations O 0 8.030222488741856e-06
, O 0 1.680641389611992e-06
associated O 0 1.8721855212788796e-06
with O 0 1.9331409930600785e-06
male B-Disease 0 5.72216886212118e-05
pseudohermaphroditism I-Disease 1 0.999996542930603
in O 0 7.916362665127963e-05
Denys B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.862194221757818e-05
fail O 0 9.17212037165882e-06
to O 0 2.3911011339805555e-06
synergize O 0 0.0006496685091406107
with O 0 2.055332879535854e-05
SF O 1 0.9999997615814209
- O 0 0.09798980504274368
1 O 0 0.0002759065537247807
. O 0 5.0439055485185236e-05

Additionally O 0 8.874820923665538e-05
, O 0 6.409714842448011e-06
the O 0 3.863902747980319e-06
X O 0 0.00013576459605246782
- O 0 3.9100141293602064e-05
linked O 0 8.326490387844387e-06
, O 0 6.28117163614661e-07
candidate O 0 5.966065259599418e-07
dosage O 0 7.066474609018769e-06
- O 0 5.652158051816514e-06
sensitive O 0 4.063454071001615e-06
sex O 0 9.72727775661042e-07
- O 0 1.846300506258558e-06
reversal O 0 3.992658093920909e-06
gene O 0 2.0326760932221077e-06
, O 0 1.0641073231454357e-06
Dax O 1 0.9921793937683105
- O 0 3.451275551924482e-05
1 O 0 8.393515599891543e-06
, O 0 9.591751677362481e-07
antagonizes O 0 3.255621049902402e-05
synergy O 0 2.0595080059138127e-05
between O 0 3.814038564087241e-06
SF O 1 0.9999904632568359
- O 0 0.00010806851059896871
1 O 0 8.659199920657557e-06
and O 0 2.328698656128836e-06
WT1 O 1 0.6339748501777649
, O 0 6.18468732227484e-07
most O 0 1.142518541996651e-07
likely O 0 5.515746437367852e-08
through O 0 4.760796556979585e-08
a O 0 1.2169032004294422e-07
direct O 0 1.4970990491747216e-07
interaction O 0 4.166547284967237e-07
with O 0 1.2216150935273618e-06
SF O 1 0.999998927116394
- O 0 0.0030178013257682323
1 O 0 9.781337575986981e-05
. O 0 2.6269961381331086e-05

We O 0 1.4693440789415035e-05
propose O 0 1.5616331438650377e-05
that O 0 3.571925162759726e-06
WT1 O 0 0.013272912241518497
and O 0 1.2451781003619544e-05
Dax O 1 0.9999891519546509
- O 0 0.00012932007666677237
1 O 0 1.0146388376597315e-05
functionally O 0 3.631684876381769e-06
oppose O 0 2.3050647257605306e-07
each O 0 3.3717530101284865e-08
other O 0 6.460464874180616e-08
in O 0 4.879029802395962e-07
testis O 0 2.0804265659535304e-05
development O 0 1.1285623031653813e-06
by O 0 1.8347981267652358e-06
modulating O 0 0.00035867333645001054
SF O 1 0.9999513626098633
- O 0 0.00021416916570160538
1 O 0 3.950353493564762e-05
- O 0 5.7728891988517717e-05
mediated O 0 5.579700518865138e-05
transactivation O 0 0.0008385597029700875
. O 0 1.5007634829089511e-05
. O 0 2.836196290445514e-05

A O 0 0.00048298004548996687
mouse O 0 8.448187145404518e-05
model O 0 1.228142537001986e-05
for O 0 1.6829264495754614e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.999998927116394
- O 1 0.9999500513076782
centre O 1 0.9998528957366943
mutations O 0 0.0001630708429729566
. O 0 4.902664659311995e-05

Imprinting O 0 0.0009676707559265196
in O 0 1.4788176486035809e-05
the O 0 1.1922224985028151e-05
15q11 O 1 0.7146387100219727
- O 0 0.0004798821755684912
q13 O 0 0.005507634021341801
region O 0 3.7213585528661497e-06
involves O 0 2.320606881767162e-06
an O 0 8.968369797912601e-07
imprinting O 0 0.0001566276914672926
centre O 0 0.008080682717263699
( O 0 8.60101317812223e-06
IC O 1 0.9999762773513794
) O 0 2.7542664611246437e-06
, O 0 3.5507687812241784e-07
mapping O 0 1.0434878277010284e-06
in O 0 1.5977686018686654e-07
part O 0 3.2370749636356777e-07
to O 0 1.5106033401934837e-07
the O 0 1.270906182071485e-06
promoter O 0 0.0011017946526408195
and O 0 3.70463772014773e-06
first O 0 1.3187674994696863e-05
exon O 0 0.00030638909083791077
of O 0 0.0001486495602875948
SNRPN O 1 0.9999827146530151
. O 0 0.00025236737565137446

Deletion O 0 0.00042860847315751016
of O 0 7.177164661698043e-05
this O 0 1.7867392671178095e-05
IC O 1 0.9989711046218872
abolishes O 0 0.00041986716678366065
local O 0 1.2512967259681318e-05
paternally O 0 0.00011418747453717515
derived O 0 6.879417924210429e-06
gene O 0 2.0057802885276033e-06
expression O 0 4.589324476000911e-07
and O 0 3.2529786153645546e-07
results O 0 2.3291006527870195e-06
in O 0 2.4158851374522783e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999990463256836
PWS B-Disease 1 1.0
) O 0 0.018988577648997307
. O 0 0.00035694034886546433

We O 0 8.544951924704947e-06
have O 0 3.734519395948155e-07
created O 0 1.3789137938147178e-06
two O 0 2.61557261183043e-07
deletion O 0 5.7113379625661764e-06
mutations O 0 1.0253965001538745e-06
in O 0 1.1786482900788542e-06
mice O 0 5.228510872257175e-06
to O 0 8.906966968424967e-07
understand O 0 1.105803585232934e-05
PWS B-Disease 1 1.0
and O 0 5.160825367056532e-06
the O 0 1.983151605600142e-06
mechanism O 0 2.885532012442127e-06
of O 0 7.541901140939444e-06
this O 0 7.483837634936208e-06
IC O 1 0.9999868869781494
. O 0 0.00016598937509115785

Mice O 0 0.0036013759672641754
harbouring O 0 0.026194024831056595
an O 0 2.3820493879611604e-05
intragenic O 0 0.26048535108566284
deletion O 0 4.8811634769663215e-05
in O 0 8.208039616874885e-06
Snrpn O 0 0.31836748123168945
are O 0 7.747220820419898e-07
phenotypically O 0 2.966414285765495e-05
normal O 0 1.5160095472310786e-06
, O 0 5.086279770694091e-07
suggesting O 0 5.748522653448163e-07
that O 0 8.35314679648036e-08
mutations O 0 3.336185727675911e-07
of O 0 3.5210443911637412e-06
SNRPN O 1 0.9998433589935303
are O 0 3.5689180322151515e-07
not O 0 2.958952052267705e-07
sufficient O 0 2.734164581852383e-06
to O 0 7.81086509960005e-06
induce O 0 0.09584885835647583
PWS B-Disease 1 1.0
. O 0 0.0010488269617781043

Mice O 0 0.00026352106942795217
with O 0 2.3869408778409706e-06
a O 0 2.8788256258849287e-06
larger O 0 2.4341070457012393e-06
deletion O 0 8.545929631509352e-06
involving O 0 3.830566129181534e-06
both O 0 1.7156239664473105e-06
Snrpn O 0 0.37096166610717773
and O 0 2.220371698058443e-06
the O 0 5.63672529096948e-06
putative O 0 0.4007262587547302
PWS O 1 1.0
- O 1 0.9882986545562744
IC O 1 0.9999954700469971
lack O 0 1.4056106010684744e-05
expression O 0 1.42946885262063e-06
of O 0 1.425877144356491e-06
the O 0 1.7330301034235163e-06
imprinted O 0 5.714109283871949e-05
genes O 0 2.3950219656398986e-06
Zfp127 O 0 0.0005447036819532514
( O 0 1.7618967831367627e-06
mouse O 0 5.390839305619011e-06
homologue O 0 1.9790930309682153e-05
of O 0 6.964288786548423e-06
ZNF127 O 1 0.999962568283081
) O 0 3.126997626168304e-06
, O 0 2.564107262514881e-06
Ndn O 1 0.7081049680709839
and O 0 4.359207196102943e-06
Ipw O 0 0.0877474918961525
, O 0 3.0284847980510676e-06
and O 0 1.2350325278021046e-06
manifest O 0 1.367337245028466e-05
several O 0 3.0145668006298365e-06
phenotypes O 0 5.850422166986391e-05
common O 0 1.670409801590722e-05
to O 0 0.00023810291895642877
PWS B-Disease 1 1.0
infants O 1 0.9878495335578918
. O 0 0.0002558663545642048

These O 0 3.1734909953229362e-06
data O 0 1.940810534506454e-06
demonstrate O 0 1.4793105265198392e-06
that O 0 9.17956270996001e-08
both O 0 8.423833719461982e-08
the O 0 2.6312719114685024e-07
position O 0 1.6575027075305115e-06
of O 0 1.3091762411931995e-06
the O 0 3.2391733384429244e-06
IC O 1 0.9999667406082153
and O 0 7.660614755877759e-07
its O 0 5.194581831347023e-07
role O 0 3.7381076367637434e-07
in O 0 1.9296381026379095e-07
the O 0 1.5100113159860484e-07
coordinate O 0 2.5199790343322093e-07
expression O 0 3.2314304121427995e-07
of O 0 6.512861432383943e-07
genes O 0 1.6541471836717392e-07
is O 0 8.941471207890572e-08
conserved O 0 5.527341500055627e-07
between O 0 2.2890773720973812e-07
mouse O 0 2.9455516141752014e-06
and O 0 1.8188261208251788e-07
human O 0 2.8459109557843476e-07
, O 0 1.6909694977584877e-07
and O 0 1.6155021853592189e-07
indicate O 0 1.4936821912669984e-07
that O 0 3.518200131225058e-08
the O 0 3.1788235332896875e-07
mouse O 0 2.24590417019499e-06
is O 0 6.73451054922225e-08
a O 0 7.015912473207209e-08
suitable O 0 3.369272292275127e-07
model O 0 2.545507129525504e-07
system O 0 3.106015356024727e-07
in O 0 1.1608437944232719e-07
which O 0 3.711157603447646e-08
to O 0 3.95230799199453e-08
investigate O 0 3.187223001077655e-07
the O 0 2.7031973104385543e-07
molecular O 0 1.45377816807013e-06
mechanisms O 0 3.2236584956990555e-07
of O 0 1.0396723837402533e-06
imprinting O 0 1.4132101568975486e-05
in O 0 3.3396045751032943e-07
this O 0 5.355536103479608e-08
region O 0 2.483185141954891e-07
of O 0 5.851257469657867e-07
the O 0 2.748745373537531e-06
genome O 0 9.928548934112769e-06
. O 0 2.7413682346377755e-06
. O 0 2.18765162571799e-05

Mutations O 0 2.257267988170497e-05
of O 0 7.1035824475984555e-06
the O 0 4.781317329616286e-06
ATM O 0 0.02707868255674839
gene O 0 9.260876140615437e-06
detected O 0 8.034971870074514e-06
in O 0 9.362171908833261e-07
Japanese O 0 0.0895056426525116
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 0 0.030547944828867912
: O 0 2.219427187810652e-06
possible O 0 1.4684242160001304e-06
preponderance O 0 0.00018275112961418927
of O 0 6.833183761045802e-06
the O 0 3.2450200251332717e-06
two O 0 1.2004995824099751e-06
founder O 0 0.3836294412612915
mutations O 0 4.4923923269379884e-05
4612del165 O 0 0.020785069093108177
and O 0 3.132516212644987e-05
7883del5 O 1 0.5850812196731567
. O 0 0.00012124497879995033

The O 0 0.00012062755558872595
ATM O 0 0.007137906737625599
( O 0 5.541870268643834e-05
A O 1 0.992863118648529
- O 1 0.9767487049102783
T O 1 0.9999969005584717
, O 0 4.234976586303674e-06
mutated O 0 5.2599184527934995e-06
) O 0 1.1205650025658542e-06
gene O 0 1.579158606546116e-06
on O 0 2.3420950583386e-06
human O 0 1.2774883543897886e-05
chromosome O 0 7.790727249812335e-05
11q22 O 0 0.0025742400903254747
. O 0 5.781715299235657e-05

3 O 0 0.00010225937148788944
has O 0 3.140506123600062e-06
recently O 0 2.521657506804331e-06
been O 0 3.4188795439149544e-07
identified O 0 2.1498580338175088e-07
as O 0 1.1964120005814038e-07
the O 0 4.0638039422447036e-07
gene O 0 5.904059321437671e-07
responsible O 0 4.995528115614434e-07
for O 0 4.448134802714776e-07
the O 0 4.126983185415156e-06
human O 0 9.328975284006447e-05
recessive B-Disease 1 0.9977447986602783
disease I-Disease 1 0.9999998807907104
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.3259761333465576
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 6.183146615512669e-05
. O 0 3.323104829178192e-05

In O 0 1.549490843899548e-05
order O 0 3.4641457204998005e-06
to O 0 9.332942454420845e-07
define O 0 9.551843049848685e-07
the O 0 5.518971306628373e-07
types O 0 4.146096216572914e-06
of O 0 0.00016516336472705007
disease O 1 0.9999943971633911
- O 0 0.013637546449899673
causing O 0 0.00032011448638513684
ATM O 0 0.0004516478511504829
mutations O 0 1.1097727110609412e-06
in O 0 4.304505409891135e-07
Japanese O 0 0.00010620572720654309
A B-Disease 1 0.9999914169311523
- I-Disease 1 0.999997615814209
T I-Disease 1 1.0
patients O 0 4.8998681450029835e-06
as O 0 3.184433694514155e-07
well O 0 1.9054681388297467e-07
as O 0 1.5993450119822228e-07
to O 0 1.1274141087369571e-07
look O 0 2.518852397770388e-07
for O 0 2.1157606511224003e-07
possible O 0 6.551622391270939e-07
mutational O 0 6.639480852754787e-05
hotspots O 0 4.2130621295655146e-05
, O 0 8.827157103041827e-07
reverse O 0 1.975728764591622e-06
- O 0 3.6169260511087487e-06
transcribed O 0 1.944508539963863e-06
RNA O 0 8.426258091276395e-07
derived O 0 4.441674263944151e-07
from O 0 3.7935248542453337e-07
ten O 0 1.0693476042433758e-06
patients O 0 6.270846597544733e-07
belonging O 0 1.1729854350051028e-06
to O 0 2.1624504142891965e-07
eight O 0 1.0450323770783143e-06
unrelated O 0 5.011053417547373e-06
Japanese O 0 0.00021796672081109136
A B-Disease 1 0.9999774694442749
- I-Disease 1 0.9996850490570068
T I-Disease 1 0.9999954700469971
families O 0 2.8102212468184007e-07
was O 0 1.985391918424284e-06
analyzed O 0 5.299880854181538e-07
for O 0 1.1771064833965283e-07
mutations O 0 3.3415221878385637e-07
by O 0 2.0606245243470767e-07
the O 0 1.134923763856932e-06
restriction O 0 5.253421022644034e-06
endonuclease O 0 6.148386455606669e-05
fingerprinting O 0 0.00010405960347270593
method O 0 2.095927447953727e-05
. O 0 1.828121457947418e-05

As O 0 5.575844261329621e-05
has O 0 4.990236902813194e-06
been O 0 1.419810246261477e-06
reported O 0 8.540019393876719e-07
by O 0 3.045782932531438e-07
others O 0 8.380897611459659e-07
, O 0 4.939518589708314e-07
mutations O 0 2.714527909120079e-07
that O 0 8.884690316790511e-08
lead O 0 1.0053212236016407e-06
to O 0 7.875767664700106e-07
exon O 0 9.257301280740649e-05
skipping O 0 8.17693944554776e-05
or O 0 2.7548810521693667e-06
premature O 0 8.609425094618928e-06
protein O 0 1.9248664102633484e-06
truncation O 0 2.294725891260896e-05
were O 0 9.045021442943835e-07
also O 0 9.024755627251579e-07
predominant O 0 1.0256801033392549e-05
in O 0 3.223352450731909e-06
our O 0 1.12587486000848e-05
mutants O 0 0.0002723030629567802
. O 0 0.0001005154917947948

Six O 0 1.272299141419353e-05
different O 0 5.942743541709206e-07
mutations O 0 1.1387475069568609e-06
were O 0 3.9992175970837707e-07
identified O 0 8.019592314667534e-07
on O 0 6.509446279778786e-07
12 O 0 1.038550635712454e-06
of O 0 1.7875871662909049e-06
the O 0 2.3582615540362895e-06
16 O 0 1.585951031302102e-05
alleles O 0 1.1256086509092711e-05
examined O 0 0.00011295614240225405
. O 0 4.489304046728648e-05

Four O 0 1.2392997632559855e-05
were O 0 2.3507955120294355e-06
deletions O 0 7.826509317965247e-06
involving O 0 7.792117685312405e-06
a O 0 5.442900601337897e-06
loss O 0 8.30526914796792e-05
of O 0 1.1659307347144932e-05
a O 0 3.401688445592299e-06
single O 0 3.855973318422912e-06
exon O 0 3.240993100916967e-05
exon O 0 4.309439464122988e-05
7 O 0 5.519336355064297e-06
, O 0 1.0449845149196335e-06
exon O 0 2.4651357307448052e-05
16 O 0 4.207774054520996e-06
, O 0 1.477125351811992e-06
exon O 0 3.583835859899409e-05
33 O 0 1.1182889465999324e-05
or O 0 4.758382146974327e-06
exon O 0 0.00023529281315859407
35 O 0 8.010793681023642e-05
. O 0 4.660478953155689e-05

The O 0 3.1526797101832926e-05
others O 0 4.4332123252388556e-06
were O 0 1.3511011047739885e-06
minute O 0 5.060740477347281e-06
deletions O 0 1.0036696039605886e-05
, O 0 1.9665183117467677e-06
4649delA O 0 3.829909837804735e-05
in O 0 2.6145899028051645e-06
exon O 0 6.441149162128568e-05
33 O 0 1.1778340194723569e-05
and O 0 3.747370328710531e-06
7883del5 O 0 0.0003758932289201766
in O 0 1.3965169273433276e-05
exon O 0 0.00041075455374084413
55 O 0 9.795358346309513e-05
. O 0 5.9787776990560815e-05

The O 0 0.00015065414481796324
mutations O 0 5.495065124705434e-05
4612del165 O 0 0.0009824599837884307
and O 0 5.8489922594162636e-06
7883del5 O 0 0.0002658198936842382
were O 0 1.292816250497708e-06
found O 0 4.769858605868649e-07
in O 0 1.2691933193309524e-07
more O 0 3.333863318744079e-08
than O 0 5.0342283230975227e-08
two O 0 4.4196848847377623e-08
unrelated O 0 5.060322223471303e-07
families O 0 9.752749718927589e-08
; O 0 1.8889815578404523e-07
44 O 0 1.164508944384579e-06
% O 0 2.0477617113101587e-07
( O 0 1.24633515952155e-07
7 O 0 4.216597631057084e-07
of O 0 7.374339929810958e-07
16 O 0 2.044480652330094e-06
) O 0 8.875240098404902e-08
of O 0 1.5422509136442386e-07
the O 0 3.754914814635413e-07
mutant O 0 4.6556920096918475e-06
alleles O 0 2.084509134192558e-07
had O 0 3.597883448946959e-07
one O 0 1.6218746168306097e-07
of O 0 5.848992259416264e-07
the O 0 1.1739534784283023e-06
two O 0 2.0804666291951435e-06
mutations O 0 3.281961471657269e-05
. O 0 3.343914431752637e-05

The O 0 0.00019506776880007237
4612del165 O 0 0.01141445804387331
mutations O 0 5.265263098408468e-06
in O 0 7.690729262321838e-07
three O 0 1.0332657751632723e-07
different O 0 2.1074070488680263e-08
families O 0 3.738595921731758e-08
were O 0 1.0062335320526472e-07
all O 0 5.6207600351854126e-08
ascribed O 0 2.096895514114294e-06
to O 0 2.0985009996365989e-07
the O 0 8.006463758647442e-07
same O 0 1.8735340745479334e-06
T O 0 0.008270169608294964
- O 0 1.7272242985200137e-05
- O 0 6.7317769207875244e-06
> O 0 2.039188075286802e-06
A O 0 1.0425598020447069e-06
substitution O 0 1.1764191185648087e-06
at O 0 3.365095835761167e-06
the O 0 6.260586360440357e-07
splice O 0 2.6252206225763075e-05
donor O 0 2.1130517779965885e-06
site O 0 1.3689629668078851e-05
in O 0 3.5265018141217297e-06
intron O 0 0.0004321117594372481
33 O 0 0.00010003691568272188
. O 0 3.2285795896314085e-05

Microsatellite O 0 0.003752779681235552
genotyping O 0 0.0013188153970986605
around O 0 3.3853601053124294e-05
the O 0 8.076649464783259e-06
ATM O 0 0.0008951574563980103
locus O 0 3.229737558285706e-05
also O 0 1.2691270967479795e-06
indicated O 0 9.293772222918051e-07
that O 0 1.0520767546040588e-07
a O 0 5.664692253048997e-07
common O 0 1.1014104757123278e-06
haplotype O 0 1.1117355825263076e-05
was O 0 8.12756934465142e-06
shared O 0 5.225501809036359e-07
by O 0 2.4688213784429536e-07
the O 0 1.097037056752015e-06
mutant O 0 5.3316935009206645e-06
alleles O 0 8.69385189616878e-07
in O 0 8.458850402348617e-07
both O 0 2.5689487301860936e-06
mutations O 0 2.2509995687869377e-05
. O 0 3.843641752609983e-05

This O 0 1.1951765372941736e-05
suggests O 0 6.401150585588766e-06
that O 0 1.8919328681477054e-07
these O 0 8.717184130091482e-08
two O 0 4.5996873154763307e-07
founder O 0 0.09486521780490875
mutations O 0 4.366942448541522e-06
may O 0 7.434417170770757e-07
be O 0 1.65203147162174e-07
predominant O 0 4.163487119512865e-06
among O 0 9.529206295155745e-07
Japanese O 0 3.143882713629864e-05
ATM O 0 0.0021080251317471266
mutant O 0 9.834348747972399e-05
alleles O 0 3.118340828223154e-05
. O 0 2.9060816814308055e-05

W474C O 0 0.004244496580213308
amino O 0 3.9590231608599424e-05
acid O 0 2.335605677217245e-05
substitution O 0 1.3825710993842222e-05
affects O 0 3.4814374885172583e-06
early O 0 1.9163492197549203e-06
processing O 0 1.9246626834501512e-06
of O 0 4.413081455822976e-07
the O 0 3.436469171447243e-07
alpha O 0 2.4783639673842117e-06
- O 0 1.8222461903860676e-06
subunit O 0 6.85797772348451e-07
of O 0 1.0120596698470763e-06
beta O 0 5.281079211272299e-06
- O 0 7.63100524636684e-06
hexosaminidase O 0 0.00016103075176943094
A O 0 5.2389823395060375e-06
and O 0 6.096449283177208e-07
is O 0 3.1999078942135384e-07
associated O 0 1.1789596783273737e-06
with O 0 2.945026608358603e-06
subacute O 1 0.9999808073043823
G B-Disease 1 0.999906063079834
( I-Disease 0 0.0005548007902689278
M2 I-Disease 1 0.9999904632568359
) I-Disease 0 8.46978000481613e-05
gangliosidosis I-Disease 0 0.03741780295968056
. O 0 0.00010203475540038198

Mutations O 0 6.360086990753189e-05
in O 0 8.025636816455517e-06
the O 0 1.5666748367948458e-05
HEXA O 1 0.9760279655456543
gene O 0 3.661145456135273e-06
, O 0 3.1712536951999937e-07
encoding O 0 2.845533515483112e-07
the O 0 5.10455095081852e-07
alpha O 0 2.2203123535291525e-06
- O 0 1.7824902442953316e-06
subunit O 0 7.868695206525445e-07
of O 0 7.361467169175739e-07
beta O 0 5.849466106155887e-06
- O 0 7.048154657240957e-06
hexosaminidase O 0 0.00018982200708705932
A O 0 2.0872648747172207e-05
( O 0 2.4571127141825855e-06
Hex O 0 9.377817332278937e-05
A O 0 1.9020808394998312e-05
) O 0 6.421030889214308e-07
, O 0 3.330593756345479e-07
that O 0 1.450097499855474e-07
abolish O 0 1.3394836969382595e-05
Hex O 0 0.00014378731430042535
A O 0 2.7435116862761788e-05
enzyme O 0 1.6295723980874754e-05
activity O 0 2.144453719665762e-05
cause O 0 0.08755990862846375
Tay B-Disease 1 1.0
- I-Disease 1 0.9999983310699463
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999991655349731
( O 0 6.551760452566668e-05
TSD B-Disease 1 0.9999998807907104
) O 0 6.549019417434465e-06
, O 0 1.0863168427022174e-06
the O 0 2.1295961687428644e-06
fatal O 0 0.09146611392498016
infantile B-Disease 0 0.0014360087225213647
form I-Disease 0 5.981994490866782e-06
of I-Disease 0 0.00015933414397295564
G I-Disease 1 0.9924631118774414
( I-Disease 0 2.370894799241796e-05
M2 I-Disease 1 0.9999641180038452
) I-Disease 0 8.160366633092053e-06
gangliosidosis I-Disease 0 0.0011307083768770099
, I-Disease 0 4.953636562277097e-06
Type I-Disease 0 7.219083636300638e-05
1 I-Disease 0 5.881361721549183e-05
. O 0 3.0379836971405894e-05

Less O 0 0.00031850807135924697
severe O 1 0.943522572517395
, O 0 0.00011206908675376326
subacute O 1 0.9999984502792358
( O 0 0.0004108371795155108
juvenile O 1 0.9999833106994629
- O 1 0.9937153458595276
onset O 1 0.9999983310699463
) O 0 3.5179480619262904e-05
and O 0 0.00012127908848924562
chronic O 1 0.9999998807907104
( O 0 6.161022611195222e-05
adult O 0 5.904125646338798e-05
- O 0 0.0024838841054588556
onset O 1 0.983307957649231
) O 0 8.201453169931483e-07
variants O 0 9.345972671326308e-07
are O 0 7.687606995432361e-08
characterized O 0 6.869577191537246e-07
by O 0 2.821497275817819e-07
a O 0 1.2347310303084669e-06
broad O 0 3.309678504592739e-06
spectrum O 0 8.721466656425036e-06
of O 0 1.3998103895573877e-05
clinical O 0 0.009797319769859314
manifestations O 0 0.00025296909734606743
and O 0 8.82199799434602e-07
are O 0 1.7709349720007594e-07
associated O 0 5.639132041324046e-07
with O 0 2.2190687332113157e-07
residual O 0 9.032464731717482e-05
levels O 0 5.168577899894444e-06
of O 0 7.812585863575805e-06
Hex O 0 0.0006405175081454217
A O 0 6.833751103840768e-05
enzyme O 0 2.5001587346196175e-05
activity O 0 2.0462384782149456e-05
. O 0 2.2586009436054155e-05

We O 0 2.656795913935639e-05
identified O 0 1.4818329873378389e-05
a O 0 6.177747309266124e-06
1422 O 0 0.004584345500916243
G O 0 0.001299473224207759
- O 0 0.0002476894296705723
- O 0 7.256098615471274e-05
> O 0 3.782181738642976e-05
C O 0 0.0001232151553267613
( O 0 8.823486723485985e-07
amino O 0 4.6259410169113835e-07
acid O 0 1.8949262994283345e-06
W474C O 0 1.6913734725676477e-05
) O 0 1.1731258808822531e-07
substitution O 0 3.408897271128808e-07
in O 0 1.5797249375282263e-07
the O 0 1.324140725955658e-07
first O 0 3.130546417651203e-07
position O 0 7.61601938847889e-07
of O 0 8.110890803436632e-07
exon O 0 9.658801900513936e-06
13 O 0 2.433037252558279e-06
of O 0 3.6123171867075143e-06
HEXA O 1 0.9720016121864319
of O 0 5.740037977375323e-06
a O 0 3.2194232062465744e-06
non O 0 1.8653900042409077e-05
- O 0 2.537650834710803e-05
Jewish O 0 5.2160259656375274e-05
proband O 1 0.726932942867279
who O 0 6.388806923496304e-06
manifested O 0 6.90525266691111e-05
a O 0 1.0493394256627653e-05
subacute O 1 0.7279838919639587
variant O 0 0.00010523270611884072
of O 0 0.0005850216839462519
G B-Disease 1 0.9985059499740601
( I-Disease 0 0.0002442616969347
M2 I-Disease 1 0.9999923706054688
) I-Disease 0 7.783227192703635e-05
gangliosidosis I-Disease 0 0.23158003389835358
. O 0 9.502864850219339e-05

On O 0 8.58747007441707e-05
the O 0 2.0313569621066563e-05
second O 0 5.999693530611694e-05
maternally O 0 0.0010619501117616892
inherited O 1 0.7658390998840332
allele O 0 8.06275875220308e-06
, O 0 1.4680699678137898e-06
we O 0 1.7458634715694643e-07
identified O 0 3.5246421248302795e-07
the O 0 1.0385922450950602e-06
common O 0 2.438104093016591e-05
infantile O 1 0.9999997615814209
disease O 1 0.9999996423721313
- O 1 0.6369208693504333
causing O 0 0.013188224285840988
4 O 0 4.6382570872083306e-05
- O 0 2.89024792436976e-05
bp O 0 2.2375841581379063e-05
insertion O 0 1.3936006325820927e-05
, O 0 2.482655190760852e-06
+ O 0 1.964606053661555e-05
TATC O 1 0.9720405340194702
1278 O 0 0.01665187068283558
, O 0 4.145708771829959e-06
in O 0 3.5160917377652368e-06
exon O 0 0.00018409745825920254
11 O 0 8.604469621786848e-05
. O 0 3.9192756958073005e-05

Pulse O 0 0.002268474316224456
- O 0 0.00020463389228098094
chase O 0 6.27705012448132e-05
analysis O 0 2.891664280468831e-06
using O 0 4.448959316505352e-06
proband O 0 0.0018380475230515003
fibroblasts O 0 4.974483817932196e-05
revealed O 0 5.892904482607264e-06
that O 0 1.0128883332072292e-07
the O 0 4.0975913861984736e-07
W474C O 0 4.637248275685124e-05
- O 0 3.951082817366114e-06
containing O 0 1.3264325389172882e-06
alpha O 0 4.141393674217397e-06
- O 0 1.87470834589476e-06
subunit O 0 1.1737541854017763e-06
precursor O 0 8.735783012525644e-06
was O 0 2.7891946956515312e-06
normally O 0 1.4370615986081248e-07
synthesized O 0 1.6230503661063267e-06
, O 0 1.1878444183821557e-07
but O 0 4.528846275775322e-08
not O 0 2.5053635610561287e-08
phosphorylated O 0 2.0484094420680776e-06
or O 0 4.466949690140609e-07
secreted O 0 2.556216486482299e-06
, O 0 2.720660177146783e-07
and O 0 2.056768693137201e-07
the O 0 9.975271950679598e-07
mature O 0 5.473685632750858e-06
lysosomal O 0 0.0002518966794013977
alpha O 0 2.5432425900362432e-05
- O 0 1.1461047506600153e-05
subunit O 0 6.019684860802954e-06
was O 0 1.0196498806180898e-05
not O 0 7.967996680235956e-07
detected O 0 2.6629242711351253e-05
. O 0 9.001641956274398e-06

When O 0 4.485727185965516e-05
the O 0 9.957146176020615e-06
W474C O 0 0.00018314237240701914
- O 0 1.0886412383115385e-05
containing O 0 5.78203480472439e-06
alpha O 0 6.613489858864341e-06
- O 0 4.961692866345402e-06
subunit O 0 2.126807430613553e-06
was O 0 3.7103056911291787e-06
transiently O 0 1.6597059584455565e-05
co O 0 4.599578005581861e-06
- O 0 1.8344971977057867e-06
expressed O 0 1.3657462716309965e-07
with O 0 6.413075226419096e-08
the O 0 2.495939384061785e-07
beta O 0 1.726176719785144e-06
- O 0 1.12132715912594e-06
subunit O 0 3.320612904644804e-07
to O 0 8.685798746910223e-08
produce O 0 7.211982051558152e-07
Hex O 0 3.288120205979794e-05
A O 0 1.7378599295625463e-05
( O 0 1.388961550219392e-06
alphabeta O 0 5.077552123111673e-05
) O 0 5.009019332646858e-07
in O 0 5.114681584927894e-07
COS O 1 0.608705997467041
- O 0 3.0089691790635698e-05
7 O 0 6.261545422603376e-06
cells O 0 7.719056043242745e-07
, O 0 1.3084419947517745e-07
the O 0 1.682872579067407e-07
mature O 0 4.0028118064583396e-07
alpha O 0 2.5842202830972383e-06
- O 0 1.8036324718195829e-06
subunit O 0 7.373116091002885e-07
was O 0 1.0486044175195275e-06
present O 0 2.3051504172144632e-07
, O 0 7.499690468648623e-08
but O 0 1.8965948811455746e-08
its O 0 5.768601596400913e-08
level O 0 7.01526971624844e-07
was O 0 2.7669402697938494e-06
much O 0 3.3390185194548394e-07
lower O 0 3.732550624135911e-07
than O 0 1.7878578617569474e-08
that O 0 1.3358014250286487e-08
from O 0 1.2271037519440142e-07
normal O 0 2.4534335807402385e-07
alpha O 0 2.712783725655754e-06
- O 0 2.210247657785658e-06
subunit O 0 1.4404357671082835e-06
transfections O 0 2.1335630663088523e-05
, O 0 1.967807463643112e-07
although O 0 7.292835135785936e-08
higher O 0 6.784340911281106e-08
than O 0 2.964520895432088e-08
in O 0 9.13303779270791e-08
those O 0 9.921271981738755e-08
cells O 0 6.945788868506497e-07
transfected O 0 3.818012828560313e-06
with O 0 8.01260782168356e-08
an O 0 4.072556691880891e-07
alpha O 0 8.795545909379143e-06
- O 0 7.707133590884041e-06
subunit O 0 3.451265911280643e-06
associated O 0 2.4304099497385323e-06
with O 0 5.005980710848235e-06
infantile O 1 0.9992891550064087
TSD B-Disease 1 0.9999923706054688
. O 0 0.000363886880222708

Furthermore O 0 0.0001732775999698788
, O 0 4.4942294152860995e-06
the O 0 1.2217828952998389e-06
precursor O 0 1.1245324458286632e-05
level O 0 1.9068656911258586e-06
of O 0 7.488654318876797e-07
the O 0 6.903754865561496e-07
W474C O 0 7.056790491333231e-05
alpha O 0 6.085115728637902e-06
- O 0 1.823084062380076e-06
subunit O 0 5.515556722457404e-07
was O 0 9.554030384606449e-07
found O 0 1.2576792585150542e-07
to O 0 5.042185335923932e-08
accumulate O 0 1.2640525710594375e-06
in O 0 2.1826974716532277e-07
comparison O 0 2.87393504549982e-07
to O 0 1.0551353568644117e-07
the O 0 3.7340421954468184e-07
normal O 0 7.478163297491847e-07
alpha O 0 5.122846687299898e-06
- O 0 4.794349024450639e-06
subunit O 0 5.03391083839233e-06
precursor O 0 2.4079588911263272e-05
levels O 0 1.2213507943670265e-05
. O 0 1.3179490451875608e-05

We O 0 1.6170824892469682e-05
conclude O 0 1.370697827951517e-05
that O 0 6.713132165714342e-07
the O 0 1.7867247379399487e-06
1422 O 0 0.054842930287122726
G O 0 0.0034385579638183117
- O 0 0.0001066253098542802
- O 0 5.6398348533548415e-05
> O 0 1.6036203305702657e-05
C O 0 0.00011220317537663504
mutation O 0 6.616572250095487e-07
is O 0 1.2209287092446175e-07
the O 0 3.189451831531187e-07
cause O 0 1.6795903547972557e-06
of O 0 1.1272295523667708e-05
Hex B-Disease 1 0.9997064471244812
A I-Disease 1 0.9997583031654358
enzyme I-Disease 1 0.9999971389770508
deficiency I-Disease 1 0.9999996423721313
in O 0 1.9946037355111912e-05
the O 0 0.00011111501225968823
proband O 1 0.980217695236206
. O 0 0.00010897482570726424

The O 0 5.252409027889371e-05
resulting O 0 5.1691531552933156e-05
W474C O 0 0.0005870425957255065
substitution O 0 2.59666376223322e-05
clearly O 0 3.834074959740974e-06
interferes O 0 4.076149707543664e-06
with O 0 3.19960292927135e-07
alpha O 0 6.89355101712863e-06
- O 0 3.626683792390395e-06
subunit O 0 1.106764671021665e-06
processing O 0 2.3561865418741945e-06
, O 0 1.637127127196436e-07
but O 0 3.716399277209348e-08
because O 0 2.9020128522461164e-08
the O 0 1.1487055928682821e-07
base O 0 9.087422654374677e-07
substitution O 0 1.974997758225072e-06
falls O 0 1.6640848116367124e-05
at O 0 1.2356592833384639e-06
the O 0 2.93014068120101e-07
first O 0 5.687335260518012e-07
position O 0 6.708166324642661e-07
of O 0 1.2029155413983972e-06
exon O 0 3.7916539440630004e-05
13 O 0 6.0889233282068744e-06
, O 0 7.665657335564902e-07
aberrant O 0 5.8900391195493285e-06
splicing O 0 1.1365873433533125e-05
may O 0 8.243475804192713e-07
also O 0 2.1998835109116044e-07
contribute O 0 4.930275281367358e-07
to O 0 1.265150103790802e-06
Hex B-Disease 1 0.9839143753051758
A I-Disease 1 0.9832144975662231
deficiency I-Disease 1 0.9994499087333679
in O 0 3.837659733108012e-06
this O 0 2.44759644374426e-06
proband O 0 0.07748809456825256
. O 0 1.0474297596374527e-05
. O 0 2.8202373869135045e-05

Two O 0 3.2284133339999244e-05
frequent O 0 5.3194515203358606e-05
missense O 0 0.000686400628183037
mutations O 0 0.00013400371244642884
in O 0 0.0012493381509557366
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.01063262764364481

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.006182018201798201
an O 1 0.7322015762329102
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999986886978149
by O 1 0.931136429309845
early O 1 0.9999997615814209
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999992847442627
goiter B-Disease 1 1.0
. O 1 0.9349638819694519

A O 0 0.0001494041207479313
century O 0 5.383881216403097e-05
after O 0 8.805130164546426e-06
its O 0 9.16527540084644e-07
recognition O 0 2.9237808121251874e-06
as O 0 4.47306365458644e-06
a O 0 6.460994336521253e-05
syndrome O 1 0.9889113903045654
by O 0 4.395357791509014e-06
Vaughan O 1 0.9999173879623413
Pendred O 1 0.9997574687004089
, O 0 5.35191338713048e-06
the O 0 1.3376073184190318e-05
disease O 1 0.9457435607910156
gene O 0 1.3854629287379794e-05
( O 0 6.882784418849042e-06
PDS O 1 0.9986383318901062
) O 0 3.3993760553130414e-06
was O 0 1.7851640222943388e-05
mapped O 0 8.907943083613645e-06
to O 0 4.029617684864206e-06
chromosome O 0 3.257241769460961e-05
7q22 O 0 0.013143802061676979
- O 0 0.0008714051218703389
q31 O 0 0.011939320713281631
. O 0 8.238363807322457e-05

1 O 0 0.00010002164344768971
and O 0 5.697025699191727e-06
, O 0 1.6469314232381294e-06
recently O 0 3.6552046367432922e-06
, O 0 5.086667442810722e-07
found O 0 3.4757735534185485e-07
to O 0 1.6245496681221994e-07
encode O 0 1.5569327160847024e-06
a O 0 7.464208465535194e-06
putative O 0 0.0006448986823670566
sulfate O 1 0.7863879799842834
transporter O 1 0.9145623445510864
. O 0 0.00022719193657394499

We O 0 1.8305843695998192e-05
performed O 0 1.9800503650913015e-05
mutation O 0 7.5967233215124e-07
analysis O 0 2.3519383773873415e-07
of O 0 6.644191330451577e-07
the O 0 5.024673100706423e-06
PDS B-Disease 1 0.9998365640640259
gene O 0 5.733882971981075e-06
in O 0 1.32126001517463e-06
patients O 0 1.5362645626737503e-06
from O 0 1.5106292039490654e-06
14 O 0 1.3821914762957022e-05
Pendred B-Disease 0 0.021936334669589996
families O 0 2.9698898629249015e-07
originating O 0 1.6154958757397253e-06
from O 0 7.050891781545943e-07
seven O 0 4.866283234150615e-07
countries O 0 3.901332945588365e-08
and O 0 5.40566304607637e-07
identified O 0 3.844957518595038e-06
all O 0 3.5846267110173358e-06
mutations O 0 2.2178101062308997e-05
. O 0 3.439909778535366e-05

The O 0 6.124872743384913e-05
mutations O 0 7.159719643823337e-06
include O 0 1.9133451587549644e-06
three O 0 7.844060405659548e-07
single O 0 1.3646020988744567e-06
base O 0 5.2543027777574025e-06
deletions O 0 5.486762347572949e-06
, O 0 8.921537641981558e-07
one O 0 8.311791930282197e-07
splice O 0 9.644080273574218e-05
site O 0 3.445047696004622e-05
mutation O 0 2.5006117994053056e-06
and O 0 1.3672909062734107e-06
10 O 0 9.927696737577207e-06
missense O 0 0.0001773525436874479
mutations O 0 4.733090827357955e-05
. O 0 6.021020817570388e-05

One O 0 7.703230949118733e-05
missense O 0 0.00026915204944089055
mutation O 0 1.8152482880395837e-05
( O 0 5.0533521971374284e-06
L236P O 0 0.010893604718148708
) O 0 1.5587124835292343e-06
was O 0 7.051274678815389e-06
found O 0 3.3714064784362563e-07
in O 0 1.0407622141883621e-07
a O 0 2.0757111940383766e-07
homozygous O 0 3.873572893553501e-07
state O 0 6.754115133844607e-08
in O 0 1.346229936416421e-07
two O 0 1.9082705193795846e-07
consanguineous O 0 2.4254770323750563e-05
families O 0 2.2068684302212205e-07
and O 0 3.385370348496508e-07
in O 0 2.5550340865265753e-07
a O 0 3.936156929285062e-07
heterozygous O 0 2.8286180508985126e-07
state O 0 9.03474770552748e-08
in O 0 2.4817552457534475e-07
five O 0 1.7390834727848414e-07
additional O 0 9.155228894996981e-07
non O 0 2.30900968745118e-05
- O 0 0.00020834602764807642
consanguineous O 0 0.0009871511720120907
families O 0 1.1772129255405162e-05
. O 0 3.498810110613704e-05

Another O 0 8.814467582851648e-05
missense O 0 0.00023140758275985718
mutation O 0 1.2955121746927034e-05
( O 0 5.285271072352771e-06
T416P O 0 0.004347613081336021
) O 0 1.6257381503237411e-06
was O 0 5.221544597588945e-06
found O 0 4.806993842976226e-07
in O 0 9.414382162731272e-08
a O 0 1.716768309734107e-07
homozygous O 0 3.068728631205886e-07
state O 0 9.638318232418897e-08
in O 0 1.858321780900951e-07
one O 0 2.853506657629623e-07
family O 0 8.208166946133133e-07
and O 0 4.201877175091795e-07
in O 0 4.362719892014866e-07
a O 0 4.4922785491507966e-07
heterozygous O 0 3.394609962015238e-07
state O 0 1.3708719848182227e-07
in O 0 3.8728416029698565e-07
four O 0 1.0582770073597203e-06
families O 0 2.5665046905487543e-06
. O 0 2.7498479539644904e-05

Pendred B-Disease 1 0.9973213076591492
patients O 0 7.65852237236686e-05
in O 0 4.725550297735026e-06
three O 0 1.9158337636326905e-06
non O 0 4.108270877622999e-05
- O 0 7.255565287778154e-05
consanguineous O 0 0.00015703728422522545
families O 0 4.397889199481142e-07
were O 0 7.352261377491232e-07
shown O 0 3.477086636394233e-07
to O 0 1.5299366395993275e-07
be O 0 4.2320351667513023e-07
compound O 0 2.1040765204816125e-05
heterozygotes O 0 2.8766997274942696e-05
for O 0 2.818608436427894e-06
L236P O 0 0.011205661110579967
and O 0 6.420745194191113e-05
T416P O 0 0.06995438039302826
. O 0 0.0001573093031765893

In O 0 1.913566666189581e-05
total O 0 6.888911229907535e-06
, O 0 1.1419024303904735e-06
one O 0 3.2925794357652194e-07
or O 0 2.6848303491533443e-07
both O 0 9.879332196760515e-08
of O 0 4.850228947361757e-07
these O 0 8.763461778471537e-08
mutations O 0 1.7395761631178175e-07
were O 0 1.2916476066493487e-07
found O 0 1.223701815433742e-07
in O 0 1.2502886193033191e-07
nine O 0 3.4989744790436816e-07
of O 0 9.60878196565318e-07
the O 0 1.910241962832515e-06
14 O 0 9.053099347511306e-06
families O 0 1.0174147746511153e-06
analyzed O 0 3.223946623620577e-05
. O 0 3.4873108234023675e-05

The O 0 2.534313352953177e-05
identification O 0 1.1616401025094092e-05
of O 0 6.05113427809556e-06
two O 0 2.112293941536336e-06
frequent O 0 1.9426348444540054e-05
PDS B-Disease 1 0.9996434450149536
mutations O 0 1.9566073206078727e-06
will O 0 3.033535165286594e-07
facilitate O 0 8.220348490795004e-07
the O 0 1.8934269974124618e-06
molecular O 0 0.00025188899599015713
diagnosis O 1 0.9625187516212463
of O 1 0.980182409286499
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0015664994716644287

Insertional O 0 0.010448068380355835
mutation O 0 2.0591820430126972e-05
by O 0 6.8788076532655396e-06
transposable O 0 0.0006943652988411486
element O 0 4.1965653508668765e-05
, O 0 5.211186817177804e-06
L1 O 0 0.01436863373965025
, O 0 1.841910830080451e-06
in O 0 9.275213415094186e-07
the O 0 4.371363047539489e-06
DMD B-Disease 1 0.9999998807907104
gene O 0 5.7330466916027945e-06
results O 0 3.2855200515768956e-06
in O 0 9.244303328159731e-06
X B-Disease 1 0.9999693632125854
- I-Disease 1 0.9999897480010986
linked I-Disease 1 0.9999805688858032
dilated I-Disease 1 0.9999934434890747
cardiomyopathy I-Disease 1 1.0
. O 0 0.0025900602340698242

X B-Disease 1 0.9994663596153259
- I-Disease 1 0.999144434928894
linked I-Disease 1 0.999782145023346
dilated I-Disease 1 0.9999984502792358
cardiomyopathy I-Disease 1 1.0
( O 1 0.7769718766212463
XLDCM B-Disease 1 1.0
) O 0 9.657678674557246e-06
is O 0 9.844268333836226e-07
a O 0 1.2880634585599182e-06
clinical O 0 0.0001298797724302858
phenotype O 0 9.342201337858569e-06
of O 0 3.2602249120827764e-05
dystrophinopathy B-Disease 1 0.999789297580719
which O 0 1.8490014781491482e-06
is O 0 5.723687763747876e-07
characterized O 0 1.7288882645516424e-06
by O 0 1.3124703173161834e-06
preferential O 0 0.00014855944027658552
myocardial B-Disease 1 0.9999980926513672
involvement I-Disease 0 4.380086102173664e-05
without O 0 1.4863386468277895e-06
any O 0 1.2049017641402315e-06
overt O 0 1.3117984963173512e-05
clinical O 0 0.0001496981712989509
signs O 0 0.00042034752550534904
of O 1 0.954433023929596
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.3404611051082611

To O 0 1.1461310350568965e-05
date O 0 1.8766346329357475e-05
, O 0 8.478637596454064e-07
several O 0 3.443834657446132e-07
mutations O 0 1.161972932095523e-06
in O 0 1.0572804285402526e-06
the O 0 0.0001472284784540534
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.997296154499054
, O 0 0.3516705632209778
DMD O 1 1.0
, O 0 6.178707280923845e-06
have O 0 1.9051809374559525e-07
been O 0 2.395391334175656e-07
identified O 0 8.125980457407422e-07
in O 0 6.149950877443189e-07
patients O 0 1.2811282203983865e-06
with O 0 1.3813381656291313e-06
XLDCM B-Disease 1 1.0
, O 0 4.867257757723564e-06
but O 0 1.7375202787661692e-07
a O 0 3.063874487452267e-07
pathogenic O 0 7.957243610690057e-07
correlation O 0 4.5384578584162227e-07
of O 0 6.127668825683941e-07
these O 0 4.1125304051092826e-07
cardiospecific O 0 0.011205945163965225
mutations O 0 5.053689619671786e-06
in O 0 9.693249012343585e-06
DMD O 1 0.9999998807907104
with O 0 3.597619752326864e-06
the O 0 4.4179287215229124e-05
XLDCM B-Disease 1 0.9999998807907104
phenotype O 0 7.430688856402412e-05
has O 0 1.630167503208213e-06
remained O 0 1.2815246918762568e-05
to O 0 1.3960928981759935e-06
be O 0 3.7869895095354877e-06
elucidated O 0 0.0009390854393132031
. O 0 5.5229294957825914e-05

We O 0 1.555880044179503e-05
report O 0 2.853595788110397e-06
here O 0 4.0473858575751365e-07
the O 0 1.201596546707151e-07
identification O 0 5.415048462964478e-07
of O 0 7.1397772671844e-07
a O 0 6.742582741026126e-07
unique O 0 1.1712618288584054e-06
de O 0 4.345184424892068e-05
novo O 0 6.882277375552803e-05
L1 O 0 0.0002027583250310272
insertion O 0 8.183707905118354e-06
in O 0 9.649498906583176e-07
the O 0 1.8692489902605303e-06
muscle O 0 2.4960327209555544e-05
exon O 0 5.223841799306683e-05
1 O 0 9.574310752213933e-06
in O 0 4.793078005604912e-06
DMD O 1 0.9999996423721313
in O 0 2.358002802793635e-06
three O 0 3.3485962376289535e-06
XLDCM B-Disease 1 0.9999983310699463
patients O 0 7.371228093688842e-06
from O 0 1.4201746125763748e-06
two O 0 4.2600524352565117e-07
unrelated O 0 1.0742152880993672e-05
Japanese O 0 0.0002264147187815979
families O 0 8.607790732639842e-06
. O 0 5.274570139590651e-05

The O 0 5.3753756219521165e-05
insertion O 0 0.00011321407509967685
was O 0 3.1416107958648354e-05
a O 0 1.9243320821260568e-06
5 O 0 2.6448547032487113e-06
- O 0 3.831589310721029e-06
truncated O 0 2.5224487671948737e-06
form O 0 5.19872003224009e-07
of O 0 1.4830621921646525e-06
human O 0 2.3331533611781197e-06
L1 O 0 0.0001794482086552307
inversely O 0 4.343131877249107e-06
integrated O 0 1.1191275916644372e-05
in O 0 7.603783274134912e-07
the O 0 9.871426982499543e-07
5 O 0 3.946955530409468e-06
- O 0 1.2827522368752398e-05
untranslated O 0 0.00014556538371834904
region O 0 1.3795688573736697e-06
in O 0 4.7283361936933943e-07
the O 0 1.1323054422973655e-06
muscle O 0 2.976470932480879e-05
exon O 0 7.203948189271614e-05
1 O 0 6.915471658430761e-06
, O 0 4.0492273001291323e-07
which O 0 9.295743552684144e-08
affected O 0 2.2814778333213326e-07
the O 0 3.57163855824183e-07
transcription O 0 2.7641233373287832e-06
or O 0 6.810685704294883e-07
the O 0 4.1801942529673397e-07
stability O 0 5.92011758726585e-07
of O 0 1.1531524251040537e-06
the O 0 3.3989092571573565e-06
muscle O 0 5.632329703075811e-06
form O 0 5.02017144299316e-07
of O 0 4.8821248128660955e-06
dystrophin O 0 0.0002534113882575184
transcripts O 0 7.54543361836113e-06
but O 0 1.647990472974925e-07
not O 0 2.4610280036085896e-08
that O 0 1.6210435660468647e-08
of O 0 2.8294303433540335e-07
the O 0 6.436237981688464e-06
brain O 1 0.947003185749054
or O 0 2.2667898520012386e-05
Purkinje O 1 0.9999905824661255
cell O 0 7.651762280147523e-05
form O 0 1.62245441970299e-06
, O 0 9.042666420100431e-07
probably O 0 1.5725340745120775e-06
due O 0 4.623334461939521e-07
to O 0 1.0378818871004114e-07
its O 0 3.378400208475796e-07
unique O 0 7.748351436021039e-07
site O 0 1.2962945220351685e-05
of O 0 9.107350706472062e-06
integration O 0 4.980792436981574e-05
. O 0 5.214201519265771e-05

We O 0 2.0739886167575605e-05
speculate O 0 1.0356673556088936e-05
that O 0 3.478313601590344e-07
this O 0 1.0935945482515308e-07
insertion O 0 2.806420297929435e-06
of O 0 9.993934781959979e-07
an O 0 8.283194006253325e-07
L1 O 0 0.006246022414416075
sequence O 0 1.5149544196901843e-06
in O 0 3.731436891030171e-06
DMD O 1 0.9999998807907104
is O 0 7.402326787087077e-07
responsible O 0 4.4664301412922214e-07
for O 0 1.0933880645325189e-07
some O 0 1.0103684644491295e-07
of O 0 3.9103628068914986e-07
the O 0 2.535341536713531e-07
population O 0 5.194250007889423e-08
of O 0 6.982996296756028e-07
Japanese O 0 6.0505131841637194e-05
patients O 0 9.781541848497e-06
with O 0 3.0407379654207034e-06
XLDCM B-Disease 1 0.9999978542327881
. O 0 3.848105188808404e-05
. O 0 4.552437167149037e-05

Severe O 1 0.9824680685997009
early O 1 0.561269998550415
- O 1 0.9999668598175049
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9997604489326477
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9991884827613831
red O 1 0.9999998807907104
hair O 1 0.9999997615814209
pigmentation O 1 0.9999845027923584
caused O 0 0.007556321565061808
by O 0 5.6982742535183206e-05
POMC O 1 0.9999992847442627
mutations O 0 4.3715601350413635e-05
in O 0 1.1739361070794985e-05
humans O 0 4.7517689381493255e-05
. O 0 3.742396074812859e-05

Sequential O 0 0.00014587744954042137
cleavage O 0 0.00011696093861246482
of O 0 1.2419677659636363e-05
the O 0 5.16562613483984e-06
precursor O 0 2.722614044614602e-05
protein O 0 1.5677229612265364e-06
pre O 0 4.8531106585869566e-05
- O 0 2.953221155621577e-05
pro O 0 0.00010176336945733055
- O 0 0.00010822134208865464
opiomelanocortin O 0 0.07382126152515411
( O 0 1.3172803846828174e-05
POMC O 1 0.9935343265533447
) O 0 1.6719624227334862e-06
generates O 0 3.3685057587717893e-06
the O 0 2.0018837858515326e-06
melanocortin O 0 0.0007085293182171881
peptides O 0 2.6168843760387972e-05
adrenocorticotrophin O 0 0.0025066062808036804
( O 0 1.1218106919841375e-05
ACTH O 0 0.005748828873038292
) O 0 1.942428980328259e-06
, O 0 1.3323302709977725e-06
melanocyte O 0 0.0011717169545590878
- O 0 6.195246533025056e-05
stimulating O 0 8.067276212386787e-05
hormones O 0 1.5459954738616943e-05
( O 0 2.945034793810919e-06
MSH O 1 0.5517240166664124
) O 0 6.028055850038072e-07
alpha O 0 3.0616740787081653e-06
, O 0 1.5208446768610884e-07
beta O 0 4.87040153984708e-07
and O 0 1.0722706633714552e-07
gamma O 0 1.0763221780507592e-06
as O 0 1.1373199271247358e-07
well O 0 1.0916980386355135e-07
as O 0 1.2984787645109463e-07
the O 0 3.8608453678534715e-07
opioid O 0 1.7437101632822305e-05
- O 0 2.2272546630119905e-05
receptor O 0 8.19521210360108e-06
ligand O 0 3.921776806237176e-05
beta O 0 0.00012917735148221254
- O 0 0.0003774520300794393
endorphin O 0 0.0024619249161332846
. O 0 6.652421870967373e-05

While O 0 7.52705309423618e-05
a O 0 8.19658725959016e-06
few O 0 2.682946160348365e-06
cases O 0 7.749185328975727e-07
of O 0 3.6027238820679486e-05
isolated O 1 0.9999889135360718
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999923706054688
have O 0 1.0168948847422143e-06
been O 0 2.800351694531855e-06
reported O 0 4.384464773465879e-06
( O 0 4.6090981413726695e-06
OMIM O 1 0.9999910593032837
201400 O 1 0.742602527141571
) O 0 1.876300188996538e-06
, O 0 5.188121576793492e-07
an O 0 1.6894863392735715e-06
inherited O 1 0.9999998807907104
POMC O 1 1.0
defect O 1 0.9998795986175537
has O 0 2.0427130493771983e-06
not O 0 2.3979444563337893e-07
been O 0 9.579594006936532e-07
described O 0 2.239331706732628e-06
so O 0 1.0836720321094617e-06
far O 0 5.446254817798035e-06
. O 0 8.807951417111326e-06

Recent O 0 3.107200245722197e-05
studies O 0 4.194865141471382e-06
in O 0 7.138993964872498e-07
animal O 0 2.1079633825138444e-06
models O 0 1.2010699492748245e-06
elucidated O 0 1.552668254589662e-05
a O 0 1.1193270665899036e-06
central O 0 5.465478238875221e-07
role O 0 8.50890046422137e-07
of O 0 2.4718610802665353e-06
alpha O 0 5.918431997997686e-05
- O 0 0.00010452742571942508
MSH O 1 0.7395362257957458
in O 0 6.527735081363062e-07
the O 0 2.6147642984142294e-07
regulation O 0 5.301286023495777e-07
of O 0 1.0536346053413581e-06
food O 0 8.189463756025361e-07
intake O 0 8.387526122533018e-07
by O 0 1.4006654680542852e-07
activation O 0 7.873919685152941e-07
of O 0 7.735659437457798e-07
the O 0 1.996364289880148e-06
brain O 0 4.120897938264534e-05
melanocortin O 0 0.0002624517073854804
- O 0 9.408147889189422e-06
4 O 0 3.1751440019434085e-06
- O 0 4.308124971430516e-06
receptor O 0 1.4572748341379338e-06
( O 0 1.05403569250484e-06
MC4 O 0 0.002594846300780773
- O 0 2.887523078243248e-05
R O 0 3.854959140880965e-05
; O 0 3.7017028375885275e-07
refs O 0 1.0662645763659384e-05
3 O 0 1.4196465372151579e-06
- O 0 2.4912292246881407e-06
5 O 0 6.852355909359176e-07
) O 0 1.4130452541394334e-07
and O 0 6.755725934226575e-08
the O 0 2.505113343431731e-07
linkage O 0 5.182847417017911e-06
of O 0 6.9801662903046235e-06
human O 0 2.8859731173724867e-05
obesity B-Disease 1 0.9925001263618469
to O 0 9.205992341776437e-07
chromosome O 0 1.726440132188145e-06
2 O 0 7.283173317773617e-07
in O 0 2.59567826788043e-07
close O 0 8.195752911888121e-07
proximity O 0 8.179059136637079e-07
to O 0 2.400916798706021e-07
the O 0 3.4438814964232733e-06
POMC O 1 0.9993171691894531
locus O 0 1.7200936781591736e-05
, O 0 3.133724533199711e-07
led O 0 5.778621812169149e-07
to O 0 1.3861863124020601e-07
the O 0 2.773479081952246e-07
proposal O 0 2.482962599970051e-07
of O 0 4.2631941710169485e-07
an O 0 6.316914209492097e-07
association O 0 9.450871402805205e-06
of O 0 0.00014864091644994915
POMC O 1 0.9999998807907104
with O 0 6.758979725418612e-05
human O 0 0.008018742315471172
obesity B-Disease 1 0.9999972581863403
. O 0 0.00030238935141824186

The O 0 3.0278664780780673e-05
dual O 0 1.890395287773572e-05
role O 0 7.062042186589679e-06
of O 0 1.3174840205465443e-05
alpha O 0 0.00029426952823996544
- O 0 0.002094734227284789
MSH O 1 0.9989726543426514
in O 0 1.3342503280000528e-06
regulating O 0 5.0187300075776875e-06
food O 0 2.336067836949951e-06
intake O 0 7.014071798039367e-06
and O 0 1.3847028412783402e-06
influencing O 0 0.00013992543972562999
hair O 1 0.8716158866882324
pigmentation O 0 0.015353485010564327
predicts O 0 8.955704288382549e-06
that O 0 1.955824160404518e-07
the O 0 1.1205938790226355e-06
phenotype O 0 3.869529791700188e-06
associated O 0 1.1179893135704333e-06
with O 0 4.4712714952765964e-07
a O 0 1.0701395694923121e-05
defect O 0 0.49962931871414185
in O 0 2.3299839085666463e-05
POMC O 1 0.9999949932098389
function O 0 3.6947019452782115e-06
would O 0 1.0000026122725103e-06
include O 0 1.5826239177840762e-05
obesity B-Disease 1 0.9999934434890747
, O 0 1.1119072951260023e-05
alteration O 0 0.010593813844025135
in O 0 9.224309178534895e-05
pigmentation O 1 0.9999580383300781
and O 0 0.2371373176574707
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
. O 0 0.00034160164068453014

The O 0 4.0007642382988706e-05
observation O 0 0.00015944083861541003
of O 0 1.6904043150134385e-05
these O 0 1.8658614635569393e-06
symptoms O 0 0.00016741134459152818
in O 0 1.1804986570496112e-06
two O 0 8.87351120582025e-07
probands O 0 0.2792923152446747
prompted O 0 7.2994907895918e-06
us O 0 1.1215229278604966e-06
to O 0 1.601179349108861e-07
search O 0 6.013844426888681e-07
for O 0 2.914569847689563e-07
mutations O 0 7.116697702258534e-07
within O 0 9.421860909242241e-07
their O 0 2.94574579129403e-06
POMC O 1 0.9985670447349548
genes O 0 3.556469891918823e-05
. O 0 3.208084308425896e-05

Patient O 0 0.0009992355480790138
1 O 0 7.235528028104454e-05
was O 0 3.8433485315181315e-05
found O 0 8.741531587475038e-07
to O 0 7.444180738502837e-08
be O 0 3.868780140692252e-08
a O 0 2.3830619966247468e-07
compound O 0 6.701926849927986e-06
heterozygote O 0 4.8330475692637265e-06
for O 0 8.57135376008955e-08
two O 0 1.0166083086460276e-07
mutations O 0 2.1988076071011164e-07
in O 0 3.120087512797909e-07
exon O 0 2.3185575628303923e-05
3 O 0 6.579456112376647e-06
( O 0 2.4584301172581036e-06
G7013T O 0 0.0024564736522734165
, O 0 3.1848667276790366e-06
C7133delta O 0 0.13174626231193542
) O 0 9.276452033191163e-07
which O 0 2.2591703441321442e-07
interfere O 0 4.1376173953722173e-07
with O 0 1.003010581257513e-07
appropriate O 0 2.2282490874658833e-07
synthesis O 0 5.927782694925554e-06
of O 0 6.8147669480822515e-06
ACTH O 0 0.018061431124806404
and O 0 1.0025446499639656e-05
alpha O 0 0.0002930474583990872
- O 0 0.001234589610248804
MSH O 1 0.9984810948371887
. O 0 0.0001448030088795349

Patient O 0 0.0008818838396109641
2 O 0 5.277271702652797e-05
was O 0 2.756811591098085e-05
homozygous O 0 4.5113119995221496e-06
for O 0 3.9641653870603477e-07
a O 0 1.0963645991068915e-06
mutation O 0 7.566674185000011e-07
in O 0 6.885292123115505e-07
exon O 0 3.7939327739877626e-05
2 O 0 1.1692422958731186e-05
( O 0 5.832470833411207e-06
C3804A O 0 0.004585763439536095
) O 0 4.0916352190834004e-06
which O 0 5.155674898560392e-06
abolishes O 0 0.001896967994980514
POMC O 1 0.9997506737709045
translation O 0 0.0004362264880910516
. O 0 0.00011057236406486481

These O 0 6.039389973011566e-06
findings O 0 3.403450591576984e-06
represent O 0 4.705398737314681e-07
the O 0 6.406656893886975e-07
first O 0 6.838717467871902e-07
examples O 0 7.263286647685163e-07
of O 0 3.886934337060666e-06
a O 0 4.065191023983061e-05
genetic B-Disease 1 0.9999932050704956
defect I-Disease 1 0.9999887943267822
within O 0 3.1930294426274486e-06
the O 0 8.010954843484797e-06
POMC O 1 0.9999985694885254
gene O 0 3.1473841772822198e-06
and O 0 3.2933834859250055e-07
define O 0 4.646691422749427e-07
a O 0 1.2414421917128493e-06
new O 0 3.1395953556057066e-05
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999974966049194
resulting O 0 5.328203769749962e-05
in O 0 7.801761967130005e-06
early O 0 0.0019487288082018495
- O 1 0.9956908822059631
onset O 1 0.9999998807907104
obesity B-Disease 1 1.0
, O 1 0.9743955135345459
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9690728783607483
red O 1 0.9999988079071045
hair O 1 0.9999982118606567
pigmentation O 1 0.9988353848457336
. O 0 2.574160862423014e-05
. O 0 5.3702769946539775e-05

A O 0 0.00031777043477632105
European O 0 4.3514632125152275e-05
multicenter O 0 0.0010505369864404202
study O 0 2.974558447021991e-05
of O 0 0.006238805595785379
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.7675363778835163e-05
classification O 0 8.635764243081212e-05
of O 0 2.7816406145575456e-05
105 O 0 7.229886250570416e-05
mutations O 0 2.1377966277214e-06
and O 0 3.997936062205554e-07
a O 0 5.631796398120059e-07
general O 0 1.1228082712477772e-06
system O 0 9.414127930540417e-07
for O 0 8.247549772022467e-07
genotype O 0 9.357413546240423e-06
- O 0 9.882806807581801e-06
based O 0 3.3120591069746297e-06
prediction O 0 5.6740358559181914e-05
of O 0 6.482285971287638e-05
metabolic O 1 0.9986740350723267
phenotype O 0 0.0005854143528267741
. O 0 6.306527939159423e-05

Phenylketonuria B-Disease 1 0.999966025352478
( O 0 0.004558268003165722
PKU B-Disease 1 0.9999991655349731
) O 0 6.702433165628463e-05
and O 0 6.300499080680311e-05
mild B-Disease 1 0.9999405145645142
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9987051486968994
MHP B-Disease 1 1.0
) O 0 2.0468201910261996e-05
are O 0 1.3330611636774847e-06
allelic B-Disease 1 0.9999923706054688
disorders I-Disease 1 0.9999998807907104
caused O 0 0.04434741660952568
by O 0 2.9832729069312336e-06
mutations O 0 2.3613717985426774e-06
in O 0 1.1651320619421313e-06
the O 0 2.6343477657064795e-06
gene O 0 5.039934876549523e-06
encoding O 0 8.513515240338165e-06
phenylalanine O 0 0.0008361520594917238
hydroxylase O 1 0.5420397520065308
( O 0 0.0003202283405698836
PAH O 1 1.0
) O 0 0.00014410422591026872
. O 0 8.985285239759833e-05

Previous O 0 5.7142184232361615e-05
studies O 0 4.465119673113804e-06
have O 0 2.2642845465270511e-07
suggested O 0 6.474873543993453e-07
that O 0 9.958905877738289e-08
the O 0 6.08923244271864e-07
highly O 0 4.0571694626123644e-06
variable O 0 7.825157808838412e-06
metabolic O 0 0.04001834988594055
phenotypes O 0 0.001251347130164504
of O 1 0.9997938275337219
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.04469865933060646
with O 0 0.0024577369913458824
PAH O 1 1.0
genotypes O 1 0.9907315373420715
. O 0 0.00041340180905535817

We O 0 1.6724916349630803e-05
identified O 0 5.846711246704217e-06
both O 0 1.553471065562917e-06
causative O 0 5.030152897234075e-05
mutations O 0 4.373990577732911e-06
in O 0 4.1957132452807855e-06
686 O 0 0.12165474146604538
patients O 0 1.6286341633531265e-05
from O 0 3.384454430488404e-06
seven O 0 6.5602766881056596e-06
European O 0 2.309941191924736e-05
centers O 0 0.00011756688036257401
. O 0 0.00010241835116175935

On O 0 1.8608627215144224e-05
the O 0 1.6751816929172492e-06
basis O 0 3.874977210216457e-07
of O 0 7.196173328338773e-07
the O 0 5.668139806402905e-07
phenotypic O 0 4.064891982125118e-06
characteristics O 0 1.6040894479374401e-06
of O 0 5.6511339607823174e-06
297 O 0 0.0003667552082333714
functionally O 0 0.005607983563095331
hemizygous O 1 0.8953152894973755
patients O 0 7.550307145720581e-06
, O 0 3.349671260366449e-07
105 O 0 1.5218777207337553e-06
of O 0 5.224385972724122e-07
the O 0 8.00167015313491e-07
mutations O 0 3.5124617170367856e-07
were O 0 2.940576564469666e-07
assigned O 0 7.04267222317867e-07
to O 0 7.871730645092612e-08
one O 0 1.7030995991262898e-07
of O 0 5.319664637681853e-07
four O 0 3.6750648746419756e-07
arbitrary O 0 1.7797963209886802e-06
phenotype O 0 1.8891340005211532e-05
categories O 0 1.5377965610241517e-05
. O 0 4.332276148488745e-05

We O 0 6.036424565536436e-06
proposed O 0 3.469763214525301e-06
and O 0 9.56146664066182e-07
tested O 0 2.247541033284506e-06
a O 0 4.30331908773951e-07
simple O 0 3.070312288855348e-07
model O 0 4.838863674194727e-07
for O 0 2.944654227121646e-07
correlation O 0 8.118622076835891e-07
between O 0 4.6713330448255874e-07
genotype O 0 4.890018317382783e-06
and O 0 1.589899511600379e-06
phenotypic O 0 2.76022037724033e-05
outcome O 0 1.8752229152596556e-05
. O 0 3.7945370422676206e-05

The O 0 6.202873191796243e-05
observed O 0 1.9983390302513726e-05
phenotype O 0 1.445488760509761e-05
matched O 0 4.350328254076885e-06
the O 0 1.555620769977395e-06
predicted O 0 3.343611751915887e-06
phenotype O 0 1.1386410960767535e-06
in O 0 2.4161107603504206e-07
79 O 0 2.479177283021272e-06
% O 0 1.4504654188840505e-07
of O 0 2.271946044629658e-07
the O 0 3.9035629129102745e-07
cases O 0 2.2146733158479037e-07
, O 0 1.8348788444200181e-07
and O 0 7.828190007330704e-08
in O 0 1.0385215176711426e-07
only O 0 6.662974527671395e-08
5 O 0 2.448249460940133e-07
of O 0 6.457477184085292e-07
184 O 0 1.0499279596842825e-05
patients O 0 4.847625405091094e-06
was O 0 5.441379926196532e-06
the O 0 4.906208914690069e-07
observed O 0 7.335215173043252e-07
phenotype O 0 3.9032985910125717e-07
more O 0 3.5600450587480736e-08
than O 0 5.733106434036017e-08
one O 0 2.3348287925273326e-07
category O 0 3.9299413856497267e-07
away O 0 1.385269342790707e-06
from O 0 7.328132483053196e-07
that O 0 5.711810899811098e-07
expected O 0 9.044089892995544e-06
. O 0 2.547701842559036e-05

Among O 0 5.182474706089124e-05
the O 0 6.03771422902355e-06
seven O 0 2.7615519684331957e-06
contributing O 0 4.761550826515304e-06
centers O 0 7.1474328251497354e-06
, O 0 4.90912043460412e-07
the O 0 3.946011588595866e-07
proportion O 0 7.297815614037972e-07
of O 0 2.181385298172245e-06
patients O 0 1.4975731801314396e-06
for O 0 2.0006419276796805e-07
whom O 0 8.168582326106844e-07
the O 0 4.1457579413872736e-07
observed O 0 1.1202071164007066e-06
phenotype O 0 8.367608756998379e-07
did O 0 1.4334139564198267e-07
not O 0 4.3089119827754985e-08
match O 0 6.606994134017441e-07
the O 0 5.12715928380203e-07
predicted O 0 1.96948712982703e-06
phenotype O 0 1.2602814649653737e-06
was O 0 2.193403133787797e-06
4 O 0 7.087465405675175e-07
% O 0 2.4852747060322145e-07
- O 0 1.2353646070550894e-06
23 O 0 1.648499733164499e-06
% O 0 4.215865487822157e-07
( O 0 4.285667216663569e-07
P O 0 3.799171463469975e-05
< O 0 7.555954198323889e-06
. O 0 3.7207297509667114e-07
0001 O 0 2.4002923964872025e-05
) O 0 3.742570129361411e-07
, O 0 9.331200345741308e-08
suggesting O 0 2.2418160483539395e-07
that O 0 1.5453448298785588e-08
differences O 0 4.587171886782926e-08
in O 0 4.14023766381888e-08
methods O 0 1.706811758594995e-07
used O 0 2.6876276137954846e-07
for O 0 3.5033687595387164e-07
mutation O 0 1.0001390364777762e-06
detection O 0 1.5327948858612217e-05
or O 0 1.7479138705311925e-06
phenotype O 0 5.647330453939503e-06
classification O 0 1.0386833309894428e-05
may O 0 4.770899977302179e-07
account O 0 1.0294279206846113e-07
for O 0 1.073793356454189e-07
a O 0 4.908155801786052e-07
considerable O 0 1.7490759773863829e-06
proportion O 0 1.644095732444839e-06
of O 0 5.3280950851331e-06
genotype O 0 8.793411689111963e-05
- O 0 0.00030765857081860304
phenotype O 0 0.00013339979341253638
inconsistencies O 0 0.0002231998078059405
. O 0 0.00013247127935755998

Our O 0 3.7163234082981944e-05
data O 0 9.027518899529241e-06
indicate O 0 2.9955092486488866e-06
that O 0 3.4660254755181086e-07
the O 0 1.1312259630358312e-05
PAH O 1 1.0
- O 0 0.05489809811115265
mutation O 0 7.323455974983517e-06
genotype O 0 4.4551579776452854e-06
is O 0 2.0465395778046513e-07
the O 0 3.051074202176096e-07
main O 0 3.948566700273659e-06
determinant O 0 1.8667102267500013e-05
of O 0 4.251517020747997e-05
metabolic O 1 0.9903366565704346
phenotype O 0 1.2517562026914675e-05
in O 0 1.6241170897046686e-06
most O 0 5.2713376135216095e-06
patients O 0 0.0002768623235169798
with O 0 0.2190714180469513
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.12850108742713928

In O 0 2.5531622668495402e-05
the O 0 2.978968723255093e-06
present O 0 1.3728438261750853e-06
study O 0 9.038485586643219e-07
, O 0 1.807774197004619e-07
the O 0 3.4630650702638377e-07
classification O 0 4.300539330870379e-06
of O 0 1.874402369139716e-05
105 O 1 0.9617859721183777
PAH O 1 1.0
mutations O 0 1.0610779099806678e-05
may O 0 3.637878762674518e-07
allow O 0 7.519398792510401e-08
the O 0 2.831006611359044e-07
prediction O 0 2.3006491574051324e-06
of O 0 5.660523356709746e-07
the O 0 5.224908932177641e-07
biochemical O 0 1.9196459106751718e-05
phenotype O 0 2.377278860876686e-06
in O 0 6.479908165601955e-07
> O 0 3.0423591397266136e-06
10 O 0 1.0378338402006193e-06
, O 0 1.4043571638922003e-07
000 O 0 1.4855139625069569e-06
genotypes O 0 3.040018555111601e-06
, O 0 1.9206602530630335e-07
which O 0 1.1438661573492936e-07
may O 0 1.1534390864653687e-07
be O 0 3.9770657878079874e-08
useful O 0 9.510887366559473e-08
for O 0 8.501910286895509e-08
the O 0 1.1112967968074372e-06
management O 0 3.38616082444787e-05
of O 0 0.0001479919155826792
hyperphenylalaninemia B-Disease 1 0.9999996423721313
in O 0 7.190291216829792e-05
newborns O 0 0.00046830266364850104
. O 0 2.8478423701017164e-05

Somatic O 0 0.0010987342102453113
instability O 0 0.00010476123134139925
of O 0 4.3352840293664485e-05
the O 0 4.9163823859998956e-05
CTG O 1 0.999670147895813
repeat O 0 5.329997293301858e-05
in O 0 4.150491349719232e-06
mice O 0 7.506919246225152e-06
transgenic O 0 2.4501779989805073e-05
for O 0 2.0132140434725443e-06
the O 0 0.001072755316272378
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.01829979382455349
is O 0 6.104644853621721e-06
age O 0 7.91367801866727e-06
dependent O 0 7.162254860304529e-07
but O 0 1.6424566240402783e-07
not O 0 6.370539296085553e-08
correlated O 0 5.849365720678179e-07
to O 0 2.0035116676808684e-07
the O 0 1.2320350606387365e-06
relative O 0 1.1186142728547566e-05
intertissue O 0 0.0031923328060656786
transcription O 0 6.136641604825854e-05
levels O 0 1.3430241779133212e-05
and O 0 1.3799628504784778e-05
proliferative O 1 0.9374963641166687
capacities O 0 0.0007003669161349535
. O 0 0.0001447341201128438

A O 0 0.0012538828887045383
( O 0 6.610091077163815e-05
CTG O 1 0.9883805513381958
) O 0 9.286984095524531e-06
nexpansion O 0 0.00012324958515819162
in O 0 1.4340279221869423e-06
the O 0 2.6837806217372417e-06
3 O 0 9.357974704471417e-06
- O 0 4.699404598795809e-05
untranslated O 0 0.0035766432993113995
region O 0 3.416223989916034e-06
( O 0 1.7319462131126784e-06
UTR O 0 0.00607026182115078
) O 0 6.903057396812073e-07
of O 0 1.4691988781123655e-06
the O 0 1.075803447747603e-05
DM O 1 1.0
protein O 0 8.918101229937747e-06
kinase O 0 2.6783221983350813e-05
gene O 0 7.224618002510397e-06
( O 0 2.842522462742636e-06
DMPK O 1 0.9998002648353577
) O 0 6.518684472212044e-07
is O 0 2.64955815509893e-07
responsible O 0 1.684865310380701e-06
for O 0 7.339095645875204e-06
causing O 1 0.9999948740005493
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999988079071045
DM B-Disease 1 1.0
) O 0 0.001534343813546002
. O 0 0.0001246721512870863

Major O 0 0.002675652736797929
instability O 0 0.000543353206012398
, O 0 9.307306754635647e-06
with O 0 1.1267212585153175e-06
very O 0 6.635939939769742e-07
large O 0 5.043315240982338e-07
expansions O 0 6.640228093601763e-06
between O 0 5.322262950357981e-07
generations O 0 1.4204576928023016e-06
and O 0 6.626511321883299e-07
high O 0 5.6585276979603805e-06
levels O 0 1.2535866744656232e-06
of O 0 3.3325779895676533e-06
somatic O 0 0.00022641904070042074
mosaicism O 1 0.6455808281898499
, O 0 1.1152110346301924e-06
is O 0 2.6536295649748354e-07
observed O 0 1.1727561286534183e-06
in O 0 2.2998744952928973e-06
patients O 0 1.9818864529952407e-05
. O 0 2.5938770704669878e-05

There O 0 2.4418413886451162e-05
is O 0 3.609896111811395e-06
a O 0 2.0157576727797277e-06
good O 0 1.3970212648928282e-06
correlation O 0 5.728257974624285e-07
between O 0 2.622406043428782e-07
repeat O 0 1.2055947991029825e-06
size O 0 1.3386704722506693e-06
( O 0 3.820049130354164e-07
at O 0 8.600559340266045e-07
least O 0 1.030524146017342e-07
in O 0 2.676118526778737e-07
leucocytes O 0 0.0011330766137689352
) O 0 8.40486109154881e-07
, O 0 5.91441221331479e-07
clinical O 0 2.0092502381885424e-05
severity O 0 1.2330422578088474e-05
and O 0 1.680585455687833e-06
age O 0 2.384995241300203e-05
of O 0 6.853498780401424e-05
onset O 1 0.9991551637649536
. O 0 0.0001179185273940675

The O 0 0.0003185952373314649
trinucleotide O 1 0.9937074780464172
repeat O 0 0.0002694216091185808
instability O 0 5.644655175274238e-05
mechanisms O 0 1.3025201042182744e-05
involved O 0 1.4951993762224447e-05
in O 0 3.753336568479426e-05
DM B-Disease 1 1.0
and O 0 9.722049981064629e-06
other O 0 3.1809026950213592e-06
human O 0 0.00019845442147925496
genetic B-Disease 1 0.9999997615814209
diseases I-Disease 1 1.0
are O 0 3.1219351512845606e-06
unknown O 0 9.625062375562266e-05
. O 0 4.967477070749737e-05

We O 0 3.495168493827805e-05
studied O 0 0.0001002427889034152
somatic O 0 0.0001507294364273548
instability O 0 1.848661486292258e-05
by O 0 2.6296113446733216e-06
measuring O 0 8.761463686823845e-05
the O 0 1.6686011804267764e-05
CTG O 1 0.9988414645195007
repeat O 0 1.0727973858593032e-05
length O 0 6.612951324314054e-07
at O 0 7.532805739174364e-07
several O 0 9.531299127729653e-08
ages O 0 4.5399644932331285e-07
in O 0 1.4531528336192423e-07
various O 0 2.4882297111616936e-07
tissues O 0 9.635121386963874e-06
of O 0 6.619211944780545e-06
transgenic O 0 0.00022288403124548495
mice O 0 3.0507178507832577e-06
carrying O 0 1.4233610272640362e-06
a O 0 1.271922315027041e-06
( O 0 1.8849051457436872e-06
CTG O 1 0.9824218153953552
) O 0 2.7081177904619835e-06
55expansion O 0 6.302085967035964e-05
surrounded O 0 1.138372863351833e-05
by O 0 3.127425145521556e-07
45 O 0 9.115110515267588e-07
kb O 0 1.058253474184312e-05
of O 0 1.5700765061410493e-06
the O 0 2.889183633669745e-06
human O 0 3.706664574565366e-05
DM B-Disease 1 1.0
region O 0 4.549956429400481e-06
, O 0 4.956988277626806e-07
using O 0 2.089110182623699e-07
small O 0 1.7120706843343214e-06
- O 0 2.9952270779176615e-05
pool O 0 8.413792966166511e-05
PCR O 0 0.0005815587937831879
. O 0 3.7226654967525974e-05

These O 0 1.711517688818276e-05
mice O 0 1.9476658053463325e-05
have O 0 1.9141468499128678e-07
been O 0 2.916671917319036e-07
shown O 0 1.9829649033908936e-07
to O 0 9.90138389056483e-08
reproduce O 0 1.1937876251977286e-06
the O 0 9.568801715431619e-07
intergenerational O 0 1.0056069186248351e-05
and O 0 1.5371130075436668e-06
somatic O 0 2.6138917746720836e-05
instability O 0 5.533255716727581e-06
of O 0 2.6771547254611505e-06
the O 0 2.466539172019111e-06
55 O 0 1.6838928786455654e-05
CTG O 1 0.8152981996536255
repeat O 0 5.495905497809872e-06
suggesting O 0 1.471268319619412e-06
that O 0 8.116897731724748e-08
surrounding O 0 9.377175729241571e-07
sequences O 0 1.9536449258339417e-07
and O 0 1.8656160705177172e-07
the O 0 3.9150197039816703e-07
chromatin O 0 1.1484232345537748e-05
environment O 0 2.0068382582394406e-06
are O 0 1.9914591575798113e-07
involved O 0 1.4419009630728397e-06
in O 0 4.083000931132119e-06
instability O 0 4.514177635428496e-05
mechanisms O 0 0.00014616317639593035
. O 0 0.00014893330808263272

As O 0 1.7337033568765037e-05
observed O 0 2.3032130229694303e-06
in O 0 2.6190917878921027e-07
some O 0 1.825742828032162e-07
of O 0 8.165903295775934e-07
the O 0 3.419529093662277e-06
tissues O 0 0.042164284735918045
of O 1 0.7153106331825256
DM B-Disease 1 1.0
patients O 0 0.45548489689826965
, O 0 1.3109003020872478e-06
there O 0 2.498373419257405e-07
is O 0 1.306359678210356e-07
a O 0 1.7593180245967233e-07
tendency O 0 5.62614388854854e-07
for O 0 2.1963994356610783e-07
repeat O 0 2.834863607859006e-06
length O 0 6.192236128299555e-07
and O 0 5.23630717452761e-07
somatic O 0 5.48287462152075e-05
mosaicism O 0 0.00015944463666528463
to O 0 1.995070988414227e-07
increase O 0 1.140463297133465e-07
with O 0 8.044612087587666e-08
the O 0 3.976478808453976e-07
age O 0 2.373679308220744e-06
of O 0 4.265713414497441e-06
the O 0 1.8917929992312565e-05
mouse O 0 0.00034516764571890235
. O 0 2.500964910723269e-05

Furthermore O 0 0.00018451518553774804
, O 0 4.745357728097588e-06
we O 0 4.786993486050051e-07
observed O 0 8.084880960268492e-07
no O 0 2.0760991503721016e-07
correlation O 0 2.1683815987216803e-07
between O 0 1.3295387191192276e-07
the O 0 5.623022047984705e-07
somatic O 0 3.6065255699213594e-05
mutation O 0 2.4418820885330206e-06
rate O 0 1.1637362149485853e-06
and O 0 2.9857408208044944e-06
tissue O 0 0.1696515530347824
proliferation O 0 0.0011741762282326818
capacity O 0 0.00010696679237298667
. O 0 3.243466926505789e-05

The O 0 8.289492689073086e-05
somatic O 0 0.00035457356716506183
mutation O 0 9.922396202455275e-06
rates O 0 1.195480649585079e-06
in O 0 3.6505326761471224e-07
different O 0 1.195992354041664e-07
tissues O 0 5.087675162940286e-06
were O 0 2.1938538452559442e-07
also O 0 1.4748152921129076e-07
not O 0 3.396370829022999e-08
correlated O 0 2.9643322818628803e-07
to O 0 8.20775341026092e-08
the O 0 3.248762254770554e-07
relative O 0 1.6893058045752696e-06
inter O 0 4.036050086142495e-05
- O 0 6.506588397314772e-05
tissue O 0 4.5377262722468004e-05
difference O 0 3.280496798652166e-07
in O 0 6.546300568288643e-08
transcriptional O 0 3.415304661302798e-07
levels O 0 1.6738547969907813e-07
of O 0 2.5877147891151253e-07
the O 0 2.11458257126651e-07
three O 0 2.303418824567416e-07
genes O 0 8.015394428184663e-07
( O 0 1.7184437410833198e-06
DMAHP O 1 0.9998708963394165
, O 0 6.862060672574444e-06
DMPK O 1 0.9771685600280762
and O 0 2.9298491881490918e-06
59 O 0 1.6317058907588944e-05
) O 0 6.135785497463075e-07
surrounding O 0 4.111940597795183e-06
the O 0 3.211891680621193e-06
repeat O 0 2.7941257940256037e-05
. O 0 5.9736821640399285e-06
. O 0 1.5657085896236822e-05

A O 0 0.00036796589847654104
novel O 0 8.350009738933295e-05
missense O 0 0.00018351715698372573
mutation O 0 9.28665576793719e-06
in O 0 3.4448930819053203e-06
patients O 0 5.1893807722080965e-06
from O 0 3.8766575016779825e-06
a O 0 2.6457417334313504e-05
retinoblastoma B-Disease 1 0.9774347543716431
pedigree O 0 0.0009067670325748622
showing O 0 2.573372876213398e-05
only O 0 1.0856984999918495e-06
mild O 0 7.992137398105115e-06
expression O 0 1.4900002724971273e-06
of O 0 7.704098607064225e-06
the O 0 0.0002994518436025828
tumor B-Disease 1 0.9999984502792358
phenotype O 0 0.00022037951566744596
. O 0 3.676032065413892e-05

We O 0 8.286619959108066e-06
have O 0 3.4063103271364525e-07
used O 0 8.520852929905232e-07
single O 0 1.0190588000114076e-06
strand O 0 3.3732760584825883e-06
conformation O 0 1.0576231943559833e-06
polymorphism O 0 9.987855946747004e-07
analysis O 0 2.568750119280594e-07
to O 0 9.005396606198701e-08
study O 0 2.8425961318134796e-07
the O 0 3.773578498567076e-07
27 O 0 3.1075078368303366e-06
exons O 0 3.363709765835665e-06
of O 0 1.267127913706645e-06
the O 0 4.75491606266587e-06
RB1 O 1 0.9987851977348328
gene O 0 1.431217583558464e-06
in O 0 1.8628746545346075e-07
individuals O 0 4.709246326228822e-08
from O 0 6.43299529201613e-07
a O 0 1.787754172255518e-06
family O 0 3.7269592212396674e-06
showing O 0 7.962505151226651e-06
mild O 0 1.0948047929559834e-05
expression O 0 2.2522208382724784e-06
of O 0 1.0428151654195972e-05
the O 0 7.2505310527049e-05
retinoblastoma B-Disease 1 0.9995540976524353
phenotype O 0 0.0006488596554845572
. O 0 9.412290819454938e-05

In O 0 5.396412961999886e-05
this O 0 3.3803030419221614e-06
family O 0 1.0103593012900092e-05
affected O 0 1.996248329305672e-06
individuals O 0 2.8504007332230685e-07
developed O 0 3.510923124849796e-05
unilateral B-Disease 0 0.0038424674421548843
tumors I-Disease 1 1.0
and O 0 3.4669451451918576e-06
, O 0 1.2642261708606384e-06
as O 0 3.728274293735012e-07
a O 0 4.000750948307541e-07
result O 0 3.5295965972181875e-07
of O 0 1.1417630503274268e-06
linkage O 0 1.0308686796633992e-05
analysis O 0 1.1108792250524857e-06
, O 0 8.550972552257008e-07
unaffected O 0 5.775030786026036e-06
mutation O 0 3.5951634913544694e-07
carriers O 0 3.258698200170329e-07
were O 0 2.353807531108032e-07
also O 0 2.963806764455512e-07
identified O 0 8.593123084210674e-07
within O 0 1.1423696832935093e-06
the O 0 4.7992666623031255e-06
pedigree O 0 0.0005842591635882854
. O 0 6.675159238511696e-05

A O 0 0.00033780207741074264
single O 0 1.6022202544263564e-05
band O 0 3.051081148441881e-05
shift O 0 3.9743513298162725e-06
using O 0 2.1162400116736535e-06
SSCP O 0 0.05310262367129326
was O 0 1.327537393081002e-05
identified O 0 1.6399911828557379e-06
in O 0 6.057821337890346e-07
exon O 0 1.6328081983374432e-05
21 O 0 2.952405566247762e-06
which O 0 1.7792076789646671e-07
resulted O 0 1.198418885905994e-06
in O 0 3.570579565348453e-07
a O 0 5.829496103615384e-07
missense O 0 4.917966634820914e-06
mutation O 0 4.788417982126703e-07
converting O 0 4.515668024396291e-06
a O 0 2.485502818672103e-06
cys O 0 0.0013379189185798168
- O 0 4.5473479985957965e-05
- O 0 3.491560710244812e-05
> O 0 1.265716946363682e-05
arg O 0 0.00011942978744627908
at O 0 6.229442078620195e-06
nucleotide O 0 2.344971335332957e-06
position O 0 2.9821637781424215e-06
28 O 0 3.4767656416079262e-06
in O 0 1.7375928109686356e-06
the O 0 9.519863851892296e-06
exon O 0 0.0009647626429796219
. O 0 4.392768823890947e-05

The O 0 0.00010434120486024767
mutation O 0 6.356406811391935e-05
destroyed O 0 0.0006609249976463616
an O 0 1.1851714589283802e-05
NdeI O 0 0.05485057085752487
restriction O 0 7.296905823750421e-05
enzyme O 0 8.322251233039424e-05
site O 0 0.0002850868331734091
. O 0 7.670297782169655e-05

Analysis O 0 1.5970381355145946e-05
of O 0 1.0492894034541678e-05
all O 0 1.4197994460118935e-06
family O 0 1.098280563383014e-06
members O 0 1.678231313917422e-07
demonstrated O 0 8.867005476531631e-07
that O 0 7.316045724792275e-08
the O 0 4.406852838201303e-07
missense O 0 2.294918340339791e-05
mutation O 0 3.370597596585867e-06
co O 0 3.0170260288286954e-05
- O 0 6.76777635817416e-05
segregated O 0 0.0003211431030649692
with O 0 1.3338825510800234e-06
patients O 0 2.3850452635088004e-05
with O 0 1.2594784493558109e-05
tumors B-Disease 1 1.0
or O 0 1.1065430953749456e-05
who O 0 3.2727737107052235e-06
, O 0 3.501782259718311e-07
as O 0 2.711767308483104e-07
a O 0 2.388579503076471e-07
result O 0 2.3872954102444055e-07
of O 0 1.2836818541472894e-06
linkage O 0 5.412279278971255e-06
analysis O 0 5.088492116556154e-07
had O 0 1.126123947869928e-06
been O 0 3.670567139124614e-07
predicted O 0 5.186929001865792e-07
to O 0 1.7977406230329507e-07
carry O 0 6.774338316972717e-07
the O 0 2.1675887182937004e-06
predisposing O 0 0.000266646413365379
mutation O 0 3.985673174611293e-05
. O 0 2.8704980650218204e-05

These O 0 5.902409156988142e-06
observations O 0 1.0449463843542617e-05
point O 0 3.3051176160370233e-06
to O 0 2.3252160019637813e-07
another O 0 7.089107612046064e-07
region O 0 5.524479433915985e-07
of O 0 1.4482485539701884e-06
the O 0 1.8936776541522704e-05
RB1 O 1 0.9999731779098511
gene O 0 3.6333133266452933e-06
where O 0 6.080962862142769e-07
mutations O 0 2.33432544405332e-07
only O 0 6.922518736018901e-08
modify O 0 5.351737968339876e-07
the O 0 2.85562748558732e-07
function O 0 1.400425162501051e-07
of O 0 5.163465743862616e-07
the O 0 9.527225302008446e-07
gene O 0 6.380936952155025e-07
and O 0 1.7363474569265236e-07
raise O 0 3.182460375228402e-07
important O 0 1.9252981076078868e-07
questions O 0 2.6782373652167735e-07
for O 0 1.5293619526346447e-07
genetic O 0 2.619661700009601e-06
counseling O 0 3.283634441686445e-06
in O 0 3.349703092681011e-07
families O 0 1.1527550469736525e-07
with O 0 1.6242908884578355e-07
these O 0 5.07691197526583e-07
distinctive O 0 6.828389450674877e-05
phenotypes O 0 8.344263187609613e-05
. O 0 1.4419542821997311e-05
. O 0 6.037205457687378e-05

Maternal B-Disease 0 0.011111828498542309
disomy I-Disease 1 0.9884932637214661
and O 0 0.002598309190943837
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.24592502415180206
with O 0 2.9951499527669512e-05
gamete O 1 0.9740120768547058
complementation O 1 0.9998582601547241
in O 0 9.476115337747615e-06
a O 0 3.6565538721333724e-06
case O 0 2.617169457153068e-06
of O 0 9.595041774446145e-06
familial O 0 0.0003186890680808574
translocation O 0 0.00010159669909626245
( O 0 3.821633526968071e-06
3 O 0 4.143621936236741e-06
; O 0 2.575635846824298e-07
15 O 0 1.427068809789489e-06
) O 0 5.232807893662539e-07
( O 0 1.2262022437425912e-06
p25 O 0 0.0005203387117944658
; O 0 1.4308244544736226e-06
q11 O 0 0.00016536902694497257
. O 0 2.520411953810253e-06
2 O 0 1.1740447007468902e-05
) O 0 6.227980975381797e-06
. O 0 1.0963343811454251e-05

Maternal B-Disease 0 0.18853674829006195
uniparental I-Disease 1 0.9999445676803589
disomy I-Disease 1 0.9999560117721558
( I-Disease 0 0.0024744372349232435
UPD I-Disease 1 0.9999996423721313
) I-Disease 0 1.2073403922840953e-05
for I-Disease 0 2.4139974357240135e-06
chromosome I-Disease 0 5.47552326679579e-06
15 I-Disease 0 1.6056321783253225e-06
is O 0 1.5652774720820162e-07
responsible O 0 3.0648504889541073e-07
for O 0 1.1933194343782816e-07
an O 0 1.4367435596795985e-07
estimated O 0 3.212989838630165e-07
30 O 0 4.827870156987046e-07
% O 0 8.466131617979045e-08
of O 0 1.753281821947894e-07
cases O 0 4.649648133181472e-07
of O 0 8.716188312973827e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999992847442627
PWS B-Disease 1 1.0
) O 0 0.0026151263155043125
. O 0 0.0002786931290756911

We O 0 1.1026739230146632e-05
report O 0 2.1062091946078e-06
on O 0 1.0139539199371939e-06
an O 0 2.6931081720249495e-07
unusual O 0 8.52081257107784e-07
case O 0 9.352035021947813e-07
of O 0 3.89888919016812e-06
maternal B-Disease 0 8.927566523198038e-05
disomy I-Disease 1 0.6573951840400696
15 I-Disease 0 6.40187090539257e-06
in O 0 7.466999250027584e-06
PWS B-Disease 1 1.0
that O 0 6.731705184392922e-07
is O 0 1.6727202023503196e-07
most O 0 9.98224010118065e-08
consistent O 0 2.275636745707743e-07
with O 0 7.187401251940173e-08
adjacent O 0 8.913594683690462e-06
- O 0 7.88846500654472e-06
1 O 0 1.808907086342515e-06
segregation O 0 5.871017037861748e-06
of O 0 4.3649379222188145e-07
a O 0 6.04401236614649e-07
paternal O 0 5.809942649648292e-06
t O 0 7.967350938997697e-06
( O 0 3.5261146535958687e-07
3 O 0 5.897903179175046e-07
; O 0 1.0863846000574995e-07
15 O 0 5.658046120515792e-07
) O 0 2.5151146587631956e-07
( O 0 8.757544947002316e-07
p25 O 0 0.000259533611824736
; O 0 1.0895892046391964e-06
q11 O 0 7.959266076795757e-05
. O 0 8.942209888118668e-07
2 O 0 1.4053247241463396e-06
) O 0 1.4147549620702193e-07
with O 0 8.959174380152035e-08
simultaneous O 0 1.9589485873439116e-06
maternal O 0 4.4121483369963244e-05
meiotic O 0 0.015761686488986015
nondisjunction O 0 0.001447219867259264
for O 0 1.0863429452001583e-05
chromosome O 0 2.9749640816589817e-05
15 O 0 2.9486767743946984e-05
. O 0 2.078285069728736e-05

The O 0 0.00013615883653983474
patient O 0 0.0002576430852059275
( O 0 2.3593014702782966e-05
J O 1 0.9086570143699646
. O 0 4.042697128170403e-06
B O 0 0.00010146725253434852
. O 0 5.324461085365328e-07
) O 0 1.774140088173226e-07
, O 0 1.339354582796659e-07
a O 0 3.234371774851752e-07
17 O 0 1.6668997204760672e-06
- O 0 2.56986004387727e-06
year O 0 1.4030696320332936e-06
- O 0 1.2942809007654432e-05
old O 0 7.817235746188089e-05
white O 0 6.154483799036825e-06
male O 0 2.522564273021999e-06
with O 0 1.778717091838189e-06
PWS B-Disease 1 1.0
, O 0 3.267087959102355e-05
was O 0 5.720509943785146e-05
found O 0 4.628796546057856e-07
to O 0 5.76932777107686e-08
have O 0 3.6003473979917544e-08
47 O 0 7.650576208106941e-07
chromosomes O 0 1.5451009005573724e-07
with O 0 7.593624928858844e-08
a O 0 1.1364227248122916e-06
supernumerary O 0 0.016029370948672295
, O 0 2.322513182662078e-06
paternal O 0 2.3603795852977782e-05
der O 0 0.028716105967760086
( O 0 1.0956213145618676e-06
15 O 0 1.0984462051055743e-06
) O 0 1.2795625536909938e-07
consisting O 0 6.786883659515297e-07
of O 0 1.3450714959617471e-06
the O 0 3.011440867339843e-06
short O 0 1.0454277798999101e-05
arm O 0 0.02303268201649189
and O 0 1.6606750250502955e-06
the O 0 5.625743142445572e-06
proximal O 0 0.032897863537073135
long O 0 2.1146093786228448e-05
arm O 0 0.0006171200657263398
of O 0 1.381009496981278e-05
chromosome O 0 6.054943696653936e-06
15 O 0 3.7941758819215465e-06
, O 0 1.884466655610595e-06
and O 0 8.399641956202686e-06
distal O 1 0.5147624015808105
chromosome O 0 0.0012856463436037302
arm O 1 0.6681731343269348
3p O 1 0.9989915490150452
. O 0 0.0004327366186771542

The O 0 0.00012411028728820384
t O 0 0.00017631020455155522
( O 0 2.2728440853825305e-06
3 O 0 1.8871824067900889e-06
; O 0 1.5967023614393838e-07
15 O 0 5.068586688139476e-07
) O 0 1.437368553069973e-07
was O 0 1.1586664641072275e-06
present O 0 1.8089002651322517e-07
in O 0 2.271120678187799e-07
the O 0 3.279967870639666e-07
balanced O 0 4.674229785450734e-07
state O 0 2.8208003755025857e-07
in O 0 5.461216119329038e-07
the O 0 2.0222657894919394e-06
patients O 0 6.6254392550035845e-06
father O 0 2.342263724131044e-05
and O 0 3.5575990295910742e-06
a O 0 2.2238862584345043e-05
sister O 0 0.0018860668642446399
. O 0 5.5040909501258284e-05

Fluorescent O 0 0.0008849603473208845
in O 0 1.1678604096232448e-05
situ O 0 0.0001349703670712188
hybridization O 0 4.275145784049528e-06
analysis O 0 1.1818967777799116e-06
demonstrated O 0 2.829224285960663e-06
that O 0 3.0097328362899134e-07
the O 0 8.969584996521007e-06
PWS B-Disease 1 1.0
critical O 0 5.4594849643763155e-05
region O 0 2.615774747027899e-06
resided O 0 1.2979731764062308e-05
on O 0 9.185164913105837e-07
the O 0 3.607775624914211e-07
derivative O 0 4.3083509808639064e-06
chromosome O 0 1.8024287555817864e-06
3 O 0 6.740312983311014e-07
and O 0 1.3815157728913618e-07
that O 0 4.1746762491357003e-08
there O 0 1.0192177768431065e-07
was O 0 1.4755146366951521e-06
no O 0 1.9055681832469418e-07
deletion O 0 1.1540259947651066e-06
of O 0 1.642884058128402e-06
the O 0 1.8113540136255324e-05
PWS B-Disease 1 1.0
region O 0 7.081019248289522e-06
on O 0 1.689918235570076e-06
the O 0 1.0169695769945974e-06
normal O 0 5.73575789530878e-07
pair O 0 9.646075795899378e-07
of O 0 2.6169498141825898e-06
15s O 0 0.0005814146134071052
present O 0 1.92288716789335e-05
in O 0 4.302385059418157e-05
J O 1 0.998566210269928
. O 0 0.00011295753938611597

B O 0 0.18099522590637207
. O 0 0.001103295711800456

Methylation O 0 9.464457252761349e-05
analysis O 0 9.888058229989838e-06
at O 0 1.3707422112929635e-05
exon O 0 3.3132953831227496e-05
alpha O 0 1.0381712854723446e-05
of O 0 2.2986268959357403e-06
the O 0 1.1481266710688942e-06
small O 0 2.258690983580891e-06
nuclear O 0 4.585192436934449e-05
ribonucleoprotein O 0 0.00109947775490582
- O 0 1.5591167539241724e-05
associated O 0 4.132173671678174e-06
polypeptide O 0 1.4809838830842637e-05
N O 0 2.521584610803984e-05
( O 0 1.3451432323563495e-06
SNRPN O 1 0.7087822556495667
) O 0 7.771521381982893e-07
gene O 0 8.668683335599781e-07
showed O 0 5.128587758918002e-07
a O 0 2.886226297960093e-07
pattern O 0 1.074467036232818e-06
characteristic O 0 8.9643680212248e-07
of O 0 9.692874982647481e-07
only O 0 1.837884013866642e-07
the O 0 7.567857664980693e-07
maternal O 0 1.9551040168153122e-05
chromosome O 0 5.583208803727757e-06
15 O 0 7.429303423123201e-06
in O 0 1.3185926945880055e-05
J O 1 0.9279794692993164
. O 0 7.625836587976664e-05

B O 0 0.4140206277370453
. O 0 0.0005407692515291274

Maternal B-Disease 0 0.003421426983550191
disomy I-Disease 1 0.7452734708786011
was O 0 0.0002012597833527252
confirmed O 0 4.881258973910008e-06
by O 0 6.49861021884135e-07
polymerase O 0 1.0591115824354347e-05
chain O 0 2.449158500894555e-06
reaction O 0 3.614515264871443e-07
analysis O 0 2.8329807832960796e-07
of O 0 6.503477152364212e-07
microsatellite O 0 2.0422110537765548e-05
repeats O 0 2.7799426334240707e-06
at O 0 4.8151155169762205e-06
the O 0 1.438585172763851e-06
gamma O 0 1.4319589354272466e-05
- O 0 1.8357173757976852e-05
aminobutyric O 0 0.00013483325892593712
acid O 0 1.1603999155340716e-05
receptor O 0 6.884898539283313e-06
beta3 O 0 0.00010692110663512722
subunit O 0 1.743638676998671e-05
( O 0 7.4731970016728155e-06
GABRB3 O 1 0.7227970957756042
) O 0 1.6183646948775277e-05
locus O 0 0.00011785511742345989
. O 0 4.296194310882129e-05

A O 0 0.0005474805948324502
niece O 0 0.003628362435847521
( O 0 2.1314621335477568e-05
B O 0 0.00026162201538681984
. O 0 1.1971270623689634e-06
B O 0 2.2888161765877157e-05
. O 0 2.2779209984946647e-07
) O 0 1.117495287417114e-07
with O 0 6.602163438174102e-08
45 O 0 4.6413856580329593e-07
chromosomes O 0 2.2934061405521788e-07
and O 0 1.2447981134755537e-07
the O 0 2.4030654799389595e-07
derivative O 0 1.1762373333112919e-06
3 O 0 1.0401445251773112e-06
but O 0 1.1694206847323585e-07
without O 0 9.733719963378462e-08
the O 0 4.405449089972535e-07
der O 0 0.0030581725295633078
( O 0 5.273320766718825e-07
15 O 0 7.268455988196365e-07
) O 0 2.1024332852448424e-07
demonstrated O 0 8.466606686852174e-07
a O 0 5.0998016831727e-07
phenotype O 0 1.2566379155032337e-06
consistent O 0 5.067633992439369e-07
with O 0 1.1440788227901066e-07
that O 0 1.0080661638767197e-07
reported O 0 7.627220384165412e-07
for O 0 7.44165276955755e-07
haploinsufficiency O 0 0.0007985194679349661
of O 0 3.221325096092187e-05
distal O 0 0.002699898323044181
3 O 0 0.00014775108138564974
p O 0 0.000276122591458261
. O 0 4.571657700580545e-05

Uniparental B-Disease 1 0.999998927116394
disomy I-Disease 1 0.9999648332595825
associated O 0 7.919050403870642e-05
with O 0 4.309904397814535e-06
unbalanced O 0 7.737162377452478e-05
segregation O 0 0.0006955514545552433
of O 0 5.494871220435016e-05
non O 0 0.0003471086092758924
- O 0 0.0010407090885564685
Robertsonian O 1 0.9397891759872437
translocations O 0 2.273617974424269e-05
has O 0 6.671614869446785e-07
been O 0 3.980990186391864e-07
reported O 0 4.539249971458048e-07
previously O 0 1.035544187288906e-06
but O 0 8.569065812480403e-08
has O 0 8.435056031430577e-08
not O 0 3.507694046334109e-08
, O 0 6.904967619902891e-08
to O 0 6.208194491819086e-08
our O 0 2.9979591431583685e-07
knowledge O 0 2.144297695849673e-06
, O 0 3.0378603810277127e-07
been O 0 1.2774057722708676e-07
observed O 0 1.647498777401779e-07
in O 0 1.9615680457718554e-07
a O 0 9.465261427976657e-07
case O 0 3.4803886137524387e-06
of O 0 0.00017555916565470397
PWS B-Disease 1 1.0
. O 0 0.0004377775767352432

Furthermore O 0 0.00045040162513032556
, O 0 1.3421137737168465e-05
our O 0 1.5789643157404498e-06
findings O 0 8.313004968840687e-07
are O 0 6.980380362620053e-08
best O 0 4.20102765019692e-07
interpreted O 0 4.53263140798299e-07
as O 0 8.884510407369817e-07
true O 0 4.028926014143508e-06
gamete O 0 0.00014000176452100277
complementation O 0 0.0654386654496193
resulting O 0 3.318418384878896e-05
in O 0 1.6940353816607967e-05
maternal B-Disease 0 0.06015334650874138
UPD I-Disease 1 0.9999997615814209
15 I-Disease 0 0.0009299066150560975
and O 0 0.0005045397556386888
PWS B-Disease 1 0.9999992847442627

Schwartz B-Disease 1 0.9836795926094055
- I-Disease 1 0.9966081380844116
Jampel I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999960660934448
type I-Disease 0 0.0014959743712097406
2 I-Disease 0 0.00018123550398740917
and O 0 2.460398718540091e-05
Stuve B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999947547912598
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999985694885254
: O 0 4.480060397327179e-06
a O 0 2.8488077532529132e-06
case O 0 3.6852500215900363e-06
for O 0 2.946436779893702e-06
" O 0 2.1905410903855227e-05
lumping O 0 0.00024628874962218106
" O 0 4.760895171784796e-05
. O 0 2.656053584360052e-05

Recent O 0 2.8435057174647227e-05
studies O 0 6.9433854150702246e-06
demonstrated O 0 3.970665147789987e-06
the O 0 6.669541221526742e-07
existence O 0 1.8829252894647652e-06
of O 0 1.0038103255283204e-06
a O 0 1.702328063402092e-06
genetically O 0 5.48988191440003e-06
distinct O 0 4.0284086821884557e-07
, O 0 2.1051056364740361e-07
usually O 0 7.636967325197475e-08
lethal O 0 5.432049761111557e-07
form O 0 1.7578105371285346e-07
of O 0 1.362137027172139e-06
the O 0 1.0883796676353086e-05
Schwartz B-Disease 1 0.9997254014015198
- I-Disease 1 0.999936580657959
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.00043237622594460845
SJS B-Disease 1 0.9999998807907104
) O 0 4.913100838166429e-06
of O 0 0.00013203870912548155
myotonia B-Disease 1 0.9999998807907104
and O 1 0.5997946262359619
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.766429133771453e-05
which O 0 2.9845136850781273e-06
we O 0 2.0445197606022703e-06
called O 0 3.401732465135865e-05
SJS B-Disease 1 0.9999823570251465
type I-Disease 0 0.00041218745172955096
2 I-Disease 0 0.00018974184058606625
. O 0 7.133108010748401e-05

This O 0 0.00025297972024418414
disorder O 1 0.998767614364624
is O 0 6.70136478220229e-06
reminiscent O 0 0.001480495324358344
of O 0 0.00018577634182292968
another O 0 0.00016264595615211874
rare O 0 0.00012848744518123567
condition O 0 0.00020565003796946257
, O 0 1.872485540843627e-06
the O 0 1.648435318202246e-05
Stuve B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999942779541016
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.014315982349216938
SWS B-Disease 1 0.9999998807907104
) O 0 8.961376806837507e-06
, O 0 1.4210633025868447e-06
which O 0 4.745126886973594e-07
comprises O 0 7.617351002409123e-06
campomelia B-Disease 0 0.054209545254707336
at O 0 0.00012128207890782505
birth O 0 0.0001340426824754104
with O 0 2.2552025257027708e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.08660230040550232
contractures B-Disease 1 0.9999996423721313
, O 0 1.328340295003727e-05
and O 0 5.745416274294257e-06
early B-Disease 0 5.171490556676872e-05
death I-Disease 0 0.0003018938878085464
. O 0 6.627834954997525e-05

To O 0 1.2884214811492711e-05
test O 0 1.0920601198449731e-05
for O 0 8.052776934164285e-07
possible O 0 1.4822477396592149e-06
nosologic O 0 0.20830699801445007
identity O 0 2.634390511957463e-06
between O 0 6.632131430706067e-07
these O 0 1.6074078530436964e-06
disorders O 1 0.9995710253715515
, O 0 1.2206625115140923e-06
we O 0 9.553723145927506e-08
reviewed O 0 2.3267266158200073e-07
the O 0 1.8966804304909601e-07
literature O 0 3.570967805899272e-07
and O 0 6.487866244242468e-08
obtained O 0 2.1856655507690448e-07
a O 0 1.9911020388008183e-07
follow O 0 1.366015851544944e-07
- O 0 1.6958724700089078e-06
up O 0 5.366497362047085e-07
of O 0 4.3969117768938304e-07
the O 0 2.8818146802223055e-07
only O 0 1.4494821698463056e-07
two O 0 1.341011000022263e-07
surviving O 0 6.707682769047096e-05
patients O 0 3.365044449310517e-06
, O 0 4.128398245484277e-07
one O 0 3.949652125356806e-07
with O 0 7.783433488839364e-07
SJS B-Disease 1 0.9999740123748779
type I-Disease 0 1.2852012332587037e-05
2 I-Disease 0 2.7866688014910324e-06
at O 0 4.10105349146761e-06
age O 0 1.2382261047605425e-06
10 O 0 2.041531530494467e-07
years O 0 2.018345526266785e-07
and O 0 1.171270227473542e-07
another O 0 8.024871362977137e-07
with O 0 7.165787110352539e-07
SWS B-Disease 1 0.9986385703086853
at O 0 3.6020435800310224e-05
age O 0 1.2139930731791537e-05
7 O 0 1.0388823284301907e-05
years O 0 1.0056020073534455e-05
. O 0 1.6590016457485035e-05

Patients O 0 0.0008837254717946053
reported O 0 2.4642919015605003e-05
as O 0 4.24931795350858e-06
having O 0 6.959295660635689e-06
either O 0 3.97001022065524e-05
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.0006447274936363101
SWS B-Disease 1 0.9999558925628662
presented O 0 1.181604056910146e-05
a O 0 2.7313942609907826e-06
combination O 0 8.670546776556876e-06
of O 0 1.9184637494618073e-05
a O 0 5.7697081501828507e-05
severe O 1 0.998333752155304
, O 0 0.00010175909119425341
prenatal O 1 0.999991774559021
- O 1 0.9999905824661255
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999611377716064
with O 1 0.9999938011169434
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999998807907104
respiratory O 1 1.0
and O 0 0.21042762696743011
feeding O 1 0.9855313301086426
difficulties O 1 0.5486942529678345
, O 0 1.6210909961955622e-05
tendency O 0 9.269738256989513e-06
to O 0 3.480477971606888e-06
hyperthermia B-Disease 1 0.9999828338623047
, O 0 4.038373845105525e-06
and O 0 7.784539093336207e-07
frequent O 0 1.4807374100200832e-06
death O 0 5.416094609245192e-06
in O 0 1.0786249049488106e-06
infancy O 0 0.00032723654294386506
) O 0 7.713779837104084e-07
with O 0 3.5757656746682187e-07
a O 0 1.774835027390509e-06
distinct O 0 1.1094372894149274e-05
campomelic B-Disease 1 0.999994158744812
- I-Disease 1 0.9999946355819702
metaphyseal I-Disease 1 0.9999998807907104
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.002306083682924509

The O 0 3.177551116095856e-05
similarity O 0 2.2316473405226134e-05
of O 0 9.649751518736593e-06
the O 0 9.856960787146818e-06
clinical O 0 0.001760970102623105
and O 0 5.1730307859543245e-06
radiographic O 0 0.21696670353412628
findings O 0 6.381439106917242e-06
is O 0 3.964161692238122e-07
so O 0 1.2333923393725854e-07
extensive O 0 1.0771365168693592e-06
that O 0 1.1719506431973059e-07
these O 0 6.99880388310703e-07
disorders O 1 0.9986814856529236
appear O 0 1.4617386341342353e-06
to O 0 3.1834500191507686e-07
be O 0 5.985904181216029e-07
a O 0 1.9714186691999203e-06
single O 0 5.387688815972069e-06
entity O 0 4.351766256149858e-05
. O 0 3.434832615312189e-05

The O 0 2.73905443464173e-05
follow O 0 4.178438757662661e-06
- O 0 1.2414764569257386e-05
up O 0 2.99125576930237e-06
observation O 0 8.083175998763181e-06
of O 0 8.653122449686634e-07
an O 0 3.0941481554691563e-07
identical O 0 9.81057496574067e-07
and O 0 3.2971982477647543e-07
unique O 0 7.43665793834225e-07
pattern O 0 4.921598247165093e-06
of O 0 0.0012246828991919756
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 6.363147804222535e-06
the O 0 2.444123083478189e-06
two O 0 8.629799594928045e-07
patients O 0 5.794057415187126e-06
( O 0 6.449919283113559e-07
one O 0 6.717768883390818e-07
with O 0 1.7360340507366345e-06
SJS B-Disease 1 0.9999960660934448
type I-Disease 0 7.768708746880293e-05
2 I-Disease 0 7.277901204361115e-06
, O 0 6.350159083012841e-07
one O 0 2.8275636054786446e-07
with O 0 6.130170504548005e-07
SWS B-Disease 1 0.9999879598617554
) O 0 2.335742692594067e-06
surviving O 0 2.7306878109811805e-05
beyond O 0 1.0891792044276372e-05
infancy O 0 4.228666875860654e-05
adds O 0 4.2775087649715715e-07
to O 0 9.94339899307306e-08
the O 0 1.9423941921559162e-07
evidence O 0 5.671449230248982e-07
in O 0 1.2614823674539366e-07
favor O 0 5.590234763985791e-07
of O 0 2.3130348836275516e-06
identity O 0 1.3513701560441405e-05
. O 0 2.442793811496813e-05

The O 0 8.645230991533026e-05
hypothesis O 0 6.27107365289703e-05
that O 0 5.925781806581654e-06
SWS B-Disease 1 0.9996540546417236
and O 0 3.254565308452584e-05
SJS B-Disease 1 0.9999959468841553
type I-Disease 0 5.519944170373492e-05
2 I-Disease 0 2.4260239115392324e-06
are O 0 5.748238507408132e-08
the O 0 4.529412080955808e-07
same O 0 1.6966456541922526e-06
disorder O 0 0.059531934559345245
should O 0 1.8647622823664278e-07
be O 0 1.4719304886057216e-07
testable O 0 3.4020615657937014e-06
by O 0 2.6020529730885755e-07
molecular O 0 3.7725383208453422e-06
methods O 0 4.384389285405632e-06
. O 0 5.701971986127319e-06
. O 0 1.3774935723631643e-05

A O 0 0.0004982183454558253
mouse O 0 0.00013063731603324413
model O 0 2.0417533960426226e-05
of O 0 0.00010473396105226129
severe O 1 0.9999985694885254
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9988667964935303
defects O 1 1.0
in O 0 0.14918813109397888
hemostasis O 1 0.9999996423721313
and O 0 0.4833729565143585
thrombosis B-Disease 1 0.9999995231628418
. O 0 0.0017037278739735484

von B-Disease 1 0.9997363686561584
Willebrand I-Disease 1 0.9999973773956299
factor I-Disease 0 0.03405291214585304
( I-Disease 0 0.004364169668406248
vWf I-Disease 1 0.9999939203262329
) I-Disease 1 0.9870985150337219
deficiency I-Disease 1 1.0
causes O 1 0.9999990463256836
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.024242406710982323
humans O 0 0.0003488943330012262
. O 0 7.381942123174667e-05

We O 0 5.879656328033889e-06
generated O 0 3.915421984856948e-06
a O 0 2.300412006661645e-06
mouse O 0 2.372547669438063e-06
model O 0 2.895705222272227e-07
for O 0 1.4139915549549187e-07
this O 0 6.035764386069786e-07
disease O 0 2.2489137336378917e-05
by O 0 2.1406107464372326e-07
using O 0 2.5452116005908465e-06
gene O 0 8.302115929836873e-06
targeting O 0 1.2144747415732127e-05
. O 0 1.4726055269420613e-05

vWf B-Disease 1 0.9675264358520508
- I-Disease 1 0.7127622961997986
deficient I-Disease 1 0.8660810589790344
mice O 0 9.277981735067442e-05
appeared O 0 6.578307875315659e-06
normal O 0 1.539334107292234e-06
at O 0 3.6497531255008653e-06
birth O 0 3.296621343906736e-06
; O 0 9.856314164835567e-08
they O 0 6.965922949575543e-08
were O 0 4.970474947185721e-07
viable O 0 8.932775017456152e-06
and O 0 5.8657224144553766e-06
fertile O 0 0.00037273412453942
. O 0 5.719882756238803e-05

Neither O 0 0.0019842006731778383
vWf O 0 0.009017342701554298
nor O 0 0.00029180929413996637
vWf O 0 0.004362117033451796
propolypeptide O 0 0.011407831683754921
( O 0 5.494782089954242e-05
von B-Disease 1 0.9794735312461853
Willebrand I-Disease 1 0.9999985694885254
antigen O 1 0.7141153812408447
II O 1 0.9999994039535522
) O 0 2.38508869188081e-06
were O 0 6.004709121043561e-07
detectable O 0 4.933421678288141e-06
in O 0 2.7883226039193687e-07
plasma O 0 1.651702041272074e-05
, O 0 2.006237309615244e-06
platelets O 0 5.67901115573477e-05
, O 0 1.369491087643837e-06
or O 0 2.1012356228311546e-06
endothelial O 0 5.951791536062956e-05
cells O 0 7.274829272319039e-07
of O 0 5.903834221498983e-07
the O 0 1.6314926369886962e-06
homozygous O 0 1.8473290765541606e-05
mutant O 0 8.797789632808417e-05
mice O 0 6.539369496749714e-05
. O 0 4.072703450219706e-05

The O 0 0.00014950160402804613
mutant O 0 0.0019837222062051296
mice O 0 0.0005114117520861328
exhibited O 0 0.015874745324254036
defects O 1 0.9973956346511841
in O 0 2.9983677450218238e-05
hemostasis O 1 0.9972213506698608
with O 0 5.248488378128968e-06
a O 0 2.690425571927335e-05
highly O 0 0.08310446888208389
prolonged O 1 0.9999762773513794
bleeding O 1 0.9998893737792969
time O 0 2.529202902223915e-06
and O 0 2.201519691880094e-06
spontaneous O 0 6.640417996095493e-05
bleeding O 0 0.002505881479009986
events O 0 6.563391252711881e-07
in O 0 4.992460844732705e-07
approximately O 0 1.8547005993241328e-06
10 O 0 1.5965957800290198e-06
% O 0 1.0449427918501897e-06
of O 0 1.248580065293936e-05
neonates O 0 0.0005859457887709141
. O 0 8.74172619660385e-05

As O 0 3.385583113413304e-05
in O 0 4.652958068618318e-06
the O 0 4.406740572449053e-06
human O 0 2.027787922997959e-05
disease O 0 0.3480486273765564
, O 0 6.349837917696277e-07
the O 0 1.3421372386801522e-06
factor O 0 1.4434374861593824e-05
VIII O 1 0.999991774559021
level O 0 4.034216544823721e-06
in O 0 2.131740757249645e-07
these O 0 8.891590397297477e-08
mice O 0 2.510894773877226e-06
was O 0 2.8358047075016657e-06
reduced O 0 4.07025794402216e-07
strongly O 0 2.150462989902735e-07
as O 0 1.1933603616398614e-07
a O 0 3.060910103158676e-07
result O 0 2.8618052283491124e-07
of O 0 7.500490823986183e-07
the O 0 8.315589639096288e-07
lack O 0 2.0240679532435024e-06
of O 0 6.337094873742899e-06
protection O 0 2.788572783174459e-05
provided O 0 5.285855877446011e-06
by O 0 1.742554741213098e-05
vWf O 0 0.016320964321494102
. O 0 8.995863754535094e-05

Defective O 1 0.9999940395355225
thrombosis B-Disease 1 0.9999449253082275
in O 0 7.698500849073753e-05
mutant O 0 0.0018198738107457757
mice O 0 6.172719440655783e-05
was O 0 1.3209274584369268e-05
also O 0 6.572285542461032e-07
evident O 0 2.1561379526247038e-06
in O 0 2.514688048904645e-07
an O 0 1.9635220382951957e-07
in O 0 7.151382419579022e-07
vivo O 0 1.8518057913752273e-05
model O 0 1.1352386536600534e-05
of O 0 0.004512143786996603
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999996423721313
. O 0 0.0005957399844191968

In O 0 2.1274780010571703e-05
this O 0 1.599604274815647e-06
model O 0 5.157140549272299e-06
, O 0 1.6643471099087037e-06
the O 0 4.61020135844592e-06
exteriorized O 0 0.045842114835977554
mesentery O 0 0.20026306807994843
was O 0 0.0002303779765497893
superfused O 0 0.0072272950783371925
with O 0 5.4411466408055276e-06
ferric O 1 0.992767333984375
chloride O 0 0.00011813968740170822
and O 0 4.928812813886907e-06
the O 0 4.275945229892386e-06
accumulation O 0 8.580298162996769e-05
of O 0 4.806660217582248e-05
fluorescently O 1 0.9432649612426758
labeled O 0 0.00029645327595062554
platelets O 0 0.00013301832950673997
was O 0 1.8434257071930915e-05
observed O 0 2.5065091904252768e-06
by O 0 2.455278490742785e-06
intravital O 0 0.0005540905403904617
microscopy O 0 0.000439707946497947
. O 0 8.370897558052093e-05

We O 0 1.7929716705111787e-05
conclude O 0 2.020475767494645e-05
that O 0 7.408428928101785e-07
these O 0 4.738881500543357e-07
mice O 0 1.8222970538772643e-05
very O 0 7.357564868470945e-07
closely O 0 2.6730983790912433e-06
mimic O 0 0.016477374359965324
severe O 1 0.8635194897651672
human O 0 0.1784517616033554
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.0224270226899534e-05
will O 0 5.406344030234322e-07
be O 0 7.679049218722866e-08
very O 0 6.964394572150923e-08
useful O 0 1.6378892553348123e-07
for O 0 7.916810318420175e-08
investigating O 0 8.763075243223284e-07
the O 0 5.722857849832508e-07
role O 0 1.1233640861973981e-06
of O 0 4.935869128530612e-06
vWf O 0 0.0002171452943002805
in O 0 1.2977908454558928e-06
normal O 0 1.671976747275039e-06
physiology O 0 3.521549660945311e-05
and O 0 1.0311705409549177e-06
in O 0 4.5946590034873225e-06
disease O 0 0.010902867652475834
models O 0 1.380477533530211e-05
. O 0 7.825927241356112e-06
. O 0 2.42680252995342e-05

Oral O 0 0.05946062132716179
contraceptives O 0 0.005456734914332628
and O 0 8.994426934805233e-06
the O 0 1.3555740224546753e-05
risk O 0 0.00022101879585534334
of O 1 0.9861478805541992
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.010523236356675625

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999276399612427
Study O 0 0.006721556186676025
Group O 0 0.0005778036429546773
. O 0 0.00013689462502952665

BACKGROUND O 0 0.0006308465381152928
Women O 0 1.2656432772928383e-05
with O 0 1.7930711919689202e-06
mutations O 0 1.7047748315235367e-06
in O 0 8.978929599834373e-07
either O 0 1.6636741975162295e-06
the O 0 6.726489118591417e-06
BRCA1 O 0 0.0002845746639650315
or O 0 2.3249838250194443e-06
the O 0 4.943788098898949e-06
BRCA2 O 0 0.00013680485426448286
gene O 0 1.5112775599845918e-06
have O 0 8.771756654368801e-08
a O 0 4.429200259892241e-07
high O 0 1.3570124792749994e-05
lifetime O 0 7.685393211431801e-05
risk O 0 4.546406853478402e-05
of O 1 0.9223851561546326
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002925485896412283

Oral O 1 0.5056003928184509
contraceptives O 1 0.9003499150276184
protect O 0 0.024273553863167763
against O 1 0.999980092048645
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.673138159385417e-06
general O 0 8.01556325313868e-06
, O 0 4.5470662257685035e-07
but O 0 8.105325122187423e-08
it O 0 3.527620862087133e-08
is O 0 2.470999582726563e-08
not O 0 2.2321875903230648e-08
known O 0 1.89800871908119e-07
whether O 0 1.315325448558724e-07
they O 0 1.1761639484575426e-07
also O 0 2.958991558443813e-07
protect O 0 2.15798536373768e-06
against O 0 9.401967872690875e-06
hereditary B-Disease 1 0.9986945986747742
forms I-Disease 0 0.0055923317559063435
of I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00048643251648172736

METHODS O 0 0.00020519265672191978
We O 0 7.333142093557399e-06
enrolled O 0 5.7405322877457365e-05
207 O 0 4.000711123808287e-05
women O 0 4.27186887463904e-06
with O 0 2.3580800188938156e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5944951883284375e-05
161 O 0 2.653524097695481e-05
of O 0 4.510804046731209e-06
their O 0 1.6663004771544365e-06
sisters O 0 2.9061202440061606e-05
as O 0 6.049450576028903e-07
controls O 0 1.3022068969803513e-06
in O 0 3.6584197005140595e-07
a O 0 9.59471663009026e-07
case O 0 4.10459824706777e-06
- O 0 4.2295665480196476e-05
control O 0 1.5157728739723098e-05
study O 0 2.1715593902627006e-05
. O 0 1.949600118678063e-05

All O 0 3.59180812665727e-05
the O 0 2.9396862373687327e-05
patients O 0 9.39207438932499e-06
carried O 0 2.777330109893228e-06
a O 0 1.9603314740379574e-06
pathogenic O 0 7.4116833275184035e-06
mutation O 0 1.7592320773474057e-06
in O 0 5.623279548672144e-07
either O 0 2.022800117629231e-06
BRCA1 O 0 5.186029738979414e-05
( O 0 1.3424394182948163e-06
179 O 0 9.079401024791878e-06
women O 0 1.4700874544359976e-06
) O 0 1.1122425576104433e-06
or O 0 3.523879513522843e-06
BRCA2 O 0 0.0002032071352005005
( O 0 3.914380158676067e-06
28 O 0 2.0029523511766456e-05
women O 0 4.799916951014893e-06
) O 0 8.895609425962903e-06
. O 0 3.197680780431256e-05

The O 0 4.863734284299426e-05
control O 0 1.6787780623417348e-05
women O 0 1.4758298902961542e-06
were O 0 8.622774885225226e-07
enrolled O 0 3.4567008242447628e-06
regardless O 0 6.414090876205591e-07
of O 0 9.347550644633884e-07
whether O 0 3.4246781410729454e-07
or O 0 6.657257358710922e-07
not O 0 8.829684361444379e-08
they O 0 9.183765570242031e-08
had O 0 2.0314898847573204e-06
either O 0 4.784136308444431e-06
mutation O 0 8.52732773637399e-06
. O 0 1.4507128980767448e-05

Lifetime O 0 0.00028067489620298147
histories O 0 1.9205797798349522e-05
of O 0 1.4645497685705777e-05
oral O 0 0.005818469449877739
- O 0 0.00023668646463193
contraceptive O 0 0.00011877075303345919
use O 0 7.882800332481565e-07
were O 0 4.4541283727994596e-07
obtained O 0 1.0275971362716518e-06
by O 0 7.473643108824035e-07
interview O 0 2.8938216019014362e-06
or O 0 3.8248538203333737e-07
by O 0 1.1631743035422915e-07
written O 0 1.688690787204905e-07
questionnaire O 0 6.271342840591387e-07
and O 0 1.9578507703954529e-07
were O 0 5.791151238554448e-07
compared O 0 2.5045330858119996e-06
between O 0 9.614822147341329e-07
patients O 0 1.6361170764866984e-06
and O 0 5.772937470283068e-07
control O 0 4.365372660686262e-06
women O 0 5.786354222436785e-07
, O 0 3.455605792623828e-07
after O 0 7.103014922904549e-07
adjustment O 0 1.153017137767165e-06
for O 0 1.8634361254044052e-07
year O 0 9.385370844938734e-07
of O 0 1.7233443259101477e-06
birth O 0 3.066831050091423e-05
and O 0 6.8925060077162925e-06
parity O 0 0.0004639082762878388
. O 0 4.85860655317083e-05

RESULTS O 0 0.00017597715486772358
The O 0 2.5856061256490648e-05
adjusted O 0 3.902552998624742e-05
odds O 0 2.4867000320227817e-05
ratio O 0 7.373470907623414e-06
for O 0 0.0001563835539855063
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.8183245629188605e-06
with O 0 1.9272030726824596e-07
any O 0 1.8542270652233128e-07
past O 0 4.1506476122776803e-07
use O 0 1.8906577281541104e-07
of O 0 1.1567894944164436e-06
oral O 0 0.00014028708392288536
contraceptives O 0 0.0267070010304451
was O 0 0.0005314936861395836
0 O 0 6.251811282709241e-05
. O 0 1.7602926163817756e-05

5 O 0 6.928780931048095e-05
( O 0 3.961119091400178e-06
95 O 0 6.813805157435127e-06
percent O 0 1.645336396904895e-06
confidence O 0 1.5000289295130642e-06
interval O 0 9.331277510682412e-07
, O 0 2.22037485286819e-07
0 O 0 2.1125366345131624e-07
. O 0 4.118295393595872e-08
3 O 0 1.8476886509688484e-07
to O 0 5.8423022863962615e-08
0 O 0 9.245637784260907e-07
. O 0 4.1420707930228673e-07
8 O 0 7.114565505617065e-06
) O 0 4.462374363356503e-06
. O 0 1.1399426512070931e-05

The O 0 0.0002056621597148478
risk O 0 6.779235991416499e-05
decreased O 0 1.3765140465693548e-05
with O 0 2.466430544245668e-07
increasing O 0 2.9138084300939227e-07
duration O 0 4.926566816720879e-07
of O 0 2.705188251184154e-07
use O 0 4.4032481127942447e-07
( O 0 6.265059937504702e-07
P O 0 4.182932570984121e-06
for O 0 1.9287217867258732e-07
trend O 0 7.59279032536142e-07
, O 0 1.281246397866198e-07
< O 0 1.0187546877205023e-06
0 O 0 2.0333280303930223e-07
. O 0 5.8326381946471884e-08
001 O 0 4.831089427170809e-06
) O 0 7.925845579848101e-08
; O 0 1.2033987140114277e-08
use O 0 2.2029018609259765e-08
for O 0 3.288430150405475e-08
six O 0 8.407845797364644e-08
or O 0 8.613915980504316e-08
more O 0 3.290538330702475e-08
years O 0 8.529129900125554e-07
was O 0 4.699399596574949e-06
associated O 0 2.3161376816460688e-07
with O 0 1.0084104218321954e-07
a O 0 6.08465825280291e-07
60 O 0 1.4723491403856315e-06
percent O 0 1.982014964596601e-06
reduction O 0 3.5252812722319504e-06
in O 0 4.007573352282634e-06
risk O 0 2.401519668637775e-05
. O 0 3.172518700012006e-05

Oral O 0 0.13639730215072632
- O 0 0.0014492092886939645
contraceptive O 0 0.0015930479858070612
use O 0 1.7474156265961938e-05
protected O 0 0.0035553660709410906
against O 1 0.9990979433059692
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 5.869599704055872e-07
for O 0 3.095452711932012e-07
carriers O 0 4.5656773295377207e-07
of O 0 1.0436242519062944e-06
the O 0 3.7329136830521747e-06
BRCA1 O 0 5.3680603741668165e-05
mutation O 0 8.384263310290407e-07
( O 0 4.565907829601201e-07
odds O 0 1.4936878187654656e-06
ratio O 0 2.908497265252663e-07
, O 0 1.1149765555273916e-07
0 O 0 1.720843272323691e-07
. O 0 3.123802727600378e-08
5 O 0 9.667039790883791e-08
; O 0 4.2395281951712604e-08
95 O 0 8.518424010617309e-07
percent O 0 6.521289037664246e-07
confidence O 0 7.311804210985429e-07
interval O 0 1.2194234386697644e-06
, O 0 2.9887698360653303e-07
0 O 0 2.2575011371372966e-07
. O 0 3.792084868337042e-08
3 O 0 9.544379508952261e-08
to O 0 5.522052148876355e-08
0 O 0 2.939752334896184e-07
. O 0 9.106406650971621e-08
9 O 0 6.070012545933423e-07
) O 0 4.7792386936862385e-08
and O 0 2.466248538723903e-08
for O 0 4.385148599794775e-08
carriers O 0 2.1457205434671778e-07
of O 0 6.593442094526836e-07
the O 0 3.6425344660528935e-06
BRCA2 O 0 8.745844388613477e-05
mutation O 0 1.556374627398327e-06
( O 0 3.8464645513158757e-07
odds O 0 2.423353180347476e-06
ratio O 0 9.92515879261191e-07
, O 0 2.968884587062348e-07
0 O 0 2.7934302693211066e-07
. O 0 4.2949139356096566e-08
4 O 0 2.8323216838543885e-07
; O 0 5.2784226767244036e-08
95 O 0 7.138149840102415e-07
percent O 0 5.098333417663525e-07
confidence O 0 4.576876619921677e-07
interval O 0 8.318897357639798e-07
, O 0 1.304589289929936e-07
0 O 0 2.1391822713212605e-07
. O 0 7.279993496922543e-08
2 O 0 2.0968846570212918e-07
to O 0 1.2191601683753106e-07
1 O 0 1.2512721241364488e-06
. O 0 4.523485301888286e-07
1 O 0 4.004035872640088e-06
) O 0 3.2487109820067417e-06
. O 0 8.974317097454332e-06

CONCLUSIONS O 0 0.0005351683357730508
Oral O 0 0.06153573840856552
- O 0 0.0006721254321746528
contraceptive O 0 0.0011844875989481807
use O 0 5.02564125781646e-06
may O 0 1.4959488225940731e-06
reduce O 0 1.5267373782990035e-06
the O 0 1.6681258330208948e-06
risk O 0 1.3529498573916499e-05
of O 1 0.8883964419364929
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.555977516749408e-06
women O 0 2.332634210233664e-07
with O 0 1.1772266361731454e-07
pathogenic O 0 4.000100943812868e-06
mutations O 0 7.825889269952313e-07
in O 0 8.495270549246925e-07
the O 0 1.9011524273082614e-05
BRCA1 O 0 0.1446913182735443
or O 0 0.0001543068647151813
BRCA2 O 0 0.13478273153305054
gene O 0 0.0006877819541841745

A O 0 0.00047364432248286903
Japanese O 0 0.0004566017887555063
family O 0 3.264104088884778e-05
with O 0 1.9285304006189108e-05
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.265171123231994e-06
a O 0 1.1091854503320064e-05
codon O 0 4.194996290607378e-05
291 O 0 3.98403535655234e-05
deletion O 0 1.5982768672984093e-05
: O 0 1.2441066701285308e-06
a O 0 2.553231979618431e-06
clinical O 0 0.0001571417087689042
, O 0 2.2384051590051968e-06
biochemical O 0 0.0013497374020516872
, O 0 1.1520924999786075e-05
pathological O 0 0.40616467595100403
, O 0 4.225089014653349e-06
and O 0 6.104720796429319e-06
genetic O 0 9.438661800231785e-05
report O 0 2.0380301066325046e-05
. O 0 5.070580300525762e-05

We O 0 1.3029052752244752e-05
report O 0 3.198216518285335e-06
a O 0 2.128446794813499e-06
Japanese O 0 3.456275589996949e-05
family O 0 1.0026315976574551e-05
with O 0 2.195403430960141e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9994264841079712
ALD B-Disease 1 1.0
) O 0 7.146758434828371e-06
with O 0 5.95923609125748e-07
a O 0 6.73212241508736e-07
three O 0 5.397379823079973e-07
base O 0 7.96607491793111e-06
pair O 0 5.2438208513194695e-06
deletion O 0 1.3397097973211203e-05
( O 0 4.639098733605351e-06
delGAG O 0 0.0005981879658065736
291 O 0 3.9546761399833485e-05
) O 0 1.6014969332900364e-06
in O 0 3.1585097985953325e-06
the O 0 9.569419489707798e-05
ALD B-Disease 1 1.0
gene O 0 0.0018581215990707278
. O 0 0.0001740648440318182

A O 0 0.00018802171689458191
variety O 0 9.490828233538195e-06
of O 0 1.0258864676870871e-05
phenotypes O 0 2.344764470763039e-05
were O 0 2.1720959466620116e-06
observed O 0 1.6357801086996915e-06
within O 0 9.325895575784671e-07
this O 0 4.2235276964674995e-07
family O 0 2.0374451196403243e-05
. O 0 3.42714338330552e-05

While O 0 4.473027365747839e-05
the O 0 1.1883255865541287e-05
proband O 1 0.5285142660140991
( O 0 9.965829121938441e-06
patient O 0 2.4044000383582897e-05
1 O 0 9.864145795290824e-06
) O 0 8.055457669797761e-07
was O 0 7.421754617098486e-06
classified O 0 1.4153476968203904e-06
as O 0 2.745012466220942e-07
having O 0 5.899568122913479e-07
a O 0 2.8552028652484296e-07
rare O 0 1.1409075568735716e-06
intermediate O 0 8.42483223095769e-06
type O 0 4.167165116086835e-06
of O 0 1.0985951121256221e-05
adult O 0 1.8735854609985836e-05
cerebral O 0 0.001462078420445323
and O 0 9.781877452041954e-06
cerebello O 1 0.9999977350234985
- O 1 0.9985418319702148
brain O 0 0.47956597805023193
stem O 0 8.97985682968283e-06
forms O 0 1.48946173794684e-06
, O 0 8.13437793567573e-07
his O 0 8.249286111094989e-06
younger O 0 3.108346936642192e-05
brother O 0 0.0013159159570932388
( O 0 4.157855983066838e-06
patient O 0 1.059522674040636e-05
2 O 0 8.056701517489273e-06
) O 0 6.45478678507061e-07
and O 0 1.1808591580120265e-06
nephew O 1 0.9879541397094727
( O 0 1.6207724911510013e-05
patient O 0 6.558261520694941e-05
3 O 0 8.86142788658617e-06
) O 0 1.3238986866781488e-06
had O 0 6.246104931051377e-06
a O 0 4.6135093725752085e-05
childhood O 1 0.9999948740005493
ALD B-Disease 1 1.0
type O 1 0.9992619156837463
. O 0 0.0006905572372488678

Another O 0 0.0003294559719506651
nephew O 1 0.7183908224105835
( O 0 4.285464819986373e-05
patient O 0 6.160428893053904e-05
4 O 0 1.3157815374142956e-05
) O 0 1.0102621672558598e-06
of O 0 6.457486506405985e-06
patient O 0 0.00011862723476951942
1 O 0 1.973619691852946e-05
was O 0 3.66877211490646e-05
classified O 0 2.6177310701314127e-06
as O 0 3.593028168324963e-07
having O 0 9.002681053971173e-07
an O 0 9.466832011639781e-07
adolescent O 0 0.00035317937727086246
form O 0 2.5367822672706097e-05
. O 0 7.369752711383626e-05

The O 0 6.967614172026515e-05
tau O 0 0.00015787054144311696
level O 0 6.146377472759923e-06
in O 0 1.1655121170406346e-06
the O 0 4.055514182255138e-06
cerebrospinal O 0 0.11354345828294754
fluid O 0 0.01402345858514309
( O 0 7.365227065747604e-05
CSF O 1 0.9999998807907104
) O 0 1.8549765172792831e-06
in O 0 1.4103164858170203e-06
patient O 0 1.1038574484700803e-05
1 O 0 4.676687240134925e-06
was O 0 1.0984861546603497e-05
as O 0 5.723076128560933e-07
high O 0 1.960060444616829e-06
as O 0 1.899123844850692e-07
that O 0 7.19766291013002e-08
of O 0 1.4186583712216816e-06
patients O 0 1.2555522516777273e-05
with O 0 6.907978968229145e-05
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 6.712847243761644e-05
AD B-Disease 0 0.05559402331709862
) O 0 1.2496474482759368e-05
. O 0 1.8080023437505588e-05

His O 0 0.0031683633569628
brain O 0 0.004267796408385038
magnetic O 0 0.00014683816698379815
resonance O 0 9.875754039967433e-05
image O 0 8.635904669063166e-05
( O 0 6.966241471673129e-06
MRI O 1 0.9905552268028259
) O 0 2.067562718366389e-06
showed O 0 8.455531315121334e-06
abnormalities B-Disease 0 8.63284949446097e-05
in I-Disease 0 1.2440414138836786e-06
the I-Disease 0 2.227189725090284e-06
bilateral I-Disease 0 6.55167896184139e-05
cerebellar I-Disease 1 0.99997878074646
hemispheres I-Disease 0 0.0005780506762675941
and O 0 3.1734383810544387e-05
brain O 1 0.8993850946426392
stem O 0 2.559192944318056e-05
, O 0 6.888168968544051e-07
but O 0 6.735538704560895e-08
not O 0 5.804250235996733e-08
in O 0 2.1995688825882098e-07
the O 0 3.142561126878718e-06
cerebral O 1 0.8092973828315735
white O 0 4.042968794237822e-05
matter O 0 2.1152857243578183e-06
, O 0 2.819722055846796e-07
where O 0 1.823654542931763e-07
marked O 0 6.892058763696696e-07
reductions O 0 3.1568533813697286e-06
of O 0 3.4559295727376593e-06
the O 0 1.731959855533205e-05
cerebral O 1 0.8944311738014221
blood O 0 5.261899787001312e-05
flow O 0 1.2896490488856216e-06
and O 0 9.250875905308931e-07
oxygen O 0 8.6979016487021e-06
metabolism O 0 4.593414814735297e-06
were O 0 3.5826877819999936e-07
clearly O 0 3.4858786079894344e-07
demonstrated O 0 4.737055974146642e-07
by O 0 2.150335802753034e-07
positron O 0 2.4383296477026306e-05
emission O 0 2.1802623450639658e-05
tomography O 0 7.25654826965183e-05
( O 0 2.1078340068925172e-05
PET O 0 0.010883046314120293
) O 0 3.002665653184522e-05
. O 0 4.237261236994527e-05

In O 0 5.861288445885293e-05
patients O 0 1.3310843314684462e-05
2 O 0 6.173700967337936e-06
and O 0 1.2540555189843872e-06
3 O 0 2.7262751700618537e-06
, O 0 4.3258015125502425e-07
the O 0 7.173492804213311e-07
autopsy O 0 1.8158889361075126e-05
findings O 0 1.5306299019357539e-06
showed O 0 3.082836883550044e-06
massive O 0 0.00013316313561517745
demyelination B-Disease 1 0.9999982118606567
of I-Disease 0 0.00010494430171092972
the I-Disease 0 0.00026537725352682173
cerebral I-Disease 1 0.9879869818687439
white I-Disease 0 3.151452983729541e-05
matter I-Disease 0 1.0351591299695428e-06
with O 0 1.954710882046129e-07
sparing O 0 3.6227775126462802e-06
of O 0 2.23275105781795e-06
the O 0 9.939150004356634e-06
U O 1 0.9999316930770874
- O 0 0.4302758276462555
fibers O 0 0.20615386962890625
, O 0 1.185743144560547e-06
compatible O 0 3.431714731050306e-06
with O 0 3.0466023304143164e-07
the O 0 1.6245401184278307e-06
findings O 0 4.405202616908355e-06
of O 0 0.0001244181185029447
childhood O 1 0.9999992847442627
ALD B-Disease 1 1.0
. O 0 0.0033773090690374374

Oleic O 0 0.01567225158214569
and O 0 8.310307748615742e-05
erucic O 0 0.3421359658241272
acids O 0 3.2894156902329996e-05
( O 0 1.1514454854477663e-05
Lorenzos O 0 0.04164388030767441
Oil O 0 1.651371167099569e-05
) O 0 3.4092678902197804e-07
were O 0 1.4346063892389793e-07
administered O 0 4.5644321744475747e-07
to O 0 1.8175117588725698e-07
patients O 0 7.89609543971892e-07
1 O 0 1.3675099808097002e-06
and O 0 5.427901896837284e-07
4 O 0 3.0153430543577997e-06
, O 0 2.8134124363532464e-07
but O 0 1.3079453253794782e-07
sufficient O 0 1.010470327855728e-06
effectiveness O 0 5.941377366980305e-06
was O 0 1.2702234926109668e-05
not O 0 8.081281066552037e-07
obtained O 0 1.0319327884644736e-05
. O 0 2.358750134590082e-05

The O 0 3.73273687728215e-05
findings O 0 1.419490945409052e-05
in O 0 1.838223965933139e-06
this O 0 3.773679395635554e-07
family O 0 1.1718249197656405e-06
suggest O 0 6.597165906896407e-07
that O 0 2.0923920374116278e-07
delGAG291 O 0 3.2513296901015565e-05
is O 0 2.568769730260101e-07
part O 0 4.69539372716099e-07
of O 0 1.073295379683259e-06
the O 0 1.4550749938280205e-06
cause O 0 9.380481969856191e-06
of O 0 4.0102524508256465e-05
Japanese O 1 0.995855987071991
ALD B-Disease 1 1.0
with O 0 1.1908531632798258e-05
phenotypic O 0 0.00011065506987506524
variations O 0 8.600958972238004e-05
. O 0 6.441002187784761e-05

Moreover O 0 0.00022297371469903737
, O 0 7.090466169756837e-06
although O 0 6.478202294601942e-07
the O 0 1.8171721194448764e-07
scale O 0 9.693170568425558e-07
of O 0 6.445972076107864e-07
the O 0 5.708228059120302e-07
study O 0 5.498031327988429e-07
is O 0 7.475896524056225e-08
limited O 0 1.9109039328668587e-07
, O 0 1.419846569206129e-07
there O 0 1.6067887997905927e-07
is O 0 9.635910203087406e-08
a O 0 1.622371144094359e-07
possibility O 0 1.2789589618478203e-06
that O 0 2.83418330582208e-07
PET O 0 0.0007070109713822603
can O 0 2.4059295355982613e-07
detect O 0 1.0866673619602807e-05
an O 0 2.391051111771958e-06
insidious B-Disease 1 0.9540250897407532
lesion I-Disease 1 0.9843682646751404
which O 0 1.2183691069367342e-06
is O 0 4.789536660609883e-07
undetectable O 0 1.2526423233794048e-05
by O 0 1.8180318761551462e-07
computed O 0 3.5232144455221714e-06
tomogram O 0 0.000358036340912804
( O 0 4.2973042582161725e-06
CT O 1 0.8449777364730835
) O 0 7.990947779035196e-07
or O 0 9.548364232614404e-07
MRI O 0 0.0003479885053820908
analysis O 0 6.733560553584539e-07
, O 0 1.9916603832825786e-07
and O 0 8.905898596367479e-08
that O 0 3.1809822331752e-08
the O 0 1.2515424430148414e-07
higher O 0 4.3499821344994416e-07
level O 0 5.143884891367634e-07
of O 0 8.903602974896785e-07
tau O 0 9.004629646369722e-06
reflects O 0 3.638298551322805e-07
the O 0 1.4194878872331174e-07
process O 0 2.4896635864024574e-07
of O 0 6.841008143965155e-06
neuronal B-Disease 1 0.7813905477523804
degeneration I-Disease 1 1.0
in O 0 0.0027278827037662268
ALD B-Disease 1 1.0
. O 0 0.0005812478484585881

Lorenzos O 0 0.23173801600933075
Oil O 0 6.454356480389833e-05
should O 0 1.2956562613908318e-06
be O 0 1.9054317590416758e-07
given O 0 1.1047941939068551e-07
in O 0 2.2418053902129031e-07
the O 0 5.694211040463415e-07
early O 0 9.573835995979607e-06
stage O 0 0.00010548537829890847
. O 0 5.2208024499122985e-06
. O 0 1.7278602172154933e-05

Nonsense O 0 0.0010105959372594953
mutation O 0 2.163429780921433e-05
in O 0 4.702591468230821e-06
exon O 0 6.095465141697787e-05
4 O 0 9.661427611717954e-06
of O 0 5.096508630231256e-06
human O 0 4.6171048779797275e-06
complement O 0 2.0139697880949825e-05
C9 O 1 0.9999880790710449
gene O 0 1.0271356586599723e-05
is O 0 4.5073025489728025e-07
the O 0 1.0738901892182184e-06
major O 0 1.098915709007997e-05
cause O 0 1.3450327060127165e-05
of O 0 2.5601792003726587e-05
Japanese O 1 0.8907372355461121
complement B-Disease 1 0.9914416670799255
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 0.00043992928112857044

Deficiency B-Disease 1 0.999901533126831
of I-Disease 0 0.0005710812984034419
the I-Disease 0 0.0001336103305220604
ninth I-Disease 1 0.9322286248207092
component I-Disease 0 0.00014743217616342008
of I-Disease 0 1.5615749362041242e-05
human I-Disease 0 1.8170678686146857e-06
complement I-Disease 0 1.8118998923455365e-05
( O 0 1.6536358089069836e-05
C9 O 1 0.9999970197677612
) O 0 2.4301966732309666e-06
is O 0 3.605416054597299e-07
the O 0 3.526571958900604e-07
most O 0 6.674256383121246e-07
common O 0 1.6686488379491493e-05
complement B-Disease 1 0.9999827146530151
deficiency I-Disease 1 1.0
in O 0 1.1503161658765748e-05
Japan O 0 6.847619806649163e-05
but O 0 7.318138273149088e-07
is O 0 2.526758180465549e-07
rare O 0 7.493154612348008e-07
in O 0 5.102360773889814e-07
other O 0 1.1764707323891344e-06
countries O 0 1.647192107157025e-06
. O 0 1.955165498657152e-05

We O 0 9.187546311295591e-06
studied O 0 9.17991746973712e-06
the O 0 5.38836388841446e-07
molecular O 0 4.300149612390669e-06
basis O 0 1.8829216514859581e-06
of O 0 9.262317325919867e-05
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999970197677612
in O 0 1.1039333003282081e-05
four O 0 6.63897480990272e-06
Japanese O 1 0.7159973978996277
C9 B-Disease 1 1.0
- I-Disease 1 0.9999958276748657
deficient I-Disease 1 0.9999862909317017
patients O 0 0.0001756639831000939
who O 0 2.1563027985394e-05
had O 0 0.0003558376629371196
suffered O 1 0.9999985694885254
from O 1 0.9999300241470337
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.0005433441256172955

Direct O 0 2.3306303774006665e-05
sequencing O 0 3.839062628685497e-05
of O 0 2.076096279779449e-05
amplified O 0 0.0001642227143747732
C9 O 0 0.029847053810954094
cDNA O 0 6.562696944456547e-05
and O 0 3.3452349725848762e-06
DNA O 0 1.156936923507601e-05
revealed O 0 4.396229996928014e-06
a O 0 4.95550409596035e-07
nonsense O 0 4.9632926675258204e-06
substitution O 0 2.641338596731657e-06
( O 0 1.0099953442477272e-06
CGA O 0 6.082917025196366e-05
- O 0 3.191000359947793e-05
- O 0 2.470018807798624e-05
> O 0 1.2302843060751911e-05
TGA O 0 0.00012607229291461408
) O 0 4.829490762858768e-07
at O 0 1.2657342267630156e-06
codon O 0 2.7295141080685426e-06
95 O 0 9.802026852412382e-07
in O 0 2.5410494686184393e-07
exon O 0 5.6811454669514205e-06
4 O 0 1.187267230307043e-06
in O 0 2.69373487071789e-07
the O 0 8.178247981049935e-07
four O 0 3.995823135483079e-06
C9 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9926577210426331
deficient I-Disease 0 0.043550360947847366
individuals O 0 1.8841930796043016e-05
. O 0 8.400597289437428e-05

An O 0 3.0316110496642068e-05
allele O 0 1.9589018847909756e-05
- O 0 1.684622111497447e-05
specific O 0 1.1037111562473e-06
polymerase O 0 3.242099774070084e-05
chain O 0 1.282622542930767e-05
reaction O 0 1.1407704505472793e-06
system O 0 1.6562244127271697e-06
designed O 0 1.4694119272462558e-06
to O 0 2.957428364425141e-07
detect O 0 2.8687179565167753e-06
exclusively O 0 3.9870388945928426e-07
only O 0 4.814141618680878e-08
one O 0 6.084077597279247e-08
of O 0 1.9379277205189283e-07
the O 0 2.2937516064303054e-07
normal O 0 2.716301992222725e-07
and O 0 1.2620805023288995e-07
mutant O 0 1.1908460919585195e-06
alleles O 0 1.3070800264358695e-07
indicated O 0 1.2748182598443236e-07
that O 0 2.4978580981382947e-08
all O 0 3.013894200876166e-08
the O 0 1.3651433050654305e-07
four O 0 2.381880648272272e-07
patients O 0 2.2363708751527156e-07
were O 0 8.21292189812084e-08
homozygous O 0 5.56218765268568e-07
for O 0 1.3650873142978526e-07
the O 0 5.423881361821259e-07
mutation O 0 5.650507546306471e-07
in O 0 3.0066030376474373e-07
exon O 0 1.220925787492888e-05
4 O 0 1.1235708825552138e-06
and O 0 1.160174107894818e-07
that O 0 3.2496043189667034e-08
the O 0 1.0282858653454241e-07
parents O 0 1.7778695848846837e-07
of O 0 1.652297669352265e-06
patient O 0 1.0839793503691908e-05
2 O 0 8.525685188942589e-06
were O 0 5.4127694966155104e-06
heterozygous O 0 3.261705205659382e-05
. O 0 4.401440673973411e-05

The O 0 4.475873356568627e-05
common O 0 8.22391393739963e-06
mutation O 0 2.983449576277053e-06
at O 0 3.7519512261496857e-06
codon O 0 6.6596726355783176e-06
95 O 0 2.6926122700388078e-06
in O 0 4.300299849546718e-07
exon O 0 1.826220250222832e-05
4 O 0 1.7413020714229788e-06
might O 0 2.402052814431954e-07
be O 0 6.914166306160041e-08
responsible O 0 3.548341567238822e-07
for O 0 2.742848437264911e-07
most O 0 3.6037251902598655e-06
Japanese O 1 0.9707457423210144
C9 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0001201591658173129
. O 0 0.00011026449647033587

BRCA1 O 0 0.00045179357402957976
required O 0 1.0146252861886751e-05
for O 0 3.0281439649115782e-06
transcription O 0 0.00031068691168911755
- O 0 0.0008666281355544925
coupled O 0 0.00043325030128471553
repair O 1 0.9785207509994507
of O 0 0.00016238779062405229
oxidative O 0 0.479617714881897
DNA O 0 0.31083545088768005
damage O 0 0.01187148131430149
. O 0 8.621488086646423e-05

The O 0 0.0014019327936694026
breast B-Disease 1 0.9999886751174927
and I-Disease 1 0.8916991353034973
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9961420893669128
gene O 0 0.00018231217109132558
BRCA1 O 0 0.00014644399925600737
encodes O 0 9.217656952387188e-06
a O 0 2.7654112273012288e-05
zinc O 0 0.2759009003639221
finger O 0 0.0002102732687490061
protein O 0 3.945160187868169e-06
of O 0 8.27708026918117e-06
unknown O 0 3.481991006992757e-05
function O 0 1.2285572665859945e-05
. O 0 3.2374497095588595e-05

Association O 0 0.0002904742141254246
of O 0 4.538371285889298e-05
the O 0 2.634874363138806e-05
BRCA1 O 0 0.00010257139365421608
protein O 0 2.051856426987797e-06
with O 0 4.732125375994656e-07
the O 0 4.15753902416327e-06
DNA O 0 0.0014961217530071735
repair O 1 0.6027672290802002
protein O 0 6.701894562866073e-06
Rad51 O 0 0.00013156778004486114
and O 0 3.0816593721283425e-07
changes O 0 8.54993160714912e-08
in O 0 8.17054797153105e-08
the O 0 1.155472517666567e-07
phosphorylation O 0 5.845517989655491e-07
and O 0 4.830619673157344e-07
cellular O 0 4.58940485259518e-06
localization O 0 4.9581453822611365e-06
of O 0 8.317104516208929e-07
the O 0 3.857610408886103e-07
protein O 0 4.854056214753655e-07
after O 0 1.953832679646439e-06
exposure O 0 4.324974270275561e-06
to O 0 4.663890535994142e-07
DNA O 0 9.096359281102195e-05
- O 0 2.120303724950645e-05
damaging O 0 1.8452514268574305e-05
agents O 0 4.5951409788358433e-07
are O 0 2.43846933756231e-08
consistent O 0 2.0610629292150406e-07
with O 0 6.651952588754284e-08
a O 0 5.887090992473532e-07
role O 0 1.7773401168597047e-06
for O 0 2.2126559997559525e-06
BRCA1 O 0 0.0001179419195977971
in O 0 8.75283785717329e-06
DNA O 0 0.00329863210208714
repair O 1 0.9336941838264465
. O 0 0.0001613562781130895

Here O 0 7.919171184767038e-05
, O 0 6.279701210587518e-06
it O 0 7.111337936294149e-07
is O 0 2.5017422444761905e-07
shown O 0 1.7236519056496036e-07
that O 0 1.1276581801666907e-07
mouse O 0 7.849007488403004e-06
embryonic O 0 4.052313670399599e-05
stem O 0 0.0001075577674782835
cells O 0 3.2343985367333516e-05
deficient B-Disease 0 0.00010677947284420952
in I-Disease 0 3.3565956982783973e-06
BRCA1 I-Disease 0 2.7926820621360093e-05
are O 0 2.090425397227591e-07
defective O 0 4.721919322037138e-05
in O 0 4.318514186252287e-07
the O 0 6.62152046970732e-07
ability O 0 2.2460554305325786e-07
to O 0 1.0854898135903568e-07
carry O 0 2.564019041528809e-07
out O 0 3.374150026047573e-07
transcription O 0 1.0707133696996607e-05
- O 0 1.7704529454931617e-05
coupled O 0 1.6711237549316138e-05
repair O 0 0.05716463923454285
of O 0 3.1484792998526245e-05
oxidative O 0 0.0029456932097673416
DNA O 0 0.23331917822360992
damage O 0 0.0008881298126652837
, O 0 8.26160089673067e-07
and O 0 2.1960875074000796e-07
are O 0 1.0871868028061726e-07
hypersensitive O 0 4.202980926493183e-05
to O 0 1.5207954220386455e-06
ionizing O 0 0.0010845331707969308
radiation O 0 0.00042500629206188023
and O 0 2.7823803065984976e-06
hydrogen O 0 3.996550731244497e-05
peroxide O 0 0.0004886436508968472
. O 0 6.363495776895434e-05

These O 0 1.2948697985848412e-05
results O 0 1.0334750186302699e-05
suggest O 0 3.0522894576279214e-06
that O 0 1.2553597343867295e-06
BRCA1 O 0 5.817548299091868e-05
participates O 0 9.330564353149384e-06
, O 0 7.50555614104087e-07
directly O 0 6.598065169782785e-07
or O 0 5.857934866071446e-07
indirectly O 0 2.826624495355645e-06
, O 0 5.833477985106583e-07
in O 0 5.110961183163454e-07
transcription O 0 1.925287324411329e-05
- O 0 4.858949614572339e-05
coupled O 0 5.5141881603049114e-05
repair O 1 0.5104974508285522
of O 0 2.0002571545774117e-05
oxidative O 0 0.01939704269170761
DNA O 0 0.11246221512556076
damage O 0 0.0011694178683683276
. O 0 9.927317478286568e-06
. O 0 1.2228005289216526e-05

Truncation O 0 0.0012164157815277576
mutations O 0 1.1430799531808589e-05
in O 0 2.423115120109287e-06
the O 0 3.0746334687137278e-06
transactivation O 0 0.00025379584985785186
region O 0 3.6115179682383314e-06
of O 0 9.774352292879485e-06
PAX6 O 1 0.9997997879981995
result O 0 2.611245918160421e-06
in O 0 2.2999140583124245e-06
dominant O 0 3.164460213156417e-05
- O 0 3.895974805345759e-05
negative O 0 9.80999720923137e-06
mutants O 0 0.00013482374197337776
. O 0 3.7687197618652135e-05

PAX6 O 1 0.9782926440238953
is O 0 3.270058368798345e-05
a O 0 7.168642696342431e-06
transcription O 0 1.9965846149716526e-05
factor O 0 3.095623014814919e-06
with O 0 2.0879329554190917e-07
two O 0 1.608324993185306e-07
DNA O 0 7.620693395438138e-06
- O 0 3.444163894528174e-06
binding O 0 6.81096480548149e-07
domains O 0 1.613151084711717e-06
( O 0 1.062064484358416e-06
paired O 0 5.860634246346308e-06
box O 0 2.1340616513043642e-05
and O 0 1.306904664488684e-06
homeobox O 0 5.448494994197972e-05
) O 0 5.691263140761293e-07
and O 0 6.783951675970457e-07
a O 0 2.466470959916478e-06
proline O 0 8.53826422826387e-05
- O 0 6.625256355619058e-05
serine O 0 0.00012245778634678572
- O 0 4.2769934225361794e-05
threonine O 0 0.00023557608074042946
( O 0 1.3183965165808331e-05
PST O 1 0.9983187913894653
) O 0 1.1529442417668179e-05
- O 0 8.989030175143853e-05
rich O 0 2.5021672627190128e-05
transactivation O 0 0.0011925242142751813
domain O 0 0.00011941407865379006
. O 0 4.9148115067509934e-05

PAX6 O 1 0.9999250173568726
regulates O 0 0.01923365518450737
eye O 0 0.0985570177435875
development O 0 1.852886998676695e-05
in O 0 2.225998514404637e-06
animals O 0 1.5556829566776287e-06
ranging O 0 3.065837745452882e-06
from O 0 2.8411157018126687e-06
jellyfish O 0 9.470748409512453e-06
to O 0 1.1628686706899316e-06
Drosophila O 0 1.016161149891559e-05
to O 0 2.3067523216013797e-06
humans O 0 1.592032094777096e-05
. O 0 2.7363497792975977e-05

Heterozygous O 0 0.00010097248741658404
mutations O 0 8.432645699940622e-06
in O 0 1.6935950952756684e-06
the O 0 2.68865824182285e-06
human O 0 1.1564174201339483e-05
PAX6 O 1 0.9999440908432007
gene O 0 7.060022198857041e-06
result O 0 6.649839860983775e-07
in O 0 1.3263120024475938e-07
various O 0 5.233496267464943e-07
phenotypes O 0 1.0715069947764277e-05
, O 0 1.2804222251361352e-06
including O 0 8.68330698722275e-06
aniridia B-Disease 1 1.0
, O 0 0.0002782521187327802
Peters B-Disease 1 0.9999997615814209
anomaly I-Disease 1 0.9999995231628418
, O 0 4.077156700077467e-05
autosomal B-Disease 0 0.06725424528121948
dominant I-Disease 1 0.9960368275642395
keratitis I-Disease 1 0.9999994039535522
, O 0 0.00011561444262042642
and O 0 0.00043783371802419424
familial B-Disease 1 0.9999995231628418
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.030039962381124496

It O 0 2.5906116206897423e-05
is O 0 2.399882760073524e-06
believed O 0 1.9336314380780095e-06
that O 0 9.051944971361081e-08
the O 0 4.345545221440261e-07
mutated O 0 3.8827333810331766e-06
allele O 0 1.2643250784094562e-06
of O 0 6.865543127787532e-06
PAX6 O 1 0.9073678851127625
produces O 0 4.851500762015348e-06
an O 0 4.983361350241466e-07
inactive O 0 2.8288977773627266e-05
protein O 0 1.5798650565557182e-06
and O 0 3.3281567084486596e-06
aniridia B-Disease 1 0.9999992847442627
is O 0 4.543071099760709e-06
caused O 0 1.827389314712491e-05
due O 0 5.477142167364946e-06
to O 0 4.864687070949003e-06
genetic O 0 0.00023608404444530606
haploinsufficiency O 1 0.6177078485488892
. O 0 8.909333701012656e-05

However O 0 6.066557398298755e-05
, O 0 3.1841013878874946e-06
several O 0 9.283248800784349e-07
truncation O 0 6.68350257910788e-05
mutations O 0 1.1051056389987934e-06
have O 0 7.353651199082378e-08
been O 0 2.6546038611741096e-07
found O 0 2.168513901779079e-07
to O 0 6.538812868939203e-08
occur O 0 6.415632469725097e-08
in O 0 1.0554171581134142e-07
the O 0 1.691035549811204e-06
C O 0 0.24042151868343353
- O 0 2.035029319813475e-05
terminal O 0 1.1262613952567335e-05
half O 0 9.864501180345542e-07
of O 0 2.8493727768363897e-06
PAX6 O 1 0.9707636833190918
in O 0 2.7409944323153468e-06
patients O 0 5.736372258979827e-06
with O 0 1.5149342971199076e-06
Aniridia B-Disease 1 0.9999983310699463
resulting O 0 1.3954997484688647e-05
in O 0 2.4842822767823236e-06
mutant O 0 3.126586079815752e-06
proteins O 0 1.825526965149038e-07
that O 0 6.27274232556374e-08
retain O 0 9.31162276174291e-07
the O 0 7.707610052420932e-07
DNA O 0 1.6850624888320453e-05
- O 0 3.789265292652999e-06
binding O 0 6.370746632455848e-07
domains O 0 7.156567676247505e-07
but O 0 1.3788491060040542e-07
have O 0 7.490969267109904e-08
lost O 0 2.8012839266011724e-06
most O 0 1.829798890184975e-07
of O 0 1.9284675545350183e-06
the O 0 9.316986506746616e-06
transactivation O 0 0.0015374998329207301
domain O 0 6.424218736356124e-05
. O 0 2.8458060114644468e-05

It O 0 2.416951974737458e-05
is O 0 1.959909013748984e-06
not O 0 2.1363688063047448e-07
clear O 0 2.3123084247345105e-07
whether O 0 1.1307886893519026e-07
such O 0 2.5271341996813135e-07
mutants O 0 2.7824553399113938e-05
really O 0 1.3891748267269577e-06
behave O 0 2.222158457243495e-07
as O 0 3.1366937491839053e-07
loss O 0 8.657152648083866e-06
- O 0 6.788224709453061e-06
of O 0 5.037964456278132e-06
- O 0 9.855193638941273e-06
function O 0 1.2371153843560023e-06
mutants O 0 6.605339876841754e-06
as O 0 9.062151775651728e-07
predicted O 0 3.4677125313464785e-06
by O 0 4.812462066183798e-06
haploinsufficiency O 0 0.11522648483514786
. O 0 0.00010766777995740995

Contrary O 0 7.008478132775053e-05
to O 0 1.1634188012976665e-06
this O 0 4.435506752997753e-07
theory O 0 2.8506310627562925e-06
, O 0 3.61136585524946e-07
our O 0 1.6939669933435653e-07
data O 0 2.6337849590163387e-07
showed O 0 2.0884645834939874e-07
that O 0 6.354687442922113e-09
these O 0 1.6550853132457632e-08
mutants O 0 7.43040573070175e-07
are O 0 5.061524177563115e-08
dominant O 0 1.6996027625282295e-06
- O 0 1.649172759243811e-06
negative O 0 3.071905894103111e-07
in O 0 1.5598651259551843e-07
transient O 0 1.8646126136445673e-06
transfection O 0 2.7925940230488777e-05
assays O 0 2.310235231561819e-06
when O 0 3.295972419437021e-07
they O 0 7.387926359569974e-08
are O 0 2.69983964074072e-08
coexpressed O 0 1.1238881597819272e-05
with O 0 4.389316359265649e-07
wild O 0 3.468155045993626e-05
- O 0 0.0021157097071409225
type O 0 0.012931594625115395
PAX6 O 1 0.9999638795852661
. O 0 0.0002512936189305037

We O 0 1.1711562365235295e-05
found O 0 3.0693217922816984e-06
that O 0 3.49635939755899e-07
the O 0 1.1894171620951965e-06
dominant O 0 1.7900259990710765e-05
- O 0 2.529962148400955e-05
negative O 0 2.045266455752426e-06
effects O 0 2.891498752433108e-06
result O 0 5.123058599565411e-07
from O 0 6.993906822572171e-07
the O 0 5.511554945769603e-07
enhanced O 0 2.771776053123176e-06
DNA O 0 4.16623925048043e-06
binding O 0 3.973411821789341e-07
ability O 0 3.6430796512831876e-07
of O 0 1.2978575796296354e-06
these O 0 1.4374634247360518e-06
mutants O 0 0.00013990848674438894
. O 0 3.882910459651612e-05

Kinetic O 0 0.00016066832176875323
studies O 0 8.59692954691127e-06
of O 0 2.920253336924361e-06
binding O 0 1.221943762175215e-06
and O 0 8.78583591656934e-07
dissociation O 0 6.1736477618978824e-06
revealed O 0 6.522758667415474e-06
that O 0 6.760559756457951e-08
various O 0 1.5491953320179164e-07
truncation O 0 1.3180821952119004e-05
mutants O 0 3.5671321256813826e-06
have O 0 7.954256631137469e-08
3 O 0 8.396233397434116e-07
- O 0 1.5569833067274885e-06
5 O 0 1.1589560244829045e-06
- O 0 1.4778285049033002e-06
fold O 0 3.944653315102187e-07
higher O 0 2.0650608689720684e-07
affinity O 0 1.069419397481397e-07
to O 0 2.8300338072995146e-08
various O 0 8.444279586683479e-08
DNA O 0 4.236240783939138e-06
- O 0 1.296396590078075e-06
binding O 0 1.652597063639405e-07
sites O 0 2.807796875003987e-07
when O 0 1.6196133856283268e-07
compared O 0 3.5200233128307445e-07
with O 0 1.0582069620568291e-07
the O 0 1.0218479928880697e-06
wild O 0 3.078646113863215e-05
- O 0 0.0022732659708708525
type O 0 0.009194710291922092
PAX6 O 1 0.9999330043792725
. O 0 0.00020013595349155366

These O 0 5.0687485781963915e-06
results O 0 3.3521748719067546e-06
provide O 0 4.846835395255766e-07
a O 0 4.854926487496414e-07
new O 0 7.507661621275474e-07
insight O 0 2.572361381680821e-06
into O 0 5.856024358763534e-07
the O 0 7.859485435801616e-07
role O 0 1.5911190303086187e-06
of O 0 5.242960924078943e-06
mutant O 0 0.0002001498796744272
PAX6 O 1 0.9998844861984253
in O 0 2.0872730601695366e-05
causing O 0 0.20597077906131744
aniridia B-Disease 1 0.9999973773956299
. O 0 3.519001620588824e-05
. O 0 3.601446223910898e-05

Reversal O 0 0.0031359009444713593
of O 1 0.7650704383850098
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.9945631623268127
excellent O 1 0.9316741824150085
neuropsychologic O 1 0.9945587515830994
outcome O 0 1.0695253877202049e-05
in O 0 2.2801038994657574e-06
very B-Disease 0 1.6716498976165894e-06
- I-Disease 0 2.5689590984256938e-05
long I-Disease 0 5.103044713905547e-06
- I-Disease 0 5.271577902021818e-05
chain I-Disease 0 5.358997077564709e-05
acyl I-Disease 0 0.00010788297367980704
- I-Disease 0 0.0004287569900043309
coenzyme I-Disease 0 0.00046809550258331
A I-Disease 1 0.9812138080596924
dehydrogenase I-Disease 1 0.9999445676803589
deficiency I-Disease 1 0.999998927116394
. O 0 0.0002881700929719955

Very B-Disease 0 0.00010557423229329288
- I-Disease 0 0.00014767263201065361
long I-Disease 0 1.9217633962398395e-05
- I-Disease 0 3.716677747434005e-05
chain I-Disease 0 1.2879116184194572e-05
acyl I-Disease 0 2.3718310330878012e-05
- I-Disease 0 2.336289435334038e-05
coenzyme I-Disease 0 2.7233150831307285e-05
A I-Disease 0 5.257265002001077e-05
dehydrogenase I-Disease 0 0.0008533541695214808
( I-Disease 0 9.334314381703734e-05
VLCAD I-Disease 1 1.0
) I-Disease 0 0.0784597396850586
deficiency I-Disease 1 0.9999980926513672
is O 0 7.365634701272938e-06
a O 0 8.02597205620259e-05
disorder O 1 0.999955415725708
of O 1 0.6976689696311951
fatty O 1 0.819238007068634
acid O 0 0.00015214469749480486
beta O 0 1.1937777344428468e-05
oxidation O 0 3.1317845241574105e-06
that O 0 2.554168929691514e-07
reportedly O 0 3.738246959983371e-06
has O 0 3.0842261367070023e-07
high O 0 4.347408776084194e-06
rates O 0 1.1544254903128603e-06
of O 0 5.665984645020217e-06
morbidity O 0 0.000801518966909498
and O 0 2.5123674276983365e-05
mortality O 0 0.0005090771592222154
. O 0 4.907701804768294e-05

We O 0 7.39196730137337e-06
describe O 0 3.7714555674028816e-06
the O 0 1.0633556257744203e-06
outcome O 0 7.63513128276827e-07
of O 0 9.90360035757476e-07
a O 0 8.12580992715084e-07
5 O 0 2.485976892785402e-06
- O 0 7.741069566691294e-06
year O 0 1.3406840935203945e-06
- O 0 1.2672121556533966e-05
old O 0 0.00029039662331342697
girl O 0 5.506348315975629e-05
with O 0 1.1258791346335784e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 6.618089537369087e-05
was O 0 6.34852476650849e-05
first O 0 3.193930979250581e-06
seen O 0 2.1680766622012015e-06
at O 0 3.1490533274336485e-06
5 O 0 6.615966299250431e-07
months O 0 3.9570795706822537e-07
of O 0 1.3315275282366201e-06
age O 0 3.942694092984311e-05
with O 0 2.22770067921374e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999994039535522
hepatomegaly B-Disease 1 1.0
, O 1 0.9999980926513672
encephalopathy B-Disease 1 1.0
, O 0 0.03341854736208916
and O 0 0.04739460349082947
hypotonia B-Disease 1 0.9999940395355225
. O 0 0.0010625750292092562

Biochemical O 0 0.005459924228489399
studies O 0 0.0008239335147663951
indicated O 1 0.995934009552002
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.9916995763778687
by O 0 1.4897195796947926e-05
a O 0 2.823816794261802e-05
stable O 0 5.8938654547091573e-05
yet O 0 1.1745441042876337e-05
inactive O 0 0.00026008253917098045
enzyme O 0 0.0001011690910672769
. O 0 2.835544728441164e-05

Molecular O 0 0.00018644839292392135
genetic O 0 1.5272853488568217e-05
analysis O 0 2.9700076993322e-06
of O 0 1.2693881217273884e-05
her O 0 9.61970363277942e-05
VLCAD O 1 0.9999986886978149
gene O 0 2.5737312171258964e-05
revealed O 0 2.3515876819146797e-05
a O 0 8.332249308296014e-06
T1372C O 0 0.2994453012943268
( O 0 8.757246177992783e-06
F458L O 0 0.005583252292126417
) O 0 3.3380551940354053e-06
missense O 0 3.3084270398830995e-05
mutation O 0 2.5634690246079117e-06
and O 0 2.4990788460854674e-06
a O 0 2.4346030841115862e-05
1668 O 1 0.9997318387031555
ACAG O 1 0.9999929666519165
1669 O 1 0.9924410581588745
splice O 0 0.004587988834828138
site O 0 0.0003377409011591226
mutation O 0 6.3661667809356e-05
. O 0 4.863989306613803e-05

After O 0 0.0001766987843438983
initial O 0 8.050332689890638e-05
treatment O 0 0.0001429060794180259
with O 0 4.245749096298823e-06
intravenous O 1 0.6112992167472839
glucose O 0 0.009557729586958885
and O 0 1.2774151400662959e-05
carnitine O 1 0.7995703220367432
, O 0 4.045752120873658e-06
the O 0 3.922347332263598e-06
patient O 0 2.299238258274272e-05
has O 0 1.2035466170345899e-06
thrived O 0 1.1451389582362026e-05
on O 0 6.466801778515219e-07
a O 0 1.3821077118336689e-06
low O 0 9.785694601305295e-06
- O 0 1.297986636927817e-05
fat O 0 1.0203346391790546e-05
diet O 0 2.5990473204728914e-06
supplemented O 0 2.4913313154684147e-06
with O 0 5.520334411812655e-07
medium O 0 2.4767126888036728e-05
- O 0 6.828019104432315e-05
chain O 0 3.483548789517954e-05
triglyceride O 0 3.621676660259254e-05
oil O 0 7.59604517952539e-06
and O 0 3.5223274608142674e-06
carnitine O 0 0.0003477644349914044
and O 0 5.630997748085065e-06
avoidance O 0 0.00032606907188892365
of O 0 0.00011084071593359113
fasting O 0 0.0006590044940821826
. O 0 5.139945278642699e-05

Her O 1 0.9820104241371155
ventricular O 1 0.9999997615814209
hypertrophy O 1 0.9999781847000122
resolved O 0 7.315647235373035e-05
significantly O 0 5.2078089538554195e-06
over O 0 1.6140051002366818e-06
1 O 0 1.638956291571958e-06
year O 0 5.504143132384343e-07
, O 0 3.3874565019687e-07
and O 0 4.014203796032234e-07
cognitively O 0 6.503728218376637e-05
, O 0 1.0468997970747296e-06
she O 0 5.451916536003409e-07
is O 0 5.678549896970253e-08
in O 0 5.762245436358171e-08
the O 0 2.658322841853078e-07
superior O 0 6.272818154684501e-06
range O 0 2.878015720853e-06
for O 0 1.702328063402092e-06
age O 0 3.7821708247065544e-05
. O 0 2.176740781578701e-05

Clinical O 0 0.0013594292104244232
recognition O 0 0.00019966533000115305
of O 1 0.9988288283348083
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 0.0006257130298763514
important O 0 8.624669135315344e-06
because O 0 1.0340105518480414e-06
it O 0 1.6995237217543036e-07
is O 0 5.13782971722776e-08
one O 0 1.0596389188322064e-07
of O 0 5.387675514612056e-07
the O 0 1.4578183709090808e-06
few O 0 2.524301862649736e-06
directly O 0 1.1606744919845369e-05
treatable O 1 0.9999984502792358
causes O 0 0.016845449805259705
of O 1 0.9859375357627869
cardiomyopathy B-Disease 1 1.0
in O 0 0.008050232194364071
children O 0 6.398258847184479e-05
. O 0 1.5866500689298846e-05
. O 0 3.358064714120701e-05

Cloning O 0 0.00031772739021107554
of O 0 3.7472491385415196e-05
a O 0 4.460787295101909e-06
novel O 0 5.550807600229746e-06
member O 0 1.5927449794617132e-06
of O 0 2.1468433715199353e-06
the O 0 3.0205985694919946e-06
low O 0 3.301326069049537e-05
- O 0 2.7559413865674287e-05
density O 0 1.4340116649691481e-05
lipoprotein O 0 0.002385627944022417
receptor O 0 4.00684293708764e-05
family O 0 2.1970370653434657e-05
. O 0 3.834814197034575e-05

A O 0 0.00020554983348120004
gene O 0 8.750484084885102e-06
encoding O 0 4.471417469176231e-06
a O 0 4.427508429216687e-06
novel O 0 8.919359061110299e-06
transmembrane O 0 1.5098159565241076e-05
protein O 0 1.3096357633912703e-06
was O 0 4.426000941748498e-06
identified O 0 5.512874281521363e-07
by O 0 1.348463172234915e-07
DNA O 0 9.79769083642168e-07
sequence O 0 6.92542485580816e-08
analysis O 0 1.9154067842919176e-07
within O 0 3.4451090868969914e-07
the O 0 1.2228798595970147e-06
insulin B-Disease 0 0.0005686341901309788
- I-Disease 0 0.12348400056362152
dependent I-Disease 0 0.062219876796007156
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 0.018062327057123184
IDDM B-Disease 1 0.9999992847442627
) O 0 3.765895598917268e-05
locus O 0 0.00017609246424399316
IDDM4 O 1 0.9239580631256104
on O 0 5.190175579627976e-05
chromosome O 0 0.00016074939048849046
11q13 O 0 0.0017210926162078977
. O 0 7.260874554049224e-05

Based O 0 3.821394784608856e-05
on O 0 4.906910362478811e-06
its O 0 2.535627118049888e-06
chromosomal O 0 2.7749161745305173e-05
position O 0 9.49462173593929e-06
, O 0 5.507798164217093e-07
this O 0 1.505213447217102e-07
gene O 0 5.444159683065664e-07
is O 0 1.0609757339352655e-07
a O 0 2.4935224018918234e-07
candidate O 0 6.577859608114522e-07
for O 0 7.197435820671672e-07
conferring O 0 0.00016452114505227655
susceptibility O 0 0.259530246257782
to O 0 0.00033118229475803673
diabetes B-Disease 1 0.9999978542327881
. O 0 0.00039649190148338675

The O 0 0.00011434110638219863
gene O 0 2.273154132126365e-05
, O 0 2.748284032350057e-06
termed O 0 1.4736844605067745e-05
low O 0 1.472917301725829e-05
- O 0 8.7634107330814e-06
density O 0 2.6157297270401614e-06
lipoprotein O 0 4.72509054816328e-05
receptor O 0 1.8168530004913919e-06
related O 0 1.3073884019831894e-06
protein O 0 1.1231273902012617e-06
5 O 0 4.036533482576488e-06
( O 0 2.077064664263162e-06
LRP5 O 1 0.9824147820472717
) O 0 9.163745744444896e-07
, O 0 2.640024092670501e-07
encodes O 0 2.1979292341711698e-07
a O 0 1.6984185435831023e-07
protein O 0 2.1688325091417937e-07
of O 0 9.619022875995142e-07
1615 O 0 1.9608363800216466e-05
amino O 0 2.43953991230228e-07
acids O 0 1.1628614515757363e-07
that O 0 2.8239837135402013e-08
contains O 0 2.1932660843049234e-07
conserved O 0 7.262739245561534e-07
modules O 0 1.3059004686510889e-06
which O 0 5.7702081335264666e-08
are O 0 1.1569640356867694e-08
characteristic O 0 2.5020048610713275e-07
of O 0 3.3397543575119926e-07
the O 0 6.746634539922525e-07
low O 0 1.4218754586181603e-05
- O 0 1.2916891137138009e-05
density O 0 6.818342626502272e-06
lipoprotein O 0 0.17937055230140686
( O 0 2.600078732939437e-05
LDL O 1 0.998654842376709
) O 0 5.68104769627098e-06
receptor O 0 1.3519877029466443e-05
family O 0 1.664735646045301e-05
. O 0 3.845834362437017e-05

These O 0 1.596240144863259e-05
modules O 0 4.9524747737450525e-05
include O 0 8.552517101634294e-06
a O 0 3.850953817163827e-06
putative O 0 2.693660462682601e-05
signal O 0 7.5552261478151195e-06
peptide O 0 3.3108592560893157e-06
for O 0 4.993194693270198e-07
protein O 0 9.419965749657422e-07
export O 0 3.468109298410127e-06
, O 0 6.539013384099235e-07
four O 0 6.049548915143532e-07
epidermal O 0 7.617660594405606e-05
growth O 0 3.734786787390476e-06
factor O 0 5.314423560776049e-06
( O 0 3.1757435863255523e-06
EGF O 0 0.004618546459823847
) O 0 6.578248985533719e-07
repeats O 0 1.2874997992184944e-06
with O 0 1.8394972300939116e-07
associated O 0 1.080801780517504e-06
spacer O 0 1.075604359357385e-05
domains O 0 2.200711378463893e-06
, O 0 7.17803004590678e-07
three O 0 1.007352807391726e-06
LDL O 0 0.040778160095214844
- O 0 3.7466703361133114e-05
receptor O 0 6.089097496442264e-06
( O 0 2.195763954659924e-06
LDLR O 1 0.8130593299865723
) O 0 7.939619877106452e-07
repeats O 0 1.6111662262119353e-06
, O 0 4.531351862624433e-07
a O 0 7.166723321461177e-07
single O 0 1.6306900079143816e-06
transmembrane O 0 1.1317697499180213e-05
spanning O 0 1.1914757124031894e-05
domain O 0 5.258729288470931e-06
, O 0 1.691706529527437e-06
and O 0 1.203070382871374e-06
a O 0 5.8717109823192e-06
cytoplasmic O 0 4.980179437552579e-05
domain O 0 6.99787269695662e-05
. O 0 3.575898153940216e-05

The O 0 3.070576349273324e-05
encoded O 0 7.67629717302043e-06
protein O 0 3.275587232565158e-06
has O 0 5.388301929087902e-07
a O 0 4.180126325081801e-07
unique O 0 5.561859097724664e-07
organization O 0 9.306651236329344e-07
of O 0 5.596792561846087e-06
EGF O 1 0.99174565076828
and O 0 7.663694304937962e-06
LDLR O 1 0.9999618530273438
repeats O 0 9.221640539180953e-06
; O 0 3.803965853421687e-07
therefore O 0 7.585661592202086e-07
, O 0 1.176163323179935e-06
LRP5 O 1 0.8166094422340393
likely O 0 6.630165216847672e-07
represents O 0 4.0038617044046987e-07
a O 0 2.4531905751246086e-07
new O 0 6.356969493026554e-07
category O 0 1.3561874538936536e-06
of O 0 2.77184221886273e-06
the O 0 1.7414149624528363e-05
LDLR O 1 0.9999977350234985
family O 0 0.000197669563931413
. O 0 5.845604027854279e-05

Both O 0 3.1793639209354296e-05
human O 0 1.2424226952134632e-05
and O 0 1.9012883058167063e-05
mouse O 0 0.0028228959999978542
LRP5 O 1 0.9999878406524658
cDNAs O 0 0.015401200391352177
have O 0 6.756627044524066e-07
been O 0 7.087721769494237e-07
isolated O 0 1.312475319537043e-06
and O 0 1.9323321964748175e-07
the O 0 3.5589596336649265e-07
encoded O 0 2.897042179483833e-07
mature O 0 5.273240617498232e-07
proteins O 0 9.441103543395002e-08
are O 0 2.6002910047395744e-08
95 O 0 9.221008667736896e-07
% O 0 1.3207784377300413e-07
identical O 0 5.251039851827954e-07
, O 0 1.7028219190251548e-07
indicating O 0 5.640928861794237e-07
a O 0 3.8505643829012115e-07
high O 0 2.1193441170908045e-06
degree O 0 1.3791058108836296e-06
of O 0 1.0742600125013269e-06
evolutionary O 0 1.2344517017481849e-05
conservation O 0 2.8096847017877735e-05
. O 0 5.523802428797353e-06
. O 0 2.588991446828004e-05

The O 0 0.00019295340462122113
APC B-Disease 0 0.0027895148377865553
variants O 0 0.00010323394235456362
I1307K O 0 0.024468792602419853
and O 0 1.3723498341278173e-05
E1317Q O 0 0.0008797126356512308
are O 0 5.556589712796267e-07
associated O 0 1.330701070401119e-05
with O 0 0.08541060239076614
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.187034442613367e-05
but O 0 4.832273816646193e-07
not O 0 1.555893760496474e-07
always O 0 3.3213984806934604e-07
with O 0 1.6461574148252112e-07
a O 0 1.7147634707725956e-06
family O 0 6.539850801345892e-06
history O 0 7.366106001427397e-05
. O 0 6.188775296323001e-05

Classical O 1 0.9785082936286926
familial B-Disease 1 0.9999991655349731
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 1 0.5382118821144104
FAP B-Disease 1 0.9999991655349731
) O 0 3.604105222621001e-05
is O 0 2.8015349471388618e-06
a O 0 9.247337402484845e-06
high O 1 0.8786856532096863
- O 1 0.9998728036880493
penetrance O 1 0.9999979734420776
autosomal B-Disease 1 0.999969482421875
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999998807907104
that O 0 1.1027453183487523e-05
predisposes O 0 0.04131997376680374
to O 0 8.042776471484103e-07
hundreds O 0 3.444058847890119e-06
or O 0 6.897213893353182e-07
thousands O 0 6.284685696300585e-06
of O 1 0.9067586064338684
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9980937838554382
carcinoma I-Disease 1 1.0
and O 0 9.977773515856825e-06
that O 0 5.540476877285982e-07
results O 0 1.4045783700566972e-06
from O 0 2.959548965009162e-06
truncating O 0 0.00011631062807282433
mutations O 0 3.9659080357523635e-06
in O 0 2.5738506792549742e-06
the O 0 2.7147190849063918e-05
APC B-Disease 1 0.9181316494941711
gene O 0 0.00021620714687742293
. O 0 6.80621451465413e-05

A O 0 0.0007354448898695409
variant O 0 0.0003997222811449319
of O 0 0.0002078374964185059
FAP B-Disease 1 0.9999943971633911
is O 0 0.0001848301908466965
attenuated B-Disease 1 0.9987156391143799
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.9988596439361572
, O 0 3.726660452230135e-06
which O 0 3.2684147299733013e-07
results O 0 8.690602726346697e-07
from O 0 5.1084252845612355e-06
germ O 1 0.9997627139091492
- O 0 0.0001235556264873594
line O 0 6.430397206713678e-06
mutations O 0 4.2680025558183843e-07
in O 0 1.73717893403591e-07
the O 0 4.99756765748316e-07
5 O 0 1.4535785339830909e-06
and O 0 4.7308978423643566e-07
3 O 0 1.1510032891237643e-06
regions O 0 3.986248486853583e-07
of O 0 2.2870858629175927e-06
the O 0 1.1311373782518785e-05
APC B-Disease 1 0.9617161750793457
gene O 0 0.00013305335596669465
. O 0 3.0219671316444874e-05

Attenuated B-Disease 1 0.9999858140945435
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
patients O 0 0.15015971660614014
have O 0 3.381799160706578e-06
" O 0 1.3860457329428755e-05
multiple O 0 0.0002197485591750592
" O 1 0.9999457597732544
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 7.3568667176004965e-06
typically O 0 4.922903826809488e-07
fewer O 0 2.6769836836137983e-07
than O 0 1.5845381540202652e-07
100 O 0 1.7260088043258293e-06
) O 0 1.7326190970834432e-07
without O 0 2.050702931910564e-07
the O 0 1.2760933714162093e-06
florid O 0 0.00024360907264053822
phenotype O 0 2.430927997920662e-05
of O 0 2.3250762751558796e-05
classical O 0 0.0012420505518093705
FAP B-Disease 1 0.9997815489768982
. O 0 0.00020388173288665712

Another O 0 0.00010561330418568105
group O 0 1.8632796127349138e-05
of O 0 3.4280907129868865e-05
patients O 0 2.3631544536328875e-05
with O 0 1.0581418337096693e-06
multiple O 0 0.0003815857053268701
adenomas B-Disease 1 0.9999953508377075
has O 0 1.9447052181931213e-06
no O 0 4.58310523754335e-07
mutations O 0 2.3319759634432558e-07
in O 0 2.272260246627411e-07
the O 0 1.542122959108383e-06
APC B-Disease 0 0.1341182142496109
gene O 0 4.099610578123247e-06
, O 0 3.750033670257835e-07
and O 0 3.0489186997328943e-07
their O 0 5.216301133259549e-07
phenotype O 0 4.823250037588878e-06
probably O 0 1.1386520100131747e-06
results O 0 2.2010755174051155e-07
from O 0 4.0370468923356384e-07
variation O 0 1.1164444231326343e-06
at O 0 4.6264931370387785e-06
a O 0 1.2684990906564053e-06
locus O 0 7.705112693656702e-06
, O 0 4.2577659087328357e-07
or O 0 3.986042997894401e-07
loci O 0 2.1887892671657028e-06
, O 0 4.89029389427742e-07
elsewhere O 0 9.740784889800125e-07
in O 0 6.771108473913046e-07
the O 0 2.4894716261769645e-06
genome O 0 4.386540240375325e-05
. O 0 2.165857222280465e-05

Recently O 0 0.0002959545818157494
, O 0 8.2903825386893e-06
however O 0 1.0723407513069105e-06
, O 0 5.165884431335144e-07
a O 0 6.634326723542472e-07
missense O 0 9.465962648391724e-06
variant O 0 6.393341209331993e-06
of O 0 1.9796103515545838e-05
APC B-Disease 1 0.9988391995429993
( O 0 2.810464684444014e-05
I1307K O 1 0.993728756904602
) O 0 3.2653288144501857e-06
was O 0 1.4454280972131528e-05
described O 0 1.9725321180885658e-06
that O 0 1.213874298855444e-07
confers O 0 2.039188075286802e-06
an O 0 3.396708336822485e-07
increased O 0 2.434706175336032e-06
risk O 0 3.8764399505453184e-05
of O 1 0.9946793913841248
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.820307812129613e-06
including O 0 4.680618530983338e-06
multiple O 0 4.698866905528121e-05
adenomas B-Disease 1 0.9999511241912842
, O 0 1.6946558389463462e-05
in O 0 2.441892502247356e-05
Ashkenazim O 0 0.06303069740533829
. O 0 0.00013275213132146746

We O 0 1.288131534238346e-05
have O 0 7.232852112792898e-07
studied O 0 3.3736685054464033e-06
a O 0 6.90624403887341e-07
set O 0 8.290836035484972e-07
of O 0 3.5042316994804423e-06
164 O 0 0.00016984825197141618
patients O 0 2.3317195882555097e-05
with O 0 4.042296495754272e-06
multiple O 1 0.9999760389328003
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.7993349432945251
/ I-Disease 1 0.9999736547470093
or I-Disease 1 0.7858456969261169
carcinoma I-Disease 1 1.0
and O 0 3.8989073800621554e-06
analyzed O 0 5.01331942359684e-06
codons O 0 1.1915598406631034e-05
1263 O 0 0.00027586473152041435
- O 0 4.959766738465987e-05
1377 O 0 0.0041062855161726475
( O 0 5.038497874920722e-06
exon O 0 6.188786937855184e-05
15G O 0 0.0001631888881092891
) O 0 5.986429414406302e-07
of O 0 9.906576678986312e-07
the O 0 2.365893578826217e-06
APC B-Disease 0 0.00036435184301808476
gene O 0 5.803773547086166e-06
for O 0 2.695343027880881e-06
germ O 1 0.9995418787002563
- O 0 0.001151615520939231
line O 0 0.00015600556798744947
variants O 0 7.259857375174761e-05
. O 0 4.554208862828091e-05

Three O 0 5.076738671050407e-05
patients O 0 2.309551382495556e-05
with O 0 9.403630087945203e-07
the O 0 7.238314537971746e-06
I1307K O 0 0.06398576498031616
allele O 0 2.9194538910815027e-06
were O 0 1.065456899596029e-06
detected O 0 3.081325985476724e-06
, O 0 1.6323626539360703e-07
each O 0 1.3567341738962568e-07
of O 0 4.5918031901237555e-06
Ashkenazi O 0 0.0013976176269352436
descent O 0 0.00019264622824266553
. O 0 9.191479330183938e-05

Four O 0 0.00010742492304416373
patients O 0 3.6100769648328424e-05
had O 0 7.67729216022417e-06
a O 0 1.1046526196878403e-05
germ O 1 0.9999498128890991
- O 0 0.0009003274026326835
line O 0 5.225884888204746e-05
E1317Q O 0 0.0004346632049418986
missense O 0 2.1621242922265083e-05
variant O 0 8.41513156046858e-06
of O 0 7.340790034504607e-06
APC O 0 0.019615594297647476
that O 0 8.466258805128746e-07
was O 0 1.0861793271033093e-05
not O 0 9.445300008792401e-08
present O 0 2.5320287022623233e-07
in O 0 3.2380629022554785e-07
controls O 0 2.177367605327163e-06
; O 0 2.0272348422167852e-07
one O 0 1.2616544609045377e-07
of O 0 2.53729609767106e-07
these O 0 6.055343249045109e-08
individuals O 0 5.753262399821324e-08
had O 0 5.91334639921115e-07
an O 0 2.5569207195985655e-07
unusually O 0 1.50646997099102e-06
large O 0 4.990666297999269e-07
number O 0 5.186483917896112e-07
of O 0 3.7327642985474085e-06
metaplastic B-Disease 1 0.754457414150238
polyps I-Disease 0 0.00033171469112858176
of I-Disease 0 8.283381248475052e-06
the I-Disease 0 4.998993972549215e-05
colorectum I-Disease 1 0.7953716516494751
. O 0 7.726973126409575e-05

There O 0 2.1716070477850735e-05
is O 0 1.7613270983929397e-06
increasing O 0 5.073886768514058e-07
evidence O 0 7.531182291131699e-07
that O 0 4.21656913829338e-08
there O 0 1.2639438295991567e-07
exist O 0 3.0717944810021436e-07
germ O 0 0.010978857055306435
- O 0 1.519422949058935e-05
line O 0 2.8484057565947296e-06
variants O 0 4.5004992443864467e-07
of O 0 6.285719678089663e-07
the O 0 2.776636165435775e-06
APC B-Disease 0 0.4167787730693817
gene O 0 3.93863047065679e-06
that O 0 2.2672858790429018e-07
predispose O 0 2.450085958116688e-06
to O 0 2.9109142474226246e-07
the O 0 6.773214522581839e-07
development O 0 2.6139516648981953e-06
of O 0 2.421353929094039e-05
multiple O 1 0.9997195601463318
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998878240585327
carcinoma I-Disease 1 1.0
, O 0 1.5824307411094196e-05
but O 0 6.50644267352618e-07
without O 0 3.52976513795511e-07
the O 0 6.684741151730123e-07
florid O 0 0.00010274055239278823
phenotype O 0 7.815551725798286e-06
of O 0 3.95277902498492e-06
classical O 0 0.00015254532627295703
FAP B-Disease 1 0.999893069267273
, O 0 2.190969553339528e-06
and O 0 6.10867118666647e-07
possibly O 0 1.326331357631716e-06
with O 0 1.5220084037537163e-07
importance O 0 1.4713816199218854e-05
for O 1 0.6985864639282227
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.3806566130369902e-05
in O 0 6.861405950076005e-07
the O 0 6.022999059496215e-07
general O 0 1.5154688526308746e-06
population O 0 4.99613804549881e-07
. O 0 2.0492886960710166e-06
. O 0 1.8599737813929096e-05

Genomic O 0 0.00013511136057786644
structure O 0 5.671336475643329e-05
of O 0 2.319459781574551e-05
the O 0 7.862540951464325e-05
human O 1 0.9994589686393738
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999972581863403
CLD B-Disease 1 1.0
) O 0 0.00021824393479619175
gene O 0 0.000224591902224347
. O 0 4.931511284667067e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999994039535522
CLD B-Disease 1 1.0
) O 0 0.0008288057870231569
is O 0 5.074335149402032e-06
caused O 0 1.5028130292193964e-05
by O 0 1.3479170775099192e-06
mutations O 0 1.1683243883453542e-06
in O 0 9.139674830294098e-07
a O 0 1.698734308774874e-06
gene O 0 2.496437673471519e-06
which O 0 6.370600544869376e-07
encodes O 0 6.048410796211101e-06
an O 0 7.74564796302002e-06
intestinal O 1 0.9998749494552612
anion O 0 0.4420454800128937
transporter O 1 0.9182500243186951
. O 0 0.00018082003225572407

We O 0 1.6222105841734447e-05
report O 0 4.166291091678431e-06
here O 0 8.418418246947112e-07
the O 0 5.398547955337563e-07
complete O 0 9.330859143119596e-07
genomic O 0 1.0924474054263555e-06
organization O 0 5.265421236799739e-07
of O 0 6.201868245625519e-07
the O 0 2.144046447938308e-06
human O 0 1.3695505913347006e-05
CLD B-Disease 1 0.999995231628418
gene O 0 4.260379682818893e-06
which O 0 5.199587462811905e-07
spans O 0 6.301465873548295e-06
approximately O 0 3.997743988293223e-06
39kb O 0 0.00016738726117182523
, O 0 1.8004084267886356e-06
and O 0 1.5145095630941796e-06
comprises O 0 2.1819156245328486e-05
21 O 0 5.734284786740318e-05
exons O 0 0.00023609056370332837
. O 0 5.3282292356016114e-05

All O 0 0.00015918942517600954
exon O 0 0.002599728060886264
/ O 0 0.0004555349296424538
intron O 0 0.00027957349084317684
boundaries O 0 6.401223799912259e-06
conform O 0 6.766404112568125e-06
to O 0 1.9565550246625207e-06
the O 0 2.6083063858095556e-05
GT O 1 0.9999463558197021
/ O 1 0.9960256814956665
AG O 1 0.9999920129776001
rule O 0 0.0002304952940903604
. O 0 8.92661337275058e-05

An O 0 8.382724445255008e-06
analysis O 0 3.3023450214386685e-06
of O 0 3.9099218156479765e-06
the O 0 5.519205387827242e-06
putative O 0 0.00015060501755215228
promoter O 0 0.0068087889812886715
region O 0 2.9372488370427163e-06
sequence O 0 1.1598161790971062e-06
shows O 0 1.4706440651934827e-06
a O 0 2.1054399894637754e-06
putative O 0 0.0002392559836152941
TATA O 1 0.9999998807907104
box O 0 0.0011036209762096405
and O 0 4.313337740313727e-06
predicts O 0 1.3183009286876768e-05
multiple O 0 1.5018267731647938e-06
transcription O 0 1.2077873179805465e-05
factor O 0 6.120804755482823e-06
binding O 0 4.297407031117473e-06
sites O 0 3.2019164791563526e-05
. O 0 1.632636849535629e-05

The O 0 2.2245587388169952e-05
genomic O 0 2.848084295692388e-05
structure O 0 2.1991796529619023e-05
was O 0 1.3732818842981942e-05
determined O 0 5.700372298633738e-07
using O 0 2.246946593231769e-07
DNA O 0 1.7722945813147817e-06
from O 0 2.0398093170115317e-07
several O 0 8.64143103740389e-08
sources O 0 1.5861407121064985e-07
including O 0 2.1691303686566243e-07
multiple O 0 4.756331293265248e-07
large O 0 4.874797468801262e-06
- O 0 0.00020056193170603365
insert O 0 0.00010767557978397235
libaries O 0 0.00014267544611357152
and O 0 4.523830341440771e-07
genomic O 0 4.677739980252227e-06
DNA O 0 2.2563772290595807e-05
from O 0 1.4435215234698262e-05
Finnish O 1 0.9998728036880493
CLD B-Disease 1 1.0
patients O 0 0.00043189115240238607
and O 0 1.9555105609470047e-05
controls O 0 0.00020055101776961237
. O 0 9.399205009685829e-05

Exon O 0 0.002388453111052513
- O 0 5.222202526056208e-05
specific O 0 3.7902484564256156e-06
primers O 0 2.909514842031058e-05
developed O 0 7.790706149535254e-06
in O 0 3.6944589965060004e-07
this O 0 1.004944678584252e-07
study O 0 2.852687828180933e-07
will O 0 5.701971872440481e-08
facilitate O 0 3.0544742912752554e-07
mutation O 0 6.503340728158946e-07
screening O 0 7.646797257621074e-07
studies O 0 9.154059625871014e-07
of O 0 2.128731011907803e-06
patients O 0 4.659245860239025e-06
with O 0 1.1850445389427477e-06
the O 0 0.0008719093166291714
disease O 1 0.9999691247940063
. O 0 9.16364006116055e-05

Genomic O 0 0.00011502941197250038
sequencing O 0 5.2068618970224634e-05
of O 0 3.502910112729296e-05
a O 0 7.389688835246488e-05
BAC O 1 0.9998123049736023
clone O 1 0.836800754070282
H O 1 0.9999984502792358
_ O 0 1.37241786433151e-05
RG364P16 O 0 0.0006585505325347185
revealed O 0 9.18114346859511e-06
the O 0 7.399390824502916e-07
presence O 0 2.829484060384857e-07
of O 0 6.017406803948688e-07
another O 0 7.697994419686438e-07
, O 0 2.294539171998622e-07
highly O 0 4.609167660873936e-07
homologous O 0 4.227722740779427e-07
gene O 0 4.328166198774852e-07
3 O 0 9.297017413700814e-07
of O 0 9.266849474443006e-07
the O 0 3.830095010926016e-06
CLD B-Disease 1 0.9999972581863403
gene O 0 5.828656867379323e-06
, O 0 3.6498747135738085e-07
with O 0 6.900938132048395e-08
a O 0 1.5310752132791094e-07
similar O 0 2.1566819441432017e-07
genomic O 0 1.4497742313324125e-06
structure O 0 2.753688477241667e-06
, O 0 7.022759973551729e-07
recently O 0 1.8548614661995089e-06
identified O 0 6.497005529126909e-07
as O 0 7.81343487687991e-07
the O 0 2.4521346858819015e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.038926444947719574
( O 0 0.00014180090511217713
PDS B-Disease 1 0.9999874830245972
) O 0 2.6208006602246314e-05
. O 0 2.0206567569402978e-05
. O 0 3.663904863060452e-05

The O 0 0.00034399089054204524
APCI1307K O 1 0.9999725818634033
allele O 0 0.00011424891272326931
and O 0 2.2448450181400403e-05
cancer B-Disease 1 0.995863676071167
risk O 0 2.9551097213698085e-06
in O 0 7.995506621227833e-07
a O 0 6.361869964166544e-07
community O 0 6.237332854652777e-07
- O 0 4.060634182678768e-06
based O 0 1.187466523333569e-06
study O 0 1.687145299911208e-06
of O 0 1.0941909749817569e-05
Ashkenazi O 0 0.026108266785740852
Jews O 0 0.00032438759808428586
. O 0 8.632634853711352e-05

Mutations O 0 0.0002650455280672759
in O 0 2.8939848562004045e-05
APC O 0 0.010251804254949093
are O 0 3.508321015033289e-06
classically O 0 0.0014523897552862763
associated O 0 3.185481909895316e-05
with O 0 4.977767457603477e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.8603712916374207
FAP B-Disease 1 1.0
) O 0 4.830614852835424e-05
, O 0 4.1717935346241575e-06
a O 0 9.000980753626209e-06
highly O 0 0.24493396282196045
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999920129776001
by O 0 0.35194385051727295
multiple O 1 0.9999961853027344
intestinal O 1 1.0
polyps B-Disease 1 0.9999982118606567
and O 0 1.3191763173381332e-05
, O 0 3.1086876788322115e-06
without O 0 9.950947514880681e-07
surgical O 1 0.7374701499938965
intervention O 0 1.1605438885453623e-05
, O 0 1.2846272738897824e-06
the O 0 2.391744146734709e-06
development O 0 3.102756090811454e-05
of O 1 0.999935507774353
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.05371595919132233
CRC B-Disease 1 0.9999953508377075
) O 0 5.480344407260418e-05
. O 0 4.764346522279084e-05

APC B-Disease 0 0.010957716964185238
is O 0 4.006506787845865e-05
a O 0 8.963778964243829e-05
tumour O 1 1.0
- O 0 0.006994813680648804
suppressor O 0 0.001071952865459025
gene O 0 5.485710516950348e-06
, O 0 9.233187370227824e-07
and O 0 1.2262584050404257e-06
somatic O 0 0.00021245259267743677
loss O 0 0.034607019275426865
occurs O 0 2.5583145543350838e-05
in O 0 6.287391443038359e-05
tumours B-Disease 1 0.9999998807907104
. O 0 0.0003330376639496535

The O 0 0.00018056125554721802
germline O 0 0.007255108095705509
T O 0 0.055301934480667114
- O 0 4.0077946323435754e-05
to O 0 3.548308086465113e-06
- O 0 2.6839959900826216e-05
A O 0 2.1060519429738633e-05
transversion O 0 0.00010844220378203318
responsible O 0 1.3941556744612171e-06
for O 0 5.18805677529599e-07
the O 0 2.900043455156265e-06
APC O 0 0.002874273806810379
I1307K O 0 0.0003047259524464607
allele O 0 9.883268603516626e-07
converts O 0 1.1238516890443861e-06
the O 0 5.293965159580694e-07
wild O 0 1.1793914609370404e-06
- O 0 2.1809214558743406e-06
type O 0 6.601608788514568e-07
sequence O 0 1.357289534098527e-07
to O 0 1.97703769799773e-07
a O 0 3.976841981057078e-06
homopolymer O 1 0.9999631643295288
tract O 1 0.9999759197235107
( O 0 6.972600385779515e-05
A8 O 1 0.9999819993972778
) O 0 2.0289573967602337e-06
that O 0 2.0500790753885667e-07
is O 0 8.961940238805255e-07
genetically O 0 2.868858791771345e-05
unstable O 0 0.0002282227505929768
and O 0 9.09734171727905e-06
prone O 0 0.000650688714813441
to O 0 6.327746177703375e-06
somatic O 0 0.009608027525246143
mutation O 0 8.116328535834327e-05
. O 0 3.6941550206393003e-05

The O 0 0.00019059731857851148
I1307K O 0 0.004749849904328585
allele O 0 7.267302862601355e-05
was O 0 3.458675564615987e-05
found O 0 4.292913672543364e-06
in O 0 5.50868298887508e-06
6 O 0 9.683299867901951e-05
. O 0 5.1704053475987166e-05

1 O 0 0.00011009931768057868
% O 0 8.512670319760218e-06
of O 0 7.491535598092014e-06
unselected O 0 0.23452885448932648
Ashkenazi O 0 0.002431513974443078
Jews O 0 2.1845266019226983e-05
and O 0 1.5974821963027352e-06
higher O 0 1.7901802493724972e-06
proportions O 0 3.832941274595214e-06
of O 0 3.854422175209038e-06
Ashkenazim O 0 0.00020853820024058223
with O 0 8.425334385719907e-07
family O 0 3.432994617469376e-06
or O 0 1.3616589740195195e-06
personal O 0 4.090975380677264e-06
histories O 0 4.175419690000126e-06
of O 0 6.883228343212977e-05
CRC B-Disease 1 0.9999996423721313
( O 0 8.056091610342264e-05
ref O 0 0.08107813447713852
. O 0 2.850805230991682e-06
2 O 0 9.60282159212511e-06
) O 0 4.064655513502657e-06
. O 0 1.0887949429161381e-05

To O 0 1.0284059499099385e-05
evaluate O 0 7.958617970871273e-06
the O 0 1.9424030597292585e-06
role O 0 2.9169298159104073e-06
of O 0 7.401885341096204e-06
I1307K O 1 0.9093860387802124
in O 0 2.9773113055853173e-05
cancer B-Disease 1 0.965597927570343
, O 0 1.2903354900117847e-06
we O 0 3.0703651532348886e-07
genotyped O 0 5.681572656612843e-05
5 O 0 3.836423275060952e-06
, O 0 2.2028384591976646e-06
081 O 0 0.0007356131682172418
Ashkenazi O 0 5.4995314712869003e-05
volunteers O 0 9.394027074449696e-06
in O 0 9.808095455809962e-07
a O 0 1.7165257304441184e-06
community O 0 4.665955657401355e-06
survey O 0 2.786042205116246e-05
. O 0 2.4273047529277392e-05

Risk O 0 0.0002474576176609844
of O 0 0.00021076103439554572
developing O 1 0.9938055276870728
colorectal B-Disease 1 1.0
, I-Disease 0 0.12100230902433395
breast I-Disease 1 0.9999352693557739
and I-Disease 0 2.8994738840992795e-06
other I-Disease 0 3.0169999263307545e-06
cancers I-Disease 0 0.0601421520113945
were O 0 1.5192022146948148e-06
compared O 0 1.8642997474671574e-06
between O 0 1.371299845231988e-06
genotyped O 1 0.823805570602417
I1307K O 0 0.04468270391225815
carriers O 0 2.132880581484642e-06
and O 0 7.036872489152302e-07
non O 0 4.8736210374045186e-06
- O 0 4.511307452048641e-06
carriers O 0 5.202906550039188e-07
and O 0 8.210916746520525e-08
their O 0 1.3084606109714514e-07
first O 0 1.7056302112905541e-06
- O 0 1.4936344996385742e-05
degree O 0 1.625025470275432e-05
relatives O 0 1.696615800028667e-05
. O 0 2.0944547941326164e-05

Sperm O 0 0.0001082604649127461
DNA O 0 5.335428795660846e-05
analysis O 0 4.755137979373103e-06
in O 0 2.985940227517858e-06
a O 0 2.6098861781065352e-05
Friedreich B-Disease 1 0.9999994039535522
ataxia I-Disease 1 0.9999990463256836
premutation O 1 0.9999949932098389
carrier O 0 0.001283310237340629
suggests O 0 1.4271138752519619e-05
both O 0 2.3521970433648676e-06
meiotic O 0 0.0002612211974337697
and O 0 3.221978658984881e-06
mitotic O 0 5.0704835302894935e-05
expansion O 0 1.6459265680168755e-05
in O 0 4.818518846150255e-06
the O 0 1.827675077947788e-05
FRDA B-Disease 1 0.9999690055847168
gene O 0 0.00015789357712492347
. O 0 6.677718192804605e-05

Friedreich B-Disease 1 0.9999994039535522
ataxia I-Disease 1 0.9999986886978149
is O 0 0.00023762120690662414
usually O 0 1.777782199496869e-05
caused O 0 2.6569276087684557e-05
by O 0 5.684184429810557e-07
an O 0 4.6145026999511174e-07
expansion O 0 4.248600816936232e-06
of O 0 8.442574653599877e-06
a O 0 6.584672064491315e-06
GAA O 0 0.02037503384053707
trinucleotide O 0 0.005579784978181124
repeat O 0 1.1594554052862804e-05
in O 0 2.4812375158944633e-06
intron O 0 7.186279981397092e-05
1 O 0 8.222369615396019e-06
of O 0 3.064951897613355e-06
the O 0 1.2613271792361047e-05
FRDA B-Disease 1 0.9999977350234985
gene O 0 0.00012544369383249432
. O 0 3.363725045346655e-05

Occasionally O 0 0.0001917617628350854
, O 0 5.6964336181408726e-06
a O 0 1.140492031481699e-06
fully O 0 1.7937400116352364e-06
expanded O 0 1.1071384733440937e-06
allele O 0 8.757360774325207e-07
has O 0 1.3572687862506427e-07
been O 0 1.8310942095922655e-07
found O 0 1.3249504604573303e-07
to O 0 6.220260928557764e-08
arise O 0 4.1875321699080814e-07
from O 0 4.922725338474265e-07
a O 0 9.768870086190873e-07
premutation O 0 0.00011237534636165947
of O 0 3.835139068542048e-06
100 O 0 5.848094133398263e-06
or O 0 2.1978735276206862e-06
less O 0 3.952552560804179e-06
triplet O 0 0.0006112470291554928
repeats O 0 0.0001620280381757766
. O 0 6.491781823569909e-05

We O 0 1.0266224307997618e-05
have O 0 6.86835846863687e-07
examined O 0 4.015576905658236e-06
the O 0 8.913738724913856e-07
sperm O 0 1.9381729998713126e-06
DNA O 0 5.995381343382178e-06
of O 0 2.245614950879826e-06
a O 0 2.3130409317673184e-05
premutation O 1 0.9131267666816711
carrier O 0 0.0005429444136098027
. O 0 6.634816236328334e-05

This O 0 4.5093158405506983e-05
mans O 0 0.0006412839866243303
leucocyte O 0 0.0018950123339891434
DNA O 0 8.000242814887315e-05
showed O 0 8.350871212314814e-06
one O 0 1.0632288649503607e-06
normal O 0 1.4370330063684378e-06
allele O 0 7.353116870945087e-07
and O 0 1.463369017074001e-07
one O 0 2.088683856982243e-07
allele O 0 5.342615168046905e-07
of O 0 9.408150276613014e-07
approximately O 0 6.279138233367121e-06
100 O 0 1.1001152415701654e-05
repeats O 0 3.61264574166853e-05
. O 0 2.411219793430064e-05

His O 0 0.0001346374483546242
sperm O 0 1.0549071703280788e-05
showed O 0 5.298276391840773e-06
an O 0 3.3902486507031426e-07
expanded O 0 2.5386273136973614e-06
allele O 0 1.1072365850850474e-06
in O 0 5.962265845482762e-07
a O 0 7.175019050009723e-07
tight O 0 3.2788746011647163e-06
range O 0 2.1255543742881855e-06
centering O 0 7.063173597998684e-06
on O 0 6.898312108205573e-07
a O 0 6.432431405301031e-07
size O 0 9.92274522104708e-07
of O 0 2.3861532554292353e-06
approximately O 0 8.03811417426914e-06
320 O 0 6.606272654607892e-05
trinucleotide O 0 0.0027973332908004522
repeats O 0 0.0001563948899274692
. O 0 9.394912922289222e-05

His O 0 0.001133649842813611
affected O 0 0.0002567191841080785
son O 0 0.0026043455582112074
has O 0 4.187155354884453e-06
repeat O 0 5.682673418050399e-06
sizes O 0 4.144704689679202e-06
of O 0 1.4597587323805783e-05
1040 O 0 0.00036556870327331126
and O 0 2.795359614538029e-05
540 O 0 0.0007720459252595901
. O 0 0.00014113950601313263

These O 0 5.323533969203709e-06
data O 0 3.12035740535066e-06
suggest O 0 1.021432922243548e-06
that O 0 1.08138578980288e-07
expansion O 0 1.6993062672554515e-06
occurs O 0 1.1412411993205751e-07
in O 0 7.065681018048053e-08
two O 0 3.915698698619963e-08
stages O 0 1.937247134264908e-06
, O 0 1.6484730736010533e-07
the O 0 1.5879767545357026e-07
first O 0 7.109086368473072e-07
during O 0 1.2089267329429276e-06
meiosis O 0 5.220175353315426e-06
followed O 0 7.087174367370608e-07
by O 0 3.0423137786783627e-07
a O 0 9.652831067796797e-07
second O 0 1.4240061318560038e-05
mitotic O 0 0.0003099727036897093
expansion O 0 0.00024590137763880193
. O 0 6.316079816315323e-05

We O 0 7.630889740539715e-06
also O 0 1.1522378144945833e-06
show O 0 6.745759719706257e-07
that O 0 5.480552545122919e-08
in O 0 1.668514073571714e-07
all O 0 9.744420026436273e-08
informative O 0 2.456156835251022e-06
carrier O 0 9.195277016260661e-06
father O 0 6.191460215632105e-06
to O 0 4.010668135379092e-07
affected O 0 1.1876093140017474e-06
child O 0 2.9612347134388983e-06
transmissions O 0 3.3708097362250555e-06
, O 0 1.735325980689595e-07
with O 0 6.347725189925768e-08
the O 0 1.9921904481634556e-07
notable O 0 7.972435582814796e-07
exception O 0 6.495592401734029e-07
of O 0 1.0096139249071712e-06
the O 0 3.836445102933794e-06
premutation O 0 0.4057444632053375
carrier O 0 1.2489087566791568e-05
, O 0 6.183390155456436e-07
the O 0 3.891824178481329e-07
expansion O 0 5.740114829677623e-06
size O 0 5.2991504162491765e-06
decreases O 0 1.4155246390146203e-05
. O 0 4.516486114880536e-06
. O 0 1.1381828699086327e-05

The O 0 0.00017536309314891696
R496H O 0 0.004244502633810043
mutation O 0 2.6818112019100226e-05
of O 0 2.7265710741630755e-05
arylsulfatase O 1 0.9867189526557922
A O 0 0.012665205635130405
does O 0 7.745780749246478e-06
not O 0 5.080034043203341e-06
cause O 0 0.0015544669004157186
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999998807907104
. O 0 0.0005532100913114846

Deficiency B-Disease 1 0.9999774694442749
of I-Disease 0 0.1513729691505432
arylsulfatase I-Disease 1 0.9999877214431763
A I-Disease 1 0.9967862367630005
( O 0 0.000527497730217874
ARSA O 1 0.9999967813491821
) O 0 2.2710089979227632e-05
enzyme O 0 6.15187018411234e-05
activity O 0 6.851414946140721e-05
causes O 0 0.017090914770960808
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.12610723078250885
MLD B-Disease 1 1.0
) O 0 0.00022492362768389285
. O 0 0.0001372624683426693

A O 0 6.319441308733076e-05
number O 0 3.6710925996885635e-06
of O 0 2.7865366064361297e-05
ARSA O 1 0.9999924898147583
gene O 0 2.9247372367535718e-05
mutations O 0 3.44007344210695e-06
responsible O 0 5.914005214435747e-06
for O 0 1.0190471584792249e-05
MLD B-Disease 1 1.0
have O 0 3.6525459563563345e-06
been O 0 4.6059781197982375e-06
identified O 0 2.2874413843965158e-05
. O 0 1.9839382730424404e-05

Recently O 0 0.0002584025205578655
, O 0 3.428067429922521e-06
the O 0 3.570685294107534e-06
R496H O 0 0.0002514112857170403
mutation O 0 2.84609745904163e-06
of O 0 8.767540748522151e-06
ARSA O 1 0.9997196793556213
was O 0 1.769403024809435e-05
proposed O 0 6.363939633047266e-07
to O 0 1.8045805916244717e-07
be O 0 1.0650307302739748e-07
a O 0 4.3041728758907993e-07
cause O 0 4.604625701176701e-06
of O 0 0.0001282179291592911
MLD B-Disease 1 1.0
( O 0 3.140640546916984e-05
Draghia O 1 0.6950644850730896
et O 0 6.839018897153437e-05
al O 0 1.9578934370656498e-05
. O 0 1.335120941803325e-06
, O 0 2.0151655917288736e-06
1997 O 0 2.150015461666044e-05
) O 0 1.0231859050691128e-05
. O 0 1.9037537640542723e-05

We O 0 1.0927268704108428e-05
have O 0 7.013583740445029e-07
investigated O 0 6.64873186906334e-06
the O 0 2.820447434714879e-06
R496H O 0 0.002389326924458146
mutation O 0 1.3199979775890824e-06
and O 0 2.1174501796394907e-07
found O 0 4.3701987806343823e-07
this O 0 5.2251131421598984e-08
mutation O 0 3.806669326422707e-07
at O 0 9.300218266616866e-07
a O 0 1.2716273545265722e-07
relatively O 0 1.837938441440201e-07
high O 0 3.368212162513373e-07
frequency O 0 1.1435268731929682e-07
in O 0 3.614535515339412e-08
an O 0 3.390746172726722e-08
African O 0 9.683020607553772e-08
American O 0 2.9451538807734323e-07
population O 0 4.693034227898352e-08
( O 0 1.343357212135743e-07
f O 0 8.738872452340729e-07
= O 0 8.50185983836127e-07
0 O 0 4.258655224020913e-07
. O 0 1.7154098941318807e-07
09 O 0 8.429621630057227e-06
, O 0 4.245136153713247e-07
n O 0 1.3409985513135325e-06
= O 0 1.5689884094172157e-06
61 O 0 5.309393145580543e-06
subjects O 0 7.420834208460292e-06
) O 0 4.924875156575581e-06
. O 0 1.4808638297836296e-05

The O 0 0.0003435550315771252
ARSA O 1 0.9921782612800598
enzyme O 0 2.0237541320966557e-05
activity O 0 3.723868303495692e-06
in O 0 7.657985747755447e-07
subjects O 0 1.4867540585328243e-06
with O 0 2.1910395275881456e-07
and O 0 4.776144351126277e-07
without O 0 6.746042799932184e-07
the O 0 1.808706997508125e-06
R496H O 0 0.013872913084924221
mutation O 0 2.6863258426601533e-06
was O 0 3.997122803411912e-06
determined O 0 6.133796546237136e-07
and O 0 2.7102572630610666e-07
found O 0 5.479569153976627e-07
to O 0 3.182290413406008e-07
be O 0 6.775036354156327e-07
normal O 0 9.324898201157339e-06
. O 0 1.080781476048287e-05

It O 0 1.9513932784320787e-05
is O 0 2.177508804379613e-06
therefore O 0 7.933420533845492e-07
concluded O 0 1.1364920737833017e-06
that O 0 9.101874098860208e-08
the O 0 4.846128263125138e-07
R496H O 0 0.0006017765263095498
mutation O 0 2.7049584332417e-06
of O 0 8.949838047556113e-06
ARSA O 1 0.9999642372131348
does O 0 1.1725704780474189e-06
not O 0 6.199580582233466e-08
negatively O 0 2.422578120331309e-07
influence O 0 4.06166151378784e-07
the O 0 3.627440605669108e-07
activity O 0 9.164226639768458e-07
of O 0 3.2834464036568534e-06
ARSA O 1 0.9995493292808533
and O 0 1.7383318891006638e-06
is O 0 7.2318590582654e-07
not O 0 1.6215683729114971e-07
a O 0 2.53359667112818e-06
cause O 0 4.371010072645731e-05
of O 0 0.0011974758235737681
MLD B-Disease 1 1.0

Down O 0 0.0008753020665608346
- O 0 6.598880281671882e-05
regulation O 0 1.3136927009327337e-05
of O 0 2.5783276214497164e-05
transmembrane O 0 0.0004927172558382154
carbonic O 1 0.9869842529296875
anhydrases O 1 0.9997230172157288
in O 0 0.035318415611982346
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 0 0.0007928685517981648
lines O 0 3.1340375699073775e-06
by O 0 1.142022256317432e-06
wild O 0 1.089706984203076e-05
- O 0 6.54665709589608e-05
type O 0 0.00016383951879106462
von B-Disease 1 0.9944233298301697
Hippel I-Disease 1 0.999968409538269
- I-Disease 1 0.8782896995544434
Lindau I-Disease 1 0.9997274279594421
transgenes O 0 0.0318303145468235
. O 0 0.00027687184046953917

To O 0 1.567552135384176e-05
discover O 0 2.411882087471895e-05
genes O 0 1.0215508154942654e-06
involved O 0 1.1268286925769644e-06
in O 0 2.2624981284025125e-06
von B-Disease 0 0.18666337430477142
Hippel I-Disease 1 0.9998629093170166
- I-Disease 0 0.48031508922576904
Lindau I-Disease 1 0.9999673366546631
( O 0 5.8523302868707106e-05
VHL B-Disease 1 0.9999679327011108
) O 0 1.1461977010185365e-05
- O 0 6.449778447858989e-05
mediated O 0 8.460893150186166e-05
carcinogenesis O 1 0.9962887763977051
, O 0 2.5425815692869946e-06
we O 0 5.355883558877395e-07
used O 0 4.6917382860556245e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 0 0.016554877161979675
lines O 0 8.739558325032704e-06
stably O 0 8.4250008512754e-05
transfected O 0 6.840022979304194e-05
with O 0 1.4871113762637833e-06
wild O 0 2.223710180260241e-05
- O 0 0.00023142587451729923
type O 0 0.006899569649249315
VHL O 1 0.9999969005584717
- O 0 0.0036572010722011328
expressing O 0 0.00021815719082951546
transgenes O 0 0.0043255421333014965
. O 0 8.384414832107723e-05

Large O 0 9.734970808494836e-05
- O 0 4.5740558562101796e-05
scale O 0 1.1891100257344078e-05
RNA O 0 6.682550520054065e-06
differential O 0 1.880724994407501e-06
display O 0 5.124029030412203e-06
technology O 0 3.750605856112088e-06
applied O 0 5.695829372598382e-07
to O 0 1.2219281586567377e-07
these O 0 1.6589719109560974e-07
cell O 0 2.867295734176878e-06
lines O 0 4.867151233156619e-07
identified O 0 2.2859076409531554e-07
several O 0 1.1185593962181883e-07
differentially O 0 1.7826806697485154e-06
expressed O 0 2.3615670841081737e-07
genes O 0 2.2041129454919428e-07
, O 0 2.1525866600313748e-07
including O 0 2.1630035007547121e-07
an O 0 4.2318211512792914e-07
alpha O 0 8.756460010772571e-05
carbonic O 0 0.002605037996545434
anhydrase O 0 0.0841154158115387
gene O 0 2.7103091269964352e-05
, O 0 8.599718057666905e-06
termed O 0 0.0003918900911230594
CA12 O 1 0.9997640252113342
. O 0 0.00012653668818529695

The O 0 3.0900111596565694e-05
deduced O 0 3.816587559413165e-05
protein O 0 2.486863877493306e-06
sequence O 0 1.7516950947538135e-06
was O 0 4.9968089115282055e-06
classified O 0 1.9817673546640435e-06
as O 0 2.385654340741894e-07
a O 0 4.5679374238716264e-07
one O 0 8.516726097695937e-07
- O 0 1.7216396372532472e-05
pass O 0 8.241138857556507e-06
transmembrane O 0 7.579278462799266e-05
CA O 0 0.00017429902800358832
possessing O 0 1.685338793322444e-05
an O 0 1.1592003374971682e-06
apparently O 0 4.472005457500927e-06
intact O 0 9.239659448212478e-06
catalytic O 0 6.705065970891155e-06
domain O 0 2.2387082481145626e-06
in O 0 8.097898671621806e-07
the O 0 4.4278376662987284e-06
extracellular O 0 0.000247896125074476
CA O 0 0.1516643613576889
module O 0 0.004251995589584112
. O 0 6.119158206274733e-05

Reintroduced O 0 0.0006595156155526638
wild O 0 0.0001813183189369738
- O 0 0.0004186434089206159
type O 0 0.0007937885238789022
VHL B-Disease 1 0.9989416003227234
strongly O 0 7.094780812622048e-06
inhibited O 0 8.583748240198474e-06
the O 0 9.399362284057133e-07
overexpression O 0 1.2385684385662898e-05
of O 0 2.7318005777487997e-06
the O 0 5.3911685427010525e-06
CA12 O 1 0.9996323585510254
gene O 0 2.338923195566167e-06
in O 0 7.463045221811626e-07
the O 0 8.870059900800698e-06
parental O 0 0.0011633880203589797
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.994350254535675
lines O 0 0.0001949984289240092
. O 0 7.534449105150998e-05

Similar O 0 1.4740555343450978e-05
results O 0 2.3456491362594534e-06
were O 0 1.1635187320280238e-06
obtained O 0 1.695762534836831e-06
with O 0 9.881675850920146e-07
CA9 O 1 0.9997856020927429
, O 0 1.3628360875372891e-06
encoding O 0 2.249767021567095e-06
another O 0 6.874925475131022e-06
transmembrane O 0 3.535955329425633e-05
CA O 0 3.595797170419246e-05
with O 0 5.61640831620025e-07
an O 0 1.4805580121901585e-06
intact O 0 9.630478598410264e-05
catalytic O 0 0.00014775869203731418
domain O 0 6.562659109476954e-05
. O 0 5.349699131329544e-05

Although O 0 2.667766239028424e-05
both O 0 1.1645222457445925e-06
domains O 0 4.493029791774461e-06
of O 0 6.001467681926442e-06
the O 0 2.363726707699243e-05
VHL B-Disease 1 0.9999290704727173
protein O 0 3.6592957712855423e-06
contribute O 0 1.0501396445761202e-06
to O 0 4.156086106377188e-07
regulation O 0 1.6016895187931368e-06
of O 0 5.140004304848844e-06
CA12 O 1 0.999911904335022
expression O 0 1.969723598449491e-06
, O 0 4.397763007091271e-07
the O 0 7.727680895186495e-07
elongin O 0 4.821208131033927e-05
binding O 0 9.675171668277471e-07
domain O 0 2.9904911116318544e-06
alone O 0 1.4506094885291532e-06
could O 0 2.9502450615837006e-07
effectively O 0 4.488669674174162e-06
regulate O 0 2.9714710763073526e-05
CA9 O 1 0.994572103023529
expression O 0 5.5595231970073655e-05
. O 0 5.1485545554896817e-05

We O 0 5.0465474487282336e-05
mapped O 0 0.00036006307345815003
CA12 O 1 0.9903746247291565
and O 0 5.6017350289039314e-05
CA9 O 1 0.9987660646438599
loci O 0 6.843461596872658e-05
to O 0 8.134167728712782e-06
chromosome O 0 3.4019594750134274e-05
bands O 0 0.00015443227312061936
15q22 O 0 0.0023943923879414797
and O 0 6.404632586054504e-05
17q21 O 0 0.01680033653974533
. O 0 0.00019057843019254506

2 O 0 0.00025260637630708516
respectively O 0 6.605567614315078e-05
, O 0 5.3440739975485485e-06
regions O 0 3.9426890907634515e-06
prone O 0 4.343900945968926e-05
to O 0 3.054269427593681e-06
amplification O 0 0.00010424791253171861
in O 0 4.6778695832472295e-06
some O 0 3.0403377877519233e-06
human O 0 8.549850463168696e-05
cancers B-Disease 1 0.9913153648376465
. O 0 7.94360094005242e-05

Additional O 0 2.3599361156811938e-05
experiments O 0 1.8720264051808044e-05
are O 0 1.807674152587424e-07
needed O 0 4.015283536773495e-07
to O 0 1.1529442645041854e-07
define O 0 3.1877883088782255e-07
the O 0 3.9527083117718576e-07
role O 0 2.5393394480488496e-06
of O 0 1.631492887099739e-05
CA O 1 0.7300695180892944
IX O 1 0.999991774559021
and O 0 1.6245050574070774e-05
CA O 0 0.10824280977249146
XII O 1 0.9998733997344971
enzymes O 0 1.5213335018415819e-06
in O 0 4.745873525280331e-07
the O 0 3.3698827905936923e-07
regulation O 0 8.471056389680598e-07
of O 0 1.946705651789671e-06
pH O 0 1.7110820408561267e-05
in O 0 7.823150554031599e-07
the O 0 9.683377584224218e-07
extracellular O 0 5.326169684849447e-06
microenvironment O 0 2.7166694053448737e-05
and O 0 2.907435145971249e-07
its O 0 3.147460461150331e-07
potential O 0 1.8166900872529368e-06
impact O 0 4.527785677055363e-06
on O 0 2.2552905647899024e-05
cancer B-Disease 1 0.9930311441421509
cell O 0 0.00016553291061427444
growth O 0 2.7960713850916363e-05
. O 0 1.4136482604953926e-05

A O 0 0.00018131709657609463
gene O 0 1.066236109181773e-05
encoding O 0 4.968497250956716e-06
a O 0 4.730613909487147e-06
transmembrane O 0 2.2930369595997036e-05
protein O 0 5.574302576860646e-06
is O 0 1.242640905729786e-06
mutated O 0 1.01236555565265e-05
in O 0 2.9209772947069723e-06
patients O 0 0.000199822272406891
with O 0 0.3050742447376251
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999995231628418
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 0.0015939705772325397
. O 0 0.0002628395741339773

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9827321171760559
WFS B-Disease 1 1.0
; O 0 0.004269343335181475
OMIM O 1 1.0
222300 O 1 0.999890923500061
) O 0 1.4524461221299134e-05
is O 0 2.3682750907028094e-06
an O 0 3.754070121431141e-06
autosomal B-Disease 1 0.9997636675834656
recessive I-Disease 1 0.9999998807907104
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.0003176092868670821
by O 0 3.764617213164456e-05
young O 0 0.016426490619778633
- O 0 0.19721248745918274
onset O 1 0.9992220401763916
non O 1 0.6984962821006775
- O 1 0.9980886578559875
immune O 1 0.9991461038589478
insulin B-Disease 1 0.9932679533958435
- I-Disease 1 0.9995905756950378
dependent I-Disease 1 0.9988396763801575
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999587535858154
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999997615814209
. O 0 0.009171281941235065

Linkage O 0 0.0004428978718351573
to O 0 9.841847713687457e-06
markers O 0 6.671327719232067e-05
on O 0 1.8492892195354216e-05
chromosome O 0 4.67538702650927e-05
4p O 0 0.26350870728492737
was O 0 3.4837881685234606e-05
confirmed O 0 3.071491619266453e-06
in O 0 5.811660912513616e-07
five O 0 1.4459354815699044e-06
families O 0 2.2266356154432287e-06
. O 0 2.941862476291135e-05

On O 0 2.094013507303316e-05
the O 0 2.5348729195684427e-06
basis O 0 2.235311967524467e-06
of O 0 1.066756794898538e-05
meiotic O 1 0.9998481273651123
recombinants O 1 0.9999728202819824
and O 0 0.0007999003282748163
disease O 1 0.9998236298561096
- O 0 9.159910405287519e-05
associated O 0 6.6564848566486035e-06
haplotypes O 0 1.562920442665927e-05
, O 0 1.4427027963392902e-06
the O 0 2.732009079409181e-06
WFS B-Disease 1 0.9999593496322632
gene O 0 4.629225713870255e-06
was O 0 6.02596173848724e-06
localized O 0 3.1216729894367745e-06
to O 0 9.96652374851692e-07
a O 0 2.13783005165169e-05
BAC O 1 0.9999957084655762
/ O 0 0.001165575347840786
P1 O 1 0.9252782464027405
contig O 0 0.00019266623712610453
of O 0 4.85613918499439e-06
less O 0 7.385339699794713e-07
than O 0 8.737747521081474e-07
250 O 0 1.465986315452028e-05
kb O 0 0.0010004934156313539
. O 0 7.506665861001238e-05

Mutations O 0 6.28319539828226e-05
in O 0 9.610756023903377e-06
a O 0 8.16571537143318e-06
novel O 0 2.2233667550608516e-05
gene O 0 1.509254434495233e-05
( O 0 5.082966254121857e-06
WFS1 O 1 0.9962999224662781
) O 0 1.4663335150544299e-06
encoding O 0 1.093960236175917e-06
a O 0 1.482090851823159e-06
putative O 0 1.1350991371728014e-05
transmembrane O 0 4.542516307992628e-06
protein O 0 7.340856313930999e-07
were O 0 4.361197341040679e-07
found O 0 2.4021352373893023e-07
in O 0 1.145333143881544e-07
all O 0 7.413078861873146e-08
affected O 0 2.6149737664127315e-07
individuals O 0 5.109742673425899e-08
in O 0 9.112190468840708e-07
six O 0 1.0349900549044833e-05
WFS B-Disease 1 0.999997615814209
families O 0 1.2936671964780544e-06
, O 0 6.434867145799217e-07
and O 0 3.159971697641595e-07
these O 0 1.9495315939366265e-07
mutations O 0 4.3411174033280986e-07
were O 0 5.802002647214977e-07
associated O 0 1.5623796798536205e-06
with O 0 1.4801515817453037e-06
the O 0 0.024396734312176704
disease O 1 0.9999994039535522
phenotype O 0 0.0015450705541297793
. O 0 9.679809591034427e-05

WFS1 O 1 0.9997898936271667
appears O 0 2.6420153517392464e-05
to O 0 5.318543685461918e-07
function O 0 3.77430183107208e-07
in O 0 5.41461474767857e-07
survival O 0 5.491955107572721e-06
of O 0 4.698345946962945e-06
islet O 0 0.00026205237372778356
beta O 0 1.8513908798922785e-05
- O 0 2.3878925276221707e-05
cells O 0 6.577529802598292e-06
and O 0 1.8084447219735011e-06
neurons O 0 1.9258950487710536e-05
. O 0 5.957814664725447e-06
. O 0 2.1321005988284014e-05

Stable O 0 0.00020499477977864444
interaction O 0 9.70181281445548e-06
between O 0 2.1750245196017204e-06
the O 0 1.2177509916000417e-06
products O 0 4.1357575355505105e-06
of O 0 5.794504886580398e-06
the O 0 2.2681306290905923e-05
BRCA1 O 0 0.008881566114723682
and O 0 2.2452282792073674e-05
BRCA2 O 0 0.4351520836353302
tumor B-Disease 1 0.8959511518478394
suppressor O 0 0.00010289075726177543
genes O 0 1.3767114523943746e-06
in O 0 1.1190923032700084e-06
mitotic O 0 5.440966197056696e-05
and O 0 1.0827798178070225e-05
meiotic O 1 0.9301588535308838
cells O 0 0.00028588512213900685
. O 0 6.177873001433909e-05

BRCA1 O 0 0.16901417076587677
and O 0 8.24497255962342e-05
BRCA2 O 0 0.0002723934012465179
account O 0 1.5238775858961162e-06
for O 0 4.3186130938011047e-07
most O 0 3.777150254791195e-07
cases O 0 2.093254209967199e-07
of O 0 3.5228647448093398e-06
familial O 0 0.006940110120922327
, O 0 5.007308573112823e-06
early O 0 0.0007131680613383651
onset O 1 0.9999977350234985
breast B-Disease 1 0.999994158744812
and I-Disease 0 0.0001265227037947625
/ I-Disease 1 0.9999707937240601
or I-Disease 1 0.9998769760131836
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1834702036139788e-06
encode O 0 7.952593250593054e-07
products O 0 2.0652610146498773e-06
that O 0 1.2529422122042888e-07
each O 0 1.6013321157970495e-07
interact O 0 9.783731229617842e-07
with O 0 4.8045012590591796e-06
hRAD51 O 0 0.003412465797737241
. O 0 8.566677570343018e-05

Results O 0 4.9932903493754566e-05
presented O 0 3.240270234527998e-05
here O 0 4.971421731170267e-06
show O 0 2.760732968454249e-06
that O 0 5.714867938877433e-07
BRCA1 O 0 4.010554766864516e-05
and O 0 1.7958026319320197e-06
BRCA2 O 0 5.668097946909256e-05
coexist O 0 1.6820139308038051e-06
in O 0 4.820568619834376e-07
a O 0 9.287039119953988e-07
biochemical O 0 2.3358550606644712e-05
complex O 0 2.9460514269885607e-05
and O 0 6.291401859925827e-06
colocalize O 0 0.010685247369110584
in O 0 8.625443115306552e-06
subnuclear O 0 0.000745100318454206
foci O 0 9.267829591408372e-05
in O 0 1.9304657143948134e-06
somatic O 0 3.755541911232285e-05
cells O 0 1.918589305205387e-06
and O 0 4.435536595792655e-07
on O 0 3.619651351982611e-07
the O 0 3.3607489058340434e-07
axial O 0 1.3325895906746155e-06
elements O 0 1.5718459280833486e-06
of O 0 6.844878043921199e-06
developing O 0 8.612440433353186e-05
synaptonemal O 0 0.29066216945648193
complexes O 0 0.0008229683735407889
. O 0 0.00011003258259734139

Like O 0 0.0009003569721244276
BRCA1 O 0 0.0034513561986386776
and O 0 8.729847468202934e-05
RAD51 O 1 0.999962568283081
, O 0 4.202031414024532e-05
BRCA2 O 0 0.00025067265960387886
relocates O 0 9.236447658622637e-05
to O 0 3.858702712022932e-06
PCNA O 0 0.49130305647850037
+ O 0 7.578823442599969e-06
replication O 0 1.6801415085865301e-06
sites O 0 4.3958385731457383e-07
following O 0 3.4700570950008114e-07
exposure O 0 3.209509486623574e-06
of O 0 2.3433751721313456e-06
S O 0 0.0006241814116947353
phase O 0 4.592834011418745e-05
cells O 0 2.95391510007903e-06
to O 0 8.98308428531891e-07
hydroxyurea O 0 0.0003307374136056751
or O 0 1.6549091014894657e-05
UV O 1 0.919607400894165
irradiation O 0 0.0006611918797716498
. O 0 5.3413848945638165e-05

Thus O 0 9.710039012134075e-05
, O 0 3.0901497666491196e-05
BRCA1 O 0 0.0001620371622266248
and O 0 3.2906061733228853e-06
BRCA2 O 0 3.1719049729872495e-05
participate O 0 1.2041493846481899e-06
, O 0 8.808605684862414e-07
together O 0 4.7011289439069515e-07
, O 0 3.15981225185169e-07
in O 0 2.344463183590051e-07
a O 0 9.3409732926375e-07
pathway O 0 5.694934316125e-06
( O 0 1.037331230691052e-06
s O 0 9.212305485561956e-06
) O 0 1.9920251759231178e-07
associated O 0 1.626428343115549e-07
with O 0 3.246710988946688e-08
the O 0 2.845731614797842e-07
activation O 0 1.325887410530413e-06
of O 0 2.141971890523564e-06
double O 0 1.7033598851412535e-05
- O 0 0.00012069208605680615
strand O 0 2.103378574247472e-05
break O 0 1.4868553080304991e-05
repair O 0 0.07423941045999527
and O 0 1.3607473192678299e-05
/ O 0 7.346912752836943e-05
or O 0 3.6162155083729886e-06
homologous O 0 1.627630990697071e-05
recombination O 0 3.5367378586670384e-05
. O 0 3.0771931051276624e-05

Dysfunction O 1 0.9866061806678772
of O 0 0.0001489894202677533
this O 0 4.627667294698767e-06
pathway O 0 2.5012201149365865e-05
may O 0 1.0093607443195651e-06
be O 0 1.5232077998916793e-07
a O 0 4.018279469164554e-07
general O 0 1.3166626331440057e-06
phenomenon O 0 2.118277279805625e-06
in O 0 2.058902026647047e-07
the O 0 3.745658716525213e-07
majority O 0 8.528042627631294e-08
of O 0 3.8955079162406037e-07
cases O 0 4.3601244215096813e-07
of O 0 5.116052125231363e-05
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9645399451255798
/ I-Disease 1 0.9999997615814209
or I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.97196155670099e-05
. O 0 5.416618296294473e-05

A O 0 0.0004766515048686415
novel O 0 7.390436076093465e-05
Arg362Ser O 0 0.00202652788721025
mutation O 0 4.2243073039571755e-06
in O 0 5.764097181781835e-07
the O 0 8.501932597937412e-07
sterol O 0 4.758090290124528e-05
27 O 0 3.0600120226154104e-05
- O 0 2.0244526240276173e-05
hydroxylase O 0 0.00013400281022768468
gene O 0 4.056129000673536e-06
( O 0 1.1039617220376385e-06
CYP27 O 1 0.9853789806365967
) O 0 5.85361249250127e-07
: O 0 1.2895330314677267e-07
its O 0 1.0101140901497274e-07
effects O 0 7.999136641956284e-07
on O 0 4.6577073931075574e-07
pre O 0 1.633322062843945e-05
- O 0 3.1379461233882466e-06
mRNA O 0 1.3725505141337635e-06
splicing O 0 5.073696229374036e-06
and O 0 7.563614872196922e-07
enzyme O 0 1.0530176041356754e-05
activity O 0 1.818999953684397e-05
. O 0 2.9910595912951976e-05

A O 0 0.0003076955326832831
novel O 0 3.0831848562229425e-05
C O 0 9.107633377425373e-05
to O 0 5.621380978482193e-07
A O 0 5.718477495975094e-06
mutation O 0 5.055869678471936e-07
in O 0 1.7001006824557408e-07
the O 0 4.1551945173523563e-07
sterol O 0 3.286518403911032e-05
27 O 0 1.965346200449858e-05
- O 0 2.2572163288714364e-05
hydroxylase O 0 0.00014102582645136863
gene O 0 5.9291792240401264e-06
( O 0 1.900565848700353e-06
CYP27 O 1 0.9786383509635925
) O 0 1.1889544566656696e-06
was O 0 3.2817526971484767e-06
identified O 0 3.290771246611257e-07
by O 0 1.8118110745035665e-07
sequencing O 0 5.3605358516506385e-06
amplified O 0 5.2325565775390714e-05
CYP27 O 1 0.9248790144920349
gene O 0 3.80491974283359e-06
products O 0 2.691685494937701e-06
from O 0 1.7789511730370577e-06
a O 0 3.970320449298015e-06
patient O 0 1.3684931218449492e-05
with O 0 2.9131795145076467e-06
cerebrotendinous B-Disease 1 0.9999998807907104
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 0.004928152542561293
CTX B-Disease 1 0.9999995231628418
) O 0 0.00015949102817103267
. O 0 8.416296623181552e-05

The O 0 9.990716353058815e-05
mutation O 0 2.7544936529011466e-05
changed O 0 6.269552613957785e-06
the O 0 5.265228537609801e-06
adrenodoxin O 0 0.0004079323261976242
cofactor O 0 4.209150210954249e-05
binding O 0 4.288294348953059e-06
residue O 0 5.9370300732553005e-05
362Arg O 0 8.150471694534644e-05
to O 0 2.687658479771926e-06
362Ser O 0 0.00032025278778746724
( O 0 1.2916841114929412e-05
CGT O 1 0.6787547469139099
362Arg O 0 0.0006520663155242801
to O 0 9.563251296640374e-06
AGT O 1 0.9999992847442627
362Ser O 0 0.032829780131578445
) O 0 2.4889848191378405e-06
, O 0 5.133289846526168e-07
and O 0 3.828331500699278e-07
was O 0 6.890172699058894e-06
responsible O 0 6.145932275103405e-06
for O 0 9.495725862507243e-06
deficiency O 1 0.9988918900489807
in O 0 4.923232154396828e-06
the O 0 6.093780029914342e-06
sterol O 0 0.0001503358653280884
27 O 0 3.1912164558889344e-05
- O 0 1.4311521226773039e-05
hydroxylase O 0 4.526894917944446e-05
activity O 0 1.6119485053422977e-06
, O 0 1.750767069097492e-07
as O 0 1.1665246546499475e-07
confirmed O 0 2.97558528927766e-07
by O 0 1.137800538231204e-07
expression O 0 2.1750878431703313e-07
of O 0 8.317857691508834e-07
mutant O 0 5.086248620500555e-06
cDNA O 0 9.465186849411111e-06
into O 0 4.943321073369589e-06
COS O 0 0.04669450968503952
- O 0 0.00010204342106590047
1 O 0 4.6765686420258135e-05
cells O 0 3.809162444667891e-05
. O 0 1.625378899916541e-05

Quantitative O 0 5.158270141691901e-05
analysis O 0 6.001491328788688e-06
showed O 0 6.663592557742959e-06
that O 0 2.0161755287517735e-07
the O 0 2.528469735807448e-07
expression O 0 3.8962099324635346e-07
of O 0 2.3407105800288264e-06
CYP27 O 1 0.9995444416999817
gene O 0 1.3902722457714844e-06
mRNA O 0 1.3378945595832192e-06
in O 0 4.0487293517799117e-07
the O 0 1.136824835157313e-06
patient O 0 8.039102795009967e-06
represented O 0 5.950194463366643e-06
52 O 0 5.136201798450202e-05
. O 0 3.0124316253932193e-05

5 O 0 0.00010886286327149719
% O 0 9.653948836785275e-06
of O 0 5.127035365148913e-06
the O 0 9.229770512320101e-06
normal O 0 2.223820411018096e-05
level O 0 7.727444608462974e-05
. O 0 4.859561158809811e-05

As O 0 2.5162205929518677e-05
the O 0 3.961987658840371e-06
mutation O 0 2.4359533199458383e-06
occurred O 0 3.0327794320328394e-06
at O 0 2.1949474557914073e-06
the O 0 7.283659329004877e-07
penultimate O 0 1.0942994776996784e-05
nucleotide O 0 9.761447472556029e-07
of O 0 1.3673574130734778e-06
exon O 0 1.3968166058475617e-05
6 O 0 4.8683623390388675e-06
( O 0 5.001319891562162e-07
- O 0 2.6097370664501796e-06
2 O 0 1.1020472356904065e-06
position O 0 8.046436050790362e-07
of O 0 1.120516913033498e-06
exon O 0 1.6471685739816166e-05
6 O 0 9.327503903477918e-06
- O 0 1.3442428098642267e-05
intron O 0 6.097151344874874e-05
6 O 0 4.213010015519103e-06
splice O 0 1.297130438615568e-05
site O 0 5.154494829184841e-06
) O 0 1.8599048701162246e-07
of O 0 4.1267804817834985e-07
the O 0 4.572788725454302e-07
gene O 0 1.1971303592872573e-06
, O 0 3.4582498642521387e-07
we O 0 6.829743171010705e-08
hypothesized O 0 6.513737389468588e-07
that O 0 5.603077113391919e-08
the O 0 4.3279104033899785e-07
mutation O 0 1.0731674819908221e-06
may O 0 4.996866778128606e-07
partially O 0 3.2394175377703505e-06
affect O 0 2.1024251850576547e-07
the O 0 1.6025741444991581e-07
normal O 0 2.080457619513254e-07
splicing O 0 5.867870527254127e-07
efficiency O 0 8.459471700916765e-07
in O 0 5.355536814022344e-07
exon O 0 1.6999812942231074e-05
6 O 0 2.781820285235881e-06
and O 0 3.843842932838015e-07
cause O 0 1.112958557314414e-06
alternative O 0 1.2073713833160582e-06
splicing O 0 4.779567007062724e-06
elsewhere O 0 9.824441349337576e-07
, O 0 1.6203115649204847e-07
which O 0 8.718065203083825e-08
resulted O 0 8.500043691128667e-07
in O 0 4.1522193328091817e-07
decreased O 0 4.331657237344189e-06
transcript O 0 5.824238996865461e-06
in O 0 1.4442789506574627e-06
the O 0 6.312942332442617e-06
patient O 0 0.000176386529346928
. O 0 3.076703069382347e-05

Transfection O 0 0.003400438232347369
of O 0 0.00013523988309316337
constructed O 0 0.03944510594010353
minigenes O 1 0.9790413975715637
, O 0 4.6064747039054055e-06
with O 0 3.279477027717803e-07
or O 0 5.412167638496612e-07
without O 0 3.5134701192873763e-07
the O 0 3.127231309463241e-07
mutation O 0 3.535789119268884e-07
, O 0 2.5057059360733547e-07
into O 0 1.2622372196346987e-06
COS O 1 0.8932107090950012
- O 0 2.6289608285878785e-05
1 O 0 3.4227982723677997e-06
cells O 0 5.264422497930354e-07
confirmed O 0 1.3303137791353947e-07
that O 0 1.4087873978496646e-08
the O 0 1.8254590372634993e-07
mutant O 0 7.131248821679037e-06
minigene O 0 0.00015878315025474876
was O 0 5.75591366214212e-06
responsible O 0 6.344099574562279e-07
for O 0 1.5014057908047107e-07
a O 0 2.6794612040248467e-07
mRNA O 0 9.725329164211871e-07
species O 0 6.897333548749884e-08
alternatively O 0 7.434155122609809e-07
spliced O 0 4.092333711014362e-06
at O 0 3.308302666482632e-06
an O 0 7.760611993035127e-07
activated O 0 6.882959860377014e-05
cryptic O 0 2.2082918803789653e-05
5 O 0 4.624887424142798e-06
splice O 0 4.9820322601590306e-05
site O 0 3.135585939162411e-05
88 O 0 2.311131356691476e-05
bp O 0 1.1527396964083891e-05
upstream O 0 2.520246198400855e-06
from O 0 4.5241540647111833e-07
the O 0 2.967265402276098e-07
3 O 0 1.2125315151934046e-06
end O 0 1.676153260632418e-06
of O 0 5.912358574278187e-06
exon O 0 0.00024090758233796805
6 O 0 0.00010786672646645457
. O 0 2.6493953555473126e-05

Our O 0 3.379672853043303e-05
data O 0 6.157137249829248e-06
suggest O 0 1.4027726820131647e-06
that O 0 2.602777726679051e-07
the O 0 9.495965969108511e-07
C O 0 2.3991433408809826e-05
to O 0 3.6321901575320226e-07
A O 0 5.917705948377261e-06
mutation O 0 7.674472044527647e-07
at O 0 1.2479341648941045e-06
the O 0 4.342641375387757e-07
penultimate O 0 8.285765943583101e-06
nucleotide O 0 7.070203196235525e-07
of O 0 6.517571478070749e-07
exon O 0 4.9190175559488125e-06
6 O 0 8.866616099112434e-07
of O 0 5.836109835399839e-07
the O 0 1.5761449958517915e-06
CYP27 O 1 0.9999786615371704
gene O 0 2.7261528430244653e-06
not O 0 8.941572815501786e-08
only O 0 2.364979252433841e-07
causes O 0 3.6269984775572084e-06
the O 0 1.1146878932777327e-05
deficiency B-Disease 1 0.948482871055603
in I-Disease 0 2.2958599856792716e-06
the I-Disease 0 1.8784861595122493e-06
sterol I-Disease 0 4.358157093520276e-05
27 I-Disease 0 1.6583246178925037e-05
- I-Disease 0 1.5588639143970795e-05
hydroxylase I-Disease 0 4.356603676569648e-05
activity I-Disease 0 1.0367872391725541e-06
, O 0 1.81620691819262e-07
but O 0 7.994654538379109e-08
also O 0 1.5041415224459342e-07
partially O 0 2.734740746745956e-06
leads O 0 3.2919859904723126e-07
to O 0 9.13906745836357e-08
alternative O 0 7.289601171578397e-07
pre O 0 1.0403765372757334e-05
- O 0 2.5528495370963356e-06
mRNA O 0 9.968775884772185e-07
splicing O 0 1.7329160755252815e-06
of O 0 1.2948509038324119e-06
the O 0 3.620677262006211e-06
gene O 0 2.1609677787637338e-05
. O 0 1.4947673662391026e-05

To O 0 1.6574709661654197e-05
our O 0 6.554811079695355e-06
knowledge O 0 9.806088201003149e-06
, O 0 7.00987925483787e-07
this O 0 1.1868479532495257e-07
is O 0 7.417619229954653e-08
the O 0 2.1392801841102482e-07
first O 0 7.001407311690855e-07
report O 0 1.3011401733820094e-07
regarding O 0 2.0873874007065751e-07
effects O 0 1.3762283970208955e-06
on O 0 8.802348929748405e-07
pre O 0 8.417604476562701e-06
- O 0 1.2202784773762687e-06
mRNA O 0 4.6474272608065803e-07
splicing O 0 8.680960945639526e-07
of O 0 3.270023398727062e-07
a O 0 3.369812304754305e-07
mutation O 0 2.799064873215684e-07
at O 0 5.196999950385361e-07
the O 0 3.5103417417303717e-07
- O 0 1.3199843351685558e-06
2 O 0 6.516434041259345e-07
position O 0 4.002937714631116e-07
of O 0 6.052468393136223e-07
a O 0 2.0379166016937234e-06
5 O 0 6.147819476609584e-06
splice O 0 0.00043406139593571424
site O 0 0.00019115641771350056
. O 0 2.8223254048498347e-05

ATM O 0 0.009855731390416622
germline O 0 0.0014157263794913888
mutations O 0 1.923747367982287e-05
in O 0 7.624880709045101e-06
classical O 0 0.2605839669704437
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.028401639312505722
in O 0 6.923014097992564e-06
the O 0 9.264179425372276e-06
Dutch O 0 0.0004554697952698916
population O 0 3.018421693923301e-06
. O 0 1.5708443243056536e-05

Germline O 0 0.002590510994195938
mutations O 0 2.201911593147088e-05
in O 0 3.41296436090488e-06
the O 0 3.5839771044265945e-06
ATM O 0 0.0009347670711576939
gene O 0 2.581198032203247e-06
are O 0 8.093723380397932e-08
responsible O 0 1.0024480161519023e-06
for O 0 7.859680408728309e-07
the O 0 0.00016813444381114095
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9998425245285034
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 7.180157263064757e-05
. O 0 5.5831977078923956e-05

In O 0 4.2226627556374297e-05
our O 0 5.319956017046934e-06
study O 0 1.4714086091771605e-06
, O 0 3.406515247661446e-07
we O 0 3.3447800973362973e-08
have O 0 1.0152903406890346e-08
determined O 0 1.1978963243564067e-07
the O 0 2.147974669242103e-07
ATM O 0 3.6310968425823376e-05
mutation O 0 4.814430667465786e-07
spectrum O 0 5.682732080458663e-07
in O 0 3.0295021247184195e-07
19 O 0 1.41490761507157e-06
classical O 0 2.3121210688259453e-05
A B-Disease 1 0.9999200105667114
- I-Disease 1 0.9999959468841553
T I-Disease 1 1.0
patients O 0 8.781214091868605e-06
, O 0 1.874134767376745e-07
including O 0 8.67224159151192e-08
some O 0 6.92109267674823e-08
immigrant O 0 2.159328573725361e-07
populations O 0 1.1600270255485157e-07
, O 0 9.166422643147598e-08
as O 0 1.4473273779458395e-07
well O 0 2.380297843274093e-07
as O 0 3.004524842253886e-07
12 O 0 1.236083562616841e-06
of O 0 1.9377221178729087e-06
Dutch O 0 4.421022458700463e-05
ethnic O 0 1.034673459798796e-06
origin O 0 7.3085184340015985e-06
. O 0 2.8515276426333003e-05

Both O 0 1.5607411114615388e-05
the O 0 5.6934459280455485e-06
protein O 0 3.737002771231346e-06
truncation O 0 8.412469469476491e-05
test O 0 3.237644341425039e-05
( O 0 3.053366526728496e-06
PTT O 0 0.00885110255330801
) O 0 5.029900194131187e-07
and O 0 1.2476455424348387e-07
the O 0 2.3676872729083698e-07
restriction O 0 7.100617267497e-07
endonuclease O 0 2.140314427379053e-05
fingerprinting O 0 3.768554233829491e-05
( O 0 2.470906338203349e-06
REF O 0 0.0022099539637565613
) O 0 1.2922637893098e-07
method O 0 1.1364559071580516e-07
were O 0 6.216168912942521e-08
used O 0 1.1003947264498493e-07
and O 0 1.2291334883229865e-07
compared O 0 1.916033482984858e-07
for O 0 5.4621960288159244e-08
their O 0 1.367886568459653e-07
detection O 0 9.101819159695879e-06
efficiency O 0 3.5072605442110216e-06
, O 0 3.1528014687864925e-07
identifying O 0 7.053474178064789e-07
76 O 0 2.238514070995734e-06
% O 0 9.288353197689503e-08
and O 0 4.914235063324668e-08
60 O 0 3.4822002703549515e-07
% O 0 7.400139168112219e-08
of O 0 2.700180345982517e-07
the O 0 1.763555928846472e-06
mutations O 0 2.9344573704292998e-06
, O 0 2.646171878950554e-06
respectively O 0 2.7376076104701497e-05
. O 0 3.157701576128602e-05

Most O 0 6.849697092548013e-05
patients O 0 2.2586871637031436e-05
were O 0 3.220430471628788e-06
found O 0 1.5037286402730388e-06
to O 0 8.941195233092003e-07
be O 0 2.158749111913494e-06
compound O 0 0.0005010940367355943
heterozygote O 0 0.0017878132639452815
. O 0 0.00010926616232609376

Seventeen O 0 0.00036204775096848607
mutations O 0 8.799875104159582e-06
were O 0 1.4216706176739535e-06
distinct O 0 8.06097546046658e-07
, O 0 3.053117438867048e-07
of O 0 5.303749048835016e-07
which O 0 2.102431153616635e-07
10 O 0 5.014554176341335e-07
were O 0 2.14180943203246e-07
not O 0 2.49845896860279e-07
reported O 0 3.7994770991645055e-06
previously O 0 1.8458778868080117e-05
. O 0 2.5295763407484628e-05

Mutations O 0 7.848712266422808e-05
are O 0 1.997684194066096e-06
small O 0 3.8795092223153915e-06
deletions O 0 1.9009294192073867e-05
or O 0 5.309256721375277e-06
point O 0 1.3982266864331905e-05
mutations O 0 2.8577790089912014e-06
frequently O 0 2.170418611058267e-06
affecting O 0 7.595856914122123e-06
splice O 0 0.0003050398954655975
sites O 0 0.00010361305612605065
. O 0 5.930782572249882e-05

Moreover O 0 0.0004530695150606334
, O 0 2.4875562303350307e-05
a O 0 3.2479583751410246e-05
16 O 0 0.0001667505275690928
. O 0 8.269295358331874e-05

7 O 0 0.00022141466615721583
- O 0 9.514424891676754e-05
kb O 0 0.0001417262974428013
genomic O 0 1.1362070836185012e-05
deletion O 0 6.5147764871653635e-06
of O 0 1.3147979416316957e-06
the O 0 1.5865717841734295e-06
3 O 0 2.663469331309898e-06
end O 0 7.24181120403955e-07
of O 0 7.14669113222044e-07
the O 0 8.309256145366817e-07
gene O 0 1.3125629720889265e-06
, O 0 1.8126804945950425e-07
most O 0 1.1136800992517237e-07
likely O 0 1.0662848382025913e-07
a O 0 9.075871787445067e-08
result O 0 1.3958157296656282e-07
of O 0 3.5181002999706834e-07
recombination O 0 9.56751478042861e-07
between O 0 2.3759795908517845e-07
two O 0 2.1575458220013388e-07
LINE O 0 3.835296956822276e-05
elements O 0 2.1953912892058725e-06
, O 0 2.5393758278369205e-06
was O 0 3.738778468687087e-05
identified O 0 2.3316841179621406e-05
. O 0 2.7346492061042227e-05

The O 0 5.297440293361433e-05
most O 0 3.2805855880724266e-06
frequently O 0 1.6256233266176423e-06
found O 0 1.1589085033847368e-06
mutation O 0 5.904853423999157e-07
, O 0 2.3109414826194552e-07
identified O 0 3.8074756503192475e-07
in O 0 2.0595814476109808e-07
three O 0 1.8108248411863315e-07
unrelated O 0 2.8248675789654953e-06
Turkish O 0 1.4561075659003109e-05
A B-Disease 1 0.9999915361404419
- I-Disease 1 0.9999116659164429
T I-Disease 1 0.9999980926513672
individuals O 0 2.4472387849527877e-07
, O 0 7.422926273648045e-07
was O 0 4.7763683141965885e-06
previously O 0 1.5837932778595132e-06
described O 0 4.676620051213831e-07
to O 0 8.513220706163338e-08
be O 0 1.1107950115274434e-07
a O 0 5.812559038531617e-07
Turkish O 0 7.444907168974169e-06
A B-Disease 1 0.9992517828941345
- I-Disease 1 0.9998824596405029
T I-Disease 1 0.9999995231628418
founder O 1 0.9878783822059631
mutation O 0 8.030120079638436e-05
. O 0 3.383181683602743e-05

The O 0 3.91743378713727e-05
presence O 0 1.0276314242219087e-05
of O 0 6.334315457934281e-06
a O 0 9.061866876436397e-06
founder O 1 0.9943522214889526
mutation O 0 3.7560105283773737e-06
among O 0 3.130456605049403e-07
relatively O 0 2.042115880840356e-07
small O 0 1.279242951568449e-07
ethnic O 0 3.299796347278061e-08
population O 0 1.8506684185126687e-08
groups O 0 1.4842599149744728e-08
in O 0 1.0925291604735321e-07
Western O 0 1.7106817722378764e-06
Europe O 0 3.873048171953997e-06
could O 0 3.0127682748570805e-07
indicate O 0 3.181592660439492e-07
a O 0 4.5032680873191566e-07
high O 0 2.5460903998464346e-06
carrier O 0 1.9201177110517165e-06
frequency O 0 4.26427988031719e-07
in O 0 1.8166296911203972e-07
such O 0 3.53878817804798e-07
communities O 0 3.0573644380638143e-06
. O 0 2.290274824190419e-05

In O 0 6.06098365096841e-05
patients O 0 1.1826818990812171e-05
of O 0 6.56550946587231e-06
Dutch O 0 8.313495345646515e-05
ethnic O 0 5.843165808983031e-07
origin O 0 1.1658179346341058e-06
, O 0 6.15166982242954e-07
however O 0 2.88243569457336e-07
, O 0 2.1998248200816306e-07
no O 0 1.439908174916127e-07
significant O 0 4.936593995807925e-07
founder O 0 0.0003173441509716213
effect O 0 4.291100594855379e-06
could O 0 9.722696177050238e-07
be O 0 1.2744892501359573e-06
identified O 0 1.1772220204875339e-05
. O 0 1.761797466315329e-05

The O 0 1.9783137759077363e-05
observed O 0 7.248814654303715e-06
genetic O 0 2.428139396215556e-06
heterogeneity O 0 6.091967406973708e-06
including O 0 1.013769292512734e-06
the O 0 5.744456643697049e-07
relative O 0 1.736910235194955e-06
high O 0 6.739921445841901e-06
percentage O 0 1.3611149825010216e-06
of O 0 9.596382142262883e-07
splice O 0 0.00011103895667474717
- O 0 1.9826691641355865e-05
site O 0 1.514572068117559e-05
mutations O 0 9.764315791471745e-07
had O 0 7.391688541247277e-07
no O 0 3.2241902658824984e-07
reflection O 0 2.4135854346241103e-06
on O 0 3.291008169981069e-06
the O 0 1.1391482985345647e-05
phenotype O 0 0.00021341594401746988
. O 0 5.4405099945142865e-05

All O 0 5.9294034144841135e-05
patients O 0 2.068854337267112e-05
manifested O 0 3.4718348615569994e-05
classical O 0 0.00021543854381889105
A B-Disease 1 0.9999830722808838
- I-Disease 1 0.9997866749763489
T I-Disease 1 0.9999966621398926
and O 0 5.461744876811281e-06
increased O 0 6.304784164967714e-06
cellular O 0 8.933630306273699e-05
radioresistant O 0 0.0008433905895799398
DNA O 0 0.00016965533723123372
synthesis O 0 0.00015280897787306458
. O 0 3.896691487170756e-05

Determination O 0 6.92461253493093e-05
of O 0 1.2971798241778743e-05
the O 0 3.007480017913622e-06
genomic O 0 5.205757588555571e-06
structure O 0 8.169702596205752e-06
of O 0 6.789286999264732e-06
the O 0 1.19157348308363e-05
COL4A4 O 1 0.9999972581863403
gene O 0 3.563323843991384e-06
and O 0 5.049297442383249e-07
of O 0 5.522205810848391e-06
novel O 0 0.0002167884522350505
mutations O 0 0.00032690417720004916
causing O 1 0.9550183415412903
autosomal B-Disease 1 0.9999845027923584
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.6059196591377258

Autosomal B-Disease 1 0.999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.005879725329577923
a O 0 0.28815674781799316
progressive O 1 0.9999996423721313
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9883904457092285
by O 0 0.011080481112003326
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9976025223731995
abnormalities I-Disease 1 0.942591667175293
and O 0 2.1918474431004142e-06
associated O 0 2.336488932996872e-06
with O 0 3.4532072845649964e-07
mutations O 0 8.669279054629442e-07
in O 0 5.050043796472892e-07
either O 0 6.042635618541681e-07
the O 0 1.7573438526596874e-06
COL4A3 O 1 0.999897837638855
or O 0 1.952685124706477e-06
the O 0 5.233878255239688e-06
COL4A4 O 1 0.9999665021896362
gene O 0 1.599591996637173e-06
, O 0 8.014869479211484e-08
which O 0 4.08724396550042e-08
encode O 0 2.2630366913745092e-07
the O 0 1.44634236676211e-06
alpha3 O 0 0.00023454894835595042
and O 0 3.1200211196846794e-06
alpha4 O 1 0.6676161289215088
type O 1 0.5672224164009094
IV O 1 1.0
collagen O 1 0.9999977350234985
chains O 0 0.0011287261731922626
, O 0 2.2487294700113125e-05
respectively O 0 4.401738624437712e-05
. O 0 2.6320065444451757e-05

To O 0 8.132942639349494e-06
date O 0 1.041607538354583e-05
, O 0 1.1532910093592363e-06
mutation O 0 6.085859354243439e-07
screening O 0 9.944857310983934e-07
in O 0 1.2290232120903966e-07
the O 0 1.810683301073368e-07
two O 0 1.2681056205110508e-07
genes O 0 2.409576040918182e-07
has O 0 2.4994790237542475e-07
been O 0 6.721440968249226e-07
hampered O 0 8.545334821974393e-06
by O 0 2.078123486626282e-07
the O 0 7.223077318485593e-07
lack O 0 1.4424565506487852e-06
of O 0 2.573114443293889e-06
genomic O 0 2.0430135919013992e-05
structure O 0 2.525940908526536e-05
information O 0 1.6545413018320687e-05
. O 0 3.295698843430728e-05

We O 0 2.116101677529514e-05
report O 0 3.3075959890993545e-06
here O 0 7.958754508763377e-07
the O 0 3.7048178569421e-07
complete O 0 1.1007090279235854e-06
characterization O 0 5.8434447964827996e-06
of O 0 2.098295908581349e-06
the O 0 1.2207021882204572e-06
48 O 0 3.1722383937449194e-06
exons O 0 2.5917404400388477e-06
of O 0 1.536487275188847e-06
the O 0 2.698347088880837e-06
COL4A4 O 1 0.9999899864196777
gene O 0 2.7876974399987375e-06
, O 0 1.9951622221014986e-07
a O 0 2.3847331931392546e-07
comprehensive O 0 8.796282031653391e-07
gene O 0 1.4336752656163299e-06
screen O 0 1.41149109822436e-06
, O 0 1.2935262816426985e-07
and O 0 7.2628232317129e-08
the O 0 1.4049908259039512e-07
subsequent O 0 5.462591161631281e-07
detection O 0 4.941020961268805e-06
of O 0 7.421900249937607e-07
10 O 0 4.957536816618813e-07
novel O 0 1.1271189350736677e-06
mutations O 0 8.447918844467495e-07
in O 0 1.3999233487993479e-06
eight O 0 3.0499842978315428e-05
patients O 1 0.8716313242912292
diagnosed O 1 0.999997615814209
with O 0 0.0018071375088766217
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9918328523635864

Furthermore O 0 0.0002133392554242164
, O 0 6.745696282450808e-06
we O 0 4.931408739139442e-07
identified O 0 7.371294827862584e-07
a O 0 5.679145260728546e-07
glycine O 0 5.800580765935592e-06
to O 0 4.501207229168358e-07
alanine O 0 6.566580395883648e-06
substitution O 0 4.45004570792662e-06
in O 0 1.7158513401227538e-06
the O 0 2.4022826892178273e-06
collagenous O 0 0.03104187548160553
domain O 0 2.6020231871370925e-06
that O 0 2.557259506374976e-07
is O 0 2.1664924076958414e-07
apparently O 0 7.976108804541582e-07
silent O 0 1.3377032246353338e-06
in O 0 1.4999845632246434e-07
the O 0 1.7270365049171232e-07
heterozygous O 0 6.308172828539682e-07
carriers O 0 5.166052119420783e-07
, O 0 5.860543978997157e-07
in O 0 3.3944781989703188e-06
11 O 0 3.112642662017606e-05
. O 0 4.6835397370159626e-05

5 O 0 5.136446634423919e-05
% O 0 1.7662338223090046e-06
of O 0 8.561229378756252e-07
all O 0 2.960732956580614e-07
control O 0 2.133838961526635e-06
individuals O 0 1.0672025041458255e-07
, O 0 2.650222654665413e-07
and O 0 1.9262421346866176e-07
in O 0 3.324894066736306e-07
one O 0 3.800571732881508e-07
control O 0 6.216744168341393e-07
individual O 0 1.4082881705235195e-07
homozygous O 0 1.8493753941584146e-06
for O 0 5.950172408120125e-07
this O 0 1.4521874618367292e-06
glycine O 0 0.0001034860615618527
substitution O 0 0.00020802087965421379
. O 0 8.41076034703292e-05

There O 0 1.8922839444712736e-05
has O 0 1.9612816686276346e-06
been O 0 5.440925860966672e-07
no O 0 2.3141041083363234e-07
previous O 0 5.462658805299725e-07
finding O 0 3.379712154583103e-07
of O 0 5.694319611393439e-07
a O 0 1.0357812243455555e-06
glycine O 0 7.332820132432971e-06
substitution O 0 3.340998091516667e-06
that O 0 1.6704245808796259e-07
is O 0 8.292031594692162e-08
not O 0 3.3682368894005776e-08
associated O 0 1.2932055426517763e-07
with O 0 7.94388625990905e-08
any O 0 3.8753466924390523e-07
obvious O 0 7.3024984885705635e-06
phenotype O 0 6.488636245194357e-06
in O 0 1.6986176660793717e-06
homozygous O 0 1.5314990378101356e-05
individuals O 0 3.566737404980813e-06
. O 0 5.748333569499664e-05

Founder O 1 0.9990560412406921
BRCA1 O 0 0.09593897312879562
and O 0 9.256639168597758e-05
BRCA2 O 0 0.001125226728618145
mutations O 0 6.2990502556203865e-06
in O 0 3.5431073683867e-06
French O 0 0.0006852343212813139
Canadian O 1 0.9969148635864258
breast B-Disease 1 1.0
and I-Disease 1 0.9999887943267822
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.572476973407902e-05
. O 0 0.00011772707512136549

We O 0 7.908653060439974e-06
have O 0 3.876078267239791e-07
identified O 0 7.128238053155656e-07
four O 0 3.254654359352571e-07
mutations O 0 3.934865446808544e-07
in O 0 2.124724289842561e-07
each O 0 8.062061596092462e-08
of O 0 2.0986681192880496e-06
the O 0 0.000965443963650614
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
- O 0 0.000385751249268651
susceptibility O 0 5.3482399380300194e-05
genes O 0 1.0472592748556053e-06
, O 0 1.3381522876443341e-06
BRCA1 O 0 2.6167346732108854e-05
and O 0 1.3635159348268644e-06
BRCA2 O 0 5.5308726587099954e-05
, O 0 5.654221695294837e-07
in O 0 5.07280788042408e-07
French O 0 0.00016867190424818546
Canadian O 1 0.9904466867446899
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 1 0.8635605573654175
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.035297934024129e-06
from O 0 1.995770253415685e-05
Quebec O 0 0.0005252693081274629
. O 0 5.0785354687832296e-05

To O 0 2.0239142031641677e-05
identify O 0 2.380023943260312e-05
founder O 0 0.34774407744407654
effects O 0 0.00043715807260014117
, O 0 2.0783406853297492e-06
we O 0 2.2199472482498095e-07
examined O 0 1.2660311767831445e-06
independently O 0 5.254270263321814e-07
ascertained O 0 6.825310265412554e-06
French O 0 2.0711462639155798e-05
Canadian O 0 0.00035513818147592247
cancer B-Disease 0 0.021692397072911263
families O 0 8.250320604474837e-08
for O 0 1.1608315730882168e-07
the O 0 2.3780924607308407e-07
distribution O 0 4.1746366719053185e-07
of O 0 7.468811986655055e-07
these O 0 2.913133130277856e-07
eight O 0 3.1596271128364606e-06
mutations O 0 1.425201480742544e-05
. O 0 1.2830654668505304e-05

Mutations O 0 2.0515006326604635e-05
were O 0 3.5721907352126436e-06
found O 0 1.2957798389834352e-06
in O 0 5.958650604043214e-07
41 O 0 4.747127604787238e-06
of O 0 4.113916929782135e-06
97 O 0 0.00011077035014750436
families O 0 6.910151114425389e-06
. O 0 2.519219742680434e-05

Six O 0 3.346504672663286e-05
of O 0 1.0647179806255735e-05
eight O 0 4.083425210410496e-06
mutations O 0 1.7106800669353106e-06
were O 0 7.788883635839738e-07
observed O 0 1.3199565955801518e-06
at O 0 4.89794774694019e-06
least O 0 2.2438703126681503e-06
twice O 0 1.738202990964055e-05
. O 0 2.5070876290556043e-05

The O 0 0.0002050019975285977
BRCA1 O 0 0.008442959748208523
C4446T O 0 0.026567654684185982
mutation O 0 1.869575135060586e-05
was O 0 9.584834515408147e-06
the O 0 8.300076501654985e-07
most O 0 1.8138632640329888e-07
common O 0 3.006823590112617e-07
mutation O 0 4.649386369237618e-07
found O 0 3.452575185747264e-07
, O 0 1.4826349570284947e-07
followed O 0 4.4712714952765964e-07
by O 0 6.232064606592758e-07
the O 0 1.1586219443415757e-05
BRCA2 O 0 0.009854838252067566
8765delAG O 0 0.00275873439386487
mutation O 0 8.28806878416799e-05
. O 0 5.69207695662044e-05

Together O 0 2.7157861040905118e-05
, O 0 2.8405631837813416e-06
these O 0 2.9142225344003236e-07
mutations O 0 4.0566601455793716e-07
were O 0 2.9387598488028743e-07
found O 0 4.4387229536368977e-07
in O 0 2.697017293940007e-07
28 O 0 1.1968701301157125e-06
of O 0 1.1306739224892226e-06
41 O 0 2.410964953014627e-06
families O 0 9.976491810448351e-08
identified O 0 4.585440080973058e-07
to O 0 2.0191752980736055e-07
have O 0 2.2279643019373907e-07
a O 0 6.328235031105578e-06
mutation O 0 2.239317836938426e-05
. O 0 2.3636930563952774e-05

The O 0 3.085246862610802e-05
odds O 0 2.152635352103971e-05
of O 0 3.511654995236313e-06
detection O 0 1.0100499821419362e-05
of O 0 1.603642772352032e-06
any O 0 3.2371644920203835e-07
of O 0 1.1416879033276928e-06
the O 0 1.6795679584902246e-06
four O 0 3.045784524147166e-06
BRCA1 O 0 0.00013975675392430276
mutations O 0 5.362985120882513e-06
was O 0 5.3357896831585094e-05
18 O 0 5.2799194236285985e-05
. O 0 4.356935096438974e-05

7x O 0 0.34381482005119324
greater O 0 2.977384974656161e-05
if O 0 2.735990392466192e-06
one O 0 9.967055802917457e-07
or O 0 3.214951505015051e-07
more O 0 9.620502083862448e-08
cases O 0 5.30748820892768e-07
of O 0 0.03798573464155197
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.264743216073839e-06
also O 0 4.3221848500252236e-07
present O 0 4.311518182475993e-07
in O 0 6.658934239567316e-07
the O 0 3.82863026970881e-06
family O 0 4.5016251533525065e-05
. O 0 6.35842588962987e-05

The O 0 3.5995028156321496e-05
odds O 0 4.1636943933553994e-05
of O 0 6.8491685851768125e-06
detection O 0 1.489679743826855e-05
of O 0 1.7112706700572744e-06
any O 0 3.1159069635577907e-07
of O 0 1.1903408676516847e-06
the O 0 3.0161427275743335e-06
four O 0 6.419491000997368e-06
BRCA2 O 0 0.00022979376080911607
mutations O 0 7.68420795793645e-06
was O 0 5.1000450184801593e-05
5 O 0 3.908179860445671e-05
. O 0 2.212256549682934e-05

3x O 0 0.0031543527729809284
greater O 0 1.904881719383411e-05
if O 0 1.2222176337672863e-06
there O 0 1.9903843906377006e-07
were O 0 2.652748776199587e-07
at O 0 1.2809681493308744e-06
least O 0 8.423945985214232e-08
five O 0 6.581192479870879e-08
cases O 0 2.763786426385195e-07
of O 0 6.920328451087698e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.999991774559021
in O 0 6.166210368974134e-06
the O 0 1.442192296963185e-05
family O 0 0.00010710681090131402
. O 0 3.881733209709637e-05

Interestingly O 0 0.00031301603303290904
, O 0 4.859271029999945e-06
the O 0 1.02859519302001e-06
presence O 0 1.4216109320841497e-06
of O 0 5.385983058658894e-06
a O 0 0.00011944140715058893
breast B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.999806821346283
case O 0 4.774054559675278e-06
< O 0 4.508369784161914e-06
36 O 0 6.525631874865212e-07
years O 0 2.0707147996290587e-07
of O 0 3.0977031428847113e-07
age O 0 1.60752892952587e-06
was O 0 1.3075466540612979e-06
strongly O 0 1.1727455984100743e-07
predictive O 0 3.6580811979547434e-07
of O 0 3.0663650818496535e-07
the O 0 1.9533598560883547e-07
presence O 0 3.441388400915457e-07
of O 0 4.124663632865122e-07
any O 0 1.6214043796480837e-07
of O 0 5.977900059406238e-07
the O 0 2.4438879790977808e-06
eight O 0 8.079785402514972e-06
mutations O 0 1.2980784049432259e-05
screened O 0 7.54524880903773e-05
. O 0 3.727578587131575e-05

Carriers O 0 4.711636938736774e-05
of O 0 1.207925561175216e-05
the O 0 3.0832190986984642e-06
same O 0 1.190213765767112e-06
mutation O 0 6.694476724078413e-07
, O 0 1.462181842271093e-07
from O 0 1.2316387199007295e-07
different O 0 1.2726725451273069e-08
families O 0 5.080568143966957e-08
, O 0 1.462785661487942e-07
shared O 0 3.1433685876436357e-07
similar O 0 2.49147575459574e-07
haplotypes O 0 5.361676358006662e-06
, O 0 4.1619244939283817e-07
indicating O 0 5.530594648917031e-07
that O 0 5.524822555003084e-08
the O 0 2.3746930821744172e-07
mutant O 0 1.525023208159837e-06
alleles O 0 1.2702868446012872e-07
were O 0 1.6657476464843057e-07
likely O 0 6.122188977997212e-08
to O 0 4.823185406621633e-08
be O 0 4.0103387277667935e-08
identical O 0 1.301706191725316e-07
by O 0 7.188923234480171e-08
descent O 0 9.852457196757314e-07
for O 0 2.1738270561399986e-07
a O 0 1.1507465842441889e-06
mutation O 0 7.148954637159477e-07
in O 0 5.033844558965939e-07
the O 0 3.376510903763119e-06
founder O 0 0.0006911906530149281
population O 0 2.4683108676981647e-06
. O 0 1.2984794011572376e-05

The O 0 2.2172476747073233e-05
identification O 0 3.129846663796343e-05
of O 0 1.9774177417275496e-05
common O 0 4.5895892981207e-05
BRCA1 O 0 0.018560189753770828
and O 0 1.4142036889097653e-05
BRCA2 O 0 0.0007018860196694732
mutations O 0 1.6213641629292397e-06
will O 0 3.188886239513522e-07
facilitate O 0 1.2631367098947521e-06
carrier O 0 8.808027814666275e-06
detection O 0 1.2179624718555715e-05
in O 0 1.1039132914447691e-06
French O 0 4.9810205382527784e-05
Canadian O 0 0.3127412497997284
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999992847442627
and O 0 0.35188788175582886
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.225042408099398e-05
. O 0 4.042174623464234e-05

Are O 0 2.7982639949186705e-05
Dp71 O 0 0.2326325923204422
and O 0 9.149347170023248e-05
Dp140 O 1 0.999983549118042
brain O 1 0.8838479518890381
dystrophin O 0 0.0005636887508444488
isoforms O 0 7.833378731447738e-06
related O 0 6.087692327128025e-06
to O 0 1.013723885989748e-05
cognitive B-Disease 1 0.9970583915710449
impairment I-Disease 1 0.9999988079071045
in O 1 0.9986079335212708
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9998694658279419

Molecular O 0 0.00018405991431791335
study O 0 1.7747619494912215e-05
and O 0 2.4750761440373026e-06
neuropsychological O 0 6.583757931366563e-05
analysis O 0 1.5680011529184412e-06
were O 0 1.146220824921329e-06
performed O 0 3.0300909656943986e-06
concurrently O 0 2.805015810736222e-06
on O 0 1.9335243450768758e-06
49 O 0 1.740647894621361e-05
patients O 0 1.1784508387790993e-05
with O 0 3.935620406991802e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999995231628418
DMD B-Disease 1 1.0
) O 0 7.419454959745053e-06
in O 0 4.020759263312357e-07
order O 0 1.9956436858592497e-07
to O 0 1.029818790243553e-07
find O 0 3.3783521757868584e-07
a O 0 2.6565538746581296e-07
molecular O 0 2.093351213261485e-06
explanation O 0 4.604546006703458e-07
for O 0 3.9938890949997585e-07
the O 0 3.5386401577852666e-06
cognitive B-Disease 0 0.06296008825302124
impairment I-Disease 0 0.43209701776504517
observed O 0 4.951974005962256e-06
in O 0 3.954256953875301e-06
most O 0 6.690402369713411e-05
DMD B-Disease 1 1.0
patients O 0 0.00869926530867815
. O 0 7.880684279371053e-05

Complete O 0 2.4001594283618033e-05
analysis O 0 2.8179551918583456e-06
of O 0 6.844584731879877e-06
the O 0 5.364663138607284e-06
dystrophin O 0 0.0024311162997037172
gene O 0 1.0723667401180137e-05
was O 0 2.5804505639825948e-05
performed O 0 3.0764517759962473e-06
to O 0 1.246568075430332e-07
define O 0 4.860735884903988e-07
the O 0 7.709683131906786e-07
localization O 0 1.0058955922431778e-05
of O 0 2.5143813218164723e-06
deletions O 0 5.19058312420384e-06
and O 0 8.773059221311996e-07
duplications O 0 2.2818157958681695e-05
in O 0 1.1734150575648528e-06
relation O 0 1.3861562138117733e-06
to O 0 7.032806479401188e-07
the O 0 5.771215001004748e-06
different O 0 9.679541108198464e-06
DMD B-Disease 1 0.9999998807907104
promoters O 1 0.8634341955184937
. O 0 0.00036093220114707947

Qualitative O 0 3.8681424484821036e-05
analysis O 0 4.125271061639069e-06
of O 0 5.824138952448266e-06
the O 0 5.181800133868819e-06
Dp71 O 1 0.6950513124465942
transcript O 0 2.2303751393337734e-05
and O 0 5.206380819799961e-07
testing O 0 1.4901422673574416e-06
for O 0 1.1097277052840582e-07
the O 0 1.2032489848934347e-07
specific O 0 8.094942671732497e-08
first O 0 9.232659294866608e-07
exon O 0 1.120908109442098e-05
of O 0 1.9173746750311693e-06
Dp140 O 0 0.0001531129382783547
were O 0 1.251916501132655e-06
also O 0 6.759914299436787e-07
carried O 0 1.8013995486398926e-06
out O 0 4.685361545853084e-06
. O 0 1.3575715456681792e-05

Neuropsychological O 0 0.004640647675842047
analysis O 0 2.5795747205847874e-05
assessed O 0 7.915827154647559e-05
verbal O 0 5.211939424043521e-05
and O 0 5.45721468370175e-06
visuospatial O 0 0.005656447261571884
intelligence O 0 1.2964675079274457e-05
, O 0 1.934088686539326e-06
verbal O 0 2.438169212837238e-05
memory O 1 0.523047924041748
, O 0 3.4408117244311143e-06
and O 0 6.192871751409257e-06
reading O 0 0.000276504346402362
skills O 0 0.00014120276318863034
. O 0 5.725765731767751e-05

Comparison O 0 4.18341915064957e-05
of O 0 1.9672026610351168e-05
molecular O 0 4.6685479901498184e-05
and O 0 4.560156412480865e-06
psychometric O 0 0.0013882258208468556
findings O 0 5.571931978920475e-06
demonstrated O 0 4.122510290471837e-06
that O 0 1.1910751140931097e-07
deletions O 0 2.6014477043645456e-06
and O 0 4.4858870751340874e-07
duplications O 0 1.2524405065050814e-05
that O 0 1.4379649826423702e-07
were O 0 3.972654383233021e-07
localized O 0 2.1287128220137674e-06
in O 0 8.836944402901281e-07
the O 0 1.5052996786835138e-06
distal O 0 2.130389111698605e-05
part O 0 1.8705758293435792e-06
of O 0 1.784517735359259e-06
the O 0 2.1678099528799066e-06
gene O 0 1.374258545183693e-06
seemed O 0 5.347718001758039e-07
to O 0 9.868522710121397e-08
be O 0 1.2327090814778785e-07
preferentially O 0 2.771234221654595e-06
associated O 0 2.9683965294680092e-06
with O 0 7.741808076389134e-06
cognitive B-Disease 1 0.9965190887451172
impairment I-Disease 1 0.9999773502349854
. O 0 0.0004473011358641088

Two O 0 3.859111529891379e-05
altered O 0 0.00019140647782478482
Dp71 O 0 0.002155911410227418
transcripts O 0 3.9698508771834895e-05
and O 0 1.940423771884525e-06
two O 0 4.239763029545429e-07
deleted O 0 5.343809334590333e-06
Dp140 O 0 5.256628355709836e-05
DNA O 0 2.5380174974998226e-06
sequences O 0 2.044124727262897e-07
were O 0 1.7650150141435006e-07
found O 0 3.7145611031519365e-07
in O 0 2.9448594318637333e-07
four O 0 1.3537322729462176e-06
patients O 0 4.376265860628337e-05
with O 0 5.9473550209077075e-05
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.17615975439548492

These O 0 1.7971415218198672e-05
findings O 0 7.4418835538381245e-06
suggest O 0 1.925468495755922e-06
that O 0 1.3381058749928343e-07
some O 0 7.885720521016992e-08
sequences O 0 9.63298845135796e-08
located O 0 8.00446343873773e-07
in O 0 1.6832001392685925e-07
the O 0 4.695353368333599e-07
distal O 0 9.554653843224514e-06
part O 0 5.996131449137465e-07
of O 0 7.265164185810136e-07
the O 0 1.0987929499606253e-06
gene O 0 5.827389486512402e-07
and O 0 1.217607774606222e-07
, O 0 1.2867764098700718e-07
in O 0 1.526695285747337e-07
particular O 0 2.1995563770360604e-07
, O 0 2.6550850407147664e-07
some O 0 4.529960904164909e-07
DMD B-Disease 1 0.9999954700469971
isoforms O 0 1.3025993439441663e-06
expressed O 0 3.092888505307201e-07
in O 0 1.0998696780006867e-06
the O 0 9.733107617648784e-06
brain O 1 0.8445609211921692
may O 0 8.531594630767358e-07
be O 0 1.3282372890444094e-07
related O 0 6.175775979500031e-07
to O 0 4.3109224634463317e-07
the O 0 7.5651114457286894e-06
cognitive B-Disease 1 0.9799137115478516
impairment I-Disease 1 0.9998573064804077
associated O 0 0.00012144399079261348
with O 0 0.0001094848703360185
DMD B-Disease 1 1.0
. O 0 0.00016535593022126704
. O 0 8.35008904687129e-05

I1307K O 1 0.5708538889884949
APC O 0 0.009032982401549816
and O 0 2.859686173906084e-05
hMLH1 O 0 0.0004874643636867404
mutations O 0 3.6538906442729058e-06
in O 0 9.154504141406505e-07
a O 0 1.1186697292941972e-06
non O 0 1.0513829693081789e-05
- O 0 1.1982522664766293e-05
Jewish O 0 1.6962161680567078e-05
family O 0 9.63193360803416e-06
with O 0 4.745049864141038e-06
hereditary B-Disease 1 0.9999990463256836
non I-Disease 1 0.9999974966049194
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.003698514774441719

We O 0 1.441114454792114e-05
describe O 0 1.143661211244762e-05
a O 0 5.703570877813036e-06
French O 0 7.583183469250798e-05
Canadian O 0 0.0010398930171504617
hereditary B-Disease 1 0.9999957084655762
non I-Disease 1 0.9999849796295166
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9989981055259705
HNPCC B-Disease 1 1.0
) O 0 3.846780600724742e-05
kindred O 0 0.0009390943450853229
which O 0 1.7622713812670554e-06
carries O 0 4.682118742493913e-06
a O 0 3.1042318369145505e-06
novel O 0 1.089427405531751e-05
truncating O 0 0.0001608705206308514
mutation O 0 8.911792065191548e-06
in O 0 1.168838753073942e-05
hMLH1 O 0 0.0015307334251701832
. O 0 8.71156807988882e-05

Interestingly O 0 0.0003966190561186522
, O 0 1.691864054009784e-05
the O 0 1.1747009011742193e-05
I1307K O 0 0.030147675424814224
APC O 0 0.004768822807818651
polymorphism O 0 2.250853503937833e-05
, O 0 1.0123965239472454e-06
associated O 0 6.98240341989731e-07
with O 0 1.7187996093070979e-07
an O 0 3.664348753318336e-07
increased O 0 2.3576722014695406e-06
risk O 0 1.2220089047332294e-05
of O 1 0.9747410416603088
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.2470289877674077e-06
is O 0 1.570549699181356e-07
also O 0 9.185482241491627e-08
present O 0 2.684077458070533e-07
in O 0 4.6692576916029793e-07
this O 0 4.443347734195413e-07
family O 0 2.3229129510582425e-05
. O 0 4.465317033464089e-05

The O 0 0.00016787827189546078
I1307K O 0 0.0031169636640697718
polymorphism O 0 5.5442222219426185e-05
has O 0 1.743954385347024e-06
previously O 0 1.455674691897002e-06
only O 0 1.0663092098184279e-07
been O 0 1.2057876119797584e-07
identified O 0 1.8225227904622443e-07
in O 0 8.262540518444439e-08
individuals O 0 7.53691651311783e-08
of O 0 1.8067862583848182e-06
self O 0 7.829798414604738e-05
- O 0 0.001937671797350049
reported O 0 3.874532922054641e-05
Ashkenazi O 0 0.00024581298930570483
Jewish O 0 5.079204129287973e-05
origins O 0 0.00021478366397786885
. O 0 8.104201697278768e-05

In O 0 2.8768177799065597e-05
addition O 0 4.150194854446454e-06
, O 0 9.431912530999398e-07
in O 0 3.6267280734136875e-07
this O 0 1.0480250978162076e-07
family O 0 9.014846114041575e-07
, O 0 4.93219374675391e-07
there O 0 2.9912507670815103e-07
appears O 0 2.811529498103482e-07
to O 0 4.811222353851008e-08
be O 0 7.974126248200264e-08
no O 0 1.5194717661870527e-07
relationship O 0 8.783845117932287e-08
between O 0 1.49051459175098e-07
the O 0 1.1519873623910826e-06
I1307K O 0 0.004332105163484812
polymorphism O 0 3.1341987778432667e-06
and O 0 3.425592751682416e-07
the O 0 4.966068445355631e-07
presence O 0 8.718295703147305e-07
or O 0 5.288223405841563e-07
absence O 0 7.367643775069155e-06
of O 0 0.0001072151426342316
cancer B-Disease 1 0.999953031539917
. O 0 1.1670431376842316e-05
. O 0 3.28145433741156e-05

Identification O 0 6.590170960407704e-05
of O 0 1.1102925782324746e-05
a O 0 3.362536062923027e-06
novel O 0 3.742124135897029e-06
mutation O 0 6.265041747610667e-07
of O 0 1.4654123106083716e-06
the O 0 4.444752448762301e-06
CPO O 1 0.7667555809020996
gene O 0 4.628589977073716e-06
in O 0 1.17797287657595e-06
a O 0 2.8530898816825356e-06
Japanese O 0 0.00045629311352968216
hereditary B-Disease 1 0.9999929666519165
coproporphyria I-Disease 1 0.9999772310256958
family O 0 0.0009168236865662038
. O 0 0.00016162284009624273

Hereditary B-Disease 1 0.9999922513961792
coproporphyria I-Disease 1 0.9999929666519165
( O 0 0.0681377500295639
HCP B-Disease 1 0.9999990463256836
) O 0 6.427061452995986e-05
is O 0 6.22202651356929e-06
an O 0 1.4069624739931896e-05
autosomal B-Disease 1 0.9999730587005615
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
characterized O 0 0.40841546654701233
by O 0 8.606111077824607e-05
a O 1 0.5969523787498474
deficiency B-Disease 1 0.9999997615814209
of I-Disease 1 0.988966166973114
coproporphyrinogen I-Disease 1 0.9999995231628418
oxidase I-Disease 0 0.18956144154071808
( O 0 4.9454796680947766e-05
CPO O 1 0.9997292160987854
) O 0 5.375069122237619e-06
caused O 0 6.170486813061871e-06
by O 0 5.923284902564774e-07
a O 0 1.679888327998924e-06
mutation O 0 1.1815259313152637e-06
in O 0 6.785776918150077e-07
the O 0 9.112076440942474e-06
CPO O 1 0.9974715709686279
gene O 0 0.00010112608288181946
. O 0 2.9751059628324583e-05

Only O 0 3.542185731930658e-05
11 O 0 1.313835491600912e-05
mutations O 0 1.56791588779015e-06
of O 0 1.698880168987671e-06
the O 0 1.9023938193640788e-06
gene O 0 1.5657866470064619e-06
have O 0 9.683611779109924e-08
been O 0 4.6351618721018895e-07
reported O 0 2.5515255401842296e-06
in O 0 1.0350511729484424e-05
HCP B-Disease 1 0.9999992847442627
patients O 0 0.01753968745470047
. O 0 0.00013743901217821985

We O 0 1.4500295947073027e-05
report O 0 4.423338396009058e-06
another O 0 2.221833028670517e-06
mutation O 0 1.1050318562411121e-06
in O 0 8.009678822418209e-07
a O 0 2.7497101200424368e-06
Japanese O 0 0.00012012661318294704
family O 0 7.57064699428156e-05
. O 0 5.8927689678967e-05

Polymerase O 0 0.0005002695834264159
chain O 0 0.0001367549120914191
reaction O 0 2.0301602489780635e-05
- O 0 4.401251862873323e-05
single O 0 2.4602429675724125e-06
strand O 0 2.2704218736180337e-06
conformational O 0 6.516875146189705e-07
polymorphism O 0 6.909222065587528e-07
and O 0 1.1006045497197192e-07
direct O 0 5.7811583076272655e-08
sequence O 0 8.624273561963491e-08
analyses O 0 2.8949543207090755e-07
demonstrated O 0 6.66956680106523e-07
a O 0 4.87343584154587e-07
C O 0 1.920515569509007e-05
to O 0 5.238135258878174e-07
T O 0 1.1148526937176939e-05
substitution O 0 5.124031190462119e-07
in O 0 2.2384298858924012e-07
exon O 0 2.7518142360349884e-06
1 O 0 6.008776267663052e-07
of O 0 7.207842713796708e-07
the O 0 1.0712337825680152e-06
CPO O 0 0.0006016604020260274
gene O 0 1.149369040831516e-06
at O 0 1.406610522280971e-06
nucleotide O 0 1.0171926305702073e-06
position O 0 1.425556206413603e-06
85 O 0 2.8410154300217982e-06
, O 0 2.7764272658714617e-07
which O 0 1.7668912732915487e-07
lies O 0 1.6184535525098909e-06
in O 0 2.8136565788372536e-07
the O 0 9.892763728203136e-07
putative O 0 2.9783563149976544e-05
presequence O 0 0.00012089379015378654
for O 0 1.1932287407034892e-06
targeting O 0 4.014152636955259e-06
to O 0 3.77784158445138e-06
mitochondria O 0 0.00024001066049095243
. O 0 4.319429717725143e-05

This O 0 1.1921985787921585e-05
mutation O 0 2.2550534595211502e-06
changes O 0 2.740646891652432e-07
the O 0 1.009452262223931e-06
codon O 0 4.907125457975781e-06
for O 0 3.4079479860338324e-07
glutamine O 0 3.8078892430348787e-06
to O 0 3.1349858886642323e-07
a O 0 9.186171610053862e-07
termination O 0 1.7106447558035143e-05
codon O 0 1.5316114513552748e-05
at O 0 6.283247785177082e-06
amino O 0 1.5923532146189245e-06
acid O 0 9.54300685407361e-06
position O 0 1.1132697181892581e-05
29 O 0 4.931995863444172e-05
. O 0 2.2445710783358663e-05

MaeI O 0 0.0036447676829993725
restriction O 0 2.746758036664687e-05
analysis O 0 5.287428848532727e-06
showed O 0 3.2900131827773293e-06
two O 0 1.7200245849835483e-07
other O 0 1.7431266030598636e-07
carriers O 0 7.01303576988721e-07
in O 0 9.374296041642083e-07
the O 0 4.7902908590913285e-06
family O 0 4.348144284449518e-05
. O 0 5.8993868151446804e-05

The O 0 0.00031222859979607165
C O 1 0.9913654327392578
- O 0 0.13250139355659485
T O 1 0.783547580242157
mutation O 0 3.107744987573824e-06
is O 0 2.2508520203246007e-07
located O 0 1.5203443126665661e-06
within O 0 2.5883517196234607e-07
a O 0 2.45733502879375e-07
recently O 0 5.611755682366493e-07
proposed O 0 3.9632845982850995e-07
putative O 0 1.8326786630495917e-06
alternative O 0 1.089826241695846e-06
translation O 0 8.132089419632393e-07
initiation O 0 4.465090114535997e-06
codon O 0 1.354390406049788e-05
( O 0 1.3114305374983815e-06
TIC O 0 0.00017588822811376303
- O 0 1.0248499165754765e-05
1 O 0 2.4265282263513654e-06
) O 0 1.4901479516993277e-07
, O 0 1.1038884650815817e-07
supporting O 0 3.184734680417023e-07
that O 0 2.48407587832844e-07
TIC O 0 0.0037761612329632044
- O 0 1.741537926136516e-05
1 O 0 2.452147782605607e-06
is O 0 1.7573947275195678e-07
the O 0 4.3355319689908356e-07
real O 0 8.12243979453342e-06
TIC O 0 0.00404296675696969
rather O 0 1.5088036207089317e-06
than O 0 2.151459057131433e-06
TIC O 0 0.001955542480573058
- O 0 6.58380231470801e-05
2 O 0 2.0744098947034217e-05
. O 0 5.073517058917787e-06
. O 0 1.25325541375787e-05

Human B-Disease 0 0.0002272501733386889
complement I-Disease 0 0.0006382681895047426
factor I-Disease 1 0.8331508636474609
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
associated O 1 0.6066662073135376
with O 1 0.9999231100082397
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9997925162315369

This O 0 6.384750122379046e-06
study O 0 2.7613752990873763e-06
reports O 0 1.5329438838307397e-06
on O 0 6.159806389405276e-07
six O 0 4.6438208300969563e-07
cases O 0 5.467803703140817e-07
of O 0 9.192636935040355e-05
deficiency B-Disease 1 0.999997615814209
in I-Disease 0 7.911126886028796e-06
the I-Disease 0 5.44478007213911e-06
human I-Disease 0 8.564928748455714e-07
complement I-Disease 0 1.721076046123926e-06
regulatory I-Disease 0 2.4104019757942297e-06
protein I-Disease 0 2.3049358333082637e-06
Factor I-Disease 0 1.4446219211095013e-05
H I-Disease 1 0.9996656179428101
( O 0 4.358130809123395e-06
FH O 1 0.8170443177223206
) O 0 2.931177505161031e-07
in O 0 1.6039717820603983e-07
the O 0 1.883913682831917e-07
context O 0 9.949524155672407e-07
of O 0 1.1458031622169074e-05
an O 0 0.015639757737517357
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.36725208163261414

Five O 0 3.085879507125355e-05
of O 0 1.553100810269825e-05
the O 0 3.6910992093908135e-06
cases O 0 4.7648663326071983e-07
were O 0 3.6662606817117194e-07
observed O 0 4.108340192487958e-07
in O 0 3.013299760823429e-07
children O 0 1.378038177790586e-06
presenting O 0 5.0140039093093947e-05
with O 0 0.0006797878304496408
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 1 0.8850204348564148
. O 0 0.0008851386955939233

Two O 0 7.385583103314275e-06
of O 0 1.0574211955827195e-05
the O 0 5.751512617280241e-06
children O 0 3.1842409953242168e-06
exhibited O 0 0.00011974588414886966
a O 0 4.021358836325817e-05
homozygous O 1 0.5105367302894592
deficiency O 1 0.9999912977218628
characterized O 0 3.607299368013628e-05
by O 0 2.0668373963417253e-06
the O 0 2.685219214981771e-06
absence O 0 6.171346285555046e-06
of O 0 2.784803882605047e-06
the O 0 1.382724690301984e-06
150 O 0 5.665995558956638e-06
- O 0 9.18027672014432e-06
kD O 0 5.913704808335751e-05
form O 0 8.115122795970819e-07
of O 0 2.6550367238087347e-06
Factor O 0 3.652839222922921e-05
H O 1 0.9981194138526917
and O 0 7.047402732496266e-07
the O 0 3.395351200197183e-07
presence O 0 4.229956971357751e-07
, O 0 1.2308143482187006e-07
upon O 0 2.990183816109493e-07
immunoblotting O 0 1.391905880154809e-05
, O 0 1.7822850395532441e-07
of O 0 3.298497404102818e-07
the O 0 5.137207494954055e-07
42 O 0 3.8560101529583335e-06
- O 0 1.0375249075877946e-05
kD O 0 0.00017242960166186094
Factor O 0 1.7856271369964816e-05
H O 0 0.009397937916219234
- O 0 6.767939794372069e-06
like O 0 6.057630912437162e-07
protein O 0 6.030436452419963e-07
1 O 0 2.6374548269814113e-06
( O 0 9.104841183216195e-07
FHL O 0 0.02186901494860649
- O 0 1.1798621926573105e-05
1 O 0 2.342202151339734e-06
) O 0 1.4252078983645333e-07
and O 0 7.704899473992555e-08
other O 0 2.3064478682499612e-07
FH O 0 0.4312029480934143
- O 0 1.904253258544486e-05
related O 0 3.7116999465069966e-06
protein O 0 5.84551253268728e-06
( O 0 7.707566510362085e-06
FHR O 1 0.9999587535858154
) O 0 9.823496839089785e-06
bands O 0 8.359275670954958e-05
. O 0 3.1758365366840735e-05

Southern O 0 0.0002543801674619317
blot O 0 0.0003385321469977498
and O 0 3.90716377296485e-06
PCR O 0 1.996282117033843e-05
analysis O 0 9.084389489544265e-07
of O 0 1.5668889545850107e-06
DNA O 0 1.1461878784757573e-05
of O 0 1.7763826463124133e-06
one O 0 1.1964045825152425e-06
patient O 0 1.3523926099878736e-05
with O 0 2.435758233332308e-06
homozygous O 0 0.017026903107762337
deficiency O 1 0.9995549321174622
ruled O 0 1.62084361363668e-05
out O 0 9.721786682348466e-07
the O 0 5.312455755301926e-07
presence O 0 3.533739345584763e-07
of O 0 4.969356268702541e-07
a O 0 2.203988884730279e-07
large O 0 4.112875728878862e-07
deletion O 0 1.9682177025970304e-06
of O 0 2.181576746806968e-06
the O 0 3.7165880257816752e-06
FH O 1 0.9998546838760376
gene O 0 2.556019126132014e-06
as O 0 1.0693812555473414e-06
the O 0 3.594807594708982e-06
underlying O 0 0.009216995909810066
defect O 0 0.022219214588403702
for O 0 9.129219506576192e-06
the O 0 0.019376616925001144
deficiency O 1 0.9999995231628418
. O 0 0.0003207862901035696

The O 0 3.328859020257369e-05
other O 0 1.8512315591578954e-06
four O 0 9.711186521599302e-07
children O 0 1.0314813607692486e-06
presented O 0 4.159799118497176e-06
with O 0 2.197431285821949e-06
heterozygous O 0 0.00031623331597074866
deficiency O 1 0.9999415874481201
and O 0 8.355379577551503e-06
exhibited O 0 0.001336156390607357
a O 0 4.7334074224636424e-06
normal O 0 3.4685856462601805e-06
immunoblotting O 0 0.0001087491400539875
pattern O 0 2.023874912993051e-06
of O 0 7.647585675840674e-07
proteins O 0 4.1495474079056294e-07
of O 0 4.322562290326459e-06
the O 0 2.5466109946137294e-05
FH O 1 0.9999376535415649
family O 0 0.00018095923587679863
. O 0 6.744544953107834e-05

Factor B-Disease 1 0.9993852376937866
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
is O 0 1.6134148609125987e-05
the O 0 9.164129551209044e-06
only O 0 1.482944207964465e-05
complement B-Disease 1 0.9999817609786987
deficiency I-Disease 1 1.0
associated O 0 0.04951883852481842
with O 0 0.005904465913772583
HUS B-Disease 1 1.0
. O 0 0.0023514290805906057

These O 0 4.188516868453007e-06
observations O 0 5.279669494484551e-06
suggest O 0 1.5351997717516497e-06
a O 0 8.386813874494692e-07
role O 0 1.2824325494875666e-06
for O 0 1.4078023014008068e-06
FH O 1 0.9988686442375183
and O 0 1.262947353097843e-05
/ O 0 0.0001990711025428027
or O 0 5.482033884618431e-06
FH O 1 0.6790027618408203
receptors O 0 2.3472691736969864e-06
in O 0 6.098740641391487e-07
the O 0 2.2136036932352e-06
pathogenesis O 1 0.758854866027832
of O 0 0.00950884073972702
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 0.0005654122796840966
. O 0 0.0001391359546687454

Further O 0 3.1832831155043095e-05
evidence O 0 8.919087122194469e-06
for O 0 9.693125093690469e-07
a O 0 2.383364972047275e-06
major O 0 9.316196155850776e-06
ancient O 1 0.670081377029419
mutation O 0 0.004833628889173269
underlying O 1 0.9999593496322632
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 0.17051619291305542
linkage O 0 0.28777244687080383
disequilibrium O 0 0.016116933897137642
studies O 0 6.268129709496861e-06
in O 0 1.744273731674184e-06
the O 0 2.1633757114614127e-06
Japanese O 0 3.082170951529406e-05
population O 0 3.150765905957087e-06
. O 0 2.0086681615794078e-05

The O 0 0.13421203196048737
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999988317489624
DM B-Disease 1 1.0
) O 0 9.737876825965941e-05
mutation O 0 8.60068485053489e-06
is O 0 5.110902634442027e-07
an O 0 5.472211341839284e-07
unstable O 0 0.002147936262190342
( O 0 1.0521834155952092e-05
CTG O 1 0.9999175071716309
) O 0 1.5653625951017602e-06
n O 0 1.0607910780890961e-06
repeat O 0 1.493017066422908e-06
, O 0 1.3997161829593097e-07
present O 0 1.4789040392315655e-07
at O 0 7.179248768807156e-07
a O 0 1.325667113860618e-07
copy O 0 3.6378960999172705e-07
number O 0 4.4435211066229385e-08
of O 0 2.520582427223417e-07
5 O 0 1.6162155134225031e-06
- O 0 5.8439068197913e-06
37 O 0 3.2828263556439197e-06
repeats O 0 8.83748384694627e-07
on O 0 3.3985196523644845e-07
normal O 0 2.606595614906837e-07
chromosomes O 0 1.0038451137006632e-07
but O 0 6.124992069089785e-08
amplified O 0 7.184762012002466e-07
to O 0 1.281897823446343e-07
50 O 0 1.5275966234185034e-06
- O 0 6.797021342208609e-06
3000 O 0 1.642187089601066e-05
copies O 0 6.761914846720174e-06
on O 0 2.2252823328017257e-05
DM B-Disease 1 0.9999984502792358
chromosomes O 0 8.651234384160489e-05
. O 0 4.435608570929617e-05

Previous O 0 9.062627941602841e-05
findings O 0 1.7467107682023197e-05
in O 0 2.701328639886924e-06
Caucasian O 0 1.2341139154159464e-05
populations O 0 6.042232030267769e-07
of O 0 5.016959221393336e-06
a O 0 0.00021596670558210462
DM B-Disease 1 1.0
founder O 1 0.9999958276748657
chromosome O 0 8.80840525496751e-06
raise O 0 8.815118803795485e-07
a O 0 4.76775284141695e-07
question O 0 1.5813678544418508e-07
about O 0 5.257723856288976e-08
the O 0 7.735601315062013e-08
molecular O 0 1.0611837524265866e-06
events O 0 4.1808996797954023e-07
involved O 0 4.0808106405165745e-07
in O 0 3.433488302562182e-07
the O 0 1.3858297052138369e-06
expansion O 0 4.924659515381791e-05
mutation O 0 2.2496817109640688e-05
. O 0 1.5844241715967655e-05

To O 0 1.348582827631617e-05
investigate O 0 1.3791932360618375e-05
whether O 0 1.5029414726086543e-06
a O 0 3.6956289477529936e-06
founder O 0 0.0017416633199900389
chromosome O 0 2.3869772576290416e-06
for O 0 4.776258606398187e-07
the O 0 1.0950532669085078e-05
DM B-Disease 1 1.0
mutation O 0 4.435622486198554e-06
exists O 0 4.94140294904355e-07
in O 0 1.1420534207218225e-07
the O 0 1.065676897837875e-07
Japanese O 0 3.0277512905740878e-06
population O 0 4.774974371457574e-08
, O 0 1.7582195255272381e-07
we O 0 1.187703944083296e-07
genotyped O 0 1.112511927203741e-05
families O 0 4.378512485914143e-08
using O 0 1.393070903077387e-07
polymorphic O 0 3.005788357768324e-06
markers O 0 6.1105397435312625e-06
near O 0 1.3372451576287858e-05
the O 0 3.0247092581703328e-06
( O 0 3.228092964491225e-06
CTG O 1 0.9812073111534119
) O 0 1.990966438825126e-06
n O 0 3.4302586300327675e-06
repeat O 0 4.334930508775869e-06
region O 0 1.8532276726546115e-06
and O 0 2.5431929771002615e-06
constructed O 0 0.00046670454321429133
haplotypes O 0 0.00036080836434848607
. O 0 5.0924005336128175e-05

Six O 0 2.417781979602296e-05
different O 0 6.042387781235448e-07
haplotypes O 0 1.0675830708350986e-05
were O 0 1.7427407783543458e-06
found O 0 3.4308147860429017e-06
and O 0 7.228367394418456e-06
DM B-Disease 1 1.0
alleles O 0 7.480098702217219e-06
were O 0 6.819233476562658e-06
always O 0 1.947466989804525e-05
haplotype O 0 0.0001252350048162043
A O 0 0.00013883417705073953
. O 0 5.354752283892594e-05

To O 0 8.916790648072492e-06
find O 0 1.7342501905659446e-06
an O 0 2.457330197103147e-07
origin O 0 2.628292463668913e-07
of O 0 7.580303531540267e-07
the O 0 2.429019559713197e-06
( O 0 5.160584350960562e-06
CTG O 1 0.9998921155929565
) O 0 8.910084829949483e-07
n O 0 1.3835214076607372e-06
repeat O 0 1.4610558309868793e-06
mutation O 0 2.8233438342795125e-07
and O 0 8.565470466237457e-08
to O 0 8.163164721963767e-08
investigate O 0 6.072415317248669e-07
the O 0 3.398451724478946e-07
mechanism O 0 4.5401637294162356e-07
of O 0 6.293433330029075e-07
the O 0 4.644919044949347e-07
expansion O 0 2.4157086500053992e-06
mutation O 0 2.1381745796134055e-07
in O 0 7.476381824744749e-08
the O 0 1.4081243193686532e-07
Japanese O 0 9.248803394257266e-07
population O 0 2.424528489086697e-08
we O 0 2.0143106738146344e-08
have O 0 2.5224574429216773e-08
studied O 0 1.0485704251550487e-06
90 O 0 2.365638692936045e-06
Japanese O 0 8.231507672462612e-05
DM B-Disease 1 0.9999998807907104
families O 0 1.5442863059433876e-06
comprising O 0 5.941536073805764e-06
190 O 0 7.956796252983622e-06
affected O 0 3.669346142487484e-06
and O 0 3.5014288641832536e-06
130 O 0 2.9785154765704647e-05
unaffected O 0 8.400909428019077e-05
members O 0 1.528386928839609e-05
. O 0 4.253836232237518e-05

The O 0 5.9677611716324463e-05
results O 0 1.1389918654458597e-05
suggest O 0 2.0005725218652515e-06
that O 0 1.8728108841514768e-07
a O 0 5.23765095294948e-07
few O 0 3.717622973908874e-07
common O 0 4.313718875437189e-07
ancestral O 0 2.8837559511885047e-05
mutations O 0 6.978343094488082e-07
in O 0 3.0138201623231e-07
both O 0 4.6710300694030593e-07
Caucasian O 0 9.350865184387658e-06
and O 0 5.461825480779225e-07
Japanese O 0 3.9532351365778595e-06
populations O 0 1.3758712213984836e-07
have O 0 2.787545483329268e-08
originated O 0 1.7402629737262032e-07
by O 0 4.256616747966291e-08
expansion O 0 7.316156711567601e-07
of O 0 6.817827511440555e-07
an O 0 2.597580248675513e-07
ancestral O 0 6.810868853790453e-06
n O 0 1.180354615826218e-06
= O 0 8.171418812707998e-07
5 O 0 4.2761627128129476e-07
repeat O 0 3.94004757708899e-07
to O 0 1.8680962909911614e-07
n O 0 1.6782693137429305e-06
= O 0 1.8034828599411412e-06
19 O 0 3.978685981564922e-06
- O 0 1.179725950350985e-05
37 O 0 1.2223853445902932e-05
copies O 0 1.4521746379614342e-05
. O 0 2.0939714886480942e-05

These O 0 7.606606686749728e-06
data O 0 4.6427630877587944e-06
support O 0 1.3709781114812358e-06
multistep O 0 1.3344754734134767e-05
models O 0 4.261939920979785e-06
of O 0 5.8349296523374505e-06
triplet O 0 0.00013803357433062047
repeat O 0 6.786858648410998e-06
expansion O 0 4.422377060109284e-06
that O 0 1.0032861297304407e-07
have O 0 4.4621721428939054e-08
been O 0 8.081613600552373e-08
proposed O 0 5.32355784343963e-07
for O 0 9.017477395900642e-07
both O 0 1.4116369129624218e-05
DM B-Disease 1 1.0
and O 0 0.0031599411740899086
Friedreichs B-Disease 1 0.9999986886978149
ataxia I-Disease 1 0.9999420642852783
. O 0 0.00012373179197311401
. O 0 0.0001187582965940237

The O 0 4.1985505959019065e-05
molecular O 0 3.0056999094085768e-05
basis O 0 8.970303497335408e-06
of O 0 0.3815121650695801
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.0662472959666047e-05
the O 0 4.428306510817492e-06
western O 0 7.026952971500577e-06
Cape O 0 0.00016565038822591305
, O 0 2.6604000140650896e-06
South O 0 1.8474100215826184e-05
Africa O 0 1.7563455912750214e-05
. O 0 2.059641519736033e-05

Deficiency B-Disease 1 0.9996362924575806
of I-Disease 0 0.0001804234052542597
the I-Disease 0 8.697656448930502e-05
sixth I-Disease 0 0.4745972454547882
component I-Disease 0 5.116852480568923e-05
of I-Disease 0 8.475852155243047e-06
human I-Disease 0 3.6534027003654046e-06
complement I-Disease 0 1.3437199413601775e-05
( O 0 1.6690530173946172e-05
C6 O 1 0.9999933242797852
) O 0 9.482246809966455e-07
has O 0 1.2379906877413305e-07
been O 0 1.280309618323372e-07
reported O 0 9.682171508984538e-08
in O 0 5.4455416176324434e-08
a O 0 6.023952181521963e-08
number O 0 3.5848270130145465e-08
of O 0 2.0416892709818057e-07
families O 0 4.087625882220891e-08
from O 0 2.2685726719373633e-07
the O 0 4.0798533973429585e-07
western O 0 2.647666178745567e-06
Cape O 0 8.489851461490616e-05
, O 0 1.6091303223220166e-06
South O 0 1.6098139894893393e-05
Africa O 0 2.1940304577583447e-05
. O 0 2.412673711660318e-05

Meningococcal B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999948740005493
is O 0 1.8289096260559745e-05
endemic O 0 0.000103205100458581
in O 0 2.034223371083499e-06
the O 0 3.648298616099055e-06
Cape O 0 0.00012772883928846568
and O 0 3.0268856221482565e-07
almost O 0 3.5886313298760797e-07
all O 0 8.45077323674559e-08
pedigrees O 0 2.2094425276009133e-06
of O 0 5.326377959136153e-06
total O 0 0.022610466927289963
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 1 0.5454792976379395
C6Q0 O 1 1.0
) O 0 2.509975502107409e-06
have O 0 1.395158335526503e-07
been O 0 2.8290767772887193e-07
ascertained O 0 1.0453650247654878e-05
because O 0 1.7551749351696344e-06
of O 0 0.00011526438902365044
recurrent O 1 0.9999998807907104
disease O 1 0.9999994039535522
. O 0 0.0002620658779051155

We O 0 1.2978369340999052e-05
have O 0 8.107062399176357e-07
sequenced O 0 4.78282254334772e-06
the O 0 6.224242383723322e-07
expressed O 0 5.232238891039742e-07
exons O 0 3.5909085909224814e-06
of O 0 3.2337532047677087e-06
the O 0 1.5450861610588618e-05
C6 O 1 0.9999960660934448
gene O 0 1.5619431223967695e-06
from O 0 2.94883847118399e-07
selected O 0 4.48991869461679e-07
cases O 0 9.717063420566774e-08
and O 0 1.0514047232845769e-07
have O 0 4.2226695029512484e-08
found O 0 3.1318813853431493e-07
three O 0 3.1767174846208945e-07
molecular O 0 0.0408606082201004
defects O 1 0.9997627139091492
leading O 0 7.489285053452477e-05
to O 0 1.7951552990780328e-06
total O 0 0.00016308980411849916
deficiency O 1 0.9999996423721313
879delG O 1 0.9956105351448059
, O 0 2.6999921374226687e-06
which O 0 2.5596997943466704e-07
is O 0 1.5958254095949087e-07
the O 0 4.7541681169605e-07
common O 0 2.805344593070913e-06
defect O 0 0.0003267935535404831
in O 0 6.829847052358673e-07
the O 0 3.7296149457688443e-06
Cape O 0 0.0002232281258329749
and O 0 1.074137003342912e-06
hitherto O 0 1.157846418209374e-05
unreported O 0 9.51846504904097e-06
, O 0 6.142378197182552e-07
and O 0 6.211338927641918e-07
1195delC O 0 5.7047876907745376e-05
and O 0 2.3153390884544933e-06
1936delG O 0 0.00019364769104868174
, O 0 6.028089956089389e-07
which O 0 1.2737281451791205e-07
have O 0 4.308049028622918e-08
been O 0 2.2838047186723998e-07
previously O 0 1.0705863360271906e-06
reported O 0 7.839715294721827e-07
in O 0 9.89000909612514e-07
African O 0 8.640038686280604e-06
- O 0 0.00010616663348628208
Americans O 0 1.419490945409052e-05
. O 0 2.3326203518081456e-05

We O 0 1.8073025785270147e-05
also O 0 2.6597099349601194e-06
show O 0 1.386665189784253e-06
that O 0 1.1703891544811995e-07
the O 0 5.605171509159845e-07
879delG O 0 0.00015392096247524023
and O 0 4.101647846255219e-06
1195delC O 1 0.9136427044868469
defects O 0 0.2188062220811844
are O 0 3.42581159884503e-07
associated O 0 1.5187778217296e-06
with O 0 1.6627971035632072e-06
characteristic O 1 0.9745103120803833
C6 O 1 1.0
/ O 1 0.9999333620071411
C7 O 1 0.9999901056289673
region O 0 7.10903805156704e-06
DNA O 0 1.7343912986689247e-05
marker O 0 2.6250805603922345e-05
haplotypes O 0 6.616870450670831e-06
, O 0 3.4753958289002185e-07
although O 0 1.7142129138392193e-07
small O 0 2.5101593337240047e-07
variations O 0 8.962205129137146e-07
were O 0 1.2859499065598357e-06
observed O 0 8.325489943672437e-06
. O 0 1.620820512471255e-05

The O 0 0.00038957211654633284
1936delG O 1 0.778705358505249
defect O 0 0.19673189520835876
was O 0 5.159465945325792e-05
observed O 0 1.4602129567720112e-06
only O 0 1.362792687586989e-07
once O 0 4.2761345753206115e-07
in O 0 1.7480142844306101e-07
the O 0 8.719850370653148e-07
Cape O 0 6.574403232662007e-05
, O 0 3.9719043343211524e-07
but O 0 1.0021940255455775e-07
its O 0 3.2034012065196293e-07
associated O 0 2.278929969179444e-06
haplotype O 0 1.2640099157579243e-05
could O 0 8.363953725165629e-07
be O 0 1.0492547062312951e-06
deduced O 0 5.0020931666949764e-05
. O 0 2.6392330255475827e-05

The O 0 3.245447078370489e-05
data O 0 5.7794441090663895e-06
from O 0 3.344861852383474e-06
the O 0 1.9176543446519645e-06
haplotypes O 0 6.02672616878408e-06
indicate O 0 4.794430878973799e-07
that O 0 4.365179151477605e-08
these O 0 2.3474651555943638e-08
three O 0 1.613682201195843e-07
molecular O 0 9.353890345664695e-05
defects O 0 0.003849186236038804
account O 0 4.471620798085496e-07
for O 0 5.141388328411267e-07
the O 0 8.480080396111589e-06
defects O 0 0.10538607090711594
in O 0 5.415575401457318e-07
all O 0 1.2649121572394506e-07
the O 0 1.1065504850193975e-06
38 O 0 7.893905603850726e-06
unrelated O 0 2.0468278307816945e-05
C6Q0 O 1 0.9952344298362732
individuals O 0 2.4020025080062624e-07
we O 0 1.381879428663524e-07
have O 0 8.733110234970809e-08
studied O 0 2.2038218503439566e-06
from O 0 2.0035377019667067e-06
the O 0 6.821177976235049e-06
Cape O 0 0.0006169630214571953
. O 0 4.711416841018945e-05

We O 0 1.2646298273466527e-05
have O 0 6.139285915196524e-07
also O 0 3.787914408803772e-07
observed O 0 1.1399177992643672e-06
the O 0 9.590326044417452e-07
879delG O 0 0.0006133567076176405
defect O 0 8.884119597496465e-05
in O 0 1.5710905927335261e-06
two O 0 1.4521818911816808e-06
Dutch O 1 0.999925971031189
C6 B-Disease 1 1.0
- I-Disease 1 0.9999680519104004
deficient I-Disease 1 0.9999741315841675
kindreds O 0 0.0005230422830209136
, O 0 1.189476165563974e-06
but O 0 1.7321052325769415e-07
the O 0 1.0170423365707393e-06
879delG O 0 0.004983546677976847
defect O 0 7.86910459282808e-05
in O 0 1.610462732060114e-06
the O 0 3.332190090077347e-06
Cape O 0 0.0004642595013137907
probably O 0 2.333413704036502e-06
did O 0 1.4390377600648208e-07
not O 0 1.9249817739819264e-08
come O 0 4.260442310055623e-08
from O 0 1.937009415087232e-07
The O 0 1.8634926846061717e-06
Netherlands O 0 8.757461182540283e-05
. O 0 5.271815552987391e-06
. O 0 1.3229382602730766e-05

Complement B-Disease 1 0.9999707937240601
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.4815707951784134e-05
seven O 0 1.14123376988573e-05
further O 0 1.4127923350315541e-05
molecular O 0 0.06899136304855347
defects O 1 0.9094887971878052
and O 0 2.4286998723255238e-06
their O 0 4.552999143925263e-06
associated O 0 4.118328433833085e-05
marker O 0 0.002971488516777754
haplotypes O 0 0.00032525716233067214
. O 0 7.151121826609597e-05

Seven O 0 6.852067599538714e-05
further O 0 1.1299514881102368e-05
molecular O 0 3.401848880457692e-05
bases O 0 7.350906525971368e-05
of O 1 0.847062885761261
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.9712073228438385e-05
described O 0 0.0003537982702255249
. O 0 0.0001259425189346075

All O 0 5.266704647510778e-06
these O 0 9.355576366942842e-07
new O 0 2.466447313054232e-06
molecular O 0 0.00019964764942415059
defects O 0 0.012511896900832653
involve O 0 4.257560703990748e-06
single O 0 3.621039923018543e-06
- O 0 4.612866632669466e-06
nucleotide O 0 9.69875600276282e-07
events O 0 4.51242470944635e-07
, O 0 4.901709758087236e-07
deletions O 0 1.3254639270599e-06
and O 0 2.4038862989073095e-07
substitutions O 0 2.8189954264234984e-06
, O 0 3.385677018741262e-07
some O 0 9.260456579340826e-08
of O 0 3.7926676554889127e-07
which O 0 3.4552499528217595e-07
alter O 0 3.759321543839178e-06
splice O 0 3.4996912290807813e-05
sites O 0 4.961314516549464e-06
, O 0 1.4867980553390225e-06
and O 0 1.1629329037532443e-06
others O 0 3.3426711070205783e-06
codons O 0 7.08913867129013e-05
. O 0 3.264826591475867e-05

They O 0 6.5069903030234855e-06
are O 0 2.601090614007262e-07
distributed O 0 6.453094556491124e-07
along O 0 1.1345135817464325e-06
the O 0 5.182007498660823e-06
C7 O 1 0.9999780654907227
gene O 0 3.6938881748938e-06
, O 0 3.903000731497741e-07
but O 0 4.865642466711506e-08
predominantly O 0 2.579246825007431e-07
towards O 0 8.316430353261239e-07
the O 0 1.3259708566693007e-06
3 O 0 1.682743641140405e-05
end O 0 3.555181319825351e-05
. O 0 3.125462535535917e-05

All O 0 1.4278488379204646e-05
were O 0 2.431369694022578e-06
found O 0 2.724318164837314e-06
in O 0 1.5402180224555195e-06
compound O 0 5.3672622016165406e-05
heterozygous O 0 1.182918822451029e-05
individuals O 0 4.938590336678317e-06
. O 0 4.1017570765689015e-05

The O 0 0.01122758723795414
C6 O 1 0.9999998807907104
/ O 1 0.9998973608016968
C7 O 1 0.9999979734420776
marker O 0 0.008629667572677135
haplotypes O 0 8.041454566409811e-05
associated O 0 6.036246304574888e-06
with O 0 2.880129841287271e-06
most O 0 5.020382013753988e-05
C7 B-Disease 1 1.0
defects I-Disease 1 0.999065101146698
are O 0 1.5864628721828922e-06
tabulated O 0 5.9879192122025415e-05
. O 0 1.3846136425854638e-05
. O 0 3.432920129853301e-05

A O 0 0.0005136911058798432
genome O 0 5.3292300435714424e-05
- O 0 3.3143161999760196e-05
wide O 0 3.8387470340239815e-06
search O 0 1.6199514902837109e-06
for O 0 9.41107600738178e-07
chromosomal O 0 0.00016832277469802648
loci O 0 6.987070810282603e-05
linked O 0 9.811362542677671e-05
to O 0 9.18188743526116e-06
mental O 1 0.9999990463256836
health O 0 0.23594504594802856
wellness O 1 0.924043595790863
in O 0 7.24195342627354e-06
relatives O 0 9.359732757729944e-06
at O 0 5.388195859268308e-05
high O 0 0.00011068861203966662
risk O 0 1.0731053407653235e-05
for O 0 4.431266643223353e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.0001282510784221813
the O 0 0.00016193673945963383
Old O 1 0.7189186811447144
Order O 0 7.798242586432025e-05
Amish O 0 0.008921989239752293
. O 0 0.00010516690235817805

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999971389770508
BPAD B-Disease 1 1.0
; O 1 0.9998772144317627
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 0.00297015393152833
is O 0 8.454934686596971e-06
characterized O 0 1.232742488355143e-05
by O 0 1.5325754247896839e-06
episodes O 0 1.2625788258446846e-05
of O 0 0.0005014494527131319
mania B-Disease 1 0.9999980926513672
and O 0 0.003802589839324355
/ O 1 0.9705528020858765
or O 0 6.072797259548679e-05
hypomania B-Disease 1 0.9991472959518433
interspersed O 0 5.112842336529866e-05
with O 0 1.991112640098436e-06
periods O 0 5.140259236213751e-05
of O 0 0.0010312736267223954
depression B-Disease 1 0.9999717473983765
. O 0 0.0005016988143324852

Compelling O 0 0.00011118304973933846
evidence O 0 3.3813495974754915e-05
supports O 0 1.4870198356220499e-05
a O 0 1.551916284370236e-06
significant O 0 1.2915974139104947e-06
genetic O 0 7.65467939345399e-06
component O 0 8.248498488683254e-06
in O 0 7.225805802590912e-07
the O 0 4.185897523711901e-06
susceptibility O 0 0.00013867858797311783
to O 0 4.953059942636173e-06
develop O 0 0.01100324559956789
BPAD B-Disease 1 1.0
. O 0 0.00020075097563676536

To O 0 8.927563612814993e-06
date O 0 2.0795878299395554e-05
, O 0 1.4722143077960936e-06
however O 0 4.5088461320119677e-07
, O 0 2.9892544262111187e-07
linkage O 0 2.9642578738275915e-06
studies O 0 5.470379846883588e-07
have O 0 5.915884671026106e-08
attempted O 0 9.587691920387442e-07
only O 0 9.409158252537964e-08
to O 0 2.561230587616592e-07
identify O 0 2.263475607833243e-06
chromosomal O 0 3.044892946491018e-05
loci O 0 1.3224727808847092e-05
that O 0 8.428170872321061e-07
cause O 0 6.5418844314990565e-06
or O 0 1.0214299663857673e-06
increase O 0 3.1362031904791365e-07
the O 0 1.2024371471852646e-06
risk O 0 3.6591072785086e-06
of O 0 1.2554324712255038e-05
developing O 0 0.0015909122303128242
BPAD B-Disease 1 1.0
. O 0 0.0002147973864339292

To O 0 1.4743691281182691e-05
determine O 0 4.372230705484981e-06
whether O 0 1.2139107639086433e-06
there O 0 5.422484719019849e-07
could O 0 3.2803811222947843e-07
be O 0 1.6985579520678584e-07
protective O 0 3.1206254789140075e-05
alleles O 0 2.8818780606343353e-07
that O 0 8.466648893090678e-08
prevent O 0 1.0081313348564436e-06
or O 0 4.241777276092762e-07
reduce O 0 5.868777179784956e-07
the O 0 9.188669309878605e-07
risk O 0 9.595851224730723e-07
of O 0 2.1346204448491335e-06
developing O 0 5.426053758128546e-05
BPAD B-Disease 1 1.0
, O 0 6.3505103753414e-07
similar O 0 9.499356679043558e-08
to O 0 8.873360712868816e-08
what O 0 9.928351829557869e-08
is O 0 4.868046943329318e-08
observed O 0 1.0247595838563939e-07
in O 0 1.454357629881997e-07
other O 0 1.2958342949787038e-06
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 3.687893331516534e-05
we O 0 1.1431935718064778e-06
used O 0 3.721579923876561e-05
mental O 1 0.9999375343322754
health O 0 0.3936099112033844
wellness O 1 0.9997897744178772
( O 0 1.0228249266219791e-05
absence O 0 4.136228744755499e-05
of O 0 3.589575499063358e-05
any O 0 0.00016491030692122877
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.9999995231628418
) O 0 3.4740016872092383e-06
as O 0 1.062976366483781e-06
the O 0 2.005569740504143e-06
phenotype O 0 3.5180100894649513e-06
in O 0 5.527852522391186e-07
our O 0 6.647575787610549e-07
genome O 0 2.9000377708143787e-06
- O 0 6.216042038431624e-06
wide O 0 3.127433046756778e-06
linkage O 0 6.511745596071705e-06
scan O 0 6.5007379816961475e-06
of O 0 6.483548418145801e-07
several O 0 3.204501126674586e-07
large O 0 1.8441729707774357e-06
multigeneration O 0 0.015446408651769161
Old O 0 0.00014331740385387093
Order O 0 5.405547199188732e-06
Amish O 0 5.773109296569601e-05
pedigrees O 0 2.9104807254043408e-05
exhibiting O 0 1.527719541627448e-05
an O 0 1.6034331338232732e-06
extremely O 0 8.949701623350848e-06
high O 0 0.00011890332825714722
incidence O 0 0.0008565157768316567
of O 0 0.00031268675229512155
BPAD B-Disease 1 1.0
. O 0 0.00041951489401981235

We O 0 9.204560228681657e-06
have O 0 4.19384633687514e-07
found O 0 8.637243240627868e-07
strong O 0 4.2044504766636237e-07
evidence O 0 7.882763384259306e-07
for O 0 2.010127815310625e-07
a O 0 1.2023109547953936e-06
locus O 0 8.19885462988168e-06
on O 0 3.1611973554390715e-06
chromosome O 0 1.0305816431355197e-05
4p O 0 0.003868304891511798
at O 0 3.836343239527196e-05
D4S2949 O 0 0.00016444710490759462
( O 0 1.073067096513114e-06
maximum O 0 1.7665588529780507e-06
GENEHUNTER O 0 0.007549095433205366
- O 0 1.645945303607732e-05
PLUS O 0 2.01555885723792e-05
nonparametric O 0 2.170952757296618e-05
linkage O 0 6.891263637953671e-06
score O 0 1.5945172435749555e-06
= O 0 1.6570427305850899e-06
4 O 0 2.2073659238230903e-06
. O 0 3.895266331710445e-07
05 O 0 1.7669734006631188e-05
, O 0 4.6641707740491256e-07
P O 0 7.363246822933434e-06
= O 0 6.91017703502439e-07
5 O 0 5.894405035178352e-07
. O 0 7.28171514197129e-08
22 O 0 3.5678289123097784e-07
x O 0 7.479418400180293e-07
10 O 0 3.8035739180486416e-07
( O 0 2.5669868364275317e-07
- O 0 1.990833652598667e-06
4 O 0 1.7376589767081896e-06
) O 0 3.5746100479627785e-07
; O 0 2.9566615467047086e-07
SIBPAL O 0 0.013391721993684769
Pempirical O 0 0.00011049732711398974
value O 0 1.5116394251890597e-06
< O 0 2.5708970952109667e-06
3 O 0 4.499361807575042e-07
x O 0 7.113413857950945e-07
10 O 0 4.930072918796213e-07
( O 0 3.0907065706742287e-07
- O 0 1.3821802440361353e-06
5 O 0 7.103502639438375e-07
) O 0 2.0672203504545905e-07
) O 0 1.2018945483305288e-07
and O 0 1.7329709578461916e-07
suggestive O 0 2.8291972284932854e-06
evidence O 0 5.649483796332788e-07
for O 0 1.6553512693917583e-07
a O 0 9.511138614470838e-07
locus O 0 7.029989319562446e-06
on O 0 2.1552375528699486e-06
chromosome O 0 5.294190032145707e-06
4q O 0 0.00036329205613583326
at O 0 1.8440463463775814e-05
D4S397 O 0 0.00012747675646096468
( O 0 1.162283297162503e-06
maximum O 0 2.439908257656498e-06
GENEHUNTER O 0 0.0522327795624733
- O 0 2.1221667338977568e-05
PLUS O 0 1.5665122191421688e-05
nonparametric O 0 2.29355318879243e-05
linkage O 0 1.0166506399400532e-05
score O 0 2.2837293727206998e-06
= O 0 1.6170280332516995e-06
3 O 0 7.714434673289361e-07
. O 0 1.2057633114181954e-07
29 O 0 8.495618999404542e-07
, O 0 1.735614034714672e-07
P O 0 4.681444352172548e-06
= O 0 6.099642178014619e-07
2 O 0 5.39493498763477e-07
. O 0 8.768127202074538e-08
57 O 0 3.9425208342436235e-07
x O 0 3.4280603244951635e-07
10 O 0 2.1701607977320236e-07
( O 0 2.863268662167684e-07
- O 0 1.203979422825796e-06
3 O 0 1.0878065950237215e-06
) O 0 2.1254884075005975e-07
; O 0 2.1507850078705815e-07
SIBPAL O 0 0.003016324480995536
Pempirical O 0 0.00010509370622457936
value O 0 1.6714698176656384e-06
< O 0 3.93219761463115e-06
1 O 0 7.440332865371602e-07
x O 0 7.159407005019602e-07
10 O 0 3.4993249187209585e-07
( O 0 4.0470962403560407e-07
- O 0 3.1261149615602335e-06
3 O 0 2.393094973740517e-06
) O 0 2.6040487455247785e-07
) O 0 1.430858418416392e-07
that O 0 4.22933581489815e-08
are O 0 6.583200473642137e-08
linked O 0 1.061561761162011e-05
to O 0 8.883646842150483e-06
mental O 1 0.9999992847442627
health O 1 0.996717631816864
wellness O 1 0.999944806098938
. O 0 0.0004436975868884474

These O 0 8.980190614238381e-06
findings O 0 4.622281721822219e-06
are O 0 1.999917031980658e-07
consistent O 0 7.620851079082058e-07
with O 0 1.7600363833025767e-07
the O 0 7.239027581817936e-07
hypothesis O 0 2.6308480300940573e-06
that O 0 8.728697054039003e-08
certain O 0 1.788325505458488e-07
alleles O 0 2.949187489775795e-07
could O 0 2.4731784264986345e-07
prevent O 0 2.071535845971084e-06
or O 0 5.709436550205282e-07
modify O 0 1.7670575971351354e-06
the O 0 1.310836523771286e-06
clinical O 0 4.227558019920252e-05
manifestations O 0 0.0002802531816996634
of O 0 0.0066010490991175175
BPAD B-Disease 1 1.0
and O 0 1.5132784028537571e-05
perhaps O 0 3.457274488027906e-06
other O 0 1.518735757599643e-06
related O 0 0.002781672403216362
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.19492332637310028

Segregation O 1 0.993874728679657
distortion O 1 0.9973154664039612
in O 0 0.10123521834611893
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.500257134437561

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999997615814209
DM B-Disease 1 1.0
) O 0 0.0011016206117346883
is O 0 6.311004199233139e-06
an O 0 1.0098304301209282e-05
autosomal B-Disease 1 0.9942910671234131
dominant I-Disease 1 0.9999992847442627
disease I-Disease 1 0.9999973773956299
which O 0 2.568042418715777e-06
, O 0 9.834218417381635e-07
in O 0 3.0039203124943015e-07
the O 0 5.873631607755669e-07
typical O 0 2.9963034648972098e-06
pedigree O 0 1.0311115147487726e-05
, O 0 2.426187393211876e-07
shows O 0 2.7946211389462405e-07
a O 0 2.766940383480687e-07
three O 0 5.724577363253047e-07
generation O 0 4.428440297488123e-05
anticipation O 0 0.0002761252108030021
cascade O 0 0.3347839415073395
. O 0 0.00010144423140445724

This O 0 3.268496584496461e-05
results O 0 3.286443097749725e-05
in O 0 4.437995085027069e-05
infertility B-Disease 1 0.9999955892562866
and O 1 0.9999443292617798
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999898672103882
CDM B-Disease 1 0.9999998807907104
) O 0 1.0664903129509185e-05
with O 0 1.5130601696000667e-06
the O 0 5.040904852648964e-06
disappearance O 0 6.130564725026488e-05
of O 0 0.00039839232340455055
DM B-Disease 1 1.0
in O 0 2.481997580616735e-05
that O 0 6.611415301449597e-06
pedigree O 0 0.000499629823025316
. O 0 5.617634087684564e-05

The O 0 2.3681581296841614e-05
concept O 0 1.3430280887405388e-05
of O 0 9.583793143974617e-06
segregation O 0 0.06112746149301529
distortion O 0 0.06571831554174423
, O 0 1.1258255199209088e-06
where O 0 4.582489054882899e-07
there O 0 9.213258778117961e-08
is O 0 4.4260879406010645e-08
preferential O 0 2.064684707647757e-07
transmission O 0 7.726340527369757e-07
of O 0 3.5356438843336946e-07
the O 0 2.2506955588141864e-07
larger O 0 5.784014547316474e-07
allele O 0 5.056265308667207e-07
at O 0 2.3402105853165267e-06
the O 0 3.6489109334070235e-06
DM B-Disease 1 1.0
locus O 0 2.9361757697188295e-05
, O 0 4.637133770302171e-07
has O 0 1.280975112649685e-07
been O 0 1.9949357010773383e-07
put O 0 6.00059308908385e-07
forward O 0 3.7680260334127524e-07
to O 0 1.556376076905508e-07
explain O 0 9.308320159107097e-07
partially O 0 5.7894176279660314e-06
the O 0 1.677886871220835e-06
maintenance O 0 0.004450479056686163
of O 0 0.00020305915677454323
DM B-Disease 1 1.0
in O 0 6.1841133174311835e-06
the O 0 2.3022798814054113e-06
population O 0 1.4773817156310542e-06
. O 0 8.86916313902475e-06

In O 0 3.5772867704508826e-05
a O 0 1.4531555279972963e-05
survey O 0 1.4048493540030904e-05
of O 0 3.4968888940056786e-05
DM B-Disease 1 1.0
in O 0 2.391285488556605e-05
Northern O 0 4.1481267544440925e-05
Ireland O 0 2.12153736356413e-05
, O 0 2.1270466277201194e-06
59 O 0 1.830474502639845e-05
pedigrees O 0 2.8919928809045814e-05
were O 0 1.0145275155082345e-05
ascertained O 0 0.00025646743597462773
. O 0 4.9810627388069406e-05

Sibships O 0 0.010629302822053432
where O 0 1.3933387890574522e-05
the O 0 2.945203505078098e-06
status O 0 8.27882615794806e-07
of O 0 6.697931667076773e-07
all O 0 1.2767748103215126e-07
the O 0 3.6103605793869065e-07
members O 0 1.2015621564387402e-07
had O 0 2.1355845092330128e-07
been O 0 1.1437253988333396e-07
identified O 0 1.7396855866991245e-07
were O 0 1.2877929123078502e-07
examined O 0 7.21101912404265e-07
to O 0 1.1863998139460818e-07
determine O 0 1.5805265718427108e-07
the O 0 6.786857511542621e-07
transmission O 0 3.7210568279988365e-06
of O 0 3.470412138995016e-06
the O 0 1.735592377372086e-05
DM B-Disease 1 1.0
expansion O 0 9.018650598591194e-05
from O 0 7.184191872511292e-06
affected O 0 1.5706621070421534e-06
parents O 0 3.2367569247071515e-07
to O 0 3.3211892969120527e-07
their O 0 1.6009320233933977e-06
offspring O 0 3.0711096769664437e-05
. O 0 3.2393709261668846e-05

Where O 0 3.293439658591524e-05
the O 0 1.1897747754119337e-05
transmitting O 0 0.0005972422659397125
parent O 0 4.602264380082488e-05
was O 0 6.301316170720384e-05
male O 0 1.4015066881256644e-05
, O 0 4.875639206147753e-06
58 O 0 6.836376996943727e-05
. O 0 3.588589606806636e-05

3 O 0 3.7884554330958053e-05
% O 0 2.5262957024096977e-06
of O 0 1.546355406389921e-06
the O 0 5.617951046588132e-07
offspring O 0 1.8355174233875005e-06
were O 0 5.53208167275443e-07
affected O 0 5.986606765873148e-07
, O 0 2.4869629555723805e-07
and O 0 1.382015142326054e-07
in O 0 1.6306606198668305e-07
the O 0 2.929660070094542e-07
case O 0 3.7063975355522416e-07
of O 0 1.3041033071203856e-06
a O 0 1.6704276504242443e-06
female O 0 5.931774921918986e-06
transmitting O 0 0.0001438752078684047
parent O 0 2.4024837330216542e-05
, O 0 1.0888946235354524e-05
68 O 0 0.00021764067059848458
. O 0 6.280260276980698e-05

7 O 0 0.00033547193743288517
% O 0 3.0315877665998414e-05
were O 0 1.9749526472878642e-05
affected O 0 7.847327651688829e-05
. O 0 7.132890459615737e-05

Studies O 0 5.498986138263717e-05
on O 0 1.909760248963721e-05
meiotic O 0 0.0013511605793610215
drive O 0 2.2327030819724314e-05
in O 0 1.638568937778473e-05
DM B-Disease 1 1.0
have O 0 6.218647286004853e-07
shown O 0 3.036096529740462e-07
increased O 0 2.029439940542943e-07
transmission O 0 5.639186042571964e-07
of O 0 3.2552472362112894e-07
the O 0 1.8228911358164623e-07
larger O 0 4.77395417419757e-07
allele O 0 4.298774172184494e-07
at O 0 1.3466142263496295e-06
the O 0 3.7274921851349063e-06
DM B-Disease 1 0.9999997615814209
locus O 0 1.728740426187869e-05
in O 0 2.6154875740758143e-06
non O 0 8.770306885708123e-05
- O 0 0.1346765160560608
DM O 1 1.0
heterozygotes O 0 0.0006383138825185597
for O 0 3.2053289032774046e-05
CTGn O 1 0.9305594563484192
. O 0 9.065461927093565e-05

This O 0 1.4225455743144266e-05
study O 0 3.15507145387528e-06
provides O 0 6.658577831331058e-07
further O 0 5.801305178465554e-07
evidence O 0 1.285685129914782e-06
that O 0 2.321281016293142e-07
the O 0 8.554728083254304e-06
DM B-Disease 1 1.0
expansion O 0 0.00035446067340672016
tends O 0 9.506944479653612e-06
to O 0 7.409559543702926e-07
be O 0 9.175674335892836e-07
transmitted O 0 9.780338587006554e-06
preferentially O 0 5.4869022278580815e-05
. O 0 2.718460382311605e-05

Diagnosis O 1 0.9996383190155029
of O 1 0.993410050868988
hemochromatosis B-Disease 1 1.0
. O 0 0.05582793802022934

If O 0 0.001800081110559404
untreated O 1 0.9999998807907104
, O 1 0.9816391468048096
hemochromatosis B-Disease 1 1.0
can O 0 0.0009135319851338863
cause O 1 0.9998729228973389
serious O 1 0.9999727010726929
illness O 1 0.9999912977218628
and O 0 3.3658402571745683e-06
early B-Disease 0 5.472766497405246e-05
death I-Disease 0 0.00010225177538814023
, O 0 6.350462058435369e-07
but O 0 1.6022838167373266e-07
the O 0 4.851519406656735e-06
disease O 1 0.83132004737854
is O 0 1.3874906699129497e-06
still O 0 2.7334424430591753e-06
substantially O 0 8.343977242475376e-06
under O 0 0.00030040432466194034
- O 1 0.9998990297317505
diagnosed O 1 0.9999803304672241
. O 0 5.867143772775307e-05

The O 0 6.231116276467219e-05
cornerstone O 0 0.03857284039258957
of O 0 1.681418507359922e-05
screening O 0 2.0259803932276554e-05
and O 0 9.236200071427447e-07
case O 0 8.358643981409841e-07
detection O 0 1.1651192835415713e-05
is O 0 2.261136131664898e-07
the O 0 2.69295895805044e-07
measurement O 0 3.225990894861752e-06
of O 0 2.4298674361489248e-06
serum O 0 7.124561670934781e-05
transferrin O 0 5.392338789533824e-05
saturation O 0 1.244529994437471e-05
and O 0 9.469252404414874e-07
the O 0 3.4038432659144746e-06
serum O 0 0.00015269262075889856
ferritin O 0 0.001252289628610015
level O 0 7.477802864741534e-05
. O 0 3.8197591493371874e-05

Once O 0 0.0003634571621660143
the O 0 7.79346955823712e-05
diagnosis O 0 0.06829363107681274
is O 0 3.214416210539639e-06
suspected O 0 3.107300653937273e-05
, O 0 1.7670407714831526e-06
physicians O 0 6.153145477583166e-06
must O 0 3.891842652592459e-07
use O 0 3.2278774142469047e-06
serum O 0 0.007420164067298174
ferritin O 1 0.9173097014427185
levels O 0 4.053214070154354e-05
and O 0 2.6623252779245377e-05
hepatic O 1 0.9997127652168274
iron O 1 0.999711811542511
stores O 0 8.835101471049711e-05
on O 0 7.177445513661951e-05
liver O 1 0.9992450475692749
biopsy O 0 0.05271701142191887
specimens O 0 5.31190016772598e-06
to O 0 6.930127369741967e-07
assess O 0 3.6753488075191854e-06
patients O 0 1.3144581316737458e-06
for O 0 2.3838055085434462e-07
the O 0 1.9794215404544957e-06
presence O 0 1.5742096366011538e-05
of O 0 0.0007303338497877121
iron B-Disease 1 0.9999998807907104
overload I-Disease 1 0.9999815225601196
. O 0 0.0002372304879827425

Liver O 1 0.999997615814209
biopsy O 1 0.9995160102844238
is O 0 3.942959665437229e-06
also O 0 3.7647720319000655e-07
used O 0 2.828488732120604e-07
to O 0 1.1988471726454009e-07
establish O 0 1.2049006272718543e-06
the O 0 8.501162938046036e-07
presence O 0 2.7248690912529128e-06
or O 0 1.929136942635523e-06
absence O 0 1.4696370271849446e-05
of O 0 0.001356516731902957
cirrhosis B-Disease 1 1.0
, O 0 5.884772690478712e-06
which O 0 1.1380408295735833e-06
can O 0 4.9571582394492e-07
affect O 0 5.449808668345213e-06
prognosis O 0 0.012456285767257214
and O 0 1.8165368601330556e-05
management O 0 0.056033141911029816
. O 0 0.00014684740744996816

A O 0 0.00029361879569478333
DNA O 0 6.75466944812797e-05
- O 0 1.5927078493405133e-05
based O 0 2.0136326384090353e-06
test O 0 1.9016825945072924e-06
for O 0 3.017507310687506e-07
the O 0 2.1631385607179254e-06
HFE O 1 0.9998220801353455
gene O 0 2.7670271265378688e-06
is O 0 1.1154573087424069e-07
commercially O 0 5.39247650976904e-07
available O 0 1.1152084056220701e-07
, O 0 8.891743163985666e-08
but O 0 2.0275667367286587e-08
its O 0 5.1438107107060205e-08
place O 0 2.8367088589220657e-07
in O 0 1.7247832317934808e-07
the O 0 6.133310535005876e-07
diagnosis O 0 0.11902640759944916
of O 0 0.03671714663505554
hemochromatosis B-Disease 1 1.0
is O 0 6.882049092382658e-06
still O 0 5.461270575324306e-06
being O 0 4.365726454125252e-06
evaluated O 0 2.731484710238874e-05
. O 0 2.232596671092324e-05

Currently O 0 6.0465739807114005e-05
, O 0 2.243919425382046e-06
the O 0 6.007017532283498e-07
most O 0 2.3072398391832394e-07
useful O 0 3.715120726610621e-07
role O 0 3.1484117357649666e-07
for O 0 1.2839447549595207e-07
this O 0 1.1699282964627855e-07
test O 0 1.1284419088042341e-06
is O 0 5.633317101683133e-08
in O 0 5.661830115855082e-08
the O 0 3.692236418828543e-07
detection O 0 5.187964052311145e-05
of O 0 0.0001231381029356271
hemochromatosis B-Disease 1 1.0
in O 0 1.9423400772211608e-06
the O 0 1.210925233863236e-06
family O 0 1.4181796359480359e-06
members O 0 1.891792180686025e-07
of O 0 2.957227025035536e-06
patients O 0 1.7842965007730527e-06
with O 0 2.3139827476370556e-07
a O 0 2.8716219730995363e-06
proven O 0 0.00010479789489181712
case O 0 2.084327206830494e-06
of O 0 1.0874541658267844e-05
the O 0 0.0069011482410132885
disease O 1 0.9999110698699951
. O 0 8.091267227428034e-05

It O 0 7.418708992190659e-05
is O 0 1.0057641702587716e-05
crucial O 0 3.9674665458733216e-05
to O 0 7.236308010760695e-05
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.9999837875366211
because O 0 0.024787629023194313
phlebotomy O 1 1.0
therapy O 1 0.9999786615371704
can O 0 1.5405723388539627e-05
avert O 1 0.999991774559021
serious O 1 1.0
chronic O 1 1.0
disease O 1 1.0
and O 0 0.00014255236601457
can O 0 5.631151793750178e-07
even O 0 7.927045544420253e-07
lead O 0 1.4225629456632305e-06
to O 0 4.094134737897548e-07
normal O 0 3.064224074478261e-06
life O 0 8.129809430101886e-06
expectancy O 0 3.7243917176965624e-05
. O 0 6.231474344531307e-06
. O 0 1.541896563139744e-05

Prevalence O 0 0.0005412586033344269
of O 0 4.3410844227764755e-05
the O 0 3.600058698793873e-05
I1307K O 1 0.7653336524963379
APC B-Disease 0 0.20831699669361115
gene O 0 1.6265108570223674e-05
variant O 0 6.6506408984423615e-06
in O 0 4.441801593202399e-07
Israeli O 0 2.009488980547758e-06
Jews O 0 2.3665459139010636e-06
of O 0 8.845948968883022e-07
differing O 0 2.1560403240528103e-07
ethnic O 0 2.0225731134360103e-07
origin O 0 7.416473408738966e-07
and O 0 2.5741871922946302e-06
risk O 0 0.00013507080439012498
for O 0 0.24157127737998962
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003682730020955205

BACKGROUND O 0 0.004558367654681206
& O 0 0.0017370939021930099
AIMS O 0 7.181745604611933e-05
Israeli O 0 8.34903221402783e-06
Jews O 0 5.206721198192099e-06
of O 0 1.7026072782755364e-06
European O 0 3.6292960885475622e-06
birth O 0 5.5281881941482425e-05
, O 0 2.1033367829659255e-06
i O 0 1.5332976772697293e-06
. O 0 2.2987576642208296e-07
e O 0 3.5434754863672424e-07
. O 0 1.714330579716261e-07
, O 0 2.996049772718834e-07
Ashkenazim O 0 1.6012394553399645e-05
, O 0 4.419533752297866e-07
have O 0 1.568355543213329e-07
the O 0 3.2297375582857057e-06
highest O 1 0.9999861717224121
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.000496053951792419
of O 0 4.190027084405301e-06
any O 0 1.1211133141841856e-06
Israeli O 0 1.1754426850529853e-05
ethnic O 0 3.995438419224229e-06
group O 0 2.3898883227957413e-05
. O 0 1.973130383703392e-05

The O 0 0.00020870250591542572
I1307K O 0 0.019898485392332077
APC B-Disease 0 0.0036231246776878834
gene O 0 5.3841482440475374e-05
variant O 0 6.97202849551104e-05
was O 0 4.274033199180849e-05
found O 0 6.678237241430907e-06
in O 0 4.1591647459426895e-06
6 O 0 7.226068555610254e-05
. O 0 5.074434739071876e-05

1 O 0 5.3403866331791505e-05
% O 0 2.7817832233267836e-06
of O 0 9.819364095164929e-07
American O 0 2.7234350454818923e-06
Jews O 0 4.406168955028988e-06
, O 0 4.808933908861945e-07
28 O 0 2.2405663457902847e-06
% O 0 2.8595871981451637e-07
of O 0 5.987114377603575e-07
their O 0 7.965770237206016e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 9.817315913096536e-06
, O 0 1.0104337206939817e-06
but O 0 2.054735546153097e-07
not O 0 9.639016695928149e-08
in O 0 4.6861291025379614e-07
non O 0 2.3504266209783964e-05
- O 0 0.00023453017638530582
Jews O 0 0.00017281771579291672
. O 0 5.127461554366164e-05

We O 0 2.0348352336441167e-05
assessed O 0 4.654048098018393e-05
the O 0 1.1253713637415785e-05
I1307K O 0 0.003610759973526001
prevalence O 0 1.9493863874231465e-05
in O 0 3.0847553489365964e-07
Israeli O 0 9.774722684596782e-07
Jews O 0 1.2178010138086393e-06
of O 0 4.1885942891894956e-07
differing O 0 1.0895845292679951e-07
ethnic O 0 1.5576263479033514e-07
origin O 0 8.180417125913664e-07
and O 0 2.5052236196643207e-06
risk O 0 0.00011521867418196052
for O 0 0.41967007517814636
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005052806809544563

METHODS O 0 9.242165833711624e-05
DNA O 0 2.5462153644184582e-05
samples O 0 4.306112259655492e-06
from O 0 1.3626852251036325e-06
500 O 0 3.4839117688534316e-06
unrelated O 0 1.9916976725653512e-06
Jews O 0 1.417792873326107e-06
of O 0 8.011382419681468e-07
European O 0 1.1282460263828398e-06
or O 0 7.184892751865846e-07
non O 0 3.2322827792086173e-06
- O 0 2.7063106244895607e-06
European O 0 2.457201446759427e-07
origin O 0 1.3565414747063187e-07
, O 0 1.0434395392167062e-07
with O 0 5.272717373827618e-08
or O 0 1.884882294689305e-07
without O 0 1.4796884784118447e-07
a O 0 2.807523742376361e-07
personal O 0 3.4958966352860443e-06
and O 0 3.0536755275534233e-06
/ O 0 0.00011718834866769612
or O 0 5.353187475520826e-07
family O 0 6.312722575785301e-07
history O 0 2.800693664539722e-06
of O 0 1.1976594578300137e-05
neoplasia B-Disease 1 0.9898175597190857
, O 0 6.14996281456115e-07
were O 0 3.127610170849948e-07
examined O 0 1.680990976637986e-06
for O 0 2.148529887335826e-07
the O 0 1.3002461400901666e-06
I1307K O 0 0.0004053277662023902
variant O 0 4.1370471990376245e-06
by O 0 3.687243008698715e-07
the O 0 8.880977588887617e-07
allele O 0 1.2495322607719572e-06
- O 0 2.9567167985078413e-06
specific O 0 7.397528065666847e-07
oligonucleotide O 0 0.00010090356227010489
( O 0 1.1888878361787647e-05
ASO O 1 0.9940524697303772
) O 0 6.855898845969932e-06
method O 0 2.554389720899053e-05
. O 0 3.963680865126662e-05

RESULTS O 0 0.00019821673049591482
In O 0 1.0190336070081685e-05
persons O 0 1.41381235607696e-06
at O 0 6.0436827880039345e-06
average O 0 3.438869953242829e-06
risk O 0 8.880437235347927e-06
for O 0 0.000173858818016015
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.4849791114102118e-05
I1307K O 0 0.04478487744927406
was O 0 2.7257496185484342e-05
found O 0 2.200893959525274e-06
in O 0 1.9359931684448384e-06
5 O 0 1.8907270714407787e-05
. O 0 2.2444768546847627e-05

0 O 0 5.410366793512367e-05
% O 0 2.940642616522382e-06
of O 0 1.3292539051690255e-06
120 O 0 5.573132966674166e-06
European O 0 7.219727649498964e-06
and O 0 1.0422504601592664e-05
1 O 0 9.216994658345357e-05
. O 0 6.654058961430565e-05

6 O 0 9.874360694084316e-05
% O 0 3.0054329727136064e-06
of O 0 1.648958800615219e-06
188 O 0 1.1814216122729704e-05
non O 0 9.433654668100644e-06
- O 0 1.4302284398581833e-05
European O 0 6.078607384552015e-06
Jews O 0 1.1265835382801015e-05
( O 0 4.582800102070905e-06
P O 0 7.20886091585271e-05
= O 0 5.676683031197172e-06
0 O 0 5.115421117807273e-06
. O 0 1.5524328773608431e-06
08 O 0 8.517161040799692e-05
) O 0 7.222124622785486e-06
. O 0 1.2465097825042903e-05

It O 0 2.797490196826402e-05
occurred O 0 2.6829084163182415e-05
in O 0 7.603038739034673e-06
15 O 0 3.809576446656138e-05
. O 0 5.3023479267721996e-05

4 O 0 7.480676140403375e-05
% O 0 3.242681486881338e-06
of O 0 2.774725089693675e-06
52 O 0 1.7816453691921197e-05
Ashkenazi O 0 6.639746425207704e-05
Israelis O 0 5.461473392642802e-06
with O 0 3.1214913178700954e-06
familial O 1 0.9803147315979004
cancer B-Disease 1 0.9999732971191406
( O 0 1.0184157872572541e-05
P O 0 0.00028159210341982543
= O 0 4.537511358648771e-06
0 O 0 1.208113076245354e-06
. O 0 2.8377911576171755e-07
02 O 0 3.662228482426144e-05
) O 0 1.6569526906096144e-07
and O 0 1.3319895231234113e-07
was O 0 2.2945794171391753e-06
not O 0 8.481082147682173e-08
detected O 0 1.001662440103246e-06
in O 0 2.826479601480969e-07
51 O 0 1.0660423868102953e-06
non O 0 1.4329739315144252e-06
- O 0 4.029237061331514e-06
European O 0 1.2361165317997802e-06
Jews O 0 6.188184215716319e-06
at O 0 8.242482726927847e-05
increased O 0 0.00010136532364413142
cancer B-Disease 1 0.9999299049377441
risk O 0 6.543299241457134e-05
. O 0 4.9842325097415596e-05

Colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9999904632568359
occurred O 0 0.0008235170971602201
personally O 0 0.00011293352872598916
or O 0 2.1826649572176393e-06
in O 0 4.289969126602955e-07
the O 0 3.5315196100782487e-07
families O 0 1.097363835356191e-07
of O 0 1.1436526392571977e-06
13 O 0 1.943572442542063e-06
of O 0 2.279234195157187e-06
20 O 0 4.390745289128972e-06
Ashkenazi O 0 0.0002336527977604419
I1307K O 0 0.0003580357297323644
carriers O 0 1.7268419014726533e-06
, O 0 4.991832724954293e-07
8 O 0 7.184166292972805e-07
of O 0 5.269259304441221e-07
whom O 0 5.555127131628979e-07
also O 0 3.0652159921373823e-07
had O 0 7.501377581320412e-07
a O 0 4.5866991627008247e-07
personal O 0 5.42342922926764e-06
or O 0 2.7068629151472123e-06
family O 0 5.067221536592115e-06
history O 0 2.5026351067936048e-05
of O 0 0.00033576099667698145
noncolonic O 1 0.9999922513961792
neoplasia B-Disease 1 0.9999794960021973
. O 0 0.0003016743576154113

CONCLUSIONS O 0 0.0005537766846828163
The O 0 0.00022100361820776016
I1307K O 1 0.9797832369804382
APC O 1 0.8681021928787231
variant O 0 0.0002434010530123487
may O 0 2.200381914008176e-06
represent O 0 8.811210250314616e-07
a O 0 2.7167473035660805e-06
susceptibility O 0 9.680936636868864e-05
gene O 0 5.791184776171576e-06
for O 0 7.969084435899276e-06
colorectal B-Disease 1 1.0
, I-Disease 0 6.482191110990243e-06
or I-Disease 0 2.0600521111191483e-06
other I-Disease 0 8.160842526194756e-07
, I-Disease 0 5.124913968757028e-06
cancers I-Disease 0 0.018551290035247803
in O 0 6.997696004873433e-07
Ashkenazi O 0 0.00019608260481618345
Jews O 0 1.2672822776949033e-05
, O 0 1.1503713039928698e-06
and O 0 1.162990656666807e-06
partially O 0 2.9713719413848594e-05
explains O 0 2.7815999601443764e-06
the O 0 9.21204332371417e-07
higher O 0 7.723621820332482e-06
incidence O 0 0.0002588399511296302
of O 1 0.8019029498100281
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.488264145649737e-06
European O 0 1.3304561434779316e-05
Israelis O 0 1.9083820006926544e-05
. O 0 3.89783235732466e-05

Systematic O 0 0.00012124474596930668
analysis O 0 2.0056551875313744e-05
of O 0 5.0158691010437906e-05
coproporphyrinogen O 1 0.9981383085250854
oxidase O 0 0.3071974217891693
gene O 0 0.000527690164744854
defects O 1 0.950268030166626
in O 0 3.058541551581584e-05
hereditary B-Disease 1 0.9999957084655762
coproporphyria I-Disease 1 0.999971866607666
and O 0 0.00016447440430056304
mutation O 0 0.00012135543511249125
update O 0 0.0001802184560801834
. O 0 0.00011554412776604295

Hereditary B-Disease 1 0.9999951124191284
coproporphyria I-Disease 1 0.999994158744812
( O 1 0.6249274611473083
HC B-Disease 1 1.0
) O 0 0.006831805221736431
is O 0 4.54465152870398e-05
an O 0 0.01308039017021656
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9812849760055542
autosomal O 1 0.9999979734420776
dominant O 1 0.9999922513961792
inheritance O 1 0.9999692440032959
caused O 1 0.9991347193717957
by O 0 7.777470455039293e-05
deficient B-Disease 0 0.03798199072480202
activity I-Disease 0 1.9663790226331912e-05
of I-Disease 0 6.574885628651828e-05
coproporphyrinogen I-Disease 1 0.999774158000946
III I-Disease 1 0.9999998807907104
oxidase I-Disease 0 0.07562597841024399
( O 0 0.00010083988308906555
CPO O 1 0.9967619180679321
) O 0 4.0574526792624965e-05
. O 0 4.0888415242079645e-05

Clinical O 0 0.04277672618627548
manifestations O 0 0.07352295517921448
of O 0 0.008472375571727753
the O 1 0.9537182450294495
disease O 1 0.9999969005584717
are O 0 9.518706747257966e-07
characterized O 0 2.828838478308171e-05
by O 0 1.110858102038037e-05
acute O 1 0.9999823570251465
attacks O 0 0.00012949173105880618
of O 1 0.9999371767044067
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 0.00014271381951402873
precipitated O 0 0.0967705026268959
by O 0 9.227288501278963e-06
drugs O 0 9.019966091727838e-05
, O 0 2.920247652582475e-06
fasting O 0 1.964145303645637e-05
, O 0 2.3623515517101623e-06
cyclical O 0 0.0022772850934416056
hormonal O 0 0.009269554167985916
changes O 0 1.1577073564694729e-05
, O 0 2.1924679458606988e-05
or O 0 0.033139415085315704
infectious B-Disease 1 0.9999998807907104
diseases I-Disease 1 0.9999995231628418
. O 0 0.0005429433658719063

Skin O 1 0.9999998807907104
photosensitivity O 1 0.9999866485595703
may O 0 0.00013424364442471415
also O 0 8.938603968999814e-06
be O 0 3.3313576750515494e-06
present O 0 1.88196081580827e-05
. O 0 5.298677206155844e-05

The O 0 5.823292303830385e-05
seven O 0 1.9120892829960212e-05
exons O 0 3.2281302992487326e-05
, O 0 2.1273815491440473e-06
the O 0 3.781925897783367e-06
exon O 0 0.00042659463360905647
/ O 0 6.043575922376476e-05
intron O 0 5.249199966783635e-05
boundaries O 0 1.778752562131558e-06
and O 0 3.5581518886829144e-07
part O 0 7.492647569051769e-07
of O 0 9.67919504546444e-07
3 O 0 2.0841305286012357e-06
noncoding O 0 7.1050321821530815e-06
sequence O 0 3.769240777273808e-07
of O 0 6.84224687574897e-07
the O 0 1.1605530971792177e-06
CPO O 0 0.007382055278867483
gene O 0 7.045440497677191e-07
were O 0 1.2212360900321073e-07
systematically O 0 1.05251979221066e-06
analyzed O 0 4.1399778183404123e-07
by O 0 1.780852727506499e-07
an O 0 3.4593088571455155e-07
exon O 0 1.5896093827905133e-05
- O 0 4.683895895141177e-06
by O 0 1.995045295188902e-06
- O 0 2.932683128165081e-05
exon O 0 7.72846833569929e-05
denaturing O 0 0.0001377975131617859
gradient O 0 3.866387123707682e-05
gel O 0 9.043668251251802e-05
electrophoresis O 0 9.467796917306259e-05
( O 0 7.828703928680625e-06
DGGE O 1 0.9448771476745605
) O 0 1.120664364862023e-06
strategy O 0 5.089763135401881e-07
followed O 0 2.1810453176840383e-07
by O 0 5.989524254346179e-08
direct O 0 7.571988192012213e-08
sequencing O 0 1.1609770353970816e-06
in O 0 2.8292546971897536e-07
seven O 0 7.666381520721188e-07
unrelated O 0 9.566826520313043e-06
heterozygous O 0 1.8531945897848345e-05
HC B-Disease 1 1.0
patients O 0 3.176284735673107e-05
from O 0 9.676402441982646e-06
France O 0 6.222233787411824e-05
, O 0 2.711699835344916e-06
Holland O 0 9.577826131135225e-05
, O 0 1.2250848158146255e-06
and O 0 1.7096916735681589e-06
Czech O 0 0.0005208939546719193
Republic O 0 0.00013516265607904643
. O 0 6.346643203869462e-05

Seven O 0 0.00010796097194543108
novel O 0 3.3150779927382246e-05
mutations O 0 3.364486246937304e-06
and O 0 5.536114144888415e-07
two O 0 2.94130586553365e-07
new O 0 1.932569375640014e-06
polymorphisms O 0 1.4086071132624056e-05
were O 0 7.658601134608034e-06
detected O 0 0.00012894967221654952
. O 0 3.23717795254197e-05

Among O 0 1.604071439942345e-05
these O 0 5.32951617060462e-07
mutations O 0 5.183156304156e-07
two O 0 1.05092155422426e-07
are O 0 9.845528836649464e-08
missense O 0 1.275696195079945e-05
( O 0 2.4886574010452023e-06
G197W O 0 0.00805511511862278
, O 0 1.6807294969112263e-06
W427R O 0 0.0005005643470212817
) O 0 4.949029062117916e-07
, O 0 1.3564456935455382e-07
two O 0 4.625116289957987e-08
are O 0 7.15619918878474e-08
nonsense O 0 3.139394539175555e-05
( O 0 2.9646112125192303e-06
Q306X O 0 0.121763676404953
, O 0 3.99599821321317e-06
Q385X O 0 0.0015213171718642116
) O 0 4.099412649338774e-07
, O 0 1.0906074976446689e-07
two O 0 2.7005349068076612e-08
are O 0 1.9592640398968797e-08
small O 0 2.598625599148363e-07
deletions O 0 4.79426216770662e-06
( O 0 1.9052770312555367e-06
662de14bp O 0 0.0008024757844395936
; O 0 2.312598098797025e-06
1168del3bp O 0 0.00015577024896629155
removing O 0 2.052890158665832e-05
a O 0 1.6719066024961649e-06
glycine O 0 8.08960794529412e-06
at O 0 3.19449736707611e-06
position O 0 2.0444922483875416e-06
390 O 0 9.898172720568255e-06
) O 0 5.833594514115248e-07
, O 0 1.3644795160416834e-07
and O 0 1.2873950083758245e-07
one O 0 1.8621766173509968e-07
is O 0 1.1276764411149998e-07
a O 0 3.290476513484464e-07
splicing O 0 5.7715456023288425e-06
mutation O 0 2.2790604816691484e-06
( O 0 1.8022656149696559e-06
IVS1 O 1 0.6307999491691589
- O 0 3.86140491173137e-05
15c O 0 0.0003816119278781116
- O 0 3.5496042983140796e-05
- O 0 1.818769123929087e-05
> O 0 1.2720177437586244e-05
g O 0 7.579451903438894e-06
) O 0 3.7769123650832626e-07
which O 0 2.462294048655167e-07
creates O 0 1.0217300996373524e-06
a O 0 4.717562092082517e-07
new O 0 1.4747381555935135e-06
acceptor O 0 4.279057975509204e-05
splice O 0 0.001226471271365881
site O 0 0.00043842155719175935
. O 0 7.127334538381547e-05

The O 0 8.994096424430609e-05
pathological O 0 0.0003300463140476495
significance O 0 2.72635788860498e-05
of O 0 9.421337381354533e-06
the O 0 3.993198788521113e-06
point O 0 5.967122888250742e-06
mutations O 0 1.9971678284491645e-06
G197W O 0 0.0002247328229714185
, O 0 1.5130081010283902e-06
W427R O 0 7.692264625802636e-05
, O 0 3.245055495426641e-07
and O 0 1.0423375584878158e-07
the O 0 4.244216995630268e-07
in O 0 6.135808803264808e-07
- O 0 1.553219226479996e-05
frame O 0 1.5712428648839705e-05
deletion O 0 5.022718596592313e-06
390delGly O 0 1.9110029825242236e-05
were O 0 4.880025699094404e-07
assessed O 0 1.1512207720443257e-06
by O 0 1.0503965341968069e-07
their O 0 1.2506654911703663e-07
respective O 0 3.4350472333244397e-07
expression O 0 3.6015845239489863e-07
in O 0 2.036506856484266e-07
a O 0 3.6694893879030133e-07
prokaryotic O 0 4.1339671952300705e-06
system O 0 1.3938193887952366e-06
using O 0 1.1555370065252646e-06
site O 0 5.2464321925072e-05
- O 0 3.6785884731216356e-05
directed O 0 1.6470305126858875e-05
mutagenesis O 0 0.0005924894358031452
. O 0 5.279421020532027e-05

These O 0 2.2546777472598478e-05
mutations O 0 1.63863933266839e-05
resulted O 0 1.4876779459882528e-05
in O 0 1.801114308364049e-06
the O 0 2.409266471659066e-06
absence O 0 1.87883142643841e-05
or O 0 2.3415477699018084e-06
a O 0 2.318551878488506e-06
dramatic O 0 1.2200725905131549e-05
decrease O 0 2.1050920622656122e-05
of O 0 6.050339652574621e-05
CPO O 1 0.9961513876914978
activity O 0 9.803797729546204e-05
. O 0 4.1166404116665944e-05

The O 0 2.064510772470385e-05
two O 0 1.1539038951013936e-06
polymorphisms O 0 3.658751438706531e-06
were O 0 8.804398134998337e-07
localized O 0 4.777830781677039e-06
in O 0 8.676764196025033e-07
noncoding O 0 7.551991984655615e-06
part O 0 6.229521432032925e-07
of O 0 5.452836830954766e-07
the O 0 9.506078413323849e-07
gene O 0 4.835975460082409e-07
1 O 0 6.338626121760171e-07
) O 0 3.634920915374096e-07
a O 0 1.7744745264280937e-06
C O 0 0.0008134905947372317
/ O 0 3.712101897690445e-05
G O 0 2.664997191459406e-05
polymorphism O 0 2.748388851614436e-06
in O 0 4.869969529863738e-07
the O 0 1.0119216540260823e-06
promotor O 0 0.0008207900100387633
region O 0 2.010968955801218e-06
, O 0 6.664651550636336e-07
142 O 0 1.02051180874696e-05
bp O 0 9.407260222360492e-06
upstream O 0 1.9315671124786604e-06
from O 0 1.8350415587065072e-07
the O 0 1.0495513436126203e-07
transcriptional O 0 8.84298060555011e-07
initiation O 0 4.592933237290708e-06
site O 0 1.1108061698905658e-05
( O 0 1.1437639386713272e-06
- O 0 9.672268788563088e-06
142C O 0 0.00048314090236090124
/ O 0 3.006046790687833e-05
G O 0 2.8378628485370427e-05
) O 0 3.2798709526105085e-07
, O 0 2.3800799908713088e-07
and O 0 1.9062532885527617e-07
2 O 0 8.881782491698686e-07
) O 0 2.2990690240476397e-07
a O 0 4.0539876522416307e-07
6 O 0 3.7837801301066065e-06
bp O 0 4.760660885949619e-06
deletion O 0 6.110302592787775e-07
polymorphism O 0 4.1101586134573154e-07
in O 0 1.3850603863829747e-07
the O 0 2.720921941090637e-07
3 O 0 8.211948170355754e-07
noncoding O 0 4.5699339352722745e-06
part O 0 6.352248078655975e-07
of O 0 5.924284778302535e-07
the O 0 1.959778273885604e-06
CPO O 0 0.12901681661605835
gene O 0 3.2323350751539692e-06
, O 0 8.661105539431446e-07
574 O 0 1.554358641442377e-05
bp O 0 1.1044977327401284e-05
downstream O 0 1.833643523241335e-06
of O 0 6.369391485350206e-07
the O 0 4.623572635864548e-07
last O 0 8.431916853623989e-07
base O 0 1.3033450159127824e-06
of O 0 3.5425463806859625e-07
the O 0 5.109669700686936e-07
normal O 0 9.925300901159062e-07
termination O 0 1.0617287443892565e-05
codon O 0 1.9155202608089894e-05
( O 0 3.480182613202487e-06
+ O 0 1.9467855963739567e-05
574 O 0 0.0003871222143061459
delATTCTT O 0 0.0023767089005559683
) O 0 1.983098263735883e-05
. O 0 4.746927515952848e-05

Five O 0 0.0001643138675717637
intragenic O 1 0.7903131246566772
dimorphisms O 0 0.010529076680541039
are O 0 1.058324528457888e-06
now O 0 1.5011652294560918e-06
well O 0 5.994267553433019e-07
characterized O 0 1.7951382460523746e-06
and O 0 2.436075874356902e-07
the O 0 9.52024038269883e-07
high O 0 4.609040843206458e-06
degree O 0 2.2203801108844345e-06
of O 0 6.846875066912617e-07
allelic O 0 1.9864561181748286e-05
heterogeneity O 0 2.386549203947652e-05
in O 0 7.142949471017346e-06
HC B-Disease 1 1.0
is O 0 3.449511950748274e-06
demonstrated O 0 1.4838332162980805e-06
with O 0 7.953240555025332e-08
seven O 0 2.2318539549814886e-07
new O 0 1.3480619998063048e-07
different O 0 5.465540908744515e-08
mutations O 0 2.2459032322785788e-07
making O 0 4.648832145903725e-07
a O 0 4.826673034585838e-07
total O 0 5.307801984599791e-07
of O 0 2.9374193672992988e-06
nineteen O 0 0.0003175541933160275
CPO O 1 0.9999908208847046
gene B-Disease 0 0.00031694714562036097
defects I-Disease 0 0.08542901277542114
reported O 0 4.464528046810301e-06
so O 0 6.82924792272388e-07
far O 0 1.534208877274068e-06
. O 0 2.2555332179763354e-06
. O 0 8.795117537374608e-06

Coincidence O 0 0.00016703124856576324
of O 0 1.6725505702197552e-05
two O 0 1.7399589751221356e-06
novel O 0 2.9418961275951006e-05
arylsulfatase O 0 0.001748912502080202
A O 0 3.1455259886570275e-05
alleles O 0 2.3128054635890294e-06
and O 0 1.7742985392033006e-06
mutation O 0 6.346082045638468e-06
459 O 0 0.00011663560871966183
+ O 0 6.82430763845332e-05
1G O 0 0.19965338706970215
> O 0 3.127361924271099e-05
A O 0 9.487399438512512e-06
within O 0 1.1199987284271629e-06
a O 0 1.02892101949692e-06
family O 0 5.113758106745081e-06
with O 0 7.327976618398679e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999996423721313
: O 0 3.2469888537889346e-06
molecular O 0 1.0910462151514366e-05
basis O 0 2.2864905986352824e-06
of O 0 7.74028740124777e-06
phenotypic O 0 0.00012279994552955031
heterogeneity O 0 0.00052720244275406
. O 0 0.00010363203182350844

In O 0 5.655799031956121e-05
a O 0 6.816677796450676e-06
family O 0 4.49290109827416e-06
with O 0 4.954757173436519e-07
three O 0 1.4330914837046294e-06
siblings O 0 2.054166907328181e-05
, O 0 1.2908019471069565e-06
one O 0 6.437469437514665e-07
developed O 0 4.765820904140128e-06
classical O 0 5.129622877575457e-05
late O 0 0.007014777511358261
infantile O 1 0.9999978542327881
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.03904490917921066
MLD B-Disease 1 1.0
) O 0 1.3323339771886822e-05
, O 0 3.166187525494024e-06
fatal O 0 0.0001653483632253483
at O 0 1.5974386769812554e-05
age O 0 5.221852916292846e-06
5 O 0 1.604058866178093e-06
years O 0 1.6319314681823016e-06
, O 0 6.724588956785738e-07
with O 0 1.3018542404097388e-06
deficient O 0 0.12079858779907227
arylsulfatase O 1 0.9749685525894165
A O 0 0.03565135598182678
( O 0 2.0130135453655384e-05
ARSA O 1 0.9999487400054932
) O 0 8.794017389845976e-07
activity O 0 1.1619706583587686e-06
and O 0 3.4025475770249614e-07
increased O 0 2.3823968149372377e-06
galactosylsulfatide O 0 0.37390539050102234
( O 0 6.639917410211638e-05
GS O 1 0.9999997615814209
) O 0 6.159042823128402e-05
excretion O 0 0.0007057841285131872
. O 0 5.791957300971262e-05

The O 0 2.2947913748794235e-05
two O 0 1.1165583373440313e-06
other O 0 9.894217782857595e-07
siblings O 0 8.845562661008444e-06
, O 0 1.2539788940557628e-06
apparently O 0 3.811671604125877e-06
healthy O 0 2.0736429178214166e-06
at O 0 3.7348722798924427e-06
12 O 0 1.6936032807279844e-06
( O 0 5.074593332210497e-07
1 O 0 4.3223972170380875e-06
/ O 0 1.1578266821743455e-05
2 O 0 1.442136067453248e-06
) O 0 1.3668773135577794e-07
and O 0 1.265382678639071e-07
15 O 0 8.92749540071236e-07
years O 0 1.0731254178608651e-06
, O 0 3.8177108763193246e-07
respectively O 0 8.153165254043415e-07
, O 0 2.1991304777202458e-07
and O 0 1.51668061221244e-07
their O 0 3.000244248596573e-07
father O 0 3.349193139001727e-05
, O 0 1.4014434555065236e-06
apparently O 0 3.54704980054521e-06
healthy O 0 9.405763989889238e-07
as O 0 2.589020482446358e-07
well O 0 3.3554260880919173e-07
, O 0 5.539372409657517e-07
presented O 0 1.1487462870718446e-05
ARSA O 1 0.9999802112579346
and O 0 1.2012144907203037e-05
GS O 1 0.999967098236084
values O 0 3.09464894598932e-06
within O 0 1.6698733134035137e-06
the O 0 1.3968799521535402e-06
range O 0 1.5491539670620114e-05
of O 0 0.00018502557941246778
MLD B-Disease 1 1.0
patients O 0 0.008605518378317356
. O 0 6.575306179001927e-05

Mutation O 0 5.9165253333048895e-05
screening O 0 1.893218905024696e-05
and O 0 9.878094715531915e-07
sequence O 0 5.157830287316756e-07
analysis O 0 3.9598390344508516e-07
disclosed O 0 3.345707227708772e-06
the O 0 5.298192604641372e-07
involvement O 0 1.1992489135081996e-06
of O 0 6.227299991223845e-07
three O 0 2.1497166358130926e-07
different O 0 1.929029025404816e-07
ARSA O 1 0.9800577163696289
mutations O 0 7.838332294340944e-07
being O 0 3.626223019637109e-07
the O 0 3.648566178071633e-07
molecular O 0 3.1359388685814338e-06
basis O 0 9.671351790530025e-07
of O 0 9.225792382494546e-06
intrafamilial O 0 0.0023054180201143026
phenotypic O 0 0.00019056207383982837
heterogeneity O 0 0.0005911779007874429
. O 0 0.00011141451977891847

The O 0 0.00012403560685925186
late O 0 0.0023382818326354027
infantile O 1 0.9998799562454224
patient O 0 0.24622982740402222
inherited O 1 0.9849867224693298
from O 0 6.77546122460626e-05
his O 0 0.00011595051182666793
mother O 0 4.1713010432431474e-05
the O 0 1.7480055021223961e-06
frequent O 0 1.5588478845529607e-06
0 O 0 2.8613462745852303e-06
- O 0 6.073473286960507e-06
type O 0 4.1113289626082405e-06
mutation O 0 2.55166673923668e-06
459 O 0 2.9681092200917192e-05
+ O 0 2.2581616576644592e-05
1G O 0 0.008189769461750984
> O 0 9.491091077507008e-06
A O 0 6.08214440944721e-06
, O 0 3.796076271100901e-07
and O 0 1.441254511291845e-07
from O 0 4.599086480538972e-07
his O 0 3.4423185297782766e-06
father O 0 1.318697104579769e-05
a O 0 1.2492403129726881e-06
novel O 0 2.686505240490078e-06
, O 0 1.0535903811614844e-06
single O 0 2.34133563026262e-06
basepair O 0 0.00011223741603316739
microdeletion O 0 8.230261300923303e-05
of O 0 3.4454221804480767e-06
guanine O 0 5.452387085824739e-06
at O 0 2.1488835955096874e-06
nucleotide O 0 7.934472705528606e-07
7 O 0 1.1995210797977052e-06
in O 0 3.2852901199476037e-07
exon O 0 1.6717085600248538e-05
1 O 0 1.0054485755972564e-05
( O 0 4.896551217825618e-06
7delG O 0 0.0004943397943861783
) O 0 1.0457339158165269e-05
. O 0 1.918178350024391e-05

The O 0 6.718417716911063e-05
two O 0 1.4547305909218267e-05
clinically O 0 0.0013233324280008674
unaffected O 0 8.55769612826407e-05
siblings O 0 1.6208807210205123e-05
carried O 0 4.700116278399946e-06
the O 0 3.855193881463492e-06
maternal O 0 2.3319153115153313e-05
mutation O 0 5.04354966324172e-06
459 O 0 8.467253064736724e-05
+ O 0 4.075854303664528e-05
1G O 0 0.08544296771287918
> O 0 2.0747482267324813e-05
A O 0 9.810652954911347e-06
and O 0 6.2575304582424e-07
, O 0 4.1529958139108203e-07
on O 0 2.474712061939499e-07
their O 0 1.0777823433727463e-07
paternal O 0 2.5668182388471905e-06
allele O 0 5.82130155635241e-07
, O 0 1.6132128166645998e-07
a O 0 3.19824522421186e-07
novel O 0 1.0605442639644025e-06
cytosine O 0 2.6818158858077368e-06
to O 0 1.7359020887397492e-07
thymidine O 0 4.622294909495395e-06
transition O 0 1.5441479490618804e-06
at O 0 3.4694787700573215e-06
nucleotide O 0 3.6240005556464894e-06
2435 O 0 0.00024168100208044052
in O 0 2.1130476852704305e-06
exon O 0 1.9636601791717112e-05
8 O 0 2.356577624595957e-06
, O 0 1.684990849071255e-07
resulting O 0 4.473732246879081e-07
in O 0 2.3333996068686247e-07
substitution O 0 2.794975443976e-06
of O 0 5.117621640238212e-06
alanine O 0 3.71804999304004e-05
464 O 0 0.00015346886357292533
by O 0 1.1439525223977398e-05
valine O 0 0.006323532201349735
( O 0 7.186664151959121e-05
A464V O 0 0.10866942256689072
) O 0 6.411402864614502e-05
. O 0 5.0512073357822374e-05

The O 0 5.189630974200554e-05
fathers O 0 9.81499397312291e-05
genotype O 0 5.143975795363076e-05
thus O 0 1.3007425877731293e-05
was O 0 0.0001704500027699396
7delG O 1 0.8364690542221069
/ O 0 0.03142401576042175
A464V O 0 0.06846045702695847
. O 0 0.0001529534492874518

Mutation O 0 0.0002925831940956414
A464V O 0 0.003069708589464426
was O 0 6.776191003154963e-05
not O 0 5.7532611208444e-07
found O 0 6.719652674291865e-07
in O 0 9.757399084264762e-07
18 O 0 1.4566659046977293e-05
unrelated O 0 0.007394539192318916
MLD B-Disease 1 1.0
patients O 0 0.00032692847889848053
and O 0 8.310813427669927e-06
50 O 0 2.6617182811605744e-05
controls O 0 8.176393748726696e-05
. O 0 5.437983418232761e-05

A464V O 0 0.0775156170129776
, O 0 3.0785991839366034e-05
although O 0 4.750600965053309e-06
clearly O 0 6.4507034949201625e-06
modifying O 0 7.89777550380677e-05
ARSA O 1 0.9996614456176758
and O 0 6.000826761010103e-05
GS O 1 0.9999969005584717
levels O 0 1.5291960153263062e-05
, O 0 2.2902900127519388e-06
apparently O 0 4.118635843042284e-06
bears O 0 2.6768279894895386e-06
little O 0 1.0086938573294901e-06
significance O 0 1.3247789638626273e-06
for O 0 4.083730686943454e-07
clinical O 0 4.522804374573752e-05
manifestation O 0 0.01226050779223442
of O 0 0.0435178168118
MLD B-Disease 1 1.0
, O 0 5.171741941012442e-05
mimicking O 0 0.0004576187639031559
the O 0 3.916122659575194e-05
frequent O 0 0.00018007674952968955
ARSA O 1 0.9999120235443115
pseudodeficiency O 1 0.7345641255378723
allele O 0 0.0003551965637598187
. O 0 8.315785089507699e-05

Our O 0 4.53786451544147e-05
results O 0 7.144441497075604e-06
demonstrate O 0 2.5684366846689954e-06
that O 0 1.5500850736316352e-07
in O 0 1.7775626304228354e-07
certain O 0 3.5479391158332874e-07
genetic O 0 1.1118479960714467e-05
conditions O 0 0.000213313614949584
MLD B-Disease 1 1.0
- O 1 0.8768569231033325
like O 0 0.00010311863297829404
ARSA O 1 0.9999871253967285
and O 0 8.043282832659315e-06
GS O 1 0.9999434947967529
values O 0 1.0103142358275363e-06
need O 0 4.12859918696995e-07
not O 0 6.831177046251469e-08
be O 0 6.043631373131575e-08
paralleled O 0 1.3193964605306974e-06
by O 0 1.3691189906239742e-06
clinical O 1 0.999453604221344
disease O 1 0.998965859413147
, O 0 2.3835059437260497e-06
a O 0 1.507816818957508e-06
finding O 0 1.502336772318813e-06
with O 0 8.655185865791282e-07
serious O 0 0.00011826524860225618
diagnostic O 0 0.36783096194267273
and O 0 3.2826184906298295e-05
prognostic O 1 0.997979462146759
implications O 0 0.000755215180106461
. O 0 0.00013849555398337543

Moreover O 0 0.000210279889870435
, O 0 9.707328899821732e-06
further O 0 1.0004624527937267e-05
ARSA O 1 0.8810126781463623
alleles O 0 5.121738013258437e-06
functionally O 0 5.810303264297545e-06
similar O 0 5.605855335488741e-07
to O 0 7.60809257371875e-07
A464V O 0 0.0019255538936704397
might O 0 7.819830898370128e-07
exist O 0 1.708231707198138e-07
which O 0 1.1332674176856017e-07
, O 0 1.1765005325514721e-07
together O 0 6.46543298898905e-08
with O 0 8.568706277856108e-08
0 O 0 2.0154056983301416e-06
- O 0 6.87442707203445e-06
type O 0 7.78803132561734e-06
mutations O 0 1.8866172695197747e-06
, O 0 1.0875825182665722e-06
may O 0 2.211382025052444e-06
cause O 0 3.373619256308302e-05
pathological O 1 0.9926266074180603
ARSA O 1 0.9999990463256836
and O 0 3.101699621765874e-05
GS O 1 0.9999998807907104
levels O 0 1.5275634723366238e-05
, O 0 4.6747425130888587e-07
but O 0 9.378162246775901e-08
not O 0 7.770841392584771e-08
clinical O 0 5.906587830395438e-06
outbreak O 0 8.416416676482186e-06
of O 0 2.22071375901578e-05
the O 1 0.5757483243942261
disease O 1 0.9999958276748657
. O 0 1.7896403733175248e-05
. O 0 4.33160676038824e-05

Human O 1 0.9993212223052979
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.9997687935829163
to O 0 0.0004223723371978849
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999998807907104
and O 0 0.002393595175817609
neurofibromatosis B-Disease 1 0.9999998807907104
type I-Disease 1 0.9474680423736572
1 I-Disease 0 0.00486334040760994
. O 0 0.00015166598313953727

Heterozygous O 0 0.0007286146283149719
germ O 1 0.9942164421081543
- O 0 0.0003725941351149231
line O 0 3.767659654840827e-05
mutations O 0 2.8309086701483466e-06
in O 0 1.2454480611268082e-06
the O 0 4.615802026819438e-06
DNA O 0 0.030076472088694572
mismatch O 1 0.99974125623703
repair O 1 0.9984331727027893
genes O 0 1.2519891242845915e-05
lead O 0 2.0746394511661492e-05
to O 0 2.8483122150646523e-05
hereditary B-Disease 1 0.9999998807907104
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0008840707596391439

The O 0 0.12294655293226242
disease O 1 0.9999710321426392
susceptibility O 0 0.0014685195637866855
of O 0 7.330661901505664e-05
individuals O 0 1.9131425688101444e-06
who O 0 4.782457835972309e-06
constitutionally O 0 1.1382849152141716e-05
lack O 0 3.294732550784829e-06
both O 0 7.795036935931421e-07
wild O 0 1.2904233699373435e-05
- O 0 4.179985626251437e-05
type O 0 1.748519207467325e-05
alleles O 0 2.347000645386288e-06
is O 0 1.2940928399984841e-06
unknown O 0 1.5863171938690357e-05
. O 0 1.7480224414612167e-05

We O 0 1.0013884093496017e-05
have O 0 8.966077871264133e-07
identified O 0 1.382925233883725e-06
three O 0 3.5821821597892267e-07
offspring O 0 3.6486708268057555e-06
in O 0 2.8191620913275983e-06
a O 0 3.555038711056113e-05
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0033909128978848457
who O 0 3.891488813678734e-05
developed O 0 0.005595169961452484
hematological B-Disease 1 0.9999991655349731
malignancy I-Disease 1 0.9999992847442627
at O 0 0.00033376365900039673
a O 0 2.30480827667634e-06
very O 0 2.0688101187715802e-07
early O 0 9.964365972336964e-07
age O 0 1.2446904520402313e-06
, O 0 1.733746302079453e-07
and O 0 9.47970022480149e-08
at O 0 1.0038504569820361e-06
least O 0 3.988164110069192e-08
two O 0 2.1382843939932172e-08
of O 0 1.9324059508107894e-07
them O 0 2.526594187202136e-07
displayed O 0 6.460689746745629e-06
signs O 0 1.1614030881901272e-05
of O 0 2.1235353415249847e-05
neurofibromatosis B-Disease 1 0.9999966621398926
type I-Disease 0 0.010887574404478073
1 I-Disease 0 0.000792883278336376
( O 0 7.809800445102155e-05
NF1 B-Disease 1 0.9999767541885376
) O 0 2.9259343136800453e-05
. O 0 3.950951941078529e-05

DNA O 0 8.572317165089771e-05
sequence O 0 2.7119945116282906e-06
analysis O 0 1.3079283007755294e-06
and O 0 4.880802748630231e-07
allele O 0 7.959611707519798e-07
- O 0 1.4741011682417593e-06
specific O 0 1.518547492196376e-07
amplification O 0 3.984944214607822e-06
in O 0 3.880590782046056e-07
two O 0 2.883513730012055e-07
siblings O 0 5.296720246406039e-06
revealed O 0 7.941475814732257e-06
a O 0 3.51601124748413e-06
homozygous O 0 2.1642261344823055e-05
MLH1 O 1 0.7864867448806763
mutation O 0 1.5914962204988115e-05
( O 0 5.708647677238332e-06
C676T O 0 0.01483689621090889
- O 0 0.0015725617995485663
- O 0 0.0010165059939026833
> O 0 0.0003260239609517157
Arg226Stop O 0 0.4869929254055023
) O 0 3.358337198733352e-05
. O 0 3.95855495298747e-05

Thus O 0 8.515627268934622e-05
, O 0 6.410619789676275e-06
a O 0 7.389577604044462e-06
homozygous O 0 7.475606980733573e-05
germ O 1 0.9999567270278931
- O 0 0.4357331693172455
line O 0 0.007834620773792267
MLH1 O 1 0.9999970197677612
mutation O 0 3.381620263098739e-05
and O 0 9.225141184288077e-06
consequent O 1 0.9997718930244446
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 0.9999998807907104
results O 0 3.777913298108615e-05
in O 0 5.051872904004995e-06
a O 0 2.234319799754303e-05
mutator O 1 0.999874472618103
phenotype O 0 5.4459753300761804e-05
characterized O 0 2.4754024707362987e-05
by O 0 3.074875712627545e-05
leukemia B-Disease 1 1.0
and O 0 0.04345026612281799
/ O 1 0.9999978542327881
or O 1 0.989982545375824
lymphoma B-Disease 1 1.0
associated O 0 0.0002539154083933681
with O 0 2.342185689485632e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.814691960811615
1 I-Disease 0 0.00118147989269346
. O 0 2.3191811123979278e-05
. O 0 3.9241040212800726e-05

Missense O 0 0.0015554995043203235
mutations O 0 5.5866588809294626e-05
in O 0 9.157192835118622e-06
the O 0 3.0945871003495995e-06
most O 0 1.0443291103001684e-06
ancient O 0 1.728143797663506e-05
residues O 0 9.952400432666764e-06
of O 0 7.837705197744071e-06
the O 0 1.9319288185215555e-05
PAX6 O 1 0.9999885559082031
paired O 0 5.506054367288016e-05
domain O 0 5.406965101428796e-06
underlie O 0 3.4916902222903445e-05
a O 0 3.831318736047251e-06
spectrum O 0 5.9402074839454144e-05
of O 0 0.005629159975796938
human O 1 0.9999901056289673
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.06586465239524841

Mutations O 0 5.294758375384845e-05
of O 0 1.9643832274596207e-05
the O 0 1.1520288353494834e-05
human O 0 2.507996396161616e-05
PAX6 O 1 0.9999977350234985
gene O 0 0.000851129530929029
underlie O 1 0.999811589717865
aniridia B-Disease 1 1.0
( O 1 0.9944281578063965
congenital B-Disease 1 1.0
absence I-Disease 0 0.009767222218215466
of I-Disease 0 0.0024746665731072426
the I-Disease 0 0.0012942046159878373
iris I-Disease 1 0.9966160655021667
) O 0 2.494269438102492e-06
, O 0 8.086715865829319e-07
a O 0 2.453268052704516e-06
rare O 0 2.981036050186958e-05
dominant O 0 0.3847676217556
malformation B-Disease 1 0.9999982118606567
of I-Disease 0 0.3556158244609833
the I-Disease 1 0.9862868189811707
eye I-Disease 1 0.9999934434890747
. O 0 0.0002626294153742492

The O 0 9.219051571562886e-05
spectrum O 0 0.00014112039934843779
of O 0 0.00018414028454571962
PAX6 O 1 0.9999828338623047
mutations O 0 5.0870177801698446e-05
in O 0 2.4321245291503146e-05
aniridia B-Disease 1 1.0
patients O 0 7.397077570203692e-05
is O 0 8.471193950754241e-07
highly O 0 1.7977114339373657e-06
biased O 0 2.4185485472116852e-06
, O 0 3.5470765169520746e-07
with O 0 1.924778558759499e-07
92 O 0 7.4889499046548735e-06
% O 0 1.9558689245968708e-07
of O 0 3.0625307090303977e-07
all O 0 1.5160831878802128e-07
reported O 0 1.4140174471322098e-06
mutations O 0 4.2068612060575106e-07
leading O 0 1.7253011037610122e-06
to O 0 3.279542397649493e-07
premature O 0 6.920327450643526e-06
truncation O 0 2.1755104171461426e-05
of O 0 2.0452607714105397e-06
the O 0 2.2777153390052263e-06
protein O 0 1.3327191936696181e-06
( O 0 9.453191864849941e-07
nonsense O 0 7.320467375393491e-06
, O 0 4.60787560996323e-07
splicing O 0 4.50137576990528e-06
, O 0 3.533028518631909e-07
insertions O 0 3.173291361235897e-06
and O 0 4.277769960481237e-07
deletions O 0 2.6758198146126233e-06
) O 0 2.2881258132656512e-07
and O 0 1.4285733129781875e-07
just O 0 5.548112085307366e-07
2 O 0 1.251026219506457e-06
% O 0 3.0779582971263153e-07
leading O 0 4.3440206809464144e-07
to O 0 5.706835182195391e-08
substitution O 0 1.660393081692746e-06
of O 0 2.2149658889247803e-06
one O 0 9.827130043049692e-07
amino O 0 1.085180883819703e-06
acid O 0 1.5925841125863371e-06
by O 0 3.8310119521156594e-07
another O 0 7.468031981261447e-06
( O 0 7.634615940332878e-06
missense O 0 0.0001440843043383211
) O 0 1.2759564924635924e-05
. O 0 3.5492590541252866e-05

The O 0 3.9081314753275365e-05
extraordinary O 0 1.6393643818446435e-05
conservation O 0 1.867657556431368e-05
of O 0 6.409605248336447e-06
the O 0 4.800768238055753e-06
PAX6 O 1 0.8395642042160034
protein O 0 2.6285406420356594e-06
at O 0 7.149853900045855e-06
the O 0 1.2696609701379202e-06
amino O 0 2.4674329779372783e-06
acid O 0 8.849249752529431e-06
level O 0 4.12003419114626e-06
amongst O 0 1.1011228707502596e-05
vertebrates O 0 4.011369310319424e-05
predicts O 0 9.60593570198398e-06
that O 0 4.440238683400821e-07
pathological O 0 0.00040217398782260716
missense O 0 4.5558379497379065e-05
mutations O 0 1.3952982271803194e-06
should O 0 1.6972981597973558e-07
in O 0 2.494818716058944e-07
fact O 0 3.8900540744180034e-07
be O 0 9.214664231649294e-08
common O 0 2.6117413653992116e-07
even O 0 2.5705830353217607e-07
though O 0 1.3597522752206714e-07
they O 0 4.142133391837888e-08
are O 0 3.609154930472869e-08
hardly O 0 1.5193877516139764e-06
ever O 0 2.592541250123759e-06
seen O 0 6.26711334916763e-06
in O 0 1.9207025616196916e-05
aniridia B-Disease 1 0.999998927116394
patients O 0 0.002066361950710416
. O 0 0.0001354608393739909

This O 0 8.217555659939535e-06
indicates O 0 6.145011866465211e-06
that O 0 1.7402099672381155e-07
there O 0 1.7593282564121182e-07
is O 0 1.1109220565685973e-07
a O 0 2.8950205432920484e-07
heavy O 0 5.247372610028833e-05
ascertainment O 0 0.42867615818977356
bias O 0 1.828448489504808e-06
in O 0 1.524323778312464e-07
the O 0 2.2807250843470683e-07
selection O 0 8.298018769892224e-07
of O 0 2.9791135602863505e-06
patients O 0 2.465694706188515e-06
for O 0 1.2744247896989691e-06
PAX6 O 1 0.9998708963394165
mutation O 0 2.4533499072276754e-06
analysis O 0 6.132415819593007e-07
and O 0 3.330504796394962e-07
that O 0 2.3837395701775677e-07
the O 0 1.3067974578007124e-06
missing O 0 4.719808202935383e-05
PAX6 O 1 0.9999792575836182
missense O 0 0.00014545160229317844
mutations O 0 6.5098702179966494e-06
frequently O 0 3.1129536637308775e-06
may O 0 4.070404429512564e-06
underlie O 0 5.838522702106275e-05
phenotypes O 0 2.5458266463829204e-05
distinct O 0 6.222507636266528e-06
from O 0 4.118469951208681e-05
textbook O 1 0.6989907026290894
aniridia B-Disease 1 0.9999932050704956
. O 0 0.00024742362438701093

Here O 0 6.700465019093826e-05
we O 0 1.935948830578127e-06
present O 0 1.525541051705659e-06
four O 0 1.2852351574110799e-06
novel O 0 2.2378575522452593e-05
PAX6 O 1 0.9992309808731079
missense O 0 8.628889918327332e-05
mutations O 0 2.017676933974144e-06
, O 0 3.5151725796822575e-07
two O 0 1.0013399531771938e-07
in O 0 7.479361556761432e-07
association O 0 3.1121878691919846e-06
with O 0 1.5214902759908e-06
atypical O 1 0.6418274641036987
phenotypes O 0 0.4683235287666321
ectopia B-Disease 1 0.9999918937683105
pupillae I-Disease 1 0.9999411106109619
( O 0 8.506964150001295e-06
displaced B-Disease 0 6.648807811870938e-06
pupils I-Disease 0 6.214228778844699e-05
) O 0 4.81968618259998e-06
and O 0 0.00015651543799322098
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999493360519409
( O 0 1.3343748832994606e-05
searching B-Disease 0 3.3487747714389116e-05
gaze I-Disease 0 7.1995600592345e-05
) O 0 6.921646900082123e-07
, O 0 2.7358419174561277e-07
and O 0 1.9459912437014282e-07
two O 0 1.1274033084873736e-07
in O 0 4.937483595313097e-07
association O 0 6.215348548721522e-06
with O 0 1.4128958127912483e-06
more O 0 5.08799530507531e-06
recognizable O 1 0.9218294024467468
aniridia B-Disease 1 0.9999991655349731
phenotypes O 0 0.002151292050257325
. O 0 0.0001731416559778154

Strikingly O 0 0.0005703314673155546
, O 0 9.362965101900045e-06
all O 0 8.976541039373842e-07
four O 0 6.844400672889606e-07
mutations O 0 8.335860570696241e-07
are O 0 7.360260667610419e-08
located O 0 4.619545052264584e-06
within O 0 1.3984874840389239e-06
the O 0 6.935272267583059e-06
PAX6 O 1 0.9998974800109863
paired O 0 2.520613452361431e-05
domain O 0 3.5374760045669973e-06
and O 0 9.509342930869025e-07
affect O 0 4.917840215057367e-07
amino O 0 3.257302694237296e-07
acids O 0 1.6429878257895325e-07
which O 0 7.65208767461445e-08
are O 0 2.4077124294308305e-08
highly O 0 2.2929862097953446e-07
conserved O 0 7.288217602763325e-07
in O 0 2.303884514276433e-07
all O 0 2.397404728071706e-07
known O 0 3.427416913837078e-06
paired O 0 7.699309207964689e-06
domain O 0 6.2019971664994955e-06
proteins O 0 4.529880243353546e-06
. O 0 1.68414662766736e-05

Our O 0 2.3475389753002673e-05
results O 0 2.174709379687556e-06
support O 0 5.297233087731001e-07
the O 0 5.08457731029921e-07
hypothesis O 0 1.3640712950291345e-06
that O 0 6.192607315824716e-08
the O 0 1.823169384351786e-07
under O 0 1.5723767319286708e-06
- O 0 2.9110992727510165e-06
representation O 0 4.7427380422959686e-07
of O 0 1.980063416340272e-06
missense O 0 3.0491699362755753e-05
mutations O 0 1.2955648571733036e-06
is O 0 3.2886757139749534e-07
caused O 0 2.825312094500987e-06
by O 0 8.45447914343822e-07
ascertainment O 1 0.965572714805603
bias O 0 7.936682777653914e-06
and O 0 3.2781198910925013e-07
suggest O 0 3.3765030593713163e-07
that O 0 5.3944113176385144e-08
a O 0 2.810966464039666e-07
substantial O 0 1.6655316130709252e-06
burden O 0 1.2709178008663002e-05
of O 0 9.57411975832656e-05
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9968441724777222
related I-Disease 1 0.9204027652740479
disease I-Disease 1 0.999661922454834
remains O 0 2.9036604246357456e-05
to O 0 5.526307518266549e-07
be O 0 5.573758699028986e-07
uncovered O 0 7.393185660475865e-05
. O 0 8.774257366894744e-06
. O 0 2.9152191928005777e-05

The O 0 6.434629176510498e-05
chromosomal O 0 7.480811473214999e-05
order O 0 5.6560238590464e-06
of O 0 9.985731594497338e-06
genes O 0 3.302464847365627e-06
controlling O 0 1.3343189493753016e-05
the O 0 4.4446719584811945e-06
major O 0 0.00010175152419833466
histocompatibility O 1 0.999961256980896
complex O 0 0.0004640539700631052
, O 0 7.391755843855208e-06
properdin O 0 0.004229648970067501
factor O 0 2.5998951969086193e-05
B O 0 0.0004087749111931771
, O 0 1.9247781892772764e-06
and O 0 2.788489837257657e-06
deficiency B-Disease 0 0.030514931306242943
of I-Disease 0 6.229335212992737e-06
the I-Disease 0 7.6553515100386e-06
second I-Disease 0 4.9727670557331294e-05
component I-Disease 0 5.8065237681148574e-05
of I-Disease 0 2.5528797777951695e-05
complement I-Disease 0 0.00011662860924843699
. O 0 4.7602414269931614e-05

The O 0 3.928521982743405e-05
relationship O 0 4.50085235570441e-06
of O 0 4.237771918269573e-06
the O 0 1.9717608665814623e-06
genes O 0 6.522564035549294e-07
coding O 0 1.529322616988793e-06
for O 0 1.1843643505926593e-06
HLA O 0 0.04573415592312813
to O 0 2.549255952999374e-07
those O 0 1.291842295358947e-07
coding O 0 1.1154332923979382e-06
for O 0 3.207763654700102e-07
properdin O 0 0.0005404603434726596
Factor O 0 2.879370003938675e-05
B O 0 0.00014991556236054748
allotypes O 0 4.2941544961649925e-05
and O 0 3.6629302258006646e-07
for O 0 1.0472632538949256e-06
deficiency B-Disease 0 0.008669950999319553
of I-Disease 0 3.238228146074107e-06
the I-Disease 0 2.4262506030936493e-06
second I-Disease 0 8.900819011614658e-06
component I-Disease 0 7.882907084422186e-06
of I-Disease 0 1.952847242137068e-06
complement I-Disease 0 7.0571409196418244e-06
( O 0 4.7456474021601025e-06
C2 O 1 0.903902530670166
) O 0 8.202195544981805e-07
was O 0 2.8731835755024804e-06
studied O 0 2.1744976947957184e-06
in O 0 1.4839604034477816e-07
families O 0 1.57878517370591e-07
of O 0 7.1080480665841606e-06
patients O 0 0.00027971825329586864
with O 0 0.006210776977241039
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.8215845227241516

Patients O 0 0.00014697137521579862
were O 0 3.5987727642350364e-06
selected O 0 2.724900014072773e-06
because O 0 3.545618767475389e-07
they O 0 1.7622264181227365e-07
were O 0 3.1306569781008875e-07
heterozygous O 0 1.4527997791446978e-06
or O 0 1.6575611425651005e-06
homozygous O 0 5.5352833442157134e-05
for O 0 0.0004845484800171107
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.014777595177292824

12 O 0 0.00011524032015586272
families O 0 6.139523520687362e-06
with O 0 3.2667867344571277e-06
15 O 0 1.7530190234538168e-05
matings O 0 9.050036169355735e-05
informative O 0 7.92807259131223e-05
for O 0 0.0006432851077988744
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 0.00013927332474850118
found O 0 8.220612653531134e-05
. O 0 6.7790417233482e-05

Of O 0 0.00011618536518653855
57 O 0 6.258068606257439e-05
informative O 0 3.533387280185707e-05
meioses O 0 0.0003893931279890239
, O 0 1.2340200328253559e-06
two O 0 9.82050920583788e-08
crossovers O 0 8.140220870700432e-07
were O 0 4.1978597664638073e-07
noted O 0 7.953678391459107e-07
between O 0 1.3168986470191157e-06
the O 0 0.0002611352829262614
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 7.983262548805214e-06
and O 0 9.437293329028762e-07
the O 0 8.903262823878322e-06
HLA O 1 0.9996541738510132
- O 0 0.00039742994704283774
B O 0 0.0006661313236691058
gene O 0 8.779854852036806e-07
, O 0 1.9096923153938405e-07
with O 0 1.0258332139301274e-07
a O 0 3.196114164438768e-07
recombinant O 0 7.352847660513362e-06
fraction O 0 5.415263331087772e-06
of O 0 9.097142537939362e-06
0 O 0 4.499977148952894e-05
. O 0 2.8297799872234464e-05

035 O 1 0.6100143790245056
. O 0 0.004137640818953514

A O 0 0.000306539295706898
lod O 0 0.0009078553412109613
score O 0 2.5134673705906607e-05
of O 0 1.1620922123256605e-05
13 O 0 8.568314115109388e-06
was O 0 4.7513713070657104e-06
calculated O 0 1.1038816865038825e-06
for O 0 6.864475494694489e-07
linkage O 0 0.00010055249003926292
between O 0 0.0006662817904725671
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 0.00035506943822838366
HLA O 1 0.9999966621398926
- O 0 0.0007236962555907667
B O 0 0.00012830967898480594
at O 0 2.6787890874402365e-06
a O 0 1.8673551949177636e-07
maximum O 0 7.143898272943261e-08
likelihood O 0 9.608069717614853e-08
value O 0 9.903367725883072e-08
of O 0 1.827155386990853e-07
the O 0 1.8651412858616823e-07
recombinant O 0 3.84209079129505e-06
fraction O 0 2.5257272682210896e-06
of O 0 4.731602075480623e-06
0 O 0 2.4937675334513187e-05
. O 0 2.0192854208289646e-05

04 O 0 0.3120622932910919
. O 0 0.0020303484052419662

18 O 0 0.00010519396892050281
families O 0 2.458181597830844e-06
with O 0 1.5326661468861857e-06
21 O 0 4.888554030912928e-06
informative O 0 5.3860858315601945e-06
matings O 0 1.1482600712042768e-05
for O 0 8.035891596591682e-07
both O 0 1.3337668178792228e-06
properdin O 0 0.0005627286736853421
Factor O 0 2.9339140382944606e-05
B O 0 0.00018112667021341622
allotype O 0 0.00018274415924679488
and O 0 4.116024683753494e-06
HLA O 1 0.9038718938827515
- O 0 0.00015618283941876143
B O 0 0.00026507582515478134
were O 0 2.6861978312808787e-06
found O 0 1.2689911272900645e-05
. O 0 1.687587246124167e-05

Of O 0 0.0001353228435618803
72 O 0 0.00022572281886823475
informative O 0 3.438365820329636e-05
meioses O 0 0.0008501451229676604
, O 0 2.793965450109681e-06
three O 0 1.6609475324003142e-06
recombinants O 0 0.0001520929072285071
were O 0 2.212778326793341e-06
found O 0 2.0673735434684204e-06
, O 0 4.653427367884433e-07
giving O 0 6.182735887705348e-07
a O 0 8.056172191572841e-07
recombinant O 0 7.932339030958246e-06
fraction O 0 7.084119715727866e-06
of O 0 1.1540112609509379e-05
0 O 0 4.141628596698865e-05
. O 0 2.1538078726734966e-05

042 O 1 0.8026260137557983
. O 0 0.003907827194780111

A O 0 0.0002846818242687732
lod O 0 0.0006068129441700876
score O 0 1.5887912013567984e-05
of O 0 6.297981144598452e-06
16 O 0 7.218846803880297e-06
between O 0 3.783282181757386e-06
HLA O 1 0.989038348197937
- O 0 0.00018793714116327465
B O 0 0.00017774327716324478
and O 0 1.520312480352004e-06
Factor O 0 1.0996181117661763e-05
B O 0 8.026569412322715e-05
allotypes O 0 4.211458872305229e-05
was O 0 2.611910758787417e-06
calculated O 0 5.513883820640331e-07
at O 0 8.392223094233486e-07
a O 0 1.2665852011650713e-07
maximum O 0 1.2005610017240542e-07
likelihood O 0 1.3725961878208182e-07
value O 0 1.1038653013883959e-07
of O 0 2.587389076325053e-07
the O 0 3.411694251553854e-07
recombinant O 0 5.066515768703539e-06
fraction O 0 2.131010205630446e-06
of O 0 5.5269006224989425e-06
0 O 0 2.2258998797042295e-05
. O 0 1.93307514564367e-05

04 O 1 0.5696554183959961
. O 0 0.002811345038935542

A O 0 0.0003217422345187515
crossover O 0 0.00013422584743238986
was O 0 5.410965241026133e-05
shown O 0 9.944174053089228e-07
to O 0 1.5431689348588407e-07
have O 0 5.9020102582962863e-08
occurred O 0 7.97931932083884e-07
between O 0 9.103593612280747e-08
genes O 0 6.733509394507564e-08
for O 0 2.0100472397643898e-07
Factor O 0 3.987023319496075e-06
B O 0 3.783083593589254e-05
and O 0 1.3610150517706643e-06
HLA O 0 0.20012779533863068
- O 0 4.7015517338877544e-05
D O 0 6.0949249018449336e-05
, O 0 2.4491137651239114e-07
in O 0 2.2865202708999277e-07
which O 0 5.153464144314057e-07
HLA O 0 0.28806939721107483
- O 0 0.00012016442633466795
D O 0 0.00220646895468235
segregared O 0 0.0003010170185007155
with O 0 2.4403641418757616e-06
HLA O 1 0.9989105463027954
- O 0 0.000131556109408848
A O 0 7.665492739761248e-05
and O 0 3.33038333337754e-05
B O 0 0.0120919868350029
. O 0 3.7285884900484234e-05

These O 0 6.554736046382459e-06
studies O 0 6.858285814814735e-06
suggest O 0 1.1758178288800991e-06
that O 0 1.1077968764539037e-07
the O 0 2.306366440052443e-07
genes O 0 1.1758690021679286e-07
for O 0 3.284926606283989e-07
Factor O 0 4.806467404705472e-05
B O 1 0.9580292105674744
and O 0 0.000985363032668829
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.4569388301642903e-07
located O 0 1.803353939067165e-06
outside O 0 5.200738542043837e-07
those O 0 5.5720530411917935e-08
for O 0 3.3262705301240203e-07
HLA O 1 0.9768127202987671
, O 0 4.497281054227642e-07
that O 0 3.2849950315494425e-08
the O 0 1.4736905029621994e-07
order O 0 2.9456876404765353e-07
of O 0 2.332937583560124e-06
genese O 0 0.0013595193158835173
is O 0 1.3579319784184918e-06
HLA O 0 0.02574622817337513
- O 0 8.193133908207528e-06
A O 0 6.88386080582859e-06
, O 0 5.569768291024957e-07
- O 0 5.46604860574007e-06
B O 0 1.8716176782618277e-05
, O 0 5.513915652954893e-07
- O 0 8.536399036529474e-06
D O 0 4.1167029849020764e-05
, O 0 4.7493870170001173e-07
Factor O 0 9.574913747201208e-06
B O 0 0.0009085687925107777
allotype O 1 0.7703893184661865
, O 0 0.00029505472048185766
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.432828523524222e-06
that O 0 1.0719455190155713e-07
the O 0 3.1370706210509525e-07
genes O 0 4.001666980002483e-07
coding O 0 8.686230103194248e-06
for O 0 4.9895250413101166e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.9278832041891292e-05
Factor O 0 0.00011144460586365312
B O 0 0.0001806234213290736
allotypes O 0 1.9712799257831648e-05
are O 0 3.1216707441217295e-08
approximately O 0 3.55208300106824e-07
3 O 0 6.020523528604826e-07
- O 0 2.9561526844190666e-06
- O 0 4.504845492192544e-06
5 O 0 1.9503031580825336e-06
centimorgans O 0 2.2354430257109925e-05
from O 0 6.735616011610546e-07
the O 0 1.4871752682665829e-06
HLA O 1 0.9889005422592163
- O 0 5.3821768233319744e-05
A O 0 1.6539495845790952e-05
and O 0 3.4349300221947487e-06
HLA O 1 0.9997401833534241
- O 0 0.0003137516032438725
B O 0 0.0005909981555305421
loci O 0 5.741494533140212e-06
, O 0 4.114429543733422e-07
and O 0 1.1134974187143598e-07
that O 0 5.4560317153118376e-08
the O 0 3.540151851666451e-07
apparent O 0 5.373490694182692e-06
lack O 0 2.657828645169502e-06
of O 0 6.2995909502205905e-06
recombinants O 0 0.014199932105839252
between O 0 1.3029472256675945e-06
the O 0 2.1039866169303423e-06
Factor O 0 3.985167859354988e-05
B O 0 0.09435521811246872
gene O 0 2.5479690521024168e-05
and O 0 0.00019076766329817474
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 4.8933598009170964e-05
suggests O 0 1.484301833443169e-06
that O 0 6.204749780636121e-08
these O 0 4.087961613663538e-08
two O 0 1.3237858809134195e-07
genes O 0 4.1424186747462954e-07
lie O 0 3.344408924021991e-06
in O 0 3.786556419527187e-07
close O 0 1.1332170970490552e-06
proximity O 0 2.07969287657761e-06
to O 0 4.981133088222123e-07
one O 0 2.925842409240431e-06
another O 0 1.450461149943294e-05
. O 0 3.242173988837749e-05

Distribution O 0 4.7349330998258665e-05
of O 0 6.897243292769417e-05
emerin O 0 0.16876576840877533
and O 0 1.981710738618858e-05
lamins O 0 0.006052158772945404
in O 0 3.5480406950227916e-06
the O 0 1.5053216884552967e-05
heart O 0 0.2530140280723572
and O 0 2.055381628451869e-06
implications O 0 1.4651868696091697e-05
for O 0 1.1671132597257383e-05
Emery B-Disease 1 0.9998849630355835
- I-Disease 1 0.9999523162841797
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.7844674587249756

Emerin O 0 0.04604930430650711
is O 0 1.9717348550329916e-05
a O 0 7.398787602141965e-06
nuclear O 0 4.5647830120287836e-05
membrane O 0 7.174552138167201e-06
protein O 0 7.903652772256464e-07
which O 0 3.209688372862729e-07
is O 0 4.2224968410664587e-07
missing O 0 2.1388304958236404e-06
or O 0 2.1280450255289907e-06
defective O 0 0.0007148160366341472
in O 0 2.09240461117588e-05
Emery B-Disease 1 0.9998323917388916
- I-Disease 1 0.9998927116394043
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999998927116394
EDMD B-Disease 1 1.0
) O 0 0.005183739122003317
. O 0 0.00021497624402400106

It O 0 9.727993528940715e-06
is O 0 1.0613182439556113e-06
one O 0 3.932715912924323e-07
member O 0 4.7257393021027383e-07
of O 0 1.3320939160621492e-06
a O 0 2.167417278542416e-06
family O 0 6.338176717690658e-06
of O 0 9.294619667343795e-05
lamina O 1 0.9999969005584717
- O 0 0.0008036784129217267
associated O 0 2.552503929109662e-06
proteins O 0 2.965766157103644e-07
which O 0 2.0911711828830448e-07
includes O 0 1.408039906891645e-06
LAP1 O 1 0.9982792139053345
, O 0 8.500233889208175e-06
LAP2 O 1 0.9487641453742981
and O 0 6.923027285665739e-06
lamin O 0 0.0006949886446818709
B O 0 0.0008617619751021266
receptor O 0 3.520800601108931e-05
( O 0 1.319664534094045e-05
LBR O 1 0.8535246253013611
) O 0 3.120550900348462e-05
. O 0 4.582954352372326e-05

A O 0 0.00022122309019323438
panel O 0 1.7701779142953455e-05
of O 0 6.145756287878612e-06
16 O 0 9.191104254568927e-06
monoclonal O 0 3.5717916034627706e-05
antibodies O 0 1.007809169095708e-05
( O 0 5.2786672313231975e-06
mAbs O 0 0.00013733538798987865
) O 0 6.350364856189117e-07
has O 0 2.1051918963621574e-07
been O 0 1.6409505576575611e-07
mapped O 0 7.624980185028107e-07
to O 0 7.710235649938113e-08
six O 0 6.43799111799126e-08
specific O 0 2.8380068073374787e-08
sites O 0 3.82132071763408e-07
throughout O 0 3.32324873397738e-07
the O 0 6.072229439268995e-07
emerin O 0 3.904677942045964e-05
molecule O 0 9.672605756350094e-07
using O 0 5.571893098021974e-07
phage O 0 2.463476630509831e-05
- O 0 3.2175692012970103e-06
displayed O 0 2.5402453047718154e-06
peptide O 0 1.2889519211967126e-06
libraries O 0 6.384126436387305e-07
and O 0 1.8248637445594795e-07
has O 0 7.846785621268282e-08
been O 0 1.4216961119473126e-07
used O 0 1.57273802869895e-07
to O 0 1.8939024926112324e-07
localize O 0 7.493720477214083e-05
emerin O 0 0.0011871017049998045
in O 0 1.968694505194435e-06
human O 0 2.7912913083127933e-06
and O 0 2.0585892343660817e-05
rabbit O 1 0.9944882988929749
heart O 1 0.9988486766815186
. O 0 8.3260762039572e-05

Several O 0 6.767686136299744e-05
mAbs O 0 0.00042353858589194715
against O 0 1.3808132280246355e-05
different O 0 1.508800664851151e-06
emerin O 0 0.001650137361139059
epitopes O 0 7.609268504893407e-05
did O 0 1.8432251636113506e-06
not O 0 2.1671121430699714e-07
recognize O 0 5.710525670110655e-07
intercalated O 0 6.663679232588038e-05
discs O 0 0.00010137343633687124
in O 0 2.460639734636061e-06
the O 0 9.30243459151825e-06
heart O 1 0.520893931388855
, O 0 5.254310622149205e-07
though O 0 1.6794993484836596e-07
they O 0 5.97780314137708e-08
recognized O 0 8.610020927335427e-07
cardiomyocyte O 0 0.00010769867367343977
nuclei O 0 1.2257824892003555e-05
strongly O 0 1.3549876030083396e-06
, O 0 3.4068366971951036e-07
both O 0 1.8425645009756408e-07
at O 0 4.937121047987603e-06
the O 0 1.9052806692343438e-06
rim O 0 5.1728711696341634e-05
and O 0 9.119492574427568e-07
in O 0 3.245589596190257e-06
intranuclear O 0 0.004003590904176235
spots O 0 3.671243030112237e-05
or O 0 7.824971362424549e-06
channels O 0 7.883215403126087e-06
. O 0 2.5975827156798914e-05

A O 0 0.0010604953859001398
polyclonal O 0 0.0038569937460124493
rabbit O 0 0.0007601536344736814
antiserum O 0 0.0006300825043581426
against O 0 8.737650932744145e-05
emerin O 0 0.20515550673007965
did O 0 3.3084224924095906e-06
recognize O 0 1.1273640438957955e-06
both O 0 3.8315346273520845e-07
nuclear O 0 1.949778561538551e-05
membrane O 0 3.962142727687024e-06
and O 0 5.954906896477041e-07
intercalated O 0 5.821999366162345e-05
discs O 0 3.1736686651129276e-05
but O 0 1.9952611296503164e-07
, O 0 1.126494098002695e-07
after O 0 2.69236068106693e-07
affinity O 0 2.498783260307391e-07
purification O 0 8.542515388398897e-06
against O 0 1.3152243809599895e-06
a O 0 1.0354393680245266e-06
pure O 0 3.6802022805204615e-05
- O 0 2.9682252716156654e-05
emerin O 0 0.0011559233535081148
band O 0 2.167407001252286e-05
on O 0 7.025151376183203e-07
a O 0 4.0169535964196257e-07
western O 0 1.570754989188572e-06
blot O 0 0.00026988849276676774
, O 0 1.937034767252044e-06
it O 0 7.879681902522861e-07
stained O 0 0.001060573267750442
only O 0 4.937648441227793e-07
the O 0 2.230910013167886e-06
nuclear O 0 0.00012957806757185608
membrane O 0 8.728981629246846e-05
. O 0 1.9404815247980878e-05

These O 0 1.1241667380090803e-05
results O 0 4.1018047340912744e-06
would O 0 4.154873352035793e-07
not O 0 6.044923139825187e-08
be O 0 5.203114739060766e-08
expected O 0 2.526057016893901e-07
if O 0 1.7459748846704315e-07
immunostaining O 0 4.084297324880026e-05
at O 0 3.1336039683083072e-06
intercalated O 0 2.6112729756277986e-05
discs O 0 1.277239789487794e-05
were O 0 2.420338205411099e-07
due O 0 2.2403905575174576e-07
to O 0 8.496365921928373e-08
a O 0 2.7292540494272544e-07
product O 0 1.052889388120093e-06
of O 0 9.414361556991935e-07
the O 0 4.046056801598752e-06
emerin O 0 0.2599260210990906
gene O 0 1.3062342532066396e-06
and O 0 3.265031409682706e-07
, O 0 3.40070840820772e-07
therefore O 0 1.310077522020947e-07
, O 0 8.738242485151204e-08
cast O 0 1.3705803780794668e-07
some O 0 8.124518302565775e-08
doubt O 0 6.122119771134749e-07
upon O 0 5.431360818874964e-07
the O 0 7.40381608466123e-07
hypothesis O 0 7.392749921564246e-06
that O 0 2.1043038032075856e-06
cardiac B-Disease 1 0.9999992847442627
defects I-Disease 1 0.9999767541885376
in O 0 0.00010219796968158334
EDMD B-Disease 1 1.0
are O 0 5.258195301394153e-07
caused O 0 6.66506048219162e-06
by O 0 9.028792646859074e-07
absence O 0 1.0785575796035118e-05
of O 0 1.709718708298169e-05
emerin O 0 0.4144003391265869
from O 0 2.8721546186716296e-05
intercalated O 0 0.49265673756599426
discs O 0 0.04040805622935295
. O 0 6.005961768096313e-05

Although O 0 0.00012001601862721145
emerin O 0 0.003082227660343051
was O 0 3.728265073732473e-05
abundant O 0 5.066390258434694e-06
in O 0 1.3226115243014647e-06
the O 0 1.2836181895181653e-06
membranes O 0 7.012486094026826e-06
of O 0 5.778363629360683e-06
cardiomyocyte O 0 0.18764446675777435
nuclei O 0 2.4481789296260104e-05
, O 0 6.386062523233704e-07
it O 0 1.8723447681168182e-07
was O 0 2.5399908736289944e-06
absent O 0 1.4580381275663967e-06
from O 0 3.7917092754469195e-07
many O 0 1.0462674282507578e-07
non O 0 6.639924322371371e-06
- O 0 0.00012415087257977575
myocyte O 1 0.9926789999008179
cells O 0 8.336636710737366e-06
in O 0 1.2979046459804522e-06
the O 0 2.0427876734174788e-05
heart O 1 0.9892238974571228
. O 0 8.932489436119795e-05

This O 0 9.769627467903774e-06
distribution O 0 4.6711643335584085e-06
of O 0 1.4798769370827358e-05
emerin O 0 0.11346787214279175
was O 0 1.52956217789324e-05
similar O 0 2.64614413936215e-07
to O 0 1.0447599407825692e-07
that O 0 5.079289167042589e-08
of O 0 1.5197065295069478e-06
lamin O 0 0.002085757674649358
A O 0 2.0697621948784217e-05
, O 0 6.302616384346038e-07
a O 0 4.323042617215833e-07
candidate O 0 8.81634605320869e-07
gene O 0 2.6182902956861653e-07
for O 0 1.5812713627383346e-07
an O 0 8.129662205647037e-07
autosomal O 0 2.926137858594302e-05
form O 0 3.4294578654225916e-05
of O 1 0.9858323335647583
EDMD B-Disease 1 1.0
. O 0 0.0020642802119255066

In O 0 5.933747161179781e-05
contrast O 0 4.9380530981579795e-05
, O 0 2.2622718461207114e-05
lamin O 0 0.018734322860836983
B1 O 1 0.9996639490127563
was O 0 0.00014187218039296567
absent O 0 2.415846029180102e-05
from O 0 6.1658338381676e-06
cardiomyocyte O 0 0.00034258642699569464
nuclei O 0 2.342134393984452e-05
, O 0 2.6689895094023086e-06
showing O 0 8.13664973975392e-06
that O 0 1.2196142051834613e-06
lamin O 0 0.07530321180820465
B1 O 1 0.995882511138916
is O 0 8.532497872693057e-07
not O 0 8.65474234501562e-08
essential O 0 4.2163279090345895e-07
for O 0 3.4070347965098335e-07
localization O 0 1.153328048530966e-05
of O 0 5.888353825866943e-06
emerin O 0 0.000336964032612741
to O 0 1.2312481203480274e-06
the O 0 6.768605089746416e-06
nuclear O 0 0.0032186147291213274
lamina O 1 0.9919834733009338
. O 0 8.353473822353408e-05

Lamin O 1 0.9989417195320129
B1 O 1 0.9999381303787231
is O 0 2.8541120627778582e-05
also O 0 4.8482356760359835e-06
almost O 0 3.749279130715877e-06
completely O 0 1.9670731489895843e-05
absent O 0 2.0636465706047602e-05
from O 0 2.968816988868639e-05
skeletal O 1 0.9999524354934692
muscle O 1 0.8763880133628845
nuclei O 0 0.00993588287383318
. O 0 0.0001156571161118336

In O 0 0.000546304858289659
EDMD B-Disease 1 0.9999991655349731
, O 0 7.121088401618181e-06
the O 0 1.6384593664042768e-06
additional O 0 1.036909793583618e-06
absence O 0 1.3126469639246352e-05
of O 0 8.849401638144627e-05
lamin O 1 0.9997172951698303
B1 O 1 0.9999985694885254
from O 0 0.0020864736288785934
heart O 1 0.9999743700027466
and O 0 0.00016629038145765662
skeletal O 1 0.9999991655349731
muscle O 1 0.694968044757843
nuclei O 0 0.0006083442713133991
which O 0 2.407066176601802e-06
already O 0 5.9364724620536435e-06
lack O 0 9.821886123972945e-06
emerin O 0 0.01879999227821827
may O 0 5.350635774448165e-07
offer O 0 1.6578931649746664e-07
an O 0 5.677597059161599e-08
alternative O 0 2.2197417592906277e-07
explanation O 0 2.7555987003324844e-07
of O 0 8.363076631212607e-07
why O 0 1.0346577710151905e-06
these O 0 1.7700654098007362e-07
tissues O 0 1.1398263268347364e-05
are O 0 1.5086193627666944e-07
particularly O 0 1.609076662134612e-06
affected O 0 4.2071242205565795e-06
. O 0 5.63174444323522e-06
. O 0 2.051072078756988e-05

Genetic O 0 0.00013367088104132563
mapping O 0 6.094831769587472e-05
of O 0 2.363542080274783e-05
the O 0 3.5369539546081796e-05
copper B-Disease 1 0.999779999256134
toxicosis I-Disease 1 0.9999113082885742
locus O 0 5.427125142887235e-05
in O 0 3.5105333608953515e-06
Bedlington O 0 0.0013227906310930848
terriers O 0 5.825647895107977e-05
to O 0 1.4125051848168368e-06
dog O 0 3.6856887163594365e-05
chromosome O 0 1.6675928691256559e-06
10 O 0 6.243814141271287e-07
, O 0 1.743716921964733e-07
in O 0 3.35371794335515e-07
a O 0 1.0754224604170304e-06
region O 0 2.28259068535408e-06
syntenic O 0 0.001173657365143299
to O 0 1.5320377997340984e-06
human O 0 6.221172498044325e-06
chromosome O 0 1.539389995741658e-05
region O 0 1.3733867490373086e-05
2p13 O 0 0.032250337302684784
- O 0 0.0019387297797948122
p16 O 0 0.004046501126140356
. O 0 8.88521972228773e-05

Abnormal O 1 0.999994158744812
hepatic B-Disease 1 0.9999996423721313
copper I-Disease 1 0.9999948740005493
accumulation I-Disease 1 0.9905244708061218
is O 0 9.05934393813368e-06
recognized O 0 5.933540251135128e-06
as O 0 3.0504095320793567e-06
an O 0 1.0295580068486743e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.018037302419543266
man O 1 0.7347373366355896
, O 0 1.4303238458523992e-05
mouse O 0 0.00021820211259182543
, O 0 1.2464492101571523e-05
rat O 1 0.5440813302993774
and O 0 2.0507710360107012e-05
dog O 0 0.0019323675660416484
. O 0 9.090427920455113e-05

The O 0 0.0001926539553096518
major O 0 0.00045281994971446693
cause O 0 0.00536039425060153
of O 1 0.863589882850647
hepatic B-Disease 1 0.9999998807907104
copper I-Disease 1 0.9999979734420776
accumulation I-Disease 1 0.9968560934066772
in O 0 5.091201455798e-05
man O 0 7.315599214052781e-05
is O 0 7.268241120073071e-07
a O 0 1.8493470861358219e-06
dysfunctional O 0 0.004502674099057913
ATP7B O 1 0.9999997615814209
gene O 0 5.39861066499725e-05
, O 0 8.003669790923595e-06
causing O 0 0.1445496678352356
Wilson B-Disease 1 0.999779999256134
disease I-Disease 1 0.9997190833091736
( O 0 0.00014430456212721765
WD B-Disease 1 0.9999902248382568
) O 0 7.677358371438459e-05
. O 0 4.0895320125855505e-05

Mutations O 0 4.640455881599337e-05
in O 0 4.641333362087607e-06
the O 0 6.423324521165341e-06
ATP7B O 1 0.9999082088470459
genes O 0 9.160941658592492e-07
have O 0 6.343549330267706e-08
also O 0 1.8380715971488826e-07
been O 0 2.1962632956729067e-07
demonstrated O 0 1.2816391290471074e-06
in O 0 1.5524981336056953e-06
mouse O 0 7.819726306479424e-05
and O 0 1.9636170691228472e-05
rat O 1 0.5844420194625854
. O 0 5.643380427500233e-05

The O 0 0.0002665502834133804
ATP7B O 1 0.9997254014015198
gene O 0 3.8890815631020814e-05
has O 0 2.322792170161847e-06
been O 0 8.963145319285104e-07
excluded O 0 3.2680891308700666e-06
in O 0 5.225606969361252e-07
the O 0 1.0217778481091955e-06
much O 0 4.3049503801739775e-06
rarer O 0 0.00018063856987282634
human O 0 5.569074710365385e-05
copper B-Disease 1 0.9999996423721313
overload I-Disease 1 0.9999998807907104
disease O 1 0.999991774559021
non B-Disease 0 0.0005006560240872204
- I-Disease 0 0.0004478092596400529
Indian I-Disease 0 0.0001744731271173805
childhood I-Disease 1 0.9999905824661255
cirrhosis I-Disease 1 1.0
, O 0 2.4831599148456007e-05
indicating O 0 7.401438779197633e-05
genetic O 0 9.264455002266914e-05
heterogeneity O 0 0.0007299741264432669
. O 0 0.00010772178939078003

By O 0 5.6192526244558394e-05
investigating O 0 8.170626097125933e-05
the O 0 2.1677953554899432e-05
common O 0 5.3813560953130946e-05
autosomal O 0 0.26362717151641846
recessive O 1 0.9779443144798279
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 0.0008105274755507708
CT B-Disease 1 0.9999772310256958
) O 0 2.4573660084570292e-06
in O 0 2.4738797037571203e-06
Bedlington O 0 0.4422272741794586
terriers O 0 0.00029666730551980436
, O 0 5.520787453860976e-07
we O 0 8.241796223273923e-08
have O 0 2.6900167426902044e-08
identified O 0 1.2241314095717826e-07
a O 0 2.340790388188907e-07
new O 0 4.820798835680762e-07
locus O 0 1.0414386451884639e-05
involved O 0 2.933698851848021e-06
in O 0 2.754354318312835e-05
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0006683009560219944

We O 0 1.2520165000751149e-05
examined O 0 2.320676503586583e-05
whether O 0 2.579908368716133e-06
the O 0 5.118969056638889e-06
WD B-Disease 1 0.9662867784500122
gene O 0 5.336263347999193e-05
ATP7B O 1 0.9995831847190857
was O 0 6.091868272051215e-05
also O 0 1.2751225995089044e-06
causative O 0 6.500750259874621e-06
for O 0 1.0524134950173902e-06
CT B-Disease 0 0.026381446048617363
by O 0 5.829746214658371e-07
investigating O 0 3.2933940019574948e-06
the O 0 1.9270739812782267e-06
chromosomal O 0 4.46656922576949e-05
co O 0 5.3719930292572826e-05
- O 0 2.8461181500460953e-05
localization O 0 2.471409061399754e-05
of O 0 7.083720902301138e-06
ATP7B O 1 0.9996864795684814
and O 0 3.0990258892416023e-06
C04107 O 0 8.227514626923949e-05
, O 0 2.910708758463443e-07
using O 0 1.2509757141287992e-07
fluorescence O 0 1.9679905562952626e-06
in O 0 4.833960360883793e-07
situ O 0 4.980326775694266e-05
hybridization O 0 1.3950393622508273e-05
( O 0 6.62858656141907e-06
FISH O 0 6.783640128560364e-05
) O 0 9.6488311100984e-06
. O 0 2.2211819668882526e-05

C04107 O 0 0.007701551076024771
is O 0 9.748342563398182e-06
an O 0 1.660930024627305e-06
anonymous O 0 2.009899981203489e-05
microsatellite O 0 0.0002450585307087749
marker O 0 0.0002834709011949599
closely O 0 5.0871849452960305e-06
linked O 0 2.4463841327815317e-05
to O 0 1.5560446627205238e-05
CT B-Disease 1 0.9999622106552124
. O 0 0.0001334597181994468

However O 0 0.0001353387051494792
, O 0 6.054974801372737e-05
BAC O 1 0.6267407536506653
clones O 0 0.00029705106862820685
containing O 0 0.00010865594958886504
ATP7B O 1 0.9999533891677856
and O 0 1.0713670235418249e-05
C04107 O 0 0.0006293245241977274
mapped O 0 9.082328688236885e-06
to O 0 7.591784196847584e-07
the O 0 3.131214270979399e-06
canine O 0 0.00047164803254418075
chromosome O 0 9.072546163224615e-06
regions O 0 1.4454502661465085e-06
CFA22q11 O 0 0.010664427652955055
and O 0 6.578357897524256e-06
CFA10q26 O 1 0.8460168242454529
, O 0 2.246283202111954e-06
respectively O 0 2.308433522557607e-06
, O 0 4.7663024815847166e-07
demonstrating O 0 1.3335289850147092e-06
that O 0 3.022279315700871e-07
WD B-Disease 0 0.014492392539978027
cannot O 0 8.711605232747388e-07
be O 0 2.38080644976435e-07
homologous O 0 2.8303982162469765e-06
to O 0 6.343498171190731e-06
CT B-Disease 1 0.994489312171936
. O 0 9.932628745445982e-05

The O 0 0.00021246433607302606
copper O 0 0.00806063786149025
transport O 0 0.0002450865868013352
genes O 0 3.081465547438711e-05
CTR1 O 1 0.9987537860870361
and O 0 1.2141713341407012e-05
CTR2 O 1 0.9920935034751892
were O 0 2.182610842282884e-06
also O 0 4.3306476982252207e-07
excluded O 0 1.742601057230786e-06
as O 0 3.101125969351415e-07
candidate O 0 9.21620880944829e-07
genes O 0 1.9868967626734957e-07
for O 0 4.981028496331419e-07
CT B-Disease 1 0.9848111867904663
since O 0 1.2773780326824635e-06
they O 0 2.139622949925979e-07
both O 0 1.3965440359697823e-07
mapped O 0 3.563779500836972e-06
to O 0 1.963452405107091e-06
canine O 0 0.0015860057901591063
chromosome O 0 9.599498298484832e-05
region O 0 4.90548882225994e-05
CFA11q22 O 0 0.48395371437072754
. O 0 7.251277565956116e-05

2 O 0 0.0010618292726576328
- O 0 0.0010413324926048517
22 O 0 0.0003670586447697133
. O 0 9.824704466154799e-05

5 O 0 0.003072350984439254
. O 0 0.0005994618404656649

A O 0 9.511177631793544e-05
transcribed O 0 1.754902405082248e-05
sequence O 0 1.5949551652738592e-06
identified O 0 1.675430894465535e-06
from O 0 1.023857521431637e-06
the O 0 1.8123743075193488e-06
C04107 O 0 0.007502254098653793
- O 0 4.905311288894154e-05
containing O 0 5.1812934543704614e-05
BAC O 1 0.9969979524612427
was O 0 1.1587225344555918e-05
found O 0 2.7716308181879867e-07
to O 0 5.1530811617794825e-08
be O 0 4.150112431489106e-08
homologous O 0 1.7503815286090685e-07
to O 0 1.2553725525776827e-07
a O 0 9.163116487798106e-07
gene O 0 5.510667051566998e-07
expressed O 0 1.0692134111423002e-07
from O 0 4.491015204166615e-07
human O 0 5.797090807391214e-07
chromosome O 0 3.0090895961620845e-06
2p13 O 0 0.00020506788860075176
- O 0 4.093223105883226e-05
p16 O 0 0.0001134277117671445
, O 0 6.447963869504747e-07
a O 0 2.68024592742222e-07
region O 0 4.7664164526395325e-07
devoid O 0 4.905301011604024e-06
of O 0 1.225316168529389e-06
any O 0 6.199219342306606e-07
positional O 0 3.0642262572655454e-05
candidate O 0 1.87144451047061e-05
genes O 0 1.905875797092449e-05
. O 0 4.580726454150863e-05

Molecular O 0 5.6333199609071016e-05
analysis O 0 6.020281489327317e-06
of O 0 6.939373179193353e-06
the O 0 4.051906671520555e-06
APC B-Disease 0 0.00043546073720790446
gene O 0 1.6265305475826608e-06
in O 0 3.707426117216528e-07
205 O 0 2.0928880530846072e-06
families O 0 1.359723853511241e-07
: O 0 2.565261638665106e-07
extended O 0 1.6213083426919184e-06
genotype O 0 1.035741479427088e-05
- O 0 1.3297583791427314e-05
phenotype O 0 5.185576810617931e-06
correlations O 0 4.276120307622477e-06
in O 0 2.0988184132875176e-06
FAP B-Disease 0 0.014774047769606113
and O 0 8.437177712039556e-07
evidence O 0 1.2374057405395433e-06
for O 0 2.7282285941510054e-07
the O 0 9.79076844487281e-07
role O 0 3.944983291148674e-06
of O 0 9.075730304175522e-06
APC B-Disease 0 0.020579246804118156
amino O 0 8.26731320557883e-06
acid O 0 1.4032572835276369e-05
changes O 0 5.250711637927452e-06
in O 0 0.023878473788499832
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9983818531036377
. O 0 0.00020823103841394186

BACKGROUND O 0 0.061733342707157135
/ O 0 0.0009366084705106914
AIMS O 0 0.00010760824079625309
The O 0 6.76401077726041e-06
development O 0 3.7669120501959696e-05
of O 1 0.9994175434112549
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.0366345526999794e-06
a O 0 6.64352000967483e-07
variable O 0 4.377435516289552e-07
range O 0 2.357460971325054e-06
of O 0 5.411298388935393e-06
extracolonic O 1 0.8216875195503235
manifestations O 0 0.008168007247149944
in O 0 6.367788591887802e-05
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.017250673845410347
FAP B-Disease 1 0.9999980926513672
) O 0 6.795414265070576e-06
is O 0 4.645539490866213e-07
the O 0 4.7429145411115314e-07
result O 0 4.7363241151288094e-07
of O 0 1.9339152004249627e-06
the O 0 4.3699083107640035e-06
dominant O 0 4.3620908400043845e-05
inheritance O 0 0.00012874059029854834
of O 0 0.16206319630146027
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999765157699585
( O 0 0.0001963276881724596
APC B-Disease 1 0.9969872832298279
) O 0 4.252153667039238e-05
gene O 0 7.738837302895263e-05
mutations O 0 6.033222598489374e-05
. O 0 5.685041469405405e-05

In O 0 2.2833895855001174e-05
this O 0 1.4587125178877614e-06
study O 0 1.0411141602162388e-06
, O 0 1.8805336310379062e-07
direct O 0 1.5101423400665226e-07
mutation O 0 1.281094910154934e-07
analysis O 0 1.0346127510274528e-07
of O 0 6.888970460749988e-07
the O 0 1.935782620421378e-06
APC B-Disease 0 0.00219682021997869
gene O 0 3.80166989089048e-06
was O 0 8.031187462620437e-06
performed O 0 1.4204156286723446e-06
to O 0 1.103071767261099e-07
determine O 0 4.157711543939513e-07
genotype O 0 7.024467322480632e-06
- O 0 7.552719580417033e-06
phenotype O 0 2.287812321810634e-06
correlations O 0 1.0110014727615635e-06
for O 0 2.587907204087969e-07
nine O 0 4.321160758991027e-06
extracolonic O 0 0.011011040769517422
manifestations O 0 4.356993667897768e-05
and O 0 6.579723503818968e-07
to O 0 3.735345899258391e-07
investigate O 0 1.434015757695306e-06
the O 0 2.21893628804537e-06
incidence O 0 1.5261786757037044e-05
of O 0 4.753755092679057e-06
APC B-Disease 0 0.01705196499824524
mutations O 0 2.0509994556050515e-06
in O 0 2.107292175423936e-06
non O 0 0.002940321806818247
- O 1 0.9999898672103882
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000635297445114702

METHODS O 0 0.00027649590629152954
The O 0 8.809626888250932e-05
APC B-Disease 0 0.0015453244559466839
gene O 0 2.329270682821516e-05
was O 0 1.7682577890809625e-05
analysed O 0 1.5381016055471264e-05
in O 0 1.4455550854108878e-06
190 O 0 6.1499599723902065e-06
unrelated O 0 1.1526473826961592e-05
FAP B-Disease 0 0.06647508591413498
and O 0 4.92316621603095e-06
15 O 0 1.9648497982416302e-05
non O 0 0.004573434125632048
- O 1 0.9999768733978271
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.6020238844212145e-05
using O 0 3.3963467558351113e-06
denaturing O 0 0.00028981719515286386
gradient O 0 4.599908061209135e-05
gel O 0 6.48023997200653e-05
electrophoresis O 0 2.1265264877001755e-05
, O 0 6.365256126628083e-07
the O 0 3.3170300639540073e-07
protein O 0 4.6370584527721803e-07
truncation O 0 9.144765499513596e-06
test O 0 3.815493528236402e-06
, O 0 3.654723172985541e-07
and O 0 4.499284500525391e-07
direct O 0 2.6493332825339166e-06
sequencing O 0 4.673274088418111e-05
. O 0 4.6216377086238936e-05

RESULTS O 0 0.0005537515971809626
Chain O 0 0.00023813880397938192
terminating O 0 3.818517143372446e-05
signals O 0 4.118502147321124e-06
were O 0 3.69666850019712e-07
only O 0 1.6609173769666086e-07
identified O 0 3.524810097133013e-07
in O 0 3.7411712128232466e-07
patients O 0 1.1339986940583913e-06
belonging O 0 4.2960382415913045e-06
to O 0 4.780432618645136e-07
the O 0 6.355639470712049e-06
FAP B-Disease 1 0.999882698059082
group O 0 3.0592826078645885e-05
( O 0 3.912999090971425e-06
105 O 0 5.099811460240744e-05
patients O 0 3.517434379318729e-05
) O 0 6.804428267059848e-06
. O 0 2.1305333575583063e-05

Amino O 0 5.2052881073905155e-05
acid O 0 1.2437823897926137e-05
changes O 0 8.867310157256725e-07
were O 0 7.1207711016541e-07
identified O 0 5.263945581646112e-07
in O 0 1.4085246391459805e-07
four O 0 3.231384084756428e-07
patients O 0 1.4854543906039908e-06
, O 0 2.0347692952782381e-07
three O 0 9.377983900549225e-08
of O 0 2.0743846107507125e-06
whom O 0 3.2977220598695567e-06
belonged O 0 3.037618807866238e-05
to O 0 4.4924843223270727e-07
the O 0 2.959193352580769e-06
non O 0 0.00011488264135550708
- O 0 0.004212964791804552
FAP O 1 0.9999433755874634
group O 0 0.00015838787658140063
of O 1 0.9999285936355591
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9386528134346008
. O 0 0.00013434198626782745

Genotype O 0 0.002228011144325137
- O 0 0.001107259769923985
phenotype O 0 8.218771108658984e-05
correlations O 0 2.5911920602084137e-05
identified O 0 4.957587407261599e-06
significant O 0 1.669959374339669e-06
differences O 0 8.418467132287333e-07
in O 0 5.816579005113454e-07
the O 0 7.892911071394337e-07
nature O 0 2.9250470561237307e-06
of O 0 3.549056145857321e-06
certain O 0 2.1394200757640647e-06
extracolonic O 1 0.9190332889556885
manifestations O 0 0.010590814985334873
in O 0 2.5357783670187928e-05
FAP B-Disease 1 0.9999967813491821
patients O 0 3.9107897464418784e-05
belonging O 0 1.6186253560590558e-05
to O 0 1.0452935157445609e-06
three O 0 3.4209022032882785e-06
mutation O 0 2.214177220594138e-05
subgroups O 0 9.476757986703888e-05
. O 0 7.69472899264656e-05

CONCLUSIONS O 0 0.0002726189268287271
Extended O 0 7.01177996234037e-05
genotype O 0 0.0001270362554350868
- O 0 8.339140185853466e-05
phenotype O 0 1.3509719792637043e-05
correlations O 0 5.941332346992567e-06
made O 0 1.2178091992609552e-06
in O 0 4.211629800465744e-07
this O 0 8.024062481126748e-08
study O 0 3.542181445936876e-07
may O 0 9.977119219684027e-08
have O 0 1.557046402922424e-08
the O 0 1.3047946367805707e-07
potential O 0 2.889939310080081e-07
to O 0 1.0429540964196349e-07
determine O 0 1.609236335298192e-07
the O 0 2.529996265820955e-07
most O 0 1.179173878540496e-07
appropriate O 0 2.2196655891093542e-07
surveillance O 0 1.707853471089038e-06
and O 0 4.3025559648413036e-07
prophylactic O 0 0.00043128785910084844
treatment O 0 0.00010978607315337285
regimens O 0 2.800514812406618e-05
for O 0 6.62395848394226e-07
those O 0 6.629931021961966e-07
patients O 0 1.8886244106397498e-06
with O 0 4.567985456560564e-07
mutations O 0 2.8803469831473194e-06
associated O 0 3.973384536948288e-06
with O 0 2.3511001927545294e-06
life O 0 0.00040709241875447333
threatening O 0 0.0012786764418706298
conditions O 0 0.00021283538080751896
. O 0 7.135324995033443e-05

This O 0 5.264515493763611e-06
study O 0 1.911840399770881e-06
also O 0 3.1017884793982375e-07
provided O 0 3.69843888847754e-07
evidence O 0 6.540235517604742e-07
for O 0 2.687871187845303e-07
the O 0 1.8403849253445514e-06
pathological O 0 0.0009843296138569713
nature O 0 2.5354893296025693e-06
of O 0 6.0402544477256015e-06
amino O 0 1.3664957805303857e-06
acid O 0 1.9011838503502076e-06
changes O 0 4.0309643623004376e-07
in O 0 1.5292889656848274e-06
APC O 0 0.0013413444394245744
associated O 0 3.058886932194582e-06
with O 0 3.3916589359250793e-07
both O 0 1.4320149830382434e-06
FAP B-Disease 1 0.9837252497673035
and O 0 6.82743211655179e-06
non O 1 0.5262622833251953
- O 1 0.9999990463256836
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.2586360573768616
. O 0 2.0305551515775733e-05
. O 0 3.9687001844868064e-05

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
and O 1 0.9766388535499573
cancer B-Disease 1 0.9999995231628418
risk O 0 5.051785410614684e-05
of O 0 5.214748307480477e-05
the O 0 0.0005265852087177336
APC O 1 0.9998904466629028
I1307K O 1 0.9859091639518738
polymorphism O 0 0.0004014818405266851
. O 0 6.637511251028627e-05

Germ O 1 0.9998340606689453
- O 0 0.0009742267429828644
line O 0 5.686635631718673e-05
and O 0 2.8067333914805204e-06
somatic O 0 4.913124939776026e-05
truncating O 0 9.415594104211777e-05
mutations O 0 2.7566682092583505e-06
of O 0 3.2808734431455377e-06
the O 0 6.624327397730667e-06
APC B-Disease 0 0.2978019118309021
gene O 0 3.1854560802457854e-06
are O 0 1.0707542941190695e-07
thought O 0 8.977954166766722e-07
to O 0 9.195121037919307e-07
initiate O 0 0.0023794681765139103
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9999988079071045
formation O 0 0.47757238149642944
in O 0 0.000577484373934567
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.6229378581047058
sporadic O 1 0.9999988079071045
colorectal O 1 1.0
carcinogenesis O 1 0.9999996423721313
, O 0 0.00020781767670996487
respectively O 0 0.0001343686308246106
. O 0 8.17578547867015e-05

Recently O 0 0.00021947386267129332
, O 0 6.616031896555796e-06
an O 0 2.5746437586349202e-06
isoleucine O 0 0.0018290822627022862
- O 0 0.00021450103668030351
- O 0 0.00010150208254344761
> O 0 1.6317884728778154e-05
lysine O 0 2.4137780201272108e-05
polymorphism O 0 4.127758529648418e-06
at O 0 3.838120846921811e-06
codon O 0 1.309619710809784e-05
1307 O 0 0.00020155862148385495
( O 0 1.7476020275353221e-06
I1307K O 0 4.9002435844158754e-05
) O 0 2.2325542659018538e-07
of O 0 4.34831463280716e-07
the O 0 1.1184969253008603e-06
APC B-Disease 0 0.006030434276908636
gene O 0 1.3529358966479776e-06
has O 0 1.018166599919823e-07
been O 0 1.0208208323092549e-07
identified O 0 1.3544060095682653e-07
in O 0 1.0824340535009469e-07
6 O 0 1.1323907074256567e-06
% O 0 2.370809824014941e-07
- O 0 1.9283424990135245e-06
7 O 0 2.1152936824364588e-06
% O 0 2.5032099415511766e-07
of O 0 4.1110757820206345e-07
the O 0 1.444830104446737e-06
Ashkenazi O 0 0.0001519723009550944
Jewish O 0 2.8501573979156092e-05
population O 0 2.4736555133131333e-06
. O 0 1.420540502294898e-05

To O 0 2.7147631044499576e-05
assess O 0 2.15917552850442e-05
the O 0 6.976306394790299e-06
risk O 0 4.715619070339017e-06
of O 0 4.459630417841254e-06
this O 0 6.426324148378626e-07
common O 0 4.619641913450323e-06
APC B-Disease 0 0.003334012348204851
allelic O 0 0.0008931442280299962
variant O 0 0.001469490467570722
in O 0 0.0008126541506499052
colorectal O 1 1.0
carcinogenesis O 1 0.9999933242797852
, O 0 3.768072701859637e-06
we O 0 1.6142040237809852e-07
have O 0 2.963350631546291e-08
analyzed O 0 2.818353550537722e-07
a O 0 1.7252668271794391e-07
large O 0 3.473176093393704e-07
cohort O 0 6.9809316300961655e-06
of O 0 3.015509946635575e-06
unselected O 0 0.01222032867372036
Ashkenazi O 0 9.427579789189622e-05
Jewish O 0 1.0539689355937298e-05
subjects O 0 1.6206644431804307e-05
with O 0 3.053687123610871e-06
adenomatous B-Disease 1 0.9999639987945557
polyps I-Disease 0 0.4454699754714966
and O 0 3.0055018669372657e-06
. O 0 6.454986760218162e-06
or O 1 0.9689521193504333
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.22785433329409e-06
for O 0 1.322037633144646e-06
the O 0 1.425232767360285e-05
APC O 1 0.9725119471549988
I1307K O 1 0.8496155738830566
polymorphism O 0 0.00026310532120987773
. O 0 7.587848085677251e-05

The O 0 0.00041029980638995767
APC O 0 0.006282926071435213
I1307K O 0 0.0018259428907185793
allele O 0 2.0988580217817798e-05
was O 0 1.3086309081700165e-05
identified O 0 1.3002883179069613e-06
in O 0 3.5200633874410414e-07
48 O 0 1.1692450243572239e-06
( O 0 3.396805823285831e-07
10 O 0 3.413175022615178e-07
. O 0 1.6665627811107697e-07
1 O 0 1.5723302340120426e-06
% O 0 3.382836837317882e-07
) O 0 3.156896468681225e-07
of O 0 2.3493228127335897e-06
476 O 0 0.016206255182623863
patients O 0 0.0006583704962395132
. O 0 9.652820153860375e-05

Compared O 0 4.1870709537761286e-05
with O 0 8.925129577619373e-07
the O 0 5.37197138328338e-07
frequency O 0 3.5000391562789446e-07
in O 0 1.3203589332988486e-07
two O 0 1.0296258956543625e-08
separate O 0 3.937087100780445e-08
population O 0 2.010372845973052e-08
control O 0 2.3204620447359048e-07
groups O 0 4.105370621232396e-08
, O 0 1.8987961425409594e-07
the O 0 7.702216748839419e-07
APC O 0 0.18803390860557556
I1307K O 0 0.07157430052757263
allele O 0 3.2058017040981213e-06
is O 0 3.2568402730248636e-07
associated O 0 1.9835286479974457e-07
with O 0 5.988541573742623e-08
an O 0 1.7620584458200028e-07
estimated O 0 7.538511681559612e-07
relative O 0 1.4137773405309417e-06
risk O 0 2.4790872430457966e-06
of O 0 6.764326826669276e-06
1 O 0 5.934890214120969e-05
. O 0 2.055617187579628e-05

5 O 0 0.0005404528928920627
- O 0 0.0012717326171696186
1 O 0 0.0002968953922390938
. O 0 0.00011266236833762378

7 O 0 0.00045520090498030186
for O 0 0.00017436867346987128
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999659061431885
( O 0 4.756824637297541e-05
both O 0 1.0732404007285368e-05
P O 0 0.001579734613187611
= O 0 4.717886622529477e-05
. O 0 1.1745508345484268e-05
01 O 0 0.0028849628288298845
) O 0 2.1828605895279907e-05
. O 0 2.1289713913574815e-05

Furthermore O 0 0.00017088858294300735
, O 0 7.954968168633059e-06
compared O 0 6.0070742620155215e-06
with O 0 2.2944395823287778e-06
noncarriers O 1 0.7893311977386475
, O 0 3.6039335100213066e-05
APC O 1 0.8637957572937012
I1307K O 0 0.18209919333457947
carriers O 0 1.0847373232536484e-05
had O 0 2.3083541691448772e-06
increased O 0 2.7589723572418734e-07
numbers O 0 3.0159333164192503e-07
of O 0 3.510918304527877e-06
adenomas B-Disease 1 0.999923586845398
and O 0 0.0017428287537768483
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9994638562202454
per O 0 8.870778401615098e-06
patient O 0 2.8281236154725775e-05
( O 0 1.4466252196143614e-06
P O 0 0.00017423271492589265
= O 0 3.5573682453104993e-06
. O 0 4.422894051003823e-07
03 O 0 6.689049769192934e-05
) O 0 4.247861227213434e-07
, O 0 1.4782511925659492e-07
as O 0 1.3429678347165463e-07
well O 0 1.0695580954234174e-07
as O 0 2.631407198805391e-07
a O 0 1.0373865961810225e-06
younger O 0 1.2114579476474319e-05
age O 0 2.1428510081022978e-05
at O 0 0.00034933534334413707
diagnosis O 0 0.06274499744176865
. O 0 6.662427767878398e-05

We O 0 2.4230264898505993e-05
conclude O 0 1.425360551365884e-05
that O 0 8.031317975110142e-07
the O 0 6.269367077038623e-06
APC O 0 0.2915976047515869
I1307K O 1 0.9088494777679443
variant O 0 0.0002178702998207882
leads O 0 1.3305424545251299e-05
to O 0 2.7742776183004025e-06
increased O 0 4.4656917452812195e-05
adenoma B-Disease 1 1.0
formation O 0 0.001063084346242249
and O 0 2.304404006281402e-06
directly O 0 9.322106961917598e-07
contributes O 0 6.671678534075909e-07
to O 0 1.5047858425987215e-07
3 O 0 5.303020884639409e-07
% O 0 2.3315132580137288e-07
- O 0 8.838663347887632e-07
4 O 0 7.665701104997424e-07
% O 0 1.0401450367680809e-07
of O 0 3.3026586265805236e-07
all O 0 1.1992889312750776e-06
Ashkenazi O 1 0.9865532517433167
Jewish O 1 0.9999831914901733
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00023673591203987598

The O 0 2.3767534003127366e-05
estimated O 0 7.6081882980361115e-06
relative O 0 6.160837983770762e-06
risk O 0 2.437735702187638e-06
for O 0 7.207169119283208e-07
carriers O 0 2.120807948813308e-06
may O 0 3.7333441582632076e-07
justify O 0 6.634642772951338e-07
specific O 0 2.002397962996838e-07
clinical O 0 3.427645651754574e-06
screening O 0 9.516418799648818e-07
for O 0 1.8249036770612292e-07
the O 0 8.540426961189951e-07
360 O 0 3.7820918805664405e-06
, O 0 1.8595608253235696e-07
000 O 0 9.409541235072538e-07
Americans O 0 7.500563015128137e-08
expected O 0 1.134280580572522e-07
to O 0 1.4812880522185878e-07
harbor O 0 7.258181085489923e-06
this O 0 1.0114212045664317e-07
allele O 0 2.3516760450092988e-07
, O 0 5.730307961471226e-08
and O 0 7.867556917062757e-08
genetic O 0 4.74958198992681e-07
testing O 0 9.154993563242897e-07
in O 0 1.2878162181095831e-07
the O 0 1.307623591628726e-07
setting O 0 5.668059088748123e-07
of O 0 1.198983682115795e-06
long O 0 1.381672745992546e-06
- O 0 5.578540822170908e-06
term O 0 2.0357060748210642e-06
- O 0 2.878704663089593e-06
outcome O 0 4.0853433347365353e-07
studies O 0 5.095688493383932e-07
may O 0 2.0959909363682527e-07
impact O 0 9.683267307991628e-07
significantly O 0 5.4397251005866565e-06
on O 0 0.018085366114974022
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.00035401066998019814
in O 0 1.1006293334503425e-06
this O 0 4.103973765268165e-07
population O 0 8.939047688727442e-07
. O 0 1.4809033928031567e-05

Localization O 0 0.0004418432363308966
of O 0 2.4609831598354504e-05
human O 0 1.038377195072826e-05
BRCA1 O 0 4.924340100842528e-05
and O 0 8.826078783386038e-07
its O 0 2.0384220533742337e-06
loss O 0 5.19409186381381e-05
in O 0 1.0695270020733005e-06
high O 0 2.6663243261282332e-05
- O 0 5.7943547290051356e-05
grade O 0 0.0016920658526942134
, O 0 2.214851747339708e-06
non B-Disease 0 0.0001451278367312625
- I-Disease 1 0.9938744902610779
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0006864958559162915

Although O 0 4.6892513637430966e-05
the O 0 7.725935574853793e-06
link O 0 6.476877388195135e-06
between O 0 1.408797402291384e-06
the O 0 1.581480319146067e-05
BRCA1 O 1 0.9997685551643372
tumour B-Disease 1 1.0
- O 0 0.07581157237291336
suppressor O 0 0.0031649242155253887
gene O 0 1.1255720892222598e-05
and O 0 5.400276222644607e-06
hereditary B-Disease 1 0.9999996423721313
breast I-Disease 1 1.0
and I-Disease 1 0.9999927282333374
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.8585303678264609e-06
established O 0 1.354786149931897e-06
, O 0 2.3765417722643178e-07
the O 0 2.456058041389042e-07
role O 0 6.945888344489504e-07
, O 0 1.9435911724485777e-07
if O 0 3.8223006981752405e-08
any O 0 6.895201920542604e-08
, O 0 1.046373299118386e-07
of O 0 1.1426290029703523e-06
BRCA1 O 0 3.265421401010826e-05
in O 0 1.812564505598857e-06
non B-Disease 0 0.0005257654702290893
- I-Disease 1 0.9887357354164124
familial I-Disease 1 0.9999908208847046
cancers I-Disease 1 0.9999908208847046
is O 0 9.268766007153317e-06
unclear O 0 2.617615791677963e-05
. O 0 3.050301347684581e-05

BRCA1 O 0 0.047611821442842484
mutations O 0 2.6077839720528573e-05
are O 0 8.108345923574234e-07
rare O 0 4.4790654101234395e-06
in O 0 2.4093124011415057e-06
sporadic B-Disease 0 0.0053344666957855225
cancers I-Disease 1 0.9987461566925049
, O 0 1.4186964563123183e-06
but O 0 4.868446694672457e-07
loss O 0 5.179604340810329e-05
of O 0 8.434269693680108e-05
BRCA1 O 0 0.0004121736856177449
resulting O 0 4.981768142897636e-06
from O 0 3.6297772112448e-06
reduced O 0 2.149395868400461e-06
expression O 0 9.827983831200982e-07
or O 0 5.392116690927651e-07
incorrect O 0 3.6170638395560673e-06
subcellular O 0 1.6794730981928296e-05
localization O 0 1.7592788935871795e-05
is O 0 5.056959935245686e-07
postulated O 0 2.477035877745948e-06
to O 0 1.1491034257460342e-07
be O 0 5.017634663317949e-08
important O 0 1.5659627194963832e-07
in O 0 2.590413430425542e-07
non B-Disease 0 2.8241373001947068e-05
- I-Disease 0 0.3108132481575012
familial I-Disease 1 0.9999964237213135
breast I-Disease 1 1.0
and I-Disease 1 0.9999901056289673
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.0005860620294697583

Epigenetic O 0 0.006758221425116062
loss O 0 0.16274617612361908
, O 0 1.0498719348106533e-05
however O 0 2.8199203825352015e-06
, O 0 6.658603979303734e-07
has O 0 1.6471813069074415e-07
not O 0 5.193180285800736e-08
received O 0 3.2018374440667685e-07
general O 0 1.4415668374567758e-06
acceptance O 0 2.337674459340633e-06
due O 0 2.3317052182392217e-06
to O 0 5.699122311852989e-07
controversy O 0 5.590534783550538e-06
regarding O 0 9.033659011947748e-07
the O 0 6.998577077865775e-07
subcellular O 0 1.645325573917944e-05
localization O 0 1.1192225429113023e-05
of O 0 4.428268312040018e-06
BRCA1 O 0 6.02748514211271e-06
proteins O 0 1.53480456788202e-07
, O 0 2.0025164815251628e-07
reports O 0 1.33584521222474e-07
of O 0 2.097418700941489e-07
which O 0 8.569735854280225e-08
have O 0 3.2485942824678204e-08
ranged O 0 8.98149949080107e-07
from O 0 1.919788559234803e-07
exclusively O 0 5.962947966509091e-07
nuclear O 0 5.4433780860563274e-06
, O 0 1.5406148179408774e-07
to O 0 7.772248977744312e-08
conditionally O 0 5.716171472158749e-06
nuclear O 0 5.621425771096256e-06
, O 0 2.0597934735633316e-07
to O 0 1.1660575438554588e-07
the O 0 3.202278776370804e-06
ER O 1 0.999963641166687
/ O 0 0.0004060027713421732
golgi O 0 0.0005134697421453893
, O 0 7.083978061928065e-07
to O 0 3.389091602912231e-07
cytoplasmic O 0 8.18135140434606e-06
invaginations O 0 8.067284215940163e-05
into O 0 2.9244611141621135e-06
the O 0 6.6051002249878366e-06
nucleus O 0 0.00017759756883606315
. O 0 3.381588248885237e-05

In O 0 2.8814767574658617e-05
an O 0 3.93788650399074e-06
attempt O 0 6.171269433252746e-06
to O 0 8.332085599249694e-07
resolve O 0 2.7699263682734454e-06
this O 0 3.104102574980061e-07
issue O 0 4.897504481959913e-07
, O 0 3.532839798481291e-07
we O 0 1.1307390934689465e-07
have O 0 6.62126851125322e-08
comprehensively O 0 1.737311322358437e-05
characterized O 0 9.154799954558257e-06
19 O 0 1.9780476577579975e-05
anti O 0 0.0005505418521352112
- O 0 0.005251467693597078
BRCA1 O 0 0.0018929338548332453
antibodies O 0 0.00010708558693295345
. O 0 4.6550776460208e-05

These O 0 9.584469808032736e-06
reagents O 0 0.0001339713780907914
detect O 0 4.7664321755291894e-05
a O 0 4.330434421717655e-06
220 O 0 1.8586226360639557e-05
- O 0 3.45038715749979e-05
kD O 0 0.00013662183482665569
protein O 0 1.4746691476830165e-06
localized O 0 2.317702865184401e-06
in O 0 2.1774457081846776e-07
discrete O 0 6.074129714761511e-07
nuclear O 0 1.1149642887176014e-05
foci O 0 1.8036385881714523e-05
in O 0 4.7466610908486473e-07
all O 0 6.10154472724389e-07
epithelial O 0 0.0010132355382665992
cell O 0 1.482166499044979e-05
lines O 0 7.521765041929029e-07
, O 0 2.1757787749265844e-07
including O 0 9.657032506993346e-08
those O 0 1.4450489516093512e-07
derived O 0 4.942067334923195e-06
from O 0 8.196143608074635e-05
breast B-Disease 1 0.999940037727356
malignancies I-Disease 1 0.9983794689178467
. O 0 0.00013431059778667986

Immunohistochemical O 0 0.03501056879758835
staining O 0 0.0036128738429397345
of O 0 0.0001133845653384924
human O 0 9.996251901611686e-05
breast O 1 0.8149203658103943
specimens O 0 9.44069615798071e-05
also O 0 5.777823844255181e-06
revealed O 0 0.00023161860008258373
BRCA1 O 0 0.00032656651455909014
nuclear O 0 0.00013871691771782935
foci O 0 0.0007395823486149311
in O 0 2.548895099607762e-05
benign O 1 0.9999830722808838
breast O 1 0.9999549388885498
, O 0 7.804371853126213e-05
invasive B-Disease 1 0.9999994039535522
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999810457229614
and O 0 2.430417953291908e-05
low B-Disease 0 0.3475794494152069
- I-Disease 1 0.999022364616394
grade I-Disease 1 0.999997615814209
ductal I-Disease 1 1.0
carcinomas I-Disease 1 0.9999998807907104
. O 0 0.0004997769719921052

Conversely O 0 0.0002899454557336867
, O 0 2.123207195836585e-05
BRCA1 O 0 9.058946307050064e-05
expression O 0 4.424439794092905e-06
was O 0 1.4695739992021117e-05
reduced O 0 3.956769432988949e-06
or O 0 8.16320948615612e-07
undetectable O 0 2.2363383322954178e-05
in O 0 1.820563255705565e-07
the O 0 1.713434869543562e-07
majority O 0 6.353091208666228e-08
of O 0 7.474997687495488e-07
high O 0 7.830239337636158e-05
- O 0 0.00457272632047534
grade O 1 0.9229292273521423
, O 0 5.523683284991421e-05
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 4.672340764955152e-06
suggesting O 0 2.124865204677917e-06
that O 0 1.8683705604871648e-07
absence O 0 4.944037755194586e-06
of O 0 4.295813414501026e-05
BRCA1 O 1 0.5941687822341919
may O 0 1.8511999542170088e-06
contribute O 0 2.947697055333265e-07
to O 0 1.8646983335202094e-07
the O 0 1.5678245972594596e-06
pathogenesis O 0 0.0006211553700268269
of O 0 2.7553539894142887e-06
a O 0 7.819651841600717e-07
significant O 0 6.882974048494361e-07
percentage O 0 1.0355915947002359e-06
of O 0 2.7838957521453267e-06
sporadic B-Disease 0 0.03183375671505928
breast I-Disease 1 0.9999983310699463
cancers I-Disease 1 0.9990434050559998
. O 0 9.750564458954614e-06
. O 0 3.137835665256716e-05

